Enke: Kleintieronkologie

Transcription

1
1
Ätiologie und Pathologie von
Krebserkrankungen
[1]
Ahern TE, Bird RC, Bird AE et al.: Expression of the oncogene
c-erbB-2 in canine mammary cancers and tumor-derived cell lines.
Am J Vet Res. 1996; 57: 693–696
[2]
Angres G, Scherf HR, Schmahl D: Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine. Cancer Treat Rev. 1990; 17: 339–345
[3]
Argyle DJ, Nasir L: Pathophysiology of cellular regulation, cell
death, and cancer. In: Dunlop R.H. and Malbert C.H. (Hrsg.), Veterinary Pathophysiology. 1. Auflg. Iowa State Press, Ames, Iowa; 2004,
25–78
[21]
Cleary MP, Grossmann ME, Ray A: Effect of obesity on breast cancer development. Vet Pathol. 2010; 47: 202–213
[22]
Cruz Cardona JA, Milner R, Alleman AR et al.: BCR-ABL translocation in a dog with chronic monocytic leukemia. Vet Clin Pathol.
2011; 40: 40–47
[23]
De Maria R, Miretti S, Iussich S et al.: met oncogene activation
qualifies spontaneous canine osteosarcoma as a suitable pre-clinical
model of human osteosarcoma. J Pathol. 2009; 218: 399–408
[24]
de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the
immune system during cancer development. Nat Rev Cancer. 2006;
6: 24–37
[25]
de Visser KE: Spontaneous immune responses to sporadic tumors:
tumor-promoting, tumor-protective or both? Cancer Immunol
Immunother. 2008; 57: 1531–1539
[4]
Argyle DJ, Blacking T: From viruses to cancer stem cells: dissecting
the pathways to malignancy. Vet J. 2008; 177: 311–323
[26]
[5]
Barnhart MD: Malignant transformation of an aneurysmal bone
cyst in a dog. Vet Surg. 2002; 31: 519–524
Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance.
Nat Rev Cancer. 2005; 5: 275–284
[27]
DeVita VT, Lawrence TS, Rosenberg SA et al. (Hrsg.): DeVita,
Hellman, and Rosenbergʼs Cancer: Principles and Practice of Oncology, 9 Aufl., Philadelphia, PA, Lippincott Williams & Wilkins,
2011
[28]
Dickinson PJ, Roberts BN, Higgins RJ et al.: Expression of receptor
tyrosine kinases VEGFR-1 (FLT-1), VEGFR-2 (KDR), EGFR-1, PDGFRalpha and c-Met in canine primary brain tumours. Vet Comp Oncol.
2006; 4: 132–140
[6]
Bergkvist GT, Argyle DJ, Morrison L et al.: Expression of epidermal
growth factor receptor (EGFR) and Ki67 in feline oral squamous cell
carcinomas (FOSCC). Vet Comp Oncol. 2011; 9: 106–117
[7]
Bernays ME, Flemming D, Peiffer RL Jr: Primary corneal papilloma
and squamous cell carcinoma associated with pigmentary keratitis
in four dogs. J Am Vet Med Assoc. 1999; 214: 215–217, 204
[8]
Bertone ER, Snyder LA, Moore AS: Environmental tobacco smoke
and risk of malignant lymphoma in pet cats. Am J Epidemiol. 2002;
156: 268–273
[29]
[9]
Bertone ER, Snyder LA, Moore AS: Environmental and lifestyle risk
factors for oral squamous cell carcinoma in domestic cats. J Vet
Intern Med. 2003; 17: 557–562
Dickinson PJ, Surace EI, Cambell M et al.: Expression of the tumor
suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet
Pathol. 2009; 46: 884–892
[30]
Dobson J, Hoather T, McKinley TJ et al.: Mortality in a cohort of
flat-coated retrievers in the UK. Vet Comp Oncol. 2009; 7: 115–121
[10]
Bettini G, Morini M, Marconato L et al.: Association between environmental dust exposure and lung cancer in dogs. Vet J. 2010; 186:
364–369
[31]
[11]
Blacking TM, Wilson H, Argyle DJ: Is cancer a stem cell disease?
Theory, evidence and implications. Vet Comp Oncol. 2007; 5: 76–
89
Donovan JCH, Slingerland J, Tannock IF: Cell Proliferation and
Tumor Growth. In: Tannock IF, Hill RP, Bristow RG et al. (Hrsg.): The
basic science of oncology. 4. Auflg. McGraw-Hill, Medical Pub. Division, New York, 2005; 167–193
[32]
[12]
Blackwood L, German AJ, Stell AJ et al.: Multicentric lymphoma in
a dog after cyclosporine therapy. J Small Anim Pract. 2004; 45:
259–262
Dubielzig RR, Everitt J, Shadduck JA et al.: Clinical and morphologic features of post-traumatic ocular sarcomas in cats. Vet Pathol.
1990; 27: 62–65
[33]
[13]
Boudrieau RJ, McCarthy RJ, Sisson RD Jr.: Sarcoma of the proximal
portion of the tibia in a dog 5.5 years after tibial plateau leveling
osteotomy. J Am Vet Med Assoc. 2005; 227: 1613–1617, 1591
Dutra AP, Granja NV, Schmitt FC et al.: c-erbB-2 expression and
nuclear pleomorphism in canine mammary tumors. Braz J Med Biol
Res. 2004; 37: 1673–1681
[34]
[14]
Bridgeford EC, Marini RP, Feng Y et al.: Gastric Helicobacter species as a cause of feline gastric lymphoma: a viable hypothesis. Vet
Immunol Immunopathol. 2008; 123: 106–113
Edwards MD, Pazzi KA, Gumerlock PH et al.: c-N-ras is activated
infrequently in canine malignant lymphoma. Toxicol Pathol. 1993;
21: 288–291
[35]
[15]
Bristow RG, Harrington L: Genomic Stability and DNA Repair. In:
Tannock IF, Hill RP, Bristow RG et al. (Hrsg.): The basic science of
oncology. 4. Auflg. McGraw-Hill, Medical Pub. Division, New York,
2005, 77–99
Ferracini R, Angelini P, Cagliero E et al.: MET oncogene aberrant
expression in canine osteosarcoma. J Orthop Res. 2000; 18: 253–
256
[36]
Fidler IJ: Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am. 2001; 10:
257–269, vii–viiii
[16]
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases.
Nature. 2000; 407: 249–257
[37]
Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’
hypothesis revisited. Nat Rev Cancer. 2003; 3: 453–458
[17]
Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298–307
[38]
Fidler IJ, Poste G: The “seed and soil” hypothesis revisited. Lancet
Oncol. 2008; 9: 808
[18]
Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis.
Science. 2011; 331: 1559–1564
[39]
[19]
Chiarugi P, Giannoni E: Anoikis: a necessary death program for
anchorage-dependent cells. Biochem Pharmacol. 2008; 76: 1352–
1364
Fieten H, Spee B, Ijzer J et al.: Expression of hepatocyte growth
factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 2009; 46: 869–877
[40]
[20]
Chu LL, Rutteman GR, Kong JM et al.: Genomic organization of
the canine p53 gene and its mutational status in canine mammary
neoplasia. Breast Cancer Res Treat. 1998; 50: 11–25
Flint AF, UʼRen L, Legare ME et al.: Overexpression of the erbB-2
proto-oncogene in canine osteosarcoma cell lines and tumors. Vet
Pathol. 2004; 41: 291–296
aus: Kessler, Kleintieronkologie (ISBN 9783830411376) © 2013 Enke Verlag
Literaturverzeichnis
2
[41]
Fox MH, Armstrong LW, Withrow SJ et al.: Comparison of DNA
aneuploidy of primary and metastatic spontaneous canine osteosarcomas. Cancer Res. 1990; 50: 6176–6178
[64]
Kass PH, Barnes WG Jr., Spangler WL et al.: Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma
tumorigenesis in cats. J Am Vet Med Assoc. 1993; 203: 396–405
[42]
Frazier KS, Hines ME 2nd, Hurvitz AI et al.: Analysis of DNA aneuploidy and c-myc oncoprotein content of canine plasma cell tumors
using flow cytometry. Vet Pathol. 1993; 30: 505–511
[65]
Khanna C, Pavlini MC: Cancer biology in dogs. In: Lindblatt-Toh K.
(Hrsg.): The dog and its genome. Cold Spring Harbor Laboratory
Press 2006; 451–473
[43]
Gama A, Gartner F, Alves A et al.: Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res Vet Sci. 2009; 87: 432–437
[66]
Kim SS, Ruiz VE, Carroll JD et al.: Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett. 2010;
305: 228–238
[44]
Gangemi R, Paleari L, Orengo AM et al.: Cancer stem cells: a new
paradigm for understanding tumor growth and progression and
drug resistance. Curr Med Chem. 2009; 16: 1688–1703
[67]
Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition:
a cancer researcherʼs conceptual friend and foe. Am J Pathol. 2009;
174: 1588–1593
[45]
Ghim S, Newsome J, Bell J et al.: Spontaneously regressing oral
papillomas induce systemic antibodies that neutralize canine oral
papillomavirus. Exp Mol Pathol. 2000; 68: 147–151
[68]
Kraegel SA, Gumerlock PH, Dungworth DL et al.: K-ras activation
in non-small cell lung cancer in the dog. Cancer Res. 1992; 52:
4724–4727
[46]
Glickman LT, Domanski LM, Maguire TG et al.: Mesothelioma in
pet dogs associated with exposure of their owners to asbestos. Environ Res. 1983; 32: 305–313
[69]
[47]
Goel GA, Kandiel A, Achkar JP et al.: Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications.
Am J Gastroenterol. 2011; 106: 719–730
Kulbe H, Thompson R, Wilson JL et al.: The inflammatory cytokine
tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007; 67:
585–592
[70]
Kusewitt DF, Rush LJ: Neoplasien und Tumorbiologie. In: McGavin
MD, Zachary JF (Hrsg.): Pathologie der Haustiere: Allgemeine, spezielle und funktionelle Veterinärpathologie. 1. Auflg. Urban &
Fischer Verlag/Elsevier GmbH, München, 2009; 231–273
[71]
Larsson SC, Rafter J, Holmberg L et al.: Red meat consumption
and risk of cancers of the proximal colon, distal colon and rectum:
the Swedish mammography cohort. Int J Cancer. 2005; 113: 829–
834
[48]
Gold LS, Slone TH, Manley NB et al.: Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect. 1991;
93: 233–246
[49]
Green EM, Adams WM, Steinberg H: Malignant transformation of
solitary spinal osteochondroma in two mature dogs. Vet Radiol
Ultrasound. 1999; 40: 634–637
[50]
Greenman C, Stephens P, Smith R et al.: Patterns of somatic
mutation in human cancer genomes. Nature. 2007; 446: 153–158
[72]
Lee CH, Kweon OK: Mutations of p53 tumor suppressor gene in
spontaneous canine mammary tumors. J Vet Sci. 2002; 3: 321–325
[51]
Gregory-Bryson E, Bartlett E, Kiupel M et al.: Canine and human
gastrointestinal stromal tumors display similar mutations in c-KIT
exon 11. BMC Cancer. 2010; 10: 559
[73]
Levine RA, Forest T, Smith C: Tumor suppressor PTEN is mutated
in canine osteosarcoma cell lines and tumors. Vet Pathol. 2002; 39:
372–378
[52]
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and
cancer. Cell. 2010; 140: 883–899
[74]
[53]
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000;
100: 57–70
Liao AT, McMahon M, London C: Characterization, expression and
function of c-Met in canine spontaneous cancers. Vet Comp Oncol.
2005; 3: 61–72
[75]
[54]
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674
[55]
Hanes MA, Stribling LJ: Fibrosarcomas in two rats arising from
hepatic cysts of Cysticercus fasciolaris. Vet Pathol. 1995; 32: 441–
444
Lingaas F, Comstock KE, Kirkness EF et al.: A mutation in the
canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet. 2003; 12: 3043–3053
[76]
[56]
Hargis AM, Ihrke PJ, Spangler WL et al.: A retrospective clinicopathologic study of 212 dogs with cutaneous hemangiomas and
hemangiosarcomas. Vet Pathol. 1992; 29: 316–328
Lingard AE, Briscoe K, Beatty JA et al.: Low-grade alimentary lymphoma: clinicopathological findings and response to treatment in
17 cases. J Feline Med Surg. 2009; 11: 692–700
[77]
Lloyd HH: Estimation of tumor cell kill from Gompertz growth curves. Cancer Chemother Rep. 1975; 59: 267–277
[57]
Hayes HM Jr, Pendergrass TW: Canine testicular tumors: epidemiologic features of 410 dogs. Int J Cancer. 1976; 18: 482–487
[78]
Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991; 51: 3075–3079
[58]
Hendrick MJ, Shofer FS, Goldschmidt MH et al.: Comparison of
fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991–1992). J Am Vet Med Assoc.
1994; 205: 1425–1429
[79]
Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008; 68: 3551–3557; discussion 3557
[80]
Looper JS, Malarkey DE, Ruslander D et al.: Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Vet
Comp Oncol. 2006; 4: 33–40
[81]
MacEwen EG, Kutzke J, Carew J et al.: c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma
cells. Clin Exp Metastasis. 2003; 20: 421–430
[82]
MacEwen EG, Pastor J, Kutzke J et al.: IGF-1 receptor contributes
to the malignant phenotype in human and canine osteosarcoma. J
Cell Biochem. 2004; 92: 77–91
[83]
Macy DW, Withrow SJ, Hoopes J: Transitional cell carcinoma of
the bladder associated with cyclophosphamide administration. J
Am Anim Hosp Assoc. 1983; 19: 965–969
[84]
Magden E, Quackenbush SL, Vandewoude S: FIV associated neoplasms-A mini-review. Vet Immunol Immunopathol. 2011; 15; 143:
227–234
[59]
Hershey AE, Dubielzig RR, Padilla ML et al.: Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with
prognosis. Vet Pathol. 2005; 42: 805–811
[60]
Horbinski C, Mojesky C, Kyprianou N: Live free or die: tales of
homeless (cells) in cancer. Am J Pathol. 2010; 177: 1044–1052
[61]
Hosoya K, Poulson JM, Azuma C: Osteoradionecrosis and radiation
induced bone tumors following orthovoltage radiation therapy in
dogs. Vet Radiol Ultrasound. 2008; 49: 189–195
[62]
Hsu WL, Huang HM, Liao JW et al.: Increased survival in dogs with
malignant mammary tumours overexpressing HER-2 protein and
detection of a silent single nucleotide polymorphism in the canine
HER–2 gene. Vet J. 2009; 180: 116–123
[63]
Jones CL, Grahn RA, Chien MB et al.: Detection of c-kit mutations
in canine mast cell tumors using fluorescent polyacrylamide gel
electrophoresis. J Vet Diagn Invest. 2004; 16: 95–100
[85]
Marconato L, Leo C, Girelli R et al.: Association between waste
management and cancer in companion animals. J Vet Intern Med.
2009; 23: 564–569
[107] Nicholls PK, Moore PF, Anderson DM et al.: Regression of canine
oral papillomas is associated with infiltration of CD4+ and CD8+
lymphocytes. Virology. 2001; 283: 31–39
[86]
Martin de las Mulas J, Ordas J, Millan Y et al.: Oncogene HER-2 in
canine mammary gland carcinomas: an immunohistochemical and
chromogenic in situ hybridization study. Breast Cancer Res Treat.
2003; 80: 363–367
[108] Nielsen C, Anderson GM: Metastasis of gastric adenocarcinoma to
the abdominal wall following placement of a gastrostomy tube in a
dog. Can Vet J. 2005; 46: 641–643
[87]
Matsuyama S, Nakamura M, Yonezawa K et al.: Expression patterns of the erbB subfamily mRNA in canine benign and malignant
mammary tumors. J Vet Med Sci. 2001; 63: 949–954
[88]
Mayr B, Schaffner G, Kurzbauer R et al.: Sequence of an exon of
tumour suppressor p53 gene – a comparative study in domestic
animals: mutation in a feline solid mammary carcinoma. Br Vet J.
1995; 151: 325–329
[109] Nikula KJ, Benjamin SA, Angleton GM et al.: Ultraviolet radiation,
solar dermatosis, and cutaneous neoplasia in beagle dogs. Radiat
Res. 1992; 129: 11–18
[110] Nilsson A, Morgan JP, Book SA: Investigations of 90Sr in dogs. I.
Pathogenesis of radiation-induced bone tumors. Acta Radiol Oncol.
1985; 24: 95–111
[89]
Mayr B, Blauensteiner J, Edlinger A et al.: Presence of p53 mutations in feline neoplasms. Res Vet Sci. 2000; 68: 63–70
[111] Nodtvedt A, Gamlem H, Gunnes G et al.: Breed differences in the
proportional morbidity of testicular tumours and distribution of histopathologic types in a population-based canine cancer registry.
Vet Comp Oncol. 2011; 9: 45–54
[90]
McCarthy PE, Hedlund CS, Veazy RS et al.: Liposarcoma associated with a glass foreign body in a dog. J Am Vet Med Assoc. 1996;
209: 612–614
[112] OʼShea JD, Jabara AG: The histogenesis of canine ovarian tumours
induced by stilboestrol administration. Pathol Vet. 1967; 4: 137–
148
[91]
McEntee MC, Page RL, Theon A et al.: Malignant tumor formation
in dogs previously irradiated for acanthomatous epulis. Vet Radiol
Ultrasound. 2004; 45: 357–361
[92]
McNiel EA, Prink AL, OʼBrien TD: Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol. 2006; 4:
2–8
[113] Okey AB, Harper PA, Grant DM et al.: Chemical and Radiation Carcinogenesis. In: Tannock IF, Hill RP, Bristow RG et al. (Hrsg.): The
basic science of oncology. 4. Auflg. McGraw-Hill, Medical Pub. Division, New York, 2005; 25–48
[93]
Mehl ML, Withrow SJ, Seguin B et al.: Spontaneous regression of
osteosarcoma in four dogs. J Am Vet Med Assoc. 2001; 219: 614–
617
[94]
Meuten DJ (Hrsg.): Tumors in domestic animals, 4. Aufl. Ames,
Iowa, Iowa State University Press, 2002
[95]
Miller DM: The occurrence of mast cell tumors in young Shar-Peis. J
Vet Diagn Invest. 1995; 7: 360–363
[96]
Miller MA, Aper RL, Fauber A et al.: Extraskeletal osteosarcoma
associated with retained surgical sponge in a dog. J Vet Diagn
Invest. 2006; 18: 224–228
[97]
[98]
[99]
Mina RB, Tateyama S, Miyoshi N et al.: Amplification of a c-yes-1related oncogene in canine lymphoid leukemia. J Vet Med Sci.
1994; 56: 773–774
Minke JM, Cornelisse CJ, Stolwijk JA et al.: Flow cytometric DNA
ploidy analysis of feline mammary tumors. Cancer Res. 1990; 50:
4003–4007
Misdorp W and Hart AA: Canine mammary cancer. II. Therapy and
causes of death. J Small Anim Pract. 1979; 20: 395–404
[100] Miyoshi N, Tateyama S, Ogawa K et al.: Abnormal structure of
the canine oncogene, related to the human c-yes-1 oncogene, in
canine mammary tumor tissue. Am J Vet Res. 1991; 52: 2046–2049
[101] Modiano JF, Breen M, Avery AC: Breed-specific canine lymphoproliferative disease. In: Ostrander EA, Giger U, Lindblatt-Toh K (Hrsg.):
The dog and its genome. Cold Spring Harbor Laboratory Press,
2006; 439–450
[102] Monteiro J, Fodde R: Cancer stemness and metastasis: therapeutic
consequences and perspectives. Eur J Cancer. 2010; 46: 1198–1203
[103] Murphy ST, Parker RB, Woodard JC: Osteosarcoma following total
hip arthroplasty in a dog. J Small Anim Pract. 1997; 38: 263–267
[104] Nambiar PR, Haines DM, Ellis JA et al.: Mutational analysis of
tumor suppressor gene p53 in feline vaccine site-associated sarcomas. Am J Vet Res. 2000; 61: 1277–1281
[105] Nasir L, Rutteman GR, Reid SW et al.: Analysis of p53 mutational
events and MDM2 amplification in canine soft-tissue sarcomas.
Cancer Lett. 2001; 174: 83–89
[106] Nerurkar VR, Seshadri R, Mulherkar R et al.: Receptors for epidermal growth factor and estradiol in canine mammary tumors. Int J
Cancer. 1987; 40: 230–232
[114] Oster S, Penn L, Stambolic V: Oncogenes and Tumor Suppressor
Genes. In: Tannock I (Hrsg.): The basic science of oncology. 4.
Auflg. McGraw-Hill, Medical Pub. Division, New York, 2005; 123–
141
[115] Padgett GA, Madewell BR, Keller ET et al.: Inheritance of histiocytosis in Bernese mountain dogs. J Small Anim Pract. 1995; 36: 93–
98
[116] Pardo AD, Adams WH, McCracken MD et al.: Primary jejunal
osteosarcoma associated with a surgical sponge in a dog. J Am Vet
Med Assoc. 1990; 196: 935–938
[117] Pauli BU, Augustin-Voss HG, el-Sabban ME et al.: Organ-preference of metastasis. The role of endothelial cell adhesion molecules.
Cancer Metastasis Rev. 1990; 9: 175–189
[118] Perez Alenza D, Rutteman GR, Pena L et al.: Relation between
habitual diet and canine mammary tumors in a case-control study. J
Vet Intern Med. 1998; 12: 132–139
[119] Perez Alenza MD, Rutteman GR, Kuipers-Dijkshoorn NJ et al.:
DNA flow cytometry of canine mammary tumours: the relationship
of DNA ploidy and S-phase fraction to clinical and histological features. Res Vet Sci. 1995; 58: 238–243
[120] Pirie CG, Dubielzig RR: Feline conjunctival hemangioma and
hemangiosarcoma: a retrospective evaluation of eight cases (1993–
2004). Vet Ophthalmol. 2006; 9: 227–231
[121] Pirie CG, Knollinger AM, Thomas CB et al.: Canine conjunctival
hemangioma and hemangiosarcoma: a retrospective evaluation of
108 cases (1989–2004). Vet Ophthalmol. 2006; 9: 215–226
[122] Pisani G, Millanta F, Lorenzi D et al.: Androgen receptor expression in normal, hyperplastic and neoplastic hepatoid glands in the
dog. Res Vet Sci. 2006; 81: 231–236
[123] Polyak K, Hahn WC: Roots and stems: stem cells in cancer. Nat
Med. 2006; 12: 296–300
[124] Qiu CW, Lin DG, Wang JQ et al.: Expression and significance of
PTEN and VEGF in canine mammary gland tumours. Vet Res Commun. 2008; 32: 463–472
[125] Rayner EL, Scudamore CL, Francis I et al.: Abdominal fibrosarcoma associated with a retained surgical swab in a dog. J Comp
Pathol. 2010; 143: 81–85
[126] Rennie P, Read J, Murphy L: Hormones and Cancer. In: Tannock IF,
Hill RP, Bristow RG et al. (Hrsg.): The basic science of oncology. 4.
Aulg. McGraw-Hill, Medical Pub. Division, New York, 2005; 400–430
3
4
[127] Ressel L, Millanta F, Caleri E et al.: Reduced PTEN protein expression and its prognostic implications in canine and feline mammary
tumors. Vet Pathol. 2009; 46: 860–868
[128] Riva F, Brizzola S, Stefanello D et al.: A study of mutations in the
c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest. 2005;
17: 385–388
[129] Rodriguez-Paredes M, Esteller M: Cancer epigenetics reaches
mainstream oncology. Nat Med. 2011; 17: 330–339
[149] Sorenmo KU, Kristiansen VM, Cofone MA et al.: Canine mammary gland tumours; a histological continuum from benign to
malignant; clinical and histopathological evidence. Vet Comp
Oncol. 2009; 7: 162–172
[150] Stevenson S: Fracture-associated sarcomas. Vet Clin North Am
Small Anim Pract. 1991; 21: 859–872
[130] Rosol TJ, Tannehill-Gregg SH, LeRoy BE et al.: Animal models of
bone metastasis. Cancer. 2003; 97(Suppl): 748–757
[151] Sugihara H, Hattori T, Imamura Y et al.: Morphology and modes
of cell proliferation in earliest signet-ring-cell carcinomas induced in
canine stomachs by N-ethyl-Nʼ-nitro-N-nitrosoguanidine. J Cancer
Res Clin Oncol. 1991; 117: 197–204
[131] Rowland PH, Moise NS, Severson D: Myxoma at the site of a subcutaneous pacemaker in a dog. J Am Anim Hosp Assoc. 1991; 27:
649–651
[152] Tamburini BA, Trapp S, Phang TL et al.: Gene expression profiles
of sporadic canine hemangiosarcoma are uniquely associated with
breed. PLoS One. 2009; 4: e5549
[132] Rungsipipat A, Tateyama S, Yamaguchi R et al.: Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53
tumor suppressor protein in canine mammary tumors. J Vet Med
Sci. 1999; 61: 27–32
[153] Tannock I: The basic science of oncology. 4. Auflg. New York,
McGraw-Hill, Medical Pub. Division, 2005
[133] Rutteman GR, Cornelisse CJ, Dijkshoorn NJ et al.: Flow cytometric
analysis of DNA ploidy in canine mammary tumors. Cancer Res.
1988; 48: 3411–3417
[134] Rutteman GR, Foekens JA, Portengen H et al.: Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Res Treat.
1994; 30: 139–146
[135] Sabattini S, Marconato L, Zoff A et al.: Epidermal growth factor
receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. J Feline Med Surg. 2010; 12: 760–
768
[136] Schioppa T, Moore R, Thompson RG et al.: B regulatory cells and
the tumor-promoting actions of TNF-{alpha} during squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011; 108: 10662–10667
[137] Schwartz DA: Helminths in the induction of cancer II. Schistosoma
haematobium and bladder cancer. Trop Geogr Med. 1981; 33: 1–7
[138] Schwartz SN: Spontaneous regression of lymphosarcoma in a dog.
J Am Vet Med Assoc. 1988; 192: 222–224
[139] Sesink AL, Termont DS, Kleibeuker JH et al.: Red meat and colon
cancer: the cytotoxic and hyperproliferative effects of dietary heme.
Cancer Res. 1999; 59: 5704–5709
[140] Sesink AL, Termont DS, Kleibeuker JH et al.: Red meat and colon
cancer: dietary haem, but not fat, has cytotoxic and hyperproliferative effects on rat colonic epithelium. Carcinogenesis. 2000; 21:
1909–1915
[141] Shaw TE, Harkin KR, Nietfeld J et al.: Aortic body tumor in full-sibling English bulldogs. J Am Anim Hosp Assoc. 2010; 46: 366–370
[142] Shiomitsu K, Johnson CL, Malarkey DE et al.: Expression of epidermal growth factor receptor and vascular endothelial growth factor
in malignant canine epithelial nasal tumours. Vet Comp Oncol.
2009; 7: 106–114
[143] Simpson CD, Anyiwe K, Schimmer AD: Anoikis resistance and
tumor metastasis. Cancer Lett. 2008; 272: 177–185
[144] Slaughter DP, Southwick HW, Smejkal W: Field cancerization in
oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953; 6: 963–968
[145] Snyder JM, Lipitz L, Skorupski KA et al.: Secondary intracranial
neoplasia in the dog: 177 cases (1986–2003). J Vet Intern Med.
2008; 22: 172–177
[146] Snyder LA, Bertone ER, Jakowski RM et al.: p53 expression and
environmental tobacco smoke exposure in feline oral squamous cell
carcinoma. Vet Pathol. 2004; 41: 209–214
[147] Snyder SA, Dewhirst MW, Hauck ML: The role of hypoxia in
canine cancer. Vet Comp Oncol. 2008; 6: 213–223
[148] Sonnenschein EG, Glickman LT, Goldschmidt MH et al.: Body conformation, diet, and risk of breast cancer in pet dogs: a case-control
study. Am J Epidemiol. 1991; 133: 694–703
[154] TenHave-Opbroek AA, Shi XB, Gumerlock PH: 3-Methylcholanthrene triggers the differentiation of alveolar tumor cells from canine
bronchial basal cells and an altered p53 gene promotes their clonal
expansion. Carcinogenesis. 2000; 21: 1477–1484
[155] Thomas R, Fiegler H, Ostrander EA et al.: A canine cancer-gene
microarray for CGH analysis of tumors. Cytogenet Genome Res.
2003; 102: 254–260
[156] Thomas R, Smith KC, Ostrander EA et al.: Chromosome aberrations in canine multicentric lymphomas detected with comparative
genomic hybridisation and a panel of single locus probes. Br J Cancer. 2003; 89: 1530–1537
[157] Thomas R, Wang HJ, Tsai PC et al.: Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res. 2009; 17: 365–377
[158] Thrasher JP, Ichinose H, Pitot HC: Osteogenic sarcoma of the
canine esophagus associated with spirocerca lupi infection. Am J
Vet Res. 1963; 24: 808–818
[159] Tierney LA, Hahn FF, Lechner JF: p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine
lung neoplasia. Radiat Res. 1996; 145: 181–187
[160] Turin L, Acocella F, Stefanello D et al.: Expression of c-kit protooncogene in canine mastocytoma: a kinetic study using real-time
polymerase chain reaction. J Vet Diagn Invest. 2006; 18: 343–349
[161] Tymchuk CN, Tessler SB, Barnard RJ: Changes in sex hormone-binding globulin, insulin, and serum lipids in postmenopausal women
on a low-fat, high-fiber diet combined with exercise. Nutr Cancer.
2000; 38: 158–162
[162] Usher SG, Radford AD, Villiers EJ et al.: RAS, FLT3, and C-KIT
mutations in immunophenotyped canine leukemias. Exp Hematol.
2009; 37: 65–77
[163] Valerius KD, Powers BE, McPherron MA et al.: Adenomatous
polyps and carcinoma in situ of the canine colon and rectum: 34
cases (1982-1994). J Am Anim Hosp Assoc. 1997; 33: 156–160
[164] Vascellari M, Mutinelli F, Cossettini R et al.: Liposarcoma at the
site of an implanted microchip in a dog. Vet J. 2004; 168: 188–190
[165] Vascellari M, Melchiotti E, Mutinelli F: Fibrosarcoma with typical
features of postinjection sarcoma at site of microchip implant in a
dog: histologic and immunohistochemical study. Vet Pathol. 2006;
43: 545–548
[166] Veldhoen N, Stewart J, Brown R et al.: Mutations of the p53 gene
in canine lymphoma and evidence for germ line p53 mutations in
the dog. Oncogene. 1998; 16: 249–255
[167] Verschueren CP, Rutteman GR, Kuipers-Dijkshoorn NJ et al.:
Flow-cytometric DNA ploidy analysis in primary and metastatic
canine thyroid carcinomas. Anticancer Res. 1991; 11: 1755–1761
[168] Vignoli M, Rossi F, Chierici C et al.: Needle tract implantation after
fine needle aspiration biopsy (FNAB) of transitional cell carcinoma
of the urinary bladder and adenocarcinoma of the lung. Schweiz
Arch Tierheilkd. 2007; 149: 314–318
[169] Waly NE, Gruffydd-Jones TJ, Stokes CR et al.: Immunohistochemical diagnosis of alimentary lymphomas and severe intestinal inflammation in cats. J Comp Pathol. 2005; 133: 253–260
[4]
Francis DM, Essex M, Cotter S et al.: Feline leukemia virus infections: the significance of chronic viremia. Leukemia Res. 1979; 3:
435–441
[170] Watrach AM, Small E, Case MT: Canine papilloma: progression of
oral papilloma to carcinoma. J Natl Cancer Inst. 1970; 45: 915–920
[5]
[171] Weinberg RA: Tumor Viruses. In: Weinberg RA (Hrsg.: The biology
of cancer. Garland Science, New York, 2007; 57–90
Giroglou T, Florin L, Schäfer F et al.: Human papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001; 75: 1565–
1570
[6]
[172] Weinberg RA: Cellular Oncogenes. In: Weinberg RA (Hrsg.): The
biology of cancer. Garland Science, New York, 2007; 91–117
Hardy WD Jr, Old LJ, Hess PW et al.: Horizontal transmission of
feline leukaemia virus. Nature. 1973; 244: 266–269
[7]
[173] Weinberg RA: The biology of cancer. New York, Garland Science,
2007
Hardy WD Jr: Feline Oncoretroviruses. In: Levy JA (Hrsg.): The Retroviridae. New York: Plenum Press; 1993: 109–180
[8]
[174] Weinberg RA: Crowd control: Tumor immunology and immunotherapy. In: Weinberg RA (Hrsg.): The biology of cancer. Garland
Science, New York, 2007; 655–724
Hoover EA, Olsen RG, Hardy WD Jr et al.: Feline leukemia virus
infection: age-related variation in response of cats to experimental
infection. J Natl Cancer Inst. 1976; 57: 365–369
[9]
Jackson ML, Haines DM, Meric SM et al.: Feline leukemia-virus
detection by immunohistochemistry and polymerase chain-reaction
in formalin-fixed, paraffin-embedded tumor-tissue from cats with
lymphosarcoma. Can J Vet Res. 1993; 57: 269–276
[176] Weinberg RA: Moving out: Invasion and metastasis. In: Weinberg
RA (Hrsg.): The biology of cancer. Garland Science, New York, 2007;
587–654
[10]
Jarrett O, Hardy WD Jr, Golder MC et al.: The frequency of occurence of feline leukaemia virus subgroups in cats. Int J Cancer.
1978; 21: 334–337
[177] Weinberg RA: p53 and Apoptosis: Master guardian and executioner. In: Weinberg RA (Hrsg.): The biology of cancer. Garland
Science, New York, 2007; 307–356
[11]
Jarrett O, Golder MC, Weijer K: A comparison of three methods of
feline leukaemia virus diagnosis. Vet Rec. 1982; 110: 325–328
[12]
Lange CE, Tobler K, Ackermann M et al.: Three novel canine papillomaviruses support taxonomic clade formation. J Gen Virol. 2009;
90: 2615–2621
[179] Weinberg RA: Growth factors and receptors. In: Weinberg RA
(Hrsg.): The biology of cancer. Garland Science, New York, 2007;
119–158
[13]
Lange CE, Tobler K, Brandes K et al.: Canine inverted papillomas
associated with DNA of four different papillomaviruses. Vet Dermatol. 2010; 21: 287–291
[180] Weinberg RA: Tumor suppressor genes. In: Weinberg RA (Hrsg.):
The biology of cancer. Garland Science, New York, 2007; 209–254
[14]
Lutz H: Feline retroviruses: a brief review. Vet Microbiol. 1990; 23:
131–146
[181] Weller RE, Wold AM, Dyjido A: Transitional cell carcinoma of the
bladder associated with cyclophosphamide therapy in a dog. J Am
Anim Hosp Assoc. 1979; 5: 733–736
[15]
Modrow S, Falke D, Truyen U, Schätzl H (Hrsg.): Molekulare Virologie. Heidelberg: Spektrum Akademischer Verlag; 2010: 499–519
[16]
[182] Wilson H, Huelsmeyer M, Chun R et al.: Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J. 2008;
175: 69–75
Mullins JI, Brody DS, Binari RC et al.: Viral transduction of c-myc
gene in naturally occuring feline leukemias. Nature. 1984; 308:
856–958
[17]
[183] Winston J, Craft DM, Scase TJ et al.: Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary
tumours. Vet Comp Oncol. 2005; 3: 8–15
Neil JC, Hughes D, McFarlane R et al.: Transduction and rearrangement of the myc gene by feline leukemia virus in naturally occuring
T-cell leukemias. Nature. 1984; 308: 814–820
[18]
Nespeca G, Grest P, Rosenkrantz WS et al.: Detection of novel
papillomaviruslike sequences in paraffin-embedded specimens of
invasive and in situ squamous cell carcinomas from cats. Am. J Vet
Res. 2006; 67: 2036–2041
[185] Wu AH, Pike MC, Stram DO: Meta-analysis: dietary fat intake,
serum estrogen levels, and the risk of breast cancer. J Natl Cancer
Inst. 1999; 91: 529–534
[19]
Pedersen NC, Meric SM, Ho E. et al.: The clinical significance of
latent feline leukaemia virus infection in cats. Feline Prac. 1984; 14:
32–48
[186] Yang TJ: Immunobiology of a spontaneously regressive tumor, the
canine transmissible venereal sarcoma (review). Anticancer Res.
1988; 8: 93–95
[20]
Pedersen NC: Virus infections of cats. In: Horzinek MC (Hrsg.):
Virus infections of vertebrates. Amsterdam: Elsevier Science Publisher; 1987: 215–388
[187] Zackheim HS: Cyclosporine-associated lymphoma. J Am Acad Dermatol. 1999; 40(6 Pt 1): 1015–1016
[21]
Rector A, Lemey P, Tachezy R et al.: Ancient papillomavirus-host
co-speciation in Felidae. Genome Biol. 2007; 8:R57
[22]
Reinacher M: Pathologie der Infektion mit dem felinen Leukämievirus (FeLV) bei der Katze. Prakt Tierarzt, Collegium veterinarium
XXIII 1992; 82–83
[23]
Rojko JL, Hoover EA, Mathes LE et al.: Pathogenesis of experimental feline leukemia virus infection. J Natl Cancer Inst. 1979; 63: 759–
768
[24]
Rojko JL, Hoover EA, Quackenbush et al.: Reactivation of latent
feline leukaemia virus infection. Nature. 1982; 298: 385–388
[25]
Sarma PS, Log T: Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralization tests. Virology.
1973; 54: 160–169
[26]
Shelton GH, Grant CK, Cotter SM et al.: Feline immunodeficiency
virus and feline leukemia virus infections and their relationship to
lymphoid malignancies in cats: a retrospective study (1968–1988).
J Acquir Immune Defic Syndr. 1990; 3: 623–630
[175] Weinberg RA: Dialogue replaces monologue: Heterotypic interactions and the biology of angiogenesis. In: Weinberg RA (Hrsg.): The
biology of cancer. Garland Science, New York, 2007; 527–586
[178] Weinberg RA: Multistep tumorigenesis. In: Weinberg RA (Hrsg.):
The biology of cancer. Garland Science, New York, 2007; 399–462
[184] Wolf JC, Ginn PE, Homer B et al.: Immunohistochemical detection
of p53 tumor suppressor gene protein in canine epithelial colorectal
2
Tumorentstehung durch Viren
2.1 Virusassoziierte Onkongenese
[1]
Bodily J, Laimins LA: Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011; 19:
33–39
[2]
Doorbar J: The papillomavirus life cycle. J Clin Virol. 2005; 32 Suppl
1: S7–15
[3]
Fehrmann F, Laimins LA: Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene.
2003; 22: 5201–5207
5
6
[27]
Snyder SP, Theilen GH: Transmissible feline fibrosarcoma. Nature.
1969; 221: 1074–1075
[28]
Sundberg JP, Van Ranst M, Montali R et al.: Feline papillomas and
papillomaviruses. Vet Pathol. 2000; 37: 1–10
[29]
Zur Hausen H: Papillomavirus infections – a major cause of human
cancers. Biochem Biophys Acta. 1996; 1288: F55–78
[20]
Cotter SM, Hardy WD, Jr., Essex M: Association of feline leukemia
virus with lymphosarcoma and other disorders in the cat. J Am Vet
Med Assoc. 1975; 166: 449–454
[21]
Cotter SM: Feline viral neoplasia. In Greene CE (Hrsg.): Infectious
diseases of the dog and cat. 2. Aufl. Philadelphia: WB Saunders;
1998
[22]
Day MJ, Schoon HA, Magnol JP et al.: A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine. 2007;
25: 4073–4084
[23]
Day NK, OʼReilly-Felice C, Hardy WD, Jr. et al.: Circulating
immune complexes associated with naturally occurring lymphosarcoma in pet cats. J Immunol. 1980; 125: 2363–2366
[24]
Dean R, Adams V, Whitbread T et al.: Study of feline injection site
sarcomas. Vet Rec. 2006; 159: 641–642
[25]
Diehl LJ, Hoover EA: Early and progressive helper T-cell dysfunction
in feline leukemia virus-induced immunodeficiency. J Acquir
Immune Defic Syndr. 1992; 5: 1188–1194
[26]
Donahue PR, Hoover EA, Beltz GA et al.: Strong sequence conservation among horizontally transmissible, minimally pathogenic
feline leukemia viruses. J Virol. 1988; 62: 722–731
2.2 FeLV-assoziierte Tumoren
[1]
Abkowitz JL, Ott RL, Nakamura JM et al.: Feline glucose-6-phosphate dehydrogenase cellular mosaicism. Application to the study
of retrovirus-induced pure red cell aplasia. J Clin Invest. 1985; 75:
133–140
[2]
Abkowitz JL, Holly RD, Adamson JW: Retrovirus-induced feline
pure red cell aplasia: the kinetics of erythroid marrow failure. J Cell
Physiol. 1987; 132: 571–577
[3]
Abkowitz JL: Retrovirus-induced feline pure red blood cell aplasia:
pathogenesis and response to suramin. Blood. 1991; 77: 1442–
1451
[4]
Anderson LJ, Jarrett WF: Membranous glomerulonephritis associated with leukaemia in cats. Res Vet Sci. 1971; 12: 179–180
[5]
Anderson MM, Lauring AS, Burns CC et al.: Identification of a cellular cofactor required for infection by feline leukemia virus.
Science. 2000; 287: 1828–1830
[27]
Dornsife RE, Gasper PW, Mullins JI et al.: Induction of aplastic
anemia by intra-bone marrow inoculation of a molecularly cloned
feline retrovirus. Leuk Res. 1989; 13: 745–755
[6]
Anderson MM, Lauring AS, Robertson S et al.: Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses. J Virol.
2001; 75: 10563–10572
[28]
[7]
Arjona A, Escolar E, Soto I et al.: Seroepidemiological survey of
infection by feline leukemia virus and immunodeficiency virus in
Madrid and correlation with some clinical aspects. J Clin Microbiol.
2000; 38: 3448–3449
Ellis JA, Jackson ML, Bartsch RC et al.: Use of immunohistochemistry and polymerase chain reaction for detection of oncornaviruses in formalin-fixed, paraffin-embedded fibrosarcomas from cats. J
Am Vet Med Assoc. 1996; 209: 767–771
[29]
Arjona A, Barquero N, Domenech A et al.: Evaluation of a novel
nested PCR for the routine diagnosis of feline leukemia virus (FeLV)
and feline immunodeficiency virus (FIV). J Feline Med Surg. 2007; 9:
14–22
Essex M, Snyder SP: Feline oncornavirus-associated cell membrane
antigen. I. Serologic studies with kittens exposed to cell-free materials from various feline fibrosarcomas. J Natl Cancer Inst. 1973; 51:
1007–1012
[30]
Forman LW, Pal-Ghosh R, Spanjaard RA et al.: Identification of
LTR-specific small non-coding RNA in FeLV infected cells. FEBS Lett.
2009; 583: 1386–1390
[31]
Francis DP, Essex M, Hardy WD, Jr.: Excretion of feline leukaemia
virus by naturally infected pet cats. Nature. 1977; 269: 252–254
[32]
Francis DP, Cotter SM, Hardy WD, Jr. et al.: Comparison of viruspositive and virus-negative cases of feline leukemia and lymphoma.
Cancer Res. 1979; 39: 3866–3870
[8]
[9]
Benveniste RE, Todaro GJ: Evolution of C-type viral genes: inheritance of exogenously acquired viral genes. Nature. 1974; 252: 456–
459
[10]
Benveniste RE, Sherr CJ, Todaro GJ: Evolution of type C viral
genes: origin of feline leukemia virus. Science. 1975; 190: 886–888
[11]
Benveniste RE, Todaro GJ: Segregation of RD-114 AND FeL-V-related sequences in crosses between domestic cat and leopard cat.
Nature. 1975; 257: 506–508
[33]
Fujino Y, Satoh H, Hisasue M et al.: Detection of the integrated
feline leukemia viruses in a cat lymphoid tumor cell line by fluorescence in situ hybridization. J Hered. 2003; 94: 251–255
[12]
Blue JT: Myelofibrosis in cats with myelodysplastic syndrome and
acute myelogenous leukemia. Vet Pathol. 1988; 25: 154–160
[34]
[13]
Boomer S, Eiden M, Burns CC et al.: Three distinct envelope
domains, variably present in subgroup B feline leukemia virus
recombinants, mediate Pit1 and Pit2 receptor recognition. J Virol.
1997; 71: 8116–8123
Gleich SE, Krieger S, Hartmann K: Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats
and risk factors for infection in Germany. J Feline Med Surg. 2009;
11: 985–992
[35]
Grosenbaugh DA, Leard T, Pardo MC: Protection from challenge
following administration of a canarypox virus-vectored recombinant
feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine. J Am Vet Med Assoc. 2006; 228: 726–727
[36]
Gryffydd-Jones TJ: A comparative study on effects of canarypox
based recombinant leikaemia vaccine (Eurifel FeLV) against a natural
FeLV challange in cats. Proceedings of the 24th World Small Animal
Association (WSAVA) Congress, Lyon, France. 1999
[37]
Haney SM, Beaver L, Turrel J et al.: Survival analysis of 97 cats
with nasal lymphoma: a multi-institutional retrospective study
(1986–2006). J Vet Intern Med. 2009; 23: 287–294
[14]
Boyce JT, Kociba GJ, Jacobs RM et al.: Feline leukemia virus-induced thrombocytopenia and macrothrombocytosis in cats. Vet
Pathol. 1986; 23: 16–20
[15]
Brightman AH, 2nd, Ogilvie GK, Tompkins M: Ocular disease in
FeLV-positive cats: 11 cases (1981–1986). J Am Vet Med Assoc.
1991; 198: 1049–1051
[16]
Brown MR, Rogers KS: Neutropenia in dogs and cats: a retrospective study of 261 cases. J Am Anim Hosp Assoc. 2001; 37: 131–139
[17]
Brown NO, Patnaik AK, Mooney S et al.: Soft tissue sarcomas in
the cat. J Am Vet Med Assoc. 1978; 173: 744–749
[38]
[18]
Cogan DC, Cotter SM, Kitchen LW: Effect of suramin on serum
viral replication in feline leukemia virus-infected pet cats. Am J Vet
Res. 1986; 47: 2230–2232
Hardy WD, Jr., Hirshaut Y, Hess P: Detection of the feline leukemia virus and other mammalian oncornaviruses by immunofluorescence. Bibl Haematol. 1973; 39: 778–799
[39]
[19]
Comazzi S, Paltrinieri S, Caniatti M et al.: Erythremic myelosis
(AML6er) in a cat. J Feline Med Surg. 2000; 2: 213–215
Hardy WD, Jr., McClelland AJ, Zuckerman EE et al.: Development
of virus non-producer lymphosarcomas in pet cats exposed to FeLV.
Nature. 1980; 288: 90–92
[40]
Hardy WD, Jr.: Hematopoetic tumors of cats. J Am Anim Hosp
Assoc. 1981; 17: 921–940
[41]
[62]
Hardy WD, Jr.: Feline oncoretroviruses. In Levy JK (Hrsg.): The Retroviridae. New York: Plenum Press; 1992: 109–180
Kass PH, Barnes WG, Jr., Spangler WL et al.: Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma
[63]
[42]
Harrus S, Klement E, Aroch I et al.: Retrospective study of 46
cases of feline haemobartonellosis in Israel and their relationships
with FeLV and FIV infections. Vet Rec. 2002; 151: 82–85
Lane SB, Kornegay JN, Duncan JR et al.: Feline spinal lymphosarcoma: a retrospective evaluation of 23 cats. J Vet Intern Med. 1994;
8: 99–104
[64]
[43]
Hartmann K, Gerle K, Leutenegger C et al.: Feline leukemia virus
– most important oncogene in cats? In: Abstracts from the 4th
International Feline Retrovirus Research Symposium. Glasgow, Scotland, UK: 1998
Legendre AM, Mitchener KL, Potgieter LN: Efficacy of a feline leukemia virus vaccine in a natural exposure challenge. J Vet Intern
Med. 1990; 4: 92–98
[65]
Legendre AM, Hawks DM, Sebring R et al.: Comparison of the
efficacy of three commercial feline leukemia virus vaccines in a
natural challenge exposure. J Am Vet Med Assoc. 1991; 199: 1456–
1462
[66]
Levy LS, Lobelle-Rich PA, Overbaugh J et al.: Coincident involvement of flvi-2, c-myc, and novel env genes in natural and experimental lymphosarcomas induced by feline leukemia virus. Virology.
1993; 196: 892–895
[44]
Hartmann K, Werner RM, Egberink H et al.: Comparison of six inhouse tests for the rapid diagnosis of feline immunodeficiency and
feline leukaemia virus infections. Vet Rec. 2001; 149: 317–320
[45]
Hartmann K, Griessmayr P, Schulz B et al.: Quality of different inclinic test systems for feline immunodeficiency virus and feline leukaemia virus infection. J Feline Med Surg. 2007; 9: 439–445
[46]
Hendrick MJ, Goldschmidt MH, Shofer FS et al.: Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical
identification of aluminum. Cancer Res. 1992; 52: 5391–5394
[67]
Louwerens M, London CA, Pedersen NC et al.: Feline lymphoma
in the post-feline leukemia virus era. J Vet Intern Med. 2005; 19:
329–335
[47]
Hendrick MJ, Shofer FS, Goldschmidt MH et al.: Comparison of
1994; 205: 1425–1429
[68]
Lutz H, Castelli I, Ehrensperger F et al.: Panleukopenia-like syndrome of FeLV caused by co-infection with FeLV and feline panleukopenia virus. Vet Immunol Immunopathol. 1995; 46: 21–33
[69]
[48]
Hines DL, Cutting JA, Dietrich DL et al.: Evaluation of efficacy and
safety of an inactivated virus vaccine against feline leukemia virus
infection. J Am Vet Med Assoc. 1991; 199: 1428–1430
Lutz H, Addie D, Belak S et al.: Feline leukaemia. ABCD guidelines
on prevention and management. J Feline Med Surg. 2009; 11: 565–
574
[70]
[49]
Hisasue M, Okayama H, Okayama T et al.: Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes. J Vet
Intern Med. 2001; 15: 471–477
Mackey L: Feline leukaemia virus and its clinical effects in cats. Vet
Rec. 1975; 96: 5–11
[71]
Hofmann-Lehmann R, Cattori V, Tandon R et al.: Vaccination
against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine. 2007; 25: 5531–5539
Macy DW: The potential role and mechanisms of FeLV vaccineinduced neoplasms. Semin Vet Med Surg (Small Anim). 1995; 10:
234–237
[72]
Hofmann-Lehmann R, Cattori V, Tandon R et al.: How molecular
methods change our views of FeLV infection and vaccination. Vet
Mendoza R, Anderson MM, Overbaugh J: A putative thiamine
transport protein is a receptor for feline leukemia virus subgroup A.
J Virol. 2006; 80: 3378–3385
[73]
Hoover EA, Kociba GJ, Hardy WD, Jr. et al.: Erythroid hypoplasia in
cats inoculated with feline leukemia virus. J Natl Cancer Inst. 1974;
53: 1271–1276
Miller AD, Miller DG, Garcia JV et al.: Use of retroviral vectors for
gene transfer and expression. Methods Enzymol. 1993; 217: 581–
599
[74]
Hoover EA, Olsen RG, Hardy WD, Jr. et al.: Horizontal transmission of feline leukemia virus under experimental conditions. J Natl
Cancer Inst. 1977; 58: 443–444
Moore AS, Cotter SM, Frimberger AE et al.: A comparison of
doxorubicin and COP for maintenance of remission in cats with lymphoma. J Vet Intern Med. 1996; 10: 372–375
[75]
Moser M, Burns CC, Boomer S et al.: The host range and interference properties of two closely related feline leukemia variants suggest that they use distinct receptors. Virology. 1998; 242: 366–377
[76]
Neil JC, Fulton R, Rigby M et al.: Feline leukaemia virus: generation
of pathogenic and oncogenic variants. Curr Top Microbiol Immunol.
1991; 171: 67–93
[77]
Nishigaki K, Okuda M, Endo Y et al.: Structure and function of the
long terminal repeats of feline leukemia viruses derived from naturally occurring acute myeloid leukemias in cats. J Virol. 1997; 71:
9823–9827
[50]
[51]
[52]
[53]
[54]
Hoover EA, Mullins JI: Feline Leukemia-Virus Infection and Diseases. J AmVet + Med Assoc. 1991; 199: 1287–1297
[55]
Jarrett O: Antigenic determinants shared by polypeptides of feline
leukaemia virus. Bibl Haematol. 1973; 39: 810–812
[56]
Jarrett O, Laird HM, Hay D: Determinants of the host range of
feline leukaemia viruses. J Gen Virol. 1973; 20: 169–175
[57]
Jarrett O, Russell PH: Differential growth and transmission in cats
of feline leukaemia viruses of subgroups A and B. Int J Cancer. 1978;
21: 466–472
[78]
[58]
Jarrett O, Hardy WD, Jr., Golder MC et al.: The frequency of occurrence of feline leukaemia virus subgroups in cats. Int J Cancer.
1978; 21: 334–337
Ogilvie GK, Tompkins MB, Tompkins WA: Clinical and immunologic aspects of FeLV-induced immunosuppression. Vet Microbiol.
1988; 17: 287–296
[79]
[59]
Jarrett O, Golder MC, Toth S et al.: Interaction between feline leukaemia virus subgroups in the pathogenesis of erythroid hypoplasia.
Int J Cancer. 1984; 34: 283–288
Onions D, Jarrett O, Testa N et al.: Selective effect of feline leukaemia virus on early erythroid precursors. Nature. 1982; 296: 156–
158
[80]
Jarrett W, Jarrett O, Mackey L et al.: Horizontal transmission of
leukemia virus and leukemia in the cat. J Natl Cancer Inst. 1973; 51:
833–841
Overbaugh J, Donahue PR, Quackenbush SL et al.: Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency
disease in cats. Science. 1988; 239: 906–910
[81]
Jordan HL, Grindem CB, Breitschwerdt EB: Thrombocytopenia in
cats: a retrospective study of 41 cases. J Vet Intern Med. 1993; 7:
261–265
Overbaugh J, Riedel N, Hoover EA et al.: Transduction of endogenous envelope genes by feline leukaemia virus in vitro. Nature.
1988; 332: 731–734
[82]
Pardi D, Hoover EA, Quackenbush SL et al.: Selective impairment
of humoral immunity in feline leukemia virus-induced immunodeficiency. Vet Immunol Immunopathol. 1991; 28: 183–200
[60]
[61]
7
8
[83]
Pedersen NC: Feline leukemia virus infection. In Pedersen NC
(Hrsg.): Feline infectious diseases. Santa Barbara, CA: American
Veterinary Publications; 1988
[103] Sand C, Englert T, Egberink H et al.: Evaluation of a new in-clinic
test system to detect feline immunodeficiency virus and feline leukemia virus infection. Vet Clin Pathol. 2010; 39: 210–214
[84]
Pedersen NC: Feline leukemia cirus infection. In Pedersen NC
(Hrsg.): Feline Husbandry, diseases and management in a multiple
cat environment. Goleta, CA: American Veterinary Publications;
1991: 210–221
[104] Sarma PS, Log T: Viral interference in feline leukemia-sarcoma
complex. Virology. 1971; 44: 352–358
[85]
Pedersen NC: Feline leukemia virus infection. In Pedersen NC
(Hrsg.): Feline husbandry, disease and management in the multiple
cat environment. Goleta, CA: American Veterinary Publications;
1991: 210–220
[86]
Pinches MD, Diesel G, Helps CR et al.: An update on FIV and FeLV
test performance using a Bayesian statistical approach. Vet Clin
Pathol. 2007; 36: 141–147
[87]
Quackenbush SL, Donahue PR, Dean GA et al.: Lymphocyte subset alterations and viral determinants of immunodeficiency disease
induction by the feline leukemia virus FeLV-FAIDS. J Virol. 1990; 64:
5465–5474
[88]
Quigley JG, Burns CC, Anderson MM et al.: Cloning of the cellular
receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus
that induces red cell aplasia. Blood. 2000; 95: 1093–1099
[105] Sarma PS, Log T: Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralization tests. Virology.
1973; 54: 160–169
[106] Sarma PS, Log T, Jain D et al.: Differential host range of viruses of
feline leukemia-sarcoma complex. Virology. 1975; 64: 438–446
[107] Sarma PS, Log T, Skuntz S et al.: Experimental horizontal transmission of feline leukemia viruses of subgroups A, B, and C. J Natl Cancer Inst. 1978; 60: 871–874
[108] Schrenzel MD, Higgins RJ, Hinrichs SH et al.: Type C retroviral
expression in spontaneous feline olfactory neuroblastomas. Acta
Neuropathol. 1990; 80: 547–553
[109] Sheets RL, Pandey R, Jen WC et al.: Recombinant feline leukemia
virus genes detected in naturally occurring feline lymphosarcomas.
J Virol. 1993; 67: 3118–3125
[110] Shelton GH, Grant CK, Cotter SM et al.: Feline immunodeficiency
virus and feline leukemia virus infections and their relationships to
lymphoid malignancies in cats: a retrospective study (1968–1988).
J Acquir Immune Defic Syndr. 1990; 3: 623–630
[89]
Reinacher M, Theilen G: Frequency and significance of feline leukemia virus infection in necropsied cats. Am J Vet Res. 1987; 48: 939–
945
[90]
Reinacher M: Infektionen mit felinem Leukämie-Virus (FeLV) bei
sezierten Katzen. Kleintierprax. 1987; 32: 65–72
[111] Shelton GH, Linenberger ML: Hematologic abnormalities associated with retroviral infections in the cat. Semin Vet Med Surg (Small
Anim). 1995; 10: 220–233
[91]
Reinacher M: Diseases associated with spontaneous feline leukemia
virus (FeLV) infection in cats. Vet Immunol Immunopathol. 1989;
21: 85–95
[112] Shimoda T, Shiranaga N, Mashita T et al.: Chronic myelomonocytic leukemia in a cat. J Vet Med Sci. 2000; 62: 195–197
[92]
Richards JR, Elston TH, Ford RB et al.: The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel report. J
Am Vet Med Assoc. 2006; 229: 1405–1441
[113] Snyder HW Jr, Fox M: Characterization of a fetal calf serum-derived
molecule reactive with human natural antibodies: its occurrence in
tissue culture-grown type C RNA viruses. J Immunol. 1978; 120:
646–651
[93]
Rickard CG, Post JE, Noronha F et al.: A transmissible virus-induced lymphocytic leukemia of the cat. J Natl Cancer Inst. 1969; 42:
987–1014
[114] Snyder SP, Theilen GH: Transmissible feline fibrosarcoma. Nature.
1969; 221: 1074–1075
[94]
Riedel N, Hoover EA, Gasper PW et al.: Molecular analysis and
pathogenesis of the feline aplastic anemia retrovirus, feline leukemia virus C-Sarma. J Virol. 1986; 60: 242–250
[115] Stewart MA, Warnock M, Wheeler A et al.: Nucleotide sequences
of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol. 1986; 58: 825–834
[95]
Riedel N, Hoover EA, Dornsife RE et al.: Pathogenic and host
range determinants of the feline aplastic anemia retrovirus. Proc
Natl Acad Sci U S A. 1988; 85: 2758–2762
[116] Stützer B, Muller F, Majzoub M et al.: Role of latent feline leukemia virus infection in nonregenerative cytopenias of cats. J Vet
Intern Med. 2010; 24: 192–197
[96]
Rigby MA, Rojko JL, Stewart MA et al.: Partial dissociation of subgroup C phenotype and in vivo behaviour in feline leukaemia viruses
with chimeric envelope genes. J Gen Virol. 1992; 73 ( Pt 11): 2839–
2847
[117] Stützer B, Simon K, Lutz H et al.: Incidence of persistent viraemia
and latent feline leukaemia virus infection in cats with lymphoma. J
Feline Med Surg. 2011; 13: 81–87
[97]
Roca AL, Pecon-Slattery J, OʼBrien SJ: Genomically intact endogenous feline leukemia viruses of recent origin. J Virol. 2004; 78:
4370–4375
[98]
Roca AL, Nash WG, Menninger JC et al.: Insertional polymorphisms of endogenous feline leukemia viruses. J Virol. 2005; 79:
3979–3986
[99]
Rohn JL, Linenberger ML, Hoover EA et al.: Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors. J Virol. 1994; 68:
2458–2467
[100] Rojko J, Essex M, Trainin Z: Feline leukemia/sarcoma viruses and
immunodeficiency. Adv Vet Sci Comp Med. 1988; 32: 57–96
[101] Rojko J, Hardy WD: Feline leukemia virus and other retroviruses. In
Sherding RG. (Hrsg.): The Cat: Diseases and clinical management.
New York: Churchill Livingstone; 1994: 263–432
[102] Roy-Burman P: Endogenous env elements: partners in generation
of pathogenic feline leukemia viruses. Virus Genes. 1995; 11: 147–
161
[118] Swenson CL, Kociba GJ, OʼKeefe DA et al.: Cyclic hematopoiesis
associated with feline leukemia virus infection in two cats. J Am Vet
Med Assoc. 1987; 191: 93–96
[119] Tailor CS, Willett BJ, Kabat D: A putative cell surface receptor for
anemia-inducing feline leukemia virus subgroup C is a member of a
transporter superfamily. J Virol. 1999; 73: 6500–6505
[120] Tandon R, Cattori V, Willi B et al.: Copy number polymorphism of
endogenous feline leukemia virus-like sequences. Mol Cell Probes.
2007; 21: 257–266
[121] Tandon R, Cattori V, Pepin AC et al.: Association between endogenous feline leukemia virus loads and exogenous feline leukemia
virus infection in domestic cats. Virus Res. 2008; 135: 136–143
[122] Taylor SS, Goodfellow MR, Browne WJ et al.: Feline extranodal
lymphoma: response to chemotherapy and survival in 110 cats. J
[123] Teske E, van Straten G, van Noort R et al.: Chemotherapy with
cyclophosphamide, vincristine, and prednisolone (COP) in cats with
malignant lymphoma: new results with an old protocol. J Vet Intern
Med. 2002; 16: 179–186
[124] Testa NG, Onions D, Jarrett O et al.: Haemopoietic colony formation (BFU-E, GM-CFC) during the development of pure red cell
hypoplasia induced in the cat by feline leukaemia virus. Leuk Res.
1983; 7: 103–116
[13]
De Nardo P: [Veterinary environmental epidemiology: the case of
respiratory pathology in the dog] Ann Ist Super Sanita. 1997; 33:
587–593
[14]
[125] Torres AN, OʼHalloran KP, Larson LJ et al.: Development and application of a quantitative real-time PCR assay to detect feline leukemia virus RNA. Vet Immunol Immunopathol. 2008; 123: 81–89
Dennis MM, Ehrhart N, Duncan CG et al.: Frequency of and risk
factors associated with lingual lesions in dogs: 1,196 cases (1995–
2004). J Am Vet Med Assoc. 2006; 228: 1533–1537
[15]
[126] Tsujimoto H, Fulton R, Nishigaki K et al.: A common proviral
integration region, fit-1, in T-cell tumors induced by myc-containing
feline leukemia viruses. Virology. 1993; 196: 845–848
Edwards DS, Henley WE, Harding EF et al.: Breed incidence of
lymphoma in a UK population of insured dogs. Vet Comp Oncol.
2003; 1: 200–206
[16]
[127] Tuomari DL, Olsen RG, Singh VK et al.: Detection of circulating
immune complexes by a Clq/protein A-ELISA during the preneoplastic stages of feline leukemia virus infection. Vet Immunol Immunopathol. 1984; 7: 227–238
Egenvall A, Bonnett BN, Hedhammar A et al.: Mortality in over
350,000 insured Swedish dogs from 1995–2000: II. Breed-specific
age and survival patterns and relative risk for causes of death. Acta
Vet Scand. 2005; 46: 121–136
[17]
[128] Vail DM, Moore AS, Ogilvie GK et al.: Feline lymphoma (145
cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. J Vet
Intern Med. 1998; 12: 349–354
Egenvall A, Bonnett BN, Ohagen P et al.: Incidence of and survival
after mammary tumors in a population of over 80,000 insured
female dogs in Sweden from 1995 to 2002. Prev Vet Med. 2005;
69: 109–127
[18]
[129] Willi B, Filoni C, Catao-Dias JL et al.: Worldwide occurrence of
feline hemoplasma infections in wild felid species. J Clin Microbiol.
2007; 45: 1159–1166
Egenvall A, Bonnett BN, Olson P et al.: Gender, age and breed
and distribution of morbidity and mortality in insured dogs in Sweden during 1995 and 1996. Vet Rec. 2000; 146: 519–525
[19]
[130] Wittmer G: Statistische Untersuchungen zur Infektion mit dem
Felinen Leukämievirus (FeLV) bei Sektionskatzen. Dissertation Institut für Veterinär-Pathologie, Justus-Liebig-Universität. Gießen: 1995
Egenvall A, Bonnett BN, Olson P et al.: Gender, age and breed
pattern of diagnoses for veterinary care in insured dogs in Sweden
during 1996. Vet Rec. 2000; 146: 551–557
[20]
Egenvall A, Bonnett BN, Shoukri M et al.: Age pattern of mortality
in eight breeds of insured dogs in Sweden. Prev Vet Med. 2000; 46:
1–14
3
Epidemiologie von Tumorerkrankungen bei
Hund und Katze
[21]
Egenvall A, Nødtvedt A, Häggström J et al.: Mortality of life-insured Swedish cats during 1999–2006: age, breed, sex, and diagnosis.
J Vet Intern Med. 2009; 23: 1175–1183
[1]
Adams VJ, Evans KM, Sampson J et al.: Methods and mortality
results of a health survey of purebred dogs in the UK. J Small Anim
Pract. 2010; 51: 512–524
[22]
Egenvall A, Nødtvedt A, Penell J et al.: Insurance data for research
in companion animals: benefits and limitations. Acta Vet Scand.
2009; 51: 42
[2]
Arnesen K, Gamlem H, Glattre E et al.: [Registration of canine cancer]. Tidsskr Nor Laegeforen. 1995; 115: 714–717
[23]
[3]
Bonnett BN, Egenvall A, Hedhammar A et al.: Mortality in over
350,000 insured Swedish dogs from 1995–2000: I. Breed-, gender-,
age- and cause-specific rates. Acta Vet Scand. 2005; 46(3): 105–
120
Egenvall A, Nødtvedt A, von Euler H: Bone tumors in a population
of 400 000 insured Swedish dogs up to 10 y of age: incidence and
survival. Can J Vet Res. 2007; 71: 292–299
[24]
Gamlem H, Nordstoga K, Glattre E: Canine neoplasia–introductory
paper. APMIS Suppl. 2008; 125: 5–18
[25]
[4]
Bonnett BN, Egenvall A, Olson P et al.: Mortality in insured Swedish dogs: rates and causes of death in various breeds. Vet Rec.
1997; 141: 40–44
Gardner DG: Spontaneous squamous cell carcinomas of the oral
region in domestic animals: a review and consideration of their
relevance to human research. Oral Dis 1996; 2(2): 148–154
[26]
[5]
Brønden LB, Nielsen SS, Toft N et al.: Data from the Danish veterinary cancer registry on the occurrence and distribution of neoplasms in dogs in Denmark. Vet Rec. 2010; 166: 586–590
Glickman L, Domanski L, Maguire T et al.: Mesothelioma in pet
dogs associated with exposure of their owners to asbestos. Environ
Res. 1983; 32: 305–313
[27]
[6]
Bronson RT: Variation in age at death of dogs of different sexes and
breeds. Am J Vet Res. 1982; 43: 2057–2059
Glickman LT, McKnee LJ, Shofer FS et al.: Epidemiologic study of
insecticide exposures, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health. 1989; 28: 407–414
[7]
Bryan JN, Keeler MR, Henry CJ et al.: A population study of neutering status as a risk factor for canine prostate cancer. Prostate.
2007; 67: 1174–1181
[28]
Glickman LT, Raghavan M, Knapp DW et al.: Herbicide exposure
and the risk of transitional cell carcinoma of the urinary bladder in
Scottish Terriers. J Am Vet Med Assoc. 2004; 224: 1290–1297
[8]
Bukowski JA, Wartenberg D: An alternative approach for investigating the carcinogenicity of indoor air pollution: pets as sentinels
of environmental cancer risk. Environ Health Perspect. 1997; 105:
1312–1319
[29]
Gobar GM, Case JT, Kass PH: Program for surveillance of causes of
death of dogs, using the internet to survey small animal veterinarians. J Am Vet Med Assoc. 1998; 213: 252–256
[30]
[9]
Cohen D, Booth S, Sussman O: An epidemiological study of canine
lymphoma and its public health significance. Am J Vet Res. 1959;
20: 1026–1031
Goldschmidt MH, Shofer FS: Skin tumors of the dog and cat. New
York, New York: Pergamon Press, 1992
[31]
Gough A, Thomas A: Rassedispositionen bei Hund und Katze.
Urban & Fischer / Elsevier GmbH, 2009
[10]
Cohen D, Reif JS, Brodney RS: Epidemiological analysis of the most
prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Research. 1974; 34: 2859–2868
[32]
Hayes HM Jr., Hoover R, Tarone RE: Bladder cancer in pet dogs: a
sentinel for environmental cancer? Am J Epidemiol. 1981; 114:
229–233
[11]
Committee on Animals as Monitors of Environmental Hazards,
Board on Environmental Studies and Toxicology, National
Research Council (Hrsg.): Animals as Sentinels of Environmental
Health Hazard. National Academy Press, Washington, 1991
[33]
Hayes H: Canine bladder cancer: Epidemiologic features. Am J Epidemiol. 1976; 104: 673–677
[34]
Heuper WC, Wiley FH, Wolfe HD: Experimental production of
bladder tumors in dogs by administration of beta-naphthylamine. J
Industr Hyg Toxicol. 1938; 20: 46–84
[12]
Craig LE: Cause of death in dogs according to breed: a necropsy
survey of five breeds. J Am Anim Hosp Assoc. 2001; 37: 438–443
9
10
[35]
Howard EB, Nielsen SE: Neoplasia of the boxer dog. Am J Vet Res.
1965; 26: 1121–1131
[36]
Kelsey JL, Moore AS, Glickman LT: Epidemiologic studies of risk
factors for cancer in pet dogs. Epidemiol Rev. 1998; 20: 204–217
[37]
Kessler M, von Bomhard D: Beitrag zur pädiatrischen Onkologie
beim Kleintier. Berl Münch Tierärztl Wochenschr. 1997; 110: 311–
314
[38]
Knapp DW, Glickman NW, DeNickola DB et al.: Naturally occurring canine transitional cell carcinoma of the urinary bladder: a relevant model of human invasive bladder cancer. Urol Oncol. 2000; 5:
47–59
[39]
Madewell BR, Priester WA, Gillette EL et al.: Neoplasms of the
nasal passages and paranasal sinuses in domesticated animals as
reported by 13 veterinary colleges. Am J Vet Res. 1976; 37: 851–
856
[40]
[41]
[58]
Rostami M, Tateyama S, Uchida K et al.: Tumors in domestic animals examined during a ten-year period (1980 to 1989) at Miyazaki
University. J Vet Med Sci. 1994; 56: 403–405
[59]
Santoro D, Marsella R, Hernandez J: Investigation on the association between atopic dermatitis and the development of mycosis
fungoides in dogs: a retrospective case-control study. Vet Dermatol.
2007; 18: 101–106
[60]
Schmidt JM, North SM, Freeman KP et al.: Canine paediatric
oncology: retrospective assessment of 9522 tumours in dogs up to
12 months (1993–2008). Vet Comp Oncol. 2010; 8: 283–292
[61]
Schneider R: Epidemiologic studies of cancer in man and animals
sharing the same environment. In: Proc. 3rd Int. symposium of the
detection and prevention of cancer. New York: 1976; 1377–1387
[62]
Mandigers PJ, Senders T, Rothuizen J: Morbidity and mortality in
928 Dobermanns born in the Netherlands between 1993 and 1999.
Vet Rec. 2006; 158: 226–229
Snyder JM, Shofer FS, Van Winkle TJ et al.: Canine intracranial primary neoplasia: 173 cases (1986–2003). J Vet Intern Med. 2006; 20
(3): 669–675
[63]
Michell AR: Longevity of British breeds of dog and its relationships
with sex, size, cardiovascular variables and disease. Vet Rec. 1999;
145: 625–629
Snyder LA, Bertone ER, Jakowski RM et al.: p53 expression and
carcinoma. Vet Pathol. 2004; 209–214
[64]
Vaccine-associated feline sarcoma task force: http: //www.avma.
org/vafstf
[42]
Misdorp W: Tumors of the mammary gland. In: Meuten DJ (Hrsg.):
Tumors in domestic animals, 4. Aufl. Ames, Iowa: Blackwell Publishing; 2002: 575–606
[65]
Vascellari M, Baioni E, Ru G et al.: Animal tumour registry of two
provinces in northern Italy: incidence of spontaneous tumours in
dogs and cats. BMC Vet Res. 2009; 5: 39
[43]
Moe L, Gamlem H, Dahl K et al.: Canine neoplasia–populationbased incidence of vascular tumours. APMIS Suppl. 2008; 125: 63–
68
[66]
[44]
Moe L: Population-based incidence of mammary tumours in some
dog breeds. J Reprod Fertil Suppl. 2001; 57: 439–443
von Bomhard D, von Bomhard W: Tumoren und tumorähnliche
Bildungen. In: Kraft W, Dürr DM, Hartmann K (Hrsg.): Katzenkrankheiten. 2. Bd.. Klinik und Therapie, 5. Aufl. Hannover: Schaper;
2003: 1191–1278
[67]
[45]
Moore GE, Burkman KD, Carter MN et al.: Causes of death or reason for euthanasia in military working dogs: 927 cases (1993–
1996). J Am Vet Med Assoc. 2001; 219: 209–214
Von Bomhard D: Epidemiologie. In: Nolte I, Nolte M (Hrsg.): Praxis
der Onkologie bei Hund und Katze. Stuttgart: Enke Verlag, 2000
[68]
Weeth LP, Fascetti AJ, Kass PH et al.: Prevalence of obese dogs in
a population of dogs with cancer. Am J Vet Res. 2007; 68: 389–398
[69]
Weiß C: Basiswissen medizinische Statistik, 3. Aufl. Heidelberg.
Springer Medizin Verlag, 2005
4
Paraneoplastische Syndrome
[1]
Ali N, Abbasi AN, Karsan F et al.: A case of finger clubbing associated with nasopharyngeal carcinoma in a young girl, and review of
pathophysiology. J Pak Med Assoc. 2009; 59: 253–254
[2]
Allenspach K, Arnold P, Glaus T et al.: Glucagon-producing neuroendocrine tumour associated with hypoaminoacidaemia and skin
lesions. J Small Anim Pract. 2000; 41: 402–406
[3]
Alpers CE, Cotran RS.: Neoplasia and glomerular injury. Kidney Int.
1986; 30: 465–473
[4]
Anderson TE, Legendre AM, McEntee MM: Probable hypercalcemia of malignancy in a cat with bronchogenic adenocarcinoma. J
[46]
Nielsen L, Andreasen SN, Andersen SD et al.: Malignant histiocytosis and other causes of death in Bernese mountain dogs in Denmark. Vet Rec. 2010; 166: 199–202
[47]
Peterson MR, Frommelt RA, Dunn DG: A study of the lifetime
occurrence of neoplasia and breed differences in a cohort of German shephard dogs and Belgian malinois military working dogs
that died in 1992. J Vet Intern Med. 2000; 14: 140–145
[48]
Priester WA, Mantel N: Occurrence of tumors in domestic animals: data form 12 United States colleges of veterinary medicine. J
Natl Cancer Inst. 1971; 47: 1333–1344
[49]
Priester WA: Canine lymphoma: Relative risk in the boxer breed. J
Natl Cancer Inst. 1967; 39: 833–845
[50]
Priester WA: Skin tumors in domestic animals: data from 12 United
States and Canadian colleges of veterinary medicine. J Natl Cancer
Inst. 1973; 50: 457–466
[51]
Proschowsky HF, Rugbjerg H, Ersboo AK: Morbidity of purebred
dogs in Denmark. Prev Vet Med. 2003; 58: 53–62
[52]
Proschowsky HF, Rugbjerg H, Ersboo AK: Mortality of purebred
and mixed-breed dogs in Denmark. Prev Vet Med. 2003; 58: 63–74
[5]
Argiles JM, Alvarez B, Lopez-Soriano FJ: The metabolic basis of
cancer cachexia. Med Res Rev. 1997; 17: 477–498
[53]
Raghavan M, Knapp DW., Dawson MH et al.: Topical flea and tick
pesticides and the risk of transitional cell carcinoma of the urinary
bladder in Scottish Terriers. J Am Vet Med Assoc. 2004; 225: 389–
394
[6]
Argiles JM, Olivan M, Busquets S et al.: Optimal management of
cancer anorexia-cachexia syndrome. Cancer Manag Res. 2010; 2:
27–38
[7]
[54]
Ragland WL, Gorham JH: Tonsillar carcinoma in rural dogs. Nature.
1967; 214: 925–926
Atkinson S, Fox SB: Vascular endothelial growth factor (VEGF)-A
and platelet-derived growth factor (PDGF) play a central role in the
pathogenesis of digital clubbing. J Pathol. 2004; 203: 721–728
[55]
Reif JS, Bruns D, Lower KS: Cancer of the nasal cavity and paranasal sinuses and exposure to environmental tabacco smoke in pet
dogs. Am J Epidemiol. 1998; 147: 488–492
[8]
Atlee BA, DeBoer DJ, Ihrke PJ: Nodular dermatofibrosis in German
Shepard dogs as a marker for renal cystadenocarcinoma. J Am Anim
Hosp Assoc. 1991; 27: 1991
[56]
Reif JS, Dunn K, Ogilvie GK et al.: Passive smoking and canine lung
cancer risk. Am J Epidemiol. 1992; 135: 324–329
[9]
Atwater SW, Powers BE, Park RD et al.: Thymoma in dogs: 23
cases (1980–1991). J Am Vet Med Assoc. 1994; 205: 1007–1013
[57]
Reif JS: The Epidemiology and incidence of cancer. In: Withrow SJ,
Vail DM (Hrsg.): Withrow and MacEwan’s Small animal clinical oncology. St. Louis, Missouri: Saunders; 2007: 68–76
[10]
Baijens LW, Manni JJ: Paraneoplastic syndromes in patients with
primary malignancies of the head and neck. Four cases and a review
of the literature. Eur Arch Otorhinolaryngol. 2006; 263: 32–36
[11]
Barrs VR, Beatty JA, McCandlish IA et al.: Hypereosinophilic paraneoplastic syndrome in a cat with intestinal T cell lymphosarcoma. J
[35]
Fossum TW, Wellman M, Relford RL et al.: Eosinophilic pleural or
peritoneal effusions in dogs and cats: 14 cases (1986–1992). J Am
Vet Med Assoc. 1993; 202: 1873–1876
[12]
Barthez PY, Marks SL, Woo J et al.: Pheochromocytoma in dogs:
61 cases (1984–1995). J Vet Intern Med. 1997; 11: 272–278
[36]
[13]
Battaglia L, Petterino C, Zappulli V et al.: Hypoglycaemia as a
paraneoplastic syndrome associated with renal adenocarcinoma in
a dog. Vet Res Commun. 2005; 29: 671–675
Fox LE, Rosenthal RC, Twedt DC et al.: Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern
Med. 1990; 4: 242–246
[37]
Bergman PJ: Paraneoplastic syndromes In: Withrow SJ, MacEwen
EG (Hrsg.) Small Animal Clinical Oncology. 4. Aufl. St. Louis: Saunders, 2007
Gilbert PA, Griffin CE, Walder EJ: Nodular dermatofibrosis and
renal cystadenoma in a German Shepherd dog. J Am Anim Hosp
Assoc. 1990; 26: 253–256
[38]
Boyiadis M, Lieberman FS, Geskin LJ et al.: Paraneoplastic Syndromes In: DeVita VT, Lawrence TS, Rosenberg SA (Hrsg.) Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott W&W, 2011
Giraudel JM, Pages JP, Guelfi JF: Monoclonal gammopathies in the
dog: a retrospective study of 18 cases (1986–1999) and literature
review. J Am Anim Hosp Assoc. 2002; 38: 135–147
[39]
Gores BR, Berg J, Carpenter JL et al.: Surgical treatment of thymoma in cats: 12 cases (1987–1992). J Am Vet Med Assoc. 1994;
204: 1782–1785
[40]
Gorse MJ: Polycythemia associated with renal fibrosarcoma in a
dog. J Am Vet Med Assoc. 1988; 192: 793–794
[41]
Green AR: 5-HT-mediated behavior. Animal studies. Neuropharmacology. 1984; 23: 1521–1528
[42]
Greenlee PG, Filippa DA, Quimby FW et al.: Lymphomas in dogs.
A morphologic, immunologic, and clinical study. Cancer. 1990; 66:
480–490
[43]
Grill V, Ho P, Body JJ et al.: Parathyroid hormone-related protein:
elevated levels in both humoral hypercalcemia of malignancy and
hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab. 1991; 73: 1309–1315
[14]
[15]
[16]
Braund KG: Remote effects of cancer on the nervous system.
Semin Vet Med Surg (Small Anim). 1990; 5: 262–270
[17]
Braund KG, Everett RM, Bartels JE et al.: Neurologic complications
of IgA multiple myeloma associated with cryoglobulinemia in a
[18]
Braund KG, Steiss JE, Amling KA et al.: Insulinoma and subclinical
peripheral neuropathy in two dogs. J Vet Intern Med. 1987; 1: 86–90
[19]
Byrne KP: Metabolic epidermal necrosis-hepatocutaneous syndrome. Vet Clin North Am Small Anim Pract. 1999; 29: 1337–1355
[20]
Chew DJ, Meuten DJ: Disorders of calcium and phosphorus metabolism. Vet Clin North Am Small Anim Pract. 1982; 12: 411–438
[21]
Chinn DR, Myers RK, Matthews JA: Neutrophilic leukocytosis associated with metastatic fibrosarcoma in a dog. J Am Vet Med Assoc.
1985; 186: 806–809
[44]
Cohen M, Post GS: Nephrogenic diabetes insipidus in a dog with
intestinal leiomyosarcoma. J Am Vet Med Assoc. 1999; 215:1818–
1820, 1806
Grindem CB, Breitschwerdt EB, Corbett WT et al.: Thrombocytopenia associated with neoplasia in dogs. J Vet Intern Med. 1994; 8:
400–405
[45]
Couto CG: Tumor-associated eosinophilia in a dog. J Am Vet Med
Assoc. 1984; 184: 837
Gross TL, Song MD, Havel PJ et al.: Superficial necrolytic dermatitis (necrolytic migratory erythema) in dogs. Vet Pathol. 1993; 30:
75–81
[46]
Couto CG, Boudrieau RJ, Zanjani ED: Tumor-associated erythrocytosis in a dog with nasal fibrosarcoma. J Vet Intern Med. 1989; 3:
183–185
Hanna F: Multiple myelomas in cats. J Feline Med Surg. 2005; 7:
275–287
[47]
Heber D, Byerley LO, Chi J et al.: Pathophysiology of malnutrition
in the adult cancer patient. Cancer. 1986; 58: 1867–1873
[22]
[23]
[24]
[25]
de Beukelaar JW, Sillevis Smitt PA: Managing paraneoplastic neurological disorders. Oncologist. 2006; 11: 292–305
[48]
Herrera MF, Stone E, Deitel M et al.: Pheochromocytoma producing multiple vasoactive peptides. Arch Surg. 1992; 127: 105–108
[26]
Degen MA, Feldman BF, Turrel JM et al.: Thrombocytosis associated with a myeloproliferative disorder in a dog. J Am Vet Med
Assoc. 1989; 194: 1457–1459
[49]
[27]
Dole RS, MacPhail CM, Lappin MR: Paraneoplastic leukocytosis
with mature neutrophilia in a cat with pulmonary squamous cell
carcinoma. J Feline Med Surg. 2004; 6: 391–395
Hickford FH, Stokol T, van Gessel YA et al.: Monoclonal immunoglobulin G cryoglobulinemia and multiple myeloma in a domestic
shorthair cat. J Am Vet Med Assoc. 2000; 217: 1029–1033, 1007–
1028
[50]
Dyer KR: Hypoglycemia: a common metabolic manifestation of
cancer. Vet Med. 1992; 87: 40, 42–47
Hogan DF, Dhaliwal RS, Sisson DD et al.: Paraneoplastic thrombocytosis-induced systemic thromboembolism in a cat. J Am Anim
Hosp Assoc. 1999; 35: 483–486
[51]
Hostutler RA, Chew DJ, Jaeger JQ et al.: Uses and effectiveness of
pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med. 2005; 19: 29–33
[52]
Howard J, Senior DF: Cachexia and nutritional issues in animals
with cancer. J Am Vet Med Assoc. 1999; 214: 632–637
[53]
Hurtado J, Esbrit P: Treatment of malignant hypercalcaemia.
Expert Opin Pharmacother. 2002; 3: 521–527
[54]
Hurvitz AI, MacEwen EG, Middaugh CR et al.: Monoclonal cryoglobulinemia with macroglobulinemia in a dog. J Am Vet Med
Assoc. 1977; 170: 511–513
[28]
[29]
Ehrlein J, Hänichen W, Herrmanns W: Hämorrhagische Diathese bei
Hündinnen mit Mammatumoren. Tierärztl Prax. 1997; 25: 469–471
[30]
Fan TM, de Lorimier LP, Charney SC et al.: Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with
primary or secondary bone involvement. J Vet Intern Med. 2005;
19: 74–80
[31]
Fearon KC, Barber MD, Moses AG: The cancer cachexia syndrome.
Surg Oncol Clin N Am. 2001; 10: 109–126
[32]
Feldman BF, Madewell BR, OʼNeill S: Disseminated intravascular
coagulation: antithrombin, plasminogen, and coagulation abnormalities in 41 dogs. J Am Vet Med Assoc. 1981; 179: 151–154
[55]
Forrester SD, Greco DS, Relford RL: Serum hyperviscosity syndrome associated with multiple myeloma in two cats. J Am Vet Med
Assoc. 1992; 200: 79–82
Ishiguro T, Kadosawa T, Takagi S et al.: Relationship of disease
progression and plasma histamine concentrations in 11 dogs with
mast cell tumors. J Vet Intern Med. 2003; 17: 194–198
[56]
Jonasdottir TJ, Mellersh CS, Moe L et al.: Genetic mapping of a
naturally occurring hereditary renal cancer syndrome in dogs. Proc
Natl Acad Sci USA. 2000; 97: 4132–4137
[57]
Joseph RJ, Carrillo JM, Lennon VA: Myasthenia gravis in the cat. J
Vet Intern Med. 1988; 2: 75–79
[33]
[34]
Forster-Van Hijfte MA, Curtis CF, White RN: Resolution of exfoliative dermatitis and Malassezia pachydermatis overgrowth in a cat
after surgical thymoma resection. J Small Anim Pract. 1997; 38:
451–454
11
12
[58]
Kadar E, Rush JE, Wetmore L et al.: Electrolyte disturbances and
cardiac arrhythmias in a dog following pamidronate, calcitonin, and
furosemide administration for hypercalcemia of malignancy. J Am
Anim Hosp Assoc. 2004; 40: 75–81
[59]
Keller ET: Immune-mediated disease as a risk factor for canine lymphoma. Cancer. 1992; 70: 2334–2337
[60]
Khanna C, Lund EM, Redic KA et al.: Randomized controlled trial
of doxorubicin versus dactinomycin in a multiagent protocol for
treatment of dogs with malignant lymphoma. J Am Vet Med Assoc.
1998; 213: 985–990
[61]
Kiebanow ER: Thymoma and aquired myasthenia gravis in the dog:
a case report and review of 13 additional cases. J Am Anim Hosp
Assoc. 1992; 28: 62–69
[62]
Klausner JS, Bell FW, Hayden DW et al.: Hypercalcemia in two
cats with squamous cell carcinomas. J Am Vet Med Assoc. 1990;
196: 103–105
[63]
[64]
[79]
Marconato L, Albanese F, Viacava P et al.: Paraneoplastic alopecia
associated with hepatocellular carcinoma in a cat. Vet Dermatol.
2007; 18: 267–271
[80]
Maruyama H, Miura T, Sakai M et al.: The incidence of disseminated intravascular coagulation in dogs with malignant tumor. J Vet
Med Sci. 2004; 66: 573–575
[81]
Matus RE, Leifer CE, MacEwen EG et al.: Prognostic factors for
multiple myeloma in the dog. J Am Vet Med Assoc. 1986; 188:
1288–1292
[82]
Mauricio O, Francis L, Athar U et al.: Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to
bisphosphonates. J Thorac Oncol. 2009; 4: 260–262
[83]
McKinlay AW: Nutritional support in patients with advanced cancer: permission to fall out? Proc Nutr Soc. 2004; 63: 431–435
[84]
Kleiter M, Hirt R, Kirtz G et al.: Hypercalcaemia associated with
chronic lymphocytic leukaemia in a Giant Schnauzer. Aust Vet J.
2001; 79: 335–338
Messinger JS, Windham WR, Ward CR: Ionized hypercalcemia in
dogs: a retrospective study of 109 cases (1998–2003). J Vet Intern
Med. 2009; 23: 514–519
[85]
Kozak KR, Milne GL, Morrow JD et al.: Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclooxygenase-2-derived prostaglandin E2. Nat Clin Pract Rheumatol.
2006; 2: 452–456; quiz following 456
Meuten DJ, Chew DJ, Capen CC et al.: Relationship of serum total
calcium to albumin and total protein in dogs. J Am Vet Med Assoc.
1982; 180: 63–67
[86]
Michel KE, Sorenmo K, Shofer FS: Evaluation of body condition
and weight loss in dogs presented to a veterinary oncology service.
J Vet Intern Med. 2004; 18: 692–695
[87]
Miller WH: Cutaneous flushing associated with intrathoracic neoplasia in a dog. J Am Anim Hosp Assoc. 1992; 28: 217–219
[88]
Milner RJ, Farese J, Henry CJ et al.: Bisphosphonates and cancer. J
Vet Intern Med. 2004; 18: 597–604
[89]
Moe L, Lium B: Hereditary multifocal renal cystadenocarcinomas
and nodular dermatofibrosis in 51 German shepherd dogs. J Small
Anim Pract. 1997; 38: 498–505
[90]
Moore AS, Madewell BR, Cardinet GH 3rd et al.: Osteogenic sarcoma and myasthenia gravis in a dog. J Am Vet Med Assoc. 1990;
197: 226–227
[91]
Mundy GR, Bertolini DR: Bone destruction and hypercalcemia in
plasma cell myeloma. Semin Oncol. 1986; 13: 291–299
[92]
Muscaritoli M, Bossola M, Bellantone R et al.: Therapy of muscle
wasting in cancer: what is the future? Curr Opin Clin Nutr Metab
Care. 2004; 7: 459–466
[93]
Nelson RW, Hager D, Zanjani ED: Renal lymphosarcoma with inappropriate erythropoietin production in a dog. J Am Vet Med Assoc.
1983; 182: 1396–1397
[94]
Nishi Y, Yufu Y, Shinomiya S et al.: Polyneuropathy in acute megakaryoblastic leukemia. Cancer. 1991; 68: 2033–2036
[95]
Ogilvie GK, Ford RB, Vail DM et al.: Alterations in lipoprotein profiles in dogs with lymphoma. J Vet Intern Med. 1994; 8: 62–66
[96]
Ogilvie GK, Vail DM, Wheeler SL et al.: Effects of chemotherapy
and remission on carbohydrate metabolism in dogs with lymphoma. Cancer. 1992; 69: 233–238
[97]
Ogilvie GK, Walters L, Salman MD et al.: Alterations in carbohydrate metabolism in dogs with nonhematopoietic malignancies. Am J
Vet Res. 1997; 58: 277–281
[98]
Ogilvie GK, Walters LM, Salman MD et al.: Resting energy expenditure in dogs with nonhematopoietic malignancies before and
after excision of tumors. Am J Vet Res. 1996; 57: 1463–1467
[99]
Osborne CA, Perman V, Sautter JH et al.: Multiple myeloma in the
[65]
Krotje LJ, Fix AS, Potthoff AD: Acquired myasthenia gravis and
cholangiocellular carcinoma in a dog. J Am Vet Med Assoc. 1990;
197: 488–490
[66]
Lainesse MF, Taylor SM, Myers SL et al.: Focal myasthenia gravis
as a paraneoplastic syndrome of canine thymoma: improvement
following thymectomy. J Am Anim Hosp Assoc. 1996; 32: 111–117
[67]
Langer CJ, Hoffman JP, Ottery FD: Clinical significance of weight
loss in cancer patients: rationale for the use of anabolic agents in
the treatment of cancer-related cachexia. Nutrition. 2001; 17: S1–
20
[68]
Lappin MR, Latimer KS: Hematuria and extreme neutrophilic leukocytosis in a dog with renal tubular carcinoma. J Am Vet Med
Assoc. 1988; 192: 1289–1292
[69]
Lee JC, Yamauchi H, Hopper J Jr.: The association of cancer and the
nephrotic syndrome. Ann Intern Med. 1966; 64: 41–51
[70]
Leifer CE, Peterson ME, Matus RE et al.: Hypoglycemia associated
with nonislet cell tumor in 13 dogs. J Am Vet Med Assoc. 1985;
186: 53–55
[71]
[72]
Lium B, Moe L: Hereditary multifocal renal cystadenocarcinomas
and nodular dermatofibrosis in the German shepherd dog: macroscopic and histopathologic changes. Vet Pathol. 1985; 22: 447–455
[73]
Lumachi F, Brunello A, Roma A et al.: Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem. 2008; 15: 415–
421
[74]
Lurye JC, Behrend EN: Endocrine tumors. Vet Clin North Am Small
Anim Pract. 2001; 31: 1083–1110, ix–x
[75]
MacEwen EG, Hurvitz AI: Diagnosis and management of monoclonal gammopathies. Vet Clin North Am. 1977; 7: 119–132
[76]
MacEwen EG, Patnaik AK, Hurvitz AI et al.: Nonsecretory multiple
myeloma in two dogs. J Am Vet Med Assoc. 1984; 184: 1283–1286
[77]
Madewell BR, Feldman BF: Characterization of anemias associated
with neoplasia in small animals. J Am Vet Med Assoc. 1980; 176:
419–425
[78]
Madewell BR, Wilson DW, Hornof WJ et al.: Leukemoid blood
response and bone infarcts in a dog with renal tubular adenocarcinoma. J Am Vet Med Assoc. 1990; 197: 1623–1625
[100] Page RL, Stiff ME, McEntee MC et al.: Transient glomerulonephropathy associated with primary erythrocytosis in a dog. J Am Vet
Med Assoc. 1990; 196: 620–622
[101] Patel RT, Caceres A, French AF et al.: Multiple myeloma in 16 cats:
a retrospective study. Vet Clin Pathol. 2005; 34: 341–352
13
[102] Peeters D, Clercx C, Thiry A et al.: Resolution of paraneoplastic
leukocytosis and hypertrophic osteopathy after resection of a renal
transitional cell carcinoma producing granulocyte-macrophage
colony-stimulating factor in a young Bull Terrier. J Vet Intern Med.
2001; 15: 407–411
[125] Stockhaus C, Kohn B, Giger U: Gerinnungsstörungen bei Hunden
mit Neoplasien: Fallbeispiele und Literaturübersicht. Kleintierprax.
1998; 43: 759–770
[103] Pelosof LC, Gerber DE: Paraneoplastic syndromes: an approach to
diagnosis and treatment. Mayo Clin Proc. 2010; 85: 838–854
[126] Strasser F, Bruera ED: Update on anorexia and cachexia. Hematol
Oncol Clin North Am. 2002; 16: 589–617
[104] Peterson ME, Zanjani ED: Inappropriate erythropoietin production
from a renal carcinoma in a dog with polycythemia. J Am Vet Med
Assoc. 1981; 179: 995–996
[127] Tasker S, Griffon DJ, Nuttall TJ et al.: Resolution of paraneoplastic
alopecia following surgical removal of a pancreatic carcinoma in a
cat. J Small Anim Pract. 1999; 40: 16–19
[105] Pressler BM, Rotstein DS, Law JM et al.: Hypercalcemia and high
parathyroid hormone-related protein concentration associated with
malignant melanoma in a dog. J Am Vet Med Assoc. 2002; 221:
263–265, 240
[128] Tepper LC, Spiegel IB, Davis GJ: Diagnosis of erythema multiforme
associated with thymoma in a dog and treated with thymectomy. J
Am Anim Hosp Assoc. 2011 ; 47: e19–25
[107] Ramaiah SK, Seguin MA, Carwile HF et al.: Biclonal gammopathy
associated with immunoglobulin A in a dog with multiple myeloma.
Vet Clin Pathol. 2002; 31: 83–89
[108] Ridyard AE, Rhind SM, French AT et al.: Myasthenia gravis associated with cutaneous lymphoma in a dog. J Small Anim Pract. 2000;
41: 348–351
[109] Rottenberg S, von Tscharner C, Roosje PJ: Thymoma-associated
exfoliative dermatitis in cats. Vet Pathol. 2004; 41: 429–433
[110] Rozanski EA, Callan MB, Hughes D et al.: Comparison of platelet
count recovery with use of vincristine and prednisone or prednisone
alone for treatment for severe immune-mediated thrombocytopenia in dogs. J Am Vet Med Assoc. 2002; 220: 477–481
[111] Rusbridge C, White RN, Elwood CM et al.: Treatment of acquired
myasthenia gravis associated with thymoma in two dogs. J Small
Anim Pract. 1996; 37: 376–380
[112] Sanpera N, Masot N, Janer M et al.: Oestrogen-induced bone marrow aplasia in a dog with a Sertoli cell tumour. J Small Anim Pract.
2002; 43: 365–369
[113] Santarpia L, Koch CA, Sarlis NJ: Hypercalcemia in cancer patients:
pathobiology and management. Horm Metab Res. 2010; 42:153–
164
[114] Saper CB, Breder CD: The neurologic basis of fever. N Engl J Med.
1994; 330: 1880–1886
[115] Savary KC, Price GS, Vaden SL: Hypercalcemia in cats: a retrospective study of 71 cases (1991–1997). J Vet Intern Med. 2000; 14:
184–189
[116] Schrauwen E: Clinical peripheral polyneuropathy associated with
canine insulinoma. Vet Rec. 1991; 128: 211–212
[117] Sellon RK, Rottman JB, Jordan HL et al.: Hypereosinophilia associated with transitional cell carcinoma in a cat. J Am Vet Med Assoc.
1992; 201: 591–593
[118] Sharkey LC, Rosol TJ, Grone A et al.: Production of granulocyte
colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by carcinomas in a dog and a cat with paraneoplastic leukocytosis. J Vet Intern Med. 1996; 10: 405–408
[119] Sheafor SE, Gamblin RM, Couto CG: Hypercalcemia in two cats
with multiple myeloma. J Am Anim Hosp Assoc. 1996; 32: 503–508
[120] Shelton GD, Willard MD, Cardinet GH 3rd et al.: Acquired myasthenia gravis. Selective involvement of esophageal, pharyngeal, and
facial muscles. J Vet Intern Med. 1990; 4: 281–284
[121] Sierko E, Wojtukiewicz MZ: Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004; 30: 95–108
[129] Tessitore L, Costelli P, Baccino FM: Humoral mediation for cachexia in tumour-bearing rats. Br J Cancer. 1993; 67: 15–23
[130] Thompson JP, Christopher MM, Ellison GW et al.: Paraneoplastic
leukocytosis associated with a rectal adenomatous polyp in a dog. J
Am Vet Med Assoc. 1992; 201: 737–738
[131] Tisdale MJ: Biology of cachexia. J Natl Cancer Inst. 1997; 89: 1763–
1773
[132] Tisdale MJ: Cancer cachexia: metabolic alterations and clinical
manifestations. Nutrition. 1997; 13: 1–7
[133] Tisdale MJ: Wasting in cancer. J Nutr. 1999; 129: 243S–246S
[134] Torres SM, Caywood DD, OʼBrien TD et al.: Resolution of superficial necrolytic dermatitis following excision of a glucagon-secreting
pancreatic neoplasm in a dog. J Am Anim Hosp Assoc. 1997; 33:
313–319
[135] Turek MM: Cutaneous paraneoplastic syndromes in dogs and cats:
a review of the literature. Vet Dermatol. 2003; 14: 279–296
[136] Uehlinger P, Glaus T, Hauser B et al.: Differenzialdiagnose der
Hyperkalzämie – eine retrospektive Studie über 46 Hunde. Schweiz
[137] Vail DM, Ogilvie GK, Wheeler SL et al.: Alterations in carbohydrate
metabolism in canine lymphoma. J Vet Intern Med. 1990; 4: 8–11
[138] Van Ham L, Braund KG, Roels S et al.: Treatment of a dog with an
insulinoma-related peripheral polyneuropathy with corticosteroids.
Vet Rec. 1997; 141: 98–100
[139] Villiers E, Dobson J: Multiple myeloma with associated polyneuropathy in a German shepherd dog. J Small Anim Pract. 1998; 39:
249–251
[140] Wagner H: Untersuchungen zur paraneoplastischen Polyneuropathie des Hundes. Diss med vet. Tierärztliche Hochschule Hannover,
2002
[141] Waterhouse DM, Natale RB, Cody RL: Breast cancer and paraneoplastic cerebellar degeneration. Cancer. 1991; 68: 1835–1841
[142] Willard MD, Krehbiel JD, Schmidt GM: Serum and urine protein
abnormalities associated with lymphocytic leukemia and glomerulonephritis. J Am Anim Hosp Assoc. 1981; 17: 381–386
[143] Williams LE, Gliatto JM, Dodge RK et al.: Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985–1995). J Am
Vet Med Assoc. 2003; 223: 825–831
[144] Zapf J: Role of insulin-like growth factor (IGF) II and IGF binding
proteins in extrapancreatic tumour hypoglycaemia. J Intern Med.
1993; 234: 543–552
[145] Zitz JC, Birchard SJ, Couto GC et al.: Results of excision of thymoma in cats and dogs: 20 cases (1984–2005). J Am Vet Med
Assoc. 2008; 232: 1186–1192
[122] Singh A, Boston SE, Poma R: Thymoma-associated exfoliative dermatitis with post-thymectomy myasthenia gravis in a cat. Can Vet J.
2010; 51:757–760
[123] Slappendel RJ: Disseminated intravascular coagulation. Vet Clin
North Am Small Anim Pract. 1988; 18: 169–184
[106] Price GS, Page RL, Fischer BM et al.: Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med. 1991; 5: 259–262
[124] Stewart AF: Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352: 373–379
14
5
Problemorientierte Diagnostik
5.1 Untersuchung von Patienten mit neoplastischen
Erkrankungen
[22]
Sellon RK, Rottman JB, Jordan HL et al.: Hypereosinophilia associated with transitional cell carcinoma in a cat. J Am Vet Med Assoc.
1992; 201: 591–593
[23]
Selvarajah GT, Kirpensteijn J: Prognostic and predictive biomarkers of canine osteosarcoma. Vet J. 2010; 185: 28–35
[24]
Sharkey LC, Rosol TJ, Grone A et al.: Production of granulocyte
colony-stimulation factor and granulocyte-macrophage colony-stimulation factor by carcinomas in a dog and a cat with paraneoplastic leukocytosis. J Vet Intern Med. 1996; 10: 405–408
[25]
Sorenmo KU, Goldschmidt M, Schofer F et al.: Immunohistochemical characterization of canine prostatic carcinoma and correlation
with castration status and castration time. Vet Comp Oncol. 2003;
1: 48–56
[1]
Animal Health Survey. In: Companion Animal News, Morris Animal
Foundation, Englewood, Colorado, 1998 und 2005
[2]
Atlee BA, DeBoer DJ, Ihrke PJ et al.: Nodular dermatofibrosis in
German Shepherd dogs as a marker for renal cystadenocarcinoma.
J Am Anim Hosp Assoc. 1991; 27: 481–487
[3]
Barrs VR, Beatty JA, McCandlish IA et al.: Hypereosinophilic paraneoplastic syndrome in a cat with intestinal T cell lymphosarcoma. J
Small Anim Prac. 2002; 43: 401–405
[4]
Bauer N, Moritz A: Evaluation of the Cardiac reader as a point-ofcare-instrument for Measurement of fibrin D-dimers in dogs. Tierärztl Prax (K). 2009; 5: 319–325
[26]
Strombeck DR: Clinicopathologic features of primary and metastatic neoplastic disease of the liver in dogs. J Am Vet Med Assoc.
1978; 173: 267–269
[5]
Capbell KL: Diagnosis and management of polycythemia in dogs.
Compend Contin Educ Small Anim Pract. 1990; 12: 543–546, 548–
50
[27]
Teske E, Naan BC, van Dijk EM et al.: Canine prostate carcinoma:
epidemiological evidence of an increased risk in castrated dogs. Mol
Cell Endocrinol. 2002; 197: 251–255
[6]
Coenen T: Untersuchungen zur Häufigkeit und klinischem Erscheinungsbild des histiozytären Sarkoms beim Berner Sennenhund
unter besonderer Berücksichtigung zytologischer Knochenmarkanalysen, ISBN:3-8359-5569-1 Diss med vet, JLU Giessen, 2009
[28]
Teske E, van Straten G, van Noort R et al.: Chemotherapy with
Med. 2002; 16: 179–186
[7]
Fry MM, Liggett JL, Baek SJ: Molecular cloning and expression of
canine hepcidin. Vet Clin Path. 2004; 33: 223–227
[29]
[8]
Geisenberger M: Erhebungen über das Vorkommen bösartiger
Tumoren bei Hunden anhand der Sektionsstatistik des Instituts für
Tierpathologie München. Diss med vet, München, 1990
Uehlinger P, Glaus T, Hauser B et al.: Differentialdiagnosen für
Hyperkalzämie – eine retrospektive Studie von 46 Hunden. Schweiz
[30]
Willson JE, Brown DE: Leukemoid reaction resembling myelogenous leukaemia in a dog. Failure of the leukocyte alkaline phosphatase test to aid in the differential diagnosis. Cornell Vet. 1965; 55:
55–63
[31]
Zapf J: Role of insulin-like growth factor (IGF) II and IGF binding
proteins in extrapancreatic tumour hypoglycaemia. J Intern Med.
1993; 234: 543–552
[9]
Giraudel JM, Pages JP, Guelfi JF: Monoclonal gammopathies in the
dog: a retrospective study of 18 cases (1986-1999) and literature
[10]
Grindem CB, Breitschwerdt EB, Corbett WT et al.: Thrombocytopenia associated with neoplasia in dogs. J Vet Intern Med. 1994; 8:
400–405
[11]
Hammer AS: Thrombocytosis in dogs and cats: a retrospective
study. Comp Haematol Intern. 1991; 1: 181–186
[12]
Hogan DF, Dhalival RS, Sisson DD et al.: Paraneoplastic thrombocytosis-induced systemic thromboembolism in a cat. J Am Anim
Hosp Assoc. 1999; 35: 483–486
[13]
Kristensen AT, Wiinberg B, Jessen LR et al.: Evaluation of human
recombinant tissue factor-activated thromboelastograhy in 49 dogs
with neoplasia. J Vet Intern Med. 2008; 22: 140–147
[14]
Louwerens M, London CA, Pedersen NC et al.: Feline lymphoma
329–335
[15]
Madewell B, Feldman BF: Characterization of anemias associatied
419–425
[16]
Med Sci. 2004; 66: 573–575
[17]
Mc Connell MF, Lumsden JH: Biochemical evaluation of metastatic
liver disease in the dog. J Am Anim Hosp Assoc. 1983; 19: 173–178
[18]
McNiel EA, Ogilvie GK, Fettman MJ et al.: Platelet hyperfunction
in dogs with malignancies. J Vet Intern Med. 1997; 11: 178–182
[19]
Mellor PJ, Haugland S, Murphy S et al.: Myeloma-related disorders
in cats commonly present as extramedullary neoplasms in contrast
to myeloma in human patients: 24 cases with clinical follow-up. J
Vet Intern Med. 2006; 20: 1376–1383
[20]
Miller AG, Morley PS, Rao S et al.: Anemia is associated with
decreased survival time in dogs with lymphoma. J Vet Intern Med.
2009; 23: 116–122
[21]
Savary KC, Price GS, Vaden SL: Hypercalcemia in cats: a retrospective study of 71 cases 1991-1997). J Vet Intern Med. 2000; 14: 184–
189
5.2 Stadieneinteilung von Tumorerkrankungen
[1]
Belleannée G: [The TNM system: only 3 letters for a rich but sometimes ambiguous language]. Ann Pathol. 2006; 26: 435–44; quiz
418
[2]
Denoix PF: Bull Inst Nat Hyg. (Paris) 1944; 1: 1–69 und 5: 52–82.3.
[3]
Epstein RJ: TNM: therapeutically not mandatory. Eur J Cancer.
2009; 45: 1111–1116
[4]
Ferreira E, Bertagnolli AC, Cavalcanti MF et al.: The relationship
between tumour size and expression of prognostic markers in
benign and malignant canine mammary tumours. Vet Comp Oncol.
2009; 7: 230–235
[5]
Gönen M, Weiser MR: Whither TNM? Semin Oncol. 2010; 37: 27–
30
[6]
Greene FL, Sobin LH: The staging of cancer: a retrospective and
prospective appraisal. CA Cancer J Clin. 2008; 58: 180–190
[7]
Kurzman ID, Gilbertson SR: Prognostic factors in canine mammary
tumors. Semin Vet Med Surg. 1986; 1: 25–32
[8]
López-Encuentra A, López-Ríos F, Conde E et al. : Composite anatomical-clinical-molecular prognostic model in non-small cell lung
cancer. Eur Respir J. 2011; 37: 136–142
[9]
MacEwen EG, Hayes AA, Harvey HJ et al.: Prognostic factors for
feline mammary tumors. J Am Vet Med Assoc. 1984; 185: 201–204
[10]
Ortmann U: Die Hauttumoren der Katze unter besonderer Berücksichtigung der Fibrosarkome. Diss med vet, München, 1986
[11]
Owen LN: World Health Organisation TNM Classification of tumors
in domestic animals. Genf, 1980
[12]
Patnaik AK, Ehler WN, MacEwen EG: Canine cutaneous mast cell
tumor: Morphologic grading and survival time in 83 dogs. Vet
Pathol. 1984; 21: 469–474
[13]
Quirke P, Cuvelier C, Ensari A et al.: Evidence-based medicine: the
time has come to set standards for staging. J Pathol. 2010; 221:
357–360
[15]
Buchholz J, Hagen R, Leo C et al.: 3D conformal radiation therapy
for palliative treatment of canine nasal tumors. Vet Radiol Ultrasound. 2009; 50: 679–683
[14]
Thiel W: Mastzelltumoren beim Hund – Auswertung pathologischhistologischer Untersuchungsbefunde der Jahre 1980–1986 mit
Hinweis auf die TNM-Klassifizierung von Tumoren bei Haustieren.
Kleintierprax. 1990; 35: 401–404.
[16]
Burch S, London C, Seguin B et al.: Treatment of canine osseous
tumors with photodynamic therapy: a pilot study. Clin Orthop Relat
Res. 2009; 467: 1028–1034
[17]
[15]
von Dewitz M: Zum Metastasierungsmuster einiger häufig auftretender maligner Geschwülste des Hundes. Diss med vet, München,
1987
Cherubini GB, Mantis P, Martinez TA et al.: Utility of magnetic
resonance imaging for distinguishing neoplastic from non-neoplastic brain lesions in dogs and cats. Vet Radiol Ultrasound. 2005; 46:
384–387
[16]
Wittekind Ch, Meyer HJ (Hrsg): TNM-Klassifikation maligner
Tumoren. 7. Aufl. Wiley, Weinheim, 2010
[18]
[17]
Wittekind C, Oberschmid B: TNM-Klassifikation maligner Tumoren
2010. Allgemeine Aspekte und Änderungen im allgemeinen Teil.
Pathologe. 2010; 31: 333–334, 336–338
Cipone M, Diana A, Gandini G et al.: Use of computed tomography in thoracic diseases of small animals. Vet Res Commun. 2003;
27 (Suppl. 1): 381–384
[19]
Cooley DM, Waters DJ: Skeletal metastasis as the initial clinical
manifestation of metastatic carcinoma in 19 dogs. J Vet Intern Med.
1998; 12: 288–293
[20]
da Costa RC, Parent JM, Dobson H et al.: Ultrasound-guided fine
needle aspiration in the diagnosis of peripheral nerve sheath tumors
in 4 dogs. Can Vet J. 2008, 49: 77–81
6
Bildgebende Verfahren in der Onkologie
[1]
Adams WM, Kleiter MM, Thrall DE et al.: Prognostic significance
of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. Vet Radiol Ultrasound. 2009; 50: 330–335
[21]
Davies GJ, Kapatkin AS, Craig LE et al.: Comparison of radiography, computed tomography, and magnetic resonance imaging for
evaluation of appendicular osteosarcoma in dogs. J Am Vet Med
Assoc. 2002; 220: 1171–1176
[2]
Allemann K, Wyss M, Wergin M et al.: Positron emission tomography: diagnostic imaging on a molecular level. Schweiz Arch Tierheilkd. 2004; 146: 359–364
[22]
Diederich S: Lungenmetastasen. In: Freyschmidt J, Galanski M
(Hrsg). Handbuch diagnostische Radiologie: Thorax. Springer Berlin
Heidelberg New York. 2003, 341–344
[3]
Ballegeer EA, Adams WM, Dubielzig RR et al.: Computed tomography characteristics of canine tracheobronchial lymph node
metastasis. Vet Radiol Ultrasound. 2010; 51: 397–403
[23]
Djupsjöbacka A, Eksell P: Frequency of radiographically detected
pulmonary metastases in bitches with mammary gland neoplasia.
Europ J Comp Anim Pract. 2003; 13: 149–156
[4]
Ballegeer EA, Forrest LA, Dickinson RM et al.: Correlation of ultrasonographic appearance of lesions and cytology and histologic
diagnosis in splenic aspirates from dogs and cats: 32 cases (2002–
2005). J Am Vet Med Assoc. 2007; 230: 690–696
[24]
Drees R, Forrest LJ, Chappell R: Comparison of computed tomography and magnetic resonance imaging for the evaluation of
canine intranasal neoplasia. J Small Anim Pract. 2009; 50: 334–340
[25]
[5]
Ballegeer EA, Forrest LA, Jeraj R et al.: PET/CT following intensitymodulated radiation therapy for primary lung tumor in a dog. Vet
Radiol Ultrasound. 2006; 47: 228–233
Espino L, Suarez M, Santamarina G et al.: First report of the simultaneous occurrence of choroid plexus papilloma and meningioma
in a dog. Acta Vet Hung. 2009, 57: 389–397
[26]
[6]
Barberet V, Baeumlin Y, Taeymans O et al.: Pre- and posttreatment ultrasonography of the thyroid gland in hyperthyroid cats. Vet
Fife WD, Sami VF, Drost WT et al.: Comparison between malignant and nonmalignant splenic masses in dogs using contrastenhanced computed tomography. Vet Radiol Ultrasound. 2004; 45:
289–297
[7]
Barr F: Percutaneous biopsy of abdominal organs under ultrasound
guidance. J Small Anim Pract. 1995; 36: 105–113
[27]
[8]
Barthez PY, Hornof WJ, Théon AP et al.: Receiver operating characteristic curve analysis of the performance of various radiographic
protocols when screening dogs for pulmonary metastases. J Am Vet
Med Assoc. 1994; 204: 237–240
Feeney DA, Anderson KL: Nuclear imaging and radiation therapy in
canine and feline thyroid disease. Vet Clin North Am Small Anim
Pract. 2007; 37: 799–821
[28]
Feeney DA, Anderson KL, Ziegler LE et al.: Statistical relevance of
ultrasonographic criteria in the assessment of diffuse liver disease in
dogs and cats. Am J Vet Res. 2008; 69: 212–221
[29]
Forrest LJ: Diagnostic Imaging in Oncology. In: Withrow SJ, Vail DM
(Hrsg): Small animal clinical oncology. Saunders, Elsevier, St. Louis.
4. Aufl., 2007, 97–111
[30]
Forrest LJ, Dodge RK, Page RL et al.: Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with
osteosarcoma. J Nucl Med. 1992; 33: 1542–1547
[31]
Forrest LJ, Graybush CA: Radiographic patterns of pulmonary
metastasis in 25 cats. Vet Radiol Ultrasound. 1998; 39: 4–8
[32]
Fuchs C, Meyer-Lindenberg A, Wohlsein P et al.: Computertomographische Charakteristika primärer Gehirntumoren von Hund und
Katze. Berl Munch Tierarztl Wochenschr. 2003; 116: 436–442
[33]
Gäbler K, Flegel T, Köhler C et al.: Röntgenologische Darstellung
entzündlicher und neoplastischer Veränderungen der Wirbelsäule
bei Hund und Katze. Tierärztl Prax (K). 2011; 39: 51–59
[34]
Galán A, Guil-Luna S, Millán Y et al.: Oligodendroglial Gliomatosis
cerebri in a Poodle. Vet Comp Onc. 2010; 8: 254–262
[35]
Gavin PR, Holmes SP: Orthopedic. In: Gavin PR, Bagley RS (Hrsg.):
Practical small animal MRI. Blackwell Scientific Publ, Oxford , 2009,
233–372
[9]
Baumann D, Hauser B, Hubler M et al.: Signs of metastatic disease
on thoracic radiographs of dogs suffering from mammary gland
tumors: a retrospective study (1990–1998). Schweiz Arch Tierheilkd. 2004; 146: 431–435
[10]
Benigni L, Corr SA, Lamb CR: Ultrasonographic assessment of the
canine sciatic nerve. Vet Radiol Ultrasound. 2007; 48: 428–433
[11]
Boroffka SA, Verbruggen AM, Grinwis GC et al.: Assessment of
ultrasonography and computed tomography for the evaluation of
unilateral orbital disease in dogs. J Am Vet Med Assoc. 2007; 230:
671–680
[12]
Both C: Nierenfunktionsszintigraphische Untersuchungen und Clearance-Messungen mit 99mTc-Mercaptoacetyltriglycin (MAG3) bei
Hund und Katze. Vet Med Diss. München, 1996
[13]
Broome MR: Thyroid scintigraphy in hyperthyroidism. Clin Tech
[14]
Buchholz J: Computerised 3-D treatment planning using MRI-CT
fusion with regard to planning target volumes of brain tumor
patients. Proc. Ann meeting EVDI, Giessen, 2010, 28
15
16
[36]
Geyer NE, Reichle JK, Valdés-Martinez J et al.: Radiographic
appearance of confirmed pulmonary lymphoma in cats and dogs.
Vet Radiol Ultrasound. 2010; 51: 386–390
[57]
Huber D: Thorax examination by computed tomography: general
aspects and presentation of clinical cases. Schweiz Arch Tierheilkd.
2005; 147: 546–548, 551–553
[37]
Gibbs C, Denny HR, Kelly DF: The radiological features of osteosarcoma of the appendicular skeleton in dogs: a review of 74 cases. J
[58]
Iseri T, Yamada K, Chijiwa K et al.: Dynamic computed tomography of the pancreas in normal dogs and in a dog with pancreatic
insulinoma. Vet Radiol Ultrasound. 2007; 48: 328–331
[38]
Giroux A, Jones JC, Bøhn JH et al.: A new device for stereotactic
CT-guided biopsy of the canine brain: design, construction, and
needle placement accuracy. Vet Radiol Ultrasound. 2002; 43: 229–
236
[59]
[39]
Guillot M, D’Anjou MA, Alexander K et al.: Can sonographic findings predict the results of liver aspirates in dogs with suspected
liver disease. Vet Radiol Ultrasound. 2009; 50: 513–518
Jager PL, Plaat BEC, de Vries EGE et al.: Imaging of soft-tissue
tumors using L-3(Iodine-123)Iodo-α-methyl-tyrosine single photon
emission computed tomography: comparison with proliferative and
mitotic activity, cellularity, and vascularity. Clin Cancer Res. 2000; 6:
2252–2259
[60]
Jeong Y, Lim C, Oh S et al.: Three-dimensional CT angiography of
the canine hepatic vasculature. J Vet Sci. 2008; 9: 407–413
[40]
Gutierrez-Quintana R, Gunn-Moore DA, Lamm CG et al.: Feline
intracranial meningioma with skull erosion and tumour extension
into an area of skull hyperostosis J Fel Med Surg. 2011; 13: 296–299
[61]
Joly H, D’Anjou MA, Alexander K et al.: Comparison of single-slice
computed tomography protocols for detection of pulmonary nodules in dogs. Vet Radiol Ultrasound. 2009; 50: 279–284
[41]
Haers H, Saunders JH: Review of clinical characteristics and applications of contrast-enhanced ultrasonography in dogs. J Am Vet
Med Assoc. 2009; 34: 460–470
[62]
[42]
Hammer AS, Bailey MQ, Sagartz JE: Retrospective assessment of
thoracic radiographic findings in metastatic canine hemangiosarcoma. Vet Radiol. 1993; 34: 235–238
Kanemoto H, Ohno K, Nakkshima K et al.: Characterization of
canine focal liver lesions with contrast-enhanced ultrasound using a
novel contrast agent – Sonazoid. Vet Radiol Ultrasound. 2009, 50:
188–194
[63]
Kessler M, Tassani-Prell M, von Bomhard D et al.: Das Osteosarkom der Katze: epidemiologische, klinische und röntgenologische
Befunde bei 78 Tieren (1990–1995). Tierärztl Prax. 1997; 25: 275–
283
[43]
Hanson JA, Papageorges M, Girard E et al.: Ultrasonographic
appearance of splenic disease in 101 cats. Vet Radiol Ultrasound.
2001; 42: 441–445
[64]
[44]
Harvey AM, Hibbert A, Barrett EL et al.: Scintigraphic findings in
120 hyperthyroid cats. J Feline Med Surg. 2009; 11: 96–106
Kiefer I, Bosch B, Haarstrick C et al.: Leberdiagnostik mit Ultraschall – aktueller Stand. Tierärztl Prax. 2010; 38(K): 254–261
[65]
[45]
Hatanaka K, Masatoshi K, Yasunori M et al.: Sonazoid-enhanced
ultrasonography for diagnosis of hepatic malignancies: comparison
with contrast-enhanced CT. Oncology. 2008; 75 (Suppl. 1): 42–47
Kiefer I, Hause A, Oechtering GU et al.: Hepatische Transitzeit des
Signalverstärkers Sonovue beim Hund. 31. Dreiländertreffen
DEGUM, ÖGUM, SGUM,19th Euroson Congress of EFSUMB: Ultraschall in der Medizin, Leipzig, 2007, 63–63
[46]
Hathcock JT, Newton JC: Computed tomographic characteristics
of multilobular tumor of bone involving the cranium in 7 dogs and
zygomatic arch in 2 dogs. Vet Radiol Ultrasound. 2000; 41: 214–
217
[66]
Kinns J, Mai W: Association between malignancy and sonographic
heterogeneity in canine and feline abdominal lymph nodes. Vet
[67]
[47]
Hecht S, Adams WH: MRI of brain disease in veterinary patients
part 1: Basic principles and congenital brain disorders. Vet Clin
Kishimoto M, Yamada K, Seok J-S et al.: Analysis of blood flow in
a third ventricular ependymoma and an olfactory bulb meningioma
by using perfusion computed tomography. J Vet Med Sci. 2008, 70:
981–983
[48]
part 2: Acquired brain disorders. Vet Clin North Am Small Anim
Pract. 2010; 40: 39–63
[68]
Kraft SL: Cancer imaging. In: Gavin PR, Bagley RS (Hrsg.): Practical
small animal MRI. Blackwell Scientific Publ, Oxford, 2009, 333–356
[69]
[49]
Hecht S, Penninck DG, Keating JH: Imaging findings in pancreatic
neoplasia and nodular hyperplasia in 19 cats. Vet Radiol Ultrasound.
2007; 48: 45–50
Kraft S, Erhardt EJ, Gall D et al.: Magnetic resonance imaging characteristics of peripheral nerve sheath tumors of the canine brachial
plexus in 18 dogs. Vet Radiol Ultrasound. 2007; 48: 1–7
[70]
[50]
Hedlund CS:. Mammary neoplasia. In: Fossum TW (Hrsg.): Small
animal surgery. Mosby Elsevier, St. Louis, 2007, 729–735
Kück G, Brinker T, Hewicker-Trautwein M et al.: Diagnostik und
chirurgische Therapie eines Oligodendroglioms bei einem Hund.
Tierärzt Prax (K). 2005, 33: 32–36
[51]
Henninger W: Use of computed tomography in the diseased feline
thorax. J Small Anim Pract. 2003, 44: 56–64
[71]
Larson SM: Molecular imaging in oncology: the diagnostic imaging
“revolution”. Clin Cancer Res. 2000; 6: 2125
[52]
Henninger W, Pavlicek M: Konventionelle CT-Untersuchungsprotokolle, erstellt nach Regionen, für den optimalen Kontrastmitteleinsatz beim Hund. Kleintierprax. 2001, 46: 685–698
[72]
Lamb CR: The principles and practice of bone scintigraphy in small
animals. Sem Vet Med Surg (Small Anim). 1991; 6: 140–153
[73]
[53]
Heyman SJ, Diefenderfer DL, Goldschmidt MH et al.: Canine axial
skeletal osteosarcoma. A retrospective study of 116 cases (1986 to
1989). Vet Surg. 1992; 21: 304–310
Lamb CR, Grierson J: Ultrasonographic appearance of primary gastric neoplasia in 21 dogs. J Small Anim Pract. 1999; 40: 211–215
[74]
Hodge SC, Degner D, Walshaw R et al.: Vascularized ulnar bone
grafts for limb-sparing surgery for the treatment of distal radial
osteosarcoma. J Am Anim Hosp Assoc. 2011; 47: 98–111
Lang J, Wortman JA, Glickman LT et al.: Sensitivity of radiographic
detection of lung metastases in the dog. Vet Radiol. 1986; 27: 74–
78
[75]
Hoh CK, Dahlbom M, Hawkins RA et al.: Basic principals of positron emission tomography in oncology: quantitation and whole
body techniques. Wien Klin Wochenschr. 1994; 106: 496–504
Lass P, Krzeminski M, Teodorczyk J: (99m)Tc-MDP uptake in softtissue osteosarcoma in a dog. Nucl Med Rev Cent East Eur. 2004; 7:
189
[76]
Lawrence J, Rohren E, Provenzale J: PET/CT today and tomorrow
in veterinary cancer diagnosis and monitoring: fundamentals, early
results and future perspectives. Vet Comp Onc. 2010; 8: 163–187
[77]
Lawrence J, Vanderhoek M, Barbee D et al.: Use of 3’Deoxy-3’(18F)Fluorothymidine PET/CT for evaluating response to cytotoxic
chemotherapy in dogs with Non-Hodgkin’s lymphoma. Vet Radiol
Ultrasound. 2009; 50: 660–668
[54]
[55]
[56]
Holt D, Van Winkle T, Schelling C et al.: Correlation between thoracic radiographs and postmortem findings in dogs with hemangiosarcoma: 77 cases (1984–1989). J Am Vet Med Assoc. 1992; 200:
1535–1539
[78]
LeBlanc AK, Daniel GB: Advanced imaging for veterinary cancer
patients. Vet Clin Noth Am Small Anim Pract. 2007; 37: 1059–1077
[100] Nyman HT, OʼBrien RT: The sonographic evaluation of lymph
nodes. Clin Tech Small Anim Pract. 2007; 22: 128–137
[79]
LeBlanc AK, Jakoby BW, Townsend DW et al.: (18FDG)-PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet
[101] Ober CP, Barber D: Comparison of two- vs. three thoracic radiographic studies on conspicuity of structured interstitial patterns in
[80]
Lee AR, Lee MS, Jung IS et al.: Imaging diagnosis – FDG-PET/CT of
a canine splenic plasma cell tumor. Vet Radiol Ultrasound. 2010; 51:
145–147
[102] OʼBrien RT: Ultrasound contrast media in tumor imaging. EVDI
annual scientific conference, Giessen, 2010
[81]
Léveillé R, Partington BP, Biller DS et al.: Complications after
ultrasound-guided biopsy of abdominal structures in dogs and cats:
246 cases (1984–1991). J Am Vet Med Assoc. 1993; 203: 413–415
[82]
Ludewig E, Aupperle H, Gäbler K et al.: Knochentumore aus Sicht
der Radiologen. 4. Leipziger Tierärztekongress, Leipzig, 2008, 245–
249
[83]
MacLeod AG, Dickinson PJ, LeCouteur RA et al.: Quantitative
assessment of blood volume and permeability in cerebral mass
lesions using dynamic contrast-enhanced computed tomography in
the dog. Acad Radiol. 2009; 16: 1187–1195
[84]
Mandara MT, Rossi F, Lepri E et al.: Cerebellar leptomeningeal carcinomatosis in a dog. J Small Anim Pract. 2007; 48: 504–507
[85]
Marolf AJ, Gibbson DS, Podell BK et al.: Computed tomographic
appearance of primary lung tumors in dogs. Vet Radiol Ultrasound.
2011; 52: 168–172
[86]
Mercier M, Heller HL, Bischoff MG et al.: Imaging diagnosis –
hyperostosis associated with meningioma in a dog. Vet Radiol Ultrasound. 2007; 48: 421–423
[87]
Mertens D, Löwe G: Computertomographische und klinische
Befunde von zwei Hunden und zwei Katzen mit intrakraniellen
Neoplasien. Kleintierprax. 2002; 47: 659–671
[88]
Miao Z, Ren G, Liu H et al.: Small-animal PET imaging of human
epidermal growth factor receptor positive tumor with a (64)Cu
labeled affibody protein. Bioconjug Chem. 2010; 21: 947–954
[89]
Miles K: Imaging abdominal masses. Vet Clin North Am Small Anim
Pract. 1997; 27: 1403–1431
[90]
Miles KG, Lattimer JC, Jergens AE et al.: A retrospective evaluation
of the radiographic evidence of pulmonary metastatic disease on
initial presentation in the dog. Vet Radiol. 1990; 31: 79–82
[91]
Moe L, Lium B: Computed tomography of hereditary multifocal
renal cystadenocarcinomas in German shepherd dogs. Vet Radiol
Ultrasound. 1997; 38: 335–343
[92]
Moissonnier P, Blot S, Devauchelle P et al.: Stereotactic CT-guided brain biopsy in the dog. J Small Anim Pract. 2002, 43: 115–123
[93]
Nakamura K, Sasaki N, Yoshikawa M et al.: Quantitative contrastenhanced ultrasonography of canine spleen. Vet Radiol Ultrasound.
2009; 50: 104–108
[94]
Nakamura K, Takagi S, Sasaki N et al.: Contrast-enhanced ultrasonography for characterization of canine focal liver lesions. Vet
[95]
Nemanic S, London CA Wiesner ER: Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary
nodules in dogs with metastatic neoplasia. J Vet Intern Med. 2006;
20: 508–515
[96]
Nitzl D: Lungenröntgen – Technik, Anatomie und Lungenmuster.
Kleintierprax. 2009; 54: 101–115
[97]
Nitzl D, Ohlerth S, Müller-Schwandt F et al.: Dynamic computed
tomography to measure tissue perfusion in spontaneous canine
tumors. Vet Radiol Ultrasound. 2009; 50: 347–352
[98]
Nyland TG, Wallack ST, Wisner ER: Needle–tract implantation following us-guided fine-needle aspiration biopsy of transitional cell
carcinoma of the bladder, urethra, and prostate. Vet Radiol Ultrasound. 2002; 43: 50–53
[99]
Nyman HT, Kristensen AT, Flagstad A et al.: A review of the sonographic assessment of tumor metastases in liver and superficial
lymph nodes. Vet Radiol Ultrasound. 2004; 45: 438–448
[103] Ohlert S, Scharf G: Computed tomography in small animals – basic
principles and state of the art applications. Vet J. 2007; 173: 254–
271
[104] Olfsen T, Betting D, Kenanova VE et al.: Recombinant anti-CD20
antibody fragments for microPET imaging of B-cell lymphoma. J
Nucl Med. 2009; 50: 1500–1508
[105] Otoni CC, Rahal SC, Vulcano LC et al.: Survey radiography and
computerizedtomography imaging of the thorax in female dogs
with mammary tumors. Acta Vet Scand. 2010; 52: 20–29
[106] Paoloni MC, Adams WM, Dubielzig RR et al.: Comparison of
results of computed tomography and radiography with histopathologic findings in tracheobronchial lymph nodes in dogs with primary
lung tumors: 14 cases (1999–2002). J Am Vet Med Assoc. 2006,
228: 1718–1722
[107] Park RD, Beck ER, LeCouteur RA: Comparison of computed tomography and radiography for detecting changes induced by malignant nasal neoplasia in dogs. J Am Vet Med Assoc. 1992, 201:
1720–1724
[108] Penninck DG, Daniel GB, Brawer R et al.: Cross-sectional imaging
techniques in veterinary ophthalmology. Clin Tech Small Anim
Pract. 2001; 16: 22–39
[109] Penninck DG, Moore AS, Gliatto L: Ultrasonography of canine
gastric epithelial neoplasia. Vet Radiol Ultrasound. 1998; 39: 342–
348
[110] Peterson ME, Becker DV: Radionuclide thyroid imaging in 135 cats
with hyperthyroidism. Vet Radiol. 1984; 25: 23–27
[111] Pollard RE, Reilly CM, Uerling MR et al.: Cross-sectional imaging
characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988–2006).J Vet Int Med. 2010;
24: 160–165
[112] Prater AB, Berry CR, Thrall DE: Use of radiography in combination
with computed tomography for the assessment of noncardiac thoracic disease in the dog and cat. Vet Radiol Ultrasound. 2005; 46:
114–121
[113] Prescott DM, Charles HC, Sostman HD et al.: Therapy monitoring
in human and canine soft tissue sarcomas using magnet resonance
imaging and spectroscopy. Int J Radiat Oncol Biol Phys. 1994; 15:
415–423
[114] Reichle JK, Wisner ER: Non-cardiac thoracic ultrasound in 75 feline
and canine patients. Vet Radiol Ultrasound. 2000; 41: 154–162
[115] Rudich SR, Feeney DA, Anderson KL et al.: Computed tomography of masses of the brachial plexus and contributing nerve roots in
[116] Saito M, Ono S, Kayanuma H et al.: Evaluation of the susceptibility
artifacts and tissue injury caused by implanted microchips in dogs
on 1.5 T magnetic resonance imaging. J Vet Med Sci. 2010; 72:
575–581
[117] Samii VF, Nyland TG, Werner LL et al.: Ultrasound-guided fineneedle aspiration biopsy of bone lesions: a preliminary report. Vet
[118] Sato AF, Solano M: Ultrasound findings in abdominal mast cell
disease: a retrospective study of 19 patients. Vet Radiol Ultrasound.
2004; 45: 51–57
[119] Scheidler J, Hricak H, Vigneron DB et al.: Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999; 213: 473–480
17
18
[120] Scherrer W, Kyles A, Samii V et al.: Computed tomographic
assessment of vascular invasion and resectability of mediastinal
masses in dogs and a cat. N Z Vet J. 2008; 56: 330–333
[141] Vignoli M, Ohlert S, Rossi F et al.: Computed tomography-guided
fine-needle aspiration and tissue-core biopsy of bone lesions in
small animals. Vet Radiol Ultrasound. 2004; 45: 125–130
[121] Schicha H: Szintigraphische Untersuchungen. In: Schicha H, Schober O (Hrsg.) Nuclearmedizin- Basiswissen und klinische Anwendung, Schattauer, Stuttgart 2007, 83–96
[142] Vignoli M, Rossi F, Chierici C et al.: Needle tract implantation after
[122] Schmidt J: Volumetrie von Pleuraergüssen mittels Sonographie und
Computertomographie. Vet Med Diss, Berlin, 2007
[123] Schuller S, Fredericksen M, Schröder H et al.: Computertomographische Differenzierung von intrathorakalen Neoplasien und Entzündungen beim Hund. Berl Munch Tierarztl Wochenschr. 2005;
118: 76–84
[124] Schultz RM, Wisner ER, Johnson EG et al.: Contrast-enhanced
computed tomography as a preoperative indicator of vascular invasion from adrenal masses in dogs. Vet Radiol Ultrasound. 2009; 50:
625–629
[125] Seyrek-Intas D, Peppler C, Marek N et al.: Ultraschalldiagnostik
von Darmwandveränderungen bei der Katze. Tierärztl Prax. 2008;
36(K): 185–190
[126] Simpson DJ, Hunt GB, Tisdall PLC et al.: Surgical removal of an
ependymoma from the third ventricle of a cat. Aust Vet J. 1999; 77:
645–648
[127] Stünzi H: Metastasierende Schilddrüsen-Karzinome des Hundes.
Svensk Veterinärtidskrift. 1947; 37: 453–482
[128] Sueda MT, Stefanacci JD: Ultrasound evaluation of the parathyroid
glands in two hypercalcemic cats. Vet Radiol Ultrasound. 2000; 41:
448–451
[129] Sundaresan G, Yazaki PJ, Shively JE et al.: 124I-labeled engineered
anti-CEA minibodies and diabodies allow high-contrast, antigenspecific small-animal PET imaging of xenografts in athymic mice. J
Nucl Med. 2003; 44: 1962–1969
[130] Suter PF, Carrig CB, OʼBrien TR et al.: Radiographic recognition of
primary and metastatic pulmonary neoplasms of dogs and cats. Vet
Radiol. 1974; 15: 3–25
[143] Wallack ST, Wisner ER, Werner JA et al.: Accuracy of magnetic
resonance imaging for estimating intramedullary osteosarcoma
extent in pre-operative planning of canine limb-salvage procedures.
[144] Walter PA, Haynes JS, Feeney DA et al.: Radiographic appearance
of pulmonary metastases from transitional cell carcinoma of the
bladder and urethra of the dog. J Am Vet Med Assoc. 1984; 185:
411–418
[145] Waters DJ, Coakley FV, Cohen MD et al.: The detection of pulmonary metastases by helical CT: a clinicopathologic study in dogs. J
Comput Assist Tomogr. 1998, 22: 235–240
[146] Weissleder R, Mahmood U: Molecular imaging. Radiology. 2001;
219: 316–333
[147] Wisner ER, Dickinson PJ, Higgins RJ: Magnestic resonance imaging features of canine intracranial neoplasia. Vet Radiol Ultrasound.
2011; 52 (Suppl. 1): 52–61
[148] Winter MD, Kinney LM, Kleine LJ: Three-dimensional helical computed tomographic angiography of the liver in five dogs. Vet Radiol
Ultrasound. 2005; 46: 494–499
[149] Withrow SJ: Osteosarcoma. Vet Q. 1998; 20 (Suppl. 1): 19–21
[150] Withrow SJ: Tumors of the respiratory system. In: Withrow SJ, Vail
DM (Hrsg.). Small animal clinical oncology. 4. Aufl., Saunders Elsevier, St. Louis; 2007; 511–525
[151] Wolf M, Pedroia V, Higgins RJ et al.: Intracranial ring enhancing
lesions in dogs: a correlative CT scanning and neuropatholgic study.
Vet Radiol Ultrasound. 1995; 36, 16–20
[152] Wood EF, OʼBrien RT, Young KM: Ultrasound-guided fine-needle
aspiration of focal parenchymal lesions of the lung of dogs and cats.
J Vet Intern Med. 1998; 12: 338–342
[131] Szatmári V, Harkányi Z, Vörös K: A review of nonconventional ultrasound techniques and contrast-enhanced ultrasonography of
noncardiac canine disorders. Vet Radiol Ultrasound. 2003; 44: 380–
391
[153] Yamazoe K, Ohashi F, Kadosawa T et al.: Computed tomography
on renal masses in dogs and cats. J Vet Med Sci.1994 ; 56: 813–816
[132] Tassani-Prell M: Computertomographie zur Diagnostik abdominaler Tumorerkrankungen. Proc. DGK-DVG Arbeitstagung, Hofheim,
2011, 104–109
[154] Yoon J, Feeney DA, Cronk DE et al.: Computed tomographic evaluation of canine and feline mediastinal masses in 14 patients. Vet
[133] Tassani-Prell M, Both C, Köstlin R: Nierenfunktionsszintigraphie
mit 99mTC Mercaptacetyltriglycin (MAG3) bei Hund und Katze.
Kleintierprax.1997; 42: 287–303
[155] Zekas LJ, Crawford JT, OʼBrien RT: Computed tomography-guided
fine-needle aspirate and tissue-core biopsy of intrathoracic lesions
in thirty dogs and cats. Vet Radiol Ultrasound. 2005; 46: 200–204
[134] Thrall DE: Radiographic diagnosis of metastatic pulmonary neoplasia. Comp Cont Educ Small Anim Pract. 1979; 1: 131–139
[156] Zwingenberger AL, Schwarz T: Dual-phase CT angiography of the
normal canine portal and hepatic vasculature. Vet Radiol Ultrasound. 2004; 45: 117–124
[135] Tidwell AS: Diagnostic pulmonary imaging. Probl Vet Med. 1992;
4:239–264
[136] Tidwell AS, Robertson ID: Magnetic resonance imaging of normal
and abnormal brain perfusion. Vet Radiol Ultrasound. 2011; 52
(Suppl. 1): 62–71
[137] Tiemessen I: Thoracic metastases of canine mammary gland
tumors: a radiographic study. Vet Radiol. 1989; 30: 249–252
[138] Troxel MT, Vite CH, Massicotte C et al.: Magnetic resonance imaging features of feline intracranial neoplasia: Retrospective analysis
of 46 cats. J Vet Intern Med. 2004; 18: 176–189
[139] van der Vlugt-Meijer RH, Meij BP, van den Ingh TS et al.: Dynamic computed tomography of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med. 2003; 17:
773–780
[140] Viglianti BL, Lora-Michels M, Poulsen JM et al.: Dynamic contrastenhanced magnetic resonance imaging as a predictor of clinical
outcome in canine spontaneous soft tissue sarcomas treated with
thermoradiotherapy. Clin Cancer Res. 2009; 15: 4993–5001
7
Gewebediagnose
7.1 Biopsie
[1]
Argyle DJ, Brearley MJ, Turek MM: Decision making in small animal oncology. Wiley-Blackwell, 2008
[2]
Brisson BA, Reggeti F, Bienzle D: Portal site metastasis of invasive
mesothelioma after diagnostic thoracoscopy in a dog. J Am Vet
Med Assoc. 2006; 229: 980–983
[3]
Choy A, McCulloch P: Induction of tumour cell shedding into effluent venous blood breast cancer surgery. Br J Cancer. 1996; 73: 79–
82
[4]
Dernell WS: Surgical oncology – biopsy techniques and margin
evaluation. Proc North Am Vet Conf, Orlando, USA, 2005
[5]
Dernell WS, Withrow SJ: Preoperative patient planning and margin evaluation. Clin Tech Small Anim Pract. 1998; 13: 17–21
[6]
Ehrhart N: Principles of tumor biopsy. Clin Tech Small Anim Pract.
1998; 13: 10–16
[7]
Epstein E, Bragg K, Linden G: Biopsy and prognosis of malignant
melanoma. J Am Med Assoc. 1969; 208: 1369–1371
[8]
Fidler IJ: Cancer metastasis. Br Med Bull. 1991; 47: 157–177
[9]
Gilson SD, Stone EA: Surgically induced tumor seeding in eight
dogs and two cats. J Am Vet Med Assoc. 1990; 196: 1811–1815
[10]
Goldfarb M, Brower S, Schwaitzberg SD: Minimally invasive surgery and cancer: controversies part 1. Surg Endosc. 2010; 24: 304–
334
[11]
Henninger W: Use of computed tomography in the diseased feline
thorax. J Small Anim Pract. 2003; 44: 56–64
[12]
[13]
Jiménez Peláez M, Bouvy BM, Dupré GP: Laparoscopic adrenalectomy for treatment of unilateral adrenocortical carcinomas: technique, complications, and results in seven dogs. Vet Surg. 2008; 37:
444–453
Kamstock DA, Ehrhart EJ, Getzy DM et al.: Recommended guidelines for submission, trimming, margin evaluation, and reporting of
tumor biopsy specimens in veterinary surgical pathology. Vet
Pathol. 2011; 48: 19–31
[14]
Langmuir VK, Patterson WB, Schwartz SI: Principles of surgical
oncology. In: Rubin P. (Hrsg.): Clinical oncology. WB Saunders Co.,
Philadelphia 1993; 41–50
[15]
Martin RA: Incisional versus excisional biopsy. Semin Vet Med Surg
(Small Anim). 1993; 8: 228–234
[16]
McMillan JC, Kleine LJ, Carpenter JL: Fluoroscopically guided percutaneous fine-needle aspiration biopsy of thoracic lesions in dogs
and cats. Vet Radiol. 1988; 29: 194–197
[17]
Nyland TG, Wallack ST, Wisner ER: Needle-tract implantation following US-guided fine-needle aspiration biopsy of transitional cell
[18]
Peters-Engl P, Konstantiniuk P, Tausch C et al.: The impact of
preoperative breast biopsy on the risk of sentinel lymph node
metastases: analysis of 2502 cases from the Austrian sentinel node
biopsy study group. Br J Cancer. 2004; 91: 1782–1786
[29]
Vignoli M, Ohlerth S, Rossi F et al.: Computed tomography-guided fine-needle aspiration and tissue-core biopsy of bone lesions in
small animals. Vet Radiol Ultrasound. 2004; 45: 125–30
[30]
Vignoli M, Rossi F, Chierici C et al.: Needle tract implantation after
[31]
Wackes J: Laparoskopische und thorakoskopische Biopsieentnahmen bei Hund und Katze. Kleintierprax. 1996; 41: 411–418
[32]
Withrow SJ, Lowes N: Biopsy techniques for use in small animal
oncology. J Am Anim Hosp Assoc. 1981; 17: 889–902
[33]
Withrow SJ: Overview of biopsy principles and surgical oncology.
Proc. WSAVA, Vancouver 2001
[34]
Withrow SJ: Biopsy principles. Vet Q. 1998; 20 Suppl 1: 14–15
[35]
Withrow SJ: Risks associated with biopsies for cancer. In: Bonagura
JD (Hrsg.) Kirkʼs current veterinary therapy XII, Philadelphia. 1995,
WB Saunders, 24–26
[36]
Wykes PM, Withrow SJ, Powers BE et al.: Closed biopsy for diagnosis of long bone tumors: Accuracy and results. J Am Anim Hosp
Assoc. 1985; 21: 489–494
[37]
Zekas LJ, Crawford JT, OʼBrien RT: Computed tomography-guided
fine needle aspirate and tissue-core biopsy of intrathoracic lesions
in thirty dogs and cats. Vet Radiol Ultrasound. 2005; 3: 200–204
7.2 Grundlagen der Histologie
[1]
Abadie JJ, Amardeilh MA, Delverdier ME: Immunohistochemical
detection of proliferating cell nuclear antigen and Ki-67 in mast cell
tumors from dogs. J Am Vet Med Assoc. 1999; 215: 1629–1634
[2]
Bauer NB, Zervos D, Moritz A: Argyrophilic nucleolar organizing
regions and Ki67 equally reflect proliferation in fine needle aspirates
of normal, hyperplastic, inflamed, and neoplastic canine lymph
nodes (n = 101). J Vet Intern Med. 2007; 21: 928–935
[3]
Berman PJ: Clinical techniques in small animal molecular oncology.
Clin Tech Small Anim Pract. 2003; 18: 88–91
[4]
Powers BE, LaRue SM, Withrow SJ et al.: Jamshidi needle biopsy
for diagnosis of bone lesions in small animals. J Am Vet Med Assoc.
1988; 193: 205–210
Bielinska M, Parviainen H, Kiiveri S et al.: Review paper: origin
and molecular pathology of adrenocortical neoplasms. Vet Pathol.
2009; 46: 194–210
[5]
[20]
Powers BE, Dernell WS: Tumor biology and pathology. Clin Tech
Breen M: Canine cytogenetics – from band to basepair. Cytogenet
Genome Res. 2008; 120: 50–60
[6]
[21]
Radlinsky MG: Complications and need for conversion from thoracoscopy to thoracotomy in small animals. Vet Clin North Am Small
Anim Pract. 2009; 39: 977–984
Breen M, Modiano JF: Evolutionary conserved cytogenetic changes
in hematological malignancies of dogs and humans – man and his
best friend share more than companionship. Chromos Res. 2008;
16: 145–154
[22]
Richter KP: Laparoscopy in dogs and cats. Vet Clin North Am Small
Anim Pract. 2001; 31: 707–727, ix
[7]
[23]
Schmiedt C: Small animal exploratory thoracoscopy. Vet Clin North
Am Small Anim Pract. 2009; 39: 953–964
Bundgaard-Andersen K, Flagstad A, Jensen AL et al.: Correlation
between the histopathological diagnosis by AgNOR count and
AgNOR area in canine mammary tumors. J Vet Intern Med. 2008;
22: 1174–1180
[24]
Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis.
Annu Rev Cell Biol. 1993; 9: 541–573
[8]
Carter PB, Beegle KH, Gebhard DH: Monoclonal antibodies. Clinical uses and potential. Vet Clin North Am Small Anim Pract. 1986;
16: 1171–1179
[25]
Stockhaus S, Schoon HA, Scharvogel S et al.: Die Bedeutung der
Zytologie für den Nachweis von Knochentumoren bei Hund und
Katze. Tierärztl Prax. 2003; 31: 117–123
[9]
Chandler HL, Colitz CM: Molecular biology for the clinician: understanding current methods. J Am Anim Hosp Assoc. 2006; 42: 326–
335
[26]
Stone EA: Biopsy: principles, technical considerations, and pitfalls.
Vet Clin North Am Small Anim Pract. 1995; 25: 33–45
[10]
Coomer AR, Liptak JM: Canine histiocytic diseases. Compend Cont
Educ Small Anim Pract. 2008; 30: 202–204, 208,219, quiz 2016–
217
[27]
Teske E, Stokhof AA, van den Ingh TSGAM et al.: Transthoracic
needle aspiration biopsy of the lung in dogs with pulmonic diseases.
[11]
Dickinson RM: Canine lymphosarcoma: overcoming diagnostic
obstacles and introduction to the latest diagnostic techniques. Can
Vet J. 2008; 49: 305–308
[28]
Tidwell AS, Johnson KL: Computed tomography-guided percutaneous biopsy in the dog and cat: description of technique and preliminary evaluation in 14 patients. Vet Radiol Ultrasound. 1994; 35:
445–456
[12]
Dungworth DL, Hauser B, Hahn FF et al.: World Health Organization International histological classification of tumors of domestic
animals. Second Series, Volume VI. Histological classification of the
tumors of the respiratory system of domestic animals. Washington,
DC: Armed Forces Institute of Pathology in cooperation with the
[19]
19
20
American Registry of Pathology and The World Health Organization
Collaborating Center for Worldwide Reference on Comparative
Oncology; 1999
[13]
Ettinger SN, Scase TJ, Oberthaler KT et al.: Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with
soft tissue sarcomas: 60 cases (1996–2002). J Am Vet Med Assoc.
2006; 228: 1053–1062
borating Center for Worldwide Reference on Comparative Oncology; 1999
[28]
Kiupel M, Bostock D, Bermann V: The prognostic significance of
AgNOR counts and PCNA-positive cell counts in canine malignant
lymphoma. J Comp Pathol 1998; 119: 407–418
[29]
Kiupel M, Teske E, Bostock D: Prognostic factors for treated
canine malignant lymphomas. Vet Pathol. 1999; 36: 292–300
[30]
Kiupel M, Capen C, Miller M et al.: World Health Organization
International histological classification of tumors of domestic animals. Second Series, Volume XII. Histological classification of
tumors of the endocrine system of domestic animals. Washington,
DC: Armed Forces Institute of Pathology in cooperation with the CL
Davis DVM Foundation and The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology;
2008
[31]
Koestner A, Bilzer T, Fatzer R et al.: World Health Organization
International histological classification of tumors of domestic animals. Second Series, Volume V. Histological classification of tumors
of the nervous system of domestic animals. Washington, DC:
Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology; 1999
[14]
Fernandez NJ, West KH, Jackson ML et al.: Immunohistochemical
and histochemical stains for differentiating canine cutaneous round
cell tumors. Vet Pathol. 2005; 42: 437–445
[15]
Fontaine J, Bovens C, Bettenay S et al.: Canine cutaneous epitheliotropic T-cell lymphoma: a review. Vet Comp Oncol. 2009; 7: 1–14
[16]
Fournel-Fleury C, Magnol J-P, Guelfi J-F: Atlas en couleur de cytologie due cancer chez le chien et le chat. Conf. Nationale de Vétérinaire Spécialsés en Petits Animaux, 1994
[17]
Fulmer AK, Mauldin GE: Canine histiocytic neoplasia: an overview.
Can Vet J. 2007; 48: 1046–1050
[18]
Gamblin RM, Sagartz JE, Couto CG: Overexpression of p53 tumor
suppressor protein in spontaneously arising neoplasms of dogs. Am
J Vet Res. 1997; 58: 857–863
[19]
Gentilini F, Calzolari C, Turba ME et al.: Prognostic value of serum
vascular endothelial growth factor (VEGF) and plasma activity of
matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected
dogs. Leuk Res. 2005; 29: 1263–1269
[32]
[20]
Goldschmidt MH, Shofer FS: Skin tumors of the dog and cat. Pergamon Press, Oxford, New York, Seoul, Tokyo, 1992
Madewell BR: Cellular proliferation in tumors: a review of methods,
interpretation, and clinical applications. J Vet Intern Med. 2001; 15:
334–340
[33]
[21]
Goldschmidt MH, Dunstan RW, Stannard AA et al.: World Health
Organization International histological classification of tumors of
domestic animals. Second Series, Volume III. Histological classification of epithelial and melanocytic tumors of the skin of domestic
animals. Washington, DC: Armed Forces Institute of Pathology in
cooperation with the American Registry of Pathology and The
World Health Organization Collaborating Center for Worldwide
Reference on Comparative Oncology; 1998
Maiolino P, Cataldi M, Paciello O et al.: Nucleomorphometric analysis of canine cutaneous mast cell tumours. J Comp Pathol. 2005;
133: 209–211
[34]
Meuten DJ (Hrsg): Tumors in Domestic Animals. 4. Aufl., Ames, IO:
Iowa State Press; 2002
[35]
Meuten DJ, Everitt J, Inskeep W et al.: World Health Organization
International histological classification of tumors of domestic animals. Second Series, Volume XI. Histological classification of tumors
of the urinary system of domestic animals. Washington, DC: Armed
Forces Institute of Pathology in cooperation with the American
Registry of Pathology and The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology;
2004
[36]
Misdorp W: Veterinary cancer epidemiology. Vet Q. 1996; 18: 32–
36
[37]
Misdorp W, Else RW, Hellmen E et al.: World Health Organization
International histological classification of tumors of domestic animals. Second Series, Volume VII. Histological classifiation of mammary tumors of the dog and the cat. Washington, DC: Armed Forces Institute of Pathology in cooperation with the American
1999
[38]
Mukaratirwa S: Prognostic and predictive markers in canine
tumours: rationale and relevance. A review. Vet Q. 2005; 27: 52–64
Henrich M, Hecht W, Weiss AT et al.: A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of
clonality in feline B-cell lymphomas. Vet Immunol Immunopathol.
2009; 130: 59–69
[39]
Newman SJ: Diagnostic pathology for the cancer patient. Clin Tech
[40]
Nolte I, Nolte M (Hrsg.): Praxis der Onkologie. Stuttgart: Enke;
2000
[25]
Henrich M, Huisinga M, Bauer N et al.: A case of intravascular
lymphoma with mixed lineage antigen expression in a cat. J Vet
Med A. 2007; 54: 575–578
[41]
Northrup NC, Harmon BG, Gieger TL et al.: Variation among
pathologists in histologic grading of canine cutaneous mast cell
tumors. J Vet Diagn Invest. 2005; 17: 245–248
[26]
Huisinga M, Henrich M, Frese K et al.: Extraventricular neurocytoma of the spinal cord in a dog. Vet Pathol. 2007; 45: 63–66
[42]
[27]
Kennedy PC, Cullen MJ, Edwards JF et al.: World Health Organization International histological classification of tumors of domestic
animals. Second Series, Volume IV. Histological classification of
tumors of the genital system of domestic animals. Washington, DC:
Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and The World Health Organization Colla-
Northrup NC, Howerth EW, Harmon BG et al.: Variation among
pathologists in the histologic grading of canine cutaneous mast cell
tumors with uniform use of a single grading reference. J Vet Diagn
Invest. 2005; 17: 561–564
[43]
Otsuki Y, Li Z, Shibata MA: Apoptotic detection methods – from
morphology to gene. Prog Histochem Cytochem. 2003; 38: 275–
339
[22]
[23]
[24]
Head KW, Cullen JM, Dubielzig RR et al.: World Health Organization International histological classification of tumors of domestic
animals. Second Series, Volume X. Histological classification of
tumors of the alimentary system of domestic animals. Washington,
DC: Armed Forces Institute of Pathology in cooperation with the
American Registry of Pathology and The World Health Organization
Collaborating Center for Worldwide Reference on Comparative
Oncology; 2003
Hendrick MJ, Mahaffey EA, Moore FM et al: World Health Organization International histological classification of tumors of domestic
animals. Second Series, Volume II. Histological classification of
mesenchenymal tumors of skin and soft tissues of domestic animals. Washington, DC: Armed Forces Institute of Pathology in
cooperation with the American Registry of Pathology and The
World Health Organization Collaborating Center for Worldwide
Reference on Comparative Oncology; 1998
[44]
Ozaki K, Yamagami T, Nomura K et al. : Prognostic significance of
surgical margin, Ki-67 and cyclin D1 protein expression in grade II
canine cutaneous mast cell tumor. J Vet Med Sci. 2007; 69: 1117–
1121
[45]
Patnaik AK, Ehler WJ, MacEwen EG: Canine cutaneous mast cell
tumor: morphologic grading and survival time in 83 dogs. Vet
Pathol. 1984; 21: S. 469–474
[46]
Preziosi R, Sarli G, Benazzi C et al.: Multiparametric survival analysis of histological stage and proliferative activity in feline mammary
carcinomas. Res Vet Sci. 2002; 73: 53–60
[47]
Preziosi R, Sarli G, Paltrinieri M: Multivariate survival analysis of
histological parameters and clinical presentation in canine cutaneous mast cell tumours. Vet Res Commun. 2007; 31: 287–296
[48]
Priester WA, McKay FW: The occurrence of tumors in domestic
animals. Bethesda, ML: Nat Cancer Inst Monographs; 1980
[49]
[50]
Reinacher M: Praxisrelevante Tumoren bei der Katze. Prakt Tierarzt.
(Coll. Vet. XXVII) 1997; 78: 10–12
[51]
Reinacher M: Tumors of the immune system of the cat. In: Pastoret
PP, Griebel P (Hrsg.): Handbook of vertebrate immunology. London:
Academic Press; 1998: 325–335
[52]
Rhind S: Veterinary oncological pathology – current and future perspectives. Vet J. 2002; 163: 7–18
[53]
Romeis B: Mikroskopische Technik. 17. Aufl., München: Urban &
Schwarzenberg; 1989
[54]
Sabattini S, Bettini G: Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Vet
Pathol. 2010; 47: 643–653
[55]
Sarli TJ, Preziosi R, Benazzi C et al.: Prognostic value of histologic
stage and proliferative activity in canine malignant mammary
tumors. J Vet Diagn Invest 2002; 14: 25–34
[56]
Scase, TJ, Edwards D, Miller J et al.: Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet
Intern Med. 2006; 20: 151–158
[57]
Slayter MV, Boosinger TR, Pool RR et al.: World Health Organization International histological classification of tumors of domestic
animals. Second Series, Volume I. Histological Classification of Bone
and Joint Tumors of Domestic Animals. Washington, DC: Armed
Forces Institute of Pathology in cooperation with the American
1994
[58]
Sorensen KC, Kitchell BE, Schaeffer DJ et al.: Expression of matrix
metalloproteinases in feline vaccine site-associated sarcomas. Am J
Vet Res. 2004; 65: 373–379
[59]
Strefezzi Rde F, Xavier JG, Catão-Dias JL: Morphometry of canine
cutaneous mast cell tumors. Vet Pathol. 2003; 40: 268–275
[60]
Strefezzi R de F, Xavier JG, Kleeb SR et al.: Nuclear morphometry
in cytopathology: a prognostic indicator for canine cuteneous mast
cell tumors. J Vet Diagn Invest. 2009; 21: 821–825
[61]
Theilen GH, Madewell BR: Veterinary Cancer Medicine, 2. Auflg.,
Philadelphia: Lea & Febiger; 1987
[62]
Tuohy JL, Milgram J, Worley DR et al.: A review of sentinel lymph
node evaluation and the need for its incorporation into veterinary
oncology. Vet Comp Oncol. 2009; 7: 81–91
[63]
Valli VE, Jacoby RM, Parodi AL et al.: World Health Organization
International histological classification of tumors of domestic animals. Second Series, Volume VIII. Histological classification of
hematopoietic tumors of domestic animals. Washington, DC:
Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology; 2002
[64]
Webster JD, Yazbasiyan-Gurkan V, Miller RA et al.: Cellular proliferation in canine cuteneous mast cell tumors: associations with
c-KIT and its role in prognostication. Vet Pathol. 2007; 44: 298–308
[65]
Webster JD, Yuzbasiyan-Gurkan V, Thamm DH et al.: Evaluation
of prognostic markers for canine mast cell tumors treated with
vinblastine and prednisone. BMC Vet Res. 2008; 4: 32
[66]
Welle MM, Bley CR, Howard J et al.: Canine mast cell tumours: a
review of pathogenesis, clinical features, pathology and treatment.
Vet Dermatol. 2008; 19: 321–339
[67]
Weiss AT, Hecht W, Henrich M et al.: Characterization of C-,
J- and V-region-genes of the feline T-cell receptor γ. Vet Immunol
Immunopathol. 2008; 124: 63–74
[68]
White RAS: Kompendium der Onkologie in der Veterinärmedizin.
Hannover: Schlütersche; 1998
[69]
Wilcock B, Dubielzig RR, Bender JA: World Health Organization
International histological classification of tumors of domestic animals. Second Series, Volume IX. Histological classification of ocular
and otic tumors of domestic animals. Washington, DC: Armed Forces Institute of Pathology in cooperation with the American
2002
[70]
William DC: Studies on canine leukocyte antigens: a significant
advance in canine immunology. Vet J. 1997; 153: 31–39
[71]
Zemke D, Yamini B, Yuzbasiyan-Gurkan VA: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade
mast cell tumors in dogs. Vet Pathol. 2002; 39: 529–535
7.3 Zytologie
[1]
Allemann AR, Bain PJ: Diagnosing neoplasia: The cytological criteria for malignancy. Vet Med. 2000; 95: 204–223
[2]
Allen SW, Prasse KW: Cytologic diagnosis of neoplasia and perioperative implementation. Compend Contin Educ Pract Vet. 1986;
8: 72–80
[3]
Allen SW, Prasse KW, Mahaffey EA: Cytologic differentiation of
benign from malignant mammary tumors. Vet Pathol. 1986; 23:
649–655
[4]
Baker R, Lumsden JH: Color atlas of cytology of the dog and cat.
Mosby St. Louis, USA 2000
[5]
Ballegeer EA, Forrest LJ, Dickinson RM et al.: Correlation of ultrasonographic appearance of lesions and cytologic and histologic
diagnoses in splenic aspirates from dogs and cats: 32 cases (2002–
2005). J Am Vet Med Assoc. 2007; 230: 690–696
[6]
Berg JW, Robbins GF: A late look at the safety of aspiration biopsy.
Cancer 1962; 15: 826–827
[7]
Bonfanti U, Bertazzolo W, Bottero E et al.: Diagnostic value of
cytologic examination of gastrointestinal tract tumors in dogs and
cats: 83 cases (2001–2004). J Am Vet Med Assoc. 2006; 229:
1130–1133
[8]
Britt T, Clifford C, Barger A et al.: Diagnosing appendicular osteosarcoma with ultrasound-guided fine-needle aspiration: 36 cases. J
[9]
Cohen M, Bohling MW, Wright JC et al.: Evaluation of sensitivity
and specificity of cytologic examination: 269 cases (1999–2000). J
Am Vet Med Assoc. 2003; 222: 964–967
[10]
Couto CG: Cytology. In: Nelson RW, Couto CG (Hrsg.): Small animal
internal medicine. 4. Aufl. Mosby Inc., St. Louis, 2009; S. 1143–
1149
[11]
Cowell RL, Tyler RD, Meinkoth JH et al.: Diagnostic cytology and
hematology of the dog and cat. 3. Aufl., Mosby Inc., St. Louis USA
2008
[12]
DeNicola D, Reagan WJ: Using cytology in the diagnosis of cancer.
In: Morrison WB (Hrsg.): Cancer in dogs and cats. Williams and Wilkins, Baltimore 1998; S. 79–94
21
22
[13]
Duncan JR, Prasse KW: Cytology of canine cutaneous round cell
[14]
Dunn JK, Gerber K: Diagnostic cytology. In: Villiers E, Blackwood L
(Hrsg.): BSAVA Manual of canine and feline clinical pathology. 2.
Aufl. British Small Animal Veterinary Association, Shurdington, Cheltenham, 2005, S. 305–339
[15]
Engzell U, Esposti PL, Rubio C et al.: Investigation on tumor spread
in connection with aspiration biopsy. Acta Radiol. 1971; 10: 385–
398
[16]
Epstein E, Bragg K, Linden G: Biopsy and prognosis of malignant
melanoma. J Am Med Assoc. 1969; 208: 1369–1371
[17]
Fournel-Fleury C, Magnol JP, Guelfi JF: Color atlas of cancer cytology of the dog and cat – Atlas en couleur de cytologie du cancer
chez le chien et le chat. Conférence Nationale des Vétérinaires Spécialisés en Petits Animaux, PCAMC éditions, Paris 1994
[18]
Freudenberg N, Kortsik C, Ross A: Grundlagen der Zytopathologie
– Kurzlehrbuch und Atlas der allgemeinen und speziellen Zytodiagnostik, Karger Verlag, Freiburg, 2002
[19]
Ghisleni G, Roccabianca P, Ceruti R et al.: Correlation between
fine-needle aspiration cytology and histopathology in the evaluation
of cutaneous and subcutaneous masses from dogs and cats. Vet
Clin Pathol. 2006; 35: 24–30
[20]
Griffith GL, Lumsden JH: Fine needle aspiration cytology and histologic correlation in canine tumors. Vet Clin Pathol. 1984; 13: 13–17
[21]
Hirschberger J: Organzytologie. In: Kraft W, Dürr UM (Hrsg.): Klinische Labordiagnostik in der Tiermedizin. 6. Aufl. Schattauer Stuttgart, 2005, S. 330–347
[36]
Simon D, Schoenrock D, Nolte I et al.: Cytologic examination of
fine-needle aspirates from mammary gland tumors in the dog:
diagnostic accuracy with comparison to histopathology and association with postoperative outcome. Vet Clin Pathol. 2009; 38: 521–
528
[37]
Stockhaus C, Teske E: Klinische Einsatzgebiete der zytologischen
Diagnostik bei der Katze. Wien Tierärztl Monatsschr. 2001; 88:
323–331
[38]
Stockhaus C, Teske E: Klinische Erfahrungen mit der zytologischen
Diagnostik beim Hund. Schweiz Arch Tierheilkd. 2001; 143: 233–
240
[39]
Wellmann ML: The cytologic diagnosis of neoplasia. Vet Clin North
[40]
Wurm S, Ueberschär S, Nolte I: Aussagekraft der Zytologie bei
Haut- und Mammatumoren des Hundes. Monatsh Vet-Med. 1993;
48: 473–478
[41]
Zinkl JG: Criteria of malignancy in cytologic preparations. Calif Vet.
1981; 35: 13–17
7.4 Zytologie maligner Körperhöhlenergüsse
Alleman AR: Abdominal, thoracic, and pericardial effusions. Vet
Clin North Am Small Anim Pract. 2003; 33: 89–118
[2]
Bauer N, Moritz A: Flow cytometric analysis of effusions in dogs
and cats with the automated haematology analyser ADVIA 120. Vet
Rec. 2005; 156: 674–678
[3]
Connally HE: Cytology and fluid analysis of the acute abdomen.
[4]
Léveillé R, Partington BP, Biller DS et al.: Complications after
ultrasound-guided biopsy of abdominal structures in dogs and cats:
Culp WT, Zeldis TE, Reese MS et al.: Primary bacterial peritonitis
in dogs and cats: 24 cases (1990–2006). J Am Vet Med Assoc.
2009; 234: 906–913
[5]
Meinkoth HJ, Cowell RL: Recognition of basic cell types and criteria
of malignancy. Vet Clin North Am Small Anim Pract. 2002; 32:
1209–1235
Dempsey SM, Ewing PJ: A review of the pathophysiology, classification, and analysis of canine and feline cavitary effusions. J Am
[6]
Else RW, Simpson JW: Diagnostic value of exfoliative cytology of
body fluids in dogs and cats. Vet Rec. 1988; 123: 70–76
Kessler M: Zur Diagnostik von Tumoren mittels Nadelaspirationszytologie. Tierärztl Prax. 1995; 23: 534–541
[23]
LeBlanc CJ, Head LL, Fry MM: Comparison of aspiration and nonaspiration techniques for obtaining cytologic samples from the
canine and feline spleen. Vet Clin Pathol. 2009; 38: 242–246
[25]
Simeonov RS: The accuracy of fine-needle aspiration cytology in
the diagnosis of canine skin and subcutaneous masses. Comp Clin
Pathol. 2012; 21: 143–147
[1]
[22]
[24]
[35]
[26]
Menard M, Fontaine M, Morin M: Fine needle aspiration biopsy of
malignant tumours in dogs and cats: a report of 102 cases. Can Vet
J. 1986; 27: 504–510
[7]
[27]
Menard M, Papageorges M: Ultrasound corner: technique for
ultrasound-guided fine needle biopsies. Vet Radiol Ultrasound
1994; 36: 137–138
Garrett LD: Mesothelioma. In: Withrow SJ, Vail DM (Hrsg.): Withrow
and MacEwenʼs Small Animal Clinical Oncology. WB Saunders Inc.,
St. Louis, Missouri. 2007; 804–808
[8]
[28]
Meyer DJ: The management of cytology specimens. Compend Contin Educ Pract Vet. 1987; 9: 10–17
Gorman ME, Villarroel A, Tornquist SJ et al.: Comparison between
manual and automated total nucleated cell counts using the ADVIA
120 for pleural and peritoneal fluid samples from dogs, cats, horses,
and alpacas. Vet Clin Pathol. 2009; 38: 388–391
[29]
Mischke R: Zytologisches Praktikum für die Veterinärmedizin.
Schlütersche Verlagsgesellschaft, Hannover, 2005
[9]
Grogan DR, Irwin RS, Channick R et al.: Complications associated
with thoracocentesis. Arch Intern Med. 1990; 150: 873–877
[30]
Nyland TG, Wallack ST, Wisner ER: Needle-tract implantation following US-guided fine-needle aspiration biopsy of transitional cell
carcinoma of the bladder, urethra and prostate. Vet Radiol Ultrasound. 2002; 43: 50–53
[10]
Hirschberger J, DeNicola DB, Hermanns W et al.: Sensitivity and
specificity of cytologic evaluation in the diagnosis of neoplasia in
body fluids from dogs and cats. Vet Clin Path. 1999; 28: 142–146
[11]
Hirschberger J: Körperhöhlenergüsse. In: Kraft W, Dürr U (Hrsg.):
Klinische Labordiagnostik in der Tiermedizin. F.K. Schattauer Verlag,
Stuttgart 2005; 241–248
[12]
Hirschberger J: Zytologie von Körperhöhlenergüssen. Tierärztl
Prax. 1995; 23: 192–199
[13]
Rakich PM, Latimer KS: Cytology. In: Latimer KS, Mahaffey EA,
Prasse KW (Hrsg.): Duncan & Prasseʼs Veterinary Laboratory Medicine: Clinical Pathology. Iowa State Press, Ames 2003, 304–330
Maher I, Tennant KV, Papasouliotis K: Effect of storage time on
automated cell count and cytological interpretation of body cavity
effusions. Vet Rec. 2010; 167: 519–522
[14]
Raskin RE, Meyer DJ: Canine and feline cytology. A color atlas and
interpretation guide. 2. Aufl., W.B. Saunders Company, Philadelphia
2010
Ottenjann M, Lübke-Becker A, Linzmann H et al.: Pyothorax bei
26 Katzen: Klinik, Labordiagnostik und Therapie (2000–2007). Berl
Munch Tierarztl Wochenschr. 2008; 121: 365–373
[15]
Permann V, Alsaker RD, Riis RC: Cytology of body fluids. In: Permann V, Alsaker RD, Riis RC (Hrsg.): Cytology of the dog and cat.
American Animal Hospital Association, Denver 1979; 17–20
[31]
Orell SR, Sterret GF, Walters MNI et al.: Punktionszytologie. Handbuch und Atlas. Georg Thieme Verlag, Stuttgart 1999
[32]
Papageorges M, Gavin PR, Sande RD et al.: Ultrasound-guided
fine needle aspiration: an inexpensive modification of the technique. Vet Radiol. 1998; 29: 269–271
[33]
[34]
23
Pinto da Cunha N, Giordano A, Caniatti M et al.: Analytical validation of the Sysmex XT-2000iV for cell counts in canine and feline
effusions and concordance with cytologic diagnosis. Vet Clin Pathol.
2009; 38: 230–241
8
Onkologische Chirurgie
8.1 Prinzipien der onkologischen Chirurgie
[1]
Aiken SW: Principles of surgery for the cancer patient. Clin Tech
[2]
Rizzi TE, Cowell RL, Tyler RD et al.: Effusions: Abdominal, thoracic,
and pericardial. In: Cowell RL, Tyler RD, Meinkoth JH et al. (Hrsg):
Diagnostic cytology and hematology of the dog and cat. Mosby
Inc., St. Louis, Missouri. 2008; 235–255
Bacon NJ, Dernell WS, Ehrhart N et al.: Evaluation of primary reexcision after recent inadequate resection of soft tissue sarcomas in
dogs: 41 cases (1999–2004). J Am Vet Med Assoc. 2007; 230:548–
554
[3]
Thrall MA: Evaluation of thoracic effusions. Part 1. Mod Vet Pract.
1983; 64: 288–293
Banks T, Straw R, Thomson M et al.: Soft tissue sarcomas in dogs:
a study assessing surgical margin, tumour grade and clinical outcome. Aust Vet Pract. 2004; 34: 158–163.
[4]
[20]
Walters JM: Abdominal paracentesis and diagnostic peritoneal
lavage. Clin Tech Small Anim Pract. 2003; 18: 32–38
Becker GD: The many faces of surgical margins. Am J Clin Oncol.
2007; 30: 556–559
[5]
[21]
Ziesche R, Matthys H: Diagnostik von Pleuraergüssen. Internist
1990; 31: 272–276
Cavanaugh R, Bacon NJ: Canine soft tissue sarcomas – what to do
with dirty margins? VSSO Newslet. 2007; 1: 3–4.
[6]
Dernell WS, Withrow SJ: Preoperative patient planning and margin evaluation. Clin Tech Small Anim Pract. 1998; 13: 17–21
7.5 Knochenmarkbiopsie
[7]
Ennekin WF: Musculoskeletal tumor surgery. Churchill-Livingstone,
New York 1983
[1]
Bauer N, Moritz A: Durchflusszytometrische Knochenmarkuntersuchung mit dem Hämatologiesystem ADVIA 120®. Tierärztl Prax.
2002; 30 (K): 472–476
[8]
[2]
Busse J: Referenzwerte der zytologischen Knochenmarkdiagnostik
beim Hund unter besonderer Berücksichtigung der Megakaryopoese. Diss med vet, TiHo Hannover, 2001
Fulcher RP, Ludwig LL, Bergman PJ et al.: Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II
cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2006;
228: 210–215
[9]
Gilson SD, Stone EA: Principles of oncologic surgery. Comp Cont
Ed Pract Vet. 1990; 12: 827–839
[3]
Coles EH: Veterinary Clinical Pathology, 4. Aufl., Saunders, Philadelphia, 1986
[10]
Gilson SD: Clinical management of the regional lymph node. Vet
[4]
Johnson CM, Gengozian N, Mergia A: Hematopoiesis in the feline
fetal liver: an assessment by flow cytometry. Vet Immunol Immunopathol. 2004; 99: 53–62
[11]
Gilson SD: Principles of surgery for cancer palliation and treatment
of metastases. Clin Tech Small Anim Pract. 1998; 13: 65–69
[5]
Keller P, Freudiger U: Atlas zur Hämatologie von Hund und Katze.
Parey, Berlin Hamburg, 1983
[12]
Harvey HJ: Surgery. In: Theilen GH, Madewell BR (Hrsg.): Veterinary
cancer medicine, 2. Aufl., Lea & Febinger, Philadelphia 1987; 121–
128
[6]
Keller P: Die Beurteilung der Megakaryopoese und des thrombozytären Systems beim Hund: Möglichkeiten zur Objektivierung von
klinischen Befunden und der Diagnosestellung in der Praxis. Kleintierprax. 1985; 30: 403–418
[13]
Hays DM, Lawrence W Jr, Wharam M et al.: Primary reexcision
for patients with ʼmicroscopic residualʼ tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg. 1989;
24: 5–10
[7]
Moritz A: Die Aussagekraft der Knochenmarkzytologie beim Hund.
Diss Med Vet, Giessen, 1993
[14]
[8]
Moritz A, Grünbaum EG: Bedeutung der Knochenmarkzytologie in
der Leukosediagnostik beim Hund. Tierärztl Prax. 1993; 21: 243–
251
444–453
[15]
[9]
Moritz A: Knochenmarkuntersuchung. In: Kraft W, Dürr UM (Hrsg.)
Klinische Labordiagnostik in der Tiermedizin. 6. Aufl., Schattauer,
Stuttgart. 2005; 93–114
Kamstock DA, Ehrhart EJ, Getzy DM et al.: Recommended guidelines for submission, trimming, margin evaluation, and reporting of
tumor biopsy specimens in veterinary surgical pathology. Vet
Pathol. 2011; 48: 19–31
[10]
Moritz A, Bauer NB, Weiss DJ et al.: Evaluation of Bone Marrow In:
Weiss DJ, Wardrop JK (Hrsg.): Schalm’s Veterinary Hematology.
6. Aufl., Blackwell Publishing, Ames. 2010
[16]
Kern KA, Pass HI, Roth JA: Surgical treatment for pulmonary
metastasis. In: Rosenberg SA (Hrsg.): Surgical treatment of metastatic cancer. JB Lippincott Co, Philadelphia 1987: 69–100
[11]
Stockham SL, Scott MA: Fundamentals of Veterinary Clinical
Pathology. 2. Aufl., Blackwell Publishing, Ames. 2008.
[17]
Kuntz CA: Thoracic surgical oncology. Clin Tech Small Anim Pract
1998; 13: 47–52
[12]
Weiss DJ: Determination of differential cell counts in feline bone
marrow by use of flow cytometry. Am J Vet Res. 2001; 62: 474–478
[18]
[13]
Weiss DJ: Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies. Vet Pathol. 2001; 38: 512–518
Mann FA, Pace LW: Marking margins of tumorectomies and excisional biopsies to facilitate histological assessment of excision completeness. Semin Vet Med Surg (Small Anim). 1993; 8: 279–283
[19]
McNiel EA, LaRue SM: Principles of adjunctive radiation therapy.
[20]
Moore GE: Debunking debulking. Surg Gynecol Obstet. 1980; 150:
395–396
[17]
[18]
[19]
Rebar AH: Diagnostic cytology in veterinary practice: current status
and interpretive principles. In: Kirk RW (Hrsg.): Current veterinary
therapy VII. Small animal practice. WB Saunders Co., Philadelphia
1980; 16–27
[14]
Weiss DJ: Flow cytometric and immunophenotypic evaluation of
acute lymphocytic leukemia in dog bone marrow. J Vet Intern Med.
2001; 15: 589–594
[21]
[15]
Weiss DJ: Use of monoclonal antibodies to refine flow cytometric
differential cell counting of canine bone marrow cells. Am J Vet Res.
2001; 62: 1273–1278
OʼBrien MG: Principles of oncologic abdominal surgery. Clin Tech
Small Anim Pract. 1998 ; 13: 42–46
[22]
Weiss DJ: Flow cytometric evaluation of canine bone marrow based
on intracytoplasmic complexity and CD45 expression. Vet Clin
Pathol. 2004; 33: 96–101
OʼBrien MG, Straw RC, Withrow SJ et al: Resection of pulmonary
metastases in canine osteosarcoma: thirty-one cases (1983–1992).
Vet Surg. 1993; 15: 105–109
[23]
Ogilvie GK: Chemotherapy and the surgery patient: principles and
recent advances. Clin Tech Small Anim Pract. 1998; 13: 22–32
[16]
[16]
24
[24]
[25]
Séguin B, McDonald DE, Kent MS et al.: Tolerance of cutaneous or
mucosal flaps placed into a radiation therapy field in dogs. Vet Surg.
2005; 34: 214–222
[16]
Grösslinger K, Lorinson D: Autotransplantation von Zehenballen
zur Rekonstruktion der Lauffläche bei einer Hauskatze. Kleintierprax. 2001; 46: 231–236
[17]
Henney LH, Pavletic MM: Axial pattern flap based on the superficial brachial artery in the dog Vet Surg. 1988; 17: 311–317
[26]
Simpson AM, Ludwig LL, Newman SJ et al.: Evaluation of surgical
margins required for complete excision of cutaneous mast cell
tumors in dogs. J Am Vet Med Assoc. 2004; 224: 236–240
[18]
Hunt GB, Tisdall PL, Liptak JM, et al.: Skin-fold advancement flaps
for closing large proximal limb and trunk defects in dogs and cats.
Vet Surg. 2001; 30: 440–448.
[27]
Soderstrom MJ, Gilson SD: Principles of surgical oncology. Vet Clin
North Am Sm Anim Pract. 1995; 25: 97–110
[19]
Hunt GB: Use of the lip-to-lid flap for replacement of the lower eyelid in five cats. Vet Surg. 2006; 35: 284–286.
[28]
Stefanello D, Morello E, Roccabianca P et al.: Marginal excision of
low-grade spindle cell sarcoma of canine extremities: 35 dogs
(1996–2006). Vet Surg. 2008; 37: 461–465
[20]
Hsu PW, Salgado CJ, Kent K, et al.: Evaluation of porcine dermal
collagen (Permacol) used in abdominal wall reconstruction. J Plast
Reconstr Aesthet Surg. 2009; 62: 1484–1489.
[29]
Szentimetrey D: Principles of reconstructive surgery for the tumor
patient. Clin Tech Small Anim Pract. 1998; 13: 70–76
[21]
Irwin DH: Tension lines in the skin of the dog. J Small Anim Pract.
1966; 7: 593–598.
[30]
van Zuilen CD, Kirpensteijn J: [Tumor surgery] Tijdschr Diergeneeskd. 1997; 122: 333–337
[22]
[31]
Withrow SJ: The evolution of veterinary surgical oncology. Clin
Tech Small Anim Pract. 1998; 13: 1–3
Jacobi S, Stanley BJ, Petersen-Jones S, et al.: Use of an axial pattern flap and nictitans to reconstruct medial eyelids and canthus in
a dog. Vet Ophthalmol. 2008; 11: 395–400.
[23]
[32]
Withrow SJ: The science of surgical oncology: past progress and
future direction. Vet Clin North Am Small Anim Pract. 1995; 25:
225–230
Kostolich M, Pavletic MM: Axial pattern flap based on the genicular branch of the saphenous artery in the dog. Vet Surg. 1987; 16:
217–222.
[24]
Lemarie RJ, Hosgood G, Read RA, et al.: Distant abdominal and
thoracic pedicle skin flaps for treatment of distal limb skin defects. J
Small Anim Pract. 1995; 36: 255–261.
[25]
Lidbetter DA, Williams FA Jr, Krahwinkel DJ, et al.: Radical lateral
body-wall resection for fibrosarcoma with reconstruction using
polypropylene mesh and a caudal superficial epigastric axial pattern
flap: a prospective clinical study of the technique and results in 6
cats. Vet Surg. 2002; 31: 57–64.
[26]
Liptak JM, Dernell WS, Rizzo SA, et al.: Reconstruction of chest
wall defects after rib tumor resection: a comparison of autogenous,
prosthetic, and composite techniques in 44 dogs. Vet Surg. 2008;
37: 479–487.
[27]
Mayhew PD, Holt DE: Simultaneous use of bilateral caudal superficial epigastric axial pattern flaps for wound closure in a dog. J Small
Anim Pract. 2003; 44: 534–538.
[28]
Munger RJ, Gourley IM: Cross lid flap for repair of large upper eyelid defects. J Am Vet Med Assoc. 1981; 178: 45–48.
8.2 Rekonstruktive Chirurgie in der Onkologie
[1]
Alexander LG, Pavletic MM, Engler SJ: Abdominal wall reconstruction with a vascular external abdominal oblique myofascial flap. Vet
Surg. 1991; 20: 379–384
[2]
Aper RL, Smeak DD: Clinical evaluation of caudal superficial epigastric axial pattern flap reconstruction of skin defects in 10 dogs
(1989–2001). J Am Anim Hosp Assoc. 2005; 41: 185–192
[3]
Aper R, Smeak D: Complications and outcome after thoracodorsal
axial pattern flap reconstruction of forelimb skin defects in 10 dogs,
1989–2001. Vet Surg. 2003; 32: 378–384
[4]
Aquino SM: Management of eyelid neoplasms in the dog and cat.
[5]
Beets GL, Go PM, van Mameren H: Foreign body reactions to
monofilament and braided polypropylene mesh used as preperitoneal implants in pigs. Eur J Surg. 1996; 162: 823–825
[29]
[6]
Brière C: Use of a reverse saphenous skin flap for the excision of a
grade II mast cell tumor on the hind limb of a dog. Can Vet J. 2002;
43: 620–622
Pavletic MM: Atlas of small animal wound management and
reconstructive surgery. 3. Auflage, John Wiley & Sons, 2010.
[30]
Pavletic MM: Anatomy and circulation of the canine skin. Microsurgery. 1991; 12: 103–112.
[7]
Butinar J, Pecar J: Hautrekonstruktion mit subdermalen und Axialhautlappen. Veterinär Spiegel. 2001; 1: 12–18
[31]
Pavletic MM: Axial pattern flaps in small animal practice. Vet Clin
North Am Small Anim Pract. 1990; 20: 105–125.
[8]
Clarke KM, Lantz GC, Salisbury SK et al. : Intestine submucosa
and polypropylene mesh for abdominal wall repair in dogs. J Surg
Res. 1996; 60: 107–114
[32]
Pavletic MM: Canine axial pattern flaps, using the omocervical,
thoracodorsal, and deep circumflex iliac direct cutaneous arteries.
Am J Vet Res. 1981; 42: 391–406.
[9]
Collaboration EH: Mesh compared with non-mesh methods of
open groin hernia repair: systematic review of randomized controlled trials. Br J Surg. 2000; 87: 854–859
[33]
Philibert D, Fowler JD: Use of muscle flaps in reconstructive surgery. Compend Cont Edu Pract Vet. 1996; 18: 395–405.
[10]
de Castro Marques AI, Hipwell F, Yool DA: The use of porcine
small-intestinal submucosa for abdominal wall reconstruction–a clinical case. J Small Anim Pract. 2009; 50: 619–623
[34]
Pope ER: Head and facial wounds in dogs and cats. Vet Clin North
Am Small Anim Pract. 2006; 36: 793–817.
[35]
Remedios AM, Bauer MS, Bowen CV et al.: Axial pattern skin flaps
in cats. Microsurgery. 1991; 12: 125–129.
[36]
Sardinas JC, Pavletic MM, Ross JT et al.: Comparative viability of
peninsular and island axial pattern flaps incorporating the cranial
superficial epigastric artery in dogs. J Am Vet Med Assoc. 1995;
207: 452–454.
[37]
Silver FH, Siperko LM, Seehra GP: Mechanobiology of force transduction in dermal tissue. Skin Res Technol. 2003; 9: 3–23.
[38]
Smith MM, Payne JT, Moon ML et al.: Axial pattern flap based on
the caudal auricular artery in dogs. Am J Vet Res. 1991; 52: 922–
925.
[11]
Degner DA: Facial reconstructive surgery. Clin Tech Small Anim
Pract. 2007; 22: 82–88
[12]
Degner DA, Bauer MS, Cozens M: Reverse saphenous conduit flap:
a case report in a cat. Vet Comp Ortho Trauma. 1993; 6: 175–177
[13]
Esson D: A modification of the Mustardé technique for the surgical
repair of a large feline eyelid coloboma. Vet Ophthalmol. 2001; 4:
159–160
[14]
Fahie MA, Smith MM: Axial pattern flap based on the cutaneous
branch of the superficial temporal artery in dogs: an experimental
study and case report. Vet Surg. 1999; 28: 141–147
[15]
Gregory CR, Gourley IM: Identification of muscle flaps in small animals. Microsurgery. 1991; 12: 136–139
[39]
Smith MM, Shults S, Waldron DR et al.: Platysma myocutaneous
flap for head and neck reconstruction in cats. Head Neck. 1993; 15:
433–439.
[12]
Kim R, Tanabe K, Emi M et al.: Potential roles of antisense therapy
in the molecular targeting of genes involved in cancer. Int J Oncol.
2004; 24: 5–17.
[40]
Spodnick GJ, Hudson LC, Clark GN et al.: Use of a caudal auricular
axial pattern flap in cats. J Am Vet Med Assoc. 1996; 208: 1679–
1682.
[13]
Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008; 68: 3551–3557
[14]
[41]
Stiles J, Townsend W, Willis M et al.: Use of a caudal auricular
axial pattern flap in three cats and one dog following orbital exenteration. Vet Ophthalmol. 2003; 6: 121–126.
Lyman GH: Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009; 7: 99–108
[15]
Marchall EK Jr: Historical perspectives in chemotherapy. Adv Chemother. 1964; 13: 1–8
[42]
Swaim SF, Henderson RA (Hrsg.): Small animal wound management, Williams and Wilkins, 1997.
[16]
[43]
Sylvestre AM, Weinstein MJ, Popovitch CA et al.: The sartorius
muscle flap in the cat: an anatomic study and two case reports.
J Am Anim Hosp Assoc. 1997; 33: 91–96.
Maughan TS, James RD, Kerr DJ et al.: Comparison of intermittent
and continuous palliative chemotherapy for advanced colorectal
cancer: a multicenter randomized trial. Lancet. 2003; 361:.457–464
[17]
Michor F, Nowak MA, Iwasa Y : Evolution of resistance to cancer
therapy. Curr Pharm Des. 2006; 12: 261–271
[44]
Szentimrey D: Principles of reconstructive surgery for the tumor
patient. Clin Tech Small Anim Pract. 1998; 13: 70–76.
[18]
Norton L, Simon R, Brereton HD et al.: Predicting the course of
Gompertzian growth. Nature. 1976; 264: 542–5
[45]
Taney K, Smith MM: Resection of mast cell tumor of the lip in a
dog. J Vet Dentistry. 2009; 26: 28–34.
[19]
Norton L, Simon R: Tumor size, sensitivity to therapy, and design
of treatment schedules. Cancer Treat Rep. 1977; 61: 1307–1317
[46]
Teunissen BD, Walshaw R, Hauptman JG et al.: Evaluation of primary critical ischemia time for the deep circumflex iliac cutaneous
flap in cats. Vet Surg. 2004; 33: 440–445.
[20]
Norton L, Simon R: The Norton–Simon hypothesis revisited. Cancer
Treat Rep. 1986; 70: 163–169
[21]
[47]
Trevor PB, Smith MM, Waldron DR et al.: Clinical evaluation of
axial pattern skin flaps in dogs and cats: 19 cases (1981–1990).
J Am Vet Med Assoc. 1992; 201: 608–612.
Saltz L, Meropol NJ, Loehrer PJ et al.: Single agent IMC–C225 has
activity in CPT–11 refractory colorectal cancer (CRC) that expresses
the epidermal growth factor receptor (EGFR). Proc Am Soc Clin
Oncol. 2002; 21:127a
[48]
Weinstein MJ, Pavletic MM, Boudrieau RJ et al.: Cranial sartorius
muscle flap in the dog. Vet Surg. 1989; 18: 286–291.
[22]
Simon D, Nolte I, Eberle N et al.: Treatment of dogs with lymphoma using a 12–week, maintenance–free combination chemotherapy protocol. J Vet Intern Med. 2006; 20: 948–954
9
Zytostatische Therapie
[23]
Simon R, Norton L: The Norton–Simon hypothesis: designing more
effective and less toxic chemotherapeutic regimens. Nat Clin Pract
Oncol. 2006; 3: 406–407
[24]
Skipper HE: Perspectives in cancer chemotherapy: Therapeutic
design. Cancer Res. 1964; 24: 1295–1302
[25]
Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to
evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of Canada. J
Natl Cancer Inst. 2000; 92: 205–216
[26]
Thornberry NA, Lazebnik Y: Caspases: enemies within. Science.
1998; 281:1312–1316
[27]
Vail DM, Michels GM, Khanna C et al.: Response evaluation criteria
for peripheral nodal lymphoma in dogs (v1.0) – a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp
Oncol. 2010; 8: 28–37
[28]
Wikman H, Vessella R, Pantel K: Cancer micrometastasis and
tumour dormancy. APMIS. 2008; 116: 754–770
9.1 Prinzipien der Chemotherapie
[1]
Bajzer Z, Vuk–Pavlovic S: New Dimensions in Gompertzian
Growth. J Theor Med, 2000; 2: 307–315
[2]
Chu E, DeVita VT: Principles of Medical Oncology. In: DeVita VT,
Hellman S, Rosenberg SA (Hrsg.) Cancer – Principles & Practice of
Oncology, 7. Auflage, 2005, 295–306
[3]
Citron ML, Berry DA, Cirrincione C et al.: Randomized trial of
dose–dense versus conventionally scheduled and sequential versus
concurrent combination chemotherapy as postoperative adjuvant
treatment of node–positive primary breast cancer: first report of
Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J
Clin Oncol. 2003; 21: 1431–1439
[4]
[5]
Frei E 3rd, Elias A, Wheeler C et al.: The relationship between
high–dose treatment and combination chemotherapy: the concept
of summation dose intensity. Clin Cancer Res. 1998; 4: 2027–2037.
Gerlinger M, Swanton C: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J
Cancer. 2010 ; 103: 1139–1143
[6]
Glaspy JA: Hematopoietic management in oncology practice. Part I.
Myeloid growth factors. Oncology. 2003; 17: 1593–1603
[7]
Goldie JH, Coldman AJ: A mathematic model for relating the drug
sensitivity of tumors to their spontaneous mutation rate. Cancer
Treat Rep. 1979; 63: 1727–1733
[8]
Green DR: Apoptotic pathways: the roads to ruin. Cell. 1998; 94:
695–698
[9]
Hennes AM, Theilen GH, Madewell BR et al.: Use of drugs based
on square meter of body surface area. J Am Vet Med Assoc. 1977;
171: 1076–1077
[10]
Hryniuk W, Frei E 3rd, Wright FA: A single scale for comparing
dose–intensity of all chemotherapy regimens in breast cancer: summation dose–intensity. J Clin Oncol. 1998; 16: 3137–3147
[11]
Iwasa Y, Nowak MA, Michor F: Evolution of resistance during clonal expansion. Genetics. 2006; 172: 2557–2566
9.2 Medikamente, Dosierungen,
Behandlungsprotokolle
[1]
Alvarez FJ, Kisseberth WC, Gallant SL et al.: Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for
dogs with relapsed lymphoma. J Vet Intern Med. 2006; 20: 1178–
1183
[2]
Anders RJ, Shanes JG, Zeller FP: Lower incidence of doxorubicininduced cardiomyopathy by once-a-week low dose administration.
Am Heart J. 1986; 111: 755–759
[3]
Arrington KA, Legendre AM, Tabeling GS et al.: Comparison of
body surface area-based and weight-based dosage protocols for
doxorubicin administration in dogs. Am J Vet Res. 1994; 55: 1587–
1592
[4]
Bacon NJ, Ehrhart NP, Dernell WS et al.: Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic
metastases after amputation for appendicular osteosarcoma: 50
cases (1999–2006). J Am Vet Med Assoc. 2008; 232:1504–1510
25
26
[5]
Bailey DB, Rassnick KM, Kristal O et al.: Phase I dose escalation of
single-agent vinblastine in dogs. J Vet Intern Med. 2008; 22: 1397–
1402
[26]
Chabner BA, Loo TL: Enzyme Therapy: L-Asparaginase. In: Chabner
BA, Longo DL (Hrsg.): Cancer Chemotherapy and Biotherapy. Lippincott-Raven, Philadelphia; 1996: 485–492
[6]
Bannink EO, Sauerbrey ML, Mullins MN et al.: Actinomycin D as
rescue therapy in dogs with relapsed or resistant lymphoma: 49
cases (1999–2006). J Am Vet Med Assoc 2008; 233: 446–451
[27]
Chu E, Allegra CJ: Antifolates. In: Chabner BA, Longo DL (Hrsg.):
Cancer Chemotherapy and Biotherapy. Lippincott-Raven, Philadelphia; 1996: 109–148
[7]
Barabas K, Milner R, Lurie D et al.: Cisplatin: a review of toxicities
and therapeutic applications. Vet Comp Oncol. 2008; 6: 1–18
[28]
[8]
Bates N: Hydroxycarbamide (hydroxyurea) toxicity in dogs. J Small
Anim Pract. 2008; 49: 216
Chun R, Garrett LD, Henry C et al.: Toxicity and efficacy of cisplatin
and doxorubicin combination chemotherapy for the treatment of
canine osteosarcoma. J Am Anim Hosp Assoc. 2005; 41: 382–7
[29]
[9]
Bell R, Mooney CT, Mansfield CS et al.: Treatment of insulinoma
in a springer spaniel with streptozotocin. J Small Anim Pract. 2005;
46: 247–250
Chun R, Garrett LD, Vail MD: Cancer Chemotherapy. In Withrow
SJ, Vail DM (Hrsg.): Withrow & MacEwen’s Small Animal Clinical
Oncology, 4. Aufl. WB Saunders, St. Louis; 2007: 163–192
[30]
[10]
Berg J. Canine osteosarcoma: amputation and chemotherapy. Vet
Chun R, Knapp DW, Widmer WR et al.: Cisplatin treatment of
transitional cell carcinoma of the urinary bladder in dogs: 18 cases
(1983–1993). J Am Vet Med Assoc. 1996; 209: 1588–1591
[11]
Berg J, Gebhardt MC, Rand WM: Effect of timing of postoperative
chemotherapy on survival of dogs with osteosarcoma. Cancer.
1997; 79: 1343–1350
[31]
Chun R, Knapp DW, Widmer WR et al.: Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder.
J Vet Intern Med. 1997; 11: 279–283
[12]
Berg J, Weinstein MJ, Schelling SH et al.: Treatment of dogs with
osteosarcoma by administration of cisplatin after amputation or
limb-sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc.
1992; 200: 2005–2008
[32]
Clifford CA, Mackin AJ, Henry CJ: Treatment of Canine Hemangiosarcoma: 2000 and Beyond. J Vet Intern Med. 2000; 14: 479–485
[33]
Bergman PJ, MacEwen EG, Kurzman ID et al.: Amputation and
carboplatin for treatment of dogs with osteosarcoma: 48 cases
(1991 to 1993). J Vet Intern Med. 1996; 10: 76–81
Cotter SM, Kanki PJ, Simon M: Renal disease in five tumor-bearing
cats treated with adriamycin. J Am Anim Hosp Assoc. 1985; 21:
405–409
[34]
Bortnowski HB, Rosenthal RC: Preclinical evaluation of L-asparaginase and methotrexate administered at intermediate doses in dogs.
Am J Vet Res. 1991; 52: 1636–1638
Cotter SM, Parker LM: High-dose methotrexate and leucovorin rescue in dogs with osteogenic sarcoma. Am J Vet Res. 1978; 39:
1943–1945
[35]
Cubeddu LX: Mechanisms by which cancer chemotherapeutic
drugs induce emesis. Semin Oncol. 1992; 19: 2–13
[13]
[14]
[15]
Bowies CA, Lucas D: CIinical and immunological response of lymphoma dogs following chemotherapy and irradiation. Camp Immunot Microbiol Infect Dis. 1980; 3: 317–326
[36]
DerneIl WS, Withrow SJ, Straw RC et al.: Intracavitary treatment
of soft tissue sarcomas in dogs using cisplatin in biodegradable
polymer. Anticancer Res. 1997; 17: 4499–4505
[16]
Bowles CA, Bull M, McCormick K et al.: Autologous bone marrow
transplantation following chemotherapy and irradiation in dogs
with spontaneous lymphomas. J Nat Cancer Inst. 1980; 65: 615–
620
[37]
DerneIl WS, Withrow SJ, Straw RC et al.: Adjuvant chemotherapy
using cisplatin by subcutaneous administration. In Vivo. 1997; 11:
345–350
[38]
[17]
Boyce KL, Kitchell BE: Treatment of canine lymphoma with COPLA/
LVP. J Am Anim Hosp Assoc. 2000; 36: 395–403
Dimski DS, Cook JR: Carmustine-induced partial remission of an
astrocytoma in a dog. J Am Anim Hosp Assoc. 1990; 26: 179–182
[39]
[18]
Bristow MR, Sageman WS, Scott RH et al.: Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular
pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980; 2: 487–515
Dominguez PA, Dervisis NG, Cadile CD et al.: Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern
Med. 2009; 23:130–137
[40]
Donehower RC: Hydroxyurea. In: Chabner BA, Longo DL (Hrsg.):
[41]
Dorman DC, Coddington KA, Richardson RC: 5-Fluorouracil toxicosis in the dog. J Vet Intern Med. 1990; 4: 254–257
[19]
Brown NO, Calvert C, MacEwen EG: Chemotherapeutic management of transmissible venereal tumors in 30 dogs. J Am Vet Med
Assoc. 1980; 176: 983–986
[20]
Buhles WC Jr, Theilen GH: Preliminary evaluation of bleomycin in
feline and canine squamous cell carcinoma. Am J Vet Res. 1973; 34:
289–291
[42]
Doroshow JH: AnthracycIines. In: Chabner BA, Longo DL (Hrsg.):
Cancer Chemotherapy and Biotherapy. Lippincott-Raven, Philadelphia 1996; 409–434
[21]
Bulakowski EJ, Philibert JC, Siegel S et al.: Evaluation of outcome
associated with subcutaneous and intramuscular hemangiosarcoma
treated with adjuvant doxorubicin in dogs: 21 cases (2001–2006). J
Am Vet Med Assoc. 2008; 233: 122–128
[43]
Elmslie RE, Glawe P, Dow SW: Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in
dogs with incompletely resected soft tissue sarcomas. J Vet Intern
Med. 2008; 22: 1373–1379
[22]
Burchardt H, Glowczewskie FP Jr, Enneking WF: The effect of
Adriamycin and methotrexate on the repair of segmental cortical
autografts in dogs. J Bone Joint Surg [Am]. 1983; 65: 103–108
[44]
[23]
Carter RF, Harris CK, Withrow SJ et al.: Chemotherapy of canine
lymphoma with histopathological correlation: doxorubicin alone
compared to COP as first treatment regimen. J Am Anim Hosp
Assoc. 1987; 23: 587–596
Euler H, Rivera P, Haggstrom J et al.: Efficacy and toxicity of a new
formulation of Paclitaxel (Paclical® Vet) in a phase I + II study for
the treatment of malignant tumours in dogs. Proc Europ Soc Vet
Onc, Cambridge, UK, 2007
[45]
Farese JP, Fox LE, Detrisac CJ et al.: Effect of thalidomide on
growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. Am J Vet Res. 2004; 65: 659–664
[24]
Cave TA, Hine R, Howie F et al.: Uterine carcinoma in a 10-monthold golden retriever. J Small Anim Pract. 2002; 43: 133–135
[46]
Finnie JW, Wilks CR: Two cases of multiple myeloma in the dog. J
[25]
Cave TA, Norman P, Mellor D: Cytotoxic drug use in treatment of
dogs and cats with cancer by UK veterinary practices (2003 to
2004). J Small Anim Pract. 2007; 48: 371–377
[47]
Fleischman RW, Baker JR,Thompson GR et al.: Bleomycin-induced
interstitial pneumonia in dogs. Thorax. 1971; 26: 675–682
[48]
Flory AB, Rassnick KM, Al-Sarraf R et al.: Combination of CCNU
and DTIC chemotherapy for treatment of resistant lymphoma in
dogs. J Vet Intern Med. 2008; 22: 164–171
[49]
Fox LE, Toshach K, Calderwood-Mays M et al.: Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R1,2–diaminocyclohexane platinum (II) in clinically normal cats. Am J
Vet Res. 1999; 60: 257–263
[70]
Hammer AS, Couto, CG, Filippi J et al.: Efficacy and toxicity of VAC
chemotherapy (vincristine, doxorubicin and cyclophosphamide) in
dogs with hemangiosarcoma. J Vet Intern Med. 1991; 5: 160–166
[71]
[50]
Friedman HS, Averbuch SD, Kurtzberg J: NoncIassic Akylating
Agents. In Chabner BA, Longo DL (Hrsg.): Cancer Chemotherapy
and Biotherapy. Lippincott-Raven, Philadelphia; 1996: 333–356
Hardy WD Jr, Old LJ: L-asparaginase in the treatment of neoplastic
diseases of the dog, rat and cow. Recent Results. Cancer Res. 1970;
33: 131–139
[72]
[51]
Frimberger AE, Moore AS, Cotter SM et al.: Initial cIinical evaluation of ifosfamide in dogs. Proc Vet Cancer Soc, Tuscon; 1995: 25–
26
Harvey HJ, MacEwen EG, Hayes AA: Neurotoxicosis associated
with use of 5-fluorouracil in five dogs and one cat. J Am Vet Med
Assoc. 1977; 171: 277–278
[73]
[52]
Frimberger AE, Moore AS, Schelling SH: Treatment of nephroblastoma in a juvenile dog. J Am Vet Med Assoc. 1995; 207: 596–598
Healy HG, Clarkson AG: Renal complications of cytotoxictherapy.
Aust NZ J Med. 1983; 13: 531–539
[74]
[53]
Fulton LM, Steinberg HS: Preliminary study of lomustine in the
treatment of intracranial masses in dogs following localization by
imaging techniques. Semin Vet Med Surg Small Anim. 1990; 5:
241–245
Heidner GL, Page RL, McEntee MC et al.: Treatment of canine
appendicular osteosarcoma using cobalt 60 radiation and intraarterial cisplatin. J Vet Intern Med. 1991; 5: 313–316
[75]
Helfand SC: Low-dose cytosine arabinoside-induced remission of
lymphoblastic leukemia in a rat. J Am Vet Med Assoc. 1987; 191:
707–710
[76]
Helfand SC, Jain NC, Paul M: Vincristine-loaded platelet therapy
for idiopathic thrombocytopenia in a dog. J Am Vet Med Assoc.
1984; 185: 224–226
[54]
Gerritsen RJ, Teske E, Kraus JS et al.: Multi-agent chemotherapy
for mast cell tumors in the dog. Vet Q. 1998; 20: 28–31
[55]
Golden DL, Langston VC: Uses of vincristine and vinblastine in
dogs and cats. J Am Vet Med Assoc. 1988; 193: 1114–1117
[56]
Grant IA, Rodriguez CO, Kent MS et al.: A phase II clinical trial of
vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern
Med. 2008; 22: 388–393
[77]
Henness AM, Theilen GH, Lewis JP: Clinical investigation of doxorubicin, daunomycin, and 6–thioguanine in normal rats. Am J Vet
Res. 1977; 38: 521–524
[57]
Gray KN, Raulston GL, Gleiser CA et al.: Histologic cIassification as
an indication of therapeutic response in malignant lymphoma of
dogs. J Am Vet Med Assoc. 1984; 184: 814–817
[78]
Henry CJ, McCaw DL, Turnquist SE et al.: Clinical evaluation of
mitoxantrone and piroxicam in a canine model of human invasive
urinary bladder carcinoma. Clin Cancer Res. 2003; 9: 906–911
[58]
Greene SN, Lucroy MD, Greenberg CB et al.: Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2007; 231:
1056–1060
[79]
Himsel CA, Richardson RC, Craig JA: Cisplatin chemotherapy for
metastatic squamous cell carcinoma in two dogs. J Am Vet Med
Assoc. 1986; 189: 1575–1578
[80]
[59]
Grem JL: 5-Flouropyrimidines. ln: Chabner BA, Longo DL (Hrsg.):
Hodgkins EM, Zinkl JG, MadeweIl BR: Chronic lymphocytic leukemia in the dog. J Am Vet Med Assoc. 1980; 177: 704–707
[81]
Hadden AG, Cotter SM, Rand W et al.: Efficacy and toxicosis of
VELCAP-C treatment of lymphoma in cats. J Vet Intern Med. 2008;
22: 153–157
Horio M, Chin KV, Currier SJ et al.: Transepithelial transport of
drugs by the multidrug transporter in cultured Madin-Darby canine
kidney cell epithelia. J Biol Chem. 1989; 64: 14880–14884
[82]
Hahn KA: Vincristine sulfate as single-agent chemotherapy in a dog
and a cat with malignant neoplasms. J Am Vet Med Assoc. 1990;
197: 504–506
Hosoya K, Kisseberth WC, Lord LK et al.: Comparison of COAP
and UW-19 protocols for dogs with multicentric lymphoma. J Vet
Intern Med. 2007; 21: 1355–1363
[83]
Hubbard BS, Vulgamott JC, Liska WD: Prostatic adenocarcinoma
in a rat. J Am Vet Med Assoc. 1990; 197: 1493–1494
[84]
Jankowski M, Fulton L, Sheafor S et al.: Ongoing evaluation of single agent thalidomide in dogs with measurable cancer. Proc. 9th
Ann Meet Vet Cancer Soc., Wood’s Hole, MA, 1999
[85]
Jeffreys AB, Knapp DW, Carlton WW et al.: Influence of asparaginase on a combination chemotherapy protocol in dogs with malignant lymphoma. J Am Animal Hosp Assoc. 2005; 41: 221–226
[86]
Jeglum KA: Treatment of metastasis. Vet Clin North Am Small Anim
Pract. 1985; 15: 659–666
[87]
Jones PD, de Lorimier LP, Kitchell BE et al.: Gemcitabine as a
radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc. 2003; 39: 463–467
[88]
Kent MS, Strom A, London CA et al.: Alternating carboplatin and
doxorubicin as adjunctive chemotherapy to amputation or limbsparing surgery in the treatment of appendicular osteosarcoma in
[60]
[61]
[62]
Hahn KA, Fields A, Hultgren JL et al.: Dose response and time
course of carboplatin-induced micronucleated polychromatic erythrocytes in the cat: implications for combination carboplatin chemotherapy. Chemotherapy. 1997; 43: 282–287
[63]
Hahn KA, Matlock CL: Nasal adenocarcinoma metastatic to bone
in two dogs. J Am Vet Med Assoc. 1990; 197: 491–495
[64]
Hahn KA, McEntee MF, Daniel GB et al.: Hematologic and systemic toxicoses associated with carboplatin administration in rats.
Am J Vet Res. 1997; 58: 677–679
[65]
Hahn KA, Richardson RC: Use of cisplatin für control of metastatic
malignant mesenchymoma and hypertrophic osteopathy in a dog. J
Am Vet Med Assoc. 1989; 195: 351–353
[66]
Hamilton TA, Morrison WB: Bleomycin chemotherapy für metastatic squamous cell carcinoma in a reffet. J Am Vet Med Assoc.
1991; 198: 107–108
[67]
Hamilton TA, Morrison WB, DeNicola DB: Cytosine arabinoside
chemotherapy für acute megakaryocytic leukemia in a rat. J Am Vet
Med Assoc. 1991; 199: 359–361
[89]
Kim SE, Liptak JM, Gall TT et al.: Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997–2004). J
Am Vet Med Assoc. 2007; 231: 1550–1557
[68]
Hammer AS, Carothers MA, Harris CL et al.: Unexpected neurotoxicity in dogs receiving a cyclophosphamide, dactinomycin, and
5-fluorouracil chemotherapy protocol. J Vet Intern Med. 1994; 8:
240–243
[90]
Kiselow MA, Rassnick KM, McDonough SP et al.: Outcome of
cats with low-grade lymphocytic lymphoma: 41 cases (1995–2005).
J Am Vet Med Assoc. 2008; 232: 405–410
[91]
[69]
Hammer AS, Couto CG, Ayl RD et al.: Treatment of tumorbearing
dogs with actinomycin D. J Vet Intern Med. 1994; 8: 236–239
Kisseberth WC, MacEwen EG, Helfand SC et al.: Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma.
J Vet Intern Med. 1995; 9: 425–428
27
28
[92]
Kisseberth WC, Vail DM, Jeglum KA et al.: Evaluation of carboplatin in tumor bearing cats: A phase I study from the veterinary oncology group. Proc. Vet Cancer Soc, Pacific Grove; 1996: 21
[93]
Kisseberth WC, Vail DM, Yaissle J et al.: Phase I Clinical Evaluation
of Carboplatin in Tumor-Bearing Cats: A Veterinary Cooperative
Oncology Group Study. J Vet Intern Med. 2008; 22: 83–88
[94]
Knapp DW, Richardson RC, Bonney PL et al.: Cisplatin therapy in
41 dogs with malignant tumors. J Vet Intern Med. 1988; 2: 41–46
[95]
Knapp DW, Richardson RC, DeNicola DB et al.: Cisplatin toxicity
in cats. J Vet Intern Med. 1987; 1: 29–35
[96]
Kosarek CE, Kisseberth WC, Gallant SL et al.: Clinical evaluation
of gemcitabine in dogs with spontaneously occurring malignancies.
J Vet Intern Med. 2005; 19: 81–86. )
[97]
Langova V, Mutsaers AJ, Phillips B et al.: Treatment of eight dogs
with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. Aust Vet J. 2004; 82:
676–680
[119] Matus RE, Leifer CE: Immunoglobulin-producing tumors. Vet CIin
[98]
Lazo JS, Chabner BA: Bleomycin. In: Chabner BA, Longo DL (Hrsg.):
Cancer Chemotherapy and Biotherapy. Lippincott-Raven, Philadelphia 1996; 379–394
[120] Matus RE, Leifer CE, MacEwen EG et al.: Prognostic factors for
1288–1292
[99]
LeBlanc AK, Cox SK, Kirk CA et al.: Effects of L-asparaginase on
plasma amino acid profiles and tumor burden in cats with lymphoma. J Vet Intern Med. 2007; 21: 760–763
[121] Mauldin GE, Fox PR, Patnaik AK et al.: Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. J Vet Intern Med. 1992; 6:
82–88
[100] LeBlanc AK, LaDue TA, Turrel JM et al.: Unexpected toxicity
following use of gemcitabine as a radiosensitizer in head and neck
carcinomas: a veterinary radiation therapy oncology group pilot
study. Vet Radiol Ultrasound. 2004; 45: 466–470
[101] Leifer CE, Matus RE: Chronic Iymphocytic leukemia in the dog: 22
[102] Leifer CE, Matus RE: Lymphoid leukemia in the dog. Acute Iymphoblastic leukemia and chronic Iymphocytic leukemia. Vet Clin
[103] Loar AS, Susaneck SJ: Doxorubicin-induced cardiotoxicity in five
dogs. Semin Vet Med Surg Small Anim. 1986; 1: 68–71
[104] MacDonald VS, Thamm DH, Kurzman ID et al.: Does L-Asparaginase influence efficacy or toxicity when added to a standard CHOP
protocol for dogs with lymphoma? J Vet Intern Med. 2005; 19:
732–736
[105] MacEwen EG, Brown NO, Patnaik AK et al.: Cyclic combination
chemotherapy of canine Iymphosarcoma. J Am Vet Med Assoc.
1981; 178: 1178–1181
[106] MacEwen EG, Drazner FH, McCIeiland AJ et al.: Treatment of
basophilic leukemia in a dog. J Am Vet Med Assoc. 1975; 166: 376–
380
[107] MacEwen EG, Hayes AA, Matus RE et al.: Evaluation of same prognostic factors for advanced multicentric Iymphosarcoma in the dog:
[108] MacEwen EG, Hurvitz AI: Diagnosis and management of monoclonal gammopathies. Vet CIin North Am Small Anim Pract. 1977; 7:
119–132
[109] MacEwen EG, Kurzman ID. Canine osteosarcoma: amputation
and chemoimmunotherapy. Vet CIin North Am Small Anim Pract.
1996; 26: 123–133
[110] MacEwen EG, Patnaik AK, Hurvitz AI et al.: Nonsecretory multiple
[111] MacEwen EG, Patnaik AK, Johnson GF et al.: Extramedullary plasmacytoma of the gastrointestinaltract in two dogs. J Am Vet Med
Assoc. 1984; 184: 1396–1398
[112] MacEwen EG, Rosenthal RC, Fox LE et al.: Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase
combined with chemotherapy. A randomized double-blind study in
canine lymphoma. J Vet Intern Med. 1992; 6: 230–234
[113] Macy DW, Ensley BA, GilIette EL: In vitra susceptibility of canine
tumor stern cells to doxorubicin. Am J Vet Res. 1988; 49: 1903–
1905
[114] Madeweil BR: Canine lymphoma. Vet CIin North Am Small Anim
Pract. 1985; 15: 709–722
[115] Mahony OM, Moore AS, Cotter SM et al.: Alimentary lymphoma
in cats: 28 cases (1988–1993). J Am Vet Med Assoc. 1995; 207:
1593–1598
[116] Marconato L, Bettini G, Giacoboni C et al.: Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med. 2008; 22: 1001–1007
[117] Marconato L, Bonfanti U, Stefanello D et al.: Cytosine arabinoside
in addition to VCAA-based protocols for the treatment of canine
lymphoma with bone marrow involvement: does it make the difference? Vet Comp Oncol. 2008; 6: 80–89
[118] Marconato L, Lorenzo RM, Abramo F et al.: Adjuvant gemcitabine
after surgical removal of aggressive malignant mammary tumours
in dogs. Vet Comp Oncol. 2008; 6: 90–101
[122] Mauldin GN, Matus RE, Patnaik AK et al.: Efficacy and toxicity of
doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med. 1988; 2: 60–65
[123] Mauldin GN, Matus RE, Withrow SJ et al.: Canine osteosarcoma.
Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med. 1988; 2:
177–180
[124] Medleau L, Dawe DL, Calvert CA: Immunosuppressive effects of
cyclophosphamide, vincristine, and L-asparaginase in dogs. Am J
Vet Res. 1983; 44: 176–180
[125] Minchin RF, Johnston MR, Aiken MA et al.: Pharmacokinetics of
doxorubicin in isolated lung of dogs and humans perfused in vivo. J
Pharmacol Exp Ther. 1984; 229: 193–198
[126] Minchinton AI, Fryer KH, Wendt KR et al.: The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs.
1996; 7: 339–343
[127] Moore AS, Cotter SM, Frimberger AE et al.: A comparison of
doxorubicin and COP for maintenance of remission in rats with lymphoma. J Vet Intern Med. 1996; 10: 372–375
[128] Moore AS, London CA, Frimberger AE et al.: Preliminary report of
lomustine (CCNU) for the treatment of relapsed lymphoma in dogs.
Proc Vet Cancer Soc, Tuscon. 1995; 39–40
[129] Moore AS, Nelson RW, Henry CJ et al.: Streptozocin for treatment
of pancreatic islet cell tumors in dogs: 17 cases (1989–1999). J Am
Vet Med Assoc. 2002; 221: 811–818
[130] Moore AS, Ogilvie GK, Ruslander D et al.: Evaluation of mitoxantrone for the treatment of lymphoma in dogs. J Am Vet Med Assoc.
1994; 204: 1903–1905
[131] Moore AS, Ogilvie GK, Vail DM: Actinomycin D for reinduction of
remission in dogs with resistant lymphoma. J Vet Intern Med. 1994;
8: 343–344
[132] Moore AS, Ruslander D, Cotter SM et al.: Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia. J Am Vet Med Assoc. 1995; 206:1550–1554
[133] Morrison WB, Vonderhaar MA, Hamilton TA et al.: Pancreatitis
associated with cytotoxic drug therapy for malignant neoplasia in
dogs. Proc Vet Cancer Soc, Minneapolis 1991; 73
[134] Murphy S, Hayes A, Adams V et al.: Role of carboplatin in multimodality treatment of canine tonsillar squamous cell carcinoma, a
case series of five dogs. J Small Anim Pract. 2006; 47: 216–220
[135] Myers NC 3rd, Moore AS, Rand WM et al.: Evaluation of multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J
Vet Intern Med. 1997; 11: 333–339
[156] Poirier VJ, Burgess KE, Adams WM et al.: Toxicity, dosage, and
efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004; 18: 536–539
[136] Nagashima N, Kano R, Hirai A et al.: Acute monocytic leukaemia
in a cat. Vet Rec. 2005; 157: 347–349
[157] Poirier VJ, Hershey AE, Burgess KE et al.: Efficacy and toxicity of
Paclitaxel (Taxol) for the treatment of canine malignant tumors. J
Vet Intern Med. 2004: 18; 219–222
[137] Neuweit, EA, Glasberg M, Frenkel E et al.: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol. 1983; 14: 316–324
[138] OgiIvie GK, Fettman MJ, Jameson VJ et al.: Evaluation of a onehour saline diuresis protocol for administration of cisplatin to dogs.
Am J Vet Res. 1992; 53: 1666–1669
[139] OgiIvie GK, Krawiec DR, Gelberg HB et al.: Evaluation of a shortterm saline diuresis protocol for the administration of cisplatin. Am
J Vet Res. 1988; 49: 1076–1078
[140] OgiIvie GK, Powers BE, Mallinckrodt CH et al.: Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med. 1996; 10:
379–384
[158] Poirier VJ, Thamm DH, Kurzman ID et al.: Liposome-encapsulated
doxorubicin (Doxil) and doxorubicin in the treatment of vaccineassociated sarcoma in cats. J Vet Intern Med. 2002; 16: 726–731
[159] Polton GA, Elwood CM: Pulmonary oedema as a suspected adverse
drug reaction following vincristine administration to a cat: a case
report. Vet J. 2008; 177: 130–133
[160] Postorino, NC, Susaneck SJ, Withrow SJ et al.: Single agent therapy with adriamycin for canine lymphosarcoma. J Am Anim Hosp
Assoc. 1989; 25: 221–225
[161] Price, GS, Page RL, Fischer BM et al.: Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric Iymphosarcoma. J Vet Intern Med. 1991; 5: 259–262
[141] Ogilvie GK, Atwater SK, Ciekot PA: Prevalence of anaphylaxis associated wirb the intramuscular administration of L-asparaginase to
81 dogs with cancer: 1989–1991. J Am Anim Hosp Assoc. 1994; 30:
62–65
[162] Puente-Redondo de la VA, Tilt N, Rowan TG et al.: Efficacy of
maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res. 2007; 68: 48–56
[142] Ogilvie GK, Felsburg PJ, Harris CW: Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol. 1988; 18: 119–127
[163] Rassnick KM, Bailey DB, Flory AB et al.: Efficacy of vinblastine for
treatment of canine mast cell tumors. J Vet Intern Med. 2008; 22:
1390–1396
[143] Ogilvie GK, Obradovich JE, Elmslie RE et al.: Toxicoses associated
wirth administration of mitoxantrone to dogs wirth malignant
tumors. J Am Vet Med Assoc. 1991; 198: 1613–1617
[164] Rassnick KM, Bailey DB, Malone EK et al.: Comparison between LCHOP and an L-CHOP protocol with interposed treatments of CCNU
and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Vet Comp
Oncol. 2010; 8: 243–253
[144] Ogilvie GK, Reynolds HA, Richardson RC et al.: Phase II evaluation
of doxorubicin for treatment of various canine neoplasms. J Am Vet
Med Assoc. 1989; 195: 1580–1583
[145] Ogilvie GK, Richardson RC, Curtis CR et al.: Acute and short-term
toxicoses associated with the administration of doxorubicin to dogs
with malignant tumors. J Am Vet Med Assoc. 1989; 195: 1584–
1587
[146] Ogilvie GK, Straw RC, Jameson VJ et al.: Evaluation of single-agent
chemotherapy for treatment of clinically evident osteosarcoma
metastases in dogs: 45 cases (1987–1991). J Am Vet Med Assoc.
1993; 202: 304–306
[147] Ogilvie GK, Vail DM, Klein MK et al.: Weekly administration of
low-dose doxorubicin for treatment of malignant lymphoma in
[148] OʼKeefe DA, Schaeffer DJ: Hematologic toxicosis associated with
doxorubicin administration in cats. J Vet Intern Med. 1992; 6: 276–
282
[149] OʼKeefe DA, Sisson DD, Gelberg HB et al.: Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med.
1993; 7: 309–317
[165] Rassnick KM, Frimberger AE, Wood CA et al.: Evaluation of Ifosfamide for treatment of various canine neoplasms, J Vet Intern Med.
2000; 14: 271
[166] Rassnick KM, Gieger TL, Williams LE et al.: Phase I evaluation of
CCNU (lomustine) in tumor-bearing cats. J Vet Intern Med. 2001;
15: 196–199
[167] Rassnick KM, Mauldin GE, Al-Sarraf R et al.: MOPP chemotherapy
for treatment of resistant lymphoma in dogs: a retrospective study
of 117 cases (1989–2000). J Vet Intern Med. 2002; 16: 576–580
[168] Rassnick KM, Moore AS, Collister KE et al.: Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in
[169] Rassnick KM, Rodriguez CO, Khanna C et al.: Results of a phase II
clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas, Am J Vet Res. 2006; 67: 517
[170] Rassnick KM, Williams LE, Kristal O et al.: Lomustine for treatment of mast cell tumors in cats: 38 cases (1999–2005). J Am Vet
Med Assoc. 2008; 232: 1200–1205
[150] Old LJ, Boyse EA, Campbell HA et al.: Treatment of lymphosarcoma in the dog with L-asparaginase. Cancer. 1967; 20: 1066–1070
[171] Reiman RA, Mauldin GE, Mauldin NG: A comparison of toxicity of
two dosing schemes for doxorubicin in the cat. J Feline Med Surg.
2008; 10: 324–331
[151] Page RL, Macy DW, Thrall DE et al.: Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog.
Cancer Res. 1988; 48: 288–290
[172] Ricci Lucas SR, Pereira Coelho BM, Marquezi ML et al.: Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma. J Am Anim Hosp Assoc. 2004; 40: 292–299
[152] Page RL, McEntee MC, George SL et al.: Pharmacokinetic and
phase I evaluation of carboplatin in dogs. J Vet Intern Med. 1993; 7:
235–240
[173] Risbon RE, de Lorimier LP, Skorupski K et al.: Response of canine
cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999–2004). J Vet Intern Med. 2006;
20: 1389–1397
[153] Page RL, Thrall DE, Dewhirst MW et al.: Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs
with malignant melanoma. Int J Hyperthermia. 1991; 7: 559–566
[154] Perkins M, Watson A: Successful treatment of hypereosinophilic
syndrome in a dog. Aust Vet J. 2001; 79: 686–689
[155] Phillips B, Powers BE, Dernell WS et al.: Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with
amputation for appendicular osteosarcoma in dogs. J Am Anim
Hosp Assoc. 2009; 45: 33–38
[174] Riviere JE, Page RL, Aucoin DP et al.: Effect of hyperthermia on
the in vitra hydrolysis of melphalan. Int J Hyperthermia. 1991; 7:
527–529
[175] Rogers KS: L-asparaginase for treatment of lymphoid neoplasia in
[176] Rogers KS, Barton CL, Benson PA et al.: Effects of single-dose
L-asparaginase on coagulation values in healthy dogs and dogs with
lymphoma. Am J Vet Res. 1992; 53: 580–584
29
30
[177] Rohrig KE: Acute myelomonocytic leukemia in a dog. J Am Vet Med
Assoc. 1983; 182: 137–141
[178] Rosenthal RC: Clinical applications of Vinca-alkaloids. J Am Vet Med
Assoc. 1981; 179: 1084–1086
[198] Spugnini EP, Citro G, Mellone P et al.: Electrochemotherapy for
localized lymphoma: a preliminary study in companion animals. J
Exp Clin Cancer Res. 2007; 26: 343–346
[179] Rowinsky K, Dowenhowe RC: Antimicrotubule Agents. In: Chabner SA, Longo DL (Hrsg.): Cancer Chemotherapy and Biotherapy.
Lippincott-Raven, Philadelphia; 1996: 263–296
[199] Spugnini EP, Crispi S, Scarabello A et al.: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced
mesothelioma in pets: preliminary observations. J Exp Clin Cancer
Res. 2008; 27: 6
[180] Ruslander D, Moore AS, Gliatto JM et al.: Cytosine arabinoside as
a single agent for the induction of remission in canine lymphoma.
J Vet Intern Med. 1994; 8: 299–301
[200] Spugnini EP, Dotsinsky I, Mudrov N et al.: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In
Vivo. 2008; 22: 47–49
[181] Saba CF, Thamm DH, Vail DM: Combination chemotherapy with
L-asparaginase, lomustine, and prednisone for relapsed or refractory
[201] Spugnini EP, Dotsinsky I, Mudrov N et al.: Biphasic pulses
enhance bleomycin efficacy in a spontaneous canine perianal
tumors model. J Exp Clin Cancer Res. 2007; 26: 483–487
[182] Schaeppi U, Phelan R, Stadnicki SW et al.: Pulmonary fibrosis following multiple treatment with bleomycin (NSC-125066) in dogs.
Cancer Chemother Rep. 1974; 58: 301–310
[202] Spugnini EP, Dotsinsky I, Mudrov N et al.: Electrochemotherapyinduced radiation recall in a cat. In Vivo. 2008; 22: 751–753
[183] Schaeppi U, Thompson GR, Fleischman RW et al.: Preclinical toxicologic evaluation of bleomycin (NSC-125066) in rhesus monkeys.
Cancer Chemother Rep. 1973; 4: 31–39
[184] Schoster JV, Wyman M: Remission orbital sarcoma in a dog, using
doxorubicin therapy. Am Vet Med Assoc. 1978; 172: 1101–1103
[185] Seo KW, Choi US, Jung YC et al.: Palliative intravenous cisplatin
treatment for concurrent peritoneal and pleural mesothelioma in a
dog. J Vet Med Sci. 2007; 69: 201–204
[186] Sersa G, Miklavcic D, Cemazar M et al.: Electrochemotherapy in
treatment of tumours. Eur J Surg Oncol. 2008; 34: 232–240
[203] Spugnini EP, Vincenzi B, Baldi F et al.: Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell
tumors. Anticancer Res. 2006; 26: 4585–4589
[204] Spugnini EP, Vincenzi B, Citro G et al.: Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine
sarcomas. In Vivo. 2007; 21: 819–822
[205] Stanclift RM, Gilson SD: Use of cisplatin, 5-fluorouracil, and
second-look laparotomy for the management of gastrointestinal
adenocarcinoma in three dogs. J Am Vet Med Assoc. 2004; 225:
1412–1417
[206] Stanton ME, Legendre AM: Effects of cycIophosphamide in dogs
and cats. Am Vet Med Assoc. 1986; 188: 1319–1322
[187] Shapiro W, Kitchell BE, Fossum TW et al.: Cisplatin for treatment
of transitional cell and squamous cell carcinomas in dogs. J Am Vet
Med Assoc. 1988; 193: 1530–1533
[207] Stein E: Data on toxicity and various therapeutic results of antineoplastic antibiotics in the dog. Tierärztl Prax. 1973; 1: 445–456
[188] Siedlecki CT, Kass PH, Jakubiak MJ et al.: Evaluation of an actinomycin-D-containing combination chemotherapy protocol with
extended maintenance therapy for canine lymphoma. Can Vet J.
2006; 47: 52–59
[208] Stolwijk JA, Minke JM, Rutteman GR et al.: Feline mammary carcinomas as a model for human breast cancer. II. Comparison of in
vivo and in vitra adriamycin sensitivity. Anticancer Res. 1989; 9:
1045–1048
[189] Simon D, Eberle N, Laacke-Singer L et al.: Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and
duration in 23 cats. J Vet Intern Med. 2008; 22: 394–400
[209] Story MD, Voehringer DW, Stephens LC et al.: L-asparaginase kills
lymphoma cells by apoptosis. Cancer Chemother Pharmacol. 1993;
32: 129–133
[190] Simon D, Moreno SN, Hirschberger J et al.: Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term
single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc.
2008; 232: 879–885
[210] Straw RC, Withrow SJ, Douple EB et al.: Effects of cisdiamminedichloroplatinum II released tram D, L-polylactic acid implanted adjacent to cortical allografts in dogs. J Orthop Res. 1994; 12: 871–877
[191] Simon D, Nolte I, Eberle N et al.: Treatment of dogs with lymphoma using a 12–week, maintenance-free combination chemotherapy protocol. J Vet Intern Med. 2006; 20: 948–954
[192] Simon D, Schoenrock D, Baumgärtner W et al.: Postoperative
adjuvant treatment of invasive malignant mammary gland tumors
in dogs with doxorubicin and docetaxel. J Vet Intern Med. 2006; 20:
1184–1190
[193] Skorupski KA, Clifford CA, Paoloni MC et al.: CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007; 21:
121–126
[194] Skorupski KA, Durham AC, Duda L et al.: Pulmonary fibrosis after
high cumulative dose nitrosurea chemotherapy in a cat. Vet Comp
Oncol. 2008; 6: 120–125
[195] Solcia E, Ballerini L, Bellini O et al.: Cardiomyopathy of doxorubicin in experimental animals, Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori. 1981; 67: 461–
472
[196] Spugnini EP, Baldi A, Vincenzi B et al.: Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas:
a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol. 2007; 59: 375–381
[197] Spugnini EP, Citro G, Dotsinsky I et al.: Ganglioneuroblastoma in
a cat: a rare neoplasm treated with electrochemotherapy. Vet J.
2008; 178: 291–293
[211] Swanson JF, Morgan S, Green RA et al.: Cerebral thrombosis and
hemorrhage in association with L-asparaginase administration. J Am
Anim Hosp Assoc. 1986; 22: 749–755
[212] Takeuchi Y, Matsuura S, Fujino Y et al.: Hypereosinophilic syndrome in two cats. J Vet Med Sci. 2008; 70: 1085–1089
[213] Tamura S, Tamura Y, Ohoka A et al.: A canine case of skull base
meningioma treated with hydroxyurea. J Vet Med Sci. 2007; 69:
1313–1315
[214] Teske E, Ruttemann GR, Hirschberger J: Randomized controlled
clinical trial to test the efficacy of liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic hemangiosarcoma.
Proc. 14. JT FG Innere Medizin und klinische Labordiagnostik DVG,
München. 2006; 45.
[215] Teske E, Rutteman GR, van Heerde P et al.: Polyethyleneglycol-Lasparaginase versus native L-asparaginase in canine non-Hodgkinʼs
lymphoma. Eur J Cancer. 1990; 26: 891–895
[216] Teske E, van Heerde P, Rutteman GR et al.: Prognostic factors for
treatment of malignant lymphoma in dogs. J AmVet Med Assoc.
1994; 205: 1722–1728
[217] Tew K, Colvin OM: Alkylating Agents. In: Chabner BA, Longo DL
(Hrsg.): Cancer Chemotherapy and Biotherapy. Lippincott-Raven,
[218] Tham P, Dougherty W, Iatropoulos MJ et al.: The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin. Am J Pathol. 1987; 128:
121–130
31
9.3 Sichere Handhabung von Chemotherapeutika
[1]
Anwar WA, Salama SI, Serafy MM: Chromosomal aberrations and
micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis. 1994; 9: 315–317
[2]
Berdel, W.E., Fink U, Rastetter J: Umgang mit Zytostatika. Münch
Med Wschr. 1987; 129: 319–324
[3]
Berufsgenossenschaft für Gesundheitsdienst und Wohlfahrtspflege: Zytostatika im Gesundheitsdienst. Informationen zur sicheren Handhabung von Zytostatika., Hamburg, Nr. M 620, 2009.b
http://www.bgwonline.de/internet/generator/Inhalt/OnlineInhalt/
Medientypen/bgw_20themen/M620_Zytostatika__im__Gesundheitsdienst,property=pdfDownload.pdf
[4]
Bonney, PL, Knapp DW: Chemotherapy safety: A guide for veterinary practitioners. Newsletter Vet Cancer Soc. 1993; 17: 10–11
[5]
Connor TH, Anderson RW, Sessink PJ et al.: Surface contamination with antineoplastic agents in six cancer treatment centers in
Canada and the United States. Am J Health Syst Pharm. 1999; 56:
1427–1432
[225] Tilmant LL, Gorman NT, Ackerman N et al.: Chemotherapy of
synovial cell sarcoma in a dog. J Am Vet Med Assoc. 1986; 188:
530–532
[6]
Chun RA, Garrett LD, Vail DM: Cancer Chemotherapy. In: Withrow
SJ, Vail DM. (Hrsg.) Small animal clinical oncology. 4. Auflg., Saunders Elsevier St Louis 2007, 163–210
[226] Trevor PB, Saunders GK, Waldron DR et al.: Metastatic extramedullary plasmacytoma of the colon and rectum in a dog. J Am Vet
Med Assoc. 1993; 203: 406–409
[7]
Dickinson KL, Ogilvie GK: Safe handling and administration of chemotherapeutic agents in veterinary medicine. In: Bonagura JD
(Hrsg.): Kirks Current Veterinary Therapy XII. Small Animal Practice.
W.B. Saunders Co, Philadelphia 1995; S. 475–478
[8]
Dietrich R: Zytostatika-Richtlinie der Länder. Dtsch Apoth Ztg.
1998; 138: 48–68
[228] Valerius KD, Ogilvie GK, Fettman MJ et al.: Comparison of the
effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. J Am Vet Med Assoc. 1999; 214: 353–356
[9]
Dranitsaris G, Johnston M, Poirier S et al.: Are health care providers who work with cancer drugs at an increased risk for toxic
events? A systematic review and meta-analysis of the literature. J
Oncol Pharm Pract. 2005; 11: 69–78
[229] Valerius KD, Ogilvie GK, Mallinckrodt CH et al.: Doxorubicin
alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric
lymphoma in dogs: 121 cases (1987–1995). J Am Vet Med Assoc.
1997; 210: 512–516
[10]
Ensslin AS, Huber R, Pethran A et al.: Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic
drugs: urinary excretion and cytogenetics studies. Int Arch Occup
Environ Health. 1997; 70: 205–208
[11]
Ensslin AS, Pethran A, Schierl R et al.: Urinary platinum in hospital
personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994; 65: 339–342
[12]
Ensslin AS, Stoll Y, Pethran A et al.: Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994; 51:
229–233
[13]
European College of Veterinary Internal Medicine – Companion
Animals (ECVIM-CA): Guidelines for preventing occupational and
environmental exposure to cytotoxic drugs in veterinary medicine,
Juli 2007. http://www.ecvimca.org/Documents/oncol2007/Guidelines%20ECVIM%20Hazards%20Cytotoxic%20drugs%202nd%20version%20July%202007.pdf
[14]
Evans RM: Guidelines for handling parenteral antineoplastics. J Am
Med Assoc. 1985; 253: 1590–1592
[15]
[235] Weller RE, Theilen GH, MadeweIl BR: Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia. J Am Vet Med
Assoc. 1982; 181: 891–893
Favier B, Gilles L, Gesage M et al.: Analysis of cyclophosphamide
in the urine of antineoplastic drug handlers. Bull Cancer. 2003; 90:
905–909
[16]
[236] Wood CA, Moore AS, Frimberger AE et al.: Phase I evaluation of
carboplatin in tumor hearing cats. Proc Vet Cancer Soc, Pacific
Grove; 1996: 39–40
Favier B, Gilles L, Latour JF et al.: Contamination of syringe plungers during the sampling of cyclophosphamide solutions. J Oncol
Pharm Practice. 2005; 11: 1–5
[17]
[237] Woods JP, Mathews KA, Binnington AG: Thalidomide for the
treatment of hemangiosarcoma in dogs. Vet Comp Oncol. 2004; 2:
108–109
Favier B, Gilles L, Ardiet C et al.: External contamination of vials
containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Practice. 2003; 9: 15–20
[18]
Fransmann WR, Vermeulen R, Kromhout H: Dermal exposure to
cyclophosphamide in hospitals during preparation, nursing and
cleaning activities. Int Arch Occup Environ Health. 2005; 78, 403–
441
[220] Thamm DH, Vail DM: Preclinical evaluation of a sterically stabilized
liposome-encapsulated cisplatin in clinically normal cats. Am J Vet
Res. 1998; 59: 286–289
[221] Theon AP, VanVechten MK, MadeweIl BR: Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of
the nasal plane in cats. Am J Vet Res. 1996; 57: 205–210
[222] Thompson GR, Baker JR, Fleischman RW et al.: Preclinical toxicologic evaluation of bleomycin (NSC 125066), a new antitumor antibiotic. Toxicol Appl Pharmacol. 1972; 22: 544–555
[223] Thompson JP, Fugent MJ: Evaluation of survival times after limb
amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteo-sarcoma in dogs: 30 cases
(1979–1990). J Am Vet Med Assoc. 1992; 200: 531–533
[224] Thrall MA: Lymphoproliferative disorders. Lymphocytic leukemia
and plasma cell myeloma. Vet Clin North Am Small Anim Pract.
1981; 11: 321–347
[227] Turner AI, Hahn KA, Rusk A et al.: Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet
Intern Med. 2006; 20: 1384–1388
[230] Van Vechten M, Helfand SC, Jeglum KA: Treatment of relapsed
canine lymphoma with doxorubicin and dacarbazine. J Vet Intern
Med. 1990; 4: 187–191
[231] Verweij J, Schellens JHM, Loo TL et al.: Antitumor Antibiotics. In:
Chabner BA, Longo DL (Hrsg): Cancer Chemotherapy and Biotherapy. Lippincott-Raven, Philadelphia; 1996: 395–408
[232] Vickery KR, Wilson H, Vail DM et al.: Dose-escalating vinblastine
for the treatment of canine mast cell tumor. Vet Comp Oncol.
2008; 6: 111–119
[233] Webster JD, Yuzbasiyan-Gurkan V, Thamm DH et al.: Evaluation
[234] Weiden PL, Starb R, Deeg HJ et al.: Prolonged disease free survival
in dogs with lymphoma after total-body irradiation and autologous
marrow transplantation consolidation of combination-chemotherapy-induced remissions. Blood. 1979; 54: 1039–1049
[238] Wray JD: Methaemoglobinaemia caused by hydroxycarbamide
(hydroxyurea) ingestion in a dog. J Small Anim Pract. 2008; 49:
211–215
[219] Thamm DH, Vail DM: Anticancer Drugs: New Drugs, Kirk’s current
vet therapy XIV. 2009; 311–314
32
[19]
Goloni-Bertollo EM, Tajara EH, Manzato AJ et al.: Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer. 1992; 50: 341–344
[20]
[41]
Grajny AE, Cristie D, Tichy AM et al.: Chemotherapy: how safe for
the caregiver? Home Healthcare Nurse. 1993; 11: 51–58
Sessink PJ, Connor TH, Jorgenson JA et al.: Reduction in surface
contamination with antineoplastic drugs in 22 hospital pharmacies
in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract. 2011; 17: 39–48
[42]
[21]
Grummt T, Grummt H-J, Schott G: Chromosomal aberrations in
peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res. 1993; 302: 19–24
Siderov J, Kirsa S, McLauchlan R: Reducing workplace cytotoxic
surface contamination using a closed-system drug transfer device. J
Oncol Pharm Pract. 2010; 16: 19–25
[43]
[22]
Hamscher G, Mohring SA, Knobloch A et al.: Determination of
drug residues in urine of dogs receiving anti-cancer chemotherapy
by liquid chromatography-electrospray ionization- tandem mass
spectrometry: is there an environmental or occupational risk? J Anal
Toxicol. 2010; 34: 142–148
Simon D, Mohring S, Knobloch A et al.: Analysis of residues in
saliva and hair of dogs receiving anti-cancer chemotherapy: first
results. Proc. Ann Meeting ESVONC, Turin, 2010
[44]
Sotaniemi EA, Sutinen S, Arranto AJ et al.: Liver damage in nurses
handling cytostatic agents. Acta Med Scand. 1983; 214: 181–189
[45]
[23]
International Society of Oncology Pharmacy Practicioners Standards Committee: ISOPP standards of practice. Safe handling of
cytotoxics. J Oncol Pharm Pract. 2007; 13 Suppl: 1–81
Stücker I, Caillard J-F, Collin R et al.: Risk of spontaneous abortion
among nurses handling antineoplastic drugs. Scand J Work Environ
Health. 1990; 16: 102–107
[46]
[24]
Jost M, Rüegger M, Liechti B et al.: Umgang mit Zytostatika:
Gefährdung, Schutzmaßnahmen. Schweizerische Unfallversicherungsgesellschaft SUVA, Luzern 1995; Nr. 18
Valanis BG, Vollmer WM, Labuhn KT et al.: Acute symptoms associated with antineoplastic drug handling among nurses. Cancer
Nurs. 1993; 16: 288–295
[47]
[25]
Kandel-Tschiederer B, Kessler M, Schwietzer A et al.: Reduction
of workplace contamination with platinum containing cytostatic
drugs in a veterinary hospital by introduction of a closed chemotherapy application system. Vet Rec. 2010 166: 822–825
Vandenbroucke J, Robays H: How to Protect Environment and
Employees Against Cytotoxic Agents. The Ghent Experience, J Oncol
Pharm Practice. 2001; 6: 146–152
[48]
Wick C, Slawson MH, Jorgenson JA, Tyler LS: Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003; 60: 2314–2320
[26]
Kiffmeyer TK, Kube C, Opiolka S et al.: Vapour pressure, evaporation behavior and air borne concentration of hazardous drugs;
Implication for occupational safety. Pharm J. 2000; 268: 331–337
[27]
Knobloch A, Mohring S, Eberle N et al.: Analysis of drug residues
in serum of dogs receiving anti-cancer chemotherapy. J Vet Intern
Med. 2010; 24: 379–383
[28]
Knobloch A, Mohring S, Eberle N et al.: Analysis of drug residues
in urine of dogs receiving anti-cancer chemotherapy. J Vet Intern
Med. 2010; 24: 384–390
[29]
Labuhn K, Valanis B, Schoeny R et al.: Nursesʼ and pharmacists
exposure to antineoplastic drugs: Findings from industrial hygiene
scans and urine mutagenicity tests. Cancer Nursing. 1998; 21: 79–
89
[30]
Lassila O, Toivanen A, Nordman E: Immune function in nurses
handling cytostatic drugs. Lancet. 1980; 2: 482
[31]
Lovejoy N, Powers L, Flessel P et al.: Mutagenicity in urine of hospital workers who prepare and administer chemotherapy agents.
EMS Abstracts. 1985; 7
[32]
Mayer DK: Hazards of chemotherapy. Cancer. 1992; 70: 988–992
[33]
Morrison WB: Chemotherapy Safety. In: Hahn KA, Richardson RC
(Hrsg.): Cancer Chemotherapy. Williams & Wilkins, Baltimore 1995;
63–75
[34]
Neiger R: Richtlinien für die Handhabung antineoplastischer Chemotherapeutika. Schweiz Arch Tierheilk.1996; 138: 383–386
[35]
Niklasson B, Bjorkner B, Hansen L: Occupational contact dermatitis from antitumor agent intermediates. Contact Dermatitis. 1990;
22: 233–235
[36]
Ogilvie GK: Chemotherapy. In: Withrow SJ, MacEwen EG (Hrsg.):
Small Animal Clinical Oncology, 2. Aufl. WB Saunders, Philadelphia
1996; 70–86
[37]
Ogilvie GK, Moore AS: Managing the veterinary cancer patient.
Veterinary Learning System, Trenton, NJ 1995; 53–57
[38]
Peelen S, Roeleveld N, Heederik D et al.: Toxic effects on reproduction in hospital personnel. 1999; Dutch Ministry of Social Affairs
and Employment
[39]
Sessink PJM, Verplanke AJW, Herber RFM et al.: Occupational
exposure to antineoplastic agents and parameters for renal dysfunction. Int Arch Occup Environ Health. 1997; 69: 215–218
[40]
Sessink PJM, Kroese ED, van Kranen HJ et al.: Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Inter Arch Occup Environ Health. 1993; 67: 317–323
9.4 Rechtliche Aspekte bei der Anwendung von
Zytostatika in der Tierarztpraxis
[1]
Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz),
Fassung vom 12. Dezember 2005, Bundesgesetzblatt I, Seite 3394.
http://www.gesetze-im-internet.de/amg_1976/index.html
[2]
Österreichisches Bundesgesetz vom 02. März 1983 über die Herstellung und das Inverkehrbringen von Arzneimitteln (Arzneimittelgesetz), Bundesgesetzblatt Nr. 181/1983. http://www.ris.bka.gv.at/
GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10010441
[3]
Schweizer Bundesgesetz über Arzneimittel und Medizinprodukte
(Heilmittelgesetz), Fassung vom 15. Dezember 2000. http://www.
admin.ch/ch/d/sr/c812_21.html
[4]
Verordnung über die Verschreibungspflicht von Arzneimitteln (Arzneimittelverschreibungsverordnung), Fassung vom 21. Dezember
2005, Bundesgesetzblatt I, Seite 3632. http://www.gesetze-iminternet.de/amvv/index.html
[5]
Verornung über tierärztliche Hausapotheken (Tierärztliche Hausapothekenverordnung), Fassung vom 27. März 1996, Bundesgesetzblatt I, Seite 554. http://www.gesetze-im-internet.de/t_hav/
index.html.
[6]
Richtlinie 98/24/EG des Rates vom 7. April 1998 zum Schutz von
Gesundheit und Sicherheit der Arbeitnehmer vor der Gefährdung
durch chemische Arbeitsstoffe bei der Arbeit, Amtsblatt der Europäischen Gemeinschaften, L 131/11. http://eurlex.europa.eu/Lex
UriServ/LexUriServ.do?uri=OJ:L:1998:131:0011:0023:DE:PDF.
[7]
Verordnung zum Schutz vor Gefahrstoffen (Gefahrstoffverordnung), Fassung vom 23. Dezember 2004, Bundesgesetzblatt I, Seiten 3758-9. http://www.gesetze-im-internet.de/gefstoffv_2005/
index.html
[8]
Technische Regeln für Gefahrstoffe 525 – Umgang mit Gefahrstoffen in Einrichtungen der humanmedizinischen Versorgung, Herausgeber: Bundesanstalt für Arbeitsschutz und Arbeitsmedizin, Dortmund, Mai 1998. http://www.baua.de/cln_137/sid_18C607F564
EFBF22CA7114D6AE85A071/de/Themen-von-A-Z/Gefahrstoffe/
TRGS/TRGS-525.html
[9]
Sichere Handhabung von Zytostatika, Herausgeber: Bundesverband
der Unfallkassen, Berlin, Nr. GUV-I 8533. http://www.unfallkasseberlin.de/res.php?id=10243
[10]
Zytostatika im Gesundheitsdienst – Informationen zur sicheren
Handhabung von Zytostatika, Herausgeber: Berufsgenossenschaft
für Gesundheitsdienst und Wohlfahrtspflege, Hamburg, Nr. M620.
http://www.bgw-online.de/internet/generator/Inhalt/OnlineInhalt/
Medientypen/bgw_20themen/M620__Zytostatika__im__Gesundheitsdienst,property=pdfDownload.pdf
[11]
Technische Regeln für Gefahrstoffe 555 – Betriebsanweisung und
Information der Beschäftigten, Herausgeber: Bundesanstalt für
Arbeitsschutz und Arbeitsmedizin, Dortmund, Februar 2008.
http://www.baua.de/cln_137/de/Themen-von-A-Z/Gefahrstoffe/
TRGS/TRGS-555.html
[12]
Gesetz zum Schutz der erwerbstätigen Mutter (Mutterschutzgesetz), Fassung vom 20. Juni 2002, Bundesgesetzblatt I, Seite 2318.
http://www.gesetze-im-internet.de/muschg/index.html
[13]
Verordnung zum Schutze der Mütter am Arbeitsplatz (Mutterschutz-Richtlinienverordnung), Fassung vom 15. April 1997, Bundesgesetzblatt I, Seite 782. http://www.gesetze-im-internet.de/
muscharbv/index.html
[14]
Gesetz zum Schutz der arbeitenden Jugend (Jugendarbeitsschutzgesetz), Fassung vom 12. April 1976, Bundesgesetzblatt I, Seite
965. http://www.gesetze-im-internet.de/juschg/index.html
[15]
Anforderungen an den Betrieb von Sicherheitswerkbänken mit Luftrückführung für Arbeiten mit krebserzeugenden oder erbgutverändernden Zytostatika, Bundesarbeitsblatt 7-8/1998, Seite 69 und 3/
2000, Seite 65. http://www.umwelt-online.de/recht/arbeitss/
arbsch/bma/00_3.htm
[16]
Qualitätsstandard für den pharmazeutisch-onkologischen Service,
Deutsche Gesellschaft für Onkologische Pharmazie, 4. Auflage,
2008. http://www.esop.li/downloads/library/quapos4_german.pdf
[17]
Jost M, Rüegger M, Liechti B, Gutzwiller A: Sicherer Umgang mit
Zytostatika, SUVA – Schweizerische Unfallversicherungsanstalt,
Abteilung Arbeitsmedizin, 6. Auflage, Juni 2004, Bestellnummer:
2869/18.d. http://www.onkologiepflege.ch/fileadmin/onkologiepflege/onkologiepflege_user/pdf/fachmaterial/downloads/suva.
Zytostatika.pdf
9.5 Komplikationen der Chemotherapie
[1]
Amantea M, Newman MS, Sullivan TM et al.: Relationship of dose
intensity to the induction of palmar-plantar erythrodysesthia by
pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol. 1999;
18: 17–26.
[9]
Charney SC, Bergman PJ, Hohenhaus AE et al.: Risk factors for
sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990–1996). J Am Vet Med Assoc. 2003; 222:
1388–1393.
[10]
Chatterjee K, Zhang J, Honbo N et al.: Doxorubicin cardiomyopathy. Cardiology. 2010; 115: 155–162.
[11]
Chretin JD, Rassnick KM, Shaw NA et al.: Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma
and osteosarcoma: a double-blind, placebo-controlled study. J Vet
Intern Med. 2007; 21: 141–148.
[12]
Christiansen S, Redmann K, Scheld HH et al.: Adriamycin-induced
cardiomyopathy in the dog – an appropriate model for research on
partial left ventriculectomy? J Heart Lung Transplant. 2002; 21:
783–790.
[13]
Cvetkovic RS, Scott LJ: Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005; 65:
1005–1024.
[14]
Daugaard G: Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull. 1990; 37: 1–12.
[15]
DeFrancesco TC, Atkins CE, Keene BW et al.: Prospective clinical
evaluation of serum cardiac troponin T in dogs admitted to a veterinary teaching hospital. J Vet Intern Med. 2002; 16: 553–557.
[16]
de la Puente-Redondo VA, Tilt N, Rowan TG et al.: Efficacy of
maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res. 2007; 68: 48–56.
[17]
FitzPatrick WM, Dervisis NG, Kitchell BE: Safety of concurrent
administration of dexrazoxane and doxorubicin in the canine cancer
patient. Vet Comp Oncol. 2010; 8: 273–282.
[18]
Flory AB, Rassnick KM, Balkman CE et al.: Oral bioavailability of
etoposide after administration of a single dose to tumor-bearing
dogs. Am J Vet Res. 2008; 69: 1316–1322.
[19]
Freifeld AG, Walsh TJ, Pizzo PA: Infections in the cancer patient.
In: DeVita VT, Hellman S, Rosenberg SA (Hrsg.): Cancer: Principles
and practices of oncology. 9. Aufl. Lippincott Philadelphia 2011.
[20]
Ghaffari MS, Aldavood SJ, Masoudifard M et al.: Transient megaoesophagus following vincristine administration in a German shepherd dog: possible vincristine-induced neuropathy. Comp Clin
Pathol. 2009; 18: 445–447.
[21]
Gillings S, Johnson J, Fulmer A et al.: Effect of a 1-hour IV infusion
of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography. Vet Ther.
2009; 10: 46–58.
[22]
Hamilton TA, Cook JR Jr, Braund KG et al.: Vincristine-induced
peripheral neuropathy in a dog. J Am Vet Med Assoc. 1991; 198:
635–638.
[23]
Hammer AS, Carothers MA, Harris CL et al.: Unexpected neurotoxicity in dogs receiving a cyclophosphamide, dactinomycin, and 5fluorouracil chemotherapy protocol. J Vet Intern Med. 1994; 8:
240–243.
[2]
Baldwin JR, Phillips BA, Overmyer SK et al.: Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics
in the dog. Cancer Chemother Pharmacol. 1992; 30: 433–438.
[3]
Barron RL: Pathophysiology of septic shock and implications for
therapy. Clin Pharm. 1993; 12: 829–845.
[4]
Bellin HJ, Cherry JM, Koss LG: Effects of a single dose of cyclophosphamide. V. Protective effect of diversion of the urinary stream on
dog bladder. Lab Invest. 1974; 30: 43-47.
[5]
Bernhardson BM, Tishelman C, Rutqvist LE: Chemosensory changes experienced by patients undergoing cancer chemotherapy: a
qualitative interview study. J Pain Symptom Manage. 2007; 34:
403–412.
[24]
Hanigan MH, Devarajan P: Cisplatin nephrotoxicity: molecular
mechanisms. Cancer Ther. 2003; 1: 47–61.
[25]
[6]
Bertazzoli C, Rovero C, Ballerini L et al.: Experimental systemic
toxicology of 4ʼ-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol. 1985; 79: 412–422.
Harvey HJ, MacEwen EG, Hayes AA: Neurotoxicosis associated
with use of 5-fluorouracil in five dogs and one cat. J Am Vet Med
Assoc. 1977; 171: 277–278.
[26]
[7]
Bravo L, Legendre AM, Hahn KA et al.: Serum granulocyte colonystimulating factor (G-CSF) and interleukin-1 (IL-1) concentrations
after chemotherapy-induced neutropenia in normal and tumor-bearing dogs. Exp Hematol. 1996; 24: 11–17.
Henness AM, Theilen GH, Madewell BR et al.: Neurotoxicosis
associated with use of 5-florouracil. J Am Vet Med Assoc. 1977;
171: 692.
[27]
Hickman MA, Cox SR, Mahabir S et al.: Safety, pharmacokinetics
and use of the novel NK-1 receptor antagonist maropitant (Cerenia)
for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther. 2008; 31: 220–229.
[28]
Hosoya K, Lord LK, Lara-Garcia A et al.: Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine).
Vet Comp Oncol. 2009; 7: 244–255.
[8]
Bray BA, Osman M, Ashtyani H et al.: The fibronectin content of
canine lungs is increased in bleomycin-induced fibrosis. Exp Mol
Pathol. 1986; 44: 353–363.
33
34
[29]
Jordan K, Kasper C, Schmoll HJ: Chemotherapy-induced nausea
and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005; 41: 199–205.
[30]
[31]
[50]
Kehoe R, Singer DH, Trapani A et al.: Adriamycin-induced cardiac
dysrhythmias in an experimental dog model. Cancer Treat Rep.
1978; 62: 963–978.
Ogilvie GK, Richardson RC, Curtis CR et al.: Acute and short-term
toxicoses associated with the administration of doxorubicin to dogs
with malignant tumors. J Am Vet Med Assoc. 1989; 195: 1584–
1587.
[51]
Keung EC, Toll L, Ellis M et al.: L-type cardiac calcium channels in
doxorubicin cardiomyopathy in rats morphological, biochemical,
and functional correlations. J Clin Invest. 1991; 87: 2108–2113.
Ogilvie GK, Obradovich JE, Elmslie RE et al.: Toxicoses associated
with the administration of Mitoxantrone to dogs with malignant
tumors. J Am Vet Med Assoc. 1991; 198: 1613–1617.
[52]
Ogilvie GK, Straw RC, Powers BE et al.: Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol
for the administration of cisplatin to dogs with malignant tumors:
61 cases (1987–1989). J Am Vet Med Assoc. 1991; 199: 613–616.
[53]
Ogilvie GK, Straw RC, Jameson VJ et al.: Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol
for the administration of cisplatin to dogs with naturally developing
neoplasms. J Am Vet Med Assoc. 1993; 202: 1845–1848.
[54]
Ogilvie GK, Atwater SW, Ciekot PA et al.: Prevalence of anaphylaxis associated with the intramuscular administration of L-Asparaginase to 81 dogs with cancer: 1989–1991. J Am Anim Hosp Assoc.
1994; 30: 62–65.
[55]
OʼKeefe DA, Sisson DD, Gelberg HB et al.: Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med.
1993; 7: 309–317.
[56]
Phillips BS, Kraegel SA, Simonson E et al.: Acute reactions in dogs
treated with doxorubicin: increased frequency with the use of a
generic formulation. J Vet Intern Med. 1998; 12: 171–172.
[57]
Philips FS, Sternberg SS, Cronin AP et al.: Cyclophosphamide and
urinary bladder toxicity. Cancer Res. 1961; 21: 1577–1589.
[58]
Plumb DC: Vincristine Sulfate. In: Plumb’s Veterinary Drug Handbook. 7th ed., Wiley-Blackwell, Ames, Iowa 2011.
[32]
Am Vet Med Assoc. 2007; 231: 1550–1557.
[33]
Knapp DW, Richardson RC, DeNicola DB et al.: Cisplatin toxicity
in cats. J Vet Intern Med. 1987; 1: 29–35.
[34]
41 dogs with malignant tumors. J Vet Intern Med. 1988; 2: 41–46.
[35]
Kraft W, Kuffer M: Behandlung schwerer Neutropenien bei Hund
und Katze mit Filgrastim. Tierärztl Prax. 1995; 23: 609–613.
[36]
Krick E, Cohen R, Gregor T et al.: Prospective clinical trial to compare vincristine and vinblastine in a COP-based protocol for feline
lymphome. Proc. VCS 2010, San Diego, CA, 71.
[37]
Kristal O, Rassnick KM, Gliatto JM et al.: Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern
Med. 2004; 18: 75–80.
[38]
Laberke S, Zenker I, Hirschberger J: Efficacy of MESNA and furosemide for prevention of sterile haemorrhagic cystitis in dogs with
malignant lymphoma receiving a cyclophosphamide-containing
chemotherapy protocol – a retrospective study of 131 dogs (1997–
2009), unveröffentliche Daten
[39]
Laing EJ, Miller CW, Cochrane SM: Treatment of Cyclophosphamide-induced hemorrhagic cystitis in five dogs. J Am Vet Med
Assoc. 1988; 193: 233–236.
[59]
Poirier VJ, Hershey AE, Burgess KE et al.: Efficacy and toxicity of
paclitaxel (Taxol) for the treatment of canine malignant tumors. J
Vet Intern Med. 2004; 18: 219–222.
[40]
Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
Cancer Treat Rev. 1993; 19: 197–228.
[60]
[41]
MacEwen EG, Rosenthal RC, Fox LE et al.: Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase
canine lymphoma. J Vet Intern Med. 1992; 6: 230–234.
Qin XY, Pilot MA, Thompson H et al.: Effects of cholinoceptor and
5-hydroxytryptamine3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis. Br J Pharmacol.
1993; 108: 44–49.
[61]
Rassnick KM, Frimberger AE, Wood CA et al.: Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med.
2000; 14: 271–276.
[42]
Mauldin GE, Fox PR, Patnaik AK et al.: Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. J Vet Intern Med. 1992; 6:
82–88.
[62]
Rassnick KM, Rodriguez CO, Khanna C et al.: Results of a phase II
clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. Am J Vet Res. 2006; 67: 517–523.
[43]
McEntee MC, Rassnick KM, Lewis LD et al.: Phase I and pharmacokinetic evaluation of the combination of orally administered
docetaxel and cyclosporin A in tumor-bearing dogs. J Vet Res. 2006;
67: 1057–1062.
[63]
Rau SE, Barber LG, Burgess KE: Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med. 2010; 24: 1452–1457.
[64]
[44]
Medina-Franco H: [Intestinal occlusion in cancer]. Rev Gastroenterol Mex. 2004; 69 Suppl 3: 100–105.
Richardson G, Dobish R: Chemotherapy induced diarrhea. J Oncol
Pharm Pract. 2007; 13: 181–198.
[65]
[45]
Menozzi A, Pozzoli C, Poli E et al.: Effect of the macrolide antibacterial drug, tylosin, on TNBS-induced colitis in the rat. Pharmacology. 2005; 74: 135–142.
Riegel EA, Kaliner M, El-Hage AN et al.: Anthracycline-induced
histamine release from rat mast cells. Agents Actions. 1982; 12:
431–437.
[66]
[46]
Moore AS, Nelson RW, Henry CJ et al.: Streptozocin for treatment
Vet Med Assoc. 2002; 221: 811–818.
Simon D, Moreno SN, Hirschberger J et al.: Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term
single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc.
2008; 232: 879–885.
[47]
Mouridsen HT, Langer SW, Buter J et al.: Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two
prospective clinical multicentre studies. Ann Oncol. 2007; 18: 546–
550
[67]
Sioka C, Kyritsis AP: Central and peripheral nervous system toxicity
of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009; 63: 761–767.
[68]
[48]
Ogilvie GK, Cockburn CA, Tranquilli WJ et al.: Hypotension and
cutaneous reactions associated with intravenous administration of
etoposide in the dog. Am J Vet Res. 1988; 49: 1367–1370.
Skorupski K, Irish A, Hammond G et al.: Prospective clinical trial
assessing the efficacy of Denamarin for prevention of CCNU induced hepatopathy in tumor-bearing dogs. Proc. VCS 2011, San
Diego, CA, 75.
[49]
Ogilvie GK, Moore AS, Curtis CR: Evaluation of cisplatin-induced
emesis in dogs with malignant neoplasia: 115 cases (1984–1987). J
Am Vet Med Assoc. 1989; 195: 1399–1403.
[69]
Snavely NR, Snavely DA, Wilson BB: Toxic effects of fluorouracil
cream ingestion on dogs and cats. Arch Dermatol. 2010; 146:
1195–1196.
[70]
Sockalingam R, Filippich L, Charles B et al.: Cisplatin-induced ototoxicity and pharmacokinetics: preliminary findings in a dog model.
Ann Otol Rhinol Laryngol. 2002; 111: 745–750.
[71]
Sorenmo KU, Harwood LP, King LG et al.: Case-control study to
evaluate risk factors for the development of sepsis (neutropenia
and fever) in dogs receiving chemotherapy. J Am Vet Med Assoc.
2010; 236: 650–656.
[72]
Takemura G, Fujiwara H: Doxorubicin-induced cardiomyopathy
from the cardiotoxic mechanisms to management. Prog Cardiovasc
Dis. 2007; 49: 330–352.
[73]
Teske E, Rutteman GR, van Heerde P et al.: Polyethylene glycol-Lasparaginase versus native L-asparaginase in canine non-Hodgkinʼs
lymphoma. Eur J Cancer. 1990; 26: 891–895.
[74]
Tew KD, Colvin OM, Jones RB: Clinical and High-Dose Alkylating
Agents. In: Chabner BA, Longo DL: Cancer Chemotherapy and Biotherapy. 4. Aufl., Lippincott Williams & Wilkins 2006, Philadelphia,
PA, 283–309.
[75]
Tyers MB, Freeman AJ: Mechanism of the anti-emetic activity of
5-HT3 receptor antagonists. Oncology. 1992; 49: 263–268.
[76]
Vail DM, Kravis LD, Cooley AJ et al.: Preclinical trial of doxorubicin
entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol.
1997; 39: 410–416.
[3]
Bristow RG, Hill RP: Molecular and cellular basis of radiotherapy.
In: Tannock IF, Hill RP, Bristow RB, Harrington L (Hrsg.): The basic
science of oncology. 4. Aufl. McGraw Hill Companies. 2004: 273–
279
[4]
Buchholz J, Hagen R, Leo C et al.: 3D conformal radiation therapy
for palliative treatment of canine nasal tumors. Vet Radiol Ultrasound. 2009; 50: 679–683
[5]
Buchholz J, Brühschwein A, Nitzl D et al.: Computerized 3-D
treatment planning using MRI-CT fusion with regard to planning
target volumes of brain tumour patients. Proceedings, ECVDI 2010;
Giessen
[6]
Choy H, Kim DW: Chemotherapy and irradiation interaction. Semin
Oncol. 2003; 4: 3–10
[7]
Collen EB, Mayer MN: Acute effects of radiation treatment: skin
reactions. Can Vet J. 2006; 47: 931–935
[8]
Collen EB, Mayer MN: Acute oropharyngeal effects of full-course
radiation treatment of tumors of the head. Can Vet J. 2008; 49:
509–512
[9]
Eckstein C, Guscetti F, Roos M et al.: A retrospective analysis of
radiation therapy for the treatment of feline vaccine-associated sarcoma. Vet Comp Onc. 2009; 7: 54–68
[10]
Farrelly J, McEntee MC: Principles and applications of radiation therapy. Clin Tech Small Anim Pract. 2003; 18: 82–87
[11]
Fidel, Schiller I, Hauser B et al.: Histiocytic sarcomas in flat-coated
retrievers: a summary of 37 cases (November 1998–March 2005).
Vet Comp Onc. 2006; 4: 63–74
[77]
Vail D, Chun R, Thamm DH: Efficacy of pyridoxine to ameliorate
the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial
using a canine model. Clin Cancer Res. 1998; 4: 1567–1571.
[12]
[78]
Vail DM, Rodabaugh HS, Conder GA et al.: Efficacy of injectable
maropitant (Cerenia) in a randomized clinical trial for prevention
and treatment of cisplatin-induced emesis in dogs presented as
veterinary patients. Vet Comp Oncol. 2007; 5: 38–46.
Forrest LJ, Chun R, Adams WM et al.: Postoperative radiotherapy
for canine soft tissue sarcoma. J Vet Intern Med. 2000; 14: 578-582
[13]
Valerius KD, Ogilvie GK, Fettman MJ et al.: Comparison of the
effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. J Am Vet Med Assoc. 1999; 214: 353–356.
Freeman KP, Hahn KA, Harris FD et al.: Treatment of dogs with
oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). J Vet Intern Med. 2003;
17: 96–101
[14]
Frimberger AE, Moore AS, LaRue SM et al.: Radiotherapy of
incompletely resected, moderately differentiated mast cell tumors
in the dog: 37 cases (1989–1993). J Am Anim Hosp Assoc. 1997;
33: 320–324
[15]
Gillette EL, LaRue SM, Gillette SM: Normal tissue tolerance and
management of radiation injury. Semin Vet Med Surg (Small Anim).
1995; 10: 209–213
[16]
Green EM, Adams WM, Forrest LJ: Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc. 2002;
38: 445–451
[17]
Gustafson NR, Lana SE, Mayer MN et al.: A preliminary assessment of whole-body radiotherapy interposed within a chemotherapy protocol for canine lymphoma. Vet Comp Oncol. 2004; 2:
125–131
[18]
Hall EJ: Time, dose, and fractionation in radiotherapy. In: Hall EJ und
Giaccia AJ (Hrsg.): Radiobiology for the radiologists, 6. Aufl. Philadelphia, PA: Lippincott William & Wilkins; 2000: 378–397
[19]
Hall EJ: Chemotherapeutic agents from the perspective of the
radiation biologist. In: Hall EJ und Giaccia AJ (Hrsg.): Radiobiology
for the radiologists, 6. Aufl. Philadelphia, PA: Lippincott William &
Wilkins; 2000: 443–446
[20]
(1986–2006). J Vet Intern Med. 2009; 23: 287–294
[21]
Harari PM, Huang S: Radiation combined with EGFR signal inhibitors: Head and neck cancer focus. Semin Radiat Oncol. 2006; 16:
38–44
[22]
Harris D, King GK, Bergman PJ: Radiation therapy toxicities. Vet
[23]
Hill RP, Bristow RG: The scientific basis of radiotherapy. In: Tannock IF, Hill RP, Bristow RB, Harrington L (Hrsg.): The basic science
of oncology. 4. Auflg. McGraw Hill Companies. 2004: 305
[79]
[80]
[81]
Van Vechten M, Helfand SC, Jeglum KA: Treatment of relapsed
Med. 1990; 4: 187–191.
Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L et al.: Prospective randomized clinical trial comparing high-dose ifosfamide +
GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant. 2000; 25: 1141–
1146.
[82]
Veterinary co-operative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or
biological antineoplastic therapy in dogs and cats v1.0. Vet Comp
Oncol 2004, 2: 195–213.
[83]
Weller RE: Intravesical instillation of dilute formalin for treatment
of Cyclophosphamide-induced hemorrhagic cystitis in two dogs. J
Am Vet Med Assoc. 1978; 172: 1206–1209.
[84]
Wiebe VJ, Simonson E: Managing Oncologic Emergencies. In:
Henry CJ, Higginbotham ML. Cancer Management in Small Animal
Practice. Saunders, Marylin Heights, Missouri, 2010.
[85]
Wohl JS, Cotter SM: Approach to complications of anticancer therapy in emergency practice. J Vet Emerg Crit Care. 1996; 5: 61–76.
10 Prinzipien der Strahlentherapie
[1]
Adams WM, Bjorling DE, McAnulty JE et al.: Outcome of accelerated radiotherapy alone or accelerated radiotherapy followed by
exenteration of the nasal cavity in dogs with intranasal neoplasia:
[2]
Brearley MJ, Hayes A, Murphy S: Hypofractionated radiation therapy for invasive thyroid carcinoma in dogs. J Small Anim Pract.
1999; 40: 206–210
35
36
[24]
Kaser-Hotz B, Rohrer CR, Stankeova S et al.: Radiotherapy of
pituitary tumors in five cats. J Small Anim Pract. 2002; 43: 303–307
[25]
Kent MS, Bommarito D, Feldman E et al.: Survival, neurologic response, and prognostic factors in dogs with pituitary masses treated
with radiation therapy and untreated dogs. J Vet Intern Med. 2007;
21: 1027–1033
[47]
Ruppert R, Seegenschmied MH, Sauer R: Radiotherapy of osteoarthritis. Indication, technique and clinical results. Der Orthopäde.
2004; 33: 56–62
[48]
Schneider U, Kaser-Hotz B: Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau
dose-response relationships. Radiat Environ Biophys. 2005; 44:
235–239
[26]
Kun LE, Beltran C: Radiation therapy for children: evolving technologies in the era of ALARA. Pedr Radiol. 2009; 39: 65–70
[49]
[27]
LaDue-Miller T, Price GS, Page RL et al.: Radiotherapy of canine
non-tonsillar squamous cell carcinoma. Vet Radiol Ultrasound.
1996; 37: 74–77
Schneider U, Lomax A, Pemler P et al.: The impact of IMRT and
proton radiotherapy on secondary cancer incidence. Strahlenther
Onkol. 2006; 182: 647–652
[50]
[28]
LaDue T, Klein MK: Toxicity criteria of the veterinary radiation therapy oncology group. Vet Radiol Ultrasound. 2001; 42: 475–476
Sellon RK, Fidel J, Houston R et al.: Linear-Accelerator-based
modified radiosurgical treatment of pituitary tumors in cats: 11
Cases (1997–2008). J Vet Intern Med. 2009; 23: 1038–1044.
[29]
LaRue SM, Vujaskovic Z: Combining radiation therapy with other
treatment modalities. Semin Vet Med Surg. 1995; 10: 197–204
[51]
[30]
Lawrence JA, Forrest LJ, Turek MM et al.: Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensitymodulated radiation therapy. Vet Radiol Ultrasound. 2010; 51:
561–570
Sfiligoi G, Théon AP, Kent MS: Response of nineteen cats with
nasal lymphoma to radiation therapy and chemotherapy. Vet Radiol
Ultrasound. 2007; 48: 388–393
[52]
Siegel S, Kornegay JN, Thrall DE: Postoperative irradiation of spinal
cord tumors in 9 dogs. Vet Radiol Ultrasound. 1996; 37: 150–153
[53]
Smith AN, Wright JC, Brawner WR Jr et al.: Radiation therapy in
the treatment of canine and feline thymomas: a retrospective study
[54]
Thamm DH, Turek MM, Vail DM: Outcome and prognostic factors
following adjuvant prednisone/vinblastine chemotherapy for highrisk canine mast cell tumour: 61 cases. J Vet Med Sci. 2006; 68:
541–548
[55]
Théon AP, Le Couteur RA, Carr EA et al.: Influence of tumor cell
proliferation and sex-hormone receptors on effectiveness of radiation therapy for dogs with incompletely resected meningiomas. J
Am Vet Med Assoc. 2000; 216: 701–707
[56]
Théon AP, Marks SL, Feldman ES et al.: Prognostic factors and patterns of treatment failure in dogs with unresectable differentiated
thyroid carcinomas treated with megavoltage irradiation. J Am Vet
Med Assoc. 2000; 216: 1775–1779
[57]
Théon AP, Rodriguez C, Madewell BR: Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc. 1997; 210:
778–784
[58]
Théon AP, Rodriguez C, Griffey S et al.: Analysis of prognostic factors and patterns of failure in dogs with periodontal tumors treated
with megavoltage irradiation. J Am Vet Med Assoc. 1997; 210:
785–788
[59]
Théon AP, Madewell BR, Harb MF et al.: Megavoltage irradiation
of neoplasms of the nasal and paranasal cavities in 77 dogs. J Am
Vet Med Assoc. 1993; 202: 1469–1475
[60]
Thrall DE: Biologic basis of radiation therapy. Vet Clin North Am
[61]
Thrall DE, LaRue SM, Yu D : Thermal dose is related to duration of
local control in canine sarcomas treated with thermoradiotherapy.
Clin Cancer Res. 2005, 11: 5206–5214
[62]
Turek MM, Forrest LJ, Adams WM et al.: Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15
cases (1991–2001). Vet Comp Oncol. 2003; 1:94–104
[63]
Vaudaux C, Schneider U, Kaser-Hotz B: Potential for intensitymodulated radiation therapy to permit dose-escalation for canine
nasal tumors. Vet Radiol Ultrasound. 2007; 48: 475–481
[64]
Weinberg BD, Allison RR, Sibata C: Results of combined photodynamic therapy (PDT) and high dose brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer
(NSCLC). Photodiagnosis Photodyn Ther. 2010, 7: 50–58
[65]
Williams LE, Johnson JL, Hauck ML et al.: Chemotherapy followed
by half-body radiation therapy for canine lymphoma. J Vet Intern
Med. 2004; 18: 703–709
[66]
Wilson GD, Betzen SM, Harari PM: Biologic basis for combining
drugs with radiation. Semin Radiat Oncol. 2006, 16: 2–9
[31]
LeBlanc AK, LaDue TA, Turrel JM et al.: Unexpected toxicity
carcinomas: A veterinary radiation therapy oncology group pilot
[32]
Lurie DM, Gordon IK, Théon AP et al.: Sequential low-dose rate
half-body irradiation and chemotherapy for the treatment of canine
multicentric lymphoma. J Vet Intern Med. 2009; 23: 1064–1070
[33]
Mayer NM, Greco DS, LaRue SM: Outcome of pituitary tumor irradiation in cats. J Vet Intern Med. 2006; 20: 1151–1154.
[34]
Melzer K, Guscetti F, Rohrer Bley C et al.: Ki67 reactivity in nasal
and periocular squamous cell carcinomas in cats treated with electron beam radiation therapy. J Vet Intern Med. 2006; 20: 676–681
[35]
McEntee MC, Page RL, Théon A: Malignant tumor formation in
dogs previously irradiated for acanthomatous epulis. Vet Radiol Ultrasound. 2004; 45: 357–361
[36]
McEntee MC: Veterinary radiation therapy: review and current
state of the art. J Am Anim Hosp Assoc. 2006; 42: 94–109
[37]
McEntee MC, Steffey M, Dykes NL: Use of surgical hemoclips in
radiation treatment planning. Vet Radiol Ultrasound. 2008; 49:
395–399
[38]
McKnight JA, Mauldin GN, McEntee MC et al.: Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. J Am
Vet Med Assoc. 2000; 217: 205–210
[39]
Moore AS: Radiation therapy for the treatment of tumours in small
companion animals. Vet J. 2002; 164: 176–187.
[40]
Müller F, Poirier V, Melzer K et al.: Palliative radiotherapy with
electrons of appendicular oteosarcoma in 54 dogs. In Vivo. 2005;
19: 713–716
[41]
[42]
[43]
Plavec T, Kessler M, Kandel B et al.: Palliative radiotherapy as
treatment for non-resectable soft tissue sarcomas in the dog – a
report of 15 cases. Vet Comp Oncol. 2006; 4: 98–103
Poirier VJ, Adams WM, Forrest LJ et al.: Radiation therapy for
incompletely excised grade 2 canine mast cell tumors. J Am Anim
Hosp Assoc. 2006; 42: 430–434
Poirier VJ, Rohrer Bley C, Roos M et al.: Efficacy of radiation therapy for the treatment of macroscopic canine oral soft tissue sarcoma. In vivo. 2006; 20: 415–420
[44]
Proulx DR, Ruslander DM, Dodge RK et al.: A retrospective analysis of 140 dogs with oral melanoma treated with external beam
radiation. Vet Radiol Ultrasound. 2003; 44: 352–359
[45]
Roberts SM, Lavach JD, Severin GA et al.: Ophthalmic complications following megavoltage irradiation of the nasal and paranasal
cavities in dogs. J Am Vet Med Assoc. 1987; 190: 43–47.
[46]
Rohrer Bley C, Sumova A, Roos M et al.: Irradiation of brain
tumors in dogs with neurological signs: A retrospective survival analysis of 46 cases (1997–2003). J Vet Intern Med. 2005; 19: 849–854
[67]
Withrow SJ: The science of surgical oncology: past progress and
future direction. Vet Clinics of North Am: Small Anim Practi. 1995;
25: 225–230
[23]
Sato E, Olson SH, Ahn J et al.: Intraepithelial CD+ tumor-infiltrating
lymphocytes and a high CD8+/regulatory T cell ratio are associated
with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A.
2005; 102: 18538–18543
[24]
Schadendorf D, Ugurel S, Schuler-Thurner B et al.: Dacarbazine
(DTIC) versus vaccination with autologous peptide-pulsed dendritic
cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC Study group of the
decog. Ann Oncol. 2006; 17: 563–570
[25]
Schreiber RD, Old LJ, Smyth MJ et al.: Cancer immunoediting:
integrating immunityʼs roles in cancer suppression and promotion.
Science. 2011; 331: 1565–1570
[26]
Shankaran V, Ikeda H, Bruce AT et al.: IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410: 1107–1111
[27]
Silverstein AM: Horror Autotoxicus, autoimmunity and immunoregulation: The early history. Transfus Med Hemother. 2005; 32: 296–
302
11 Prinzipien der Immuntherapie
11.1 Tumorimmunologie
[1]
Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for
cancer dormancy. Nat Rev Cancer. 2007; 7: 834–846
[2]
Bindea G, Mlecnik B, Fridman WH et al.: Natural immunity to cancer in humans. Curr Opin Immunol. 2010; 22: 215–222
[3]
Callaway MP, Briggs JC: The incidence of late recurrence (greater
than 10 years); an analysis of 536 consecutive cases of cutaneous
melanoma. Br J Plast Surg. 1989; 42: 46–49
[4]
Danial NN, Korsmeyer SJ: Cell Death: Critical control points. Cell.
2004; 116: 205–219
[5]
Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev
Immunol. 2009; 27: 83–117
[28]
Smyth MJ, Thia KY, Street SE et al.: Differential tumor surveillance
by natural killer (Nk) and Nkt cells. J Exp Med. 2000; 191: 661–668
[6]
Du C, Wang Y: The immunoregulatory mechanisms of carcinoma for
its survival and development. J Exp Clin Cancer Res. 2011; 30: 12
[29]
[7]
Dunn GP, Bruce AT, Ikeda H et al.: Cancer immunoediting: from
immuno-surveillance to tumor escape. Nat Immunol. 2002; 3: 991–
998
Smyth MJ, Thia KY, Street SE et al.: Perforin-mediated cytotoxicity
is critical for surveillance of spontaneous lymphoma. J Exp Med.
2000; 192: 755–760
[30]
Teicher BA: Transforming Growth Factor-beta and the immune response to malignant disease: Clin Cancer Res: 2007; 13: 6247–6251
[8]
Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and
cancer immunoediting. Nat Rev Immunol. 2006; 6: 836–848
[31]
Tizard IR: Veterinary immunology: an introduction. 8. Aufl. St.
Louis: Saunders 2009
[9]
Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer
immuno-surveillance and immunoediting. Immunity. 2004; 21:
137–148
[32]
[10]
Essex M, Grant CK, Cotter SM et al.: Leukemia specific antigens:
Focma and immune surveillance. Haematol Blood Transfus. 1979;
23: 453–486
Traversari C, van der Bruggen P, Luescher IF et al.: A nonapeptide
encoded by human gene Mage-1 is recognized on HLA-A1 by
cytolytic T lymphocytes directed against tumor antigen MZ2-E. J
Exp Med. 1992; 176: 1453–1457
[33]
Vajdic CM, McDonald SP, McCredie MR et al.: Cancer incidence
before and after kidney transplantation. JAMA. 2006; 296: 2823–
2831
[11]
Finn OJ: Cancer immunology: N Engl J Med. 2008; 358: 2704–2715
[12]
Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960–1964
[34]
Vesely MD, Kershaw MH, Schreiber RD et al.: Natural innate and
adaptive immunity to cancer. Annu Rev Immunol. 2011; 29: 235–
271
[13]
Karrison TG, Ferguson DJ, Meier P: Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999; 91: 80–85
[35]
Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin
Immunol. 2007; 19: 217–223
[14]
Khong HT, Wang QJ, Rosenberg SA: Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single
patient: tumor escape by antigen loss and loss of MHC expression. J
Immunother. 2004; 27: 184–190
[36]
Wei H, Wang S, Zhang D et al.: Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces
potent antitumor immunity in mice. Clin Cancer Res. 2009; 15:
4612–4621
[15]
Koebel CM, Vermi W, Swann JB et al.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450: 903–
907
[37]
Yang F, Yang XF: New Concepts in tumor antigens: Their significance in future immunotherapies for tumors. Cell Mol Immunol.
2005; 2: 331–341
[16]
Melief CJ: Cancer immunotherapy by dendritic cells. Immunity.
2008; 29: 372–383
[38]
[17]
Moloney FJ, Comber H, OʼLorcain P et al.: A population-based
study of skin cancer incidence and prevalence in renal transplant
recipients. Br J Dermatol. 2006; 154: 498–504
Zitvogel L, Tesniere A, Kroemer G et al.: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev
Immunol. 2006; 6: 715–727
[39]
Zorn E, Hercend T: A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol. 1999; 29: 592–
601
[18]
Muller AJ, Prendergast GC: Indoleamine 2,3-dioxygenase in
immune suppression and cancer. Curr Cancer Drug Targets. 2007;
7: 31–40
[19]
Palucka K, Ueno H, Banchereau J: Recent developments in cancer
vaccines. J Immunol. 2011; 186: 1325–1331
[20]
Peter ME, Krammer PH: The CD5(Apo-1/Fas) disc and beyond. Cell
Death Differ. 2003; 10: 26–35
[21]
Rizzi R, Curci P, Delia M et al.: Spontaneous remission of “Methotrexate-Associated Lymphoproliferative Disorders” after discontinuation of immuno-suppressive treatment for autoimmune disease.
Review of the literature. Med Oncol. 2009; 26: 1–9
[22]
Rosenberg SA: Development of effective immunotherapy for the
treatment of patients with cancer. J Am Coll Surg. 2004; 198: 685–
696
11.2 Klinischer Einsatz der Immuntherapie
[1]
Abrams VK, Hwang B, Lesnikova M et al.: A novel monoclonal
antibody specific for canine CD25 (P4A10): Selection and evaluation
of canine Tregs. Vet Immunol Immunopathol. 2010; 135: 257–265
[2]
Alexander AN, Huelsmeyer MK, Mitzey A et al.: Development of
an allogeneic whole-cell tumor vaccine expressing xenogeneic
gp100 and its implementation in a phase II clinical trial in canine
patients with malignant melanoma. Cancer Immunol Immunopathol. 2006; 55: 433–442
37
38
[3]
Berg G: Der Einsatz von Baypamun HK in der Mammatumorbehandlung der Hündin. [Dissertation med. vet.]. München, LudwigMaximilians-Universität; 1994
[23]
Hess AD, Catchatourian R, Zander AR et al.: Intralesional Bacillus
Calmette-Guérin immunotherapy of canine venereal tumors. Cancer
Res. 1977; 37: 3990–3994
[4]
Bergman PJ, Camps-Palau MA, McKnight JA et al.: Development
of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006; 24: 4582–4585
[24]
[5]
Bergman PJ, McKnight J, Novosad A et al.: Long-term survival of
dogs with advanced malignant melanoma after DNA vaccination
with xenogeneic human tyrosinase: A phase I trial. Clin Cancer Res.
2003; 9: 1284–1290
Hogge GS, Burkholder JK, Culp J et al.: Development of human
granulocyte-macrophage colony-stimulating factor-transfected
tumor cell vaccines for the treatment of spontaneous canine cancer.
Hum Gene Ther. 1998; 9: 1851–1861
[25]
Biller BJ, Dow S: Immunotherapy of Cancer. In Small Animal Clinical
Oncology S. 211–235, eds. Withrow SJ & Vail DM. Saunders, St.
Louis, 4. Auflg. 2007
Hüttinger C, Hirschberger J, Jahnke A et al.: Neoadjuvant gene
delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas:
a phase I trial. J Gene Med. 2008; 10: 655–667
[26]
Biller BJ, Elmslie RE, Burnett RC et al.: Use of FoxP3 expression to
identify regulatory T cells in healthy dogs and dogs with cancer. Vet
Impellizeri JA, Howell K, McKeever KP et al.: The role of rituximab
in the treatment of canine lymphoma: an ex vivo evaluation. Vet J.
2006; 171: 556–558
[27]
Jahnke A, Hirschberger J, Fischer C et al.: Intratumoral gene delivery of feIL-2, feIFN-γ and feGM-CSF using magnetofection as a
neoadjuvant treatment option for feline fibrosarcomas – a phase-I
study. J Vet Med A. 2007; 54: 599–606
[6]
[7]
[8]
Bird RC, Deinnocentes P, Lenz S et al.: An allogeneic hybrid-cell
fusion vaccine against canine mammary cancer. Vet Immunol
Immunopathol. 2008; 123: 289–304
[28]
[9]
Chou PC, Chuang TF, Jan TR et al.: Effects of immunotherapy of
IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
Vet Immunol Immunopathol. 2009; 130: 25–34
Jeglum KA: Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Vet Clin North Am Small
Anim Pract. 1996; 26: 73–85
[29]
[10]
Chuang TF, Lee SC, Liao KW et al.: Electroporation-mediated IL-12
gene therapy in a transplantable canine cancer model. Int J Cancer.
2009; 125: 698–707
Jourdier TM, Moste C, Bonnet MC et al: Local immunotherapy of
spontaneous feline fibrosarcomas using recombinant poxviruses
expressing interleukin 2 (IL2). Gene Ther. 2003; 10: 2126–2132
[30]
[11]
Coley W: The treatment of inoperable sarcoma by bacterial toxins
(mixed toxins of Steptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med Surg Sect. 1909; 3
Jubala CM, Wojcieszyn JW, Valli VE et al.: CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet
Pathol. 2005; 42: 468–476
[31]
[12]
Cutrera J, Torrero M, Shiomitsu KS et al.: Intratumoral Bleomycin
and IL-12 electrochemogenetherapy for treating head and neck
tuomors in dogs. Methods Mol Biol. 2008; 423: 319–325
Kamstock D, Elmslie R, Thamm D et al.: Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother. 2007; 56: 1299–1309
[32]
[13]
Dean GA, Barger A, Lavoy A: Cloning and expression of feline interleukin 15: Cytokine. 2005; 29: 77–83
[14]
Dow SW, Elmslie RE, MacEwen EG et al.: Phase I trial of intravenous delivery of liposome–DNA complexes encoding the IL-2 gene
for treatment of dogs with osteosarcoma metastases. Hum Gene
Ther. 2005; 16: 937–946
Kamstock D, Guth A, Elmslie R et al.: Liposome-DNA complexes
infused intravenously inhibit angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther. 2005; 13:
306–317
[33]
Kantoff WP, Higano CS, Shore ND et al.: Sipuleucel-T immunotherapy for Castration-Resistant Prostate Cancer. New Engl J Med 2010;
363: 411–422
[34]
Khanna C, Anderson PM, Hasz DE et al.: Interleukin-2 liposome
inhalation therapy is safe and effective for dogs with spontaneous
pulmonary metastasis. Cancer. 1997; 79: 1409–1421
[35]
Khanna C, Hasz DE, Klausner J et al.: Aerosol delivery of interleukin 2 liposomes in nontoxic and biologically effective: canine studies. Clin Cancer Res. 1996; 2: 721–734
[36]
Kurzman ID, MacEwen EG, Rosenthal RC et al.: Adjuvant therapy
for osteosarcoma in dogs: results of randomized clinical trials using
combined liposome-encapsulated muramyl tripeptide and cisplatin.
Clin Cancer Res. 1995; 1: 1595–1601
[15]
Dow SW, Elmslie RE, Willson AP et al.: In vivo tumor transfection
with superantigen plus cytokine genes induces tumor regression
and prolongs survival in dogs with malignant melanoma. J Clin
Invest. 1998; 101: 2406–2414
[16]
Euler von H, Sadeghi A, Carlsson B et al.: Efficient adenovector
CD40 ligand immunotherapy of canine malignant melanoma. J
Immunother. 2008; 31: 377–384
[17]
Finocchiaro LM, Fiszman GL, Karara AL et al.: Suicide gene and
cytokines combined nonviral gene therapy for spontaneous canine
melanoma. Cancer Gene Ther. 2008; 15: 165–172
[18]
Finocchiaro LM, Glikin GC: Cytokine-enhanced vaccine and suicide
gene therapy as surgery adjuvant treatments for spontaneous
canine melanoma. Gene Ther. 2008; 15: 267–276
[37]
Lankford S, Petty C, LaVoy A et al.: Cloning of feline FOXP3 and
detection of expression in CD4+CD25+ regulatory T cells. Vet Immunol Immunopathol. 2008; 122: 159–166
[19]
Fox LE, MacEwen EG, Kurzman ID et al.: Liposome-encapsulated
muramyl tripeptide phosphatidylethanolamine for the treatment of
feline mammary adenocarcinoma – a multicenter randomized
double-blind study. Cancer Biotherapy. 1995; 10: 125–130
[38]
Liao JCF, Gregor P, Wolchok JD et al.: Vaccination with human
tyrosinase DNA induces antibody responses in dogs with advanced
melanoma. Cancer Immunity. 2006; 6: 8–17
[39]
[20]
Gill VL, Bergman PJ, Baer KE et al.: Use of imiquimod 5% cream
(AldaraTM) in cats with multicentric squamous cell carcinoma in
situ: 12 cases (2002–2005). Vet Comp Oncol. 2008; 6: 55–64
[21]
Gyorffy S, Rodriguez-Lecompte JC, Woods JP et al.: Bone-marrow
derived dendritic cell vaccination in dogs with naturally occuring
melanoma by using human gp100 antigen. J Vet Intern Med. 2005;
19: 56–63
MacEwen EG, Kurzman ID, Vail DM et al.: Adjuvant therapy for
melanoma in dogs: Results of randomized clinical trials using surgery, liposome–encapsulated muramyl tripeptide, and granulocyte
macrophage colony–stimulating factor. Clin Cancer Res. 1999; 5:
4249–4258
[40]
MacEwen EG, Patnaik AK, Harvey HJ et al.: Canine oral melanoma: comparison of sugery versus surgery plus Corynebacterium
parvum. Cancer Invest. 1986; 4: 397–402
[41]
Mason NJ, Coughlin CM, Overley B et al.: RNA–loaded CD40–activated B cells stimulate antigen–specific T–cell responses in dogs
with spontaneous lymphoma. Gene Ther. 2008; 15: 955–965
[22]
Hemminki A, Kanerva A, Kremer EJ et al.: A canine conditionally
replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther. 2003; 7: 163–173
[42]
Milner RJ, Salute M, Crawford C et al.: The immune response to
disialoganglioside GD3 vaccination in normal dogs: a melanoma
surface antigen vaccine. Vet Immunol Immunopathol. 2006; 114:
273–284
[43]
Misdorp W: Incomplete surgery, local immunostimulation, and
recurrence of some tumor types in dogs and cats. Vet Quarterly.
1987; 9: 279–286
[2]
Alberts B: Mechanisms of Cell Communication. In: Alberts B (Hrsg):
Molecular biology of the cell. 5. Aufl. New York: Garland Science;
2008: 879–964
[3]
Altucci L, Gronemeyer H: The promise of retinoids to fight against
cancer. Nat Rev Cancer. 2001; 1: 181–193
[4]
Backlund B, Cianciolo RE, Cook AK et al.: Minimal change glomerulopathy in a cat. J Feline Med Surg. 2011; 13: 291–295
[44]
Moore AS, Theilen GH, Newell AD et al.: Preclinical study of
sequential tumor necrosis factor and interleukin–2 in the treatment
of spontaneous canine neoplasms. Cancer Res. 1991; 51: 233–238
[5]
Baek SJ, McEntee MF, Legendre AM: Review paper: Cancer chemopreventive compounds and canine cancer. Vet Pathol. 2009; 46:
576–588
[45]
Parodi AL, Misdorp W, Mialot JP et al.: Intratumoral BCG and
Corynebacterium parvum therapy of canine mammary tumors
before radical mastectomy. Cancer Immunol Immunother. 1983;
15: 172–177
[6]
Bardagi M, Fondevila D, Ferrer L: Immunohistochemical detection
of COX-2 in feline and canine actinic keratoses and cutaneous squamous cell carcinoma. J Comp Pathol. 2012; 146: 11–7
[7]
[46]
Quintin–Colonna F, Devauchelle P, Fradelizi D et al: Gene therapy
of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing
human interleukin–2. Gene Ther. 1996; 3: 1104–1112
Beam SL, Rassnick KM, Moore AS et al.: An immunohistochemical
study of cyclooxygenase-2 expression in various feline neoplasms.
Vet Pathol. 2003; 40: 496–500
[8]
Bellamy F, Bader T, Moussy A et al.: Pharmacokinetics of masitinib
in cats. Vet Res Commun. 2009; 33: 831–837
[9]
Bergkvist GT, Yool DA: Epidermal growth factor receptor as a therapeutic target in veterinary oncology. Vet Comp Oncol. 2011; 9:
81–94
[10]
Boria PA, Murry DJ, Bennett PF et al.: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma
and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc.
2004; 224: 388–394
[11]
Boria PA, Glickman NW, Schmidt BR et al.: Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol. 2005; 3: 73–80
[12]
Borrego JF, Cartagena JC, Engel J: Treatment of feline mammary
tumours using chemotherapy, surgery and a COX-2 inhibitor drug
(meloxicam): a retrospective study of 23 cases (2002–2007). Vet
Comp Oncol. 2009; 7: 213–221
[13]
Borzacchiello G, Paciello O, Papparella S: Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas. J Comp Pathol. 2004;
131: 70–76
[14]
Borzacchiello G, Russo V, Russo M: Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas. J Vet Med A
Physiol Pathol Clin Med. 2007; 54: 247–249
[15]
Cadot P, Hensel P, Bensignor E et al.: Masitinib decreases signs of
canine atopic dermatitis: a multicentre, randomized, double-blind,
placebo-controlled phase 3 trial. Vet Dermatol. 2011; 22: 554–564
[16]
Carlsten K, Thamm D, London C et al.: Hypofractionated radiation
therapy plus toceranib for unresectable canine mast cell tumours.
30th Ann Conf VCS, San Diego, CA, USA, 2010
[17]
Chakraborti AK, Garg SK, Kumar R et al.: Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010; 17: 1563–1593
[18]
Clifford C, Vail D, Thamm D et al.: Biological activity of toceranib
(Palladia) in canine anal gland anal SAC adenocarcinoma (AGASACA). 30th Ann Conf VCS, San Diego, CA, USA, 2010
[19]
Vail DM, MacEwen EG, Kurzman ID et al.: Liposome–encapsulated
muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi–
institutional clinical trial. Clin Cancer Res. 1995; 1:1165–1170
Cuzick J, Otto F, Baron JA et al.: Aspirin and non-steroidal antiinflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10: 501–507
[20]
Ziekman PGPM: Local low–dose IL–2 therapy of tumours in companion animals. Anticancer Res. 1999; 19: 2016
Daigle J, Moussy A, Mansfield CD et al.: Masitinib for the treatment of canine atopic dermatitis: a pilot study. Vet Res Commun.
2010; 34: 51–63
[21]
Daikoku T, Tranguch S, Trofimova IN et al.: Cyclooxygenase-1 is
overexpressed in multiple genetically engineered mouse models of
epithelial ovarian cancer. Cancer Res. 2006; 66: 2527–2531
[22]
Daly M, Sheppard S, Cohen N et al.: Safety of masitinib mesylate
in healthy cats. J Vet Intern Med. 25: 297–302
[23]
de Mello Souza CH, Toledo-Piza E, Amorin R et al.: Inflammatory
mammary carcinoma in 12 dogs: clinical features, cyclooxygenase2 expression, and response to piroxicam treatment. Can Vet J.
2009; 50: 506–510
[47]
Rosales C, Jeglum KA, Obrocka M et al.: Cytolytic activity of
murine anti–dog lymphoma monoclonal antibodies with canine
effector cells and complement. Cell Immunol. 1988; 115: 420–428
[48]
Siddiqui F, Li CY, LaRue SM et al.: A phase I trial of hyperthermia–
induced interleukin–12 gene therapy in spontaneously arising feline
soft tissue sarcomas. Mol Cancer Ther. 2007; 6: 380–389
[49]
Smith BF, Curiel DT, Ternovoi VV et al.: Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother Radiopharm. 2006; 21: 601–606
[50]
Suter SE, Chein MB, von Messling V et al.: In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic
therapy for lymphoma. Clin Cancer Res. 2005; 11: 1579–1587
[51]
Tamura K, Arai H, Ueno E et al.: Comparison of Dendritic Cell–
mediated immune responses among canine malignant cells. Vet
Med Sci. 2007; 69: 925–930
[52]
Thamm D, King I, Zujin Li et al.: Systemic administration of an
attenuated, tumor–targeting Salmonella typhimurium to dogs with
spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 2005;
11: 4827–4834
[53]
Thamm DH, Kurzman ID, MacEwen EG et al.: Intralesional lipid–
complex cytokine/superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 2003; 52:
473–480
[54]
Turek M, Thamm D, Mitzey A et al.: Human granulocyte and macrophage colony–stimulating factor DNA cationic–lipid complexed
autologous tumour cell vaccination in the treatment of canine B–
cell multicentric lymphoma. Vet Comp Oncol. 2007; 5: 219–231
[55]
U’Ren L, Biller B, Elmslie R et al.: Evaluation of an allogeneic
tumor vaccine in dogs with oral melanoma. Proc Ann Conf Vet Cancer Soc. Kansas City, MO. 2004; 104
[56]
[57]
[58]
U’Ren LW, Biller BJ, Elmslie RE et al.: Evaluation of a novel tumor
vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007; 21:
113–120
12 Tyrosinkinase-Inhibitoren, CyclooxygenaseInhibitoren und Retinoide
[1]
Ahmadi M, Emery DC, Morgan DJ: Prevention of both direct and
cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res.
2008; 68: 7520–7529
39
40
[24]
de Mello Souza CH, Valli VE, Selting KA et al.: Immunohistochemical detection of retinoid receptors in tumors from 30 dogs diagnosed with cutaneous lymphoma. J Vet Intern Med. 2010; 24:
1112–1117
[25]
de Vos J, Brearley M: First-line and rescue therapy with masitinib
integrated protocols for canine cutaneous mast cell tumours. Ann
Conf Vet Cancer Soc, San Diego, USA, 2010
[26]
de Vos JP, Burm AG, Focker AP et al.: Piroxicam and carboplatin as
a combination treatment of canine oral non-tonsillar squamous cell
carcinoma: a pilot study and a literature review of a canine model
of human head and neck squamous cell carcinoma. Vet Comp
Oncol. 2005; 3: 16–24
[27]
Dias Pereira P, Lopes CC, Matos AJ et al.: COX-2 expression in
canine normal and neoplastic mammary gland. J Comp Pathol.
2009; 140: 247–253
[45]
Hahn KA, Ogilvie G, Rusk T et al.: Masitinib is safe and effective
for the treatment of canine mast cell tumors. J Vet Intern Med.
2008; 22: 1301–1309
[46]
Hahn KA, Legendre AM, Shaw NG et al.: Evaluation of 12– and
24–month survival rates after treatment with masitinib in dogs
with nonresectable mast cell tumors. Am J Vet Res. 2010; 71:
1354–1361
[47]
Hanson PD, Maddison JE: Nonsteroidal anti-inflammatory drugs
and chondroprotective agents. In: Maddison JE, Page SW, Church D
(Hrsg), Small animal clinical pharmacology. 2. Aufl. Edinburgh:
Saunders/Elsevier; 2008: 287–308
[48]
Harris SG, Padilla J, Koumas L et al.: Prostaglandins as modulators
of immunity. Trends Immunol. 2002; 23: 144–150
[49]
DiBernardi L, Dore M, Davis JA et al.: Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor
treatment. Prostaglandins Leukot Essent Fatty Acids. 2007; 76:
245–250
Hayes A, Scase T, Miller J et al.: COX-1 and COX-2 expression in
feline oral squamous cell carcinoma. J Comp Pathol. 2006; 135: 93–
99
[50]
Hayes A: Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory drugs – can we combine all three? Vet Comp Oncol. 2007; 5:
1–13
[29]
Dore M, Lanthier I, Sirois J: Cyclooxygenase-2 expression in canine
mammary tumors. Vet Pathol. 2003; 40: 207–212
[51]
[30]
Dore M: Cyclooxygenase-2 expression in animal cancers. Vet
Pathol. 2010; 48: 254–265
Hayes AM, Adams VJ, Scase TJ et al.: Survival of 54 cats with oral
squamous cell carcinoma in United Kingdom general practice. J
[52]
[31]
Downing S, Chien MB, Kass PH et al.: Prevalence and importance
of internal tandem duplications in exons 11 and 12 of c-kit in mast
cell tumors of dogs. Am J Vet Res. 2002; 63: 1718–1723
Heller DA, Clifford CA, Goldschmidt MH et al.: Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic
sarcoma, and mast cell tumor. Vet Pathol. 2005; 42: 350–353
[53]
[32]
Dubreuil P, Letard S, Ciufolini M et al.: Masitinib (AB1010), a
potent and selective tyrosine kinase inhibitor targeting KIT. PLoS
One. 2009; 4: e7258
Heller DA, Clifford CA, Goldschmidt MH et al.: Cyclooxygenase-2
expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol. 2005; 42: 776–780
[54]
[33]
Elmslie RE, Glawe P, Dow SW: Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in
Med. 2008; 22: 1373–1379
Heller DA, Fan TM, de Lorimier LP et al.: In vitro cyclooxygenase-2
protein expression and enzymatic activity in neoplastic cells. J Vet
Intern Med. 2007; 21: 1048–1055
[55]
Henfrey JI: Treatment of multiple intracutaneous cornifying epitheliomata using isotretinoin. J Small Anim Pract. 1991; 32: 363–365
[28]
[34]
EMEA: EPAR Scientific Discussion for the approval of Masivet. European Medicines Agency (EMEA), London, 2008, 1–17
[56]
[35]
EMEA: Committee for medicinal products for veterinary use summary of opinion: Masivet: International Non-proprietary Name
(INN): Masitinib mesylate. In: Inspections EMAVMa (Hrsg), London,
2008
[57]
Hochhaus A: Imatinib mesylate (Glivec, Gleevec) in the treatment
of chronic myelogenous leukemia (CML) and gastrointestinal
stromal tumors (GIST). Ann Hematol. 2004; 83 Suppl 1: S65–66
[36]
EMEA: EPAR Scientific Discussion for the approval of Palladia. European Medicines Agency (EMEA), London, 2009, 1–17
[58]
[37]
Evans AG, Madewell BR, Stannard AA: A trial of 13–cis-retinoic
acid for treatment of squamous cell carcinoma and preneoplastic
lesions of the head in cats. Am J Vet Res. 1985; 46: 2553–2557
Hohenhaus A, Henry A, Greene S et al.: Biological activity and
adverse event profile in cats treated with toceranib phosphate. 30th
Ann Conf VCS, San Diego, CA, USA, 2010
[59]
Hong SH, Kadosawa T, Nozaki K et al.: In vitro retinoid-induced
growth inhibition and morphologic differentiation of canine osteosarcoma cells. Am J Vet Res. 2000; 61: 69–73
[60]
Humbert M, de Blay F, Garcia G et al.: Masitinib, a c-kit/PDGF
receptor tyrosine kinase inhibitor, improves disease control in
severe corticosteroid-dependent asthmatics. Allergy. 2009; 64:
1194–1201
[38]
Fields AL, Soprano DR, Soprano KJ: Retinoids in biological control
and cancer. J Cell Biochem. 2007; 102: 886–898
[39]
Fieten H, Spee B, Ijzer J et al.: Expression of hepatocyte growth
factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 2009; 46: 869–877
[40]
Fukuda R, Kelly B, Semenza GL: Vascular endothelial growth factor
gene expression in colon cancer cells exposed to prostaglandin E2 is
mediated by hypoxia-inducible factor 1. Cancer Res. 2003; 63:
2330–2334
[61]
Imai K, Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714–727
[62]
Impellizeri JA, Esplin DG: Expression of cyclooxygenase-2 in canine
nasal carcinomas. Vet J. 2008; 176: 408–410
[41]
Fux R, Schwab M, Thon KP et al.: Cyclooxygenase-2 expression in
human colorectal cancer is unrelated to overall patient survival. Clin
Cancer Res. 2005; 11: 4754–4760
[63]
[42]
Greenhough A, Smartt HJ, Moore AE et al.: The COX-2/PGE2
pathway: key roles in the hallmarks of cancer and adaptation to the
tumour microenvironment. Carcinogenesis. 2009; 30: 377–386
Isotani M, Tamura K, Yagihara H et al.: Identification of a c-kit
exon 8 internal tandem duplication in a feline mast cell tumor case
and its favorable response to the tyrosine kinase inhibitor imatinib
mesylate. Vet Immunol Immunopathol. 2006; 114: 168–172
[64]
Grosch S, Maier TJ, Schiffmann S et al.: Cyclooxygenase-2 (COX2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006; 98: 736–747
Isotani M, Ishida N, Tominaga M et al.: Effect of tyrosine kinase
inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet
Intern Med. 2008; 22: 985–988
[65]
Isotani M, Yamada O, Lachowicz JL et al.: Mutations in the fifth
immunoglobulin-like domain of kit are common and potentially
sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol. 2009; 148: 144–153
[43]
[44]
Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4:
361–370
[66]
Jagielski D, Chapuis T, Lebruneau J et al: Positive response in the
treatment of epitheliotropic T-Cell lymphoma (Mycosis Fungoides)
with Masitinib. Ann Conf Europ Soc Vet Oncol, Glasgow, United
Kingdom, 2011
[86]
Linnekin D, Keller JR, Ferris DK et al.: Stem cell factor induces
phosphorylation of a 200 kDa protein which associates with c-kit.
Growth Factors. 1995; 12: 57–67
[87]
[67]
Jones CL, Grahn RA, Chien MB et al.: Detection of c-kit mutations
in canine mast cell tumors using fluorescent polyacrylamide gel
electrophoresis. J Vet Diagn Invest. 2004; 16: 95–100
London C, Mathie T, Stingle N et al.: Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours.
Vet Comp Oncol. 2012; 10: 194–205
[88]
[68]
Katayama R, Huelsmeyer MK, Marr AK et al.: Imatinib mesylate
inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol. 2004; 54: 25–33
London CA, Galli SJ, Yuuki T et al.: Spontaneous canine mast cell
tumors express tandem duplications in the proto-oncogene c-kit.
Exp Hematol. 1999; 27: 689–697
[89]
London CA, Hannah AL, Zadovoskaya R et al.: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase
inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res.
2003; 9: 2755–2768
[90]
London CA: Tyrosine kinase inhibitors in veterinary medicine. Top
Companion Anim Med. 2009; 24: 106–112
[91]
London CA, Malpas PB, Wood-Follis SL et al.: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib
phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the
treatment of dogs with recurrent (either local or distant) mast cell
tumor following surgical excision. Clin Cancer Res. 2009; 15: 3856–
3865
[69]
Kay-Mugford P, Benn SJ, LaMarre J et al.: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in
dogs. Am J Vet Res. 2000; 61: 802–810
[70]
Khan KN, Knapp DW, Denicola DB et al.: Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in
dogs. Am J Vet Res. 2000; 61: 478–481
[71]
Khan KN, Stanfield KM, Trajkovic D et al.: Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol. 2001; 38: 116–
119
[72]
Kleiter M, Malarkey DE, Ruslander DE et al.: Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet Radiol Ultrasound. 2004; 45: 255–260
[92]
Knapp DW, Richardson RC, Chan TC et al.: Piroxicam therapy in
34 dogs with transitional cell carcinoma of the urinary bladder. J Vet
Intern Med. 1994; 8: 273–278
Lyles S, Milner R, Kow K et al.: Evaluation of the receptor tyrosine
kinase inhibitor, Masitinib Mesylate, in canine hemangiosarcoma
cell lines. Ann Conf Vet Cancer Soc, San Diego, USA, 2010
[93]
Marks SL, Song MD, Stannard AA et al.: Clinical evaluation of etretinate for the treatment of canine solar-induced squamous cell carcinoma and preneoplastic lesions. J Am Acad Dermatol. 1992; 27:
11–16
[73]
[74]
Knapp DW, Chan TC, Kuczek T et al.: Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor
cells. Am J Vet Res. 1995; 56: 801–805
[94]
[75]
Knottenbelt C, Chambers G, Gault E et al.: The in vitro effects of
piroxicam and meloxicam on canine cell lines. J Small Anim Pract.
2006; 47: 14–20
Marquez C, Bair SM, Smithberger E et al.: Systemic retinoids for
chemoprevention of non-melanoma skin cancer in high-risk
patients. J Drugs Dermatol. 2010; 9: 753–758
[95]
[76]
Knottenbelt C, Mellor D, Nixon C et al.: Cohort study of COX-1
and COX-2 expression in canine rectal and bladder tumours. J Small
Anim Pract. 2006; 47: 196–200
McEntee MF, Cates JM, Neilsen N: Cyclooxygenase-2 expression in
spontaneous intestinal neoplasia of domestic dogs. Vet Pathol.
2002; 39: 428–436
[96]
[77]
Knottenbelt CM, Simpson JW, Tasker S et al.: Preliminary clinical
observations on the use of piroxicam in the management of rectal
tubulopapillary polyps. J Small Anim Pract. 2000; 41: 393–397
Millanta F, Citi S, Della Santa D et al.: COX-2 expression in canine
and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast
Cancer Res Treat. 2006; 98: 115–120
[78]
LʼEplattenier HF, Lai CL, van den Ham R et al.: Regulation of COX2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. J Vet Intern Med. 2007; 21:
776–782
[97]
[79]
Lachowicz JL, Post GS, Brodsky E: A phase I clinical trial evaluating
imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern
Med. 2005; 19: 860–864
Millanta F, Silvestri G, Vaselli C et al.: The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting
tumour angiogenesis in feline and canine mammary carcinomas: a
preliminary study of autocrine and paracrine loops. Res Vet Sci.
2006; 81: 350–357
[98]
Miyajima N, Watanabe M, Ohashi E et al.: Relationship between
retinoic acid receptor alpha gene expression and growth-inhibitory
effect of all-trans retinoic acid on canine tumor cells. J Vet Intern
Med. 2006; 20: 348–354
[99]
Mohammed SI, Bennett PF, Craig BA et al.: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and
angiogenesis in a canine model of human invasive urinary bladder
cancer. Cancer Res. 2002; 62: 356–358
[80]
Lana S, UʼRen L, Plaza S et al.: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J
Vet Intern Med. 2007; 21: 764–769
[81]
Lavalle GE, Bertagnolli AC, Tavares WL et al.: Cox-2 expression in
canine mammary carcinomas: correlation with angiogenesis and
overall survival. Vet Pathol. 2009; 46: 1275–1280
[82]
Lee-Fowlera TM, Gunturb V, Dodama J et al.: A randomized,
blinded, placebo-controlled study of the tyrosine kinase inhibitor
masitinib for treatment of experimental feline asthma. 28th Vet
Comp Resp Symposium, Raleigh, North Carolina, 2010
[83]
Lee JY, Tanabe S, Shimohira H et al.: Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein
in canine transitional cell carcinoma. Res Vet Sci. 2007; 83: 210–
216
[84]
Liang K, Lu Y, Jin W et al.: Sensitization of breast cancer cells to
radiation by trastuzumab. Mol Cancer Ther. 2003; 2: 1113–1120
[85]
Liao AT, McCleese J, Kamerling S et al.: A novel small molecule
Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet Comp Oncol. 2007; 5: 177–196
[100] Mohammed SI, Craig BA, Mutsaers AJ et al.: Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy
on tumor response, apoptosis, and angiogenesis in a canine model
of human invasive urinary bladder cancer. Mol Cancer Ther. 2003;
2: 183–188
[101] Mohammed SI, Khan KN, Sellers RS et al.: Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins
Leukot Essent Fatty Acids. 2004; 70: 479–483
[102] Mohammed SI, Dhawan D, Abraham S et al.: Cyclooxygenase
inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol
Cancer Ther. 2006; 5: 329–336
[103] Muller GH, Kirk RW, Scott DW et al.: Dermatologic Therapy. In:
Muller GH, Kirk RW, Scott DW et al. (Hrsg), Muller & Kirkʼs Small
Animal Dermatology. 6 Aufl. Philadelphia: Saunders; 2001: 207–
274
41
42
[104] Mullins MN, Lana SE, Dernell WS et al.: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med. 2004;
18: 859–865
[125] Rossmeisl JH, Jr, Robertson JL, Zimmerman KL et al.: Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas. Vet
Comp Oncol. 2009; 7: 173–180
[105] Mutsaers AJ, Glickman NW, DeNicola DB et al.: Evaluation of
treatment with doxorubicin and piroxicam or doxorubicin alone for
multicentric lymphoma in dogs. J Am Vet Med Assoc. 2002; 220:
1813–1817
[126] Sanchez-Alcazar JA, Bradbury DA, Pang L et al.: Cyclooxygenase
(COX) inhibitors induce apoptosis in non-small cell lung cancer
through cyclooxygenase independent pathways. Lung Cancer.
2003; 40: 33–44
[106] Mutsaers AJ, Mohammed SI, DeNicola DB et al.: Pretreatment
tumor prostaglandin E2 concentration and cyclooxygenase-2
expression are not associated with the response of canine naturally
occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot Essent Fatty Acids. 2005; 72:
181–186
[127] Sano H, Kawahito Y, Wilder RL et al.: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995; 55:
3785–3789
[107] Newman SJ, Mrkonjich L: Cyclooxygenase-2 expression in feline
pancreatic adenocarcinomas. J Vet Diagn Invest. 2006; 18: 590–593
[129] Schmidt BR, Glickman NW, DeNicola DB et al.: Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J
Am Vet Med Assoc. 2001; 218: 1783–1786
[108] OʼByrne KJ, Dalgleish AG: Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001; 85: 473–483
[109] Ogilvie G, Rusk A, Legendre A et al.: Evaluation of safety of masitinib in combination with doxorubicin in advanced canine tumors.
Proc Mid-Year Conf Vet Cancer Soc, 2010
[128] Sayasith K, Sirois J, Dore M: Molecular characterization of feline
COX-2 and expression in feline mammary carcinomas. Vet Pathol.
2009; 46: 423–429
[130] Serres F, Meyer C, Tierny D et al.: Masitinib for maintenance chemotherapy of two dogs with T-cell muliticentric lymphoma. Ann
Conf Europ Soc Vet Oncol, 2010
[110] Ogilvie G, Rusk A, Legendre A, Moussy A et al.: Evaluation of
safety of masitinib in combination with carboplatin in advanced
canine tumors. Proc Mid-Year Conf Vet Cancer Soc, 2010
[131] Sleijfer S, Wiemer E, Seynaeve C et al.: Improved insight into
resistance mechanisms to imatinib in gastrointestinal stromal
tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007; 12: 719–726
[111] Ohashi E, Miyajima N, Nakagawa T et al.: Retinoids induce growth
inhibition and apoptosis in mast cell tumor cell lines. J Vet Med Sci.
2006; 68: 797–802
[132] Sonzogni-Desautels K, Knapp DW, Sartin E et al.: Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary
tumours. Vet Comp Oncol. 2011; 9:161–171
[112] Ohmori K, Kawarai S, Yasuda N et al.: Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
[133] Sorenmo KU, Goldschmidt MH, Shofer FS et al.: Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of
cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp
Oncol. 2004; 2: 13–23
[113] Paglia D, Dubielzig RR, Kado-Fong HK et al.: Expression of cyclooxygenase-2 in canine uveal melanocytic neoplasms. Am J Vet Res.
2009; 70: 1284–1290
[114] Pestili de Almeida EM, Piche C, Sirois J et al.: Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in
dogs. J Histochem Cytochem. 2001; 49: 867–875
[134] Streppa HK, Jones CJ, Budsberg SC: Cyclooxygenase selectivity of
nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res.
2002; 63: 91–94
[135] Sum SO, Hensel P, Rios L et al.: Drug-induced minimal change
nephropathy in a dog. J Vet Intern Med. 2010; 24: 431–435
[115] Pires I, Garcia A, Prada J et al.: COX-1 and COX-2 expression in
canine cutaneous, oral and ocular melanocytic tumours. J Comp
Pathol. 2010; 143: 142–149
[136] Thamm DH, Rose B, Kow K et al.: Masitinib as a chemosensitizer
of canine tumor cell lines: A proof of concept study. Vet J. 2012;
191: 131–134
[116] Preziosi R, Morini M, Sarli G: Expression of the KIT protein
(CD117) in primary cutaneous mast cell tumors of the dog. J Vet
Diagn Invest. 2004; 16: 554–561
[137] Toma S, Noli C: Isotretinoin in the treatment of multiple benign
pilomatrixomas in a mixed-breed dog. Vet Dermatol. 2005; 16:
346–350
[117] Procoli F: Clinical trial on the efficacy of masitinib in canine IBD. Vet
Rec. 2011; 167: 760
[138] Tremblay C, Dore M, Bochsler PN et al.: Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J Natl Cancer Inst. 1999; 91: 1398–1403
[118] Pronovost N, Suter MM, Mueller E et al.: Expression and regulation of cyclooxygenase-2 in normal and neoplastic canine keratinocytes. Vet Comp Oncol. 2004; 2: 222–233
[119] Queiroga FL, Perez-Alenza MD, Silvan G et al.: Cox-2 levels in
canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
Anticancer Res. 2005; 25: 4269–4275
[120] Queiroga FL, Alves A, Pires I et al.: Expression of Cox-1 and Cox-2
in canine mammary tumours. J Comp Pathol. 2007; 136: 177–185
[121] Queiroga FL, Pires I, Parente M et al.: COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary
cancer. Vet J. 2011; 189: 7–82
[122] Reguera MJ, Rabanal RM, Puigdemont A et al.: Canine mast cell
tumors express stem cell factor receptor. Am J Dermatopathol.
2000; 22: 49–54
[123] Robat C, London C, Bunting L et al.: Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a
phase I dose-finding study. Vet Comp Oncol. 2012: 10: 174–183
[124] Roos A, Fraytag S, Moussy A et al.: A c-Kit inhibitor (Masivet®)
shows therapeutic potential in dog neurofibrosarcoma. Proc Ann
Conf Europ Soc Vet Oncol, 2010
[139] Vail DM, Young KM: Hematopoietic Tumors. In: Withrow SJ, Vail
DM (Hrsg), Withrow and MacEwenʼs Small Animal Clinical Oncology. 4 Aufl. St. Louis: Saunders/Elsevier; 2007: 699–733
[140] Watanabe M, Chen IY, Ishikura Y et al.: Tumor cell growth inhibition and cell differentiation analysis in a canine mammary tumor
cell line (MCM-B2) treated with four chemical reagents. J Vet Med
Sci. 2009; 71: 1413–1417
[141] Webster JD, Kiupel M, Kaneene JB et al.: The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous
mast cell tumors. Vet Pathol. 2004; 41: 371–377
[142] Webster JD, Kiupel M, Yuzbasiyan-Gurkan V: Evaluation of the
kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC
Cancer. 2006; 6: 85
[143] Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB et al.: The role of
c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell
tumors. Neoplasia. 2006; 8: 104–111
[144] Webster JD, Yuzbasiyan-Gurkan V, Miller RA et al.: Cellular proliferation in canine cutaneous mast cell tumors: associations with
43
[146] White SD, Rosychuk RA, Scott KV et al.: Use of isotretinoin and
etretinate for the treatment of benign cutaneous neoplasia and
cutaneous lymphoma in dogs. J Am Vet Med Assoc. 1993; 202:
387–391
[17]
14 Photodynamische Therapie
[1]
Allman R, Cowburn P, Mason M: Effect of photodynamic therapy
in combination with ionizing radiation on human squamous cell carcinoma cell lines of the head and neck. Br J Cancer. 2000; 83: 655–
661
[2]
Borgatti-Jeffreys A, Hooser SB, Miller MA et al.: Phase I clinical
trial of the use of zinc phthalocyanine tetrasulfonate as a photosensitizer for photodynamic therapy in dogs. Am J Vet Res. 2007; 68:
399–404
[3]
Buchholz J, Kaser-Hotz B: Kombination von photodynamischer
Therapie und Hyperthermie mit wassergefiltertem Infrarotlicht zur
Behandlung kutaner Plattenepithelkarzinome bei 15 Katzen: Eine
Pilotstudie. Kleintierprax. 2010; 50: 248–254
[4]
Buchholz J, Walt H, Fidel J: Photodynamische Therapie beim felinen Plattenepithelkarzinom sowie bei verschiedenen kaninen
Tumoren, Kleintierprax. 2003; 48: 405–418
[5]
Buchholz J, Kaser-Hotz B, Khan T et al.: Optimizing photodynamic
therapy: in vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma. Clin Cancer Res.
2005; 11: 7538–7544
[6]
Buchholz J, Wergin M, Walt H et al.: Photodynamic therapy of
feline cutaneous squamous cell carcinoma using a newly developed
liposomal photosensitizer: Preliminary results concerning drug
safety and efficacy. J Vet Intern Med. 2007; 21: 770–775
[147] Wolfesberger B, Walter I, Hoelzl C et al.: Antineoplastic effect of
the cyclooxygenase inhibitor meloxicam on canine osteosarcoma
cells. Res Vet Sci. 2006; 80: 308–316
[148] Wolfesberger B, Tonar Z, Gerner W et al.: The tyrosine kinase
inhibitor sorafenib decreases cell number and induces apoptosis in
a canine osteosarcoma cell line. Res Vet Sci. 2010; 88: 94–100
[149] Zandvliet M, Teske E, Fink-Gienimels J et al.: The cytotoxic effect
of masitinib (Masivet) on a canine leukemia cell line does not result
from inhibition of the ABC-transporters P-GP and MRP-1. 23. Conf
ECVIM, Toulouse, 2010
[150] Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast
cell tumors in dogs. Vet Pathol. 2002; 39: 529–535
Zacarian SA: Cryosurgery for skin cancer and cutaneous disorders.
St. Louis: Mosby Co; 1985
13 Kryochirurgie
[1]
Clin Tech Small Anim Pract 2007; 22: 46–54
[2]
Clarke RE: Cryosurgical treatment of feline cutaneous squamous
cell carcinoma. Aust Vet Pract. 1991; 21: 148–153
[3]
Featherstone HJ, Renwick P, Heinrich CL et al.: Efficacy of lamellar
resection, cryotherapy, and adjunctive grafting for the treatment of
canine limbal melanoma. Vet Ophthalmol. 2009; 12 Suppl 1: 65–72
[7]
[4]
Gianonne JA: Cryotherapy for lesions of the ear, eye and nose. Mod
Vet Pract. 1984; 65: 905
Bergh van den H: On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy. 1998; 30:
392–407
[8]
[5]
Harvey HJ: Cryosurgery of oral tumors in dogs and cats. Vet Clin
Chen B, Pogue BW, Hoopes PJ et al.: Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr. 2006;
16: 279–305
[6]
Idowu AL: Cryosurgery of canine transmissible venereal tumor.
Trop Vet. 1985; 3: 74–78
[9]
[7]
Lana SE, Ogilvie GK, Withrow SJ et al.: Feline cutaneous squamous cell carcinoma of the nasal planum and the pinnae: 61 cases.
Chen Q, Huang Z, Chen H et al.: Improvement of tumor response
by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol. 2002; 76: 197–203
[10]
[8]
Latimer KS, Kaswan RL, Sundberg JP: Corneal squamous cell carcinoma in a dog. J Am Vet Med Assoc. 1987; 190: 1430–1432
Dolmans DE, Kadambi A, Hill JS et al.: Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated
photosensitizer dosing photodynamic therapy. Cancer Res. 2002;
62: 4289–4294
[9]
Martens A. Kryochirurgie. In: Kramer M (Hrsg.): Kompendium der
allgemeinen Veterinärchirurgie. Hannover: Schlütersche; 2004:
323–325
[11]
Ferreira I, Rahal SC, Rocha NS et al.: Hematoporphyrin-based photodynamic therapy for cutaneous squamous cell carcinoma in cats.
Vet Dermatol. 2009; 20: 174–178
[10]
Multari D, Vascellari M, Mutinelli F: Hemangiosarcoma of the
third eyelid in a cat. Vet Ophthalmol. 2002; 5: 273–276
[12]
Fingar VH, Kik PK, Haydon PS et al.: Analysis of acute vascular
damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer. 1999; 79: 1702–1708
[11]
Queiroz GF: Clinical study of cryosurgery efficacy in the treatment
of skin and subcutaneous tumors in dogs and cats. Vet Surg. 2008;
37: 438–434
[13]
[12]
Siebert J, Behrens A: Kryochirurgie in der Tiermedizin. Stuttgart:
Enke; 1996
Fingar V, Wieman T, Wiehle S et al.: The role of microvascular
damage in photodynamic therapy: the effect of treatment on vessel
constriction, permeability, and leukocyte adhesion. Cancer Res.
1992; 52: 4914–4921
[14]
[13]
Sinclair RD, Dawber RP: Cryosurgery of malignant and premalignant diseases of the skin: A simple approach. Aust J Dermatol.
1995; 36: 133–142
Frimberger AE, Moore AS, Cincotta L et al.: Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer. Clin Cancer Res. 1998; 4: 2207–
2218
[14]
Toursel W: Kryobiologische Grundzüge. In: Matthäus W (Hrsg.):
Kryotherapie in der Ophthalmologie und Dermatologie und Grundlagen der therapeutischen Kälteanwendung. Leipzig: Johann Ambrosius Barth; 1989: 21–29
[15]
Gollnick SO, Vaughan L, Henderson BW: Generation of effective
antitumor vaccines using photodynamic therapy. Cancer Res. 2002;
62: 1604–1608
[16]
[15]
Ward DA, Latimer KS, Askren RM: Squamous cell carcinoma of
the corneoscleral limbus in a dog. J Am Vet Med Assoc. 1992; 200:
1503–1506
Gomer CJ, Ferrario A, Murphree AL: The effect of localised porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer. 1987; 56: 27–32
[17]
[16]
Withrow SJ: Cryosurgery. In: Withrow SJ, Vail DM (Hrsg.): Small
Animal Oncology. 4. Aufl. St. Louis: Saunders; 2007: 275–280
Hahn KA, Panjehpour M, Legendre AM: Photodynamic therapy
response in cats with cutaneous squamous cell carcinoma as a function of fluence. Vet Dermatol. 1998; 9: 3–7
[145] Weinberg RA: Growth Factors, Receptors, and Cancer. In: Weinberg RA (Hrsg): The biology of cancer. New York: Garland Science;
2007: 119–158
44
[18]
Henderson BW, Waldow SM, Mang TS et al.: Tumor destruction
and kinetics of tumor cell death in two experimental mouse tumors
following photodynamic therapy. Cancer Res. 1985; 45: 572–576
[39]
Stell AJ, Dobson JM, Langmack K: Photodynamic therapy of feline
superficial squamous cell carcinoma using topical 5-aminolaevulinic
acid. J Small Anim Pract. 2001; 42: 164–169
[19]
Jacobs TM, Rosen GM: Photodynamic therapy as a treatment for
esophageal squamous cell carcinoma in a dog. J Am Anim Hosp
Assoc. 2000; 36: 257–261
[40]
Svaasand L, Wyss P, Wyss MT et al.: Dosimetry model for photodynamic therapy with topically administered photosensitizers.
Lasers Surg Med. 1996; 18: 139–149
[20]
Kelleher DK, Bastian J, Thews O et al.: Enhanced effects of aminolaevulinic acid based photodynamic therapy through local hyperthermia in rat tumors. Br J Cancer. 2003; 89: 405–411
[41]
Thomas JP, Girotti AW: Glucose administration augments in vivo
uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivate. Photochem Photobiol. 1989; 49: 241–247
[21]
Kelty CJ, Brown NJ, Reed MW et al.: The use of 5-aminolaevulinic
acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci. 2002; 1: 158–168
[42]
Tromberg BJ, Orenstein A, Kimel S et al.: In vivo tumor oxygen
tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol. 1990; 52: 375–385
[22]
Knapp DW, Adams LG, DeGrand AM: Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. European Urology. 2007; 52: 1700–1709
[23]
Korbelik M, Dougherty GJ: Photodynamic therapy-mediated
immune response against subcutaneous mouse tumors. Cancer
Res. 1999; 59: 1941–1946
[24]
Lucroy MD, Edwards B, Peavy GM et al.: Preclinical study in cats
of the pro-photosensitizer 5-aminolevulinic acid. Am J Vet Res.
1999; 60: 1364–1370
15 Hyperthermie
[1]
Aoki H, Kakinuma K, Morita K et al.: Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive
liposome: evaluation of drug distribution in a rat glioma model. Int J
Hyperthermia. 2004; 20: 595–605
[2]
Arora D, Cooley D, Perry T et al.: MR thermometry-based feedback control of efficacy and safety in minimum-time thermal therapies: phantom and in-vivo evaluations. Int J Hyperthermia. 2006;
22: 29–42
[3]
Breasted JH: The Edwin Smith surgical papyrus. In: Licht S (Hrsg.):
Therapeutic heat and cold. 2. Aufl. New Haven: Waverly Press;
1930: 196
[25]
Lucroy MD, Ridgway TD, Peavy GM: Preclinical evaluation of
5-aminolevulinic acid-based photodynamic therapy for canine transitional cell carcinoma. Vet Comp Oncol. 2003; 1: 76–85
[26]
Lucroy MD, Long KR, Blaik MA: Photodynamic therapy for the
treatment of intranasal tumors in 3 dogs and 1 cat. J Vet Intern
Med. 2003; 17: 727–729
[27]
Lucroy MD, Bowles MH, Russell GH et al.: Photodynamic therapy
for prostatic carcinoma in a dog. J Vet Intern Med. 2003; 17: 235–
237
[4]
Buscarini E, Savoia A, Brambilla G et al.: Radiofrequency ablation
of liver tumors, Eur Radiol. 2005; 15: 884–894
[5]
Ma LW, Moan J, Steen HB et al.: Anti-tumor activity of photodynamic therapy in combination with mitomycin C in nude mice with
human colon adenocarcinoma. Br J Cancer. 1995; 71: 950–956
Carter DL, MacFall JR, Clegg ST et al: Magnetic resonance thermometry during hyperthermia for human high-grade sarcoma, Int J
Radiat Oncol Biol Phys. 1998; 40: 815–822
[6]
Magne ML, Rodriguez CO, Autry SA et al.: Photodynamic therapy
of facial squamous cell carcinoma in cats using a new photosensitizer. Lasers Surg Med. 1997; 20: 202–209
Cernicanu A, Lepetit-Coiffé M, Viallon M et al.: New horizons in
MR-controlled and monitored radiofrequency ablation of liver
tumours. Cancer Imaging. 2007; 7: 160–166
[7]
Maisch T, Szeimies RM, Lehn N et al.: Antibacterial photodynamic
therapy. A new treatment for superficial bacterial infections? Hautarzt. 2005; 56: 1048–1055.
Chen Q, Tong S, Dewhirst MW et al.: Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther. 2004; 3: 1311–1317
[8]
Mazière JC, Morlière P, Santus R: The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours. Photochem Photobiol. 1991; 8: 351–360
Cheng KS, Stakhursky V, Stauffer P et al.: Online feedback focusing algorithm for hyperthermia cancer treatment. Int J Hyperthermia. 2007; 23: 539–554
[9]
McCaw DL, Pope ER, Payne JT et al.: Treatment of canine oral
squamous cell carcinomas with photodynamic therapy. Br J Cancer.
2000; 82: 1297–1299
Clasen S, Pereira PL: Magnetic resonance guidance for radiofrequency ablation of liver tumors. J Magn Reson Imaging. 2008; 27:
421–433
[10]
Coley WB: The treatment of malignant tumors by repeated inoculation of erysipelas, with a report of ten original cases. Am J Med
Sci. 1893; 105: 487–511 und Clin Orthop Relat Res. 1991; 262: 3–
11
[28]
[29]
[30]
[31]
[32]
[33]
McCaw DL, Payne JT, Pope ER et al.: Treatment of canine hemangiopericytomas with photodynamic therapy. Lasers Surg Med.
2001; 29: 23–26
[11]
[34]
Payne JT, McCaw DL, Rogers K et al.: Treatment of naturally occuring hemangiopericytoma and oral squamous cell carcinoma in
dogs using surgery and photodynamic therapy with HPPH as a photosensitizer. SPIE. 1995; 2395: 622–626
Das SK, Macfall J, McCauley R et al.: Improved magnetic resonance thermal imaging by combining proton resonance frequency
shift (PRFS) and apparent diffusion coefficient (ADC) data. Int J
Hyperthermia. 2005; 21: 657–667
[12]
[35]
Peaston AE, Leach MW, Higgins RJ: Photodynamic therapy for
nasal and aural squamous cell carcinoma in cats. J Am Vet Med
Assoc. 1993; 202: 1261–1265
Dayanc BE, Beachy SH, Ostberg JR et al.: Dissecting the role of
hyperthermia in natural killer cell mediated anti-tumor responses.
Int J Hyperthermia. 2008; 24: 41–56
[13]
[36]
Reeds KB, Ridgway TD, Higbee RG et al.: Non-coherent light for
photodynamic therapy of superficial tumours in animals. Vet Comp
Oncol. 2004; 2: 157–163
Deandrea M, Limone P, Basso E et al.: US-guided percutaneous
radiofrequency thermal ablation for the treatment of solid benign
hyperfunctioning or compressive thyroid nodules. Ultrasound Med
Biol Jan. 2008; 34: 784–791
[37]
Ridgway TD, Lucroy MD: Phototoxic effects of 635-nm light on
canine transitional cell carcinoma cells incubated with 5-aminolevulinic acid. Am J Vet Res. 2003; 64: 131–136
[14]
[38]
Schneider R, Tirand L, Frochot C et al.: Recent improvements in
the use of synthetic peptides for a selective photodynamic therapy.
Anticancer Agents Med Chem. 2006; 6: 469–488
Denman DL, Legorreta RA, Kier AB et al.: Therapeutic responses
of spontaneous canine malignancies to combinations of radiotherapy and hyperthermia. Int J Radiat Oncol Biol Phys. 1991; 21: 415–
422
[15]
Dewey WC, Hopwood LE, Sapereto SA et al: Cellular responses to
combination of hyperthermia and radiation, Radiology. 1977; 123:
463–474
[37]
Kinsey AM, Diederich CJ, Tyreus PD et al.: Multisectored interstitial ultrasound applicators for dynamic angular control of thermal
therapy. Med Phys. 2006; 33: 1352–1363
[16]
Dewhirst MW, Vujaskovic Z, Zones E et al: Re-setting the biological rationale for thermal therapy, Int J Hyperthermia. 2005; 21:
779–790
[38]
[17]
Dewhirst MW, Prosnitz L, Thrall D et al.: Hyperthermic treatment
of malignant diseases: current status and a view toward the future.
Semin Oncol. 1997; 24: 616–625
Kleiter MM, Yu D, Mohammadian LA et al.: A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res. 2006;
12: 6800–6807
[39]
Klingler HC, Susani M, Seip R et al.: A novel approach to energy
ablative therapy of small renal tumours: Laparoscopic High-Intensity Focused Ultrasound. Eur Urol. 2007; 53: 810–816
[40]
Kong G, Braun RD, Dewhirst MW: Characterization of the effect
of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001; 61: 3027–3032
[18]
Dewhirst MW, Sim DA, Connor WG: Importance of tumor temperature in determining early and long-term responses of spontaneous canine and feline tumors to heat and radiation, Cancer Res.
1984; 44: 43–50
[19]
Dewhirst MW, Sim DA: The utility of thermal dose as a predictor
of tumor and normal tissue responses to combined radiation and
hyperthermia. Cancer Res. 1984; 44 (Suppl 10): 4772–4780
[41]
Kong G, Braun RD, Dewhirst MW: Hyperthermia enables tumorspecific nanoparticle delivery: effect of particle size. Cancer Res.
2000, 60: 4440–4405
[20]
Dvorak J, Zoul Z, Melichar B et al.: Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and
improving locoregional efficacy in the treatment of solid tumors. J
Chemother. 2004; 16 (Suppl 5): 34–36
[42]
Kong G, Anyarambhatla G, Petros WP et al.: Efficacy of liposomes
and hyperthermia in a human tumor xenograft model: importance
of triggered drug release. Cancer Res. 2000; 60: 6950–6957
[43]
[21]
El-Sharkawy AM, Sotiriadis PP, Bottomley PA et al.: Absolute
temperature monitoring using RF radiometry in the MRI scanner.
IEEE Trans Circuits Syst I Regul Pap. 2006; 53: 2396–2404
Kong G, Dewhirst MW: Hyperthermia and liposomes, Int J Hyperthermia. 1999; 15: 345–370
[44]
Frew DG, Dobson JM, Stenning SP et al.: Response of 145 spontaneous canine head and neck tumours to radiation versus radiation
plus microwave hyperthermia: results of a randomized phase III clinical study. Int J Hyperthermia. 1995; 11: 217–230
Kouloulias VE, Koukourakis GV, Petridis AK et al.: The efficacy of
caelyx and hyperthermia for anticancer treatment. Recent Patents
Anticancer Drug Discov. 2007; 2: 246–250
[45]
Larue SM, Fox MH, Ogilvie GK et al.: Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy
alone or combined with whole body hyperthermia. Int J Hyperthermia. 1999; 15: 475–486
[46]
Lee RJ, Buchanan M, Kleine LJ et al.: Arrays of multielement ultrasound applicators for interstitial hyperthermia. IEEE Trans Biomed
Eng. 1999; 46: 880–890
[47]
Liang P, Wang Y: Microwave ablation of hepatocellular carcinoma.
Oncology. 2007; 72 (Suppl 1): 124–131
[48]
Lohr F, Hu JK, Huang Q et al.: Enhancement of radiotherapy by
hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys.
2000; 48: 1513–1518
[49]
Lora-Michiels M, Yu D et al.: Extracellular pH and P-31 magnetic
resonance spectroscopic variables are related to outcome in canine
soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer
Res. 2006; 12: 5733–5740
[50]
MacFall JR, Soher BJ: From the RSNA refresher courses: MR imaging
in hyperthermia. Radiographics. 2007; 27: 1809–1818
[22]
[23]
Gadelta C, Catino A, Ranieri G et al: Radiofrequency thermal ablation of 69 lung neoplasms, J Chemother. 2004; 16 (Suppl. 5): 86–89
[24]
Germain D, Chevallier P, Laurent A et al.: MR monitoring of
tumour thermal therapy. MAGMA. 2001; 13: 47–59
[25]
Gerweck L, Rottinger E: Enhancement of mammalian cell sensitivity to hyperthermia by pH alteration. Radiat Res. 1976; 67: 508–
511
[26]
Gillette SM, Dewhirst MW, Gillette EL et al.: Response of canine
soft tissue sarcomas to radiation or radiation plus hyperthermia: a
randomized phase II study. Int J Hyperthermia. 1992; 8: 309–320
[27]
Gillette EL, McChesney SL, Dewhirst MW et al.: Response of
canine oral carcinomas to heat and radiation. Int J Radiat Oncol Biol
Phys. 1987; 13: 1861–8167
[28]
Gillette EL, Ensley BA: Effect of heat, radiation and pH on mouse
mammary tumor cells. Int J Radiat Oncol Bio Phys. 1983; 9: 1521–
1525
[51]
[29]
Habash RW, Bansal R, Krewski D et al.: Thermal therapy, Part IV:
electromagnetic and thermal dosimetry. Crit Rev Biomed Eng.
2007; 35: 123–182
Mahnken AH, Gunther RW, Tacke J: Radiofrequency ablation of
renal tumors, Eur Radiol. 2004; 14: 1449–1455
[52]
McTaggart RA, Dupuy DE: Thermal ablation of lung tumors. Tech
Vasc Interv Radiol. 2007; 10: 102–113
[30]
Habash RW, Bansal R, Krewski D et al.: Thermal therapy, Part III:
ablation techniques. Crit Rev Biomed Eng. 2007; 35: 37–121
[53]
[31]
Hall EJ: Hyperthermia. In Hall EJ (Hrsg.): Radiobiology for the radiologist. 5. Aufl. Philadelphia: Lippincott Williams& Wilkins; 2000:
495–520
Mallery KF, Pollard RE, Nelson RW et al.: Percutaneous ultrasound-guided radiofrequency heat ablation for treatment of hyperthyroidism in cats. J Am Vet Med Assoc. 2003; 223: 1602–1607
[54]
Masunaga S, Nagata K, Suzuki M et al.: Inhibition of repair of
radiation-induced damage by mild temperature hyperthermia,
referring to the effect on quiescent cell populations. Radiat Med.
2007; 25: 417–425
[32]
Hauck ML, LaRue SM, Petros WP et al.: Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous
canine tumors. Clin Cancer Res. 2006; 12: 4004–4010
[55]
[33]
Hauck ML, Price GS, Ogilvie GK et al.: Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in
dogs with lymphoma. Int J Hyperthermia. 1996; 12: 309–320
Matteucci ML, Anyarambhatla G, Rosner G et al.: Hyperthermia
increases accumulation of technetium-99m-labeled liposomes in
feline sarcomas. Clin Cancer Res. 2000; 6: 3748–3755
[56]
[34]
Huang Q, Hu JK, Lohr F et al: Heat-induced gene expression as a
novel targeted cancer gene strategy, Cancer Res 2000; 60: 3435–
3439
Mazzaglia PJ, Berber E, Siperstein AE.: Radiofrequency thermal
ablation of metastatic neuroendocrine tumors in the liver. Curr
Treat Options Oncol. 2007; 8: 322–330
[57]
[35]
Hynynen K.: The feasibility of interstitial ultrasound hyperthermia.
Med Phys. 1992; 19: 979–987
[36]
Jones E, Thrall D, Dewhirst MW et al.: Prospective thermal dosimetry: the key to hyperthermiaʼs future. Int J Hyperthermia. 2006;
22: 247–253
Needham D, Anyarambhatla G, Kong G et al.: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res.
2000; 60: 1197–1201
45
46
[58]
Nicholl MB, Bilchik AJ: Thermal ablation of hepatic malignancy:
Useful but still not optimal. Eur J Surg Oncol. 2008; 34: 318–323
[59]
[60]
[80]
Novotney CA, Page RL, Macy DW et al.: Phase I evaluation of
doxorubicin and whole-body hyperthermia in dogs with lymphoma.
J Vet Intern Med. 1992; 6: 245–249
Seegenschmidt MG, Fessenden P, Vernon CC (Hrsg.): Thermoradiotherapy- and Thermochemotherapy. Volume 1: Biology, Physiology, Physics. Berlin Heidelberg: Springer-Verlag 1995
[81]
Ostberg JR, Repasky EA: Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function.
Cancer Immunol Immunother. 2006; 55: 292–298
Siddiqui F, Li CY, Larue SM et al.: A phase I trial of hyperthermiainduced interleukin-12 gene therapy in spontaneously arising feline
soft tissue sarcomas. Mol Cancer Ther. 2007; 6: 380–389
[82]
Siddiqui F, Li CY, Zhang X et al.: Characterization of a recombinant
adenovirus vector encoding heat-inducible feline interleukin-12 for
use in hyperthermia-induced gene-therapy. Int J Hyperthermia.
2006; 22: 117–1134
[83]
Song CW, Park H, Griffin RJ: Improvement of tumor oxygenation
by mild hyperthermia. Radiat Res. 2001; 155: 515–28
[84]
Stern JM, Cadeddu JA: Emerging use of nanoparticles for the therapeutic ablation of urologic malignancies. Urol Oncol. 2008; 26: 93–
96
[85]
Stern JM, Stanfield J, Kabbani W et al.: Selective prostate cancer
thermal ablation with laser activated gold nanoshells. J Urol. 2008;
179: 748–753
[86]
Tashjian JA, Dewhirst MW, Needham D et al.: Rationale for and
measurement of liposomal drug delivery with hyperthermia using
non-invasive imaging techniques. Int J Hyperthermia. 2008; 24: 79–
90
[61]
Page RL, Lee J, Riviere JE et al.: Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors.
Int J Radiat Oncol Biol Phys. 1995; 32: 1097–1102
[62]
Page RL, McEntee MC, Williams PL et al.: Effect of whole body
hyperthermia on carboplatin disposition and toxicity in dogs. Int J
Hyperthermia. 1994; 10: 807–816
[63]
Page RL, Thrall DE, George SL et al.: Quantitative estimation of
the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs. Int J Hyperthermia. 1992; 8:
761–769
[64]
Page RL, Macy DW, Ogilvie GK et al.: Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. Int J
Hyperthermia. 1992; 8: 187–197
[65]
Page RL, Thrall DE, Dewhirst MW et al.: Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs
with malignant melanoma. Int J Hyperthermia. 1991; 7: 559–566
[87]
Park BK, Kim CK: Using an electrode as a lever to increase the distance between renal cell carcinoma and bowel during CT-guided
radiofrequency ablation. Eur Radiol. 2008; 18: 743–746
Théon AP, Madewell BR, Moore AS et al.: Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours.
Int J Hyperthermia. 1991; 7: 881–892
[88]
Thrall DE, Larue SM, Pruitt AF et al.: Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in
spontaneous canine sarcomas. Int J Hyperthermia. 2006; 22: 365–
73
[66]
[67]
Ponce AM, Viglianti BL, Yu D et al.: Magnetic resonance imaging
of temperature-sensitive liposome release: drug dose painting and
antitumor effects. J Natl Cancer Inst. 2007; 99: 53–63
[89]
[68]
Poulsen JM: Hyperthermia. In Withrow SJ, Vail DM (Hrsg.): Withrowʼs & Mac Ewenʼs Small Animal Clinical Oncology. 4. Aufl. St.
Louis, Missouri: Saunders Elsevier 2007: 280–282
Thrall DE, LaRue SM, Yu D et al.: Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res. 2005; 11: 5206–5214
[90]
[69]
Pritchard MT, Wolf SF, Kraybill WF et al.: The anti-tumor effect of
interleukin-12 is enhanced by mild (fever-range) thermal therapy.
Immunol Invest. 2005; 34: 361–380
Thrall DE, Rosner GL, Azuma C et al.: Using units of CEM 43
degrees C T90, local hyperthermia thermal dose can be delivered as
prescribed. Int J Hyperthermia. 2000; 16: 415–428
[91]
[70]
Repasky E, Issels R: Physiological consequences of hyperthermia:
heat, heat shock proteins and the immune response. Int J Hyperthermia. 2002; 18: 486–489
Thrall DE, LaRue SM, Powers BE: Use of whole body hyperthermia
as a method to heat inaccessible tumours uniformly: a phase III trial
in canine brain masses. Int J Hyperthermia. 1999; 15: 383–398
[92]
[71]
Rhim H, Lim HK, Kim YS et al.: Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. Am J Roentgenol. 2008; 190: 91–98
Thrall DE, Prescott DM, Samulski TV et al.: Radiation plus local
hyperthermia versus radiation plus the combination of local and
whole-body hyperthermia in canine sarcomas. Int J Radiat Oncol
Biol Phys. 1996; 34: 1087–1096
[72]
Rieke V, Butts Pauly K: MR thermometry. J Magn Reson Imaging.
2008; 27: 376–390
[93]
[73]
Rieke V, Kinsey AM, Ross AB et al.: Referenceless MR thermometry for monitoring thermal ablation in the prostate. IEEE Trans
Med Imaging. 2007; 26: 813–821
Trembly BS, Douple EB, Ryan TP et al.: Effect of phase modulation
on the temperature distribution of a microwave hyperthermia
antenna array in vivo. Int J Hyperthermia. 1994; 10: 691–705
[94]
van der Heijden AG, Verhaegh G, Jansen CF et al.: Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently
used for the treatment of transitional cell carcinoma of the bladder:
an in vitro study. J Urol. 2005; 173: 1375–1380
[74]
Rine GP, Dewhirst MW, Cobb ED et al.: Feasibility of estimating
the temperature distribution in a tumor heated by a waveguide
applicator. Int J Radiat Oncol Biol Phys. 1992; 23: 1009–1019
[95]
[75]
Robins HI, Woods JP, Schmitt CL et al.: A new technological
approach to radiant heat whole body hyperthermia. Cancer Lett.
1994; 79: 137–145
van Rhoon GC, Wust P: Introduction: non-invasive thermometry
for thermotherapy. Int J Hyperthermia. 2005; 21: 489–495
[96]
[76]
Roti JL: Cellular responses to hyperthermia (40–46 degrees C): Cell
killing and molecular events. Int J Hyperthermia. 2008; 24: 3–15
Viglianti BL, Abraham SA, Michelich CR et al.: In-vivo monitoring
of tissue pharmacokinetics of liposome/drug using MRI: Illustration
of targeted delivery. Magn Reson Med. 2004; 51: 1153–1162
[97]
[77]
Ryan TP, Hartov A, Colacchio TA et al.: Analysis and testing of a
concentric ring applicator for ultrasound hyperthermia with clinical
results. Int J Hyperthermia. 1991; 7: 587–603
Vujaskovic Z, Song CW: Physiological mechanisms underlying
heat-induced radiosensitization. Int J Hyperthermia. 2004: 20: 163–
174
[98]
[78]
Ryan TP, Wikoff RP, Hoopes PJ: Design of an automated temperature mapping system for ultrasound or microwave hyperthermia. J
Biomed Eng. 1991; 13: 348–354
Vujaskovic Z, Poulsen JM, Gaskin AA et al: Temperature-dependent changes in physiologic parameters of spontaneous canine soft
tissue sarcomas after combined radiotherapy and hyperthermia
treatment. Int J Radiat Oncol Biol Phys. 2000; 46: 179–185
[79]
Schirmang TC, Dupuy DE: Image-guided thermal ablation of nonresectable hepatic tumors using the Cool-Tip radiofrequency ablation system. Expert Rev Med Devices. 2007; 4: 803–14
[99]
Yeh MM, Trembly BS, Douple EB et al.: Theoretical and experimental analysis of air cooling for intracavitary microwave hyperthermia applicators. IEEE Trans Biomed Eng. 1994; 41: 874–882
[100] Wu NZ, Braun RD, Gaber MH et al.: Simultaneous measurement
of liposome extravasation and content release in tumors. Microcirculation. 1997; 4: 83–101
[19]
Giger U: Erythropoetin and its clinical use. Comp Cont Educ. 1992;
14: 25
[20]
Giger U, Gelens CJ, Callan MB et al.: An acute hemolytic transfusion reaction caused by dog erythrocyte antigen 1.1 incompatibility
in a previously sensitized dog. J Am Vet Med Assoc. 1995; 206:
1358–1362
[21]
Giger U, Stieger K, Palos H: Comparison of various canine bloodtyping methods. Am J Vet Res. 2005; 66: 1386–1392
[22]
Graf C, Kohn B: Vascular endothelial growth factor (VEGF) in canine
blood transfusion products. Proceedings of the ECVIM, Porto, 2009:
275
[23]
Abrams-Ogg ACG: Platelet and granulocyte transfusions. In: Feldman BF, Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology.
Philadelphia: Lippincott Williams & Wilkins; 2000: 844–848
Griot-Wenk ME, Giger U: Feline transfusion medicine. Blood types
and their clinical importance. Vet Clin North Am Small Anim Pract.
1995; 25: 1305–1322
[24]
Abrams-Ogg ACG: Triggers for prophylactic use of platelet transfusions and optimal platelet dosing in thrombocytopenic dogs and
cats. Vet Clin North Am Small Anim Pract. 2003; 33: 1401–1418
Harrell KA, Kristensen AT: Canine transfusion reactions and their
management. Vet Clin North Am Small Anim Pract. 1995; 25:
1333–1364
[25]
Hohenhaus AE: Transfusion reactions. In: Feldman BF, Zinkl JG, Jain
NC (Hrsg.): Schalm’s Veterinary Hematology. Philadelphia: Lippincott Williams & Wilkins; 2000: 864–868
[26]
Hohenhaus AE: Transfusion issues in the cancer patient. Clin Techn
[27]
Hohenhaus AE: Blood transfusion and blood substitutes. In: DiBartola SP (Hrsg.) Fluid, electrolyte and acid-base disorders in small animal practice. St. Louis: Saunders Elsevier; 2006: 567–583
[101] Xu Y, Choi J, Hylander B et al.: Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin. Int J
Hyperthermia. 2007; 23: 513–527
16 Supportive Therapie
16.1 Management tumorbedingter Anämien
[1]
[2]
[3]
Andrews GA: Red blood cell antigens and blood groups in the dog
and cat. In: Feldman BF, Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology. Philadelphia: Lippincott Williams & Wilkins; 2000:
767–773
[4]
Auer L, Bell K: The AB-blood group system of cats. Anim Blood
Groups Biochem Genet. 1981; 12: 287–297
[5]
Bell K: The blood groups of domestic animals. In: Agar AS, Board
PG P.G. (Hrsg.): Red blood cells of domestic mammals. Amsterdam:
Elsevier Science Publishers; 1983: 133–164
[28]
Beutler E: Preservation and clinical use of erythrocytes and whole
blood. In; Lichtman MA, Beutler E, Kipps TJ et al. (Hrsg.): Williams
Hematology. New York: McGraw-Hill Medical; 2006: 2159–2173
Jonas LD, Thrall MA, Weiser MG: Nonregenerative form of
immune-mediated hemolytic anemia in dogs. J Am Anim Hosp
Assoc. 1987; 23: 201–204
[29]
Kerl ME, Hohenhaus AE: Packed red blood cell transfusions in dogs:
131 cases (1989). J Am Vet Med Assoc. 1993; 202: 1495–1499
[6]
[7]
Blais MC, Berman L, Oakley DA et al.: Canine Dal blood type: a
red cell antigen lacking in some Dalmatians. J Vet Intern Med. 2007;
21: 281–286
[30]
Kohn B, Niggemeier A, Reitemeyer S et al.: Blutgruppenbestimmung bei der Katze mit Hilfe einer neuen Testkartenmethode.
Kleintierprax. 1997; 42, 937–1022
[8]
Blumberg N, Heal JM: Effects of transfusion on immune function:
cancer reoccurence and infection. Arch Pathol Lab Med. 1994; 118:
371–379
[31]
Kohn B, Reitemeyer S, Giger U: Bestimmung der Blutgruppe DEA
1.1 und deren Bedeutung beim Hund. Kleintierprax. 1998; 43: 77–
86
[9]
Bokemeyer C, Oechsle K, Hartmann J-T: Anaemia in cancer
patients: pathophysiology, incidence and treatment. Europ J Clin
Invest. 2005; 35 (Suppl. 3): 26–31
[32]
Kohn B, Reitemeyer S, Giger U et al.: Etablierung einer Blutbank
für Hunde an einer Kleintierklinik. Kleintierprax. 2000; 5: 331–343
[33]
[10]
Brooks M: Transfusion of plasma and plasma derivatives. In: Feldman BF, Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology.
Kohn B, Engelbrecht R, Leibold W et al.: Klinische Befunde, Diagnostik und Behandlungserfolge bei der primären und sekundären
immunbedingten Thrombozytopenie beim Hund. Kleintierprax.
2000; 45: 893–907
[11]
Busch ORC, Hop WCJ, Marquet RL et al.: Prognostic impact of
blood transfusions on disease-free survival in colorectal carcinoma.
Scand J Gastroenterol. 1993; 200: 21–23
[34]
Kohn B, Roleff S, Reif S: Chronische Blutungsanämie bei 15 Hunden. Kleintierprax. 2004; 49: 551–562
[35]
[12]
Callan MB: Red blood cell transfusion in the dog and cat. In: Feldman BF, Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology.
Kohn B, Giger U: Anämien, Polyzythämien, Gerinnungsstörungen.
In: Suter PF, Kohn B (Hrsg.): Praktikum der Hundeklinik. 10. Auflage,
Stuttgart: Parey; 2006: 582–613
[36]
[13]
Callan MB, Rentko VT: Clinical application of a haemoglobin-based
oxygen carrying solution. Vet Clin North Am Small Anim Pract.
2003; 33: 1277–1293
Kohn B, Linden T, Leibold W: Platelet-bound antibodies detected
by a flow cytometric assay in cats with thrombocytopenia. J Fel Med
Surg. 2006; 8: 254–260
[37]
[14]
Council of Europe: Guide to the preparation, use and quality assurance of blood components. 6. Aufl., 2000
Kohn B, Galke D, Beelitz P et al.: Clinical features of canine granulocytic anaplasmosis in 18 naturally infected dogs. J Vet Intern Med.
2008; 22: 1289–1295
[15]
Dellinger EP, Anaya DA: Infectious and immunologic consequences
of blood transfusion. Critical Care. 2004; 8: S18–S23
[38]
Laird J: Erythropoietin: Can we afford to use it? Can we afford not
to? Transfusion Medicine. 2006; 16, 204–205
[16]
Feldman BF: Nonregenerative anemia. In: Ettinger SJ, Feldman EC
(Hrsg.): Textbook of Veterinary Internal Medicine. St. Louis: Elsevier
Saunders, St. Louis; 2005: 1908–1917
[39]
[17]
Gibson GR, Callan MB, Hoffmann V et al.: Use of hemoglobinbased oxygen-carrying solution in cats: 72 cases (1998–2000). J Am
Vet Med Assoc. 2002; 221: 96–102
Maniwa Y, Okada N, Ishii N et al.: Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of
micrometastases in metastatic lung cancer. Chest. 1998; 114:
1668–1675
[40]
Miller AG, Morley PS, Rao S et al.: Anemia is associated with
decreased survival time in dogs with lymphoma. J Vet Intem Med.
2009; 23: 116–122
[41]
Moullet I, Salles G, Ketterer N et al.: Frequency and significance of
anemia in non-hodgkin’s lymphoma patients. Ann Oncol. 1998; 9:
1109–1115
[18]
Giger U, Bücheler J: Transfusion of type-A and type-B blood to
cats. J Am Vet Med Assoc. 1991; 198: 411–418
47
48
[42]
Muir WW, Wellmann ML: Hemoglobin solutions and tissue oxygenation. J Vet Intern Med. 2003; 17: 127–135
[43]
Nielsen HJ, Werther K, Mynster T et al.: Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion. 1999; 39: 1078–1083
[4]
Fukushima R, Saito H, Taniwaka K et al.: Different roles of IL-1
and TNF on hemodynamics and interorgan amino acid metabolism
in awake dogs. Am J Physiol. 1992; 262(3 Pt 1): E275–281
[5]
Mazzaferro EM, Hackett TB, Stein TP et al.: Metabolic alterations
in dogs with osteosarcoma. Am J Vet Res. 2001; 62: 1234–1239
[44]
Patel H, Lall DG, Nasir FA et al.: Blood products have increased
angiogenesis stimulating effects following storage. Blood. 2002;
100: 282a
[6]
Merlo A, Rezende BCG, Franchini ML et al.: Serum C-reactive protein concentrations in dogs with multicentric lymphoma undergoing chemotherapy. J Am Vet Med Assoc. 2007; 230: 522–526
[45]
Putsche J, Kohn B: Primary immune-mediated thrombocytopenia
in 30 dogs (1997–2003). J Am Anim Hosp Assoc. 2008; 44: 250–
257
[7]
Michel KE, Sorenmo K, Shofer FS: Evaluation of body condition
and weight loss in dogs presented to a veterinary oncology service.
J Vet Int Med. 2004; 18: 692–695
[46]
Reitemeyer S, Kohn B, Brunnberg L et al.: Transfusionen von Vollblut und Erythrozytenkonzentrat beim Hund. Kleintierprax. 2000;
45: 669–684
[8]
Mischke R, Waterston M, Eckersall PD: Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Vet J. 2007;
174: 188–192
[47]
Rentko VT, Sharpe TA: Red blood cell substitutes. In: Feldman BF,
Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology. Philadelphia: Lippincott Williams & Wilkins; 2000: 874–878
[9]
[48]
Rudloff E: The role of blood component therapy in the management of canine and feline patients with cancer. Vet Clin North Am
Small Anim Pract. 1995; 25: 1403–1416
Ogilvie GK, Fettman MJ, Mallinckrodt CH et al.: Effect of fish oil,
arginine, and doxorubicin chemotherapy on remission and survival
time for dogs with lymphoma: a double-blind, randomized placebocontrolled study. Cancer. 2000; 88: 1916–1928
[10]
Ogilvie GK, Salman MD, Kesel ML et al.: Effect of anesthesia and
surgery on energy expenditure determined by indirect calorimetry
in dogs with malignant and nonmalignant conditions. Am J Vet Res.
1996; 57: 1321–1326
[49]
Schneider A: Principles of blood collection and processing. In: Feldman BF, Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology.
[11]
[50]
Stieger K, Palos H, Giger U: Comparison of various blood-typing
methods for the feline AB blood group system. Am J Vet Res. 2005;
66: 1393–1399
Ogilvie GK, Walters L, Salman MD et al.: Alterations in carbohydrate metabolism in dogs with nonhematopoietic malignancies. Am J
Vet Res. 1997; 58: 277–281
[12]
[51]
Tocci LJ, Ewing PJ: Increasing patient safety in veterinary transfusion medicine: an overview of pretransfusion testing. J Vet Emerg
Crit Care. (San Antonio) 2009; 19:66–73
Ogilvie GK, Walters LM, Fettman MJ et al.: Energy expenditure in
dogs with lymphoma fed two specialized diets. Cancer. 1993; 71:
3146–3152
[13]
[52]
Wardrop KJ: Selection of anticoagulant preservatives for canine
and feline blood storage. Vet Clin North Am Small Anim Pract.
1995; 25: 1263–1276
Ogilvie GK, Walters LM, Salman MD et al.: Resting energy expenditure in dogs with nonhematopoietic malignancies before and
after excision of tumors. Am J Vet Res. 1996; 57: 1463–1467
[14]
[53]
Wardrop KJ: Clinical blood typing and crossmatching. In: Feldman
BF, Zinkl JG, Jain NC (Hrsg.): Schalm’s Veterinary Hematology. Philadelphia: Lippincott Williams & Wilkins; 2000: 795–798
Seidel A, Gueck T, Fuhrmann H: The Influence of long-chain polyunsaturated fatty acids on total lipid fatty acid composition of a
canine mastocytoma cell line. J Vet Med A Physiol Pathol Clin Med.
2005; 52: 219–224
[54]
Wardrop KJ, Brooks MB: Stability of hemostatic proteins in canine
fresh frozen plasma units. Vet Clin Pathol. 2001; 30: 91–95
[15]
Shimada A, Morita T, Ikeda N et al.: Hypoglycaemic brain lesions
in a dog with insulinoma. J Comp Pathol. 2000; 122: 67–71
[55]
Wardrop KJ, Reine N, Birkenheuer A et al.: Canine and feline
blood donor screening for infectious disease. J Vet Intern Med.
2005; 19: 135–142
[16]
Tisdale MJ: Cancer cachexia. Langenbecks Arch Surg. 2004; 389:
299–305
[17]
[56]
Weingart C, Giger U, Kohn B: Whole blood transfusions in 91 cats:
a clinical evaluation. J Fel Med Surg. 2004; 6: 139–148
Vail DM, Ogilvie GK, Wheeler SL et al.: Alterations in carbohydrate
metabolism in canine lymphoma. J Vet Intern Med. 1990; 4: 8–11
[18]
[57]
Weingart C, Arndt G, Kohn B: Prävalenz der Blutgruppen A, B und
AB bei Haus- und Rassekatzen im Raum Berlin und Brandenburg.
Washizu T, Azakami D, Bonkobara M et al.: Changes in activities
of enzymes related to energy metabolism in canine lymphoma
cells. J Vet Med Sci. 2005; 67: 615–616
[19]
[58]
Weingart C, Kohn B: Clinical use of a haemoglobin-based oxygen
carrying solution (Oxyglobin®) in 48 cats (2002–2006). J Fel Med
Surg. 10: 431–438
Zentek J: Entwicklungen und Perspektiven der Diätetik bei Tumorerkrankungen. Übers Tierernährg. 1996; 24: 229–253
16.3 Ernährung des Tumorpatienten
[59]
Weinstein NM., Blais MC, Harris K et al.: A newly recognized
blood group in domestic shorthair cats: the Mik red cell antigen. J
Vet Intern Med. 2007; 21: 287–292
[60]
Weingart C, Kohn B: Transfusion von Blut und Blutersatzstoffen bei
der Katze. Kleintierprax. 2009; 54: 502–515
[1]
Armstrong PJ, Blanchard G: Hepatic lipidosis in cats. (Special
Issue: Hepatology). Vet Clin North Am Small Anim Pract. 2009; 39:
599–616
[2]
Bauer JE, Heinemann KM, Bigley KE et al: Maternal diet alpha-linolenic acid during gestation and lactation does not increase docosahexaenoic acid in canine milk. J Nutr. 2004; 134: 2035s–2038s
[3]
Arai T, Ogawa T, Hosoya M et al.: Changes in activities of enzymes
related to energy metabolism in testicular tissues of dogs with
seminoma. Vet Res Commun. 2002; 26: 347–352
Biondo PD, Brindley DN, Sawyer MB et al.: The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids
during chemotherapy. J Nutr Biochem. 2008; 19: 787–796
[4]
Arai T, Ogino T, Gunji M et al.: Changes in glucose transport activities in mammary adenocarcinoma of dogs. Res Vet Sci. 1997; 62:
85–86
Chan DL, Freeman LM, Labato MA et al.: Retrospective evaluation
of partial parenteral nutrition in dogs and cats. J Vet Intern Med.
2002; 16: 440–445
[5]
Chandler ML, Payne-James JJ: Prospective evaluation of a peripherally administered three-in-one parenteral nutrition product in
dogs. J Small Anim Pract. 2006; 47: 518–523
16.2 Stoffwechselveränderungen bei
Krebserkrankungen
[1]
[2]
[3]
Argiles JM, Busquets S, Toledo M et al.: The role of cytokines in
cancer cachexia. Curr Opinio Supp Pall Care. 2009; 3: 263–268
[6]
Colomer R, Moreno-Nogueira JM, Garcia-Luna PP et al.: N-3 fatty
acids, cancer and cachexia: a systematic review of the literature. Br J
Nutr. 2007; 97: 823–831
[7]
Farlopulos S: Klinische und ernährungsphysiologische Untersuchungen zur parenteralen Ernährung von Hunden Hannover: Vet
Med Diss, Hannover; 2000
[8]
Haderer A: Vitaminkonzentrationen im Blut von Hunden mit chronischen Lebererkrankungen, chronischen Nierenerkrankungen
sowie von Hunden vor und nach Chemotherapie. Vet Med Diss,
Wien; 2007
[9]
Hand MS, Thatcher CD, Remillard RL, et al.: Klinische Diätetik für
Kleintiere. Hannover: Schlütersche Verlagsanstalt 2003
[10]
Heinemann KM, Waldron MK, Bigley KE et al.: Long-chain (n-3)
polyunsaturated fatty acids are more efficient than alpha-linolenic
acid in improving electroretinogram responses of puppies exposed
during gestation, lactation, and weaning. J Nutr. 2005; 135: 1960–
1966
[11]
Isolauri E, Juntunen M, Wiren S et al.: Intestinal permeability
changes in acute gastroenteritis: effects of clinical factors and nutritional management. J Ped Gastroent Nutr. 1989; 8: 466–473
[12]
Jergens AE, Morrison JA, Miles KG et al.: Percutaneous endoscopic
gastrojejunostomy tube placement in healthy dogs and cats. J Vet
Intern Med. 2007; 21: 18–24
[13]
Kearns RJ, Hayek MG, Turek JJ et al.: Effect of age, breed and dietary omega-6 (n-6):omega-3 (n-3) fatty acid ratio on immune function, eicosanoid production, and lipid peroxidation in young and
aged dogs. Vet Immunol Immunpathol. 1999; 69: 165–183
[14]
Laflamme D: Developmental and validation of a body condition
score system for dogs. Can Pract. 1997; 22:10–15
[15]
LeBlanc CJ, Horohov DW, Bauer JE et al.: Effects of dietary supplementation with fish oil on in vivo production of inflammatory
mediators in clinically normal dogs. Am J Vet Res. 2008; 69: 486–
493
[26]
Vail DM, Ogilvie GK, Wheeler SL: Metabolic alterations in patients
with cancer cachexia. Comp Cont Ed Pract Vet. 1990; 12: 381–386
[27]
Weeth LP, Fascetti AJ, Kass PH et al.: Prevalence of obese dogs in
a population of dogs with cancer. Am J Vet Res. 2007; 68: 389–398
[28]
Zentek: Developments and perspectives in the dietetic treatment
of cancer. Übers Tierernährg. 1996; 24: 229–253
[29]
Zentek J, Stephan I, Kramer S et al.: Response of dogs to shortterm infusions of carbohydrate- or lipid-based parenteral nutrition. J
Vet Med A. 2003; 50: 313–321
[30]
Zoran DL: Obesity in dogs and cats: a metabolic and endocrine disorder. (Special Issue: Obesity, diabetes, and adrenal disorders.). Vet
16.4 Tumorschmerz
[1]
Bockstahler B, Levine D, Millis D (Hrsg.): Physiotherapie auf den
Punkt gebracht. Rehabilitation und Schmerzmanagement. Babenhausen: BE Vet Verlag; 2004
[2]
Boria PA, Murry DJ, Bennett PF et al.: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma
2004; 224: 388–394
[3]
Doré M, Lanthier I, Sirois J: Cyclooxygenase-2 expression in canine
[4]
Engert M: Klinischer Einsatz von Fentanyl-Patches beim Hund.
Pharmakokinetik, Wirkungen und Nebenwirkungen. Diss med vet.
Gießen; 2010
[5]
Erhardt W, Henke J, Kroker R: Pharmaka im Rahmen der Anästhesie und der perioperativen Schmerzlinderung. In: Erhardt W, Henke
J, Haberstroh J (Hrsg): Anästhesie und Analgesie beim Klein- und
Heimtier. Stuttgart-New-York; Schattauer; 2004: 15–138
[6]
Gaynor JS, Muir WW (Hrsg.): Handbook of Veterinary Pain
Management. St. Louis, Missouri: Mosby; 2008
[16]
Lippert AC.: Enteral and parenteral nutritional support in dogs and
cats with gastrointestinal disease. Sem Vet Med Surg Small Anim.
1989; 4: 232–240
[7]
Haskins S: Therapy for Shock. In: Bonagura J (Hrsg.): Kirk’s Current
Veterinary Therapy XIII Small Animal Practice. Philadelphia: WB
Saunders; 2000; 140–147
[17]
Mawby DI, Bartges JW, DʼAvignon A et al.: Comparison of various
methods for estimating body fat in dogs. J Am Anim Hosp Assoc.
2004; 40: 109–114
[8]
Hellebrekers LJ: Practical analgesic treatment in canine patients.
In: Hellebrekers LJ (Hrsg.): Animal pain. Utrecht: Van der Wees;
2000: 117–129
[9]
expression is associated with histological tumor type in canine
mammary carcinoma. Vet Pathol. 2005; 42: 776–780
[10]
Henke J, Erhardt W. (Hrsg.): Schmerzmanagement bei Klein- und
Heimtieren. Stuttgart: Enke; 2001
[11]
Henke J, Erhardt W: Analgesie. In: Erhardt W, Henke J, Haberstroh
J (Hrsg): Anästhesie und Analgesie beim Klein- und Heimtier. Stuttgart-New-York: Schattauer; 2004: 369–407
[12]
mitxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res. 2003; 9: 906–911
[13]
Keates HL, Cramond T, Smith MT: Intraarticular and periarticular
opioid binding in inflamed tissue in experimental canine arthritis.
Anesth Analg. 1999; 89: 409–415
[18]
Meyer H, Zentek J: Ernährung des Hundes. Stuttgart: MVS 2010
[19]
Michel KE, Freeman LM: Critical care nutrition. past, present, and
future. J Vet Emerg Crit Care. 2006; 16: S1
[20]
Mohr AJ, Leisewitz AL, Jacobson LS et al.: Effect of early enteral
nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. J Vet Intern Med.
2003; 17: 791–798
[21]
Ogilvie GK, Fettman MJ, Mallinckrodt CH et al.: Effect of fish oil,
arginine, and doxorubicin chemotherapy on remission and survival
time for dogs with lymphoma: a double-blind, randomized placebocontrolled study. Cancer. 2000; 88: 1916–1928
[22]
Pyle SC, Marks SL, Kass PH: Evaluation of complications and prognostic factors associated with administration of total parenteral nutrition in cats: 75 cases (1994–2001). J Am Vet Med Assoc. 2004;
225: 242–250
[14]
[23]
Roudebush P, Davenport DJ, Novotny BJ: The use of nutraceuticals in cancer therapy. (Nutraceuticals and other biologic therapies).
Lamont AL: Management of chronic pain. In: Green SA (Hrsg.):
Veterinary anesthesia and pain management secrets. Philadelphia:
Hanley & Belfus, 2002: 345–352
[15]
[24]
Selting KA, Ogilvie GK, Gustafson DL et al.: Evaluation of the
effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res. 2006;
67: 145–151
Mohammed SI, Bennett PF, Craig BA et al.: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and
angiogenesis in a canine model of human invasive urinary bladder
cancer. Cancer Res. 2002; 62: 356–358
[16]
[25]
Sonnenschein EG, Glickman LT, Goldschmidt MH et al.: Body conformation, diet, and risk of breast cancer in pet dogs: a case-control
study. Am J Epid. 1991; 133: 694–703
Naruse T, Nishida Y, Hosono K et al.: Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent
and independent routes. Carcinogenesis. 2006; 27: 584–592
49
50
[17]
Paddleford RR: Analgesia and pain management. In: Paddleford RR
(Hrsg.): Manual of small animal anesthesia. 2. Auflg. Philadelphia,
Saunders; 1999: 227–246
[14]
Goblirsch MJ, Mathews W, Lynch C et al.: Radiation treatment
decreases bone cancer pain, osteolysis and tumor size. Radiat Res.
2004; 161: 228–234
[18]
Pieper K, Schuster T, Levionois O et al.: Antinociceptive efficacy
and plasma concentrations of transdermal buprenorphine in dogs.
Vet J. 2011; 187: 335–341
[15]
Goblirsch MJ, Lynch C, Mathews W et al.: Radiation treatment
decreases bone cancer pain through direct effect on tumor cells.
Radiat Res. 2005; 164: 400–408
[19]
Piersma FE, Daemen MA, Bogaard AE et al.: Interference of pain
control employing opioids in vivo immunological experiments. Lab
Anim. 1999; 33: 328–333
[16]
Goblirsch MJ, Zwolak PP, Clohisy DR: Biology of bone cancer pain.
Clin Cancer Res. 2006; 12: 6231–6235
[17]
[20]
Queiroga FL, Alves A, Pires I et al.: Expression of COX-1 and COX-2
in canine mammary tumours. J Comp Pathol. 2007; 136: 177–185
Green EM, Adams WM, Forrest LJ: Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc. 2002;
38: 445–451
[21]
Ricketts AP, Lundy KM, Seibel SB: Evaluation of selective inhibition
of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res. 1998; 59: 1441–1446
[18]
Heidner GL, Page RL, McEntee MC et al.: Treatment of canine
appendicular osteosarcoma using cobalt 60 radiation and intraaterial cisplatin. J Vet Intern Med. 1991; 5: 313–316
[22]
Schele HA: Tumorschmerz. In: Diener HC, Maier C (Hrsg.): Das
Schmerztherapiebuch. München, Wien, Baltimore: Urban und
Schwarzenberg; 1997
[19]
Hof H, Debus J: Treatment of metastases–the place of radiotherapy. MMW Fortschr Med. 2005; 147: 31–33
[20]
[23]
Tacke S: Schmerzbehandlung in der Kleintiermedizin – anschaulich,
verständlich, interaktiv. CD-ROM. Stuttgart: Enke-Verlag; 2005
Kandel-Tschiederer B: Palliative Bestrahlung mit 60Co-Teletherapie
beim appendikularen Osteosarkom des Hundes Vet med Diss, Leipzig 2008
[24]
Tranquilli W: Physiology of chronic pain. In: Green SA (Hrsg.): Veterinary anesthesia and pain management secrets. Philadelphia: Hanley & Belfus; 2002: 349– 347
[21]
Kessler M, Kandel-Tschiederer B, Schwietzer A et al.: Palliative
radiation therapy in 100 dogs with appendicular osteosarcoma.
Proc. 20th Ann Conf ECVIM, Toulouse, 2010
[25]
Wolfesberger B, Walter I, Hoelzl C et al.: Antineoplastic effect of
cells. Res Vet Sci. 2006; 80: 308–316
[22]
Kleiter M, Kren G, Willmann M et al.: Palliative Bestrahlungstherapie bei sechs Hunden mit einem Osteosarkom des Gliedmaßenskeletts. Tierärztl Prax. 2002; 30(K): 29–33
[23]
Knapp-Hoch HM, Fidel JL, Sellon RK et al.: An expedited palliative
radiation protocol for lytic or proliferative lesions of appendicular
bone in dogs. J Am Anim Hosp Assoc. 2009; 45: 24–32
[24]
Konski A, Feigenberg S, Chow E: Palliative radiation therapy.
Semin Oncol. 2005; 32: 156–164
[25]
Lamb HM, Faulds D: Samarium 153SM lexidronam. Drugs Aging.
1997; 11: 413–419
[26]
Lattimer JC, Corwin LA Jr, Stapleton J et al.: Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J Nucl Med. 1990; 31: 601–602
[27]
Lattimer JC, Corwin LA Jr, Stapleton J et al.: Clinical and clinicopathologic response of canine bone tumor patients to treatment with
samarium-153-EDTMP. J Nucl. Med. 1990; 31: 1316–1325
[28]
Liptak JM, Dernell WS, Ehrhart N et al.: Appendicular Osteosarcoma: Diagnosis and palliative treatment. Comp Cont Educ. 2004;
26: 172–183
[29]
McEntee MC, Page RL, Novotney CA et al.: Palliative radiotherapy
for canine appendicular osteosarcoma. Vet Radiol Ultrasound.
1993; 34: 367–370
[30]
Mayer MN, Grier CK: Palliative radiation therapy for canine osteosarcoma. Can Vet J. 2006; 47: 707–709
[31]
Mellor PJ, Polton GA, Brearley M et al.: Solitary plasmacytoma of
bone in two successfully treated cats. J Feline Med Surg. 2007; 9:
72–77
[32]
Milner RJ, Dormehl I, Louw WK et al.: Targeted radiotherapy with
Sm-153-EDTMP in nine cases of canine primary bone tumours. J S
Afr Vet Assoc. 1998; 69: 12–17
[33]
Moe L, Boysen M, Aas M et al.: Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. J Small Anim Pract. 1996; 37: 241–246
[34]
Mueller F, Poirier V, Melzer K et al.: Palliative radiotherapy with
electrons of appendicular osteosarcoma in 54 dogs. In Vivo. 2005;
19: 713–716
[35]
Nielson OS, Bentzen SM, Sandberg E et al.: Randomized trial of
single dose versus fractionated palliative radiotherapy of bone
metastases. Radiother Oncol. 1998; 47: 233–240
[36]
Paes FM, Serafini AN: Systemic metabolic radiopharmaceutical
therapy in the treatment of metastatic bone pain. Semin Nuc Med.
2010; 40: 89–104
16.5 Strahlentherapie zur Schmerzbehandlung von
Tumorerkrankungen
[1]
Affolter VK: Histiocytic proliferative diseases in dogs and cats. Proc
29th WSAVA World Congress. Rhodes 2004
[2]
Anderson P, Nunez R: Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Expert Rev Anticancer Ther. 2007; 7: 1517–1527
[3]
[4]
[5]
[6]
Barnard SM, Zuber RM, Moore AS: Samarium SM 153 lexidronam
for the palliative treatment of dogs with primary bone tumors: 35
Bateman KE, Catton PA, Pennock PW et al.: 0-7-21 Radiation therapy for the palliation of advanced cancer in dogs. J Vet Intern Med.
1994; 8: 394–399
Bennett D, Morton C: A study of owner observed behavioural and
lifestyle changes in cats with musculoskeletal disease before and
after analgesic therapy. J Feline Med Surg. 2009; 11: 997–1004
Boston SE, Ehrhart NP, Dernell WS et al.: Evaluation of survival
time in dogs with stage III osteosarcoma that undergo treatment:
[7]
Brown DC, Boston R, Coyne JC et al.: A novel approach to the use
of animals in studies of pain: validation of the canine brief pain
inventory in canine bone cancer. Pain Med. 2009; 10: 133–142
[8]
Ciezki JP, Komurcu S, Macklis RM: Palliative Radiotherapy. Semin
Oncol. 2000; 27: 90–93
[9]
Coomer A, Farese J, Milner R et al.: Radiation therapy for canine
appendicular osteosarcoma. Vet Comp Oncol. 2009; 7: 15–27
[10]
Fan TM, Charney SC, de Lorimier LP et al.: Double-blind placebocontrolled trial of adjuvant pamidronate with palliative radiotherapy
and intravenous doxorubicin for canine appendicular osteosarcoma
bone pain. J Vet Intern Med. 2009; 23: 152–160
[11]
Farrelly J, McEntee MC: Principles and applications of radiation therapy. Clin Tech Small Anim Pract. 2003; 18: 82–87
[12]
Fidel J, Schiller I, Hauser B et al.: Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998–March
2005). Vet Comp Oncol. 2006; 4: 63–74
[13]
Gaynor JS: Control of cancer pain in veterinary patients. Vet Clin
[37]
Price P, Hoskin PJ, Easton D et al.: Prospective randomized trial of
single and multifraction radiotherapy schedules in the treatment of
painful bony metastases. Radiother Oncol. 1986; 6: 247–255
[38]
Ramirez O, Dodge RK, Page RL et al.: Palliative radiotherapy of
appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound.
1999; 40: 517–522
[39]
Rubin P: Clinical oncology. Philiadelphia. W.B. Saunders; 1993
[40]
Rusbridge C, Wheeler SJ, Lamb CR et al.: Vertebral plasma cell
tumors in 8 dogs. J Vet Intern Med. 1999; 13: 126–133
[41]
Siegel S, Cronin K: Palliative radiotherapy. Vet Clin North Am
(Small Anim Pract). 1997; 27: 149–155
[42]
Thrall DE, LaRue SM: Palliative radiation therapy. Sem Vet Med
Surg. 1995; 10: 205–208
[43]
[13]
Baer KE, Helton K: Multicentric squamous cell carcinoma in situ
resembling Bowenʼs disease in cats. Vet Pathol. 1993; 30: 535–543
[14]
Baer KE, Patnaik AK, Gilbertson SR et al.: Cutaneous plasmacytomas in dogs: a morphologic and immunhistochemical study. Vet
Pathol. 1989; 26: 216–221
[15]
Baez JL, Hendrick MJ, Shofer FS et al.: Liposarcomas in dogs: 56
[16]
Bailey DB, Rassnick KM, Kristal O et al.: Phase I dose escalation of
single-agent vinblastine in dogs. J Vet Intern Med. 2008; 22: 1397–
1402
[17]
Baines SJ, McCormick D, McInnes E et al.: Cutaneous T cell lymphoma mimicking cutaneous histiocytosis: differentiation by flow
cytometry. Vet Rec. 2000; 147: 11–16
Vakaet LA, Boterberg T: Pain control by ionizing radiation of bone
metastasis. Int J Dev Biol. 2004; 48: 599–606
[18]
Bak EJ, Chae CH: Histopathology of canine basal cell tumour.
Korean J Vet Res. 1995; 35: 361–368
[44]
Weinstein JI, Payne S, Poulson JM et al.: Use of force plate analysis
to evaluate the efficacy of external beam radiation to alleviate
osteosarcoma pain. Vet Radiol Ultrasound. 2009; 50: 673–678
[19]
Baker-Gabb M, Hunt GB, France MP: Soft tissue sarcomas and
mast cell tumours in dogs; clinical behaviour and response to surgery. Aust Vet J. 2003; 81: 732–738
[45]
Wiseman-Orr ML, Scott EM, Reid J et al.: Validation of a structured questionnaire as an instrument to measure chronic pain in
dogs on the basis of effects on health-related quality of life. Am J
Vet Res. 2006; 67: 1826–1836
[20]
Barber LG, Sorenmo KU, Cronin KL et al.: Combined doxorubicin
and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc. 2000; 36: 416–421
[21]
Bardagí M, Fondevila D, Ferrer L: Immunohistochemical detection
of COX-2 in feline and canine actinic keratoses and cutaneous squamous cell carcinoma. J Comp Pathol. 2012; 146: 11–17
[22]
Beale KM, Bolon B: Canine cutaneous lymphosarcoma: epitheliotropic and non epitheliotropic, a retrospective study. In: Ihrke PJ,
Mason IS, White SD (Hrsg.) Advances in Veterinary Dermatology.
Band 2, New York, Pergamon Press, 1993; 273–284
17 Tumoren der Haut
[1]
[Anonym]: CVMP advice on injection-site fibrosarcomas in cats. Vet
Rec. 2003; 152: 381–382
[2]
Abadie JJ, Amardeilh MA, Delverdier ME: Immunohistochemical
detection of proliferating cell nuclear antigen and Ki-67 in mast cell
tumors from dogs. J Am Vet Med Assoc. 1999; 215: 1629–1634
[23]
Bell A, Mason K, Michell G et al.: Visceral and cutaneous mast cell
neoplasia in a cat. Aust Vet Pract. 1994; 24: 86–91
[24]
[3]
Abramo F, Pratesi F, Cantile C et al.: Survey of canine and feline
follicular tumours and tumour-like lesions in central Italy. J Small
Anim Pract. 1999; 40: 479–481
Bell JA, Sundberg JP, Ghim SJ et al.: A formalin-inactivated vaccine
protects against mucosal papillomavirus infection: a canine model.
Pathobiology. 1994; 62: 194–198
[25]
[4]
Affolter VK, Gross TL, Moore PF: Indolent cutaneous T-cell lymphoma presenting as cutaneous lymphocytosis in dogs. Vet Dermatol. 2009; 20: 577–585
Bergman PJ, Withrow SJ, Straw RC et al.: Infiltrative lipoma in
dogs: 16 cases (1981—1992). J Am Vet Med Assoc. 1994; 205: 322–
324
[26]
[5]
Affolter VK, Moore PF: Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol. 2000; 22: 40–48
Bexfield NH, Stell AJ, Gear RN et al.: Photodynamic therapy of
superficial nasal planum squamous cell carcinomas in cats: 55
cases. J Vet Intern Med. 2008; 22: 1385–1389
[27]
[6]
Al-Dissi AN, Haines DM, Singh B et al.: Immunohistochemical
expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas. J
Comp Pathol. 2009; 141: 229–236
Bohn AA, Wills T, Caplazi P: Basal cell tumor or cutaneous basilar
epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell
tumors. Vet Clin Pathol. 2006; 35: 449–453
[28]
Bolon B, Calderwood-Mays MB, Hall BJ: Characteristics of canine
melanomas and comparison of histology and DNA ploidy to their
biologic effect. Vet Pathol. 1990; 27: 96—102
[29]
Bostock DE, Dye MT: Prognosis after surgical excision of canine fibrous connective tissue sarcomas. Vet Pathol. 1980; 17: 581–588
[30]
Bostock DE, Dye MT: Prognosis after surgical excision of fibrosarcomas in cats. J Am Vet Med Assoc. 1979; 175: 727–728
[31]
Bostock DE, Crocker J, Harris K et al.: Nuclear organiser regions as
indicators of postsurgical prognosis in canine spontaneous mast cell
tumors. Br J Cancer. 1989; 59: 915–918
[32]
Bostock DE: Prognosis after surgical excision of canine melanomas.
Vet Pathol. 1979; 16: 32–40
[7]
[8]
[9]
[10]
Anis EA, OʼNeill SH, Newkirk KM et al.: Molecular characterization
of the L1 gene of papillomaviruses in epithelial lesions of cats and
comparative analysis with corresponding gene sequences of human
and feline papillomaviruses. Am J Vet Res. 2010; 71: 1457–1461
Antognoni MT, Spaterna A, Lepri E et al.: Characteristic clinical,
haematological, and histopathological findings in feline mastocytoma. Vet Res Commun 203; 27 (Suppl 1): 727–730
Aronson MG, Carpenter JL: Distal extremity melanocytic nevi and
malignant melanomas in dogs. J Am Anim Hosp Assoc. 1990; 26:
605–612
Aupperle H: Prognosestellung beim caninen Mastzelltumor: Welche histologischen und immunhistochemischen Aspekte sind hilfreich? Proc. Arbeitstagung Onkologie, Fachgruppe Kleintiermedizin
DVG, Hofheim, 2011
[11]
Avallone G, Helmbold P, Caniatti M et al.: The spectrum of canine
cutaneous perivascular wall tumors: morphologic, phenotypic and
clinical characterization. Vet Pathol. 2007; 44: 607–620
[12]
Bacon NJ, Dernell WS, Ehrhart N et al.: Evaluation of primary reexcision after recent inadequate resection of soft tissue sarcomas in
dogs: 41 cases (1999–2004). J Am Vet Med Assoc. 2007; 230: 548–
554
[32a] Bostock DE: The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract. 1973; 14: 27–40
[33]
Bregazzi VS, LaRue SM, McNiel E et al.: Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and
radiation alone for cats with vaccine-associated sarcomas: 25 cases
(1995–2000). J Am Vet Med Assoc. 2001; 218: 547–550
[34]
Bregman CL, Hirth RS, Sundberg JS et al.: Cutaneous neoplasms
in dogs associated with canine oral papillomavirus vaccine. Vet
Pathol. 1987; 24: 477–487
51
52
[35]
Briscoe CM, Lipscomb TP, McKinney L: Pulmonary metastasis of a
feline vaccination-site fibrosarcoma. J Vet Diagn Invest. 1998; 10:
79–82
[55]
Carew JS, Schmidt JA, Humphrey SA et al.: Growth factor expression and vaccine-associated sarcoma tumorigenicity (abstr). Proc
Vet Cancer Soc. 1999; 19: 25
[36]
Brocks BA, Neyens IJ, Teske E et al.: Hypotonic water as adjuvant
therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study. Vet Surg. 2008;
37: 472–478
[56]
Carminato A, Vascellari M, Marchioro W et al.: Microchip-associated fibrosarcoma in a cat. Vet Dermatol. 2011; 22: 565–569
[57]
Carothers MA, Johnson GC, DiBartola SD et al.: Extramedullary
plasmacytoma and immunglobulin-associated amyloidosis in a cat.
J Am Vet Med Assoc. 1989; 195: 1593–1597
[37]
Brown CA, Chalmers SA: Diffuse cutaneous mastocytosis in a cat.
Vet Pathol. 1990; 27: 366–369
[58]
[38]
Brown NO, Patnaik AK, Mooney S et al.: Soft tissue sarcomas in
Carroll EE, Fossey SL, Mangus LM et al.: Malignant pilomatricoma
in 3 dogs. Vet Pathol. 2010; 47: 937–943
[59]
[39]
Brunnert SR, Altman NH: Identification of immunoglobulin light
chains in canine extramedullary plasmacytomas by thioflavine T
and immunohistochemistry. J Vet Diagn Invest. 1991; 3: 245–251
Chaffin K, Thrall DE: Results of radiation therapy in 19 dogs with
cutaneous mast cell tumor and regional lymph node metastasis.
[60]
[40]
Buchholz J, Wergin M, Walt H et al.: Photodynamic therapy of
feline cutaneous squamous cell carcinoma using a newly developed
liposomal photosensitizer: preliminary results concerning drug
safety and efficacy. J Vet Intern Med. 2007; 21: 770–775
Chalita MC, Matera JM, Alves MT et al.: Nonaspiration fine needle
cytology and its histologic correlation in canine skin and soft tissue
tumors. Anal Quant Cytol Histol. 2001; 23: 395–399
[61]
Chase D, Bray J, Ide A et al.: Outcome following removal of canine
spindle cell tumours in first opinion practice: 104 cases. J Small
Anim Pract. 2009; 50: 568–574
[62]
Chastain CB, Turk MA, OʼBrien D: Benign cutaneous mastocytomas in two litters of Siamese kittens. J Am Vet Med Assoc. 1988;
193: 959–960
[63]
Chaubert P, Baur Chaubert AS, Sattler U et al.: Improved polymerase chain reaction-based method to detect early-stage epitheliotropic T-cell lymphoma (mycosis fungoides) in formalin-fixed, paraffin-embedded skin biopsy specimens of the dog. J Vet Diagn Invest.
2010; 22: 20–29
[41]
Buerger RG, Scott DW: Cutaneous mast cell neoplasia in cats: 14
cases (1975—1985). J Am Vet Med Assoc. 1987; 190: 1440–1444
[42]
Bulakowski EJ, Philibert JC, Siegel S et al.: Evaluation of outcome
associated with subcutaneous and intramuscular hemangiosarcoma
treated with adjuvant doxorubicin in dogs: 21 cases (2001–2006). J
Am Vet Med Assoc. 2008; 233: 122–128
[43]
Buracco P, Martano M, Morello E et al.: Vaccine-associated-like
fibrosarcoma at the site of a deep nonabsorbable suture in a cat.
Vet J. 2002; 163: 105–107
[44]
Burke JK, Sorenmo K, Duda L et al.: The effect of adjuvant orthovoltage radiation therapy on feline vaccine-associated fibrosarcomas: a retrospective study of 15 cases (abstr), Proc Vet Cancer Soc.
1999; 19: 20
[64]
Chijiwa K, Uchida K, Tateyama S: Immunohistochemical evaluation of canine peripheral nerve sheath tumors and other soft tissue
sarcomas. Vet Pathol. 2004; 41: 307–318
[65]
[45]
Burnett RC, Vernau W, Modiano JF et al.: Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor
genes. Vet Pathol. 2003; 40: 32–41
Clark GN, Berg J, Engler SJ et al.: Extramedullary plasmacytomas
in dogs: results of surgical excision in 131 cases. J Am Anim Hosp
Assoc. 1992; 28: 105–111
[66]
[46]
Burton JH, Mitchell L, Thamm DH et al.: http://www.ncbi.nlm.nih.
gov/pubmed?term=%22Dow%20SW%22%5BAuthor%5DLow-dose
cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet Intern
Med. 2011; 25: 920–926
Clarke RE: Cryosurgical treatment of feline cutaneous squamous
cell carcinoma. Aust Vet Pract. 1991; 21: 148–153
[67]
Cohen M, Wright JC, Brawner WR et al.: Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment
of vaccine-associated sarcomas in cats: 78 cases (1996–2000). J Am
Vet Med Assoc. 2001; 219: 1582–1589
[47]
Buyukmihci N, Stannard AA: Canine conjunctival angiokeratomas.
J Am Vet Med Assoc. 1981; 178: 1279–1782
[68]
[48]
Cahalane AK, Payne S, Barber LG et al.: Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated
surgically with or without adjunctive treatment: 68 cases (1994–
2002). J Am Vet Med Assoc. 2004; 225: 401–408
Couto SS, Griffey SM, Duarte PC et al.: Feline vaccine-associated
fibrosarcoma: morphologic distinctions. Vet Pathol. 2002; 39: 33–
41
[69]
Coyne MJ, Reeves NC, Rosen DK: Estimated prevalence of injection-site sarcomas in cats during 1992. J Am Vet Med Assoc. 1997;
210: 249–251
[70]
Cronin KL, Page RL, Spodnick G et al.: Radiation therapy and surgery for fibrosarcoma in 33 cats. Vet Radiol Ultrasound. 1998; 39:
51–56
[71]
Culbertson MR Jr: Hemangiosarcoma of the canine skin and tongue. Vet Pathol. 1982; 19: 556–558
[72]
Cunha SC, Carvalho LA, Canary PC et al.: Radiation therapy for
feline cutaneous squamous cell carcinoma using a hypofractionated
protocol. J Feline Med Surg. 2010; 12: 306–313
[73]
Daly MK, Saba CF, Crochik SS et al.: Fibrosarcoma adjacent to the
site of microchip implantation in a cat. J Feline Med Surg. 2008; 10:
202–205
[74]
Dambach D, Carlson J, Riddle D et al.: Immunohistochemical identification and localization of growth factors in feline postvaccinal
lesions. Vet Pathol. 1996; 33: 607
[75]
Dank G, Chien MB, London CA: Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of
cats. Am J Vet Res. 2002; 63: 1129–1133
[76]
Davidson EB, Gregory, Kass PH: Surgical excision of soft tissue fibrosarcomas in cats. Vet Surg. 1997; 26: 265–269
[49]
Callan MB, Preziosi D, Mauldin E: Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in
a dog following chronic treatment with prednisone and cyclosporine. Vet Dermatol. 2005; 16: 338–345
[50]
Campbell KL, Sundberg JP, Goldschmidt MH et al.: Cutaneous
inverted papillomas in dogs. Vet Pathol. 1988; 25: 67–71
[51]
Camps-Palau MA, Leibman NF, Elmslie R et al.: Treatment of
canine mast cell tumours with vinblastine, cyclophosphamide and
prednisone: 35 cases (1997–2004). Vet Comp Oncol. 2007; 5: 156–
167
[52]
[53]
[54]
Cangul IT, Wijnen M, Van Garderen E et al.: Clinico-pathological
aspects of canine cutaneous and mucocutaneous plasmacytomas. J
Vet Med A Physiol Pathol Clin Med. 2002; 49: 307–312
Caniatti M, Ghisleni G, Ceruti R et al.: Cytological features of
canine haemangiopericytoma in fine needle aspiration biopsy. Vet
Rec. 2001; 149: 242–244
Cantaloube B, Raymond-Letron I, Regnier A: Multiple eyelid apocrine hidrocystomas in two Persian cats. Vet Ophthalmol. 2004; 7:
121–125
53
[77]
Davies DR, Wyatt KM, Jardine JE et al.: Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J
[99]
[78]
Davis KM, Hardie EM, Lascelles BD et al.: Feline fibrosarcoma:
perioperative management. Compend Contin Educ Vet. 2007; 29:
712–729
[100] Dunstan RW, Rosser EJ: Comparative aspects of cutaneous melanocytic neoplasms in the dog. Comp Dermatopathol. 1985; 7: 197–
201
[79]
Davis KM, Hardie EM, Martin FR et al.: Correlation between perioperative factors and successful outcome in fibrosarcoma resection
in cats. Vet Rec. 2007; 161: 199–200
[80]
Day DG, Couto CG, Weisbrode SE et al.: Basal cell carcinoma in
two cats. J Am Anim Hosp. Assoc. 1994; 30: 265–269
[101] Eggers Carroll E, Dubielzig RR, Schultz RD: Cats differ from Mink
and Ferrets in their response to commercial vaccines: A histologic
comparison of early vaccine reactions. Vet Pathol. 2002; 39: 216–
227
[81]
Day MJ, Lucke VM: Melanocytic neoplasia in the cat. J Sm Anim
Pract. 1995; 36: 207–213
[82]
Day MJ: Immunophenotypic characterization of cutaneous lymphoid neoplasia in the dog and cat. J Comp Pathol. 1995; 112: 79–
96
[83]
de Lorimier LP: Updates on the management of canine epitheliotropic cutaneous T-cell lymphoma. Vet Clin North Am Small Anim
Pract. 2006; 36: 213–228, viii-ix
[84]
De Man MM, Ducatelle RV: Bilateral subcutaneous fibrosarcomas
in a cat following feline parvo-, herpes- and calicivirus vaccination. J
Feline Med Surg. 2007; 9: 432–434
[85]
de Mello Souza CH, Valli VE, Selting KA et al.: Immunohistochemical detection of retinoid receptors in tumors from 30 dogs diagnosed with cutaneous lymphoma. J Vet Intern Med. 2010; 24:
1112–1117
[86]
DeBey BM, Bagladi-Swanson M, Kapil S et al.: Digital papillomatosis in a confined Beagle. J Vet Diagn Invest. 2001; 13: 346–348
[87]
Dennis MM, McSporran KD, Bacon NJ et al.: Prognostic factors for
cutaneous and subcutaneous soft tissue sarcomas in dogs. Vet
Pathol. 2011; 48: 73–84
[102] Ehrhart N: Soft-tissue sarcomas in dogs: a review. J Am Anim Hosp
Assoc. 2005; 41: 241–246
[103] Ellis JA, Jackson ML, Bartsch RC et al.: Use of immunohistochemistry and polymerase chain reaction for detection of oncornaviruses in formalin-fixed, paraffin-embedded fibrosarcomas from cats. J
Am Vet Med Assoc. 1996; 209: 767–771
[104] Elmslie RE, Glawe P, Dow SW: Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in
Med. 2008; 22: 1373–1379
[105] Elston LB, Sueiro FAR, Cavalcanti JN: The importance of the mitotic index as a prognostic factor for survival of canine cutaneous
mast cell tumors: a validation study. Vet Pathol. 2009; 46: 362–364
[106] Esplin DG, Bigelow M, McGill LD et al.: Fibrosarcoma at the site of
a lufenuron injection in a cat. Vet Cancer Soc Newsletter. 1999; 23:
8–9
[107] Esplin DG, Campbell R: Widespread metastasis of a fibrosarcoma
associated with a vaccination site in a cat. Feline Pract. 1995; 23:
13–16
[108] Esplin DG: Infiltrative lipoma in a cat. Feline Pract. 1984; 14: 24–25
[109] Ettinger SN, Scase TJ, Oberthaler KT et al.: Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with
soft tissue sarcomas: 60 cases (1996–2002). J Am Vet Med Assoc.
2006; 228: 1053–1062
[88]
Diessler ME, Castellano MC, Massone AR et al.: Cutaneous lymphangiosarcoma in a young dog: clinical, anatomopathological and
lectinhistochemical description. J Vet Med A Physiol Pathol Clin
Med. 2003; 50: 452–456
[89]
Dillon CJ, Mauldin GN, Baer KE: Outcome following surgical removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992–
2000). J Am Vet Med Assoc. 2005; 227: 1955–1957
[90]
Diters RW, Walsh KM: Feline basal cell tumors: a review of 124
cases. Vet Pathol. 1984; 21: 51–56
[91]
Dobson J, Cohen S, Gould S: Treatment of canine mast cell
tumours with prednisolone and radiotherapy. Vet Comp Oncol.
2004; 2: 132–141
[92]
Dobson JM, Samuel S, Milstein H et al.: Canine neoplasia in the
UK: estimates of incidence rates from a population of insured dogs.
J Small Anim Pract. 2002; 43: 240–246
[93]
Dobson JM, Scase TJ: Advances in the diagnosis and management
of cutaneous mast cell tumours in dogs. J Small Anim Pract. 2007;
48: 424–431
[94]
Doddy FD, Glickman LT, Glickman NW et al.: Feline fibrosarcomas
at vaccination sites and non-vaccination sites. J Comp Pathol. 1996;
114: 165–174
[95]
Dorn CR, Taylor DON, Scheider R: Sunlight exposure and risk of
developing cutaneous and oral squamous cell carcinomas in white
cats. J Natl Cancer Inst. 1971; 46: 1073–1078
[116] Fivenson DP, Saed GM, Beck ER et al.: T-cell receptor gene
rearrangement in canine mycosis fungoides: further support for a
canine model of cutaneous T-cell lymphoma. J Invest Dermatol.
1994; 102: 227–230
[96]
Doster AR, Tomlison MJ, Mahaffey EA et al.: Canine liposarcoma.
Vet Pathol. 1986; 23: 87–88
[117] Fontaine J, Bovens C, Bettenay S et al.: Canine cutaneous epitheliotropic T-cell lymphoma: a review. Vet Comp Oncol. 2009; 7: 1–14
[97]
Downing S, Chien MB, Kass PH et al.: Prevalence and importance
of internal tandem duplications in exons 11 and 12 of c-kit in mast
cell tumors of dogs. Am J Vet Res. 2002; 63: 1718–1723
[118] Fontaine J, Heimann M, Day MJ: Canine cutaneous epitheliotropic
T-cell lymphoma: a review of 30 cases. Vet Dermatol. 2010; 21:
267–275
[98]
Dubielzig RR, Hawkins KL, Miller PE: Myofibroblastic sarcoma originating at the site of rabies vaccination in a cat. J Vet Diagn Invest.
1993; 5: 637–638
[119] Fontaine J, Heimann M, Day MJ: Cutaneous epitheliotropic T-cell
lymphoma in the cat: a review of the literature and five new cases.
Vet Dermatol. 2011; 22: 454–461
[110] Ettinger SN: Principles of treatment for soft-tissue sarcomas in the
dog. Clin Tech Small Anim Pract. 2003; 18: 118–122
[111] Evans SM: Canine hemangiopericytoma. A retrospective analysis of
response to surgery and orthovoltage radiation. Vet Radiol. 1987;
28: 13–16
[112] Fehrer SL, Lin SH: Multicentric basal cell tumors in a cat. J Am Vet
Med Assoc. 1986; 189: 1469–1470
[113] Fernandez NJ, West KH, Jackson ML et al.: Immunohistochemical
and histochemical stains for differentiating canine cutaneous round
cell tumors. Vet Pathol. 2005; 42: 437–445
[114] Ferreira I, Rahal SC, Rocha NS et al.: Hematoporphyrin-based photodynamic therapy for cutaneous squamous cell carcinoma in cats.
Vet Dermatol. 2009; 20: 174–178
[115] Fidel JL, Egger E, Blattmann H et al.: Proton irradiation of feline
nasal planum squamous cell carcinomas using an accelerated protocol. Vet Radiol Ultrasound. 2001; 42: 569–575
tumors. Mast cell tumor, histiocytoma, lymphosarcoma and transmissible venereal tumor. Vet Pathol. 1979; 16: 673–679
54
[120] Forrest LJ, Chun R, Adams WM et al.: Postoperative radiotherapy
for canine soft tissue sarcoma. J Vet Intern Med. 2000; 14: 578–582
[121] Fossum TW, Miller MW, Mackie JT: Lymphangiosarcoma in a dog
presenting with massive head and neck swelling. J Am Anim Hosp
Assoc. 1998; 34: 301–304
[122] Foster AP, Evans E, Kerlin RL et al.: Cutaneous T-cell lymphoma
with Sézary syndrome in a dog. Vet Clin Pathol. 1997; 26: 188–192
[123] Foster SF, Charles JA, Swinney GR et al.: Multiple crusted cutaneous plaques in a cat. Aust Vet J. 1999; 77: 360, 367–8
[124] Fox LE, Rosenthal RC, Twedt DC: Plasma histamine and gastrin
concentrations in 17 dogs with mast cell tumors. J Vet Int Med
1990; 4: 242–246
[143] Gil da Costa RM, Matos E, Rema A et al.: CD117 immunoexpression in canine mast cell tumours: correlations with pathological
variables and proliferation markers. BMC Vet Res. 2007; 3: 19
[144] Gilbert S, Affolter VK, Gross TL et al.: Clinical, morphological and
immunohistochemical characterization of cutaneous lymphocytosis
in 23 cats. Vet Dermatol. 2004; 15: 3–12
[145] Gill VL, Bergman PJ, Baer KE et al.: Use of imiquimod 5% cream
(Aldara) in cats with multicentric squamous cell carcinoma in situ:
12 cases (2002–2005). Vet Comp Oncol. 2008; 6: 55–64
[146] Gillick A, Spiegle M: Dacarbazine treatment of malignant melanoma in a dog. Can Vet J. 1987; 28: 204
[125] Frazier FS, Herron AJ, Dee JF et al.: Infiltrative lipoma in a stifle
joint. J Am Anim Hosp. 1993; 29: 81–83
[147] Ginel PJ, Lucena R, Millán Y et al.: Expression of oestrogen and
progesterone receptors in canine sebaceous gland tumours. Vet
Dermatol. 2010; 21: 297–302
[126] Frese K, Durchfeld B, Eskens U: Klassifikation und biologisches Verhalten der Haut- und Mammatumoren von Hund und Katze. Prakt
Tierarzt. 1989; 9: 69–84
[148] Giudice C, Muscolo MC, Rondena M et al.: Eyelid multiple cysts of
the apocrine gland of Moll in Persian cats. J Feline Med Surg. 2009;
11: 487–491
[127] Frese K: Verlaufsuntersuchungen bei Melanomen der Haut und
Mundschleimhaut des Hundes. Vet Pathol. 1978; 15: 461–473
[149] Giudice C, Stefanello D, Sala M et al.: Feline injection-site sarcoma: recurrence, tumour grading and surgical margin status evaluated using the three-dimensional histological technique. Vet J.
2010; 186: 84–88
[128] Frimberger AE, Moore AS, LaRue SM et al.: Radiotherapy of
incompletely resected, moderately differentiated mast cell tumors
in the dog: 37 cases (1989–1993). J Am Anim Hosp Assoc. 1997;
33: 320–324
[129] Fuentealba IC, Illanes OG, Haines DM: Eccrine adenocarcinoma of
the footpads in 2 cats. Can Vet J. 2000; 41: 401–403
[130] Fukui K, Nakayama H, Uchida K et al.: Two cases of malignant
basal cell tumors in dogs. J Jap Vet Med Assoc. 1992; 45: 856–857
[131] Fulcher RP, Ludwig LL, Bergman PJ et al.: Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II
cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2006;
228: 210–215
[132] Galeotti F, Barzagli F, Vercelli A et al.: Feline lymphangiosarcoma–
definitive identification using a lymphatic vascular marker. Vet Dermatol. 2004; 15: 13–18
[133] Gallegos J, Schmiedt CW, McAnulty JF: Cosmetic rostral nasal
reconstruction after nasal planum and premaxilla resection: technique and results in two dogs. Vet Surg. 2007; 36: 669–674
[134] Gamlem H, Nordstoga K, Arnesen K: Canine vascular neoplasia–a
population-based clinicopathologic study of 439 tumours and
tumour-like lesions in 420 dogs. APMIS Suppl. 2008; 125: 41–54
[135] Garner MT: Der Einsatz von Megavoltage-Bestrahlungstherapie und
Elektronen bei der Behandlung von Weichteilsarkomen des Hundes.
Eine retrospektive Studie von 73 Hunden. Diss med vet, FU Berlin,
2004
[150] Gobar GM, Kass PH: World Wide Web-based survey of vaccination
practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc. 2002; 220: 1477–1482
[151] Goldschmidt MH, Dunstan RW, Stannard AA et al.: Melanocytic
tumors and tumor-like lesions. In: Histological classification of epithelial and melanocytic tumors of the skin of domestic animals.
Goldschmidt MH, Dunstan RW, Stannard AA et al. (Hrsg.): Armed
Forces Institute of Pathology, Washington, DC, 1998, 38–40
[152] Goldschmidt MH, Kennedy JS, Kennedy DR et al.: Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs. J Virol.
2006: 80: 6621–6628
[153] Goldschmidt MH, Shofer FS: Skin tumors of the dog and cat. Pergamon Press, Oxford 1992
[154] Goldschmidt MH, Thrall DE, Jeglum KA et al.: Malignant pilomatricoma in a dog. J Cutan Pathol. 1981; 8: 375–381
[155] Goldschmidt MH: Benign and malignant melanocytic neoplasms of
domestic animals. Am J Dermatopathol. 1985; 7(Suppl): 203–212
[156] Goodfellow M, Hayes A, Murphy S et al.: A retrospective study of
(90)Strontium plesiotherapy for feline squamous cell carcinoma of
the nasal planum. J Feline Med Surg. 2006; 8: 169–176
[157] Grabarevic Z, Spoljar JB, Kurilj AG et al.: Mast cell tumor in dogs–
incidence and histopathological characterization. Coll Antropol.
2009; 33: 253–258
[136] Gaskell RM, Gettinby G, Graham SJ et al.: Veterinary Products
Committee working group report on feline and canine vaccination.
Vet Rec. 2002; 150: 126–134
[158] Grain E, Walder EJ: Hypercalcemia associated with squamous cell
carcinoma in a dog. J Am Vet Med Assoc. 1982; 181: 165
[137] Gemmill LT: The issue of injection site sarcomas. J Am Vet Med
Assoc. 1997; 210: 889–890
[159] Grant IA, Rodriguez CO, Kent MS et al.: A phase II clinical trial of
vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern
Med. 2008; 22: 388–393
[138] George C, Summers BA: Angiokeratoma: a benign vascular tumour
of the dog. J Small Anim Pract. 1990; 31: 390–392
[139] Gerritsen RJ, Teske E, Kraus JS et al.: Multi-agent chemotherapy
for mast cell tumours in the dog. Vet Q. 1998; 20: 28–31
[140] Ghim S, Newsome J, Bell J et al.: Spontaneously regressing oral
papillomas induce systemic antibodies that neutralize canine oral
papillomavirus. Exp Mol Pathol. 2000; 68: 147–151
[141] Ghisleni GP, Roccabianca R, Ceruti D et al.: Correlation between
fine-needle aspiration cytology and histopathology in the evaluation
of cutaneous and subcutaneous masses from dogs and cats. Vet
Clin Pathol. 2006; 35: 24–30
[142] Gieger TL, Théon AP, Werner JA et al.: Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases
(1990–2001). J Vet Intern Med. 2003; 17: 687–692
[160] Grier RL, DiGuardo G, Myers R et al.: Mast cell tumor destruction
in dogs by hypotonic solution. J Small Anim Pract 1995; 36: 385–
388
[161] Gross TL, Brimacomb BH: Multifocal intraepidermal carcinoma in a
dog histologically resembling Bowenʼs disease. Am J Dermatopathol. 1986; 8: 509–515
[162] Grösslinger K, Alton K, Lorison D: Histologische Bestimmung der
Tumorgrenzen und Evaluierung der Rezidivrate beim felinen vakzine-induzierten Fibrosarkom. Kleintierprax. 2003; 48: 261–268
[163] Guerre R, Millet P, Groulade P: Systemic mastocytosis in a cat:
remission after splenectomy. J Small Anim Pract. 1979; 20: 769–
772
[164] Gumbrell RC, Rest JR, Bredelius K et al.: Dermal fibropapillomas in
cats. Vet Rec 1998; 142: 376
[165] Hadzijusufovic E, Peter B, Rebuzzi L et al.: Growth-inhibitory
effects of four tyrosine kinase inhibitors on neoplastic feline mast
cells exhibiting a Kit exon 8 ITD mutation. Vet Immunol Immunopathol. 2009; 132: 243–250
[187] Hendrick MJ, Shofer FS, Goldschmidt MH et al.: Comparison of
1994; 205: 1425–1429
[166] Hahn KA, King GK, Carreras JK: Efficacy of radiation therapy for
incompletely resected grade-III mast cell tumors in dogs: 31 cases
(1987–1998). J Am Vet Med Assoc. 2004; 224: 79–82
[188] Henfrey JI: Treatment of multiple intracutaneous cornifying epitheliomata using isotretinoin. J Sm Anim Pract. 1991; 32: 363–365
[167] Hahn KA, Lantz GC, Salisbury SK et al.: Comparison of survey
radiography with ultrasonography and x-ray computed tomography
for clinical staging of subcutaneous neoplasms in dogs. J Am Vet
Med Assoc. 1990; 196: 1795–1798
[189] Henry CJ, Downing S, Rosenthal RC et al.: Evaluation of a novel
immunomodulator composed of human chorionic gonadotropin
and bacillus Calmette-Guerin for treatment of canine mast cell
tumors in clinically affected dogs. Am J Vet Res. 2007; 68: 1246–
1251
[168] Hahn KA, Ogilvie G, Rusk T et al.: Masitinib is safe and effective
for the treatment of canine mast cell tumors. J Vet Intern Med.
2008; 22: 1301–1309
[190] Hershey AE, Sorenmo KU, Hendrick MJ et al.: Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases
(1986–1996). J Am Vet Med Assoc. 2000; 216: 58–61
[169] Ham L van, Bree H van, Maenhout T et al.: Metastatic pilomatrixoma presenting as paraplegia in a dog. J Small Anim Pract. 1991;
32: 27–30
[191] Hillers KR, Lana SE, Fuller CR et al.: Effects of palliative radiation
therapy on nonsplenic hemangiosarcoma in dogs. J Am Anim Hosp
Assoc. 2007; 43: 187–192
[170] Handharyani E, Ochiai K, Kadosawa T et al.: Canine hemangiopericytoma: an evaluation of metastatic potential. J Vet Diagn Invest.
1999; 11: 474–478
[192] Himsel CA, Richardson RC, Craig JA: Cisplatin chemotherapy for
Assoc. 1986; 189: 1575–1578
[171] Hanna PE, Dunn D: Cutaneous fibropapilloma in a cat (feline sarcoid). Can Vet J. 2003; 44: 601–602
[193] Hinrichs U, Puhl S, Rutteman GR et al.: Lymphangiosarcomas in
cats: a retrospective study of 12 cases. Vet Pathol. 1999; 36: 164–
167
[172] Hargis AM, Ihrke PJ, Spangler WL et al.: A retrospective clinicopathologic study of 212 dogs with cutaneous hemangiomas and
hemangiosarcomas. Vet Pathol. 1992; 29: 316–328
[173] Hargis AM, Thomassen RW, Phemister RD: Chronic dermatosis
and cutaneous squamous cell carcinoma in the beagle dog. Vet
Pathol. 1977; 14: 218–228
[174] Hargis AM, Thomassen RW: Animal model: solar dermatosis (keratosis) and solar dermatosis with squamous cell carcinoma. Am J
Pathol. 1979; 94: 193–196
[175] Hartley C, Ladlow J, Smith KC: Cutaneous haemangiosarcoma of
the lower eyelid in an elderly white cat. J Feline Med Surg. 2007; 9:
78–81
[176] Hasier UC: Malignant mastocytosis and duodenal ulceration in a
cat. Schweiz Arch Tierheilk 1978; 120: 263–268
[177] Havlicek M, Straw RS, Langova V et al.: Intra-operative cisplatin
for the treatment of canine extremity soft tissue sarcomas. Vet
Comp Oncol. 2009; 7: 122–129
[178] Headley SA, Faria Dos Reis AC, Bracarense AP: Cutaneous myxosarcoma with pulmonary metastases in a dog. J Comp Pathol. 2011;
145: 31–34
[179] Hendrick MJ, Brooks JJ: Postvaccinal sarcomas in the cat: histology
and immunohistochemistry. Vet Pathol. 1994; 31: 126–129
[180] Hendrick MJ, Dunagan CA: Focal necrotizing granulomatous panniculitis associated with subcutaneous injection of rabies vaccine in
cats and dogs: 10 cases (1988–1989). J Am Vet Med Assoc. 1991;
198: 304–305
[181] Hendrick MJ, Goldschmidt MH, Shofer FS et al.: Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical
identification of aluminum. Cancer Res. 1992; 52: 5391–5394
[182] Hendrick MJ, Goldschmidt MH: Do injection site reactions induce
fibrosarcomas in cats? J Am Vet Med Assoc. 1991; 199: 968
[183] Hendrick MJ, Kass PH, McGill LD et al.: Postvaccinal sarcomas in
cats. J Natl Cancer Inst. 1994; 86: 341–343
[194] Hirschberger J, Kessler M: Das feline Fibrosarkom. Tierärztl Prax.
2001; 29: 66–71
[195] Hirschberger J: Aktueller Stand der internistischen Fibrosarkomtherapie bei der Katze. Tierärztl Prax. 2010; 38 (Suppl 1): S37–S40
[196] Hosoya K, Kisseberth WC, Alvarez FJ et al.: Adjuvant CCNU
(lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc.
2009; 45: 14–18
[197] Hottendorf GH, Nielson SW: Survey of 300 extirpated canine mastocytomas. Ztrbl Vet Med A 1967; 14: 272–281
[198] Howard EB, Sawa TR, Nielson SW et al.: Mastocytoma and gastroduodenal ulceration. Vet Pathol. 1969; 6: 146–158
[199] Hume CT, Kiupel M, Rigatti L et al.: Outcomes of dogs with grade
3 mast cell tumors: 43 cases (1997–2007). J Am Anim Hosp Assoc.
2011; 47: 37–44
[200] Ishiguro T, Kadosawa T, Takagi S et al.: Relationship of disease
progression and plasma histamine concentrations in 11 dogs with
mast cell tumors. J Vet Intern Med. 2003; 17: 194–198
[201] Isotani M, Tamura K, Yagihara H et al.: Identification of a c-kit
exon 8 internal tandem duplication in a feline mast cell tumor case
and its favorable response to the tyrosine kinase inhibitor imatinib
mesylate. Vet Immunol Immunopathol. 2006; 114: 168–172
[202] Isotani M, Yamada O, Lachowicz JL et al.: Mutations in the fifth
immunoglobulin-like domain of kit are common and potentially
sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol. 2010; 148: 144–153
[203] Itoh T, Mikawa K, Mikawa M et al.: Lymphangiosarcoma in a dog
treated with surgery and chemotherapy. J Vet Med Sci. 2004; 66:
197–199
[204] Iwamoto KS, Bennett LR, Norman A et al.: Linoleate produces
remission in canine mycosis fungoides. Cancer Lett. 1992; 64: 17–
22
[184] Hendrick MJ, Mahaffey EA, Moore FM et al.: Histiocytic tumors.
In: WHO International histological classification of mesenchymal
tumors of skin and soft tissues of domestic animals, Second Series,
Bd. II, Armed Forces Institute of Pathology, Washington DC 1998;
29–31
[205] Jackson K, Boger L, Goldschmidt M et al.: Malignant pilomatricoma in a soft-coated Wheaten Terrier. Vet Clin Pathol. 2010; 39:
236–240
[185] Hendrick MJ: Feline vaccine-associated sarcomas: current studies
on pathogenesis. J Am Vet Med Assoc. 1998; 213: 1425–1426
[207] Jörger K: Hauttumoren bei Katzen. Vorkommen und Häufigkeit im
Untersuchungsgut (Biopsien 1984–1987) des Institutes für Veterinärpathologie Zürich. Schweiz Arch Tierheilk. 1988; 130: 559–569
[186] Hendrick MJ: Historical review and current knowledge of risk factors involved in feline vaccine-associated sarcomas. J Am Vet Med
Assoc. 1998; 213: 1422–1423
[206] Jönsson L, Gustafsson PO: Bone-metastasizing squamous-cell carcinoma of the skin in a dog. J Small Anim Pract. 1973; 14: 159–165
55
56
[208] Jösten M, Rudolph R: Methods for the differentiation of giant cells
in canine and feline neoplasias in paraffin sections. J Vet Med Sci.
1997; 44: 159–166
[209] Johannes CM, Henry CJ, Turnquist SE et al.: Hemangiosarcoma in
1851–1856
[210] Johnson JA, Patterson JM: Canine epidermotropic lymphoproliferative disease resembling Pagetoid reticulosis in man. Vet Pathol.
1981; 18:487–493
[211] Johnson TO, Schulman FY, Lipscomb TP et al.: Histopathology
and biologic behavior of pleomorphic cutaneous mast cell tumors
in fifteen cats. Vet Pathol. 2002; 39: 452–457
[212] Jones SE, Knapp DW, Hogenesch H et al.: Pilot study of piroxicam
therapy of non-resectable squamous cell carcinoma in dogs. Proc
Vet Cancer Soc. 1993; 53–54
[213] Kaim U, Moritz A, Failing K et al.: The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2,
TNF-alpha, IFN-gamma and iNOS mRNA. Immunology. 2006; 118:
472–482
[214] Kalaher KM, Anderson WI, Scott DW: Neoplasms of the apocrine
sweat glands in 44 dogs and 10 cats Vet Rec. 1990; 127: 400–403
[215] Kang SK, Park NY, Cho HS et al.: Relationship between DNA ploidy
and proliferative cell nuclear antigen index in canine hemangiopericytoma. J Vet Diagn Invest. 2006; 18: 211–214
[216] Kanjilal S, Banerji N, Fifer A et al.: p53 tumor suppressor gene
alterations in vaccine-associated feline sarcoma (abstr). Proc Vet
Cancer Soc. 1999; 19: 48
[217] Kass PH, Barnes WG, Spangler WL et al.: Epidemiologic evidence
for the causal relationship between vaccination and fibrosarcoma
[218] Kass PH, Spangler WL, Hendrick MJ et al.: Multicenter case-control study of risk factors associated with development of vaccineassociated sarcomas in cats. J Am Vet Med Assoc. 2003; 223: 1283–
1292
[219] Kessler M, Bomhard von D: Plattenepithelkarzinome bei Hunden
und Katzen – Prävalenz, Rasseprädisposition und Primärlokalisationen. Proc 22. Kongress DVG, Bad Nauheim, 1997
[220] Kessler M, Bomhard von D, Matis U: Mastzelltumoren bei Hunden
und Katzen. Epidemiologie, Diagnose und Therapie. Kleintierprax.
1997; 42: 361–374
[221] Kessler M, Bomhard von D: Auswertung von 28 Fällen caniner
Liposarkome. (unveröffentlicht), 1997
[222] Kessler M, Bomhard von D: Beitrag zur pädiatrischen Onkologie
bei Hunden und Katzen. Berl Münch Tierärztl Wschr. 1997; 110:
311–314
[223] Kessler M, Bomhard von D: Epithelioma malherbe (Pilomatrixom):
Rasse- und Lokalisationsverteilung bei 163 Fällen (unveröffentlicht),
1997
[224] Kessler M, Bomhard von D: Primärlokalisationen kutaner Hämangiome und Hämangiosarkome bei der Katze: 84 Fälle. (unveröffentlicht), 1997
[225] Kessler M, Bomhard von D: Rasseprädispositionen und Lokalisationsverteilung kutaner und mukokutaner (extramedullärer) Plasmozytome bei 106 Hunden (unveröffentlicht), 1997
[226] Kessler M: Studies on the epidemiology of feline vaccine-associated
fibrosarcomas in Germany. Proc. FECAVA Berlin, 2001
[227] Kidney BA, Ellis JA, Haines DM et al.: Comparison of endogenous
feline leukemia virus RNA content in feline vaccine and nonvaccine
site-associated sarcomas. Am J Vet Res. 2001; 62: 1990–1994
[228] Kidney BA, Haines DM, Ellis JA et al.: Evaluation of formalin-fixed
paraffin-embedded tissues from vaccine site-associated sarcomas
of cats for papillomavirus DNA and antigen. Am J Vet Res. 2001; 62:
833–839
[229] Kipar A, Baumgärtner W, Kremmer E et al.: Expression of major
histocompatibility complex class II antigen in neoplastic cells of
canine cutaneous histiocytoma. Vet Immunol Immunopathol.
1998; 62: 1–13
[230] Kirpensteijn J, Withrow SJ, Straw RC: Combined resection of the
nasal planum and premaxilla in three dogs. Vet Surg. 1994; 23:
341–346
[231] Kirpensteijn J: Feline injection site-associated sarcoma: Is it a reason to critically evaluate our vaccination policies? Vet Microbiol.
2006; 117: 59–65
[232] Kitchell BK, Orenberg EK, Brown DM et al.: Intralesional sustained-release chemotherapy with therapeutic implants for treatment
of canine sun-induced squamous cell carcinoma. Eur J Cancer.
1995; 31A: 2093–2098
[233] Kiupel M, Webster JD, Bailey KL et al.: Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more
accurately predict biological behaviour. Vet Pathol. 2011; 48: 147–
155
[234] Kiupel M, Webster JD, Miller RA et al.: Impact of tumour depth,
tumour location and multiple synchronous masses on the prognosis
of canine cutaneous mast cell tumours. J Vet Med A Physiol Pathol
Clin Med. 2005; 52: 280–286
[235] Kleiter M, Leschnik M: Postoperative Chemotherapie zur Behandlung eines zweifach rezidivierten Vakzine-assoziierten Fibrosarkoms.
[236] Kleiter M, Tichy A, Willmann M et al.: Concomitant liposomal
doxorubicin and daily palliative radiotherapy in advanced feline soft
tissue sarcomas. Vet Radiol Ultrasound. 2010; 51: 349–355
[237] Kobayashi T, Hauck ML, Dodge R et al.: Preoperative radiotherapy
for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound.
2002; 43: 473–479
[238] Komori S, Nakamura S, Takahashi K et al.: Use of lomustine to
treat cutaneous nonepitheliotropic lymphoma in a cat. J Am Vet
Med Assoc. 2005; 226: 237–9, 219
[239] Kostorz A: Radiotherapie von Weichteilsarkomen bei Hund und
Katze: Eine retrospektive Studie der Bestrahlungsfälle zur Bestimmung prognostischer Parameter. Diss med vet. Vetsuisse Fakultät
Zürich, 2001
[240] Kraft I, Frese K: Histological studies on canine pigmented moles:
the comparative pathology of the naevus problem. J Comp Pathol.
1976; 86: 143–155
[241] Kramek BA, Spackmann CJA, Hayden DW: Infiltrative lipoma in
three dogs. J Am Vet Med Assoc. 1982; 186: 81–82
[242] Krick EL, Billings AP, Shofer FS et al.: Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and
survival. Vet Comp Oncol. 2009; 7: 130–138
[243] Kryriazidou A, Brown PJ, Lucke VM: Immunohistochemical staining of neoplastic and inflammatory plasma cell lesions in feline tissues. J Comp Pathol. 1989; 100: 337–341
[244] Kube P, Audige L, Kuther K et al.: Distribution, density and heterogeneity of canine mast cells and influence of fixation techniques.
Histochem Cell Biol. 1998; 110: 129–135
[245] Kuntsi-Vaattovaara H, Verstraete FJM, Newsome JT et al.: Resolution of persistent oral papillomatosis in a dog after treatment
with a recombinant canine oral papillomavirus vaccine. Vet Comp
Oncol. 2003; 1: 57–63
[246] Kuntz CA, Dernell WS, Powers BE et al.: Prognostic factors for
surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986–
1996). J Am Vet Med Assoc. 1997; 211: 1147–1151
[247] Kutzner H, Schnieder-Stock R: Perivaskuläre Tumoren. In: Klöppel
G, Kreipe HH, Remmele W (Hrsg.): Pathologie, Band 1, 3. Aufl.;
Springer, Berlin 2009; 556–571
[248] LaDue T, Price GS, Dodge R et al.: Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound. 1998;
39: 57–62
[249] Lamm CG, Stern AW, Smith AJ et al.: Disseminated cutaneous
mast cell tumors with epitheliotropism and systemic mastocytosis
in a domestic cat. J Vet Diagn Invest. 2009; 21: 710–715
[272] Luong RH, Baer KE, Craft DM et al.: Prognostic significance of intratumoral microvessel density in canine soft-tissue sarcomas. Vet
Pathol. 2006; 43: 622–631
[250] Lana SE, Ogilvie GK, Withrow SJ et al.: Feline cutaneous squamous cell carcinoma of the nasal planum and the pinnae: 61 cases.
J Am Anim Hosp Assoc. 1997; 33: 329—332
[273] Ma Y, Longley BJ, Wang X et al.: Clustering of activating mutations in c-KIT’s juxtamembrane coding region in canine mast cell
neoplasms. J Invest Dermatol. 1999; 112: 165–170
[251] Lange CE, Tobler K, Markau T et al.: Sequence and classification of
FdPV2, a papillomavirus isolated from feline Bowenoid in situ carcinomas. Vet Microbiol. 2009; 137: 60–65
[274] Macy DW, Bergman PJ, Powers B: Postvaccinal reactions associated with three rabies and three leukemia virus vaccines in cats. Proc
Vet Cancer Soc. 1994; 14: 90–91
[252] Lansigan F, Foss FM: Current and emerging treatment strategies
for cutaneous T-cell lymphoma. Drugs. 2010; 70: 273–286
[275] Macy DW, Couto CG: Prevention and treatment of injection-site
sarcomas. J Feline Med Surg. 2001; 3: 169–170
[253] Laprie C, Abadie J, Amardeilh MF et al.: MIB-1 immunoreactivity
correlates with biologic behaviour in canine cutaneous melanoma.
Vet Dermatol. 2001; 12: 139–147
[276] Macy DW, Hendrick MJ: The potential role of inflammation in the
development of postvaccinal sarcomas in cats. Vet Clin North Am
[254] Lascelles BD, Parry AT, Stidworthy MF et al.: Squamous cell carcinoma of the nasal planum in 17 dogs. Vet Rec. 2000; 147: 473–476
[277] Macy DW: Canine and feline mast cell tumors: biologic behavior,
diagnosis, therapy. Semin Vet Med Surg. 1986; 1: 72–83
[255] Lawrence J, Forrest L, Adams W et al.: Four-fraction radiation therapy for macroscopic soft tissue sarcomas in 16 dogs. J Am Anim
Hosp Assoc. 2008; 44: 100–108
[278] Macy DW: The potential role and mechanisms of FeLV vaccineinduced neoplasms. Semin Vet Med Surg Small Anim. 1995; 10:
234–237
[256] Le Net JL, Orth G, Sundberg JP et al.: Multiple pigmented cutaneous papules associated with a novel canine papillomavirus in an
immunosuppressed dog. Vet Pathol. 1997; 34: 8–14
[279] Macy DW: Vaccine-induced tumors: a common pathway. Proc 14.
ACVIM Forum San Antonia, Texas, 1996; 631
[257] Lemarie SL, Eddlestone SM: Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. Vet Dermatol. 1997; 8: 41–46
[258] Lenard ZM, Foster SF, Tebb AJ et al.: Lymphangiosarcoma in two
cats. J Feline Med Surg. 2007; 9: 161–167
[259] Lepri E, Ricci G, Leonardi L et al.: Diagnostic and prognostic features of feline cutaneous mast cell tumours: a retrospective analysis
of 40 cases. Vet Res Commun. 2003; 27 (Suppl 1): 707–709
[260] Letard S, Yang Y, Hanssens K et al.: Gain-of-function mutations in
the extracellular domain of KIT are common in canine mast cell
tumors. Mol Cancer Res. 2008; 6: 1137–1145
[261] Leveque NW: Update on vaccine-associated sarcoma. J Am Vet
Med Assoc 1998; 212:1350
[262] Lidbetter DA, Williams FA Jr, Krahwinkel DJ et al.: Radical lateral
body-wall resection for fibrosarcoma with reconstruction using
polypropylene mesh and a caudal superficial epigastric axial pattern
flap: a prospective clinical study of the technique and results in 6
cats. Vet Surg. 2002; 31: 57–64
[263] Liggett AD, Frazier KS, Styer EL: Angiolipomatous tumors in dogs
and a cat. Vet Pathol. 2002; 39: 286–289
[264] Linek M, Mecklenburg L: Multiple cutaneous histiocytomas in a
Flat-coated Retriever. Kleintierprax. 2001; 46: 507–511
[265] Litster AL, Sorenmo KU: Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J
Feline Med Surg. 2006; 8: 177–183
[266] Little LK, Goldschmidt M: Cytologic appearance of a keloidal fibrosarcoma in a dog. Vet Clin Pathol. 2007; 36: 364–367
[267] Loh ZH, Allan GS, Nicoll RG et al.: Ultrasonographic characteristics
of soft tissue tumours in dogs. Aust Vet J. 2009; 87: 323–329
[268] London CA, Malpas PB, Wood-Follis SL et al.: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib
phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the
treatment of dogs with recurrent (either local or distant) mast cell
tumor following surgical excision. Clin Cancer Res. 2009; 15: 3856–
3865
[269] Lopez A, Spracklin D, McConkey S et al.: Cutaneous mucinosis
and mastocytosis in a shar-pei. Can Vet J. 1999; 40: 881–883
[270] Lucke VM: Primary cutaneous plasmacytomas in the dog and cat. J
[271] Luna LD, Higginbotham ML, Henry CJ et al.: Feline non-ocular
melanoma: a retrospective study of 23 cases (1991–1999). J Feline
Med Surg. 2000; 2: 173–181
[280] Madewell BR, Akita GY, Vogel P: Cutaneous mastocytosis and
mucinosis with gross deformity in a shar pei dog. Vet Dermatol.
1992; 3: 171–175
[281] Madewell BR, Conroy JD, Hodgkins EM: Sunlight-skin cancer association in the dog: A report of three cases. J Cutan Pathol. 1981; 8:
434–443
[282] Madewell BR, Griffey SM, McEntee MC et al.: Feline vaccine-associated fibrosarcomas: an ultrastuctural study of 20 cases (1996–
1999). Vet Pathol. 2001; 38: 196–202
[283] Magi GE, Di Pasquale S, Renzoni G: Cutaneous lymphomatoid granulomatosis (angiotropic lymphoma) in a dog: immunophenotyping analysis. Vet Res Commun. 2009; 33 (Suppl 1): 145–147
[284] Maglennon GA, Murphy S, Adams V et al.: Association of Ki67
index with prognosis for intermediate-grade canine cutaneous mast
cell tumours. Vet Comp Oncol. 2008; 6: 268–274
[284a]Magnol JP, Toulemonde N: Histoprognostic du mastocytome
cutané canin. Calidité du grading de Patnaik. Rec Med Vet. 1987;
138: 125–129
[285] Majzoub M, Breuer W, Platz SJ et al.: Histopathologic and immunophenotypic characterization of extramedullary plasmacytomas in
nine cats. Vet Pathol. 2003; 40: 249–253
[286] Marconato L, Bettini G, Giacoboni C et al.: Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med. 2008; 22: 1001–1007
[287] Marconato L, Marchetti V, Francione D et al.: Morphometrical
approach for predicting regional lymph node micrometastatic load
in canine mast cell tumours: preliminary results. Vet Comp Oncol.
2008; 6: 162–170
[288] Marks SL, Song MD, Stannard AA et al.: Clinical evaluation of etretinate for the treatment of canine solar-induced squamous cell carcinoma and preneoplastic lesions. J Am Acad Dermatol. 1992; 27:
11–16
[289] Martano M, Morello E, Buracco P: Feline injection-site sarcoma:
Past, present and future perspectives. Vet J. 2011; 188: 136–141
[290] Martínez CM Dr, Peñafiel-Verdú C, Vilafranca M et al.: Cyclooxygenase-2 expression is related with localization, proliferation, and
overall survival in canine melanocytic neoplasms. Vet Pathol. 2011;
48:1204–1211
[291] Masserdotti C, Bonfanti U, De Lorenzi D et al.: Use of Oil Red O
stain in the cytologic diagnosis of canine liposarcoma. Vet Clin
Pathol. 2006; 35: 37–41
[292] Masserdotti C, Ubbiali FA: Fine needle aspiration cytology of pilomatricoma in three dogs. Vet Clin Pathol. 2002; 31: 22–25
57
58
[293] Matteucci ML, Anyarambhatla G, Rosner G et al.: http://www.
ncbi.nlm.nih.gov/pubmed?term=%22Azuma%20C%22%5BAuthor%5D
Hyperthermia increases accumulation of technetium-99m-labeled
liposomes in feline sarcomas. Clin Cancer Res. 2000; 6: 3748–3755
[294] Mayr B, Furtmueller G, Schleger W et al.: Trisomy 2 in three cases
of canine haemangiopericytoma. Br Vet J. 1992; 148: 113–118
[295] Mayr B, Wallner A, Reifinger M et al.: Reciprocal translocation in
a case of canine basal cell carcinoma. J Small Anim Pract. 1998; 39:
96–97
[296] Mays MB, Bergeron JA: Cutaneous histiocytosis in dogs. J Am Vet
Med Assoc. 1986; 188: 377–381
[297] Mazzei M, Millanta F, Citi S et al.: Haemangiopericytoma: histological spectrum, immunohistochemical characterization and prognosis. Vet Dermatol. 2002; 13: 15–21
[298] McAbee KP, Ludwig LL, Bergman PJ et al.: Feline cutaneous
hemangiosarcoma: a retrospective study of 18 cases (1998–2003).
[299] McCarthy PE, Hedlund CS, Veazy RS et al.:http://www.ncbi.nlm.
nih.gov/pubmed?term=%22Prescott-Mathews%20J%22%5BAuthor%
5D Liposarcoma associated with a glass foreign body in a dog. J Am
Vet Med Assoc. 1996; 209: 612–614
[300] McCaw DL, Miller MA, Bergmann PJ: Vincristine therapy for mast
cell tumors in dogs. J Vet Int Med. 1997; 11: 375–378
[301] McCaw DL, Miller MA, Ogilvie GK et al.: Response of canine mast
cell tumors to treatment with oral prednisone. J Vet Int Med. 1994;
8: 406–408
[302] McCaw DL, Payne JT, Pope ER et al.: Treatment of canine hemangiopericytomas with photodynamic therapy. Lasers Surg Med.
2001; 29: 23–26
[303] McChesney SL, Withrow SJ, Gillette EL et al.: Radiotherapy of
canine soft tissue sarcomas. J Am Vet Med Assoc. 1989; 194: 60–63
[304] McChesney SL, Stephans LC, Lebel J et al.: Infiltrative lipoma in
dogs. Vet Pathol. 1980; 17: 316–322
[305] McEntee MC, Page RL, Mauldin GN et al.: Results of irradiation of
infiltrative lipoma in 13 dogs. Vet Radiol Ultrasound. 2000; 41:
554–556
[306] McEntee MC, Thrall DE: Computed tomographic imaging of infiltrative lipoma in 22 dogs. Vet Radiol Ultrasound. 2001; 42: 221–225
[307] McKnight JA, Mauldin GN, McEntee MC et al.: Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. J Am
Vet Med Assoc. 2000; 217: 205–210
[308] McManus PM: Frequency and severity of mastocytemia in dogs
with and without mast cell tumors: 120 cases (1995–97). J Am Vet
Med Assoc 1999; 215: 355–357
[309] McNiel EA, Prink AL, O’Brien TD: Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol. 2006; 4:
2–8
[310] McSporran KD: Histologic grade predicts recurrence for marginally
excised canine subcutaneous soft tissue sarcomas. Vet Pathol.
2009; 46: 928–933
[311] Meierhenry EF: Metastatic liposarcoma with extensive osteolysis in
the dog. J Am Anim Hosp Assoc. 1974; 10: 478–481
[312] Melzer K, Guscetti F, Rohrer Bley C et al.: Ki67 reactivity in nasal
and periocular squamous cell carcinomas in cats treated with electron beam radiation therapy. J Vet Intern Med. 2006; 20: 676–681
[313] Michels GM, Knapp DW, DeNicola DB et al.: Prognosis following
surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc. 2002; 38: 458–466
[314] Mikaelian I, Gross TL: Keloidal fibromas and fibrosarcomas in the
dog. Vet Pathol. 2002; 39: 149–153
[315] Millanta F, Fratini F, Corazza M et al.: Proliferation activity in oral
and cutaneous canine melanocytic tumours: correlation with histological parameters, location, and clinical behaviour. Res Vet Sci.
2002; 73: 45–51
[316] Miller MA, Ramos JA, Kreeger JM: Cutaneous vascular neoplasia in
15 cats: clinical, morphological, and immunohistochemical studies.
Vet Pathol. 1992; 29: 329–336
[317] Miller WH, Scott DW, Anderson WI: Feline cutaneous melanocytic neoplasms: a retrospective analysis of 43 cases (1979–1993).
Vet Dermatol. 1993; 4: 19–26
[318] Mills JHL, Nielsen SW: Canine hemangiopericytomas – a survey of
200 tumors. J Small Anim Pract. 1967; 8: 599–604
[319] Mischke R, Neuber A: Zytologische Diagnostik in der Veterinärdermatologie. Prakt Tierarzt. 2004; 5: 310–327
[320] Misdorp W: Incomplete surgery, local immunostimulation, and
recurrence of some tumor types in dogs and cats. Vet Q. 1987; 9:
279–286
[321] Molander-McCrary H, Henry CJ, Potter K et al.: Cutaneous mast
cell tumors in cats: 32 cases (1991–1994). J Am Anim Hosp Assoc.
1998; 34: 281–284
[322] Montgomery KW, van der Woerdt A, Aquino SM et al.: Periocular cutaneous mast cell tumors in cats: evaluation of surgical excision (33 cases). Vet Ophthalmol. 2010; 13: 26–30
[323] Moore PF: Systemic histiocytosis of Bernese mountain dogs. Vet
Pathol 1984; 21: 554–563
[324] Moore PF, Affolter VK, Graham PS et al.: Canine epitheliotropic
cutaneous T-cell lymphoma: an investigation of T-cell receptor
immunophenotype, lesion topography and molecular clonality. Vet
Dermatol. 2009; 20: 569–576
[325] Moore PF, Olivry T, Naydan D: Canine cutaneous epitheliotropic
lymphoma (mycosis fungoides) is a proliferative disorder of CD8+ T
cells. Am J Pathol. 1994; 144: 421–429
[326] Moore PF, Schrenzel MD, Affolter VK et al.: Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that
expresses CD1 and specific beta 2-integrin molecules. Am J Pathol.
1996; 148: 1699–1708
[327] Moore RA, Walcott S, White KL et al.: Therapeutic immunisation
with COPV early genes by epithelial DNA delivery. Virology. 2003;
314: 630–635
[328] Morrison WB, Starr RM: Vaccine-associated feline sarcomas. J Am
Vet Med Assoc. 2001; 218: 697–702
[329] Mullins MN, Dernell WS, Withrow SJ et al.: Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998–2004). J Am Vet Med Assoc. 2006;
228: 91–95
[330] Munday JS, Dunowska M, De Grey S: Detection of two different
papillomaviruses within a feline cutaneous squamous cell carcinoma: case report and review of the literature. N Z Vet J. 2009; 57:
248–251
[331] Munday JS, French A, Martin S: Cutaneous malignant melanoma
in an 11-month-old Russian blue cat. N Z Vet J. 2011; 59: 143–146
[332] Munday JS, Gibson I, French AF: Papillomaviral DNA and increased
p16(CDKN2A) protein are frequently present within feline cutaneous squamous cell carcinomas in ultraviolet-protected skin. Vet
Dermatol. 2011; 22: 360–366
[333] Munday JS, Hanlon EM, Howe L et al.: Feline cutaneous viral papilloma associated with human papillomavirus type 9. Vet Pathol.
2007; 44: 924–927
[334] Munday JS, Kiupel M: Papillomavirus-associated cutaneous neoplasia in mammals. Vet Pathol. 2010; 47: 254–264
[335] Munday JS, Kiupel M, French AF et al.: Amplification of papillomaviral DNA sequences from a high proportion of feline cutaneous in
situ and invasive squamous cell carcinomas using a nested polymerase chain reaction. Vet Dermatol. 2008; 19: 259–263
[336] Munday JS, Kiupel M, French AF et al.: Detection of papillomaviral
sequences in feline Bowenoid in situ carcinoma using consensus primers. Vet Dermatol. 2007; 18: 241–245
59
[337] Munday JS, Knight CG: Amplification of feline sarcoid-associated
papillomavirus DNA sequences from bovine skin. Vet Dermatol.
2010; 21: 341–344
[356] Ogilvie GK, Sundberg JP, OʼBanion MK et al.: Papillary squamous
cell carcinoma in three young dogs. J Am Vet Med Assoc. 1988;
192: 933–936
[338] Munday JS, Knight CG, Howe L: The same papillomavirus is present in feline sarcoids from North America and New Zealand but
not in any non-sarcoid feline samples. J Vet Diagn Invest. 2010; 22:
97–100
[357] Ohmori K, Kawarai S, Yasuda N et al.: Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
[340] Murphy KM, Olivry T: Comparison of T-lymphocyte proliferation in
canine epitheliotropic lymphosarcoma and benign lymphocytic dermatoses. Vet Dermatol 2000; 11: 99–105
[341] Murphy S, Sparkes AH, Blunden AS et al.: Effects of stage and
number of tumours on prognosis of dogs with cutaneous mast cell
tumours. Vet Rec. 2006; 158: 287–291
[342] Murphy S, Sparkes AH, Smith KC et al.: Relationships between the
histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec. 2004; 154:
743–746
[343] Nagata M, Nanko H, Moriyama A et al.: Pigmented plaques associated with papillomavirus infection in dogs: is this epidermodysplasia verruciformis? Vet Dermatol. 1995; 6: 179–186
[344] Nagata M: Canine papillomaviruses. In: Bonagura JD (Hrsg.): Kirk’s
current veterinary therapy XIII, WB Saunders, Philadelphia, 2000;
568–571
[345] Nambiar PR, Jackson ML, Ellis JA: Immunohistochemical detection
of tumor suppressor gene p53 protein in feline injection site-associated sarcomas. Vet Pathol. 2001; 38: 236–238
[346] Narama I, Ozaki K, Maeda H et al.: Cutaneous papilloma with viral
replication in an old dog. J Vet Med Sci. 1992; 54: 387–389
[358] OʼKeefe DA, Couto CG, Burke-Schwartz C et al.: Systemic mastocytosis in 16 dogs. J Vet Int Med. 1987; 1: 75–80
[359] Olivry T, Moore PF, Naydan DK et al.: Investigation of epidermotropism in canine mycosis fungoides: expression of intercellular
adhesion molecule-1 (ICAM-1) and beta-2 integrins. Arch Dermatol
Res. 1995; 287: 186–192
[360] OʼNeill SH, Newkirk KM, Anis EA et al.: Detection of human papillomavirus DNA in feline premalignant and invasive squamous cell
carcinoma. Vet Dermatol. 2011; 22: 68–74
[361] Orenberg EK, Luck EE, Brown DM et al.: Implant delivery system:
intralesional delivery of chemotherapy for treatment of spontanous
skin tumors in veterinary patients. Clin Dermatol. 1991; 9: 561–568
[362] Ortmann U.: Die Hauttumoren der Katze unter besonderer Berücksichtigung der Fibrosarkome. Diss med vet., München 1986
[363] Ozaki K, Yamagami T, Nomura K et al.: Prognostic significance of
surgical margin, Ki-67 and cyclin D1 protein expression in grade II
canine cutaneous mast cell tumor. J Vet Med Sci. 2007; 69: 1117–
1121
[364] Passantino L, Passantino G, Cianciotta A et al.: Expression of
proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors. Immunopharmacol
Immunotoxicol. 2008; 30: 609–621
[365] Patnaik AK, Ehler WN, MacEwen EG: Canine cutaneous mast cell
tumor: Morphologic grading and survival time in 83 dogs. Vet
Pathol. 1984; 21: 469–474
[347] Narama I, Kobayashi Y, Yamagami T, et al. : Pigmented cutaneous
papillomatosis (pigmented epidermal nevus) in three pug dogs; histopathology, electron microscopy and analysis of viral DNA by the
polymerase chain reaction. J Comp Pathol. 2005; 132: 132–138
[366] Patnaik AK, Liu SK: Angiosarcoma in cats. J Small Anim Pract.
1977; 18: 191–198
[348] Nespeca G, Grest P, Rosenkrantz WS et al.: Detection of novel
papillomaviruslike sequences in paraffin-embedded specimens of
invasive and in situ squamous cell carcinomas from cats. Am J Vet
Res. 2006; 67: 2036–2041
[368] Pavletic MM: Atlas of small animal wound management and
reconstructive surgery. 3. Auflage, John Wiley & Sons, 2010
[349] Newman SJ, Mrkonjich L, Walker KK et al.: Canine subcutaneous
mast cell tumour: diagnosis and prognosis. J Comp Pathol. 2007;
136: 231–239
[350] Nicholls PK, Klaunberg BA, Moore RA: Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity,
virus characterization, and experimental infection. Virology. 1999;
265: 365–374
[351] Nicholls PK, Moore PF, Anderson DM et al.: Regression of canine
oral papillomas is associated with infiltration of CD4+ and CD8+
lymphocytes. Virology. 2001; 283: 31–39
[352] Nikula KJ, Benjamin SA, Angleton GM et al.: Ultraviolet radiation,
solar dermatosis, and cutaneous neoplasia in Beagle dogs. Radiation
Res. 1992; 129: 11–18
[353] Northrup NC, Howerth EW, Harmon BG et al.: Variation among
pathologists in the histologic grading of canine cutaneous mast cell
tumors with uniform use of a single grading reference. J Vet Diagn
Invest. 2005; 17: 561–564
[354] Nyman HT, Kristensen AT, Lee MH et al.: Characterization of
canine superficial tumors using gray-scale B mode, color flow mapping, and spectral doppler ultrasonography–a multivariate study.
[355] Ogilvie GK, Macy DW, Ford RB: Controversies in oncology: Should
we give cancer-inducing vaccines? Proc. 14. ACVIM Forum, San
Antonio, Texas, 1996; 644–645
[367] Patnaik AK, Mooney S: Feline melanoma: a comparative study of
ocular, oral and dermal neoplasms. Vet Pathol. 1988; 25: 105–112
[369] Pérez J, Bautista MJ, Rollón E et al.: Immunohistochemical characterization of hemangiopericytomas and other spindle cell tumors in
the dog. Vet Pathol. 1996; 33: 391–397
[370] Pérez J, Day MJ, Martín MP et al.: Immunohistochemical study of
the inflammatory infiltrate associated with feline cutaneous squamous cell carcinomas and precancerous lesions (actinic keratosis).
[371] Pestili de Almeida EM, Piché C, Sirois J et al.: Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in
dogs. J Histochem Cytochem. 2001; 49: 867–875
[372] Peters-Kennedy J, Scott DW, Miller WH Jr. et al.: Apparent clinical
resolution of pinnal actinic keratoses and squamous cell carcinoma
in a cat using topical imiquimod 5% cream. J Feline Med Surg. 2008;
10: 593–599
[373] Pires I, Garcia A, Prada J et al.: COX-1 and COX-2 expression in
canine cutaneous, oral and ocular melanocytic tumours. J Comp
Pathol. 2010; 143: 142–149
[374] Pires I, Queiroga FL, Alves A et al.: Decrease of E-cadherin expression in canine cutaneous histiocytoma appears to be related to its
spontaneous regression. Anticancer Res. 2009; 29: 2713–2717
[375] Platz SJ, Breuer W, Geisel O et al.: Identification of λ light chain
amyloid in eight canine and two feline extramedullary plasmacytomas. J Comp Pathol. 1997; 116: 45–54
[376] Platz SJ, Breuer W, Pfleghaar S et al.: Prognostic value of histopathological grading in canine extramedullary plasmacytomas. Vet
Pathol. 1999; 36: 23–27
[339] Munday JS, OʼConnor KI, Smits B: Development of multiple pigmented viral plaques and squamous cell carcinomas in a dog infected by a novel papillomavirus. Vet Dermatol. 2011; 22: 104–110
60
[377] Plavec T, Kessler M, Kandel B et al.: Palliative radiotherapy as
treatment for non-resectable soft tissue sarcomas in the dog – a
report of 15 cases. Vet Comp Oncol. 2006; 4: 98–103
[398] Riva F, Brizzola S, Stefanello D et al.: A study of mutations in the
c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest. 2005;
17: 385–388
[378] Poirier VJ, Adams WM, Forrest LJ et al.: Radiation therapy for
incompletely excised grade II canine mast cell tumors. J Am Anim
Hosp Assoc. 2006; 42: 430–434
[399] Rodríguez F, Herráez P, Rodríguez E et al.: Metastatic pilomatrixoma associated with neurological signs in a dog. Vet Rec. 1995;
137: 247–248
[379] Poirier VJ, Thamm DH, Kurzman ID et al.: Liposome-encapsulated
doxorubicin (Doxil) and doxorubicin in the treatment of vaccineassociated sarcoma in cats. J Vet Intern Med. 2002; 16: 726–731
[400] Rodriguez-Cariño C, Fondevila D, Segalés J et al.: Expression of
KIT receptor in feline cutaneous mast cell tumors. Vet Pathol. 2009;
46: 878–883
[380] Postorino NC, Berg RJ, Powers BE et al.: Prognostic variables for
canine hemangiopericytoma: 50 cases (1979–1984). J Am Anim
Hosp Assoc. 1988; 24: 501–509
[401] Roels S, Tilmant K, Ducatelle R: P53 expression and apoptosis in
melanomas of dogs and cats. Res Vet Sci. 2001; 70: 19–25
[381] Preziosi R, Morini M, Sarli G: Expression of the KIT protein
(CD117) in primary cutaneous mast cell tumors of the dog. J Vet
Diagn Invest. 2004; 16: 554–561
[382] Preziosi R, Sarli G, Paltrinieri M: Multivariate survival analysis of
histological parameters and clinical presentation in canine cutaneous mast cell tumours. Vet Res Commun. 2007; 31: 287–296
[383] Rakich PM, Latimer KS, Weiss R et al.: Mucocutaneous plasmacytomas in dogs: 75 cases (1980–1987). J Am Vet Med Assoc. 1989;
194: 803–810
[384] Ramírez GA, Altimira J, García B et al.: Chondro-osteoblastic
metaplasia in canine benign cutaneous lipomas. J Comp Pathol.
2010; 142: 89–93
[385] Ramos-Vara JA, Miller MA, Johnson GC et al.: Melan A and S100
protein immunohistochemistry in feline melanomas: 48 cases. Vet
Pathol. 2002; 39: 127–132
[386] Ramos-Vara JA, Miller MA, Valli VE: Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/
IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.
Vet Pathol. 2007; 44: 875–884
[387] Ramos-Vara JA, Miller MA: Immunohistochemical expression of
E-cadherin does not distinguish canine cutaneous histiocytoma
from other canine round cell tumors. Vet Pathol. 2011; 48: 758–763
[388] Ranst M van, Smith EK, Herron A et al.: Identification of canine
papillomavirus in the skin of an immunosuppressed dog. Europ J
Cancer. 1991; 27: S92
[389] Rassnick KM, Bailey DB, Flory AB et al.: Efficacy of vinblastine for
treatment of canine mast cell tumors. J Vet Intern Med. 2008; 22:
1390–1396
[390] Rassnick KM, Moore AS, Williams LE et al.: Treatment of canine
mast cell tumors with CCNU (lomustine). J Vet Intern Med. 1999;
13: 601–605
[391] Rassnick KM, Ruslander DM, Cotter SM et al.: Use of carboplatin
for treatment of dogs with malignant melanoma: 27 cases (1989–
2000). J Am Vet Med Assoc. 2001; 218: 1444–1448
[392] Rassnick KM, Williams LE, Kristal O et al.: Lomustine for treatment of mast cell tumors in cats: 38 cases (1999–2005). J Am Vet
Med Assoc. 2008; 232: 1200–1205
[393] Rassnick KM: Medical management of soft tissue sarcomas. Vet
[394] Rees CA, Goldschmidt MH: Cutaneous horn and squamous cell
carcinoma in situ (Bowenʼs disease) in a cat. J Am Anim Hosp Assoc.
1998; 34: 485–486
[402] Roels S, Tilmant K, Ducatelle R: PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic
tumours in cats and dogs. J Comp Pathol. 1999; 121: 13–24
[403] Rogers KS, Helman RG, Walker MA: Squamous cell carcinoma of
the canine nasal planum: eight cases (1988–1994). J Am Anim
Hosp Assoc. 1995; 31: 373–378
[404] Romanelli G, Marconato L, Olivero D et al.: Analysis of prognostic
factors associated with injection-site sarcomas in cats: 57 cases
(2001–2007). J Am Vet Med Assoc. 2008; 232: 1193–1199
[405] Romansik EM, Reilly CM, Kass PH et al.: Mitotic index is predictive
for survival for canine cutaneous mast cell tumors. Vet Pathol.
2007; 44: 335–341
[406] Rowland PH, Valentine BA, Stebbins KE et al.: Cutaneous plasmacytomas with amyloid in six dogs. Vet Pathol. 1991; 28: 125–130
[407] Rudd RG, Veatch JK, Whitehair JG et al.: Lymphangiosarcoma in
dogs. J Am Anim Hosp Assoc. 1989; 25: 695–698
[408] Rudmann DG, Van Alstine WG, Doddy F et al.: Pulmonary and
mediastinal metastases of a vaccination-site sarcoma in a cat. Vet
Pathol. 1996; 33: 466–469
[409] Rudolph R, Gray AP, Leipold HW: Intracutaneous cornifying epithelioma (“keratoakanthoma”) of dogs and keratoakanthoma of
man. Cornell Vet. 1977; 67: 254–264
[410] Rudolph R: Spontanes Keratoakanthom – Tiermodell für den Tumor
des Menschen? Dtsch Tierärztl Wschr. 1983; 90: 349–352
[411] Sabattini S, Bettini G: An immunohistochemical analysis of canine
haemangioma and haemangiosarcoma. J Comp Pathol. 2009; 140:
158–168
[412] Sabattini S, Bettini G: Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Vet
Pathol. 2010; 47: 643–653
[413] Sabattini S, Marconato L, Zoff A et al.: Epidermal growth factor
receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. J Feline Med Surg. 2010; 12: 760–
768
[414] Sagartz JE, Lairmore MD, Haines D et al.: Lymphangiosarcoma in
a young dog. Vet Pathol. 1996; 33: 353–356
[415] Sandler I, Teeger M, Best S: Metastatic vaccine associated fibrosarcoma in a 10–year-old cat. Can Vet J. 1997; 38: 374
[416] Santoro D, Marsella R, Hernandez J: Investigation on the association between atopic dermatitis and the development of mycosis
2007; 18: 101–106
[395] Reimann N, Nolte I, Bonk U et al.: Cytogenetic investigation of
canine lipomas. Cancer Genet Cytogenet. 1999; 111: 172–174
[417] Sato AF, Solano M: Ultrasonographic findings in abdominal mast
cell disease: a retrospective study of 19 patients. Vet Radiol Ultrasound. 2004; 45: 51–57
[396] Riedel K, Müller K, Schoon H-A: Kanine und feline Schweißdrüsentumoren – stellen Myoepithelzellen den Ursprung von Mischtumoren dar? Proc. 54. JT DVG Fachgruppe Pathologie. Fulda. 2011, 39
[418] Scase TJ, Edwards D, Miller J et al. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet
Int Med. 2006; 20: 151–158
[397] Risbon RE, de Lorimier LP, Skorupski K et al.: Response of canine
cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999–2004). J Vet Intern Med. 2006;
20: 1389–1397
[419] Scavelli TD, Patnaik AK, Mehlhaff CJ et al.: Hemangiosarcoma in
the cat: retrospective evaluation of 31 surgical cases. J Am Vet Med
Assoc. 1985; 187: 817–819
[420] Schmidt JM, North SM, Freeman KP et al.: Canine paediatric
oncology: retrospective assessment of 9522 tumours in dogs up to
12 months (1993–2008). Vet Comp Oncol. 2010; 8: 283–292
61
[422] Schmidt K, Bertani C, Martano M et al.: Reconstruction of the
lower eyelid by third eyelid lateral advancement and local transposition cutaneous flap after “en bloc” resection of squamous cell carcinoma in 5 cats. Vet Surg. 2005; 34: 78–82
[423] Schulman FY, Krafft AE, Janczewski T: Feline cutaneous fibropapillomas: clinicopathologic findings and association with papillomavirus infection. Vet Pathol. 2001; 38: 291–296
[442] Shiga A, Shirota K, Une Y et al.: Lymphangiosarcoma in a dog. J
Vet Med Sci. 1994; 56: 1199–1202
[443] Shimada A, Shinya K, Awakura T et al.: Cutaneous papillomatosis
associated with papillomavirus infection in a dog. J Comp Pathol.
1993; 108: 103–107
[444] Shimazaki T, Nagata M, Goto-Koshino Y et al.: A case of canine
lymphomatoid granulomatosis with cutaneous lesions. J Vet Med
Sci. 2010; 72: 1067–1069
[445] Simko E, Wilcock BP, Yager JA: A retrospective study of 44 canine
apocrine sweat gland adenocarcinomas. Can Vet J. 2003; 44: 38–42
[424] Schultheiss PC: A retrospective study of visceral and nonvisceral
hemangiosarcoma and hemangiomas in domestic animals. J Vet
Diagn Invest. 2004; 16: 522–526
[446] Simoes JP, Schoning P, Butine M: Prognosis of canine mast cell
tumors: a comparison of three methods. Vet Pathol. 1994; 31:
637—647
[425] Schultheiss PC: Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. J Vet Diagn
Invest. 2006; 18: 422–425
[447] Simoes JP, Schoning P: Canine mast cell tumors: a comparison of
staining techniques. J Vet Diagn Invest. 1994; 6: 458–465
[426] Schultze AE, Frank LA, Hahn KA: Repeated physical and cytologic
characterizations of subcutaneous postvaccinal reactions in cats.
Am J Vet Res. 1997; 58: 719–724
[427] Schwartz W, Liska W: Metastatic basal cell epithelioma in a cat.
Southwestern Vet. 1982; 35: 14
[428] Schwegler K, Walter JH, Rudolph R: Epithelial neoplasms of the
skin, the cutaneous mucosa and the transitional epithelium in dogs:
an immunolocalization study for papillomavirus antigen. Zbl Vet
Med A. 1997; 44: 115–123
[429] Scott DW, Anderson WI: Canine hair follicle neoplasms: a retrospective analysis of 80 cases (1986–1987). Vet Dermatol. 1991; 2:
143–150
[430] Scott DW, Anderson WI: Canine sebaceous gland tumors: a retrospective analysis of 172 cases. Canine Pract. 1990; 15: 19–27
[448] Simon D, Ruslander DM, Rassnick KM et al.: Orthovoltage radiation and weekly low dose of doxorubicin for the treatment of
incompletely excised soft-tissue sarcomas in 39 dogs. Vet Rec.
2007; 160: 321–326
[449] Simpson AM, Ludwig LL, Newman SJ et al.: Evaluation of surgical
margins required for complete excision of cutaneous mast cell
[450] Smith AJ, Njaa BL, Lamm CG: Immunohistochemical expression of
c-KIT protein in feline soft tissue fibrosarcomas. Vet Pathol. 2009;
46: 934–939
[451] Smith SH, Goldschmidt MH, McManus PM: A comparative review
of melanocytic neoplasms. Vet Pathol. 2002; 39: 651–678
[452] Son YS, Chae CH: Histopathology of canine sweat gland neoplasms.
Korean J Vet Res. 1995; 35: 353–360
[431] Scott DW, Anderson WI: Hair follicle neoplasms in three cats.
Feline Pract. 1991; 19: 14–16
[453] Spangler WL, Kass PH: The histologic and epidemiologic bases for
prognostic considerations in canine melanocytic neoplasia. Vet
Pathol. 2006; 43: 136–149
[432] Scott FW, Geissinger CM: Duration of immunity in cats vaccinated
with an inactivated feline panleukopenia, herpesvirus, and calicivirus vaccine. Feline Pract. 1997; 25: 12–19
[454] Spugnini EP, Vincenzi B, Baldi F et al.: Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell
tumors. Anticancer Res. 2006; 26: 4585–4589
[433] Scott FW, Geissinger CM: Long-term immunity in cats vaccinated
with an inactivated trivalent vaccine. Am J Vet Res. 1999; 60: 652–
658
[455] Spugnini EP, Vincenzi B, Citro G et al.: Electrochemotherapy for
the treatment of squamous cell carcinoma in cats: a preliminary
report. Vet J. 2009; 179: 117–120
[434] Scott, DW, Anderson WI: Feline sebaceous gland tumors: a retrospective analysis of nine cases. Feline Pract. 1991; 19: 16–21
[456] Srebrenik N, Appleby RC: Breed prevalence and sites of hemangioma and hemangiosarcoma in dogs. Vet Rec. 1991; 129: 408–
409
[435] Séguin B, Besancon MF, McCallan JL et al.: Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast
cell tumors: 28 dogs (1994–2002). J Vet Intern Med. 2006; 20:
933–940
[436] Séguin B, Leibman NF, Bregazzi VS et al.: Clinical outcome of
dogs with grade-II mast cell tumors treated with surgery alone: 55
[437] Selting KA, Powers BE, Thompson LJ et al.: Outcome of dogs with
high-grade soft tissue sarcomas treated with and without adjuvant
doxorubicin chemotherapy: 39 cases (1996–2004). J Am Vet Med
Assoc. 2005; 227: 1442–1448
[438] Sfiligoi G, Rassnick KM, Scarlett JM et al.: Outcome of dogs with
mast cell tumors in the inguinal or perineal region versus other
cutaneous locations: 124 cases (1990–2001). J Am Vet Med Assoc.
2005; 226: 1368–1374
[439] Shapiro W, Kitchell BE, Fossum TW et al.: Cisplatin for treatment
Med Assoc. 1988; 193: 1530—1533
[440] Sharif M, Reinacher M: Clear cell trichoblastomas in two dogs. J
[441] Shaw SC, Kent MS, Gordon IK et al.: Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990–2006). J
Am Vet Med Assoc. 2009; 234: 376–380
[457] Stampehl M, Laik C: Diagnostik und palliative Therapie einer Mycosis fungoides bei einer Golden-Retriever-Hündin. Kleintierprax.
2010; 55: 196–203
[458] Stanclift RM, Gilson SD: Evaluation of neoadjuvant prednisone
administration and surgical excision in treatment of cutaneous
mast cell tumors in dogs. J Am Vet Med Assoc. 2008; 232: 53–62
[459] Stannard AA, Pulley LT: Intracutaneous cornifying epithelioma
(keratoakanthoma) in the dog: a retrospective study of 25 cases. J
Am Vet Med Assoc. 1975; 167: 385—388
[460] Starr RM: Vaccine-Associated Feline Sarcoma Task Force: a new
model for problem solving in veterinary medicine. J Am Vet Med
Assoc. 1998; 213: 1428–1429
[461] Stefanello D, Morello E, Roccabianca P et al.: Marginal excision of
low-grade spindle cell sarcoma of canine extremities: 35 dogs
(1996–2006). Vet Surg. 2008; 37: 461–465
[462] Steger-Lieb A, Kostorz A, Hauser B et al.: Einsatz der Strahlentherapie bei vakzine-assoziierten Sarkomen der Katze. Erfahrungen aus
18 Fällen (1994–1999). Tierärztl Prax. 2002; 30: 35–40
[463] Stell AJ, Dobson JM, Langmack K: Photodynamic therapy of feline
superficial squamous cell carcinoma using topical 5–aminolaevulinic acid. J Small Anim Pract. 2001; 42:164–169
[464] Stiglmair-Herb MT: Hauttumoren bei Katzen – eine retrospektive
Studie. Tierärztl. Umschau. 1987; 42: 681–686
[421] Schmidt JM, North SM, Freeman KP et al.: Feline paediatric oncology: retrospective assessment of 233 tumours from cats up to one
year (1993 to 2008). J Small Anim Pract. 2010; 51: 306–311
62
[465] Stockhaus C, Schoon HA, Grevel V et al.: Diagnostische Aussagekraft der Zytologie für den Nachweis von Weichteilsarkomen bei
Hund und Katze. Tierärztl Prax. 2003; 31(K): 136–198
[466] Stockhaus C, Teske E, Rudolph R et al.: Assessment of cytological
criteria for diagnosing basal cell tumours in the dog and cat. J Small
Anim Pract. 2001; 42: 582–586
[467] Stokking LB, Ehrhart EJ, Lichtensteiger CA: Pigmented epidermal
plaques in three dogs. J Am Anim Hosp Assoc. 2004; 40: 411–417
[468] Strafuss AC, Bozarth AJ: Liposarcoma in dogs. J Am Anim Hosp
Assoc. 1973; 9: 183–187
[469] Strafuss AC: Sebaceous gland adenomas in dogs. J Am Vet Med
Assoc. 1976; 169: 640–642
[470] Strafuss AC: Sebaceous gland carcinoma in dogs. J Am Vet Med
Assoc. 1976; 169: 325–326
[471] Sugiyama A, Takeuchi T, Morita T et al.: Lymphangiosarcoma in a
cat. J Comp Pathol. 2007; 137: 174–178
[472] Sulaimon SS, Kitchell BE: The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med. 2003; 17: 760–772
[473] Sundberg JP, Van Ranst M, Montali R et al.: Feline Papillomas and
Papillomaviruses. Vet Pathol. 2000; 37: 1–10
[474] Takahashi T, Kadosawa T, Nagase M et al.: Inhibitory effects of
glucocorticoids on proliferation of canine mast cell tumor. J Vet
Med Sci. 1997; 59: 995—1001
[475] Taylor DON, Dorn CR, Luis OH: Morphologic and biologic characteristics of the canine cutaneous histiocytoma. Cancer Res. 1969;
29: 83–92
[476] Taylor F, Gear R, Hoather T et al.: Chlorambucil and prednisolone
chemotherapy for dogs with inoperable mast cell tumours: 21
cases. J Small Anim Pract. 2009; 50: 284–289
[477] Thamm DH, Mauldin EA, Vail DM: Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992–1997). J Vet
Intern Med. 1999; 13: 491–497
[478] Thamm DH, Turek MM, Vail DM: Outcome and prognostic factors
following adjuvant prednisone/vinblastine chemotherapy for highrisk canine mast cell tumour: 61 cases. J Vet Med Sci. 2006; 68:
581–587
[479] Théon AP, Madewell BR, Shearn V et al.: Prognostic factors associated with radiotherapy of squamous cell carcinoma of the nasal
plane in cats. J Am Vet Med Assoc. 1995; 206: 991–996
[487] Tokita H, Konishi S: Studies on canine oral papillomatosis. II. Oncogenicity of canine oral papilloma virus to various tissues of dog with
special reference to eye tumor. Nippon Juigaku Zasshi. (Jap J Vet Sci)
1975; 37: 109–120
[488] Toma S, Noli C: Isotretinoin in the treatment of multiple benign
pilomatrixomas in a mixed-breed dog. Vet Dermatol. 2005; 16:
346–350
[489] Trigo FJ, Hargis AM: Canine cutaneous plasmacytoma with regional lymph node metastasis. Vet Med Small Anim Clin. 1983; 78:
1749—1751
[490] Trojani M, Contesso G, Coindre JM et al.: Soft-tissue sarcomas of
adults: study of pathological prognostic variables and definition of a
histopathological grading system. Int J Cancer. 1984; 33: 37–42
[491] Trumel C, Bourgès-Abella N, Touron C et al.: Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment:
a retrospective study in fourteen dogs with mast cell tumours. J Vet
Med A Physiol Pathol Clin Med. 2005; 52: 275–279
[492] Turrel JM, Farrelly J, Page RL, e t al.: Evaluation of strontium 90
irradiation in treatment of cutaneous mast cell tumors in cats: 35
[493] Turrel JM, Kitchell BE, Miller LM et al.: Prognostic factors for radiation treatment of mast cell tumors in 85 dogs. J Am Vet Med Assoc.
1988; 193: 936–940
[494] Tzannes S, Ibarrola P, Batchelor DJ et al.: Use of recombinant
human interferon alpha-2a in the management of a dog with epitheliotropic lymphoma. J Am Anim Hosp Assoc. 2008; 44: 276–282
[495] Vala H, Esteves F: A case of angiokeratoma. Vet Pathol. 2001; 38:
324–325
[496] van der Linde-Sipman JS, de Wit MM, van Garderen E et al.:
Cutaneous malignant melanomas in 57 cats: identification of (amelanotic) signet-ring and balloon cell types and verification of their
origin by immunohistochemistry, electron microscopy, and in situ
hybridization. Vet Pathol. 1997; 34: 31–38
[497] Vascellari M, Mutinelli F, Cossettini R et al.: Liposarcoma at the
site of an implanted microchip in a dog. Vet J. 2004 Sep; 168: 188–
190
[498] Vickery KR, Wilson H, Vail DM et al.: Dose-escalating vinblastine
for the treatment of canine mast cell tumour. Vet Comp Oncol.
2008; 6: 111–119
[499] Volta A, Bonazzi M, Gnudi G et al.: Ultrasonographic features of
canine lipomas. Vet Radiol Ultrasound. 2006; 47: 589–591
[480] Thiel W: Mastzelltumoren beim Hund – Auswertung pathologischhistologischer Untersuchungsbefunde der Jahre 1980–1986 mit
Hinweis auf die TNM-Klassifizierung von Tumoren bei Haustieren.
[500] Von Buest BR, Suter MM, Summers BA: Factor VIII-related antigen
in canine endothelial neoplasms. Vet Pathol. 1988 ; 25: 251–255
[481] Thomas R, Valli VE, Ellis P et al.: Microarray-based cytogenetic
profiling reveals recurrent and subtype-associated genomic copy
number aberrations in feline sarcomas. Chromosome Res. 2009;
17: 987–1000
[502] Walter J: A cytokeratin profile of canine epithelial skin tumours. J
Comp Pathol. 2000; 122: 278–287
[482] Thompson JJ, Pearl DL, Yager JA et al.: Canine subcutaneous mast
cell tumor: Characterization and prognostic indices. Vet Pathol.
2011; 48: 156–168
[483] Thomson MJ, Withrow SJ, Dernell WS et al.: Intermuscular lipomas of the thigh region in dogs: 11 cases. J Am Anim Hosp Assoc.
1999; 35: 165–167
[484] Thompson JJ, Yager JA, Best SJ et al.: Canine subcutaneous mast
cell tumors: cellular proliferation and KIT expression as prognostic
indices. Vet Pathol. 2011; 48: 169–181. http://www.ncbi.nlm.nih.
gov/pubmed?term=%22Coomber%20BL%22%5BAuthor%5D
[485] Thrall MA, Macy DW, Snyder SP et al.: Cutaneous lymphosarcoma
and leukemia in a dog resembling Sézary syndrome in man. Vet
Pathol. 1984; 21: 182–186
[486] Tinsley PE, Taylor DO: Immunotherapy for multicentric malignant
mastocytoma in a dog. Mod Vet Pract. 1987; 68: 225–228
[501] Walsh KM, Abbott DP: Lymphangiosarcoma in two cats. J Comp
Pathol. 1984; 94: 611
[503] Ward H, Fox L, Calderwood-Mays MB et al.: Cutaneous hemangiosarcoma in 25 dogs: a retrospective study. J Vet Intern Med.
1994; 8: 345–348
[504] Warren AL, Summers BA: Epithelioid variant of hemangioma and
hemangiosarcoma in the dog, horse, and cow. Vet Pathol. 2007;
44: 15–24
[505] Watach AM, Hanson LE, Meyer RC: Canine papilloma. The structural characterization of oral papilloma virus. J Natl Cancer Inst. 1969;
43: 453–458
[506] Webb JA, Boston SE, Armstrong J et al.: Lymphangiosarcoma
associated with primary lymphedema in a Bouvier des Flandres. J
Vet Intern Med. 2004; 18: 122–124
[507] Webster JD, Kiupel M, Yuzbasiyan-Gurkan V: Evaluation of the
kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC
Cancer. 2006; 6: 85
[508] Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB et al.: The role of
c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell
tumors. Neoplasia. 2006; 8: 104–111
[509] Webster JD, Yuzbasiyan-Gurkan V, Miller RA,et al.: Cellular proliferation in canine cutaneous mast cell tumors: associations with
[3]
Andrade FH, Figueiroa FC, Bersano PR et al.: Malignant mammary
tumor in female dogs: environmental contaminants. Diagn Pathol.
2010; 5: 45
[510] Webster JD, Yuzbasiyan-Gurkan V, Thamm DH et al.: Evaluation
[4]
Antuofermo E, Miller MA, Pirino S et al.: Spontaneous mammary
intraepithelial lesions in dogs–a model of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2247–2256
[511] Wedemeyer J, Tsai M, Galli SJ: Roles of mast cells and basophils in
innate and acquired immunity. Curr Opin Immunol. 2000; 12: 624–
631
[5]
Arnicke U: Mammatumoren bei der Hündin: Immunhistochemischer Nachweis von Metastasen und Mikrometastasen im Axillarlymphknoten und im Knochen. Diss med vet. Berlin; 1998
[512] Weisse C, Shofer FS, Sorenmo K: Recurrence rates and sites for
grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc. 2002; 38: 71–73
[6]
Bae BK, Kim CW, Choi US et al.: Hypercalcemia and high parathyroid hormone-related peptide concentration in a dog with a complex mammary carcinoma. Vet Clin Pathol. 2007; 36: 376–378
[513] Welle MM, Bley CR, Howard J et al.: Canine mast cell tumours: a
review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol. 2008; 19: 321–339
[7]
Baumann D, Hauser B, Hubler M et al.: Signs of metastatic disease
on thoracic radiographs of dogs suffering from mammary gland
tumours: a retrospective study (1990–1998). Schweiz Arch Tierheilkd. 2004; 146: 431–435
[8]
Bearss JJ, Schulman FY, Carter D: Histologic, immunohistochemical and clinical features of 27 mammary tumors in 18 male dogs.
Vet Pathol. 2012; 49: 602–607
[9]
Bender AP, Dorn RC, Schneider R: An epidemiological study of
canine multiple primary neoplasia involving the female and male
reproductive systems. Prev Vet Med.1984; 2: 715–731
[10]
Benjamin SA, Lee AC, Saunders WJ: Classification and behavior of
canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol. 1999; 36: 423–436
[11]
Bostock DE: The prognosis following the surgical excision of canine
mammary neoplasms. Eur J Cancer. 1975; 11: 389–396
[12]
Brodey RS, Fidler IJ, Howson AE: The relationship of estrous irregularity, pseudopregnancy, and pregnancy to the development of
canine mammary neoplasms. J Am Vet Med Assoc. 1966; 149:
1047–1049
[13]
Brodey RS, Goldschmidt MH, Roszel JR: Canine mammary gland
neoplasms. J Am Anim Hosp Assoc. 1983; 19: 61–90
[14]
Brown DC, Purushotham AD, Birnie GD et al.: Detection of intraoperative tumor cell dissemination in patients with breast cancer by
use of reverse transcription and polymerase chain reaction. Surgery.
1995; 117: 95–101
[522] Woldemeskel M, Rajeev S: Mast cells in canine cutaneous hemangioma, hemangiosarcoma and mammary tumors. Vet Res Commun. 2010; 34: 153–160
[15]
Callan MB, Giger U, Catalfamo JL: Effect of desmopressin on von
Willebrand factor multimers in Doberman Pinschers with type 1
von Willebrand disease. Am J Vet Res. 2005; 66: 861–867
[523] Wood C, Almes K, Bagladi-Swanson M et al.: Sézary syndrome in
a cat. J Am Anim Hosp Assoc. 2008; 44: 144–148
[16]
[524] Yager JA, Wilcock BP: The behavior of epidermotropic lymphoma
in twenty five dogs. Can Vet J. 1989; 30: 754–756
Cameron AM, Faulkin LJ Jr: Hyperplastic and inflammatory nodules
in the canine mammary gland. J Natl Cancer Inst. 1971; 47: 1277–
1287
[17]
[525] Zaugg N, Nespeca G, Hauser B et al.: Detection of novel papillomaviruses in canine mucosal, cutaneous and in situ squamous cell
carcinomas. Vet Dermatol. 2005; 16: 290–298
Casey HW, Giles RC, Kwapien RP: Mammary neoplasia in animals:
pathologic aspects and the effects of contraceptive steroids. Recent
Results Cancer Res. 1979; 66: 129–160
[18]
Cassali GD, Gobbi H, Malm C et al.: Evaluation of accuracy of fine
needle aspiration cytology for diagnosis of canine mammary
tumours: comparative features with human tumours. Cytopathology. 2007; 18: 191–196
[19]
Chang CC, Tsai MH, Liao JW et al.: Evaluation of hormone receptor
expression for use in predicting survival of female dogs with malignant mammary gland tumors. J Am Vet Med Assoc. 2009; 235:
391–396
[20]
Chang CY, Chiou PP, Chen WJ et al.: Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor
cell lines. Res Vet Sci. 2009; 88: 285–293
[21]
Chang SC, Chang CC, Chang TJ et al.: Prognostic factors associated
with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998–2002). J Am Vet Med Assoc. 2005;
227: 1625–1629
[22]
Claus EB, Schildkraut JM, Thompson WD et al.: The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77: 2318–
2324
[514] White JV, Dunstan RW: Clinical and histopathologic evaluation of
canine dermal angiosarcoma. A case report. J Am Anim Hosp Assoc.
1984; 20: 607–611
[515] White SD, Rosychuk RAW, Scott KV et al.: Use of isotretinoin and
etretinate for the treatment of benign cutaneous neoplasia and
cutaneous lymphoma in dogs. J Am Vet Med Assoc. 1993; 202:
387–391
[516] Wilcock BP, Yager JA, Zink MC: The morphology and behavior of
feline cutaneous mastocytomas. Vet Pathol. 1986; 23: 320–324
[517] Wiley JL, Rook KA, Clifford CA et al.: Efficacy of doxorubicinbased chemotherapy for non-resectable canine subcutaneous haemangiosarcoma. Vet Comp Oncol. 2010; 8: 221–233
[518] Wilhelm S, Degorce-Rubiales F, Godson D et al.: Clinical, histological and immunohistochemical study of feline viral plaques and
bowenoid in situ carcinomas. Vet Dermatol. 2006; 17: 424–431
[519] Williams JH: Lymphangiosarcoma of dogs: a review. J S Afr Vet
Assoc. 2005; 76:127–131
[520] Williams LE, Rassnick KM, Power HT et al.: CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med. 2006;
20: 136–143
[521] Withrow SJ, Straw RC: Resection of the nasal planum in nine cats
and five dogs. J Am Anim Hosp Assoc. 1990; 26: 219–222
[526] Zavodovskaya R, Chien MB, London CA: Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. J
Vet Intern Med. 2004; 18: 915–917
[527] Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast
cell tumors in dogs. Vet Pathol. 2002; 39: 529–535
18 Mammatumoren
18.1 Mammatumoren des Hundes
[1]
Ahern TE, Bird RC, Bird AE et al.: Expression of the oncogene
c-erbB-2 in canine mammary cancers and tumor-derived cell lines.
Am J Vet Res. 1996; 57: 693–696
[2]
Allen SW, Prasse KW, Mahaffey EA: Cytologic differentiation of
benign from malignant canine mammary tumors. Vet Pathol. 1986;
23: 649–655
63
64
[23]
Cleary MP, Grossmann ME, Ray A: Effect of obesity on breast cancer development. Vet Pathol. 2010; 47: 202–213
[24]
Clemente M, De Andres PJ, Pena L et al.: Survival time of dogs
with inflammatory mammary cancer treated with palliative therapy
alone or palliative therapy plus chemotherapy. Vet Rec. 2009; 165:
78–81
[25]
Clemente M, Perez M, Illera J et al.: Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in
canine mammary cancer. Vet Pathol. 2010; 47: 265–274
[26]
Clemente M, Perez-Alenza MD, Pena L: Metastasis of canine
inflammatory versus non-inflammatory mammary tumours. J
Comp Pathol. 2010; 143: 157–163
[27]
de Las Mulas JM, Millan Y, Dios R: A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet
Pathol. 2005; 42: 200–212
[43]
Gilbertson SR, Kurzman ID, Zachrau RE et al.: Canine mammary
epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol. 1983; 20: 127–142
[44]
Giron S, Tejera AM, Ripoll GV et al.: Desmopressin inhibits lung
and lymph node metastasis in a mouse mammary carcinoma
model of surgical manipulation. J Surg Oncol. 2002; 81: 38–44
[45]
Gobello C, Corrada, Y.: Canine mammary tumors: An endocrine
clinical approach. Comp Cont Educ Pract Vet. 2001; 23: 705–710
[46]
Goldschmidt M, Pena L, Rasotto R et al.: Classification and grading of canine mammary tumors. Vet Pathol. 2011; 48: 117–131
[47]
Gomez DE, Ripoll GV, Giron S et al.: Desmopressin and other synthetic vasopressin analogues in cancer treatment. Bull Cancer.
2006; 93: E7–12
[48]
Gonzalez de Bulnes A, Garcia Fernandez P, Mayenco Aguirre AM
et al.: Ultrasonographic imaging of canine mammary tumours. Vet
Rec. 1998; 143: 687–689
[49]
Gottwald D: Ein Beitrag zur Häufigkeit von Mammatumoren beim
Hund. Statistische Auswertung der Einsendungen einer Praxis für
Tierpathologie aus den Jahren 1990 bis 1995. Diss med vet;
München; 1998
[50]
Griffey SM, Madewell BR, Dairkee SH et al.: Immunohistochemical reactivity of basal and luminal epithelium-specific cytokeratin
antibodies within normal and neoplastic canine mammary glands.
Vet Pathol. 1993; 30: 155–161
[28]
de M. Souza CH, Toledo-Piza E, Amorin R et al.: Inflammatory
mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2
expression, and response to piroxicam treatment. Can Vet J. 2009;
50: 506–510
[29]
Djupsjöbacka A, Eksell P: Frequency of radiographically detected
pulmonary metastases in bitches with mammary gland neoplasia.
Europ J Comp Anim Pract. 2003; 13: 149–156
[30]
Dobson JM, Samuel S, Milstein H et al.: Canine neoplasia in the
UK: estimates of incidence rates from a population of insured dogs.
[51]
Griffiths GL, Lumsden JH, Valli VE: Fine needle aspiration cytology
and histologic correlation in canine tumors. Vet Clin Pathol. 1984;
13: 13–17
[31]
Donnay I, Rauis J, Devleeschouwer N et al.: Comparison of estrogen and progesterone receptor expression in normal and tumor
mammary tissues from dogs. Am J Vet Res. 1995; 56: 1188–1194
[52]
Guil-Luna S, Sanchez-Cespedes R, Millan Y et al.: Aglepristone
decreases proliferation in progesterone receptor-positive canine
mammary carcinomas. J Vet Intern Med. 2011; 25: 518–523
[32]
Dore M, Lanthier I, Sirois J: Cyclooxygenase-2 expression in canine
[53]
[33]
Dore M: Cyclooxygenase-2 expression in animal cancers. Vet
Pathol. 2010; 48: 254–265
Hahn KA, Richardson RC, Knapp DC: Canine malignant mammary
neoplasia: biological behavior, diagnosis, and treatment alternatives. J Am Anim Hosp Assoc. 1992; 28: 251–256
[54]
[34]
Dorn CR, Taylor DO, Schneider R et al.: Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer
morbidity in dogs and cats from Alameda County. J Natl Cancer
Inst. 1968; 40: 307–318
Hamilton JM: Comparative aspects of mammary tumors. Adv Cancer Res. 1974; 19: 1–45
[55]
Hampe JF, Misdorp W: Tumours and dysplasias of the mammary
gland. Bull WHO. 1974; 50: 111–133
[56]
Harb MF, Nelson RW, Feldman EC et al.: Central diabetes insipidus
in dogs: 20 cases (1986–1995). J Am Vet Med Assoc. 1996; 209:
1884–1888
[57]
expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol. 2005; 42: 776–780
[58]
Hellmen E, Bergstrom R, Holmberg L et al.: Prognostic factors in
canine mammary tumors: a multivariate study of 202 consecutive
cases. Vet Pathol. 1993; 30: 20–27
[59]
Henry CJ: Mammary Cancer. In: Bonagura JD (Hrsg.): Kirk’s current
veterinary therapy XIV. Saunders Elsevier, St. Louis, Missouri, 2009,
363–368
[60]
Hermo GA, Torres P, Ripoll GV et al.: Perioperative desmopressin
prolongs survival in surgically treated bitches with mammary gland
tumours: a pilot study. Vet J. 2008; 178: 103–108
[61]
Hermo GA, Turic E, Angelico D et al.: Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma
and its relation to histologic grade. J Am Anim Hosp Assoc. 2011;
47: 21–27
[62]
Hoffmann B, Schuler G: Receptor blockers – general aspects with
respect to their use in domestic animal reproduction. Anim Reprod
Sci. 2000; 60–61: 295–312
[63]
Holohan TV, Phillips TM, Bowles C et al.: Regression of canine
mammary carcinoma after immunoadsorption therapy. Cancer Res.
1982; 42: 3663–3668
[64]
Itoh T, Uchida K, Ishikawa K et al.: Clinicopathological survey of
101 canine mammary gland tumors: differences between smallbreed dogs and others. J Vet Med Sci. 2005; 67: 345–347
[35]
Egenvall A, Bonnett BN, Ohagen P et al.: Incidence of and survival
after mammary tumors in a population of over 80,000 insured
female dogs in Sweden from 1995 to 2002. Prev Vet Med. 2005;
69: 109–127
[36]
Ellis LM, Bland KI, Copeland EM 3rd: Inflammatory breast cancer:
advances in therapy. Semin Surg Oncol. 1988; 4: 261–267
[37]
Ferreira E, Bertagnolli AC, Cavalcanti MF et al.: The relationship
between tumour size and expression of prognostic markers in
benign and malignant canine mammary tumours. Vet Comp Oncol.
2009; 7: 230–235
[38]
Fidler IJ, Brodey RS: The biological behavior of canine mammary
neoplasms. J Am Vet Med Assoc. 1967; 151: 1311–1318
[39]
Fowler EH, Wilson GP, Koestner A: Biologic behavior of canine
mammary neoplasms based on a histogenetic classification. Vet
Pathol. 1974; 11: 212–229
[40]
Fowler EH, Vaughan T, Gotcsik F: Pathologic changes in mammary
glands and uteri from beagle bitches receiving low levels of medroxyprogesterone acetate: an overview of research in progress. In:
Garattini S, Berendes HW (Hrsg.), Pharmacology of steroid contraceptive drugs. Raven Press, New York, 1977, xvi, 375
[41]
[42]
Frank DW, Kirton KT, Murchison TE et al.: Mammary tumors and
serum hormones in the bitch treated with medroxyprogesterone
acetate or progesterone for four years. Fertil Steril. 1979; 31: 340–
346
Gama A, Alves A, Schmitt FC: Clinicopathologic features of mammary invasive micropapillary carcinoma (IMC) in dogs. Vet Pathol.
2008; 45: 600–601
[65]
Janni W, Hepp P: Adjuvant aromatase inhibitor therapy: outcomes
and safety. Cancer Treat Rev. 2010; 36: 249–261
[66]
Karayannopoulou M, Kaldrymidou E, Constantinidis TC et al.:
Adjuvant post-operative chemotherapy in bitches with mammary
cancer. J Vet Med A Physiol Pathol Clin Med. 2001; 48: 85–96
[67]
Karayannopoulou M, Kaldrymidou E, Constantinidis TC et al.:
Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol. 2005;
133: 246–252
[87]
MacVean DW, Monlux AW, Anderson PS Jr et al.: Frequency of
canine and feline tumors in a defined population. Vet Pathol. 1978;
15: 700–715
[88]
Marconato L, Lorenzo RM, Abramo F et al.: Adjuvant gemcitabine
after surgical removal of aggressive malignant mammary tumours
in dogs. Vet Comp Oncol. 2008; 6: 90–101
[89]
Marconato L, Romanelli G, Stefanello D et al.: Prognostic factors
for dogs with mammary inflammatory carcinoma: 43 cases (2003–
2008). J Am Vet Med Assoc. 2009; 235: 967–972
[90]
Marquardt C: Untersuchungen zur präoperativen Dignitätserfassung kaniner Mammatumoren mittels Ultraschall und Nadelbiopsie.
Diss med vet; JL-Universität Giessen; 2003
[91]
Martin PM, Cotard M, Mialot JP et al.: Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and
survival rate. Cancer Chemother Pharmacol. 1984; 12: 13–17
[68]
Karayannopoulou M, Polizopoulou ZS, Koutinas AF et al.: Serum
alkaline phosphatase isoenzyme activities in canine malignant
mammary neoplasms with and without osseous transformation.
Vet Clin Pathol. 2006; 35: 287–290
[69]
Klopfleisch R, von Euler H, Sarli G et al.: Molecular carcinogenesis
of canine mammary tumors: news from an old disease. Vet Pathol.
2011; 48: 98–116
[70]
Knapp DW, Richardson RC, Bottoms GD et al.: Phase I trial of
piroxicam in 62 dogs bearing naturally occurring tumors. Cancer
Chemother Pharmacol. 1992; 29: 214–218
[92]
Med Sci. 2004; 66: 573–575
[71]
2006; 47: 14–20
[93]
Merlo DF, Rossi L, Pellegrino C et al.: Cancer incidence in pet
dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet
Intern Med. 2008; 22: 976–984
[72]
Kott C: Zur Aussagekraft der HER2 Rezeptorexpression in caninen
Mammatumoren als diagnostischer und prognostischer Faktor Diss
med vet; Stiftung Tierärztliche Hochschule Hannover; 2004
[94]
Millanta F, Calandrella M, Bari G et al.: Comparison of steroid
receptor expression in normal, dysplastic, and neoplastic canine
and feline mammary tissues. Res Vet Sci. 2005; 79: 225–232
[73]
Kubo K, Matsuyama S, Katayama K et al.: Frequent expression of
the c-kit proto-oncogene in canine malignant mammary tumor. J
Vet Med Sci. 1998; 60: 1335–1340
[95]
[74]
Kuntz CA, Dernell WS, Powers BE et al.: Extraskeletal osteosarcomas in dogs: 14 cases. J Am Anim Hosp Assoc. 1998; 34: 26–30
Millanta F, Silvestri G, Vaselli C et al.: The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting
tumour angiogenesis in feline and canine mammary carcinomas: a
preliminary study of autocrine and paracrine loops. Res Vet Sci.
2006; 81: 350–357
[75]
Kurzman ID, Gilbertson SR: Prognostic factors in canine mammary
tumors. Semin Vet Med Surg (Small Anim). 1986; 1: 25–32
[96]
[76]
Lakhani SR: The transition from hyperplasia to invasive carcinoma
of the breast. J Pathol. 1999; 187: 272–278
Mischke R, Wohlsein P, Busse L et al.: Verbrauchskoagulopathie
und Hyperfibrinolyse bei Hunden mit metastasierendem Mammakarzinom. Schweiz Arch Tierheilkd. 1998; 140: 497–505
[97]
Langenbach A, Anderson MA, Dambach DM et al.: Extraskeletal
osteosarcomas in dogs: a retrospective study of 169 cases (1986–
1996). J Am Anim Hosp Assoc. 1998; 34: 113–120
Misdorp W, den Herder BA: Bone metastasis in mammary cancer.
A report of 10 cases in the female dog and some comparison with
human cases. Br J Cancer. 1966; 20: 496–503
[98]
Misdorp W, Hart AA: Prognostic factors in canine mammary cancer. J Natl Cancer Inst. 1976; 56: 779–786
[99]
Misdorp W, Hart AA: Canine mammary cancer. I. Prognosis. J
[77]
[78]
[79]
[80]
[81]
Langenbach A, McManus PM, Hendrick MJ et al.: Sensitivity and
specificity of methods of assessing the regional lymph nodes for
evidence of metastasis in dogs and cats with solid tumors. J Am Vet
Med Assoc. 2001; 218: 1424–1428
Lavalle GE, Bertagnolli AC, Tavares WL et al.: Cox-2 expression in
canine mammary carcinomas: correlation with angiogenesis and
overall survival. Vet Pathol. 2009; 46: 1275–1280
Lee JJ, Chen PB, Yang SH et al.: Effect of the VP3 gene of chicken
anemia virus on canine mammary tumor cells. Am J Vet Res. 2007;
68: 411–422
Lohr CV, Teifke JP, Failing K et al.: Characterization of the proliferation state in canine mammary tumors by the standardized AgNOR
method with postfixation and immunohistologic detection of Ki-67
and PCNA. Vet Pathol. 1997; 34: 212–221
[100] Misdorp W, Hart AA: Canine mammary cancer. II. Therapy and
causes of death. J Small Anim Pract. 1979; 20: 395–404
[101] Misdorp W: Canine mammary tumours: protective effect of late
ovariectomy and stimulating effect of progestins. Vet Q. 1988; 10:
26–33
[102] Misdorp W: Tumors of the mammary gland. In: Meuten DJ (Hrsg.),
Tumors in Domestic Animals. Iowa State Press, Ames, Iowa, 2002,
575–606, 764
[103] Misdorp W, Else RW, Hellmen E et al.: Histologic Classification of
mammary tumors of the dog and the cat, 2nd Ed. Armed Force
Institute of Pathology and World Health Organization. 1999; 7: 59
London CA, Hannah AL, Zadovoskaya R et al.: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase
inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res.
2003; 9: 2755–2768
[104] Moe L: Population-based incidence of mammary tumours in some
dog breeds. J Reprod Fertil Suppl. 2001; 57: 439–443
[83]
Losco PE: Local and peripheral eosinophilia in a dog with anaplastic
mammary carcinoma. Vet Pathol. 1986; 23: 536–538
[84]
MacEwen EG, Patnaik AK, Harvey HJ et al.: Estrogen receptors in
canine mammary tumors. Cancer Res. 1982; 42: 2255–2259
[106] Morris JS, Dobson JM, Bostock DE et al.: Effect of ovariohysterectomy in bitches with mammary neoplasms. Vet Rec. 1998; 142:
656–658
[85]
MacEwen EG, Harvey HJ, Patnaik AK et al.: Evaluation of effects of
levamisole and surgery on canine mammary cancer. J Biol Response
Mod. 1985; 4: 418–426
[82]
[86]
MacFarlane RJ, Gelmon KA: Lapatinib for breast cancer: a review of
the current literature. Expert Opin Drug Saf. 2010; 10: 109–121
[105] Morris JS, Dobson JM, Bostock DE: Use of tamoxifen in the control
of canine mammary neoplasia. Vet Rec. 1993; 133: 539–542
[107] Moulton JE, Taylor DO, Dorn CR et al.: Canine mammary tumors.
Pathol Vet. 1970; 7: 289–320
[108] Moulton JE, Rosenblatt LS, Goldman M: Mammary tumors in a
colony of beagle dogs. Vet Pathol. 1986; 23: 741–749
[109] Müller F: Hochauflösende Ultraschallverfahren und Doppler-Sonographie zur Mammadiagnostik bei der Hündin. Diss med vet. Universität Leipzig; 2010
65
66
[110] Nemanic S, London CA, Wisner ER: Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary
20: 508–515
[111] Nieto A, Pena L, Perez-Alenza MD et al.: Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical
and pathologic associations and prognostic significance. Vet Pathol.
2000; 37: 239–247
[112] Nyman HT, Nielsen OL, McEvoy FJ et al.: Comparison of B-mode
and Doppler ultrasonographic findings with histologic features of
benign and malignant mammary tumors in dogs. Am J Vet Res.
2006; 67: 985–991
[129] Peruzzi D, Mesiti G, Ciliberto G et al.: Telomerase and HER-2/neu
as targets of genetic cancer vaccines in dogs. Vaccine. 2009; 28:
1201–1208
[130] Philibert JC, Snyder PW, Glickman N et al.: Influence of host factors on survival in dogs with malignant mammary gland tumors. J
Vet Intern Med. 2003; 17: 102–106
[131] Poirier VJ, Hershey AE, Burgess KE et al.: Efficacy and toxicity of
paclitaxel (Taxol) for the treatment of canine malignant tumors. J
Vet Intern Med. 2004; 18: 219–222
[132] Priester WA, Mantel N: Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst. 1971; 47: 1333–1344
Med Assoc. 1989; 195: 1580–1583
[133] Priester WA: Occurrence of mammary neoplasms in bitches in relation to breed, age, tumour type, and geographical region from
which reported. J Small Anim Pract. 1979; 20: 1–11
[114] Ogilvie GK, Obradovich JE, Elmslie RE et al.: Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc. 1991;
198: 1618–1621
[134] Queiroga FL, Pires I, Lobo L et al.: The role of Cox-2 expression in
the prognosis of dogs with malignant mammary tumours. Res Vet
Sci. 88: 441–445
[115] Orlando L, Schiavone P, Fedele P et al.: Molecularly targeted
endocrine therapies for breast cancer. Cancer Treat Rev. 2010; 36
(Suppl 3): S67–71
[135] Queiroga FL, Perez-Alenza MD, Silvan G et al.: Cox-2 levels in
canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
Anticancer Res. 2005; 25: 4269–4275
[116] Otoni CC, Rahal SC, Vulcano LC et al.: Survey radiography and
computerized tomography imaging of the thorax in female dogs
with mammary tumors. Acta Vet Scand. 2010; 52: 20
[117] Owen L: Classification of Tumors in Domestic Animals, 1. Auflg.
Geneva, 1980
[118] Parodi AL, Misdorp W, Mialot JP et al.: Intratumoral BCG and
Corynebacterium parvum therapy of canine mammary tumours
before radical mastectomy. Cancer Immunol Immunother. 1983;
15: 172–177
[119] Patsikas MN, Dessiris A: The lymph drainage of the mammary
glands in the bitch: a lymphographic study. Part II: The 3rd mammary gland. Anat Histol Embryol. 1996; 25: 139–143
[120] Patsikas MN, Karayannopoulou M, Kaldrymidoy E et al.: The
lymph drainage of the neoplastic mammary glands in the bitch: a
lymphographic study. Anat Histol Embryol. 2006; 35: 228–234
[121] Pena L, Perez-Alenza MD, Rodriguez-Bertos A et al.: Canine
inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Res
Treat. 2003; 78: 141–148
[122] Pena LL, Nieto AI, Perez-Alenza D et al.: Immunohistochemical
detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest. 1998;
10: 237–246
[123] Pereira CT, Rahal SC, de Carvalho Balieiro JC et al.: Lymphatic
drainage on healthy and neoplasic mammary glands in female
dogs: can it really be altered? Anat Histol Embryol. 2003; 32: 282–
290
[124] Pereira CT, Luiz Navarro Marques F, Williams J et al.: 99mTclabeled dextran for mammary lymphoscintigraphy in dogs. Vet
[125] Perez Alenza D, Rutteman GR, Pena L et al.: Relation between
habitual diet and canine mammary tumors in a case-control study. J
Vet Intern Med. 1998; 12: 132–139
[126] Perez Alenza MD, Pena L, Nieto AI et al.: Clinical and pathological
prognostic factors in canine mammary tumors. Ann Ist Super
Sanita. 1997; 33: 581–585
[127] Perez Alenza MD, Pena L, del Castillo N et al.: Factors influencing
the incidence and prognosis of canine mammary tumours. J Small
Anim Pract. 2000; 41: 287–291
[128] Perez Alenza MD, Tabanera E, Pena L: Inflammatory mammary
carcinoma in dogs: 33 cases (1995–1999). J Am Vet Med Assoc.
2001; 219: 1110–1114
[136] Queiroga FL, Perez-Alenza MD, Silvan G et al.: Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem
Mol Biol. 2005; 94: 181–187
[137] Queiroga FL, Perez-Alenza MD, Silvan G et al.: Crosstalk between
GH/IGF-I axis and steroid hormones (progesterone, 17beta-estradiol) in canine mammary tumours. J Steroid Biochem Mol Biol.
2008; 110: 76–82
[138] Queiroga FL, Pires I, Lobo L et al.: The role of Cox-2 expression in
the prognosis of dogs with malignant mammary tumours. Res Vet
Sci. 2009; 88: 441–445
[139] Riley JH, Riley MG: Metastatic mammary carcinoma treated with
cytotoxic drugs. Vet Rec. 1982; 111: 8–11
[140] Rivera P, von Euler H: Molecular biological aspects on canine and
human mammary tumors. Vet Pathol. 2011; 48: 132–146
[141] Rossi G, Errico G, Perez P et al.: Paraneoplastic hypoglycemia in a
diabetic dog with an insulin growth factor-2–producing mammary
carcinoma. Vet Clin Pathol. 2010; 39: 480–484
[142] Roszel JF: Canine metastatic mammary carcinoma cells in smears
from genital epithelium. Vet Pathol. 1974; 11: 20–28
[143] Rutqvist LE, Rose C, Cavallin-Stahl E: A systematic overview of
radiation therapy effects in breast cancer. Acta Oncol. 2003; 42:
532–545
[144] Rutteman G: Mammatumoren des Hundes. In: Kessler M. (Hrsg.),
Kleintieronkologie. 1 Auflg. Parey, Berlin, 1999, 261–272
[145] Rutteman GR, Willekes-Koolschijn N, Bevers MM et al.: Prolactin
binding in benign and malignant mammary tissue of female dogs.
Anticancer Res. 1986; 6: 829–835
[146] Rutteman GR, Misdorp W, Blankenstein MA et al.: Oestrogen
(ER) and progestin receptors (PR) in mammary tissue of the female
dog: different receptor profile in non-malignant and malignant
states. Br J Cancer. 1988; 58: 594–599
[147] Rutteman GR, Bevers MM, Misdorp W et al.: Anterior pituitary
function in female dogs with mammary tumors: II. Prolactin. Anticancer Res. 1989; 9: 241–245
[148] Rutteman GR: Hormones and mammary tumour disease in the
female dog: an update. In Vivo. 1990; 4: 33–40
[149] Rutteman GR: Contraceptive steroids and the mammary gland: is
there a hazard?-Insights from animal studies. Breast Cancer Res
Treat. 1992; 23: 29–41
[150] Rutteman GR, Misdorp W: Hormonal background of canine and
feline mammary tumours. J Reprod Fertil Suppl. 1993; 47: 483–487
67
[152] Rutten VP, Misdorp W, Gauthier A et al.: Immunological aspects
of mammary tumors in dogs and cats: a survey including own studies and pertinent literature. Vet Immunol Immunopathol. 1990;
26: 211–225
[153] Saba CF, Rogers KS, Newman SJ et al.: Mammary gland tumors in
male dogs. J Vet Intern Med. 2007; 21: 1056–1059
[154] Saluja PG, Hamilton JM, Gronow M et al.: Pituitary prolactin levels
in canine mammary cancer. Eur J Cancer. 1974; 10: 63–66
[172] Slaughter DP, Southwick HW, Smejkal W: Field cancerization in
oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953; 6: 963–968
[173] Sonnenschein EG, Glickman LT, Goldschmidt MH et al.: Body conformation, diet, and risk of breast cancer in pet dogs: a case-control
study. Am J Epidemiol. 1991; 133: 694–703
[174] Sorenmo K: Canine mammary gland tumors. Vet Clin North Am
[175] Sorenmo KU, Shofer FS, Goldschmidt MH: Effect of spaying and
timing of spaying on survival of dogs with mammary carcinoma. J
Vet Intern Med. 2000; 14: 266–270
[155] Sarli G, Preziosi R, Benazzi C et al.: Prognostic value of histologic
stage and proliferative activity in canine malignant mammary
tumors. J Vet Diagn Invest. 2002; 14: 25–34
[176] Sorenmo KU, Kristiansen VM, Cofone MA et al.: Canine mammary gland tumours; a histological continuum from benign to
malignant; clinical and histopathological evidence. Vet Comp
Oncol. 2009; 7: 162–172
[156] Sartin EA, Barnes S, Toivio-Kinnucan M et al.: Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. Anticancer Res.
1993; 13: 229–236
[177] Sorenmo KU, Rasotto R, Zappulli V et al.: Development, anatomy,
histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol.
2010; 48: 85–97
[157] Schafer KA, Kelly G, Schrader R et al.: A canine model of familial
mammary gland neoplasia. Vet Pathol. 1998; 35: 168–177
[178] Stockhaus C, Kohn B, Rudolph R et al.: Correlation of haemostatic
abnormalities with tumour stage and characteristics in dogs with
mammary carcinoma. J Small Anim Pract. 1999; 40: 326–331
[158] Schena CJ, Stickle RL, Dunstan RW et al.: Extraskeletal osteosarcoma in two dogs. J Am Vet Med Assoc. 1989; 194: 1452–1456
[159] Schmitt I, Allgoewer I, Walter J et al.: Laser-induzierte Thermotherapie (LITT) an Mammatumoren von Hunden – In vitro- und
In-vivo-Untersuchungen. Kleintierprax. 1996; 41: 871–880
[160] Schneider R, Dorn CR, Taylor DO: Factors influencing canine
mammary cancer development and postsurgical survival. J Natl
Cancer Inst. 1969; 43(6): 1249–1261
[161] Schneider R: Comparison of age, sex, and incidence rates in human
and canine breast cancer. Cancer. 1970; 26: 419–426
[162] Sedlacek HH, Hagmayer G, Seiler FR: Tumor therapy of neoplastic
diseases with tumor cells and neuraminidase. Further experimental
studies on chessboard vaccination in canine mammary tumors.
Cancer Immunol Immunother. 1986; 23: 192–199
[163] Selman PJ, Mol JA, Rutteman GR et al.: Progestin-induced growth
hormone excess in the dog originates in the mammary gland. Endocrinology. 1994; 134: 287–292
[164] Shofer FS, Sonnenschein EG, Goldschmidt MH et al.: Histopathologic and dietary prognostic factors for canine mammary carcinoma. Breast Cancer Res Treat. 1989; 13: 49–60
[165] Silver IA: The anatomy of the mammary gland of the dog and cat. J
[166] Simeonov R, Simeonova G: Computerized morphometry of mean
nuclear diameter and nuclear roundness in canine mammary gland
tumors on cytologic smears. Vet Clin Pathol. 2006; 35: 88–90
[167] Simeonov R, Simeonova G: Fractal dimension of canine mammary
gland epithelial tumors on cytologic smears. Vet Clin Pathol. 2006;
35: 446–448
[168] Simeonov R, Simeonova G: Computerized cytomorphometric analysis of nuclear area, nuclear perimeter and mean nuclear diameter
in spontaneous canine mammary gland tumours. Vet Res Commun.
2007; 31: 553–558
[169] Simon D, Knebel JW, Baumgartner W et al.: In vitro efficacy of
chemotherapeutics as determined by 50% inhibitory concentrations
in cell cultures of mammary gland tumors obtained from dogs. Am
J Vet Res. 2001; 62: 1825–1830
[170] Simon D, Schoenrock D, Baumgartner W et al.: Postoperative
adjuvant treatment of invasive malignant mammary gland tumors
in dogs with doxorubicin and docetaxel. J Vet Intern Med. 2006; 20:
1184–1190
[171] Simon D, Schoenrock D, Nolte I et al.: Cytologic examination of
fine-needle aspirates from mammary gland tumors in the dog: diagnostic accuracy with comparison to histopathology and association
with postoperative outcome. Vet Clin Pathol. 2009; 38: 521–528
[179] Stockhaus C, Teske E: Klinische Erfahrungen mit der zytologischen
Diagnostik beim Hund. Schweiz Arch Tierheilkd. 2001; 143: 233–
240
[180] Stovring M, Moe L, Glattre E: A population-based case-control
study of canine mammary tumours and clinical use of medroxyprogesterone acetate. APMIS. 1997; 105: 590–596
[181] Stratmann N, Failing K, Richter A et al.: Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg. 2008; 37: 82–
86
[182] Susaneck SJ, Allen TA, Hoopes J et al: Inflammatory mammary
carcinoma in the dog. J Am Anim Hosp Assoc. 1983; 19: 971–976
[183] Tavares WL, Lavalle GE, Figueiredo MS et al.: Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet
Scand. 2010; 52: 67
[184] Taylor GN, Shabestari L, Williams J et al.: Mammary neoplasia in a
closed beagle colony. Cancer Res. 1976; 36: 2740–2743
[185] Teske E, Rutteman GR, van den Ingh TS et al.: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a
randomized clinical trial in dogs with mammary carcinoma. Anticancer Res. 1998; 18: 1015–1019
[186] Thamm DH, Kurzman ID, Clark MA et al.: Preclinical investigation
of PEGylated tumor necrosis factor alpha in dogs with spontaneous
tumors: phase I evaluation. Clin Cancer Res. 2010; 16: 1498–1508
[187] Thamm DH, Rose B, Kow K et al.: Masitinib as a chemosensitizer
of canine tumor cell lines: A proof of concept study. Vet J. 2012; 19:
131–134
[188] Tymchuk CN, Tessler SB, Barnard RJ: Changes in sex hormone-binding globulin, insulin, and serum lipids in postmenopausal women
on a low-fat, high-fiber diet combined with exercise. Nutr Cancer.
2000; 38: 158–162
[189] Überreiter O: [The effect of pregnancy and pseudopregnancy on
the development of mammary tumors in bitches]. Berl Munch Tierarztl Wochenschr. 1966; 79(23): 451–456
[190] VanGarderen E, de Wit M, Voorhout WF et al.: Expression of
growth hormone in canine mammary tissue and mammary tumors.
Evidence for a potential autocrine/paracrine stimulatory loop. Am J
Pathol. 1997; 150: 1037–1047
[191] Visonneau S, Cesano A, Jeglum KA et al.: Adoptive therapy of
canine metastatic mammary carcinoma with the human MHC nonrestricted cytotoxic T-cell line TALL-104. Oncol Rep. 1999; 6: 1181–
1188
[192] Walsh T, King MC: Ten genes for inherited breast cancer. Cancer
Cell. 2007; 11: 103–105
[151] Rutteman GR, Withrow SJ, MacEwen EG: Tumors of the mammary gland. In: Withrow SJ, MacEwen EG (Hrsg.): Small Animal Clinical Oncology. 3. Auflg. WB Saunders, Philadelphia, PA, 2001, 455–
477
68
[193] Wey N, Kohn B, Gutberlet K et al.: Mammatumore bei der Hündin:
Klinische Verlaufsstudie (1995–1997). Kleintierprax. 1999; 44: 565–
578
[14]
Hahn KA, Bravo L, Avenell JS: Feline breast carcinoma as a pathologic and therapeutic model for human breast cancer. In Vivo.
1994; 8: 825–828
[194] Wu AH, Pike MC, Stram DO: Meta-analysis: dietary fat intake,
serum estrogen levels, and the risk of breast cancer. J Natl Cancer
Inst. 1999; 91: 529–534
[15]
Hamilton JM, Else RW, Forshaw P: Oestrogen receptors in feline
mammary carcinomas. Vet Rec. 1976; 99: 477–479
[16]
Hayes HM, Milne KL, Mandell CP: Epidemiologic features of feline
mammary carcinoma. Vet Rec. 1981; 108: 476–479
[17]
Ito T, Kadosawa T, Mochizuki M et al.: Prognosis of malignant
mammary tumor in 53 cats. J Vet Med Sci. 1996, 58: 723–726
[196] Yamagami T, Kobayashi T, Takahashi K et al.: Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. J Small Anim Pract. 1996; 37: 462–464
[18]
Jeglum KA, DeGuzman E, Young K: Chemotherapy of advanced
mammary adenocarcinoma in 14 cats. J Am Vet Med Assoc. 1985;
187: 157–160
[197] Yamashita A, Maruo K, Suzuki K et al.: Experimental chemotherapy against canine mammary cancer xenograft in SCID mice and
its prediction of clinical effect. J Vet Med Sci. 2001; 63: 831–836
[19]
Jurka P, Max A: Treatment of fibroadenomatosis in 14 cats with
aglepristone – changes in blood parameters and follow-up. Vet Rec.
2009; 165: 657–660
[198] Yazawa M, Setoguchi A, Hong SH et al.: Effect of an adenoviral
vector that expresses the canine p53 gene on cell growth of canine
osteosarcoma and mammary adenocarcinoma cell lines. Am J Vet
Res. 2003; 64: 880–888
[20]
Keskin A, Yilmazbas G, Yilmaz R et al.: Pathological abnormalities
after long-term administration of medroxyprogesterone acetate in
a queen. J Feline Med Surg. 2009; 11: 518–521
[21]
Kessler M, von Bomhard D: Mammary tumors in male cats – 86
cases. Proc. 5th. Ann Congr Europ Soc Vet Oncology (ESVONC),
Veldhoven, 1996
[22]
Kessler M, von Bomhard D: Mammatumoren bei Katzen – eine
Auswertung von 2.386 Fällen. Kleintierprax. 1997; 42: 459–465
[23]
Kühnel S, Kessler M: Mammakarzinome der Katze – klinische
Befunde und Therapieverlauf bei 34 Patienten. Kleintierprax. 2012
(in Druck)
[24]
MacEwen EG, Hayes AA, Harvey HJ et al.: Prognostic factors for
feline mammary tumors. J Am Vet Med Assoc. 1984; 185: 201–204
[25]
Mauldin GN, Matus RE, Patnaik AK et al.: Efficacy and toxicity of
doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med. 1988; 23: 60–65
[26]
Mauldin GE, Mooney SC, Amiya MA et al.: Adjuvant doxorubicin
for feline mammary adeocarcinoma. Proc Ann Conf Vet Cancer
Soc., 1994
[27]
Mayr B, Jugl M, Brem G et al.: Cytogenetic variation in six cases of
feline mammary tumours. Zbl Vet Med A. 1999; 46: 367–377
[28]
Mayr B, Ortner W, Reifinger M et al.: Loss of chromosome B2material in three cases of feline mammary tumours. Res Vet Sci.
1995; 59: 61–63
[195] Yamagami T, Kobayashi T, Takahashi K et al.: Prognosis for canine
malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci. 1996; 58: 1079–1083
18.2 Mammatumoren der Katze
[1]
[2]
Borrego JF, Cartagena JC, Engel J: Treatment of feline mammary
tumours using chemotherapy, surgery and a COX-2 inhibitor drug
(meloxicam): a retrospective study of 23 cases (2002–2007). Vet
Comp Oncol. 2009; 7: 213–221
Castagnaro M, Casalone C, Bozzetta E et al.: Tumor grading and
the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol. 1998; 119: 263–275
[3]
Castagnaro M, Casalone C, Ru G et al.: Argyrophilic nucleolar
organiser regions (AgNORs) count as indicator of post-surgical
prognosis in feline mammary carcinomas. Res Vet Sci. 1998; 64:
97–100
[4]
Castagnaro M, De Maria R, Bozzetta E et al.: Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas.
Res Vet Sci. 1998; 65: 223–226
[5]
De las Mulas JM, van Niel M, Millan Y et al.: Immunohistochemical analysis of estrogen receptors in feline mammary gland benign
and malignant lesions: comparison with biochemical assay. Domest
Anim Endocrinol. 2000; 18: 111–125
[6]
De las Mulas JM, van Niel M, Millan Y et al.: Progesterone receptors in normal, dysplastic and tumourous feline mammary glands.
Comparison with oestrogen receptors status. Res Vet Sci. 2002; 72:
153–161
[29]
Mayr B, Schaffner G, Kurzbauer R et al.: Sequence of an exon of
tumour suppressor p53 gene – a comparative study in domestic
animals: mutation in a feline solid mammary carcinoma. Br Vet J.
1995; 151: 325–329
[7]
De Maria R, Olivero M, Iussich S et al.: Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis
human breast cancer. Cancer Res. 2005; 65: 907–912
[30]
McNeill CJ, Sorenmo KU, Shofer FS et al.: Evaluation of adjuvant
doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. J Vet Intern Med. 2009; 23: 123–129
[8]
De Vico G, Maiolino P: Prognostic value of nuclear morphometry
in feline mammary carcinomas. J Comp Pathol. 1997; 117: 99–105
[31]
[9]
Dhaliwal RS, Kitchell BE, Hintermeister J: Efficacy of carboplatin
in feline mammary carcinoma. Proc. WSAVA Conf., 2002
Millanta F, Calandrella M, Bari G et al.: Comparison of steroid
receptor expression in normal, dysplastic, and neoplastic canine
and feline mammary tissues. Res Vet Sci. 2005; 79: 225–232
[32]
[10]
Epping J: Immunhistochemischer Nachweis von Tumormetastasen
feliner Mammakarzinome in den regionären Lymphknoten. Diss
med vet, Berlin 1999
Millanta F, Calandrella M, Citi S et al.: Overexpression of HER-2 in
feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol. 2005; 42:
30–34
[11]
Fox LE, MacEwen EG, Kurzman ID et al.: Liposome-encapsulated
muramyl tripeptide phosphatidylethanolamine for the treatment of
feline mammary adenocarcinoma – a multicenter randomized
double-blind study. Cancer Biother. 1995; 10: 125–130
[33]
Minke JM, Cornelisse CJ, Stolwijk JA et al.: Flow cytometric DNA
ploidy analysis of feline mammary tumors. Cancer Res. 1990; 50:
4003–4007
[34]
[12]
Giménez F, Hecht S, Craig LE et al.: http://www.ncbi.nlm.nih.gov/
pubmed?term=%22Legendre%20AM%22%5BAuthor%5DEarly detection, aggressive therapy: optimizing the management of feline
mammary masses. J Feline Med Surg. 2010; 12: 214–224
Misdorp W, Romijn A, Hart AAM: Feline mammary tumors: a
case-control study of hormonal factors. Anticancer Res. 1991; 11:
1793–1797
[35]
Misdorp W, Romijn A, Hart AAM: Over de betekenis van ovariectomie en progestativa voor het ontstaan van het mammacarcinoom
bij de kat. [The significance of ovariectomy and progestagens in the
development of mammary carcinoma in cats] Tijdschr Diergeneeskd 1992; 117: 2–4
[13]
Hahn KA: Adjuvant chemotherapy in feline mammary carcinoma.
Proc ACVIM Forum, 1995
[36]
[37]
[38]
Mol JA, van Garderen E, Rutteman GR et al.: New insights in the
molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol. 1996; 57: 67–71
[55]
Viste JR, Myers SL, Singh B et al.: Feline mammary adenocarcinoma: tumor size as a prognostic indicator. Can Vet J. 2002; 43:
33–37
[56]
Murakami Y, Tateyama S, Rungsipipat A et al.: Amplification of
the cyclin A gene in canine and feline mammary tumors. J Vet Med
Sci. 2000; 62: 783–787
Vollmerhaus B, Roos H, Meier A: Über die regionären Lymphknoten des Gesäuges der Hauskatze – eine summative Studie. Kleintierprax. 1997; 42: 221–229
[57]
Novosad CA, Bergman PJ, OʼBrien MG et al.: Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary
gland adenocarcinoma: 67 cases. J Am Anim Hosp Assoc. 2006; 42:
110–120
Waters DJ, Honeckman A, Cooley DM et al.: Skeletal metastasis in
feline mammary carcinoma: case report and literature review. J Am
Anim Hosp Assoc. 1998; 34: 103–108
[58]
Wehrend A, Bostedt H: Die feline Fibroadenomatose. Prakt Tierarzt 2000; 82: 694–696
[59]
Wehrend A, Hospes R, Gruber AD: Treatment of feline mammary
fibroadenomatous hyperplasia with a progesterone-antagonist Vet
Rec. 2001; 148: 346–347
[60]
Weijer K, Hart AA: Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst. 1983; 70: 709–716
[61]
Papadopoulou PL, Patsikas MN, Charitanti A et al.: The lymph
drainage pattern of the mammary glands in the cat: a lymphographic and computerized tomography lymphographic study. Anat
Histol Embryol. 2009; 38: 292–299
Winston J, Craft DM, Scase TJ et al.: Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary
tumours. Vet Comp Oncol. 2005; 3: 8–15
[62]
Zappulli V, De Zan G, Cardazzo B et al.: Feline mammary tumours
in comparative oncology. J Dairy Res. 2005; 72: 98–106
Pérez-Alenza MD, Jiménez Á, Nieto AI: First description of feline
inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases. Breast Cancer Res.
2004; 6: R300–R307
19 Tumoren des Gastrointestinaltrakts
Preziosi R, Sarli G, Benazzi C et al.: Detection of proliferating cell
nuclear antigen (PCNA) in canine and feline mammary tumours. J
Comp Pathol. 1995; 113: 301–313
[1]
Abbott DP, Walsh K, Diters RW: Calcifying epithelial odontogenic
tumors in three cats and a dog. J Comp Pathol. 1986; 96: 131–136
[39]
Overley B, Shofer FS, Goldschmidt MH et al.: Association between
ovariohysterectomy and feline mammary carcinoma. J Vet Intern
Med. 2005; 19: 560–563
[40]
Ozawa S, Minami T, Utsunomiya H et al.: Study on histopathological prognostication of mammary gland tumor in cat (97 cases).
Proc. 14th Ann Conf Vet Cancer Soc, 2002
[41]
[42]
[43]
19.1 Tumoren der Maulhöhle
[44]
Preziosi R, Sarli G, Benazzi C et al.: Multiparametric survival analysis of histological stage and proliferative activity in feline mammary
carcinomas. Res Vet Sci. 2002; 73: 53–60
[2]
Barnes L, Eveson JW, Reichart P et al. (Hrsg.): World Health Organization Classification of Tumours, Pathology & Genetics, Head and
Neck Tumours. Lyon: IARC Press 2005
[45]
Raharison F, Sautet J: Lymph drainage of the mammary glands in
female cats. J Morphol. 2006; 267: 292–299
[3]
[46]
Raharison F, Sautet J: The topography of the lymph vessels of
mammary glands in female cats. Anat Histol Embryol. 2007; 36:
442–452
Bateman KE, Catton PA, Pennock PW et al.: 0-7-21 Radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med.
1994; 8: 267–272
[4]
Rasotto R, Caliari D, Castagnaro M et al.: An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp
Pathol. 2011; 144: 170–179
Vet Pathol. 2003; 40: 496–500
[5]
Beatty JA, Charles JA, Malik R et al.: Feline inductive odontogenic
tumour in a Burmese cat. Aust Vet J. 2000; 78: 452–455
[47]
[48]
Rutteman GR, Blankenstein MA, Minke J et al.: Steroid receptors
in mammary tumours of the cat. Acta Endocrinol (Copenh). 1991;
125 (Suppl 1): 32–37
[6]
Beck ER, Withrow SJ, McChesney AE et al.: Canine tongue
tumors: a retrospective review of 57 cases. J Am Anim Hosp Assoc.
1986; 22: 525–532
[49]
Sarli G, Preziosi R, Benazzi C et al.: Rate of apoptosis in feline
mammary tumors is not predictive of postsurgical survival. J Vet
Diagn Invest. 2003; 15: 115–122
[7]
Berg J: Principles of oncologic orofacial surgery. Clin Tech Small
Anim Pract. 1998;13: 38–41
[8]
[50]
Sayasith K, Sirois J, Doré M: Molecular characterization of feline
COX-2 and expression in feline mammary carcinomas. Vet Pathol.
2009; 46: 423–429
Bergman PJ, McKnight J, Novosad A et al.: Long-term survival of
dogs with advanced malignant melanoma after DNA vaccination
with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res.
2003; 9: 1284–2190
[51]
Seixas F, Palmeira C, Pires MA et al.: Grade is an independent
prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet J. 2011; 187: 65–71.http://www.
ncbi.nlm.nih.gov/pubmed?term=%22Bento%20MJ%22%5BAuthor%
5D
[9]
Bergman PJ, Camps-Palau MA, McKnight JA et al.: Development
of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006; 24: 4582–4585
[10]
Bjorling DE, Chambers JN, Mahaffey DA: Surgical treatment of
epulides in dogs: 25 cases (1974–1984). J Am Vet Med Assoc.
1987; 190: 131–138
[11]
Blackwood L, Dobson JM: Radiotherapy of oral malignant melanoms in dogs. J Am Vet Med Assoc. 1996; 209: 98–102
[12]
Boehm B, Breuer W, Hermans W: Odontogene Tumoren bei Hund
und Katze. Tierärztl Prax. 2011; 39 (K): 305–312
[13]
Boria PA, Murry DJ, Bennett PF, et al.: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma
2004; 224: 388–394.
[14]
Vet Pathol. 1979; 16: 32–40
[52]
Skorupski KA, Overley B, Shofer FS et al.: Clinical characteristics
of mammary carcinoma in male cats. J Vet Intern Med. 2005; 19:
52–55
[53]
Tamada H, Kawate N, Inaba T et al.: Long-term prevention of
estrus in the bitch and queen using chlormadinone acetate. Can Vet
J. 2003; 44: 416–417
[54]
Van der Heyden S, Chiers K, Vercauteren G et al.: Expression of
multidrug resistance-associated P-glycoprotein in feline tumours. J
Comp Pathol. 2011; 144: 164–169
69
70
[15]
Bostock DE: Prognosis after surgical excision of fibrosarcomas in
cats. J. Am Vet Med Assoc. 1979; 175: 727–728
[16]
Bostock, DE, White RAS: Classification and behaviour after surgery
of canine “epulides”. J Comp Pathol. 1987; 97: 197–206
[17]
[37]
Dorn CR, Taylor DON, Schneider R et al.: Survey of animal neoplasms in Alameda and Contra Costa counties, California. II. Cancer
morbidity in dogs and cats from Alameda county. J Natl Cancer Inst.
1968; 40: 307–318
Bradley RL, MacEwen EG, Loar AS: Mandibular resection for removal of oral tumors in 30 dogs and 6 cats. J Am Vet Med Assoc. 1984;
184: 460–463
[38]
Dubielzig RR, Adams WM, Brodey RS: Inductive Fibroameloblastoma, an unusual dental tumor of young cats. J Am Vet Med Assoc.
1979; 174: 720–722
[18]
Bregazzi VS, LaRue SM, Powers BE et al.: Response of feline oral
squamous cell carcinoma to palliative radiation therapy. Vet Radiol
Ultrasound. 2001; 42: 77-79
[39]
Dubielzig RR, Thrall DE: Ameloblastoma and keratinizing ameloblastoma in dogs. Vet Pathol. 1982; 19: 596–607
[40]
[19]
Brewer WG, Turrel JM: Radiotherapy and hyperthermia in the
treatment of fibrosarcomas in the dog. J Am Vet Med Assoc. 1982;
181: 146–150
Dubielzig RR, Goldschmidt MH, Brodey RS: The nomenclature of
periodontal epulides in dogs. Vet Pathol. 1979; 16: 209–214
[41]
Dubielzig RR: Proliferative dental and gingival diseases of dogs and
cats. J Am Anim Hosp Assoc. 1982; 18: 577–584
[20]
Brooks MB, Matus RE, Leifer CE et al.: Chemotherapy versus chemotherapy plus radiotherapy in the treatment of tonsillar squamous
cell carcinoma in the dog. J Vet Intern Med. 1988; 2: 206–211
[42]
Dvorak LD, Beaver DP, Ellison GW et al.: Major glossectomy in
dogs: a case series and proposed classification system. J Am Anim
Hosp Assoc. 2004; 40: 331–337
[21]
Bryant KJ, Moore K, McAnulty JF: Angularis oris axial pattern buccal flap for reconstruction of recurrent fistulae of the palate. Vet
Surg. 2003; 32: 113–119
[43]
Eickhoff M, Seeliger F, Simon D et al.: Erupted bilateral compound
odontomas in a dog. J Vet Dent. 2002; 19: 137–143
[44]
[22]
Buracco P, Bonioli A, Romanelli G et al.: Surgery/chemotherapy in
43 canine and feline oral tumors. Proc 14th Ann Conf Vet Canc Soc.
1994; 51–52
Elmslie RE, Dow SW, Potter TA: Genetic immunotherapy of canine
oral melanoma. Proc 14th Ann Conf Vet Cancer Soc. 1994; 111–
112
[45]
[23]
Burk RL: Radiation therapy in the treatment of oral neoplasia. Vet
Clin North Am Sm Anim Pract. 1996; 26: 155–163
[24]
Cangul IT, van Garderen E, van der Linde-Sipman JS et al.: Canine
balloon and signet-ring cell melanomas: a histological and immunohistochemical characterization. J Comp Pathol. 2001; 125: 166-173
Esplin DG: Survival of dogs following surgical excision of histologically well-differentiated melanocytic neoplasms of the mucous
membranes of the lips and oral cavity. Vet Pathol. 2008; 45: 889–
896
[46]
Carpenter LG, Withrow SJ, Powers BE et al.: Squamous cell carcinoma of the tongue in 10 dogs. J Am Anim Hosp Assoc. 1993; 29:
17–24
Evans SM, Shofer F: Canine oral nontonsillar squamous cell carcinoma: prognostic factors for recurrence and survival following
orthovoltage radiation therapy. Vet Radiol. 1988; 29: 133–137
[47]
Cheung LK: An animal model for maxillary reconstruction using a
temporalis muscle flap. J Oral Maxillofac Surg. 1996; 54: 1439–
1445.
Felizzola CR, Stopiglia AJ, de Araújo VC, et al.: Evaluation of a
modified hemimandibulectomy for treatment of oral neoplasms in
dogs. J Vet Dent. 2002;19: 127–135
[48]
Fidel JL, Sellon RK, Houston RK et al.: A nine-day accelerated
radiation protocol for feline squamous cell carcinoma. Vet Radiol
Ultrasound. 2007; 48: 482–485.
[49]
Fox LE, Geoghegan SL, Davis HL: Owner satisfaction with partial
mandibulectomy or maxillectomy for treatment of oral tumors in
27 dogs
[50]
Freeman KP, Hahn KA, Harris FD et al.: Treatment of dogs with
oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). J Vet Intern Med. 2003;
17: 96–101
[51]
Frew DG, Dobson JM: Radiological assessment of 50 cases of incisive or maxillary neoplasia in the dog. J Small Anim Pract. 1992; 33:
11–18
[25]
[26]
[27]
Ciekot PA, Powers BE, Withrow SJ et al.: Histologically low grade
yet biologically high grade fibrosarcomas of the mandible and
maxilla of 25 dogs (1982 to 1991). J Am Vet Med Assoc. 1994; 204:
610–615
[28]
Colgin LM, Schulman FY, Dubielzig RR: Multiple epulides in 13
cats. Vet Pathol. 2001; 38: 227–229
[29]
Cotter SM: Oral pharyngeal neoplasms in the cat. J Am Anim Hosp
Assoc. 1981; 17: 917–920
[30]
De Bruijn ND, Kirpensteijn J, Neyens IJS et al.: A clinicopathological study of 52 feline epulides. Vet Pathol. 2007; 44: 161–169
[31]
Delverdier M, Guire F, van Harverbeke G: Les tumeurs de la cavité
buccale du chien: étude anatomoclinique a partir de 117 cas. Rev
Med Vet. 1991; 142: 811–816
[52]
Dennis MM, Ehrhart N, Duncan CG et al.: Frequency of and risk
factors associated with lingual lesions in dogs: 1,196 cases (1995–
2004). J Am Vet Med Assoc. 2006; 228: 1533–1537
Gardner DG: Ameloblastomas in cats: a critical evaluation of the
literature and the addition of one example. J Oral Pathol Med. 1998;
27: 39–42
[53]
Dewitz M von: Zum Metastasierungsmuster einiger häufig auftretender maligner Geschwülste des Hundes. Diss med vet., München,
1987
Gardner DG: Canine acanthomatous epulis – The only common
spontaneous ameloblastoma in animals. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 1995; 79: 612–615
[54]
Gardner DG: Epulides in the dog: a review. J Oral Pathol Med. 1996;
25: 32–37
[55]
Gardner DG, Baker DC: The relationship of canine acanthomatous
epulis to ameloblastoma. J Comp Path. 1993; 108: 47–55
[56]
Gardner DG, Dubielzig RR, McGee EV: The so-called calcifying epithelial odontogenic tumor in dogs and cats (amyloid-producing
odontogenic tumor). J Comp Pathol. 1994; 111: 221–230
[57]
Gardner DG, Dubielzig RR: The histological features of canine keratinizing Ameloblastoma. J Comp Path. 1993; 109: 423–428
[58]
Garner MT: Der Einsatz von Megavoltage-Bestrahlungstherapie und
Elektronen bei der Behandlung von Weichteilsarkomen des Hundes
Eine retrospektive Studie von 73 Hunden. Diss med vet FU Berlin
2004
[32]
[33]
[34]
[35]
[36]
De Vos JP, Burm AGD, Focker AP et al.: Piroxicam and carboplatin
as a combination treatment of canine oral non-tonsillar squamous
cell carcinoma: a pilot study and a literature review of a canine
model of human head and neck squamous cell carcinoma. Vet
Comp Onc. 2005; 3: 16–24
DiBernardi L, Doré M, Davis JA et al.: Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor
treatment. Prostaglandins Leukot Essent Fatty Acids. 2007; 76:
245–250
Dorn CR, Priester WA: Epidemiologic analyses of oral and pharyngeal cancers in dogs, cats, horses and cattle. J Am Vet Med Assoc.
1976; 169: 1202–1206
[59]
Gendler A, Lewis JR, Reetz JA et al.: Computed tomographic features of oral squamous cell carcinoma in cats: 18 cases (2002–2008).
J Am Vet Med Assoc. 2010; 236: 319–325
[80]
Kessler M, von Bomhard D: Plattenepithelkarzinome bei Hunden
und Katzen – Prävalenz, Rasseprädispositionen und Primärlokalisationen. Proc. 22. Kongress der DVG, Bad Nauheim 1997
[60]
Giudice C, Ceciliani F, Rondena M et al.: Immunohistochemical
investigation of PNL2 reactivity of canine melanocytic neoplasms
and comparison with Melan A. J Vet Diagn Invest. 2010; 22: 389–
394
[81]
Kessler M, Kühnel S: Chirurgische Therapie oraler Plattenepithelkarzinome beim Hund – eine retrospektive Untersuchung bei 40
Patienten. Proc. 57. Jahreskongress DGK-DVG, Berlin 2011
[82]
[61]
Guptill L, Knapp DW, Hank K et al.: Retrospective study of cisplatin treatment for canine malignant melanoma. Proc 13th Ann Conf
Vet Cancer Soc. 1993; 65–66
Kinzel S, Hein S, Stopinski T, et al.: Die hypofraktionierte Strahlentherapie zur Behandlung des malignen Melanoms und des Plattenepithelkarzinoms von Hund und Katze. Berl Münch Tierärztl Wschr.
2003; 116: 134–138.
[62]
Hahn KA, DeNicola DB, Richardson RC et al.: Canine oral malignant melanoma: prognostic utility of an alternative staging system.
[83]
Kitchell BE, Brown DM, Luck EE et al.: Intralesional implant for
treatment of primary malignant melanoma in dogs. J Am Vet Med
Assoc. 1994; 204: 229–236
[63]
Harvey HJ, MacEwen EG, Braun D et al.: Prognostic criteria for
dogs with oral melanoma. J Am Vet Med Assoc. 1981; 178: 580–
582
[84]
Klima LJ, Goldstein GS: Surgical management of compound odontoma in a dog. J Vet Dent. 2007; 24: 100–106
[85]
[64]
99
Kosovsky JK, Matthiesen DT, Marretta SM et al.: Results of partial
mandibulectomy for the treatment of oral tumors in 142 dogs. Vet
Surg. 1991; 20: 397–401
[86]
[65]
Hayes AM, Adams VJ, Scase TJ et al.: Survival of 54 cats with oral
squamous cell carcinoma in United Kingdom general practice. J
Kühnel S, Kessler M: Tonsilläre Plattenepithelkarzinome beim
Hund: eine retrospektive Untersuchung bei 33 Patienten. Tierärztl
Prax. 2010; 38: 367–373
[87]
[66]
Head KW: Tumors of the upper alimentary tract. Bull WHO. 1976;
53: 145–166
Lascelles BD, Thomson MJ, Dernell WS, et al.: Combined dorsolateral and intraoral approach for the resection of tumors of the
maxilla in the dog. J Am Anim Hosp Assoc. 2003; 39: 294–305
[67]
Head KW, Else RW, Dubielzig DD: Tumours of the alimentary
tract. In: Meuten DJ (Hrsg.): Tumours in Domestic Animals. 4. Auflg.
Iowa State Press, Ames 2002, 401–482
[88]
[68]
Head KW: Tumors of odontogenic origin. In: Histological classification of tumors of the alimentary system of domestic animals. In:
Head KW, Cullen JM, Dubielzig RR et al. (Hrsg.): WHO second series,
vol. X, 48–53, Armed Forces Institute of Pathology, Washington DC.
2003
Lascelles BD, Henderson RA, Seguin B et al.: Bilateral rostral
maxillectomy and nasal planectomy for large rostral maxillofacial
neoplasms in six dogs and one cat. J Am Anim Hosp Assoc. 2004;
40: 137–146
[89]
Lester S, Pratschke K: Central hemimaxillectomy and reconstruction using a superficial temporal artery axial pattern flap in a
domestic short hair cat. J Feline Med Surg. 2003; 5: 241–244
[69]
[70]
[71]
[90]
Herring ES, Smith MM, Robertson JL: Lymph node staging of oral
and maxillofacial neoplasms in 31 dogs and cats. J Vet Dent. 2002;
19: 122–126
Lucke VM, Pearson GR, Gregory SP et al.: Tonsillar polyps in the
dog. J Small Anim Pract. 1988; 29: 373–379
[91]
Höinghaus R, Mischke R, Hewicker-Trautwein M: Use of immunocytochemical techniques in canine melanoma. J Vet Med A Physiol Pathol Clin Med. 2002; 49: 198–202
MacCaw DL, Pope ER, Payne JT et al.: Treatment of canine oral
squamous cell carcinomas with photodynamic therapy. Br J Cancer.
2000; 82: 1297–1299
[92]
Hörsting N, von Reiswitz A, Wohlsein P et al.: Oropharyngeale
Tumoren des Hundes – Eine klinische Studie über 79 Fälle. Berl
Münch Tierärztl Wschr. 1998; 111: 242–247
MacEwen EG, Patnaik AK, Harvey HJ et al.: Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium
parvum. Cancer Invest. 1986; 4: 397–402
[93]
MacEwen EG, Kurzman ID, Vail DM et al.: Adjuvant therapy for
melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte
macrophage colony-stimulating factor. Clin Cancer Res. 1999; 5:
4249–4258
[94]
MacMillan R, Withrow SJ, Gilette EL: Surgery and regional irradiation for treatment of canine tonsillar squamous cell carcinoma: retrospective review of eight cases. J Am Anim Hosp Assoc. 1982; 18:
311–314
[72]
Hutson CA, Willauer CC, Walder EJ et al.: Treatment of mandibular squamous cell carcinoma in cats by use of mandibulectomy and
radiotherapy: seven cases (1987–1989). J Am Vet Med Assoc. 1992;
201: 777–781
[73]
Jeglum KA, Sadanaga K: Oral tumors: the surgeon and the medical
oncologist. Vet Clin North Am Sm Anim Pract. 1996; 26: 145–153
[74]
Jones PD, de Lorimier LP, Kitchell BE et al.: Gemcitabine as a
radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc. 2003; 39: 463–467.
[95]
Kafka UC, Carstens A, Steenkamp G et al.: Diagnostic value of
magnetic resonance imaging and computed tomography for oral
masses in dogs. J S Afr Vet Assoc. 2004; 75: 163–168
Matthiesen DT, Marretta SM: Results and complications associated with partial mandibulectomy and maxillectomy techniques.
Probl Vet Med. 1990; 2: 248–275
[96]
Kapatkin AS, Marretta SM, Patnaik AK et al.: Mandibular swelling
in cats: a prospective study of 24 cats. J Am Anim Hosp Assoc.
1991; 27: 575–580
Mauldin GN, Mauldin GE, Meleo KA: Treatment of feline oral squamous cell carcinoma with radiation therapy alone or radiation therapy and hyperthermia. Newslet Vet Cancer Soc. 1992; 16: 4–5
[97]
Kessler M: Kieferresektion zur Therapie knocheninvasiver oraler
Tumoren des Hundes – eine retrospektive Untersuchung bei 31
Patienten. Kleintierprax. 2003; 48: 289–300
Mauldin GN, Meleo KA, Burk RL: Radiation therapy for the treatment of incompletely resected soft tissue sarcomas in dogs: 21
cases. Proc. 13th Ann Conf Vet Cancer Soc. 1993; 11158
[98]
Kessler M, von Bomhard D: Tumoren der Maulhöhle beim Hund:
Epidemiologische Untersuchungen bei 491 Fällen. (unveröffentlicht), 1997
McEntee MC, Page RL, Théon A et al.: Malignant tumor formation
in dogs previously irradiated for acanthomatous epulis. Vet Radiol
Ultrasound. 2004; 45: 357–361
[99]
Millanta F, Fratini F, Corazza M et al.: Proliferation activity in oral
and cutaneous canine melanocytic tumours: correlation with histological parameters, location, and clinical behaviour. Res Vet Sci.
2002; 73: 45–51
[75]
[76]
[77]
[78]
[79]
Kessler M, von Bomhard D: Beitrag zur pädiatrischen Onkologie
beim Kleintier. Berl Münch Tierärztl Wschr. 1997; 110: 311–314
71
72
[100] Miller TL, Price GS, Page RL et al.: Radiotherapy of canine non-tonsillar squamous cell carcinoma. Proc. 14th Ann Conf Vet Canc Soc.
1994; 20–21
[101] Miller AD, Alcaraz A, McDonough SP: Tonsillar lymphangiomatous
polyp in an adult dog. J Comp Pathol. 2008; 138: 215–217
[102] Moore AS, Theilen GH, Newell AD et al.: Preclinical study of
sequential tumor necrosis factor and interleukin-2 in the treatment
of spontaneous canine neoplasms. Cancer Res. 1991; 51: 233–238
[103] Moore AS, Wood CA, Engler SJ et al.: Radiation therapy for longterm control of odontogenic tumours and epulis in three cats. J
Feline Med Surg 2000; 2: 57–60
[124] Ramos-Vara JA, Beissenherz ME, Miller MA et al.: Retrospective
study of 338 canine oral melanomas with clinical, histologic, and
immunohistochemical review of 129 cases. Vet Pathol. 2000; 37:
597–608
[125] Rassnick KM, Ruslander DM, Cotter SM et al.: Use of carboplatin
for treatment of dogs with malignant melanoma: 27 cases (1989–
2000). J Am Vet Med Assoc. 2001; 218: 1444–1448
[126] Reichart PA, Philipsen HP, Dürr U-M: Epulides in dogs. J Oral Path
Med. 1989; 18: 92–96
[127] Reif JS, Cohen D: The environmental distribution of canine respiratory tract neoplasms. Arch Environ Health. 1971; 22: 136–140
[104] Mouatt JG, Straw RC: Use of mandibular symphysiotomy to allow
extensive caudal hemimaxillectomy in a dog. Aust Vet J. 2002; 80:
272–276
[128] Roels S, Tilmant K, Ducatelle R: PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic
tumours in cats and dogs. J Comp Pathol. 1999; 121: 13–24
[105] Muir P, Rosin E: Parotid duct obstruction after caudal maxillectomy
in a dog. Vet Rec. 1995; 136: 46
[129] Roes F, Lierz U, Rudolph R: Teilmandibulektomie bei einem Akanthom einer Katze. Kleintierprax. 2005; 50: 349–408
[106] Murphy S, Hayes A, Adams V et al.: Role of carboplatin in multimodality treatment of canine tonsillar squamous cell carcinoma – a
case series of five dogs. J Small Anim Pract. 2006: 47; 216–220
[130] Rieder JC: Vergleichende klinische und immunhistochemische Charakterisierung keratozystischer odontogener Tumoren und Ameloblastome im Hinblick auf das Rezidivverhalten. Diss med dent.,
2008
[107] Northrup NC, Selting KA, Rassnick KM et al.: Outcomes of cats
with oral tumors treated with mandibulectomy: 42 cases. J Am
Anim Hosp Assoc. 2006; 42: 350–360
[108] Oakes MG, Lewis DD, Hedlund CS et al.: Canine oral neoplasia.
Comp Cont Educ Pract Vet. 1993; 15: 15–30
[131] Salisbury SK, Lantz GC: Long-term results of partial mandibulectomy for treatment of oral tumors in 30 dogs. J Am Anim Hosp
Assoc. 1988; 24: 285–294
[109] Owen LN: TNM classification of tumors in domestic animals. Bull
WHO. Genf 1980
[132] Salisbury SK, Richardson DC, Lantz GC: Partial maxillectomy and
premaxillectomy in the treatment of oral neoplasia in the dog and
cat. Vet Surg. 1986; 15: 16–26
[110] Oyamada T, Tanaka H, Park CH et al.: Pathology of canine oral
malignant melanoma with cartilage and/or osteoid formation. J Vet
Med Sci. 2007; 69: 1155–1161
[133] Schantz SP, Harrison LB, Hong WK: Cancer of the head and neck.
In: DeVita VT, Hellman S, Rosenberg SA (Hrsg.): Cancer: Principles
and Practice of Oncology. Lippincott, Philadelphia 1993; 604–612
[111] Papadimitriou S, Papazoglou LG, Tontis D et al.: Compound
maxillary odontoma in a young German shepherd dog. J Small
Anim Pract. 2005; 46: 146–150
[134] Schmidt A, Kessler M, Tassani – Prell M: Computertomographische Erscheinungsformen akanthomatöser Ameloblastome – eine
retrospektive Untersuchung bei 52 Hunden. Tierärztl Prax. 2012; 3:
155–160
[112] Patnaik AK: Histologic and immunohistochemical studies of granular cell tumors in seven dogs, three cats, one horse, and one bird.
Vet Pathol. 1993; 30: 176–185
[113] Patnaik AK, Mooney S: Feline melanoma: a comparative study of
ocular, oral and dermal neoplasms. Vet Pathol. 1988; 25: 105–112
[114] Pestili de Almeida EM, Piche C, Sirois J et al.: Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in
dogs. J Histochem Cytochem.2001; 49: 867–875
[115] Pindborg JJ, Kramer IRH, Torloni H: Histological typing of odontogenic tumors, jaw cysts, and allied lesions. In: International histologic classification of tumors, No 5. WHO, Genf 1971
[116] Platz SJ, Breuer W, Pfleghaar S et al.: Prognostic value of histopathological grading in canine extramedullary plasmacytomas Vet
Pathol 1999; 36: 23–27
[117] Poirier VJ, Bley CR, Roos M et al.: Efficacy of radiation therapy for
the treatment of macroscopic canine oral soft tissue sarcoma. In
Vivo. 2006; 20: 415–419
[118] Poulet FM, Valentine BA, Summers BA: A survey of epithelial
odontogenic tumors and cysts in dogs and cats. Vet Pathol. 1992;
29: 369–380
[119] Postorino Reeves NC, Turrel JM, Withrow SJ: Oral squamous cell
carcinoma in the cat. J Am Anim Hosp Assoc. 1993; 29: 438–441
[120] Proulx DR, Ruslander DM, Dodge RK et al.: A retrospective analysis of 140 dogs with oral melanoma treated with external beam
radiation. Vet Radiol Ultrasound. 2003; 44: 352–359
[121] Quigley PJ, Leedale AH: Tumors involving bone in the domestic
cat: a review of fifty-eight cases. Vet Pathol. 1983; 20: 670–686
[122] Ragland WL, Gorham JR: Tonsillar carcinoma in rural dogs. Nature.
1967: 214: 925–926
[123] Rakich PM, Latimer KS, Weiss R et al.: Mucocutaneous plasmacytomas in dogs: 75 cases (1980–1987). J Am Vet Med Assoc. 1989;
194: 803–810
[135] Schmidt BR, Glickman NW, DeNicola DB et al.: Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J
Am Vet Med Assoc. 2001; 218: 1783–1786
[136] Schwarz PD, Withrow SJ, Curtis CR et al.: Mandibular resection as
a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc.
1991; 27: 601–610
[137] Schwarz PD, Withrow SJ, Curtis CR et al.: Partial maxillary resection as a treatment for oral cancer in 61 dogs. J Am Anim Hosp
Assoc. 1991; 27: 617–624
[138] Smith MM: Surgical approach for lymph node staging of oral and
maxillofacial neoplasms in dogs. J Am Anim Hosp Assoc. 1995; 31:
514–518
[139] Smith SH, Goldschmidt MH, McManus PM: A comparative review
of melanocytic neoplasms. Vet Pathol. 2002; 39: 651-678
[140] Snyder LA, Bertone ER, Jakowski RM et al.: p53 expression and
[141] Spangler WL, Kass PH: The histologic and epidemiologic bases for
Pathol. 2006; 43: 136–149
[142] Stebbins KE, Morse CC, Goldschmidt MH: Feline oral neoplasia: A
ten year survey. Vet Pathol. 1989; 26: 121–128
[143] Syrcle JA, Bonczynski JJ, Monette S et al.: Retrospective evaluation
of lingual tumors in 42 dogs: 1999–2005. J Am Anim Hosp Assoc.
2008; 44: 308–319
[144] Syverton JT: The pathogenesis of rabbit papilloma-to-carcinoma
sequence. Ann NY Acad Sci. 1952; 54: 1126–1140
[145] Théon AP, Rodriquez C, Madewell BR: Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc. 1997; 210:
778–784
[146] Theon AP, Rodriguez C, Griffey S et al.: Analysis of prognostic factors and patterns of failure in dogs with periodontal tumors treated
with megavoltage irradiation. J Am Vet Med Assoc. 1997; 210:
785–788
[4]
Burek KA, Munn RJ, Madewell BR: Metastatic adenocarcinoma of
a minor salivary gland in a cat. Zbl Vet Med A. 1994; 41: 485–490
[5]
[147] Thrall DE: Orthovoltage radiotherapy of acanthomatous epulides in
39 dogs. J Am Vet Med Assoc. 1984; 184: 826–829
Buyukmihci N, Rubin LF, Harvey CE: Exophthalmos secondary to
zygomatic adenocarcinoma in a dog. J Am Vet Med Assoc. 1975;
167: 162–165
[6]
[148] Thrall DE, Goldschmidt MH, Biery DN: Malignant tumor formation
at the site of previously irradiated acanthomatous epulides in four
Carberry CA, Flanders JA, Harvey HJ et al.: Salivary gland tumors
in dogs and cats: a literature and case review. J Am Anim Hosp
Assoc. 1988; 24: 561–567
[7]
[149] Thrall DE: Orthovoltage radiotherapy of oral fibrosarcomas in dogs.
J Am Vet Med Assoc. 1981; 179: 159–162
Couto CG, Hammer AS: Oncology. In: Sherding RS (Hrsg.): Diseases
of the cat. Churchill Livingstone, New York 1994; 755–818
[8]
Elsinghorst TA: First cases of animal diseases published since 2000.
6. First update of dog diseases. Vet Q. 2004; 26: 12–17
[9]
[151] Verstraete FJM, Ligthelm AJ, Weber A: The histological nature of
epulides in dogs. J Comp Path. 1992; 106: 169–182
Evans SM, Thrall DE: Post-operative orthovoltage radiation therapy
of the parotid salivary gland adenocarcinoma in three dogs. J Am
Vet Med Assoc. 1983; 182: 993–994
[10]
[152] Vos JH, van der Gaag I: Canine and feline oro-pharyngeal tumors.
Vet Med. 1987; 34: 420–427
Faustino AM, Dias Pereira P: A salivary malignant myoepithelioma
in a dog. Vet J. 2007; 173: 223–226
[11]
Giudice C, Marco R, Mirko R et al.: Zygomatic gland adenoma in a
dog: histochemical and immunohistochemical evaluation. Vet Ophthalmol. 2005; 8: 13–16
[12]
Grevel V, Schmidt S, Mettler F: Multiple Kochenmetastasen eines
Speicheldrüsenkarzinoms bei einem Hund. Schweiz Arch Tierheilkd.
1978; 120: 13–22
[13]
Habin DJ, Else RW: Parotid salivary gland adenocarcinoma with
bilateral ocular and osseous metastases in a dog. J Small Anim
Pract. 1995; 36: 445–449
[14]
[158] White RAS: Mandibulectomy and maxillectomy in the dog. Results
of 75 cases. Vet Surg. 1987; 16: 105–110
Hammer AS, Getzy D, Ogilvie GK et al.: Salivary gland neoplasia in
the dog and cat: Survival times and prognostic factors. J Am Anim
Hosp Assoc. 2001; 37: 478–482
[15]
[159] White RAS, Gorman NT, Watkins SB et al.: The surgical management of bone-involved oral tumors in the dog. J Small Anim Pract.
1985; 26: 693–708
Kaewamatawong T, Rungsipipat A, Chutatep S: Canine extraskeletal osteosarcoma of the salivary gland. Thai J Vet Med. 2000; 30:
65–73
[16]
Karbe E, Schiefer B: Primary salivary gland tumors in carnivores.
Can Vet J. 1967; 8: 212–215
[17]
Kessler M, Kühnel S: Tumoren der Speicheldrüsen bei 8 Katzen.
2012 (unveröffentlicht)
[161] Withrow SJ, Holberg DL: Mandibulectomy in the treatment of oral
cancer. J Am Anim Hosp Assoc. 1981; 19: 273–286
[18]
Kim H, Nakaichi M, Itamoto K et al.: Malignant mixed tumor in
the salivary gland of a cat. J Vet Sci. 2008; 9: 331–333
[162] Withrow SJ, Nelson AW, Manley PA: Premaxillectomy in the dog.
[19]
[163] Wright ZM, Rogers KS, Mansell J: Survival data for canine oral extramedullary plasmacytomas: a retrospective analysis (1996–2006).
Kitshoff AM, Millward IR, Williams JH et al.: Infiltrative angiolipoma of the parotid salivary gland in a dog. J S Afr Vet Assoc.
2010; 81: 258–261
[20]
[164] Wypij JM, Fan TM, Fredrickson RL et al.: In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in
cats. J Vet Intern Med. 2008; 22: 158–163
Köstner A, Bürger L: Primary neoplasms of salivary glands in animals compared to similar tumors in man. Vet Pathol. 1965; 2: 201–
226
[21]
[165] Yoshida K, Watarai Y, Sakai Y et al.: The effect of intralesional
bleomycin on canine acanthomatous epulis. J Am Anim Hosp Assoc.
1998; 34: 457–461
Louw GJ, van Schouwenburg SJ: A case of a highly invasive carcinoma of a salivary gland in a crossbred dog. J S Afr Vet Assoc. 1984;
55: 131–132
[22]
[166] Yoshida K, Yanai T, Iwasaki T et al.: Clinicopathological study of
canine oral epulides. J Vet Med Sci. 1999; 61: 897–902
Mazzullo G, Sfacteria A, Ianelli N et al.: Carcinoma of the submandibular salivary glands with multiple metastases in a cat. Vet Clin
Pathol. 2005; 34: 61–64
[23]
[167] Zaugg N, Nespeca G, Hauser B, et al.: Detection of novel papillomaviruses in canine mucosal, cutaneous and in situ squamous cell
carcinomas. Vet Dermatol. 2005;16: 290–298
Militerno G, Bazzo R, Marcato PS: Cytological diagnosis of mandibular salivary gland adenocarcinoma in a dog. J Vet Med A Physiol
Pathol Clin Med. 2005; 52: 514–516
[24]
Oshikata T, Kuwasaki E, Katoku K et al.: Malignant mixed tumor
of salivary gland in a dog. J Toxicol Pathol. 2006; 19; 147–150
[25]
Pérez-Martínez C, García Fernández RA, Reyes Avila LE et al.:
Malignant fibrous histiocytoma (giant cell type) associated with a
malignant mixed tumor in the salivary gland of a dog. Vet Pathol.
2000; 37: 350–353
[150] Todoroff RJ, Brodey RS: Oral and pharyngeal neoplasia in the dog:
a retrospective survey of 361 cases. J Am Vet Med Assoc. 1979;
175: 567–571
[153] Vrieling HE, Schepman KP, Theyse LF, et al.: [Oral carcinoma in 34
dogs]. Ned Tijdschr Tandheelkd. 1999; 106: 122–125
[154] Wallace J, Matthiesen DT, Patnaik AK: Hemimaxillectomy for the
treatment of oral tumors in 69 dogs. Vet Surg. 1992; 21: 337–341
[155] Walsh KM, Denholm DJ, Cooper BJ: Epithelial odontogenic tumors
in domestic animals. J Comp Pathol. 1987; 97: 503–521
[156] Watrach AM, Small E, Case MT: Canine papilloma: progression of
oral papilloma to carcinoma. J Natl Cancer Inst. 1970; 45: 915–920
[157] White RAS: Mandibulectomy and maxillectomy in the dog: long
term survival in 100 cases. J Small Anim Pract. 1991; 32: 69–74
[160] Williams LE, Packer RA: Association between lymph node size and
metastasis in dogs with oral malignant melanoma: 100 cases
(1987-2001). J Am Vet Med Assoc. 2003; 222: 1234–1236
19.2 Tumoren der Speicheldrüsen
[1]
Bartoe JT, Brightman AH, Davidson HJ: Modified lateral orbitotomy for vision-sparing excision of a zygomatic mucocele in a dog.
Vet Ophthalmol. 2007; 10: 127–131
[26]
[2]
Brocks BA, Peeters ME, Kimpfler S: Oncocytoma in the mandibular salivary gland of a cat. J Fel Med Surg. 2008; 10: 188–191.
Ratto A, Pfeiffer RL, Peruccio C et al.: Zygomatic salivary gland
adenocarcinoma in a dog. Prog Vet Comp Ophth. 1991; 1: 59–62
[27]
[3]
Brown NO: Salivary gland diseases. Diagnosis, treatment, and associated problems. Probl Vet Med. 1989; 1: 281–294
Shimoyama Y, Yamashita K, Ohmachi T et al.: Pleomorphic adenoma of the salivary gland in two dogs. J Comp Pathol. 2006; 134:
254–259
73
74
[28]
Smrkovski OA, LeBlanc AK, Smith SH et al.: Carcinoma ex pleomorphic adenoma with sebaceous differentiation in the mandibular
salivary gland of a dog. Vet Pathol. 2006; 43: 374–377
[15]
Head KW, Else RW, Dubielzig RR: Tumours of the alimentary
tracts. In Meuten DJ (Hrsg.): Tumors of domestic animals. 4. Aufl.,
Iowa State Press, Ames 2002; 439–443.
[29]
Sozmen M, Brown PJ, Eveson JW: Salivary gland basal cell adenocarcinoma: a report of cases in a cat and two dogs. J Vet Med A Physiol Pathol Clin Med. 2003; 50: 399–401
[16]
Holmberg DL, Kuzma AB, Miller CW: Free bowel transfer for esophageal reconstruction in the dog. Microsurgery. 1991; 12: 140–
144
[30]
Sozmen M, Brown PJ, Eveson JW: Cytokeratin immunostaining in
normal dog major and minor salivary glands. Vet Res. 1998; 29:
457–465
[17]
Kirberger RM, Dvir E, van der Merwe LL: The effect of positioning
on the radiographic appearance of caudodorsal mediastinal masses
in the dog. Vet Radiol Ultrasound. 2009; 50: 630–634
[31]
Sozmen M, Brown PJ, Eveson JW: Sebaceous carcinoma of the
salivary gland in a cat. J Vet Med A Physiol Pathol Clin Med. 2002;
49: 425–427
[18]
Kook PH, Wiederkehr D, Makara M et al.: Megaösophagus infolge
eines ösophagealen Leiomyoms und Ösophagitis beim Hund.
Schweiz Arch Tierheilkd. 2009; 151: 497–501
[32]
Sozmen M, Brown PJ, Eveson JW: Salivary duct carcinoma in five
cats. J Comp Pathol. 1999; 121: 311–319
[19]
[33]
Spangler WL, Culbertson MR: Salivary disease in dogs and cats.
Kuzma AB, Holmberg DL, Miller CW et al.: Esophageal replacement in the dog by microvascular colon transfer. Vet Surg. 1989;
18: 439–445
[20]
[34]
Thomsen BV, Myers RK: Extraskeletal osteosarcoma of the mandibular salivary gland in a dog. Vet Pathol. 1999; 36: 71–73
Kyles AE: Esophagus. In Slatter D (Hrsg.): Textbook of Small Animal
Surgery (3. Aufl). Philadelphia PA, Saunders, 2002, 573–592
[21]
[35]
van der Woerdt A: Orbital inflammatory disease and pseudotumor
in dogs and cats. Vet Clin North Am Small Anim Pract. 2008; 38:
389–401, vii–viii
Lawson DD, Pirie HM: Conditions of the canine esophagus – (II)
vascular rings, achalasia, tumors, and peri-esophageal lesions. J
[22]
[36]
Wells GA, Robinson M: Mixed tumour of salivary gland showing
histological evidence of malignancy in a cat. J Comp Pathol. 1975;
85: 77–85
Lindsay N, Kirberger R, Williams M: Imaging diagnosis – spinal
cord chondrosarcoma associated with spirocercosis in a dog. Vet
[23]
Mazaki-Tovi M, Baneth G, Aroch I et al.: Canine spirocercosis: clinical, diagnostic, pathologic, and epidemiologic characteristics. Vet
Parasitol. 2002; 107: 235–250
[24]
McCaw D, Pratt M, Walshaw R: Squamous cell carcinoma of the
esophagus in a dog, J Am Anim Hosp Assoc. 1980; 16: 561–563
[25]
Mori T: [An experimental study on the hemodynamics of the gastric tube for esophageal reconstruction] Nippon Geka Hokan. 1991;
60: 250–263
[26]
Münster M, Ballauf B, Kraft W: Zwei Fälle von sekundären Speiseröhrenkarzinomen bei der Katze. Tierarztl Prax. 1987; 15: 225–228
[27]
Patnaik AK, Erlandson RA, Lieberman PH: Esophageal neuroendocrine carcinoma in a cat. Vet Pathol. 1990; 27: 128–130
[28]
Pavletic MM: Stapling in esophageal surgery. Vet Clin North Am
Small Anim Pract. 1994; 24: 395–412.
[29]
Ranen E, Shamir MH, Shahar R et al.: Partial esophagectomy with
single layer closure for treatment of esophageal sarcomas in 6
dogs. Vet Surg. 2004; 33: 428–434
[30]
Ranen E, Lavy E, Aizenberg I et al.: Spirocercosis-associated esophageal sarcomas in dogs. A retrospective study of 17 cases (1997–
2003). Vet Parasitol. 2004; 119: 209–221
[31]
Ridgway RL, Suter PF: Clinical and radiographic signs in primary
and metastatic esophageal neoplasms of the dog. J Am Vet Med
Assoc. 1979; 174: 700–704
19.3 Tumoren des Ösophagus
[1]
[2]
Becker H, Seufert RM, Hottenrott C et al.: Tierexperimentelle
Untersuchungen der Magendurchblutung. III. Restdurchblutung
des skelettierten Magens. Res Exp Med (Berl). 1979; 176: 103–106
Berube D, Scott-Moncrieff JC, Rohleder J et al.: Primary esophageal squamous cell carcinoma in a cat. J Am Anim Hosp Assoc.
2009; 45: 291–295
[3]
Bouayad H, Caywood DD, Alyakine H et al.: Surgical reconstruction of partial circumferential esophageal defect in the dog. J Invest
Surg. 1992; 5: 327–342
[4]
Carb AV, Goodmann DG: Esophageal carcinoma in the dog. J Small
Anim Pract. 1973; 14: 91–99
[5]
Cotchin E: Some tumours of dogs and cats of comparative veterinary and human interest. Vet Rec. 1959; 71: 1040–1054
[6]
Dvir E, Kirberger RM, Mukorera V et al.: Clinical differentiation
between dogs with benign and malignant spirocercosis. Vet Parasitol. 2008; 155: 80–88
[7]
Farese JP, Bacon NJ, Ehrhart NP et al.: Oesophageal leiomyosarcoma in dogs: surgical management and clinical outcome of four
cases. Vet Comp Onc. 2008; 6: 31–38
[8]
Fernandes FH, Hawe RS, Loeb WF: Primary squamous cell carcinoma of the esophagus in a cat. Comp Anim Pract. 1987: 1: 16–22
[32]
[9]
Fox SM, Burns J, Hawkins J: Spirocercosis in dogs. Comp Cont Ed
Shinozuka J, Nakayama H, Suzuki M et al.: Esophageal adenosquamous carcinoma in a cat. J Vet Med Sci. 2001; 63: 91–93
[33]
[10]
Gibson CJ, Parry NM, Jakowski RM et al.: Adenomatous polyp
with intestinal metaplasia of the esophagus (Barrett esophagus) in
a dog. Vet Pathol. 2010; 47: 116–119
Sumner-Smith G: Oesophagotomy and oesophageal resection. J
[34]
van der Merwe LL, Kirberger RM, Clift S et al.: Spirocerca lupi
infection in the dog: a review. Vet J. 2008; 176: 294–309
[11]
Gualtieri M, Monzeglio MG, Di Giancamillo M: Oesophageal squamous cell carcinoma in two cats. J Small Anim Pract. 1999; 40: 79–
83
[35]
Vernon FF, Roudebush P: Primary esophageal carcinoma in a cat. J
[36]
Withrow SJ: Osophageal Cancer. In: Withrow SJ, Vail DM (Hrsg.):
Small animal clinical oncology. 4. Aufl., WB Saunders Co, St. Louis,
Missouri 2007; 477–478
[12]
Gualtieri M, Olivero D: Reflux esophagitis in three cats associated
with metaplastic columnar esophageal epithelium. J Am Anim Hosp
Assoc. 2006; 42: 65–70
[13]
Hamilton TA, Carpenter JL: Esophageal plasmacytoma in a dog. J
Am Vet Med Assoc. 1994; 204: 1210–1211
[14]
Happé RP, van der Gaag I, Wolvekamp WT et al.: Esophageal
squamous cell carcinoma in two cats. Tijdschr Diergeneeskd. 1978;
103: 1080–1086
19.4 Tumoren des Magens
[1]
Bagley RS, Levy JK, Malarkey DE: Hypoglycemia associated with
intra-abdominal leiomyoma and leiomyosarcoma in six dogs. J Am
Vet Med Assoc. 1996; 208: 69–71
[2]
Beck JA, Simpson DS: Surgical treatment of gastric leiomyoma in a
dog. Aust Vet J. 1999; 77: 161–163
[3]
Beck C, Slocombe RF, OʼNeill T, et al.: The use of ultrasound in the
investigation of gastric carcinoma in a dog. Aust Vet J. 2001; 79:
332–334
[26]
Lecoindre P, Richard S: Les anomalies digestives associées au syndrome respiratoire obstructif des brachycéphales. A propos de 30 cas
(1999–2001). Revue Méd Vét 2004; 155: 141–146
[4]
Bilek A, Hirt RA: Magenkarzinome beim Chow-Chow: rasseassoziierte Häufung. Wien Tierärztl Mschr. 2007; 94: 71 – 79
[27]
[5]
Bonfanti U, Bertazzolo W, Bottero E, et al.: Diagnostic value of
1130–1133
Lecoindre P: Ultrasonographic and endoscopic examination of gastric and colo-rectal tumours. Proc. 6th Ann Conf Europ Soc Vet Int
Med., Veldhoven, NL 1996; 6–8
[28]
Leib MS, Larson MM, Panciera DL, et al.: Diagnostic utility of
abdominal ultrasonography in dogs with chronic vomiting. J Vet
Intern Med. 2010; 24: 803–808
[6]
Bridgeford EC, Marini RP, Feng Y, et al.: Gastric Helicobacter species as a cause of feline gastric lymphoma: a viable hypothesis. Vet
[29]
Lingeman CH, Garner FM, Taylor DON: Spontaneous gastric adenocarcinomas of dogs: a review. J Natl Cancer Inst. 1971; 47:137–
153
[7]
Brunnert SR, Dee LA, Herron AJ, et al.: Gastric extramedullary
plasmacytoma in a dog. J Am Vet Med Assoc. 1992; 200: 1501–
1502
[30]
Lubbes D, Mandigers PJ, Heuven HC, et al.: [Incidence of gastric
carcinoma in Dutch Tervueren shepherd dogs born between 1991
and 2002]. Tijdschr Diergeneeskd. 2009; 134: 606–610
[8]
Carrasco V, Canfrán S, Rodríguez-Franco F, et al.: Canine gastric
carcinoma: immunohistochemical expression of cell cycle proteins
(p53, p21, and p16) and heat shock proteins (Hsp27 and Hsp70).
Vet Pathol. 2011; 48: 322–329
[31]
Mahony OM, Moore AS, Cotter SM, et al.: Alimentary lymphoma
1593–1598
[32]
[9]
Cohen M, Post GS, Wright JC: Gastrointestinal leiomyosarcoma in
14 dogs. J Vet Int Med. 2003; 17: 107–110
Murray M, McKeating FJ, Lauder IM: Primary gastric neoplasia in
the dog. a clinicopathological study. Vet Rec. 1972; 91: 474–479
[33]
[10]
Couto GC, Rutgers HC, Sherding RG, et al.: Gastrointestinal lymphoma in 20 dogs: a retrospective study. J Vet Int Med. 1989; 3:
474–479
Neuerer F, Hartmann K: Der klinische Fall: Anämie durch chronische gastrointestinale Blutung aufgrund eines ulzerierten Adenokarzinoms des Magens mit sekundärem Eisenmangel bei einem Hund.
Tierärztl Prax. 2006 34: 252–267
[11]
Culbertson R., Branam JE, Rosenblatt LS: Esophageal/gastric leiomyoma in the laboratory Beagle. J Am Vet Med Assoc. 1983; 183:
1168–1171
[34]
Olivieri M, Gosselin Y, Sauvageau R: Gastric adenocarcinoma in a
dog: six-and-one-half month survival following partial gastrectomy
and gastroduodenostomy. J Am Anim Hosp Assoc. 1984; 20: 78–82
[12]
DellʼOrco M, Bertazzolo W, Vergine M, et al.: Gastric mucinous
adenocarcinoma with cutaneous metastases in a dog: diagnosis by
fine-needle aspiration cytology. J Small Anim Pract. 2005; 46: 449–
453
[35]
Qvigstad G, Kolbjørnsen Ø, Skancke E, et al.: Gastric neuroendocrine carcinoma associated with atrophic gastritis in the norwegian
lundehund. J Comp Pathol. 2008; 139: 194–201
[36]
[13]
Dennis MM, Bennett N, Ehrhart EJ: Gastric adenocarcinoma and
chronic gastritis in two related Persian cats. Vet Pathol. 2006; 43:
358–362.
Park CH, Ishizuka Y, Tsuchida Y, et al.: Gastric pleomorphic leiomyosarcoma in a Shetland sheepdog. J Vet Med Sci. 2007; 69: 873–
876
[37]
[14]
Eisele J, McClaran JK, Runge JJ, et al.: Evaluation of risk factors for
morbidity and mortality after pylorectomy and gastroduodenostomy in dogs. Vet Surg. 2010; 39: 261–267
Patnaik AK, Hurvitz AI, Johnson GF: Canine gastrointestinal neoplasms. Vet Pathol. 1977; 14: 547–555
[38]
Penninck DG, Moore AS, Gliatto J: Ultrasonography of canine gastric neoplasia. Vet Radiol Ultrasound. 1998; 39: 342–348
[15]
Fant P, Caldin M, Furlanello T, et al.: Primary gastric histiocytic sarcoma in a dog–a case report. J Vet Med A Physiol Pathol Clin Med.
2004; 51: 358–362
[39]
Pohlman LM, Higginbotham ML, Welles EG, et al.: Immunophenotypic and histologic classification of 50 cases of feline gastrointestinal lymphoma. Vet Pathol. 2009; 46: 259–268
[16]
Fossum TW, Hedlund CS: Gastric and intestinal surgery. Vet Clin
North Am Small Anim Pract. 2003; 33: 1117–1145, viii
[40]
[17]
Frank JD, Reimer SB, Kass PH, et al.: Clinical outcomes of 30 cases
(1997–2004) of canine gastrointestinal lymphoma. J Am Anim Hosp
Assoc. 2007; 43: 313–321
Rivers BJ, Walter PA, Johnston GR, et al.: Canine gastric neoplasia.
Utility of ultrasonography in diagnosis. J Am Anim Hosp Assoc.
1997; 33: 144–155
[41]
Rossmeissl JH Jr, Forester SD, Robertson JL et al.: Chronic vomiting associated with gastric carcinoid in a cat. J Am Anim Hosp
Assoc. 2002; 38: 61–66
[18]
Gualtieri M, Monzeglio MG, Scanziani E: Gastric neoplasia. Vet
[42]
[19]
Gualtieri M, Monzeglio MG, Scanziani E: Gastrointestinal polyps in
small animals. Proc. 6th Ann Conf Europ Soc Vet Int Med, Veldhoven,
NL 1996; 8–10
Sautter JH, Hanlon GF: Gastric neoplasms in the dog: a report of
20 cases. J Am Vet Med Assoc. 1975; 166: 691–696
[43]
Scanziani E, Giusti AM, Gualteri M, et al.: Gastric carcinoma in the
Belgian shepherd dog. J Small Anim Pract. 1991; 32: 465–469
[20]
Hayden DW, Nielsen SW: Canine alimentary neoplasia. Zbl Vet
Med A 1973; 20: 1–22
[44]
[21]
Kapatkin AS, Mullen HS, Matthiesen DT, et al.: Leiomyosarcoma
1077–1079
Seigner P, Parodi AL: Les tumeurs primitives du tractus gastrointestinal chez le chien. Etude restrospective sur une période de 10
années. Prat Méd Chir Anim. 1991; 26: 99–107
[45]
Shimosato Y, Tanaka N, Kogure K, et al.: Histopathology of
tumors of canine alimentary tract produced by N-methyl-Nʼ-nitroN-nitrosoguanidine, with particular reference of gastric carcinoma. J
Natl Cancer Inst. 1971; 47: 1053–1070
[46]
Simon D, Meneses F, Nolte I: Möglichkeiten der Diagnostik von
Tumorerkrankungen am Magen-Darm-Trakt. Tierärztl Prax K. 2005;
33: 401–406
[22]
Kerpsack SJ, Birchard SJ: Removal of leiomyomas and other noninvasive masses from the cardiac region of the canine stomach. J
[23]
Krauser K: Neoplasien des Magens beim Hund. Berl Münch Tierärztl
Wschr. 1985; 98: 48–53
[24]
Lamb CR, Grierson J: Ultrasonographic appearance of primary gastric neoplasia in 21 dogs. J Small Anim Pract. 1999; 40: 211–215
[47]
Sullivan M, Lee R, Fischer EW, et al.: A study of 31 cases of gastric
carcinoma in dogs. Vet Rec. 1987; 120: 79–83
[25]
Landes C, von Sandersleben J: Primäre Neoplasien und Schleimhauthyperplasien im Magen des Hundes. Tierärztl Prax. 1985; 1:
139–158
[48]
Swann HM, Holt DE: Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986–1999) and literature review. J Am Anim Hosp Assoc. 2002; 38: 157–164
75
76
[49]
Turk MA, Gallina AM, Russell TS: Nonhematopoietic gastrointestinal neoplasia in cats: a retrospective study of 44 cases Vet Pathol.
1981; 18: 614–620
[20]
Feeney DA, Klausner J, Johnston GR: Chronic bowel obstruction
caused by primary intestinal neoplasia: A report of five cases. J Am
[50]
van der Gaag I: Gastrointestinal tumors in dogs and cats: a retrospective study. Proc 15th Meeting Europ Soc Vet Path, SassariAlghero (Italien) 1997
[21]
Fondacaro JV, Richter KP, Carpenter JL et al: Feline gastrointestinal lymphoma: 76 cases (1988–1996). Eur J Comp Gastroenterol.
1999; 4: 5–11
[51]
Walter MC, Matthiesen DT, Stone EA: Pylorectomy and gastroduodenostomy in the dog: Technique and clinical results in 28
cases. J Am Vet Med Assoc. 1985; 187: 909–914
[22]
Frank JD, Reimer SB, Kass PH et al.: Clinical outcomes of 30 cases
Assoc. 2007; 43: 313–321
[23]
French RA, Seitz SE, Valli VE: Primary epitheliotropic alimentary Tcell lymphoma with hepatic involvement in a dog. Vet Pathol. 1996;
33: 349–352
[24]
Frost D, Lasota J, Miettinen M: Gastrointestinal stromal tumors
and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol. 2003; 40:
42–54
[25]
Gaag van der I: Gastrointestinal tumors in dogs and cats: a retrospective study. Proc 15th Meeting Europ Soc Vet Pathol. 1997
[26]
Gabor LJ, Canfield PJ, Malik R: Immunophenotypic and histological
characterisation of 109 cases of feline lymphosarcoma. Aust Vet J.
1999; 77: 436–441
[27]
Gabor LJ, Canfield PJ, Malik R: Haematological and biochemical
findings in cats in Australia with lymphosarcoma. Aust Vet J. 2000;
78: 456–461
19.5 Tumoren des Dünndarms
[1]
Bagley RS, Levy JK, Malarkey DE: Hypoglycemia associated with
intra-abdominal leiomyoma and leiomyosarcoma in six dogs. J Am
Vet Med Assoc. 1996; 208: 69–71
[2]
Barker I, Van Dreumel A: The alimentary system. In: Jubb KVF,
Kennedy PC, Palmer N (Hrsg.), Pathology of Domestic Animals. Vol.
2, Orlando: 3. Aufl. Academic Press, 1985; 1–237
[3]
Beaudry D, Knapp DW, Montgomery T et al.: Hypoglycemia in
four dogs with smooth muscle tumors. J Vet Int Med. 1995; 9: 415–
418
[4]
Benitah N, deLorimier LP, Gaspar M et al.: Chlorambucil induced
myoclonus in a cat with lymphoma. J Am Anim Hosp Assoc. 2003;
39: 283–287
[5]
Birchard, SJ, Couto GC, Johnson S: Nonlymphoid intestinal neoplasia
in 32 dogs and 14 cats. J Am Anim Hosp Assoc. 1986; 22: 533–537
[28]
[6]
Bonfanti U, Bertazzolo W, Bottero E et al.: Diagnostic value of
1130–1133
Gaschen L: Ultrasonography of small intestinal inflammatory and
neoplastic diseases in dogs and cats. Vet Clin North Am Small Anim
Pract. 2011; 41: 329–344
[29]
Gibbs C, Pearson H: Localized tumors of canine small intestine: a
report of twenty cases. J Small Anim Pract. 1986; 27: 507–519
[30]
Gieger T: Alimentary lymphoma in cats and dogs. Vet Clin North
[31]
Gillespie V, Baer K, Farrelly J et al.: Canine gastrointestinal stromal
tumors: immunohistochemical expression of CD34 and examination of prognostic indicators including proliferation markers Ki67
and AgNOR. Vet Pathol. 2011; 48: 283–291.http://www.ncbi.nlm.
nih.gov/pubmed?term=%22Craft%20D%22%5BAuthor%5D
[32]
Goggin JM, Biller DS, Debey BM et al.: Ultrasonographic measurement of gastrointestinal wall thickness and the ultrasonographic
appearance of the ileocolic region in healthy cats. J Am Anim Hosp
Assoc. 2000; 36: 224–228
[7]
Bortnowski HB, Rosenthal RC: Gastrointestinal mast cell tumors
and eosinophilia in two cats. J Am Anim Hosp Assoc. 1992; 28:
271–275
[8]
Bruecker KA, Withrow SJ: Intestinal leiomyosarcomas in six dogs. J
Am Hosp Assoc. 1988; 24: 281–284
[9]
Carakostas MC, Kennedy GA, Kittleson MD et al.: Malignant foregut carcinoid in a domestic cat. Vet Pathol. 1979; 16: 607–609
[10]
Carreras JK, Goldschmidt M, Lamb M et al.: Feline epitheliotropic
intestinal malignant lymphoma: 10 cases (1997–2000) J Vet Intern
Med. 2003; 17: 326–331
[11]
Cesari A, Bettini G, Vezzali E: Feline intestinal T-cell lymphoma:
assessment of morphologic and kinetic features in 30 cases. J Vet
Diagn Invest. 2009; 21: 277–279
[33]
Grooters AM, Biller DS, Ward H et al.: Ultrasonographic appearance of feline alimentary lymphoma. Vet Radiol Ultrasound 1994;
35: 468–472
[12]
14 dogs. J Vet Intern Med. 2003; 17: 107–110
[34]
[13]
Cotter SM: Treatment of lymphoma and leukemia with cyclophosphamid, vincristin and prednisone. II. Treatment of cats. J Am
Anim Hosp Assoc. 1983; 19: 166–172
Halsey CHC, Powers BE, Kamstock DA: Feline intestinal sclerosing
mast cell tumour: 50 cases 1997–2008. Vet Comp Oncol. 2010; 8:
72–79
[35]
Couto CG , Rutgers HC, Sherding RG, et al.: Gastrointestinal lymphoma in 20 dogs. A retrospective study. J Vet Intern Med. 1989; 3:
73–78
Howl JH, Petersen MG: Intestinal mast cell tumor in a cat: presentation as eosinophilic enteritis. J Am Anim Hosp Assoc.1995; 31:
457–461
[36]
Jackson MW, Helfand SC. Smedes L et al.: Primary IgG secreting
plasma cell tumor in the gastrointestinal tract of a dog. J Am Vet
Med Assoc. 1994; 204: 404–406
[37]
Jackson ML, Wood SL, Misra V et al.: Immunohistochemical identification of B and T lymphocytes in formalin fixed, paraffin embedded feline lymphosarcomas: relation to feline leukemia virus status,
tumor site and patient age. Can J Vet Res. 1996; 60: 199–204
[14]
[15]
Coyle KA, Steinberg H: Characterization of lymphocytes in canine
gastrointestinal lymphoma. Vet Pathol. 2004; 41:141–146
[16]
Crawshaw J, Berg J, Sardinas JC et al.: Prognosis for dogs with
nonlymphomatous, small intestinal tumors treated by surgical excision. J Am Anim Hosp Assoc. 1998; 34: 451–456
[17]
Darbes J, Majzoub M, Breuer W et al.: Large granular lymphocyte
leukemia/lymphoma in six cats. Vet Pathol. 1998; 35:370–379
[38]
Jeglum KA, Whereat A, Young K: Chemotherapy of lymphoma in
75 cats. J Am Vet Med Assoc. 1987; 190: 174–178
[18]
Davenport DJ, Leib MS, Roth L: Progression of lymphocytic-plasmacytic enteritis to gastrointestinal lymphoma in three cats. Proc
7th Ann Conf Vet Cancer Soc, Madison 1987
[39]
Juopperi TA, Cesta M, Tomlinson L et al.: Extensive cutaneous
metastases in a dog with duodenal adenocarcinoma. Vet Clin
Pathol. 2003; 32: 88–91
[19]
Evans SE, Bonczynski JJ, Broussard JD et al.: Comparison of endoscopic and full-thickness biopsy specimens for diagnosis of inflammatory bowel disease and alimentary tract lymphoma in cats. J Am
Vet Med Assoc. 2006; 229: 1447–1450
[40]
Kapatkin AS, Mullen HS, Matthiesen DT et al.: Leiomyosarcoma
1077–1079
[41]
Kiselow MA, Rassnick KM, McDonough SP et al.: Outcome of
cats with low-grade lymphocytic lymphoma: 41 cases (1995–
2005). J Am Vet Med Assoc. 2008; 232: 405–410
[61]
Parshley DL, Larue SM, Kitchell B et al.: Abdominal irradiation as a
rescue therapy for feline gastrointestinal lymphoma: a retrospective
study of 11 cats (2001–2008). J Feline Med Surg. 2011; 13: 63–68
[42]
Kiupel M, Smedley RC, Pfent C et al.: Diagnostic algorithm to differentiate lymphoma from inflammation in feline small intestinal
biopsy samples. Vet Pathol. 2011; 48: 212–222
[62]
Patnaik AK, Hurvitz AI, Johnson GF: Canine gastroinestinal neoplasms. Vet Pathol. 1977; 14: 547–555
[63]
[43]
Kleinschmidt S, Harder J, Nolte I et al.: Chronic inflammatory and
non-inflammatory diseases of the gastrointestinal tract in cats:
diagnostic advantages of full-thickness intestinal and extraintestinal
biopsies. J Feline Med Surg. 2010; 12: 97–103
Patnaik AK, Hurvitz AI, Johnson GF: Canine intestinal adenocarcinoma and carcinoid. Vet Pathol. 1980; 17: 149–163
[64]
Patnaik AK, Twedt DC, Marretta SM: Intestinal mast cell tumor in
a dog. J Small Anim Pract. 1980; 21: 207–212
[65]
Patnaik AK, Liu SK, Johnson GF: Feline intestinal adenocarcinoma.
A clinicopathologic study of 22 cases. Vet Pathol. 1976; 13: 1–10
[66]
Patterson-Kane JC, Kugler BP, Francis K: The possible prognostic
significance of immunophenotype in feline alimentary lymphoma: a
pilot study. J Comp Pathol. 2004; 130: 220–222
[67]
Peaston AE, Griffey SM: Visceral mast cell tumour with eosinophilia
and eosinophilic peritoneal and pleural effusions in a cat. Aust Vet J.
1994; 71: 215–217
[68]
Penninck DG, Smyers B, Webster CR et al.: Diagnostic value of
ultrasonography in differentiating enteritis from intestinal neoplasia
in dogs. Vet Radiol Ultrasound. 2003; 44: 570–575
[69]
Penninck DG: Characterization of gastrointestinal tumors. Vet Clin
[70]
Pfeil C, Loupal G: Tumoren im Darmtrakt des Hundes. Ztbl Vet
Med A 1984; 31: 146–159
[71]
Pohlman LM, Higginbotham ML, Welles EG et al.: Immunophenotypic and histologic classification of 50 cases of feline gastrointestinal lymphoma. Vet Pathol. 2009; 46: 259–268
[72]
Rassnick KM, Moore AS, Collister KE et al.: Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in
[73]
Richter KP: Feline gastrointestinal lymphoma. Vet Clin North Am
Small Anim Pract. 2003; 33: 1083–98, vii
[74]
Rissetto K, Villamil JA, Selting KA et al.: Recent trends in feline
intestinal neoplasia: an epidemiologic study of 1,129 cases in the
veterinary medical database from 1964 to 2004. J Am Anim Hosp
Assoc. 2011; 47: 28–36
[75]
Rivers BJ, Walter PA, Feeney DA et al.: Ultrasonographic features
of intestinal adenocarcinoma in five cats. Vet Radiol Ultrasound.
1997; 38: 300–306
[76]
Roccabianca P, Vernau W, Caniatti M et al.: Feline large granular
lymphocyte (LGL) lymphoma with secondary leukemia: primary
intestinal origin with predominance of a CD3/CD8(alpha)(alpha)
phenotype. Vet Pathol. 2006; 43: 15–28
[77]
Russell KN, Mehler SJ, Skorupski KA et al.: Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors
from leiomyosarcomas in dogs: 42 cases (1990–2003). J Am Vet
Med Assoc. 2007; 230: 1329–1333
[78]
Sako T, Uchida E, Okamoto M et al.: Immunohistochemical evaluation of a malignant intestinal carcinoid in a dog. Vet Pathol.
2003; 40: 212–215
[79]
Sato AF, Solano M: Ultrasonographic findings in abdominal mast
[80]
Schwandt CS: Low-grade or benign intestinal tumours contribute
to intussusception: a report on one feline and two canine cases. J
[81]
Simon D, Eberle N, Laacke-Singer L et al.: Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and
[82]
Simon D, Meneses F, Nolte I: Möglichkeiten der Diagnostik von
Tumorerkrankungen am Magen-Darm-Trakt. Tierärztl Prax (K).
2005; 33: 401–406
[83]
Spugnini EP, Gargiulo M, Assin R et al.: Adjuvant carboplatin for
the treatment of intestinal carcinoid in a dog. In Vivo. 2008; 22:
759–761
[44]
[45]
[46]
Kodama A, Sakai H, Kobayashi K et al.: B-cell intestinal lymphoma
with Mott cell differentiation in a 1-year-old miniature Dachshund.
Vet Clin Pathol. 2008; 37: 409–415
Kosovsky JE, Matthiesen DT, Patnaik AK: Small intestinal adenocarcinoma in cats: 32 cases (1978–1985). J Am Vet Med Assoc.
1988; 192: 233–235
Krick EL, Little L, Patel R et al.: Description of clinical and pathological findings, treatment and outcome of feline large granular lymphocyte lymphoma (1996–2004). Vet Comp Oncol. 2008; 6: 102–
110
[47]
Lingard AE, Briscoe K, Beatty JA et al.: Low-grade alimentary lymphoma: clinicopathological findings and response to treatment in
17 cases J Feline Med Surg. 2009: 11: 692–700
[48]
Litster AL, Sorenmo KU: Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J
Feline Med Surg. 2006; 8: 177–183
[49]
[50]
Louwerens M, London CA, Pedersen NC et al.: http://www.ncbi.
nlm.nih.gov/pubmed?term=%22Lyons%20LA%22%5BAuthor%5DFeline lymphoma in the post-feline leukemia virus era. J Vet Intern
Med. 2005; 19: 329–335
Maas CP, ter Haar G, van der Gaag I et al.: Reclassification of small
intestinal and cecal smooth muscle tumors in 72 dogs: clinical, histologic, and immunohistochemical evaluation. Vet Surg. 2007; 36:
302–313
[51]
MacDonald JM, Mullen HS, Moroff SD: Adenomatous polyps of
the duodenum in cats: 18 cases (1985–1990). J Am Vet Med Assoc.
1993; 202: 647–651
[52]
MacEwen EG, Patnaik AK, Johnson GF et al.: Extramedullary plasmacytoma of the gastrointestinal tract in two dogs. J Am Vet Med
Assoc. 1984; 184: 1396–1398
[53]
Mahony OM, Moore AS, Cotter SM et al.: Alimentary lymphoma
1593–1598
[54]
Miettinen M, Lasota J: Gastrointestinal stromal tumors – definition, clinical, histologic, immunohistochemical and molecular genetic features and differential diagnosis. A review. Virchows Arch.
2001; 438:1–12
[55]
Molander-McCrary H, Henry CJ, Potter K et al.: Cutaneous mast
cell tumors in cats: 332 cases (1991–1994). J Am Anim Hosp Assoc.
1998; 34: 281–284
[56]
Moore PF, Woo JC, Vernau W et al.: Characterization of feline T
cell receptor gamma (TCRG) variable region genes for the molecular diagnosis of feline intestinal T cell lymphoma. Vet Immunol
Immunopathol. 2005; 106: 167–178
[57]
Orr CM, Gruffydd-Jones TJ, Kelly DF: Ileal polyps in Siamese cats. J
[58]
Ozaki K, Yamagami T, Nomura K et al.: T-cell lymphoma with
eosinophilic infiltration involving the intestinal tract in 11 dogs. Vet
Pathol. 2006; 43: 339–344
[59]
Ozaki K, Yamagami T, Nomura K et al.: Mast cell tumors of the
gastrointestinal tract in 39 dogs. Vet Pathol. 2002; 39: 557–564
[60]
Paoloni MC, Penninck DG, Moore AS: Ultrasonographic and clinicopathologic findings in 21 dogs with intestinal adenocarcinoma.
77
78
[84]
Stacy NI, Nabity MB, Hackendahl N et al.: B-cell lymphoma with
Mott cell differentiation in two young adult dogs. Vet Clin Pathol.
2009; 38: 113–120
[9]
Frank JD, Reimer SB, Kass PH et al.: Clinical outcomes of 30 cases
Assoc. 2007; 43: 313–321
[85]
Stein TJ, Pellin M, Steinberg H et al.: Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids. J Am Anim Hosp Assoc. 2010; 46: 413–417
[10]
[86]
Sykes GP, Cooper BJ: Canine intestinal carcinoids. Vet Pathol. 1982;
19: 120–131
Frost D, Lasota J, Miettinen M: Gastrointestinal stromal tumors
and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol. 2003; 40:
42–54
[11]
[87]
Seyrek-Intas D, Peppler C, Marek N et al.: Ultraschalldiagnostik
von Darmwandveränderungen bei der Katze. Tierärztl Prax (K).
2008; 36: 185–190
Gillespie V, Baer K, Farrelly J et al.: Canine gastrointestinal stromal
tumors: immunohistochemical expression of CD34 and examination of prognostic indicators including proliferation markers Ki67
and AgNOR. Vet Pathol. 2011; 48: 283–291
[88]
Takahashi T, Kadosawa T, Nagase M et al.: Visceral mast cell
tumors in dogs: 10 cases (1982–1997). J Am Vet Med Assoc. 2000;
216: 222–226
[12]
Gregory-Bryson E, Bartlett E, Kiupel M et al.: Canine and human
gastrointestinal stromal tumors display similar mutations in c-KIT
exon 11. BMC Cancer. 2010; 10: 559
[89]
Turk MAM, Gallina AM, Russel TS: Nonhematopoietic gastrointestinal neoplasia in cats: A retrospective study of 44 cases. Vet Pathol.
1981; 18: 614–620
[13]
Hampson EC, Wilkinson GT, Sutton RH et al.: Cutaneous metastasis of a colonic carcinoma in a dog. J Small Anim Pract. 1990; 31:
155–158
[90]
Waly NE, Gruffydd-Jones TJ, Stokes CR, et al.: Immunohistochemical diagnosis of alimentary lymphomas and severe intestinal
inflammation in cats. J Comp Pathol. 2005; 133: 253–260
[14]
Holt PE: Evaluation of transanal endoscopic treatment of benign
canine rectal neoplasia. J Small Anim Pract. 2007; 48: 17–25
[15]
[91]
Wellman ML, Hammer AS, DiBartola SP et al.: Lymphoma involving large granular lymphocytes in cats: 11 cases (1982–1991). J
Am Vet Med Assoc. 1992; 201:1265–1269
Holt PE, Durdey P: Transanal endoscopic treatment of benign
canine rectal tumours: preliminary results in six cases (1992 to
1996). J Small Anim Pract. 1999; 40: 423–427
[16]
[92]
Williams LE, Pruitt AF, Thrall DE: Chemotherapy followed by
abdominal cavity irradiation for feline lymphoblastic lymphoma. Vet
Holt PE, Lucke VM: Rectal neoplasia in the dog: A clinicopathological review of 31 cases. Vet Rec. 1985; 116: 400–405
[17]
Klein A, Scotti S, Hidalgo A et al.: Rectovaginal fistula following
colectomy with an end-to-end anastomosis stapler for a colorectal
adenocarcinoma. J Small Anim Pract. 2006; 47: 751–753
[18]
Knottenbelt CM, Simpson JW, Tasker S et al.: Preliminary clinical
observations on the use of piroxicam in the management of rectal
tubulopapillary polyps. J Small Anim Pract. 2000; 41: 393–397
[19]
Maas CP, ter Haar G, van der Gaag I et al.: Reclassification of small
intestinal and cecal smooth muscle tumors in 72 dogs: clinical, histologic, and immunohistochemical evaluation. Vet Surg. 2007; 36:
302–313
[20]
McEntee MF, Cates JM, Neilsen N: Cyclooxygenase-2 expression in
spontaneous intestinal neoplasia of domestic dogs. Vet Pathol.
2002; 39: 428–436
[21]
McPherron MA, Withrow SJ, Seim HB et al.: Colorectal leiomyomas in seven dogs. J Am Anim Hosp Assoc. 1992; 28: 43–46
[22]
Miettinen M, Lasota J: Gastrointestinal stromal tumors—definition,
clinical, histologic, immunohistochemical and molecular genetic
features and differential diagnosis. A review. Virchows Arch. 2001;
438: 1–12
[23]
Miura T, Maruyama H, Sakai M et al.: Endoscopic findings on alimentary lymphoma in 7 dogs. J Vet Med Sci. 2004; 66: 577–580
[24]
Morello E, Martano M, Squassino C et al.: Transanal pull-through
rectal amputation for treatment of colorectal carcinoma in 11 dogs.
Vet Surg. 2008; 37: 420–426
[25]
Paoloni MC, Penninck DG, Moore AS: Ultrasonographic and clinicopathologic findings in 21 dogs with intestinal adenocarcinoma.
[26]
Patnaik AK, Hurvitz AI, Johnson GF: Canine gastrointestinal neoplasms. Vet Pathol. 1977; 14: 547–555
[27]
Patnaik AK, Hurvitz AI, Johnson GF: Canine gastrointestinal adenocarcinoma and carcinoid. Vet Pathol. 1980; 17: 149–163
[28]
Pfeil C, Loupal G: Tumoren im Darmtrakt des Hundes. Zbl Vet Med
A 1984; 31: 146–159
[29]
Rannou B, Hélie P, Bédard C: Rectal plasmacytoma with intracellular hemosiderin in a dog. Vet Pathol. 2009; 46: 1181–1184
[30]
Russell KN, Mehler SJ, Skorupski KA et al.: Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors
from leiomyosarcomas in dogs: 42 cases (1990–2003). J Am Vet
Med Assoc. 2007; 230: 1329–1333
[93]
Wilson HM: Feline alimentary lymphoma: demystifying the
enigma. Top Companion Anim Med. 2008; 23: 177–184
[94]
Vail DM, Moore AS, Ogilvie GK et al.: Feline lymphoma (145
cases): Proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. J Vet
Intern Med. 1998; 12: 349–354
[95]
Zwahlen CH, Lucroy MD, Kraegel SA et al: Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases
(1993–1997). J Am Vet Med Assoc. 1998; 213: 1144–1149
[96]
Zwingenberger AL, Marks SL, Baker TW et al.: Ultrasonographic
evaluation of the muscularis propria in cats with diffuse small intestinal lymphoma or inflammatory bowel disease. J Vet Intern Med.
2010; 24: 289–292
19.6 Tumoren des Kolons und Rektums
[1]
Anderson GI, McKeown DB, Partlow GD et al.: Rectal resection in
the dog. A new surgical approach and the evaluation of its effect on
fecal continence. Vet Surg. 1987; 16: 119–125
[2]
Anson LW, Betts CW, Stone EA: A retrospective evaluation of the
rectal pull-through technique. Procedure and postoperative complications. Vet Surg. 1988; 17:141–146
[3]
Church EM, Mehlhaff CJ, Patnaik AK: Colorectal adenocarcinoma
727–730
[4]
[5]
Danova NA, Robles-Emanuelli JC, Bjorling DE: Surgical excision of
primary canine rectal tumors by an anal approach in twenty-three
dogs. Vet Surg. 2006; 35: 337–340
[6]
Doster AR, Yhee JY, Kim JH et al.: CDX-2 and HER-3 expression in
canine gastric and colorectal adenocarcinomas. J Comp Pathol.
2011; 145: 12–19
[7]
Feeney DA, Klauser JS, Johnson GR: Chronic bowel obstruction
caused by primary intestinal neoplasia: a report of five cases. J Am
[8]
Foy DS, Bach JF: Endoscopic polypectomy using endocautery in
three dogs and one cat. J Am Anim Hosp Assoc. 2010; 46: 168–173
[31]
Sato K, Hikasa Y, Morita T et al.: Secondary erythrocytosis associated with high plasma erythropoietin concentrations in a dog with
cecal leiomyosarcoma. J Am Vet Med Assoc. 2002; 220: 486–490,
464
[11]
Hayes HM, Wilson GP: Hormone dependent neoplasms of the
canine perianal gland. Cancer Res. 1977; 37: 2068–2071
[12]
Hobson HP, Brown MR, Rogers KS: Surgery of metastatic anal sac
adenocarcinoma in five dogs. Vet Surg. 2006; 35: 267–270
[32]
Slawienski MJ, Mauldin GE, Mauldin GN et al.: Malignant colonic
neoplasia in cats: 46 cases (1990–1996). J Am Vet Med Assoc.
1997; 211: 878–881
[13]
Kessler M: Der klinische Fall – Analbeutelkarzinom mit Hyperkalzämie bei einer Hündin. Tierärztl Prax. 1995; 23: 436, 521–524
[14]
[33]
Stampley AR, Swayne DE, Prasse KW: Meningeal carcinomatosis
secondary to a colonic signet-cell carcinoma in a dog. J Am Anim
Hosp Assoc. 1987; 23: 655–658
Kessler M, von Bomhard D: Rasseprädispositionen und Geschlechtsverteilung bei 106 Hunden mit Analbeutelkarzinom. (unveröffentlicht), 1997
[15]
[34]
Swiderski J, Withrow S: A novel surgical stapling technique for rectal mass removal: a retrospective analysis. J Am Anim Hosp Assoc.
2009; 45: 67–71
Kessler M, Kühnel S: Das canine Analbeutelkarzinom – eine retrospektive Untersuchung bei 32 Patienten. (unveröffentlicht), 2011
[16]
Kornberg M, Affolter V: Hyperkalzämie durch ein Analbeutelkarzinom. Kleintierprax. 1990; 35: 465–471
[17]
Liska WD, Withrow SJ: Cryosurgical treatment of perianal gland
adenomas in the dog. J Am Anim Hosp Assoc. 1978; 14: 457–463
[18]
Mellanby RJ, Craig R, Evans H et al.: Plasma concentrations of
parathyroid hormone-related protein in dogs with potential disorders of calcium metabolism. http://www.ncbi.nlm.nih.gov/pubmed?term=%22Herrtage%20ME%22%5BAuthor%5DVet Rec. 2006;
159: 833–838
[19]
Mellanby RJ, Foale R, Friend E et al.: Anal sac adenocarcinoma in a
Siamese cat. J Feline Med Surg. 2002; 4: 205–207
[20]
Meuten DJ, Segre GV, Capen CC: Hypercalcemia in dogs with adenocarcinoma derived from apocrine glands of the anal sac. Biochemical and histomorphometric investigations. Lab Invest. 1983; 48:
428–435
[21]
Veterinary Learning Systems Co. Trenton, 1995, S. 359
[22]
Parry NM: Anal sac gland carcinoma in a cat. Vet Pathol. 2006; 43:
1008–1009
[23]
Petterino C, Martini M, Castagnaro M: Immunohistochemical
detection of growth hormone (GH) in canine hepatoid gland
tumors. J Vet Med Sci. 2004; 66: 569–572
[24]
Pisani G, Millanta F, Lorenzi D et al.: Androgen receptor expression in normal, hyperplastic and neoplastic hepatoid glands in the
dog. Res Vet Sci. 2006; 81: 231–236
[25]
Polton G: Examining the heritability of anal sac gland carcinoma in
cocker spaniels. J Small Anim Pract. 2009; 50: 57
[26]
Polton G: Anal sac gland carcinoma in cocker spaniels. Vet Rec.
2007; 160: 244
[35]
Sykes GP, Cooper BJ: Canine intestinal carcinoids. Vet Pathol. 1982;
19: 120–131
[36]
Thompson JP, Christopher MM, Ellison GW et al.: Paraneoplastic
leukocytosis associated with a rectal adenomatous polyp in a dog. J
Am Vet Med Assoc. 1992; 201: 737–738
[37]
Tomlinson MJ, McKeever PJ, Nordine RA: Colonic adenocarcinoma
with cutaneous metastasis in a dog. J Am Anim Hosp Assoc. 1982;
180: 1344–1345
[38]
Turrel JM, Theon AP: Single high-dose irradiation for selected
canine rectal carcinomas. Vet Radiol. 1986; 27: 141–145
[39]
Valerius KD, Powers BE, McPherron MA et al.: Adenomatous polyps
and carcinoma in situ of the canine colon and rectum: 34 cases
[40]
White RAS, Gorman NT: The clinical diagnosis and management of
rectal and pararectal tumors in the dog. J Small Anim Pract. 1987;
28: 87–107
[41]
Wolf JC, Ginn PE, Homer B et al.: Immunohistochemical detection
of p53 tumor suppressor gene protein in canine epithelial colorectal
[42]
Yoon HY, Mann FA: Bilateral pubic and ischial osteotomy for surgical management of caudal colonic and rectal masses in six dogs
and a cat. J Am Vet Med Assoc. 2008; 232:1016–1020
19.7 Tumoren im Bereich des Afters
[1]
Bennett PF, DeNicola DB, Bonney P et al.: Canine anal sac adenocarcinomas: clinical presentation and response to therapy. J Vet
Intern Med. 2002; 16: 100–104
[2]
Berrocal A, Vos JH, van den Ingh TS et al.: Canine perineal
tumours. Zbl Vet Med A. 1989; 36: 739–749
[27]
Polton GA, Brearley MJ: Clinical stage, therapy, and prognosis in
canine anal sac gland carcinoma. J Vet Intern Med. 2007; 21: 274–280
[3]
Dow SW, Olsen PN, Rosychuck RAW et al.: Perianal adenomas
and hypertestosteronemia in a spayed bitch with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc. 1988; 192: 1439–
1441
[28]
Polton GA, Brearley MJ, Green LM et al.: http://www.ncbi.nlm.nih.
gov/pubmed?term=%22Scase%20TJ%22%5BAuthor%5DExpression
of E-cadherin in canine anal sac gland carcinoma and its association
with survival. Vet Comp Oncol. 2007; 5: 232–238
[4]
Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J. 2005; 83: 340–
343
[29]
Polton GA, Mowat V, Lee HC et al.: Breed, gender and neutering
status of British dogs with anal sac gland carcinoma. Vet Comp
Oncol. 2006; 4: 125–131
[5]
Esplin DG, Wilson SR, Hullinger GA: Squamous cell carcinoma of
the anal sac in five dogs. Vet Pathol. 2003; 40: 332–334
[30]
[6]
Farris HE, Fraunfelder FT, Firth CH: Cryosurgical treatment of
canine perianal gland adenomas. Canine Pract. 1976; 3: 34–37
Preziosi R, Della Salda L, Ricci A et al.: Quantification of nucleolar
organiser regions in canine perianal gland tumours. Res Vet Sci.
1995; 58: 277–281
[31]
[7]
Frese K, Durchfeld D, Eskens U: Klassifikation und biologisches
Verhalten der Haut- und Mammatumoren von Hund und Katze.
Prakt Tierarzt. 1989; 70: 69–82
Rijnberk A, Elsinghorst AM, Koeman JP: Pseudohyperparathyreoidism associated with perirectal adenocarcinomas in elderly female
dogs. Tijdschr Diergeneesk. 1978; 103: 1069–1075
[32]
Ganguly A, Wolfe LG: Canine perianal gland carcinoma-associated
antigens defined by monoclonal antibodies. Hybridoma (Larchmt).
2006; 25: 10–14
Rohrer-Bley C, Stankeova S, Sumova A et al.: Perianaldrüsenkarzinom-Metastasen bei einem Hund: Palliative Tumortherapie. Schweiz
[33]
Ross JT, Scavelli TD, Matthiesen DT et al.: Adenocarcinoma of the
apocrine glands of the anal sac in dogs: a review of 32 cases. J Am
Anim Hosp Assoc. 1991, 27: 349–355
[34]
Rosol TJ, Capen CC, Danks JA et al.: Identification of parathyroid
hormone-related protein in canine apocrine adenocarcinoma of the
anal sac. Vet Pathol. 1990; 27: 89–95
[8]
[9]
Gillette EL: Radiation therapy of canine and feline tumors. J Am
Anim Hosp Assoc. 1976; 12: 359–362
[10]
Hause WR, Stevenson S, Meuten DJ et al.: Pseudohyperparathyreoidism associated with adenocarcinomas of anal sac origin in four
79
80
[35]
Shoieb AM, Hanshaw DM: Anal sac gland carcinoma in 64 cats in
the United Kingdom (1995–2007). Vet Pathol. 2009; 46: 677–683
[36]
Vail DM, Withrow SJ, Schwarz PD et al.: Perianal adenocarcinoma
in the canine male: a retrospective study of 41 cases. J Am Anim
Hosp Assoc. 1990; 26: 329–334
[37]
Vos JH, van den Ingh TS, Ramaekers FC et al.: The expression of
keratins, vimentin, neurofilament proteins, smooth muscle actin,
neuron-specific enolase, and synaptophysin in tumors of the specific glands in the canine anal region. Vet Pathol. 1993; 30: 352–361
[38]
White RAS, Gorman NT: The clinical diagnosis and management of
rectal and pararectal tumors in the dog. J Small Anim Pract. 1987;
28: 87–107
[39]
Williams LE, Gliatto JM, Dodge RK et al.: Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985–1995). J Am
Vet Med Assoc. 2003; 223: 825–831
[40]
Wilson GP, Hayes HM: Castration for treatment of perianal gland
adenomas in the dog. J Am Vet Med Assoc. 1979; 174: 1301–1303
[41]
Wright ZM, Fryer JS, Calise DV et al.: Carboplatin chemotherapy
in a cat with a recurrent anal sac apocrine gland adenocarcinoma. J
20 Tumoren des Respirationstrakts
[14]
Chang Y, Thompson H, Reed N et al.: Clinical and magnetic resonance imaging features of nasopharyngeal lymphoma in two cats
with concurrent intracranial mass. J Small Anim Pract. 2006; 47:
678–681
[15]
Ching SV, Gillette SM, Powers BE et al.: Radiation-induced ocular
injury in the dog: a histological study. Int J Radiat Oncol Biol Phys.
1990; 19: 321–328
[16]
Clercx C, Wallon J, Gilbert S et al.: Imprint and brush cytology in
the diagnosis of canine intranasal tumours. J Small Anim Pract.
1996; 37: 423–427
[17]
Codner EC, Lurus AG, Miller JB et al.: Comparison of computed
tomography with radiography as a noninvasive diagnostic technique for chronic nasal disease in dogs. J Am Vet Med Assoc. 1993;
202: 1106–1110
[18]
Colin PH: Concomitant chemotherapy and radiotherapy. Theoretical basis and clinical experience. Anticancer Res. 1994; 14: 2357–
2362
[19]
Correa SS, Mauldin GN, Mauldin G et al.: Efficacy of Cobalt-60
radiation therapy for the treatment of nasal cavity nonkeratinizing
squamous cell carcinoma in the dog. J Am Anim Hosp Assoc. 2003;
39: 86–89
[20]
Couto CG: Advances in the treatment of the cat with lymphoma in
practice. J Feline Med Surg. 2000; 2: 95–100
[21]
Couto, CG, Boudrieau RJ, Zanjani ED: Tumor-associated erythrocytosis in a dog with nasal fibrosarcoma. J Vet Intern Med. 1989; 3:
183–185
[22]
Cox NR, Brawner WR, Powers RD et al.: Tumors of the nose and
paranasal sinuses in cats: 32 cases with comparison to national
database (1977–1987). J Am Anim Hops Assoc. 1991; 27: 339–347
20.1 Tumoren der Nasenhöhle und Nasennebenhöhlen
[1]
Adams WM, Kleiter MM, Thrall DE et al.: Prognostic significance
of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. Vet Radiol Ultrasound. 2009; 50: 330–335
[2]
Adams WM, Bjorling DE, McAnulty JE et al.: Outcome of accelerated radiotherapy alone or accelerated radiotherapy followed by
exenteration of the nasal cavity in dogs with intranasal neoplasias:
[23]
Cox NR, Power RD: Olfactory neuroblastomas in two cats. Vet
Pathol. 1989; 26: 341–343
[24]
[3]
Adams WM, Miller PE, Vail DM et al.: An accelerated technique
for irradiation of malignant canine nasal and paranasal sinus
Day MJ, Henderson SM, Belshaw Z et al.: An immunohistochemical investigation of 18 cases of feline nasal lymphoma. J Comp
Pathol. 2004; 130: 152–161
[25]
Demko JL, Cohn LA: Chronic nasal discharge in cats: 75 cases
(1993–2004). J Am Vet Med Assoc. 2007; 230: 1032–1037
[4]
Adams WM, Withrow SJ, Walshaw R et al.: Radiotherapy of
malignant nasal tumors in 67 dogs. J Am Vet Med Assoc. 1987;
191: 311–315
[26]
Detweiler DA, Johnson LR, Kass PH et al.: Computed tomographic
evidence of bulla effusion in cats with sinonasal disease: 2001–
2004. J Vet Intern Med. 2006; 20: 1080–1084
[5]
Agthe P, Caine AR, Gear RN et al.: Prognostic significance of specific magnetic resonance imaging features in canine nasal tumours
treated by radiotherapy. J Small Anim Pract. 2009; 50: 641–648
[27]
Drees R, Forrest LJ, Chappell R: Comparison of computed tomography and magnetic resonance imaging for the evaluation of
canine intranasal neoplasia. J Small Anim Pract. 2009; 50: 334–340
[6]
Allen HS, Broussard J, Noone K: Nasopharyngeal diseases in cats: a
retrospective study of 53 cases (1991–1998). J Am Anim Hosp
Assoc. 1999; 35: 457–461
[28]
Dungworth DL, Hauser B, Hahn FF et al.: Classification of tumors
of the respiratory system of domestic animals, 2nd series, vol. VI, S.
16–21. Armed Forces Institute of Pathology, Washington, DC, 1999
[7]
Anderson GM, Lane I, Fischer J et al.: Hypercalcaemia and parathyroid hormone-related protein in a dog with undifferentiated
nasal carcinoma. Can Vet J. 1999; 40: 341–342
[29]
Elmslie RE, Ogilvie GK, Gilette EL et al.: Radiotherapy with and
without chemotherapy for localized lymphoma in 10 cats. Vet
Radiol. 1991; 32: 277–280
[8]
Avner A, Dobson JM, Sales JI et al.: Retrospective review of 50
canine nasal tumours evaluated by low-field magnetic resonance
imaging. J Small Anim Pract. 2008; 49: 233–239
[30]
Evans SM, Hendrick M: Radiotherapy of feline nasal tumors: a
retrospective study of nine cases. Vet Radiol. 1989; 30: 128–132
[31]
[9]
Beck ER, Withrow SJ: Tumors of the canine nasal cavity. Vet Clin
Evans SM, Goldschmidt M, McKee LJ et al.: Prognostic factors and
survival after radiotherapy for intranasal neoplasms in dogs: 70
[10]
Borzacchiello G, Paciello O, Papparella S: Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas. J Comp Pathol. 2004;
131: 70–76
[32]
Evans SM, Hendrick M: Radiotherapy of feline nasal tumors. Vet
Radiol. 1986; 30: 128–132
[33]
Boswald KL, Kessel AE, Lucy RJ: Squamous cell carcinoma with sarcomatous stroma in the nasal cavity of a dog. Aust Vet J. 2004; 82:
553–555
Gieger T, Rassnick K, Siegel S et al.: Palliation of clinical signs in 48
dogs with nasal carcinomas treated with coarse-fraction radiation
therapy. J Am Anim Hosp Assoc. 2008; 44: 116–123
[34]
Hahn KA, Knapp DW, Richardson RC et al.: Clinical response of
nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs. J Am
Vet Med Assoc. 1992; 200: 355–357
[35]
Hahn KA, Matlock CL: Nasal adenocarcinoma metastatic to bone
in two dogs. J Am Vet Med Assoc. 1990; 197: 491–494
[11]
[12]
Bradley PA, Harvey CE: Intranasal tumors in the dog: an evaluation
of prognosis. J Am Anim Hosp Assoc. 1989; 25: 103–114
[13]
Capucchio MT, Lotti D, Cornaglia E et al.: Histological and immunohistochemical study of a neuroblastoma in a dog. Clin Neuropathol. 2003; 22: 176–179
[36]
(1986–2006). J Vet Intern Med. 2009; 23: 287–294
[37]
[38]
[58]
Hänichen T, Schiefer B: Morphology and incidence of primary
tumors of the nasal cavity and paranasal sinuses in dogs and cats. Z
Krebsforsch. 1968; 71: 255–266
Langova V, Mutsaers AJ, Phillips B et al.: Treatment of eight dogs
with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. Aust Vet J. 2004; 82:
676–680
[59]
Hara K, Shimada A, Morita T et al.: Olfactory neuroepithelioma in
a dog: an immunohistochemical and electron microscopic study. J
Vet Med Sci. 2002; 64: 391–393
Lawrence TS, Blackstone AW, McGinn C: The mechansism of
action of radiosensitization of conventional chemotherapeutic
agents. Semin Radiat Oncol. 2003; 13: 13–21
[60]
LeBlanc AK, LaDue TA, Turrel JM et al.: Unexpected toxicity
carcinomas: a veterinary radiation therapy oncology group pilot
[39]
Hayes HM Jr, Wilson GP, Fraumeni HF Jr: Carcinoma of the nasal
cavity and paranasal sinuses in dogs: Descriptive epidemiology. Cornell Vet. 1982; 72: 168–179
[61]
[40]
Henderson SM, Bradley K, Day MJ et al.: Investigation of nasal
disease in the cat – a retrospective study of 77 cases. J Feline Med
Surg. 2004; 6: 245–257
Lecoindre P, Bergeaud P: Diagnostic des affections naso-sinusales:
intérêt de la rhinoscopie. Etude rétrospective de 324 cas. Prat Med
Chirur Anim Comp. 2003; 38: 263–275
[62]
[41]
Henry CJ, Brewer WG Jr, Tyler JW et al.: Survival in dogs with
nasal adenocarcinoma: 64 cases (1981–1995). J Vet Intern Med.
1998; 12: 436–439
Lefebvre J, Kuehn NF, Wortinger A: Computed tomography as an
aid in the diagnosis of chronic nasal disease in dogs. J Small Anim
Pract. 2005; 46: 280–285
[63]
[42]
Hicks DG, Fidel JL: Intranasal malignant melanoma in a dog. J Am
Anim Hosp Assoc. 2006; 42: 472–476
Legendre AM: Canine nasal and paranasal sinus tumors. J Am Anim
Hosp Assoc. 1983; 19: 115–123
[64]
[43]
Hoerlein BF, Evans LE: Clinical diagnosis and surgical removal of
nasal tumors in the dog. Vet Med Small Anim Clin. 1962; 2: 65–73
Lent SE, Hawkins EC: Evaluation of rhinoscopy and rhinoscopyassisted mucosal biopsy in diagnosis of nasal disease in dogs: 119
[44]
Hunacharek M, Kupelnick B: Combined chemoradiation versus
radiation therapy alone in locally advanced nasopharyngeal carcinoma. Results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol. 2002; 25: 219–223
[65]
Little L, Patel R, Goldschmidt M: Nasal and nasopharyngeal lymphoma in cats: 50 cases (1989–2005). Vet Pathol. 2007; 44: 885–
892
[66]
[45]
Jamieson VE, Davidson MG, Naisse MP et al.: Ocular complications following Cobalt 60 radiotherapy of neoplasms in the head
region. J Am Anim Hosp Assoc. 1991; 27: 51–55
Louwerens ML, London CA, Pedersen NC et al.: Feline lymphoma
in the post-feline leukaemia virus era. J Vet Int Med. 2005; 19: 329–
335
[67]
[46]
Kaldrymidou E, Papaioannou N, Poutahidis T et al.: Malignant
lymphoma in nasal cavity and paranasal sinuses of a dog. J Vet Med
A Physiol Pathol Clin Med. 2000; 478: 457–462
Lucroy MD, Long KR, Blaik MA et al.: Photodynamic therapy for
the treatment of intranasal tumors in 3 dogs and 1 cat. J Vet Intern
Med. 2003; 17: 727–729
[68]
[47]
Kinzel S, Hein S, Stopinski T et al.: Hypofractionated radiation therapy for the treatment of malignant melanoma and squamous cell
carcinoma in dogs and cats. Berl Munch Tierarztl Wochenschr.
2003; 116: 134–138
MacEwen EG, Withrow SJ, Patnaik AK: Nasal tumors in the dog:
retrospective evaluation of diagnosis, prognosis, and treatment. J
Am Vet Med Assoc. 1977; 170: 45–48
[69]
Madewell BR, Priester WA, Gillette EL et al.: Neoplasms of the
nasal passages and paranasal sinuses in domesticated animals as
reported by 13 veterinary colleges. Am J Vet Res. 1976; 37: 851–
856
[48]
Kitagawa M, Okada M, Yamamura K et al.: Diagnosis of olfactory
neuroblastoma in a dog by magnetic resonance imaging. Vet Rec.
2006;159: 288–289
[70]
[49]
Kleiter M, Malarkey DE, Ruslander DE et al.: Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet Radiol Ultrasound. 2004; 45: 255–260
Mellanby RJ, Stevenson RK, Herrtage ME et al.: Long-term outcome of 56 dogs with nasal tumours treated with four doses of
radiation at intervals of seven days. Vet Rec. 2002; 151: 253–257
[71]
[50]
Klueter S, Krastel D, Ludewig E et al.: High-dose rate brachytherapy for intranasal tumours in dogs: results of a pilot study. Vet
Comp Oncol. 2006; 4: 218–231
McEntee MC: A survey of veterinary radiation facilities in the United
States during 2001. Vet Radiol Ultrasound. 2004; 45: 476–479
[72]
McEntee MC, Page RI, Heidner GL et al.: Factors influencing survival after radiotherapy of nasal tumors in 130 dogs. Vet Radiol Ultrasound. 1999; 32: 135–139
[73]
Meyer W: The nasal cavity and paranasal sinuses. In: Thrall D
(Hrsg.): Veterinary Diagnostic Radiology. WB Saunders Co, Philadelphia 1994
[74]
Moore MP, Gavin PR, Kraft SL et al.: MR, CT and clinical features
from four dogs with nasal tumors involving the rostral cerebrum.
Vet Radiol. 1991; 32: 19–25
[75]
Morris JS, Dunn KJ, Dobson JM et al.: Radiological assessment of
severity of canine nasal tumors and relationship with survival. J
[76]
Morris JS, Dunn KJ, Dobson JM et al.: Effects of radiotherapy alone
and surgery and radiotherapy on survival of dogs with nasal tumors.
[77]
Morrison T, Read R, Eger C: A retrospective study of nasal tumors
in 37 dogs. Aust Vet Pract. 1989; 19: 130–134
[78]
Moore AS: Treatment of feline lymphoma. Feline Pract. 1996; 24:
17–20
[51]
41 dogs with malignant tumors. J Vet Int Med. 1988; 2: 41–46
[52]
Koestner A, Bilzer T, Fatzer R et al.: Tumors of neuroepithelial tissue. Histological classification of tumors of the nervous system of
domestical animals. 2. Aufl, Armed Forces Institute of Pathology,
Washington, D.C., USA, 1999; 24
[53]
LaDue TA, Dodge RD, Page RL et al. : Factors influencing survival
after radiotherapy of nasal tumors in 130 dogs. Vet Radiol Ultrasound. 1999; 40: 312–317
[54]
Laing EJ, Binnington AG: Surgical therapy of canine nasal tumors.
A retrospective study (1982–1986). Can Vet J. 1988; 29: 803–813
[55]
Lamb CR, Richbell S, Mantis P: Radiographic signs in cats with
nasal disease. J Feline Med Surg. 2003; 5: 227–235
[56]
Lana SE, Dernell WS, Lafferty MH et al.: Use of radiation and
slow-release cisplatin formulation for treatment of canine nasal
[57]
Lana SE, Dernell WS, LauRue SM et al.: Slow release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet
81
82
[79]
Mukaratirwa S, van der Linde-Sipman JS, Gruys E: Feline nasal
and paranasal sinus tumors: Clinicopathological study, histomorphological description and diagnostic immunohistochemistry of
123 cases. J Feline Med Surg. 2001; 3: 235–245
[80]
Naganobu K, Ogawa H, Uchida K et al.: Mast cell tumor in the
nasal cavity of a dog. J Vet Med Sci. 2000; 62: 1009–1011
[81]
Norris AM: Intranasal neoplasm in the dog. J Am Anim Hosp Assoc.
1979; 15: 231–236
[82]
Northrup NC, Etue SM, Ruslander DM et al.: Retrospective study
of orthovoltage radiation therapy for nasal tumors in 42 dogs. J Vet
Int Med. 2001; 15: 183–189
[83]
OʼBrien RT, Evans SM, Wortman JA et al.: Radiographic findings in
cats with intranasal neoplasia or chronic rhinitis: 29 cases (1982–
1988). J Am Vet Med Assoc. 1996; 208: 385–389
[84]
Moore AS, Oglivie GK: Nasal tumors. In: Ogilvie GK, Moore AS
(Hrsg): Feline Oncology. Veterinary Learning Sytems. Trenton, NJ:
2001: 369–374
[85]
Ogilvie GK, Morre AS, Obradovich JE et al.: Toxicosis and efficacy
associated with the adminiatration of mitoxantrone to cats with
mailgnant tumors. J Am Vet Med Assoc. 1993; 202: 1839–1844
[86]
Owen LN: TNM Classification of tumors of in domestic animals.
Geneva: World Health Organization, 1999
[87]
Papazoglou LG, Koutinas AF, Pleraki AG et al.: Primary intranasal
transmissible venereal tumour in the dog: a retrospective study of
six spontaneous cases. J Vet Med A Physiol Pathol Clin Med. 2001;
48: 391–400
[88]
Park RD, Beck ER, LeCouteur RA: Comparison of computed tomography and radiography for detecting changes induced by malignant nasal neoplasia in dogs. J Am Vet Med Assoc. 1992; 201:
1720–1724
[89]
Patnaik AK: Canine sinonasal neoplasms: clinicopathological study
of 285 cases. J Am Anim Hosp Assoc. 1989; 25: 102–114
[90]
Patnaik AK, Lieberman PH, Erlandson RA et al.: Canine sinonasal
skeletal neoplasms: chondrosarcomas and osteosarcomas. Vet
Pathol. 1984; 21: 475–482
[91]
Petite AF, Dennis R: Comparison of radiography and magnetic
resonance imaging for evaluating the extent of nasal neoplasia in
dogs. J Small Anim Pract. 2006; 47: 529–536
[92]
[93]
[94]
Popovitch CA, Weinstein MJ, Goldschmidt MH et al.: Chondrosarcoma: a retrospective study of 97 dogs (1987–1990). J Am Anim
Hosp Assoc. 1994; 30: 81–85
Rassnick KM, Goldkamp CE, Erb HN et al.: Evaluation of factors
associated with survival in dogs with untreated nasal carcinomas:
Reetz JA, Muravnick KB, Goldschmidt MH et al.: Computed
tomographic evaluation of anatomic and pathologic variations in
the feline nasal septum and paranasal sinuses. Vet Radiol Ultrasound. 2006; 47: 321–327
[101] Saunders JH, van Bree H, de Rooster H: Diagnostic value of computed tomography in dogs with chronic nasal disease. Vet Radiol
Ultrasound. 2003; 44: 409–413
[102] Schoenborn WC, Wisner ER, Kass PP et al.: Retrospective assessment of computed tomographic imaging of feline sinonasal disease
in 62 cats. Vet Radiol Ultrasound. 2003; 44: 185–195
[103] Schrenzel MD, Higgins RJ, Hinrichs SH et al.: Type C retroviral
expression in spontaneous feline olfactory neuroblastomas. Acta
Neuropathol. 1990; 80: 547–53
[104] Schwietzer A., Kandel B, Kessler M: Palliative 60Cobalt-Bestrahlung bei Hunden mit weit fortgeschrittenen Tumoren der Nasenund Nasennebenhöhlen. Kleintierprax 2005; 50: 145–151
[105] Schwietzer A, Kessler M, Kandel-Tschiederer B: Palliative Therapie
intranasaler Tumoren des Hundes mit hypofraktionierter Cobalt60–
Bestrahlung und Carboplatin Chemotherapie. Tierärztl Prax. 2012;
40, 333–340
[106] Sfiligoi G, Theon AP, Kent MS: Response of nineteen cats with
nasal lymphoma to radiation therapy and chemotherapy. Vet Radiol
Ultrasound. 2007; 48: 388–393
[107] Smith MO, Turrel JM, Bailey CS et al.: Neurologic abnormalities as
the predominant signs of neoplasia of the nasal cavity in dogs and
cats: seven cases (1973–1986). J Am Vet Med Assoc. 1989; 195:
242–245
[108] Straw RC, Withrow SJ, Gilette EL et al.: Use of radiotherapy for
the treatment of intranasal tumors in cats: Six cases (1980–1985). J
Am Vet Med Assoc. 1986; 89: 927–929
[109] Tasker S, Knottenbelt CM, Munro EA et al.: Aetiology and diagnosis of persistent nasal disease in the dog: a retrospective study of 42
cases. J Small Anim Pract. 1999; 40: 473–478
Med. 2002; 16: 179–186
[112] Theon A, Peaston AE, Madewell BR et al.: Irradiation of nonlymphoproliferative neoplasms of the nasal cavity and paranasal sinuses
in 16 cats. J Am Vet Med Assoc. 1994; 204: 78–83
[113] Theon AP, Madewell BR, Harb MF et al.: Megavoltage irradiation
of neoplasms of the nasal and paranasal cavities in 77 dogs. J Am
Vet Med Assoc. 1993; 202: 1469–1475
[114] Thrall DE, McEntee MC, Novotney C et al.: A boost technique of
malignant canine nasal tumors. Vet Radiol Ultrasound. 1993; 34:
295–300
[115] Thrall DE, Heidner GL, Novotney CA et al.: Failure patterns following cobalt irradiation in dogs with nasal carcinoma. Vet Radiol Ultrasound. 1993; 34: 126–133
[95]
Reif JS, Bruns C, Lower KS: Cancer of the nasal cavity and paranasal
sinuses and exposure to environmental tobacco smoke in pet dogs.
Am J Epidemiol. 1998; 147: 488–492
[116] Thrall DE, Robertson ID, McLeod DA et al.: A comparison of radiographic and computed tomographic findings in 31 dogs with malignant nasal cavity tumors. Vet Radiol. 1989; 30: 59–66
[96]
Reif JS, Cohen D: The environmental distribution of canine respiratory tract neoplasms. Arch Environ Health. 1971; 22: 136–140
[117] Thrall DE, Harvey CE: Radiotherapy of malignant nasal tumors in
21 dogs. J Am Vet Med Assoc. 1983; 183: 663–666
[97]
Rogers KS, Walker MA, Helman RG: Squamous cell carcinoma of
the canine nasal cavity and frontal sinus. J Am Anim Hosp Assoc.
1996; 32:103–110
[98]
Russo M, Lamb CR, Jakovljevic S: Distinguishing rhinitis and nasal
neoplasia by radiography. Vet Radiol Ultrasound. 2000; 41: 118–
124
[118] Tromblee TC, Jones JC, Etue AE et al.: Association between clinical
characteristics, computed tomography characteristics, and histologic diagnosis for cats with sinonasal disease. Vet Radiol Ultrasound.
2006; 47: 241–248
[99]
Sako T, Shimoyama Y, Akihara Y et al.: Neuroendocrine carcinoma
in the nasal cavity of ten dogs. J Comp Pathol. 2005; 133: 155–163
[100] Sapierzynski R, Zmudzka M: Endoscopy and histopathology in the
examination of the nasal cavity in dogs. Pol J Vet Sci. 2009; 12:
195–201
[119] Ueno H, Kobayashi Y, Yamada K: Olfactory esthesioneuroblastoma
treated with orthovoltage radiotherapy in a dog. Aust Vet J. 2007;
85: 271–275
[120] Turek MM, Lana SE : Canine nasosinal tumors. In Withrow SJ, Vail
DM (Hrsg): Withrow & MacEwensʼs Small Animal Clinical Oncology.
4. Aufl. St.Louis: Saunders; 2007: 525–539
[121] Willard MD, Radlinsky MA: Endoscopic examination of the choanae in dogs and cats: 118 cases (1988–1998). J Am Vet Med Assoc.
1999; 215: 1301–1305
[23]
Hill JE, Mahaffey EA, Farrell RL: Tracheal carcinoma in a dog. J
Comp Pathol. 1987; 97: 705–707
[24]
[122] Yoon JH, Feeney DA, Jessen CR et al.: External-beam Co-60 radiotherapy for canine nasal tumors: a comparison of survival by treatment protocol. Res Vet Sci. 2008; 84: 140–149
Holt TL, Mann FA: Soft tissue application of lasers. Vet Clin North
[25]
Jakubiak MJ, Siedlecki CT, Zenger E et al.: Laryngeal, laryngotracheal, and tracheal masses in cats: 27 cases (1998–2003). J Am
Anim Hosp Assoc. 2005; 41: 310–316
20.2 Tumoren des Larynx und der Trachea
[26]
Kneller SK: Larynx, pharynx and trachea. In: Thrall DE (Hrsg.): Textbook of veterinary diagnostic radiology. 5. Aufl., Saunders St. Louis
2007; 489–494
[27]
Lobetti RG, Williams MC: Anaplastic tracheal squamous cell carcinoma in a cat. J South Afr Vet Assoc. 1992; 63: 132–133
[28]
Lopez NA: The basics of soft tissue laser surgery. Vet Med. 2002; 4:
294–301
[29]
Ludwig LL: Surgical emergencies of the respiratory system. Vet Clin
[30]
Mahler SP, MooToo NFA, Reece JLM et al.: Surgical resection of a
primary tracheal fibrosarcoma in a dog. J Sm Anim Pract. 2006; 47:
537–540
[1]
Ackerman LJ: Dermatologic applications of radio-wave surgery
(radiosurgery). Comp Cont Educ Small Anim. 1997; 19: 463–471
[2]
Aron DN, DeVries R, Short CE: Primary tracheal chondrosarcoma
in a dog: A case report with description of surgical and anesthetic
techniques. J Am Anim Hosp Assoc. 1980; 16: 31–37
[3]
Besancon MF, Stacy BA, Kyles AE et al.: Nodular immunocytederived (AL) amyloidosis in the trachea of a dog. J Am Vet Med
Assoc. 2004; 224: 1302–1306
[4]
Bjorling D, McAnulty J: Surgically treatable upper respiratory disorders. Vet Clin North Am Small Anim Pract. 2000; 30: 1227–1251
[5]
Black AP, Liu S, Randolph JF: Primary tracheal leiomyoma in a dog.
J Am Vet Med Assoc. 1981; 179: 905–907
[31]
[6]
Brodey RS, O’Brien J, Berg P et al.: Osteosarcoma of the upper airway in the dog. J Am Vet Med Assoc. 1969; 155: 1460–1464
Meuten DJ, Calderwood Mays MB, Dillman RC et al.: Canine
laryngeal rhabdomyoma. Vet Pathol 1985; 22: 533–539
[32]
[7]
Brown EM, Rademacher N, Gieger TL et al.: What is your diagnosis? Tracheal lymphoma. J Am Vet Med Assoc. 2010; 236: 953–954
Newell SM, Mahaffey MB, Roberts RE et al.: Laryngeal adenocarcinoma in a dog. Vet Radiol Ultrasound. 1994; 35: 217–220
[33]
[8]
Brown MR, Rogers KS, Mansell KJ et al.: Primary intratracheal
lymphosarcoma in four cats. J Am Anim Hosp Assoc. 2003; 39:
468–472
O’Hara AJ, McConnell M, Wyatt K et al.: Laryngeal rhabdomyoma
in a dog. Aust Vet J. 2001; 79: 817–821
[34]
Pass DA, Huxtable CR, Cooper BJ et al.: Canine laryngeal oncocytomas. Vet Pathol. 1980; 17: 672–677
[9]
Brown MR, Rogers KS: Primary tracheal tumors in dogs and cats.
Comp Cont Educ Small Anim. 2003; 25: 854–860
[35]
Rossi G, Magi GE, Tarantino C et al.: Tracheobronchial neuroendocrine carcinoma in a cat. J Comp Pathol. 2007; 137: 165–168
[10]
Bryan RD, Frame RW, Kier AB: Tracheal leiomyoma in a dog. J Am
Vet Med Assoc. 1981; 178: 1069–1070
[36]
Rossi G, Tarantino C, Taccini E et al.: Granular cell tumor affecting
the left vocal cord in a dog. J Comp Pathol. 2007; 136: 74–78
[11]
Carlisle CH, Biery DN, Thrall DE: Tracheal and laryngeal tumors in
the dog and cat: Literature review and 13 additional patients. Vet
Radiol. 1991; 32: 229–235
[37]
Rudorf H, Brown P: Ultrasonography of laryngeal masses in six cats
and one dog. Vet Radiol Ultrasound. 1998; 39: 430–434
[38]
[12]
Chaffin K, Cross AR, Allen SW et al.: Extramedullary plasmacytoma in the trachea of a dog. J Am Vet Med Assoc.1998; 212:
1579–1581
Saik JE, Toll SL, Diters RW et al.: Canine and feline laryngeal neoplasia: A 10-year survey. J Am Anim Hosp Assoc. 1986; 22: 359–365
[39]
Schwartz P, Bellah JR, Wolfersteig D: What is your diagnosis? Primary tracheal tumor. J Am Vet Med Assoc. 2005; 226: 1299–1300
[40]
Sessons RB, Harrison LB, Forastierre AA: Tumors of the larynx and
hypolarynx. In: DeVita VT, Hellman S, Rosenberg SA (Hrsg.): Cancer:
Principles and practice of oncology. Lippincott-Raven Philadelphia,
1997
[41]
Sheaffer KA, Dillon AR: Obstructive tracheal mass due to an
inflammatory polyp in a cat. J Am Anim Hosp Assoc. 1996; 32: 431
[13]
Clifford CA, Sorenmo KU: Tumors of the larynx and trachea. In
King LG (Hrsg.): Textbook of respiratory disease in dogs and cats.
Saunders 2004, St. Louis, 339–345
[14]
Culp WTN, Weisse C, Cole SG et al.: Intraluminal stenting for
treatment of tracheal narrowing in three cats. Vet Surg. 2007; 36:
107–113
[15]
Essman S, Wells K: What is your diagnosis? A sharply marginated
soft-tissue mass occluding the lumen of the cervical region of the
trachea with possible involvement of the esophagus. J Am Vet Med
Assoc. 2002; 220: 451–452
[42]
Stepnik MW, Mehl ML, Hardie EM et al.: Outcome of permanent
tracheostomy for treatment of upper airway obstruction in cats: 21
[43]
[16]
Gonzalez JL, Rollan E, Garcia P et al.: Laryngeal adenocarcinoma in
a dog. J Sm Anim Pract. 1993; 34: 146–148
Tasker S, Foster DJ, Corcoran BM et al.: Obstructive inflammatory
laryngeal disease in three cats. J Feline Med Surg. 1999; 1: 53–59
[44]
[17]
Griffon DJ: Upper airway obstruction in cats: Diagnosis and treatment. Comp Cont Educ Small Anim. 2000; 22: 897–908
Taylor SS, Goodfellow MR, Browne WJ et al.: Feline extranodal
Sm Anim Pract. 2009; 50: 584–592
[18]
Griffon DJ: Upper airway obstruction in cats: Pathogenesis and clinical signs. Comp Cont Educ Small Anim. 2000; 22: 822–830
[45]
[19]
Guenther-Yenke CL, Rozanski EA: Tracheostomy in cats: 23 cases
(1998–2006). J Feline Med Surg. 2007; 9: 451–457
Taylor SS, Harvey AM, Barr FJ et al.: Laryngeal disease in cats: a
retrospective study of 35 cases. J Feline Med Surg. 2009; 11: 954–
962
[46]
[20]
Hahn KA, Anderson TE: Tumors of the respiratory tract. In: Bonagura JD (Hrsg.): Kirk’s current veterinary therapy XIII. WB Saunders,
Weigand K, Gerhards H, Köstlin R: Einsatzmöglichkeiten der
Laserchirurgie in der Tiermedizin. Teil 3: Laseranwendungen: Literaturübersicht und eigene Erfahrungen. Tierärztl Prax. 1997; 25: 289–
302
[21]
Harvey HJ, Sykes G: Tracheal mast cell tumor in a dog. J Am Vet
Med Assoc. 1982; 180: 1097–1100
[47]
[22]
Hayes AM, Hayes AM, Gregory SP et al.: Solitary extramedullary
plasmacytoma of the canine larynx. J Sm Anim Pract. 2007; 48:
228–291
Weigt AK, McCracken MD, Krahwinkel DJ: Extramedullary plasmacytoma in the canine trachea: case report and literature review.
Comp Cont Educ Small Anim. 2001; 23: 143–152
[48]
Wheeldon EB, Suter PF, Jenkins T: Neoplasia of the larynx in the
83
84
[49]
Withrow SJ, Holmberg DL, Rosychuck RA et al.: Treatment of a
tracheal osteochondroma with an overlapping end-to-end tracheal
anastomosis. J Am Anim Hosp Assoc. 1978; 14: 469–473
[21]
Fox LE, King RR: Cancers of the respiratory system. In Morrison WB
(Hrsg.): Cancer in Dogs and Cats. Jackson, 2002, Teton NewMedia:
505–509
[22]
Gottfried SD, Popovitch CA, Goldschmidt MH et al.: Metastatic
digital carcinoma in the cat: a retrospective study of 36 cats (1992–
[23]
Gourley IM, Gregory CR: Pneumektomie. In Gourley IM, Gregory
CR (Hrsg.): Atlas der Weichteiloperationen bei Hund und Katze.
Schlütersche, Hannover, 1993, 10.4–10.5
[24]
Grierson JM, Burton CA: Hypertrophic osteopathy secondary to
pulmonary sarcoma in a cat. Vet Comp Oncol. 2003; 1: 227–231
[25]
Hahn FF, Muggenburg BA, Griffith WC: Primary lung neoplasia in
a beagle colony. Vet Pathol. 1996; 33: 633–638
[26]
Hahn KA, Anderson TE: Tumors of the respiratory tract. In: Bonagura JD (Hrsg.): Kirkʼs Current Veterinary Therapy XIII Small Animal
Practice. Saunders Company Philadelphia 2000, 500–504
[27]
Hahn KA, McEntee MF: Prognosis factors for survival in cats after
removal of a primary lung tumor: 21 cases (1979–1994). Vet Surg.
1998; 27: 307–311
[28]
Hahn KA, McEntee MF: Primary lung tumors in cats: 86 cases
(1979–1994). J Am Vet Med Assoc. 1997; 211: 1257–1260
[29]
Hammer AS, Couto CG: Adjuvant chemotherapy for sarcomas and
carcinomas. Vet Clin North Am Small Anim Pract. 1990; 20: 1015–
1036
[30]
Hammond EC, Auerbach O, Kirman D et al.: Effects of cigarette
smoking on dogs. CA Cancer J Clin. 1971; 21: 78–94
[31]
99
[32]
Jacobs TM, Tomlinson MJ: The lung-digit syndrome in a cat. Fel
Pract. 1997; 25: 31–36
[33]
Johnson VS, Ramsey IK, Thompson H et al.: Thoracic high-resolution computed tomography in the diagnosis of metastatic carcinoma. J Small Anim Pract. 2004; 45: 134–143
[34]
Kessler M, Tassani-Prell M, Kandel B: Röntgenologische Erscheinungsformen primärer Lungentumoren bei der Katze. Eine retrospektive Untersuchung von 48 Fällen. Tierärztl Prax. 2007; 35(K),
47–54
[35]
2006; 47: 14–20
[36]
Koblik PD: Radiographic appearance of primary lung tumors in
cats. A review of 41 cases. Vet Radiol. 1986; 27: 66–73
[37]
Kovak JR, Ludwig LL, Bergman PJ et al.: Use of thoracoscopy to
determine the etiology of pleural effusion in dogs and cats: 18
[38]
Kuntz CA: Thoracic surgical oncology. Clin Tech Small Anim Pract.
1998; 13: 47–52
[39]
Langenbach A, McManus PM, Hendrick MJ et al.: Sensitivity and
specificity of methods of assessing the regional lymph nodes for
evidence of metastasis in dogs and cats with solid tumors. J Am Vet
Med Assoc. 2001; 218: 1424–1428
20.3 Lungentumoren und
20.4 Lymphomatoide Granulomatose
[1]
Ballegeer EA, Forrest LJ, Stepien RL: Radiographic appearance of
bronchoalveolar carcinoma in nine cats. Vet Radiol Ultrasound.
2002; 43: 267–271
[2]
Barr FJ, Gibbs C, Brown PJ: The radiological features of primary
lung tumours in the dog: a review of thirty-six cases. J Small Anim
Pract. 1986; 27: 493–505
[3]
Bauer TG: Lung biopsy. Vet Clin North Am Small Anim Pract. 2000;
30: 1207–1225
[4]
Bergman PJ: Paraneoplastic syndromes. In: Withrow SJ, Vail DM
(Hrsg.): Small Animal Clinical Oncology. Saunders Elsevier, St. Louis
2007, 88–89
[5]
Bernard F, Kudnig ST, Monnet E: Hemodynamic effects of interpleural lidocaine and bupivicaine combination in anesthetized dogs
with and without an open pericardium. Vet Surg. 2006; 35: 252–
258
[6]
Berry CR, Moore PF, Thomas WP et al.: Pulmonary lymphomatoid
granulomatosis in seven dogs (1976–1987). J Vet Int Med. 1990; 4:
157–166
[7]
Bertazzola W, Zuliani D, Pogliani E et al.: Diffuse bronchioloalveolar carcinoma in a dog. J Small Anim Pract. 2002; 43: 265–268
[8]
Bettini G, Morini M, Marconato L et al: Association between environmental dust exposure and lung cancer in dogs. Vet J. 2010; 186:
364–369
[9]
Bolln G, Schmidt C, Nickel R: Endoskopische partielle Perikardektomie: Eine retrospektive Studie von sieben Fällen (2003–2005) mit
Literaturübersicht. Kleintierprax. 2006; 51: 133–142
[10]
Med Assoc. 2006; 229: 980–983
[11]
Brodey RS, Craig PG: Primary pulmonary neoplasms in the dog: A
review of 29 cases. J Am Vet Med Assoc. 1965; 147: 1628–1643
[12]
Clements DN, Hogan AM, Cave TA: Treatment of a well differentiated pulmonary adenocarcinoma in a cat by pneumonectomy and
adjuvant mitoxantrone chemotherapy. J Feline Med Surg. 2004; 6:
199–205
[13]
Corr SA, Blackwood L: What is your diagnosis? Pulmonary tumor
(carcinoma) with digital metastases. J Small Anim Pract. 2003; 44:
240
[14]
Dallman MJ, Martin RA, Roth L: Pneumothorax as the primary
problem in two cases of bronchioalveolar carcinoma in the dog. J
[15]
Davis KM, Roe SC, Mathews KG et al.: Median sternotomy closure
in dogs: a mechanical comparison of technique stability. Vet Surg.
2006; 35: 271–277
[16]
DeBerry JD, Norris CR, Samii VF et al.: Correlation between fineneedle aspiration cytopathology and histopathology of the lung in
dogs and cats. J Am Anim Hosp Assoc. 2002; 38: 327–336
[40]
Dungworth DL, Hauser B, Hahn FF et al.: Histological classification
of tumors of the respiratory system of domestic animals. 1999
second series Volume VI, Armed Forces Institute of Pathology
Lansdowne JL, Monnet E, Twedt DC et al.: Thoracoscopic lung
lobectomy for treatment of lung tumors in dogs. Vet Surg. 2005;
34: 530–535
[41]
Dupré GP, Corlouer JP, Bouvy B: Thoracoscopic pericardectomy
performed without pulmonary exclusion in 9 dogs. Vet Surg. 2001;
30: 21–27
Liptak JM, Monnet E, Dernell WS et al.: Pneumonectomy: four
case studies and a comparative review. J Small Anim Pract. 2004,
45: 441–447
[42]
Liptak JM, Monnet E, Dernell WS et al.: Pulmonary metastatectomy in the management of four dogs with hypertrophic osteopathy. Vet Comp Oncol. 2004; 2: 1–12
[43]
Loser C, Lawrenz B, Werner HG et al.: Primäre Lungentumore mit
Metastasierung in die Phalangen bei der Katze. Kleintierprax. 1998;
43: 425–442
[17]
[18]
[19]
Favrot C, Degorce-Rubiales F: Cutaneous metastases of a bronchial adenocarcinoma in a cat. Vet Dermatol. 2005; 16: 183–196
[20]
Flynn CJ, Danjoux C. Wong J et al.: Two cases of acrometastasis to
the hands and review of the literature. Curr Oncol. 2008; 15: 51–58
[44]
Magnol JP, Marchal T, Delisle F et al.: Les tumeurs du poumon. In:
Magnol JP (Hrsg.): Cancérologie Clinique du Chien. Lyon 1998:
121–126
[45]
Martinez-Lavin M, Vargas A, Rivera-Vinas M: Hypertrophic osteoarthropathy: a palindrome with a pathogenic connotation. Curr
Opin Rheumatol. 2000; 20: 88–91
[65]
Reif JS, Cohen D: The environmental distribution of canine respiratory tract neoplasms. Arch Environ Health. 1971; 22: 136–40
[66]
Reif JS, Dunn K, Ogilvie GK et al.: Passive smoking and canine lung
cancer risk. Am J Epidemiol. 1992; 135: 234–239
[67]
Rooney MB, Mehl M, Monnet E: Intercostal thoracotomy closure:
transcostal sutures as a less painful alternative to circumcostal
suture placement. Vet Surg. 2004; 33: 209–213
[46]
McCarthy T: Resolution of chylothorax in a cat: Vet Med. 2003; 98:
823–833
[68]
[47]
McCarthy TC: Diagnostic thoracoscopy. Clin Tech Small Anim Pract.
1999; 14: 213–219
Rossi F, Vignoli M, Sarli G et al.: Unusual radiographic appearance
of lung carcinoma in a cat. J Small Anim Pract. 2003; 44: 273–276
[69]
[48]
McNiel EA, Ogilvie GK, Powers BE et al.: Evaluation of prognostic
factors for dogs with primary lung tumors: 67 cases (1985–1992). J
Am Vet Med Assoc. 1997; 211: 1422–1427
Shimazaki T, Nagata M, Goto-Koshino Y et al.: A case of canine
lymphomatoid granulomatosis with cutaneous lesions. J Vet Med
Sci. 2010; 72: 1067–1069
[70]
[49]
Melhaff CJ, Leifer CE, Patnaik AM et al.: Surgical treatment of primary pulmonary neoplasia in 15 dogs. J Am Anim Hosp Assoc.
1984; 20: 799–803
Spann DR, Sellon RK, Thrall DE et al.: Computed tomographic
diagnosis: use of computed tomography to distinguish a pulmonary
mass from alveolar disease. Vet Radiol Ultrasound. 1998; 39: 532–
535
[50]
Moulton JE, von Tscharner C, Schneider R: Classification of lung
carcinomas in the dog and cat. Vet Pathol. 1981; 18: 513–528
[71]
[51]
Nelson AW, Monnet E: Lungs. In: Slatter (Hrsg.): Textbook of Small
Animal Surgery, 3. Aufl., Saunders Philadelphia 2003: 887–888
Teske E, Stokhof AA, Van den Ingh TSGAM et al.: Transthoracic
needle aspiration biopsy of the lung in dogs with pulmonic diseases.
[72]
[52]
Nemanic S, London CA, Wisner ER: Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary
nodules in dogs with metastatic neoplasia. J Vet Int Med. 2006; 20:
508–515
Tidwell AS, Johnson KL: Computed tomography–guided percutaneous biopsy in the dog and cat: description of technique and preliminary evaluation in 14 patients. Vet Radiol Ultrasound. 1994; 35:
445–456
[73]
[53]
Ogilvie GK, Haschek WM, Withrow SJ et al.: Classification of primary lung tumors in dogs: 210 cases (1975–1985). J Am Vet Med
Assoc. 1989; 195: 106–108
Valentine BA, Blue JT, Zimmer JF et al.: Pulmonary lymphomatoid
granulomatosis in a cat. J Vet Diagn Invest. 2000; 12: 465–467
[74]
Van der Linde-Sipman JS, Van den Ingh TSGAM: Primary and
metastatic carcinomas in the digits of cats. Vet Quart. 2000; 22:
141–145
[75]
Vignoli M, Rossi F, Chierici C et al.: Needle tract implantation after
Arch Tierheilk. 2007; 149: 314–318
[76]
Withrow S: Lung cancer. In Withrow S, Vail DM, (Hrsg.): Small Animal Clinical Oncology. 4. Aufl., Saunders St. Louis, 2007: 517–525
[54]
[55]
[56]
Ogilvie GK, Weigel RM, Haschek WM et al.: Prognostic factors for
tumor remission and survival in dogs after surgery for primary lung
tumor: 76 cases (1975–1985). J Am Vet Med Assoc. 1989; 195:
109–112
Paoloni MC, Adams WM, Dubielzig RR et al.: Comparison of results of computed tomography and radiography with histopathologic findings in tracheobronchial lymph nodes in dogs with primary
lung tumors: 14 cases (1999–2002). J Am Vet Med Assoc. 2006;
228: 1718–1722
Park HM, Hwang DN, Kang BT et al.: Pulmonary lymphomatoid
granulomatosis in a dog: evidence of immunophenotypic diversity
and relationship to human pulmonary lymphomatoid granulomatosis and pulmonary Hodgkin’s disease. Vet Pathol. 2007; 44: 921–
923
21 Tumoren der parenchymatösen Organe
21.1 Tumoren der Leber
[1]
Adler R, Wilson DW: Biliary cystadenoma of cats. Vet Pathol.
1995; 32: 415–418
[57]
Pavletic MM: Surgical stapling devices in small animal surgery.
Comp Small Anim Prac. 1990; 12: 1724–1741
[2]
[58]
Petterino C, Guazzi P, Ferro S et al.: Bronchogenic adenocarcinoma in a cat: an unusual case of metastasis to the skin. Vet Clin
Path. 2005; 34: 401–404
Badylak SF, Dodds WJ, Van Vleet JF: Plasma coagulation factor
abnormalities in dogs with naturally occurring hepatic disease. Am J
Vet Res. 1983; 44: 2336—2340
[3]
Balkman C: Hepatobiliary neoplasia in dogs and cats. Vet Clin
[59]
Poirier VJ, Burgess KE, Adams WM et al.: Toxicity, dosage and
efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Int Med. 2004; 18: 536–539
[4]
[60]
Polton GA, Brearley MJ, Powell SM et al.: Impact of primary
tumor stage on survival in dogs with solitary lung tumors. J Small
Anim Pract. 2008; 49: 66–71
Carter JE, Tarigo JL, Vernau W et al.: Erythrophagocytic low-grade
extranodal T-cell lymphoma in a cat. Vet Clin Pathol. 2008; 37:
416–421
[5]
[61]
Poulson JM, Vujaskovic Z, Gillette SM et al.: Volume and doseresponse effects for severe symptomatic pneumonitis after fractionated irradiation of canine lung. Int J Radiat Biol. 2000; 76: 463–
468
Center SA, Baldwin BH, Erb HN et al.: Bile acid concentrations in
the diagnosis of hepatobiliary disease in the dog. J Am Vet Med
Assoc. 1985; 187: 935–940
[6]
[62]
Prather AB, Berry CR, Thrall DE: Use of radiography in combination with computed tomography for the assessment of noncardiac
thoracic disease in the dog and cat. Vet Radiol Ultrasound. 2005;
46: 114–121
Center SA, Slater MR, Manwarren T et al.: Diagnostic efficacy of
serum alkaline phosphatase and gamma-glutamyltransferase in
dogs with histologically confirmed hepatobiliary disease: 270 cases.
J Am Vet Med Assoc. 1992; 201: 1258–1264
[7]
Chikata S, Nakamura S, Katayama R et al.: Primary chondrosarcoma in the liver of a dog. Vet Pathol. 2006; 43:1033–1036
[8]
[63]
Radlinsky MA, Mason DE, Biller DS et al.: Thoracoscopic visualization and ligation of the thoracic duct in dogs. Vet Surg. 2002; 31:
138–146
Cienava EA, Barnhart KF, Brown R et al.: Morphologic, immunohistochemical, and molecular characterization of hepatosplenic
T-cell lymphoma in a dog. Vet Clin Pathol. 2004; 33: 105–110
[9]
[64]
Reichle JK, Wisner EP: Non-cardiac thoracic ultrasound in 75 feline
and canine patients. Vet Radiol Ultrasound. 2000; 41: 154–162
Clifford CA, Pretorius ES, Weisse C et al.: Magnetic resonance
imaging of focal splenic and hepatic lesions in the dog. J Vet Intern
Med. 2004; 18: 330–338
85
86
[10]
Cohen M, Bohling MW, Wright JC et al.: Evaluation of sensitivity
and specificity of cytologic examination: 269 cases (1999–2000). J
Am Vet Med Assoc. 2003; 222: 964–967
[34]
Lawrence HJ, Erb HN, Harvey HJ: Nonlymphomatous hepatobiliary
masses in cats: 41 cases (1972–1991). Vet Surg. 1994; 23: 365–
368
[11]
Cole TL, Center SA, Flood SN et al.: Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. J Am
Vet Med Assoc. 2002; 220: 1483–1490
[35]
Lamb CR, Hartzband LE, Tidwell AS et al.: Ultrasonographic findings in hepatic and splenic lymphosarcoma in dogs and cats. Vet
Radiol. 1991; 32: 117–120
[12]
Crabtree AC, Spangler E, Beard D et al.: Diagnostic accuracy of
gray-scale ultrasonography for the detection of hepatic and splenic
lymphoma in dogs. Vet Radiol Ultrasound. 2010; 51: 661–664
[36]
Leifer CE, Peterson ME, Matus RE et al.: Hypoglycemia associated
with non-islet cell tumor in 13 dogs. J Am Vet Med Assoc. 1985;
186: 53–55
[13]
Cuccovillo A, Lamb CR: Cellular features of sonographic target
lesions of the liver and spleen in 21 dogs and a cat. Vet Radiol Ultrasound. 2002; 43: 275–278
[37]
Liptak JM, Dernell WS, Monnet E et al.: Massive hepatocellular
carcinoma in dogs: 48 cases (1992–2002). J Am Vet Med Assoc.
2004; 225: 1225–1230
[14]
Cullen JM, Popp JA: Tumors of the liver and gall bladder. In: Meuten
DJ. (Hrsg.) Tumors in domestic animals. 4. Auflg. Iowa State Press
2002, 483–508
[38]
Lowseth LA, Gillett NA, Chang IY et al.: Detection of serum
α-fetoprotein in dogs with hepatic tumors. J Am Vet Med Assoc.
1991; 199: 735–741
[15]
Culp WT, Drobatz KJ, Glassman MM et al.: Feline visceral hemangiosarcoma. J Vet Intern Med. 2008; 22: 148–152
[39]
Magne ML: Primary epithelial hepatic tumors in the dog. Comp
Cont Educ Pract Vet. 1984; 6: 506–515
[16]
Dhaliwal RS, Johnson TO, Kitchell BE: Primary extraskeletal hepatic
osteosarcoma in a cat. J Am Vet Med Assoc. 2003; 222: 340–342,
316
[40]
Marconato L, Albanese F, Viacava P et al.: Paraneoplastic alopecia
associated with hepatocellular carcinoma in a cat. Vet Dermatol.
2007; 18: 267–271
[17]
Eichelberger J: Multiple Gallengangszysten bei einer 11-jährigen
Perserkatze. Kleintierprax. 1996; 41: 299–303
[41]
McCaw DL, da Silva Curiel JMA, Shaw DP: Hepatic myelolipomas
in a cat. J Am Vet Med Assoc. 1990; 197: 243–244
[18]
Evans SM: The radiographic appearance of primary liver neoplasia
in dogs. Vet Radiol. 1987; 28: 192–196
[42]
McConnel MF, Lumsden JH: Biochemical evaluation of metastatic
liver diesase in the dog. J Am Anim Hosp Assoc. 1983; 19: 173–178
[19]
Feeney DA, Johnston GR, Hardy RM: Two-dimensional, gray-scale
ultrasonography for assessment of hepatic and splenic neoplasia in
the dog and cat. J Am Vet Med Assoc. 1987; 184: 68–81
[43]
Monteiro CB, OʼBrien RT: A retrospective study on the sonographic
findings of abdominal carcinomatosis in 14 cats. Vet Radiol Ultrasound. 2004; 45: 559–564
[20]
Ferreira-Neves P, Lezmi S, Lejeune T et al.: Immunohistochemical
characterization of a hepatic neuroendocrine carcinoma in a cat. J
Vet Diagn Invest. 2008; 20: 110–114
[44]
Nakamura K, Takagi S, Sasaki N et al.: Contrast-enhanced ultrasonography for characterization of canine focal liver lesions. Vet Radiol
Ultrasound. 2010; 51: 79–85.
[21]
Fry PD, Rest JR: Partial hepatectomy in two dogs. J Small Anim
Pract. 1993; 34: 192–195
[45]
[22]
Fry MM, Vernau W, Pesavento PA et al.: Hepatosplenic lymphoma
in a dog. Vet Pathol. 2003; 40: 556–562
Neumann S, Kaup FJ: Usefulness of Ki-67 proliferation marker in
the cytologic identification of liver tumors in dogs. Vet Clin Pathol.
2005; 34: 132–136
[46]
[23]
Tumoren beim Hund anhand der Sektionsstatistik des Institutes für
Tierpathologie, München. Diss med vet, München 1990
Neumann S: Auswirkungen unterschiedlicher Lebererkrankungen
auf die Thrombozytenzahl beim Hund. Dtsch Tierarztl Wochenschr.
2006; 113: 224–227
[47]
[24]
Gunn C, Gourely IM, Koblick PD: Hepatic dearterialization in the
dog. Am J Vet Res. 1986; 47: 170–175
Newell SM, Selcer BA, Girard E et al.: Correlations between ultrasonographic findings and specific hepatic diseases in cats: 72 cases
(1985–1997). J Am Vet Med Assoc. 1998; 213: 94–98
[25]
Hammer AS, Sikkema DA: Hepatic neoplasia in the dog and cat.
Vet Clin North Am Sm Anim Pract. 1995; 25: 419–435
[48]
Nyland TG: Ultrasonic patterns of canine hepatic lymphosarcoma.
Vet Radiol. 1984; 25:167–172
[26]
Hayes HM, Morion MM, Rubenstein DA: Canine biliary carcinoma:
epidemiological comparisons with man. J Comp Pathol. 1983; 93:
99–107
[49]
Nyland TG, Koblik PD, Tellyer SE: Ultrasonographic evaluation of
biliary cystadenomas in cats. Vet Radiol Ultrasound. 1999; 40: 300–
306
[27]
Jacobs TM, Snyder PW: Mucinous cholangiocarcinoma in a cat. J
[50]
[28]
Kessler M, Tassani-Prell M, Maurus Y et al.: Tumoren der Bauchund Beckenhöhle beim Hund. Klinische, röntgenologische und
labordiagnostische Befunde bei 145 Patienten. Tierärztl Prax. 1997;
25: 472–479
Nyman HT, Kristensen AT, Flagstad A et al.: A review of the sonographic assessment of tumor metastases in liver and superficial
lymph nodes. Vet Radiol Ultrasound. 2004; 45: 438–448
[51]
Ogilvie GK, Obradovich JE, Elmslie RE et al.: Efficacy of Mitoxantrone against various neoplasms in the dog. J Am Vet Med Assoc.
1991; 198: 1618–1621
[52]
Patnaik AK, Newman SJ, Scase T et al.: Canine hepatic neuroendocrine carcinoma: an immunohistochemical and electron microscopic study. Vet Pathol. 2005; 42: 140–146
[29]
Kessler M, von Bomhard D: Lebertumoren bei Katzen: 133 Fälle
(unveröffentlicht), 1998
[30]
Kessler M, Kühnel S: Verlaufsuntersuchungen bei 15 Hunden nach
Resektion maligner Lebertumoren. (unveröffentlicht), 2010
[53]
[31]
Kitao S, Yamada T, Ishikawa T et al.: Alpha-fetoprotein in serum
and tumor tissues in dogs with hepatocellular carcinoma. J Vet
Diagn Invest. 2006; 18: 291–295
Patnaik AK: A morphologic and immunocytochemical study of
hepatic neoplasms in cats. Vet Pathol 1992; 29: 405–415
[54]
Patnaik AK, Hurvitz AI, Liebermann PH et al.: Canine bile duct
[55]
Patnaik AK, Hurvitz AI, Liebermann PH et al.: Canine hepatocellular carcinoma. Vet Pathol. 1981; 18: 427–438
[56]
Patnaik AK, Hurvitz AI, Liebermann PH: Canine hepatic neoplasms: A clinicopathologic study. Vet Pathol. 1980; 17: 553–564
[57]
Patnaik AK, Liebermann PH, Hurvitz AI et al.: Canine hepatic carcinoids. Vet Pathol. 1981; 18: 445–453
[32]
Kosovsky JE, Manfra-Martetta S, Matthiesen DT et al.: Results of
partial hepatectomy in 18 dogs with hepatocellular carcinoma. J
[33]
Kristensen AT, Weiss DJ, Klausner JS et al.: Liver cytology in cases
of canine and feline hepatic disease. Comp Cont Educ Pract Vet.
1990; 12: 797–809
87
Patnaik AK, Liu SK, Hurvitz AI et al.: Nonhematopoietic neoplasms in cats. J Natl Cancer Inst. 1975; 54; 855–860
[59]
Patnaik AK, Lieberman PH, Erlandson RA et al.: Hepatobiliary
neuroendocrine carcinoma in cats: a clinicopathologic, immunohistochemical, and ultrastructural study of 17 cases. Vet Pathol. 2005;
42: 331–337
[60]
Ponomarkov V, Mackey LJ: Tumors of the liver and biliary system.
Bull WHO. 1976; 53: 187–194
[61]
Post G, Patnaik AK: Nonhematopoietic hepatic neoplasms in cats:
21 cases (1983–1988). J Am Vet Med Assoc. 1992; 201; 1080–1082
[62]
Richter KP: Laparoscopy in dogs and cats. Vet Clin North Am Small
Anim Pract. 2001; 31: 707–727, ix
[63]
Roth L: Comparison of liver cytology and biopsy diagnoses in dogs
and cats: 56 cases. Vet Clin Pathol. 2001; 30: 35–38
[64]
Schuh JCL: Hepatic nodular myelolipomatosis (myelolipomas) associated with a peritoneo-pericardial diaphragmatic hernia in a cat. J
Comp Pathol. 1987; 97: 231–235
[65]
Shiroma JT, Myer CW, Mattrey RF: Improved detection of liver
metastases in canine hemangiosarcoma using perfluorooctylbromide as an ultrasonic contrast agent: preliminary results. Proc 10th
Ann Conf Vet Cancer Soc., Auburn, AL 1990
21.2 Tumoren der Milz
[1]
Akhtar N, Padilla ML, Dickerson EB et al.: Interleukin-12 inhibits
tumor growth in a novel angiogenesis canine hemangiosarcoma
xenograft model. Neoplasia. 2004; 6: 106–116
[2]
Allan R, Halsey TR, Thompson KG: Splenic mast cell tumour and
mastocytaemia in a cat: case study and literature review. N Z Vet J.
2000; 48: 117–121
[3]
Al-Rukibat RK, Bani Ismail ZA: Unusual presentation of splenic
myelolipoma in a dog. Can Vet J. 2006; 47: 1112–1114
[4]
Aronsohn MG, Dubiel B, Roberts B et al.: Prognosis for acute nontraumatic hemoperitoneum in the dog: A retrospective analysis. J
[5]
Ballegeer EA, Forrest LJ, Dickinson RM et al.: Correlation of ultrasonographic appearance of lesions and cytologic and histologic
diagnoses in splenic aspirates from dogs and cats: 32 cases (2002–
2005). J Am Vet Med Assoc. 2007; 230: 690–696
[6]
Bertazzolo W, DellʼOrco M, Bonfanti U et al.: Canine angiosarcoma: cytologic, histologic, and immunohistochemical correlations.
[7]
Brown NO, Patnaik AK, MacEwen EG: Canine hemangiosarcoma:
Retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985;
186: 56–58
[66]
Stockhaus C, Teske E: Klinische Anwendbarkeit der Leberzytologie
bei Hund und Katze. Kleintierprax. 1997; 42: 687–700
[8]
[67]
Stockhaus C, van den Ingh T, Rothuizen J et al.: A multistep
approach in the cytologic evaluation of liver biopsy samples of dogs
with hepatic diseases. Vet Pathol. 2004; 41: 461–470
Carpenter JL, Andrews LK, Holzworth J: Tumors and tumor-like
lesions. In: Holzworth J (Hrsg.): Diseases of the cat. Medicine and
surgery. WB Saunders Co, Philadelphia 1987
[9]
[68]
Stowater JL, Lamb CR, Schelling SH: Ultrasonographic features of
canine hepatic nodular hyperplasia. Vet Radiol. 1990; 31: 268–272
Carter JE, Tarigo JL, Vernau W et al.: Erythrophagocytic low-grade
extranodal T-cell lymphoma in a cat. Vet Clin Pathol. 2008; 37:
416–421
[69]
Strafuss AC: Bile duct carcinoma in dogs. J Am Vet Med Assoc.
1976; 169: 429
[10]
[70]
Strombeck DR, Krum S, Meyer D et al.: Hypoglycemia and hypoinsulinemia associated with hepatoma in a dog. J Am Vet Med
Assoc. 1976; 169: 811–812
Cavanna MT, Ratto A, Capurro C et al.: Canine hemangiosarcoma:
A preliminary study on grading system. Proc. 1st World Conference
on spontaneous animal tumors, Genua 1995
[11]
Christopher MM: Cytology of the spleen. Vet Clin North Am Small
Anim. 2003; 33: 135–152
[71]
Strombeck DR: Clinicopathologic features of primary and metastatic neoplastic disease of the liver in dogs. J Am Vet Med Assoc.
1978; 173: 267–269
[12]
Chun R: Feline and canine hemangiosarcoma. Compend Contin
Educ Pract Vet. 1999; 21: 622–629
[13]
[72]
Taniura T, Marukawa K, Yamada K et al.: Differential diagnosis of
hepatic tumor-like lesions in dog by using dynamic CT scanning.
Hiroshima J Med Sci. 2009; 58: 17–24
Clifford CA, Pretorius ES, Weisse C et al.: Magnetic resonance
imaging of focal splenic and hepatic lesions in the dog. J Vet Intern
Med. 2004; 18: 330–338
[14]
[73]
Tashbaeva RE, Hwang DN, Song GS et al.: Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and
neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Vet Pathol. 2007; 44: 600–606
Couto CG. Canine hemangiosarcoma: Whatʼs new in diagnosis
and treatment. Vet Cancer Soc Newslett. 1989; 13: 1–6
[15]
Cooley DM, Allen DK, Waters DJ: Vascular neoplasms of dogs.
[16]
Cortese L, Paciello O, Papparella S: Morphological characterisation
of malignant histiocytosis in a cat. Folia Morphol (Warsz). 2008; 67:
299–303
[74]
Trigo FJ, Thompson H, Breeze RG: The pathology of liver tumors in
the dog. J Comp Pathol. 1982; 92: 21–39
[75]
van der Luer R, van den Ingh T et al.: [Feline paraneoplastic alopecia]. Tijdschr Diergeneeskd. 2008; 133: 182–183
[17]
Crawford MA: Challenging cases in internal medicine: What’s your
diagnosis? Vet Med. 1989; 84: 1126–1143
[76]
Wang KY, Panciera DL, Al-Rukibat RK et al.: Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990–2000). J Am Vet Med Assoc.
2004; 224: 75–78
[18]
Cruz-Arámbulo R, Wrigley R, Powers B: Sonographic features of
histiocytic neoplasms in the canine abdomen. Vet Radiol Ultrasound. 2004; 45: 554–558
[77]
Whiteley MB, Feeney DA, Whiteley LO et al.: Ultrasonographic
appearance of primary and metastatic canine hepatic tumors – a
review of 48 cases. J Ultrasound Med. 1989; 8: 621–630
[19]
Culp WTN, Drobatz KJ, Glassman MM et al.: Feline visceral
hemangiosarcoma. J Vet Intern Med. 2008; 22: 148–152
[20]
Dahl K, Gamlem H, Tverdal A et al.: Canine vascular neoplasia – a
population-based study of prognosis. APMIS 2008; 116 (Suppl 125):
55–62
[21]
Dank G, Chien MB, London CA: Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of
cats. Am J Vet Res. 2002; 63: 1129–1133
[22]
Day MJ, Lucke VM, Pearson H: A review of pathological diagnoses
made from 87 canine splenic biopsies. J Small Anim Pract. 1995;
36: 426–433
[23]
Dickerson EB, Thomas R, Fosmire SP et al.: Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine
hemangiosarcoma. Vet Pathol. 2005; 42: 618–632
[78]
[79]
[80]
Wiersma L, Kuiper RV, Gröne A: Hepatic extraskeletal chondroblastic osteosarcoma with unusual angioinvasion of the caudal vena
cava in a dog. Tijdschr Diergeneeskd. 2010; 135: 940–943
Yamada T, Fujita M, Kitao S et al.: Serum alpha-fetoprotein values
in dogs with various hepatic diseases. J Vet Med Sci. 1999; 61: 657–
659
Zawie DA, Garvey MS: Feline hepatic disease. Vet Clin North Am
Small Anim Pract 1984; 14: 1201–1230
[58]
88
[24]
Elmore SA, Basseches J, Anhalt GJ et al.: Paraneoplastic pemphigus in a dog with splenic sarcoma. Vet Pathol. 2005; 42: 88–91
[25]
Fees DL, Withrow SJ: Canine hemangiosarcoma. Compend Contin
Educ Pract Vet. 1981; 3: 1047–1051
[26]
Feinmehl R, Matus R, Maulden GN et al.: Splenic mast cell tumors
in 43 cats. Proc 12th Annu Conf Vet Cancer Soc. 1992; 12: 50
[27]
Fife WD, Samii VF, Drost WT et al.: Comparison between malignant and nonmalignant splenic masses in dogs using contrastenhanced computed tomography. Vet Radiol Ultrasound. 2004; 45:
289–297
[28]
Fosmire SP, Dickerson EB, Scott AM et al.: Canine malignant
hemangiosarcoma as a model of primitive angiogenic endothelium.
Lab Invest. 2004; 84: 562–572
[29]
Friedrichs KR, Young KM: Histiocytic sarcoma of macrophage origin in a cat: case report with a literature review of feline histiocytic
malignancies and comparison with canine hemophagocytic histiocytic sarcoma. Vet Clin Pathol. 2008; 37: 121–128
[45]
Holt D, Van Winkle T, Schelling C et al.: Correlation between thoracic radiographs and postmortem findings in dogs with hemangiosarcoma: 77 cases (1984–1989). J Am Vet Med Assoc. 1992; 200:
1535–1539
[46]
Huber TL, Kouskoff V, Fehling HJ et al.: Haemangioblast commitment is initiated in the primitive streak of the mouse embryo.
Nature. 2004; 432: 625–630
[47]
Ide K, Setoguchi-Mukai A, Nakagawa T et al.: Disseminated histiocytic sarcoma with excessive hemophagocytosis in a cat. J Vet
Med Sci. 2009; 71: 817–820
[48]
Irausquin RA, Scavelli TD, Corti L et al.: Comparative evaluation of
the liver in dogs with a splenic mass by using ultrasonography and
contrast-enhanced computed tomography. Can Vet J. 2008; 49:
46–52
[49]
Johannes CM, Henry CJ, Turnquist SE et al.: Hemangiosarcoma in
1851–1856
[30]
Fritz D, Hopfner CL, Guilhot-Chrétien JC: Systemic mast cell diseases in cats, retrospective study of seven cases, benefits of bone
marrow biopsy, comparative aspects. Revue Méd Vét. 2004; 155:
362–370
[50]
Johnson KA, Powers BE, Withrow SJ et al.: Splenomegaly in dogs.
Predictors of neoplasia and survival after splenectomy. J Vet Int
Med. 1989; 3: 160–166
[51]
[31]
Gamlem H, Nordstoga K: Canine vascular neoplasia – histologic
classification and immunohistochemical analysis of 221 tumours
and tumour-like lesions. APMIS 2008; 116 (Suppl 125): 19–40
Kapatkin AS, Muller HS, Mathiesen DT et al.: Leiomyosarcoma in
dogs: 44 cases (1983–1988). J Am Vet Med Assoc. 1992; 201:
1077–1086
[52]
[32]
Gamlem H, Nordstoga K, Glattre E: Canine neoplasia-introductory
paper. APMIS 2008; 116 (Suppl 125): 5–18
Kerlin RL, Hendrick MJ: Malignant fibrous histiocytoma and malignant histiocytosis in the dog – convergent or divergent phenotypic
differentiation? Vet Pathol. 1996; 33: 713–716
[33]
Gamlem H, Nordstoga K, Arnesen K: Canine vascular neoplasia –
a population-based clinicopathologic study of 439 tumours and
tumour-like lesions in 420 dogs. APMIS 2008; 116 (Suppl 125): 41–
54
[53]
Kessler M, Fickenscher Y, von Bomhard: Zum Vorkommen primärer Tumoren der Milz bei der Katze. Kleintierprax. 1998; 43: 601–
608
[54]
[34]
Geisel O, Kusch S, Klein H: Vorkommen, Primärsitz und Metastasierungsmuster des Hämangioendothelioms beim Hund. Eine Auswertung des Sektionsmaterials aus den Jahren 1970–1985. Tierärztl
Prax. 1986; 14: 389–395
Kessler M, Hammer AS: Canines Hämangiosarkom: Diagnose und
Therapie. Kleintierprax. 1991; 36: 637–648
[55]
Kessler M, Maurus Y, Köstlin R: Das Hämangiosarkom der Milz –
Klinische Aspekte bei 52 Hunden. Tierärztl Prax. 1997; 25: 651–656
[56]
Kessler M, Tassani-Prell P, Maurus Y et al.: Tumoren der Bauchund Beckenhöhle beim Hund: Klinische, röntgenologische und
25: 472–479
[57]
Kessler M, von Bomhard D, Matis U: Mastzelltumoren bei Hunden
und Katzen – Epidemiologie, Diagnose und Therapie. Kleintierprax.
1997; 42: 361–374
[35]
Tumoren beim Hund anhand der Sektionsstatistik des Institutes für
Tierpathologie, München, 1951–1969. Diss med vet, München
1990
[36]
Gordon SSN, McClaran JK, Bergman PJ et al.: Outcome following
splenectomy in cats. J Fel Med Surg. 2010; 12: 256–261
[37]
Guerre R, Millet P, Groulade P: Systemic mastocytosis in a cat:
Remission after splenectomy. J Small Anim Pract. 1979; 20: 769–
772
[58]
Am Vet Med Assoc. 2007; 231:1550–1557
[38]
Hammer AS, Couto CG, Filippi J et al.: Efficacy and toxicity of VAC
chemotherapy (Vincristine, Doxorubicin and Cyclophosphamide) in
dogs with hemangiosarcoma. J Vet Int Med. 1991; 5: 160–166
[59]
Kisseberth WC, MacEwen EG, Kurzman ID et al.: L-MTP-PE and
chemotherapy for canine splenic hemangiosarcoma. Proc Ann Conf
Vet Cancer Soc. 1994
[39]
Hammer AS, Bailey MQ, Sagartz JE: Retrospective assessment of
thoracic radiographic findings in metastatic canine hemangiosarcoma. Vet Radiol Ultrasound. 1993; 34: 235–238
[60]
Kraje AC, Mears EA, Hahn KA et al.: Unusual metastatic behavior
and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma. J Am Vet Med Assoc. 1999; 214: 670–672
[40]
Hammond TN, Pesillo-Crosby SA: Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum
requiring a transfusion: 71 cases (2003–2005). J Am Vet Med Assoc.
2008; 232: 553–558
[61]
Kusch S: Erhebungen über das Vorkommen bösartiger Blastome
beim Hund anhand der Sektionsstatistik des Institutes für Tierpathologie, München 1970–1985. Diss med vet, München 1985
[62]
[41]
Hanson JA, Papageorges M, Girard E et al.: Ultrasonographic
appearance of splenic disease in 101 cats. Vet Radiol Ultrasound.
2001: 42: 441–445
Lamerato-Kozicki AR, Helm KM, Jubala CM et al.: Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 2006; 34: 870–878
[63]
[42]
Heller DA, Clifford CA, Goldschmidt MH et al.: Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic
Lana S, UʼRen LW, Plaza S et al.: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J
Vet Int Med. 2008; 21: 764–769
[64]
[43]
Helfand SC: Canine hemangiosarcoma: A tumor of contemporary
interest. Cancer Therapy. 2008; 6: 457–462
Liska WD, MacEwen EG, Zaki FA et al.: Feline systemic mastocytosis: A review and results of splenectomy in seven cases. J Am Anim
Hosp Assoc. 1979; 15: 589–597
[44]
Hendrick MJ, Brooks JJ, Bruce EH: Six cases of malignant fibrous
histiocytoma of the canine spleen. Vet Pathol. 1992; 29: 351–354
[65]
Litster AL, Sorenmo KU: Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J
Feline Med Surg. 2006; 8: 177–183
[66]
Macy DW: Canine and feline mast cell tumors: biologic behavior,
diagnosis, and therapy. Sem Vet Med Surg (Sm Anim). 1986; 1: 72–
83
[89]
Sorenmo KU, Baez JL, Clifford CA et al.: Efficacy and toxicity of a
dose-intensified doxorubicin protocol in canine hemangiosarcoma. J
Vet Intern Med. 2004; 18: 209–213
[67]
Madewell BR, Munn RJ, Phillips LP: Mast cell phagocytosis of red
blood cells in a cat. Vet Pathol. 1983; 20: 638–640
[90]
[68]
Maurus Y: Abdominale Tumoren bei Hund und Katze. Eine retrospektive Studie aus der chirurgischen Tierklinik München (1990–
1994). Diss med vet, München 1995
Sorenmo K, Duda L, Barber L et al.: Canine hemangiosarcoma
treated with standard chemotherapy and minocycline. J Vet Intern
Med. 2000; 14: 395–398.
[91]
Mayer B, Zwetkoff S, Schaffer G et al.: Tumour suppressor gene
p53 mutation in a case of haemangiosarcoma in a dog. Acta Vet
Hung. 2002; 50: 157–160
Sorenmo KU, Jeglum KA, Helfand SC: Chemotherapy of canine
hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet
Intern Med. 1993; 7: 370–376
[92]
Sorenmo K, Samluk M, Clifford C et al.: Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated
liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med. 2007; 21: 1347–1354.
[69]
[70]
Miller JM, Walshaw R, Bourque AC: Primary splenic mesenchymal
chondrosarcoma in a dog. Can Vet J. 2005; 46: 163–165
[71]
Moe L, Gamlem H, Dahl K et al.: Canine neoplasia – populationbased incidence of vascular tumours. APMIS 2008; 116 (Suppl 125):
63–68
[93]
Spangler WL, Culbertson MR: Prevalence, type, and importance of
splenic diseases in dogs: 1,480 cases (1985–1989). J Am Vet Med
Assoc. 1992; 200: 829–834
[72]
Moore PF, Affolter VK, Vernau W: Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet
Pathol. 2006; 43: 632–645
[94]
Spangler WL, Culbertson MR: Prevalence and type of splenic
diseases in cats: 455 cases (1985–1991). J Am Vet Med Assoc.
1992; 201: 773–776
[73]
Ng CY, Mills NJ: Clinical und hematological features of hemangiosarcoma in dogs. Aus Vet J. 1985; 62: 1–4
[95]
[74]
Trenton, Veterinary Learning Systems 1995
[75]
Ogilvie GK, Powers BE, Mallinckrodt CH et al.: Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med. 1996; 10:
379–384
Spangler WL, Culbertson MR, Kass PH: Primary mesenchymal
(nonangiomatous/nonlymphomatous) neoplasms occurring in the
canine spleen: anatomic classification, immunohistochemistry, and
mitotic activity correlated with patient survival. Vet Pathol. 1994,
31: 37–47
[96]
Spangler WL, Kass PH: Pathologic factors affecting postsplenectomy survival in dogs. J Vet Intern Med. 1997; 11: 166–171
[76]
Oksanen A: Hemangiosarcoma in dogs. J Comp Pathol. 1978; 88:
585–595
[97]
[77]
Ottenjann M, Kohn B, Weingart C et al.: Rupturiertes Hämangiosarkom der Milz als Ursache eines Hämoperitoneums bei 4 Katzen.
Srebernik N, Appleby EC: Breed prevalence and sites of hemangioma and hemangiosarcoma in dogs. Vet Rec. 1991; 129: 408–
409
[98]
[78]
Patnaik AK, Liu SK: Angiosarcoma in cats. J Small Anim Pract.
1977; 18: 191–198
Stockhaus C, Werner HG, Stolle A: Die systemische Mastozytose:
Eine seltene Ursache für chronisches Erbrechen der Katze. Kleintierprax. 1996; 41: 767–773
[99]
[79]
Priester WA: Hepatic angiosarcoma in dogs: An excessive frequency as compared with man. J Natl Cancer Inst. 1976; 57: 451–
453
Tamburini BA, Trapp S, Phang TL et al.: Gene expression profiles
of sporadic canine hemangiosarcoma are uniquely associated with
breed. Public Library of Science (PLoS) ONE 2009; 4: e5549
[80]
Prymak C, McKee LJ, Goldschmidt MH et al.: Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma in dogs: 217 cases (1985). J Am Vet Med Assoc. 1988;
193: 706–711
[81]
Rassnick KM, Frimberger AE, Wood CA et al.: Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med.
2000; 14: 271–276
[82]
Rossi F, Leone VF, Vignoli M et al.: Use of contrast-enhanced ultrasound for characterization of focal splenic lesions. Vet Radiol Ultrasound. 2008; 49: 154–164
[83]
Sanladerer B: Maligne Hämangioendotheliome beim Hund. Eine
retrospektive Untersuchung klinischer Fälle aus dem Ontario Veterinary College in Guelph, Kanada, 1983–1992. Diss med vet, München, 1994
[84]
Sato AF, Solano M: Ultrasonographic findings in abdominal mast
[85]
Scavelli TD, Patnaik AK, Mehlhaff CJ et al.: Hemangiosarcoma in
the cat: retrospective evaluation of 31 surgical cases. J Am Vet Med
Assoc. 1985; 187: 817–819
[86]
Schulmann A: Splenic mastocytosis in a cat. California Vet. 1987;
17: 17–18
[87]
Schwarz LA, Penninck DG, Gliatto J: Canine splenic myelolipomas.
[88]
Snyder JM, Lipitz L, Skorupski KA et al.: Secondary intracranial
2008; 22: 172–177
[100] UʼRen LW, Biller BJ, Elmslie RE et al.: Evaluation of a novel tumor
vaccine in dogs with hemangiosarcoma J Vet Int Med. 2008; 21:
113–120
[101] Vail DM, MacEwen EG, Kurzman ID et al.: Liposome-encapsulated
muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized
multi-institutional clinical trial. Clin Cancer Res. 1995; 1: 1165–
1170
[102] Waters DJ, Caywood DD, Hayden DW et al.: Metastatic pattern in
dogs with splenic hemangiosarcoma: Clinical implications. J Small
Anim Pract. 1988; 29: 805–814
[103] Webster N, Holloway A: Use of contrast ultrasonography in the
diagnosis of metastatic feline visceral haemangiosarcoma. J Feline
Med Surg. 2008; 10: 388–394
[104] Weinstein MJ, Carpenter JL, Melhaff-Schunk CJ: Nonangiogenic
and nonlymphomatous sarcomas of the canine spleen: 57 cases
(1975–1987). J Am Vet Med Assoc. 1989; 195: 784–788
[105] Wood CA, Moore AS, Gliatto JM et al.: Prognosis for dogs with
stage I or II splenic hemangiosarcoma treated by splenectomy
alone: 32 cases (1991–1993). J Am Anim Hosp Assoc. 1998; 34:
417–421
[106] Wrigley RH, Park RD, Konde LJ et al.: Ultrasonographic features of
splenic hemangiosarcoma in dogs: 18 cases (1980–1986). J Am Vet
Med Assoc. 1988; 192: 1113–1117
[107] Zhu Z: PDGFRβ: a multifaceted player in vascular and hematopoietic development. Blood. 2006; 108: 1788–1789
89
90
21.3 Tumoren des exokrinen Pankreas
[1]
Allen SW, Cornelius LM, Mahaffey EA: A comparison of two
methods of partial pancreatectomy in the dog. Vet Surg. 1989; 18:
274–278
[2]
Anderson NV, Johnson KH: Pancreatic carcinoma in the dog. J Am
Vet Med Assoc. 1967; 150: 286–295
[3]
Andrews LK: Tumors of the exocrine pancreas. In: Holzworth J
(Hrsg.): Diseases of the cat. (1. Aufl.). Philadelphia, WB Saunders;
1987: 505–507
[4]
Bennett PF, Hahn KA, Toal RL et al.: Ultrasonographic and cytopathological diagnosis of exocrine pancreatic carcinoma in the dog
and cat. J Am Anim Hosp Assoc. 2001; 37: 466–473
[5]
Brabb T, Maggio-Price L, Dale D et al.: Pancreatic adenocarcinoma in two grey collie dogs with cyclic hematopoiesis. Lab Anim
Sci. 1995; 45: 357–362
[6]
Bright JM: Pancreatic adenocarcinoma in a dog with a maldigestion
syndrome. J Am Vet Med Assoc. 1985; 187: 420–421
[7]
Brooks DG, Campbell KJ, Dennis JS et al.: Pancreatic paraneoplastic alopecia in three cats. J Am Anim Hosp Assoc. 1994; 30: 557–
563
[8]
Brown PJ, Manson KV, Merrett DJ et al.: Multifocal necrotising
steatitis associated with pancreatic carcinoma in three dogs. J Small
Anim Pract. 1994; 35: 129–132
[9]
Cave TA, Evans H, Hargreaves J et al.: Metabolic epidermal necrosis in a dog associated with pancreatic adenocarcinoma, hyperglucagonaemia, hyperinsulinaemia and hypoaminoacidaemia. J Small
Anim Pract. 2007; 48; 522–526
[10]
Chang SC, Liao JW, Lin YC et al.: Pancreatic acinar cell carcinoma
with intracranial metastasis in a dog. J Vet Med Sci. 2007; 69: 91–
93
[11]
Cobb LF, Merrell RC: Total pancreatectomy in dogs. J Surg Res.
1984; 37: 235–240
[12]
Davenport D: Pancreatic carcinoma in twenty dogs and five cats.
Proc Ann Conf Vet Cancer Soc, 1985
[13]
Dennis MM, OʼBrien TD, Wayne T et al.: Hyalinizing pancreatic
adenocarcinoma in six dogs. Vet Pathol. 2008; 45: 475–483
[14]
Driver J: Statistische Untersuchungen zu Abgangsursachen bei
Hunden anhand des Sektionsgutes des Institutes für VeterinärPathologie der Justus-Liebig-Universität Giessen aus den Jahren
1978–1992. Vet Med Diss, Giessen 1997
[15]
Eloy R, Bouchet P, Clendinnen G et al.: New technique of total
pancreatectomy without duodenectomy in the dog. Am J Surg.
1980; 140: 409–412
[16]
Fabbrini F, Anfray P, Viacava P et al.: Feline cutaneous and visceral
necrotizing panniculitis and steatitis associated with a pancreatic
tumour. Vet Dermatol. 2005; 16: 413–419
[17]
Fazal S, Saif MW: Supportive and palliative care of pancreatic cancer. JOP Journal of the Pancreas. 2007; 8: 240–253
[18]
Forman MA, Marks SL, De Cock HE et al.: Evaluation of feline
pancreatic lipase immunoreactivity and helical computed tomography versus conventional testing for the diagnosis of feline pancreatitis. J Vet Intern Med. 2004; 18: 807–815
[19]
Gerhardt A, Steiner JM, Williams DA et al.: Comparison of the
sensitivity of different diagnostic tests for pancreatitis in cats. J Vet
Intern Med. 2001; 15: 329–333
[20]
Ghadirian P, Simard A, Baillargeon J: Tobacco, alcohol, and coffee
and cancer of the pancreas. A population-based, case-control study
in Quebec, Canada. Cancer. 1991; 67: 2664–2670
[21]
Ghaneh P, Costello E, Neoptolemos JP: Biology and management
of pancreatic cancer. Gut. 2007; 56: 1134–1152
[22]
Godfrey DR: A case of feline paraneoplastic alopecia with secondary
Malassezia-associated dermatitis. J Small Anim Pract. 1998; 39:
394–396
[23]
Head LL, Daniel GB, Becker TJ et al.: Use of computed tomography
and radiolabeled leukocytes in a cat with pancreatitis. Vet Radiol
Ultrasound. 2005; 46: 263–266
[24]
Head LL, Daniel GB, Tobias K et al.: Evaluation of the feline pancreas using computed tomography and radiolabeled leukocytes. Vet
[25]
Hecht S, Penninck DG, Keating JH: Imaging findings in pancreatic
neoplasia and nodular hyperplasia in 19 cats. Vet Radiol Ultrasound.
2007; 48: 45–50
[26]
Hughes D, Goldschmidt MH, Washabau RJ et al.: Serum alpha-1antitrypsin concentration in dogs with panniculitis. J Am Vet Med
Assoc. 1996; 209: 1582–1584
[27]
Kamano T, Azuma N, Katami A et al.: Preliminary observation on
pancreatic duct adenocarcinoma induced by intraductal administration of N-ethyl-Nʼ-nitro-N-nitrosoguanidine in dogs. Jpn J Cancer
Res. 1988; 79: 1–4
[28]
Kessler M, Tassani-Prell M. Maurus Y et al.: Tumoren der Bauchund Beckenhöhle beim Hund. Klinische, röntgenologische und
25: 472–479
[29]
Kipperman BS, Nelson RW, Griffey SM et al.: Diabetes mellitus
and exocrine pancreatic neoplasia in two cats with hyperadrenocorticism. J Am Anim Hosp Assoc. 1992; 28: 415–418
[30]
Kircher CH, Nielsen SW: Tumours of the pancreas. Bull World
Health Organ. 1976; 53: 195–202
[31]
Lamb CR, Simpson KW, Boswood A et al.: Ultrasonography of
pancreatic neoplasia in the dog: a retrospective review of 16 cases.
Vet Rec. 1995; 137: 65–68
[32]
Larsson MHMA, Dagli MLZ, Xavier JG et al.: Obstructive jaundice
caused by a metastatic adenocarcinoma of the pancreas in a cat.
Ars Veterinaria. 1989; 5: 113–116
[33]
Lyon JL, Slattery ML, Mahoney AW et al.: Dietary intake as a risk
factor for cancer of the exocrine pancreas. Cancer Epidemiol Biomarkers Prev. 1993; 2: 513–518
[34]
Martinez-Ruzafa I, Dominguez PA, Dervisis NG et al.: Tolerability
of gemcitabine and carboplatin doublet therapy in cats with carcinomas. J Vet Intern Med. 2009; 23: 570–577
[35]
Mayr B, Schaffner G, Reifinger M et al.: K-ras protooncogene
mutations in feline pancreatic adenocarcinomas. Vet Rec. 2003;
153: 468–469
[36]
Mayr B, Schaffner G, Reifinger M: K-ras mutations in canine pancreatic cancers. Vet Rec. 2003; 153: 87–89
[37]
Münster M, Reusch C: Tumoren des exokrinen Pankreas. Tierärztl
Prax. 1988; 16: 317–320
[38]
National Comprehensive Cancer Network: NCCC Clinical Practice
Guidelines in Oncology: Pancreatic Adenocarcinoma. Available at:
www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.
Accessed 7/16, 2007
[39]
Neoptolemos JP, Cunningham D, Friess H et al.: Adjuvant therapy
in pancreatic cancer: historical and current perspectives. Ann
Oncol. 2003; 14: 675–692
[40]
Newman SJ, Mrkonjich L: Cyclooxygenase-2 expression in feline
pancreatic adenocarcinomas. J Vet Diagn Invest. 2006; 18: 590–593
[41]
Newman SJ, Steiner JM, Woosley K et al.: Correlation of age and
incidence of pancreatic exocrine nodular hyperplasia in the dog. Vet
Pathol. 2005; 42: 510–513
[42]
Ota A, Kusano M, Ishii H et al.: A new reconstructive procedure
after segmental pancreatectomy: an experimental study of pancreatic end-to-end (duct-to-duct) anastomosis. J Hepatobiliary Pancreat Surg. 2001; 8: 342–348
[43]
Owens JM, Drazner FH, Gilbertson SR: Pancreatic disease in the
cat. 1975; 11: 83–89
[44]
Patel A, Whitbread TJ, McNeil PE: A case of metabolic epidermal
necrosis in a cat. Vet Dermatol. 1996; 7: 221–226
[45]
Posch B: Pankreasdiagnostik mittels Computertomographie bei
Hund und Katze. Vet Med Diss, Veterinärmedizinische Universität
Wien, 2002
[46]
[47]
[48]
[10]
Priester WA: Data from eleven United States and Canadian colleges
of veterinary medicine on pancreatic carcinoma in domestic animals. Cancer Res. 1974; 34: 1372–1375
Comstock KE, Lingass F, Kirkness EF et al.: A high-resolution comparative map of canine chromosome 5q14.3-q33 constructed utilizing the 1.5x canine genome sequence. Mamm Genome. 2004; 15:
544–551
[11]
Quigley KA, Jackson ML, Haines DM: Hyperlipasemia in 6 dogs
with pancreatic or hepatic neoplasia: evidence for tumor lipase production. Vet Clin Pathol. 2001; 30: 114–120
Cosenza SF, Seely JC: Generalized nodular dermatofibrosis and
renal cystadenocarcinomas in a German Shepherd dog. J Am Vet
Med Assoc. 1986; 189: 1587–1590
[12]
Cotchin E: Neoplasia in the cat. Vet Rec. 1957; 69: 425–434
[13]
Rüst S: Computertomographische Darstellung des Pankreas beim
Hund. Vet Med Diss, Fachbereich Veterinärmedizin, Justus-LiebigUniversität Giessen, 2001
Crow SE: Urinary tract neoplasms in dogs and cats. Compend Contin Educ Pract Vet. 1985; 7: 607–618
[14]
Crow SE, Allen DP, Murphy CJ et al.: Concurrent renal adenocarcinoma and polycythemia in a dog. J Am Anim Hosp Assoc. 1995; 31:
29–33
[49]
Seaman RL: Exocrine pancreatic neoplasia in the cat: a case series. J
[15]
[50]
Spillmann T, Happonen I, Kahkonen T et al.: Endoscopic retrograde cholangiopancreatography in healthy beagles. Vet Radiol Ultrasound. 2005; 46: 97–104
Crow SE, Bell TG, Wortman JA: Hematuria associated with renal
hemangiosarcoma in a dog. J Am Vet Med Assoc. 1980; 176: 531–
533
[16]
[51]
Spillmann T, Moritz A, Burkhardt E: Die Stellung der Laparoskopie
in der Diagnostik von Pankreaserkrankungen. Tierärztl Prax. 2000;
28(K): 349–355
Daniel GB, Mitchell SK, Mawby D et al.: Renal nuclear medicine: A
review. Vet Radiol. 1999; 40: 572–587
[17]
Dome JS, Coppes MJ: Recent advances in Wilms Tumor genetics.
Curr Opin Pediatr. 2002; 14: 5–11
[52]
Spillmann T, Schnell-Kretschmer H, Dick M et al.: Endoscopic retrograde cholangiopancreatography in dogs with chronic gastrointestinal problems. Vet Radiol Ultrasound. 2005; 46: 293–299
[18]
Durno AS, Webb JA, Gauthier MJ et al.: Polycythemia and inappropriate erythropoietin concentrations in two dogs with renal
T-cell lymphoma. J Am Anim Hosp Assoc. 2011; 47: 122–128
[53]
Srikureja W, Chang KJ: Endoscopic palliation of pancreatic adenocarcinoma. Curr Opin Gastroenterol. 2005; 21: 601–605
[19]
Eddlestone S, Tabaoda J, Senior D et al.: Renal hemangioma in a
dog. J Small Anim Pract. 1999; 40:132–135
[54]
Steiner JM, Newman SJ, Xenoulis PG et al.: Histologic findings
and minimally-invasive serum markers in dogs with neoplasia
involving the pancreas. Proc 25th Conf. ACVIM, Seattle, WA 2007
[20]
Frimberger AE, Moore AS, Schelling SH: Treatment of nephroblastoma in a young dog. J Am Anim Med Assoc. 1995; 207: 596–598
[21]
[55]
Sultana A, Smith CT, Cunningham D et al.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J
Clin Oncol. 2007; 25: 2607–2615
Gabor LJ, Malik R, Canfield PJ: Clinical and anatomical features of
lymphosarcoma in 118 cats. Aust Vet J. 1998, 76: 725–732
[22]
Gajanayke I, Priestnall SL, Benigni L et al.: Paraneoplastic hypercalcemia in a dog with benign renal angiomyxoma. J Vet Diagn
Invest. 2010; 22: 775–780
[23]
Gasser AM, Bush WW, Smith S et al.: Extradural spinal, bone marrow, and renal nephroblastoma. J Am Anim Hosp Assoc. 2003; 39:
80–85
[24]
Gorse MJ: Polycythemia associated with renal fibrosarcoma in a
[25]
Haers H, Vignoli M, Paes G et al.: Contrast harmonic ultrasonographic appearance of space occupying renal lesions. Vet Radiol Ultrasound. 2010; 51: 516–522
[56]
Tasker S, Griffon DJ, Nuttall TJ et al.: Resolution of paraneoplastic
alopecia following surgical removal of a pancreatic carcinoma in a
22 Tumoren der Harnorgane
22.1 Tumoren der Nieren
[1]
Baskin GB, De Paoli A: Primary renal neoplasms of the dog. Vet
Pathol. 1977; 14: 591–605
[26]
[2]
Batchelor DJ, Bright SR, Ibarrola P et al.: Long-term survival after
combination chemotherapy for bilateral renal malignant lymphoma
in a dog. N Z Vet J. 2006; 54: 147–150
Hartmann M, Steidl T: Sekundäre Polyzythämie infolge Nephroblastom bei einem Deutschen Schäferhund. Kleintierprax. 1997; 7:
577–588
[27]
[3]
Battaglia L, Petterino C, Zapulli V et al.: Hypoglycemia as a paraneoplastic syndrome associated with renal adenocarcinoma in a
dog. Vet Res Commun. 2005; 29: 671–675
Hayes HM, Fraumeni JF: Epidemiologic features of canine renal
neoplasms. Cancer Res. 1977; 37: 2553–2556
[28]
Haziroglu R, Kul O, Tunca R et al.: Osteoclast-like giant cell tumour
arising from the kidney in a dog. Acta Vet Hung. 2005; 53: 225–
230
[4]
Borjesson DL: Renal cytology. Vet Clin North Am Small Anim Pract.
2003; 33: 119–134
[29]
[5]
Bryan JN, Henry CJ, Turnquist SE et al.: Primary renal neoplasia of
Henry CJ, Turnquist SE, Smith A et al.: Primary renal tumors in
cats: 19 cases (1992–1998). J Feline Med Surg. 1999; 1: 165–170
[30]
[6]
Carpenter JL, Andrews LK, Holzworth J et al.: Tumors and tumorlike lesions. In: Holzworth, J. (Hrsg). Diseases of the cat: medicine
and surgery. Philadelphia, WB Saunders, 1987: 406–596
Hess M: Anaplastic renal spindle cell sarcoma in a dog. J Small Anim
Pract. 2010; 51: 407
[31]
Hilscher K, Eberle N: Polyzythämie bei einem Hund mit renalem
T-Zell-Lymphom. Prakt Tierarzt. 2004; 85: 470–475
[7]
Cavana P, Sammartano F, Capucchio MT: Peripheral neuropathy in
a cat with renal lymphoma. J Feline Med Surg. 2009; 11. 869–872
[32]
Huff V: Wilms tumor genetics. Am J Med Genet. 1998; 79: 260–
267
[8]
Caywood DD, Osborne CA, Stevens JB et al.: Hypertrophic osteoarthropathy associated with an atypical nephroblastoma in a dog. J
Am Anim Hosp. 1980; 16: 855–865
[33]
Jonasdottir TJ, Mellersh CS, Moe L et al.: Genetic mapping of a
naturally occurring hereditary renal cancer syndrome in dogs. Proc
Natl Acad Sci USA. 2000; 97: 4132–4137
[9]
Chiang YC, Liu CH, Ho SY et al.: Hypertrophic osteopathy associated with disseminated metastases of renal cell carcinoma in the
dog: a case report. J Vet Med Sci. 2007; 69: 209–212
[34]
Kessler M: Secondary polycythaemia associated with high plasma
erythropoietin concentrations in a dog with necrotizing pyelonephritis. J Small Anim Pract. 2008; 49: 363–366
91
92
[35]
Klainbart S, Segev G, Loeb E et al.: Resolution of renal adenocarcinoma-induced secondary inappropriate polycythaemia after nephrectomy in two cats. J Feline Med Surg. 2008; 10: 264–268
[36]
Klein MK, Cockerell GL, Harris CK et al.: Canine primary renal neoplasms. A retrospective review of 54 cases. J Am Anim Hosp Assoc.
1988; 24: 443–452
[58]
Mooney SC, Hayes AA, Matus RE et al.: Renal lymphoma in cats:
28 cases (1977–1984). J Am Vet Med Assoc. 1987: 191; 1473–1477
[59]
Mosenco AS, Culp WT, Johnson V et al.: Renal cystadenoma in a
domestic shorthair. J Feline Med Surg. 2008; 10: 102–105
[60]
Mott JC, McAnulty JF, Darien DL et al.: Nephron sparing by partial
median nephrectomy for treatment of renal hemangioma in a dog.
J Am Vet Med Assoc. 1996; 208: 1274–1276
[37]
Konde LJ, Wrigley LH, Park RD et al.: Sonographic appearance of
renal neoplasia in the dog. Vet Radiol. 1985; 26: 74–81
[61]
[38]
Krawiec DR, Badertscher RR 2nd, Twardock AR et al.: Evaluation
of 99mTc-DTPA nuclear imaging for quantitative determination of
glomerular filtration in dogs. Am J Vet Res. 1996; 10: 2175–2179
Munday JS, Egins J, Selcer BA et al.: Renal osteosarcoma in a dog.
[62]
Krieger-Huber S, Faussner M.: Nierenkarzinome und noduläre
Dermatofibrose mit erblicher Disposition – Eine neue Erbkrankheit
beim Deutschen Schäferhund. Kleintierprax. 1985; 30: 235–242
Nafe LA, Herron AJ, Burk RL: Hypertrophic osteopathy in a cat
associated with renal papillary adenoma. J Am Anim Hosp Assoc.
1981; 17: 659–662
[63]
Nakayama HT, Hayashi R, Takahashi R et al.: Nephroblastoma
with liver and lung metastases in an adult dog. Jpn J Vet Sci. 1984;
46: 897–900
[39]
[40]
Küfner G: Nephroblastom bei einem vier Monate alten Deutschen
Schäferhund. Prakt Tierarzt. 2000; 81: 6–11
[64]
[41]
Laluha P, Grest P, Eichenberger S et al.: Leiomyom einer Niere
beim Hund: eine seltene Diagnose. Schweiz Arch Tierheilk. 2006;
148: 303–307
Nelson RW, Hager D, Zanjani ED: Renal lymphosarcoma with inappropriate erythropoietin production in a dog. J Am Vet Med Assoc.
1983; 182: 1396–1397
[65]
[42]
Lane EP, Lobetti RG: Renal T-cell lymphoma with cerebral metastasis in a dog with chronic canine ehrlichiosis. J S Afr Vet Assoc. 2002;
73: 83–85
Nitsche EK: Erythrocytosis in dogs and cats: Diagnosis and management. Compend Contin Educ Pract Vet. 2004; 26: 104–118
[66]
Nowicki M, Rychlik A, Nieradka R et al.: Usefulness of laparoscopy
guided renal biopsy. Pol J Vet Sci. 2010; 13: 363–371
[43]
Lappin R, Latimer KS: Hematuria and extreme neutrophilic leukocytosis in a dog with renal tubular carcinoma. J Am Vet Med Assoc.
1988; 192: 1289–1292
[67]
O’Dell-Anderson KJ, Twardock R, Grimm JB et al.: Determination
of glomerular filtration rate in dogs using contrast-enhanced computed tomography. Vet Radiol Ultrasound. 2006; 47: 127–135
[44]
Lascelles BD, Monnet E, Liptak JM et al.: Surgical treatment of
right-sided renal lymphoma with invasion of the caudal vena cava. J
[68]
[45]
Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of
the kidney. J Urol. 2003; 170: 2163–2172
Peeters D, Clercx C, Thiry A et al.: Resolution of paraneoplastic
leucocytosis and hypertrophic osteopathy after resection of a renal
transitional cell carcinoma producing granulocyte-macrophage
colony-stimulating factor in a young Bull Terrier. J Vet Intern Med.
2001; 15: 407–411
[46]
[69]
Peterson ME, Zanjani ED: Inappropriate erythropoietin production
in a dog with polycythemia. J Am Vet Med Assoc. 1981; 179: 995–
996
[70]
[47]
Lipp O, Pitschi A, Geyer C: Nierenadenom bei einer Katze mit akuter Lahmheit. Tierärztl Prax. 2007; 6: 412
Picut CA, Valentine BA: Renal fibroma in four dogs. Vet Pathol.
1985; 22: 422–423
[71]
[48]
Lium B, Moe L: Hereditary multifocal renal cystadenocarcinoma
and nodular dermatofibrosis in the German shepherd dog: Macroscopic and histopathological changes. Vet Pathol. 1985, 22: 447–
455
Pressler BM, Williams LE, Ramos-Vara JA et al.: Sequencing of
the von Hippel-Lindau gene in canine renal carcinoma. J Vet Intern
Med. 2009; 23: 592–597
[72]
Sale CS, Skeritt GC, Smith KC: Spinal nephroblastoma in a crossbred dog. J Small Anim Pract. 2004; 45: 267–271
[73]
Sato T, Aoki K, Shibuya H et al.: Leiomyosarcoma of the kidney in
a dog. J Vet Med A Physiol Pathol Clin Med. 2003: 50; 366–369
[74]
Seaman RL, Patton CS: Treatment of renal nephroblastoma in an
adult dog. J Am Anim Hosp Assoc. 2003; 39: 76–79
[75]
Taylor SS, Goodfellow MR, Browne WJ et al.: Feline extranodal
[76]
Teske E, van Straten G, van Noort R et al.: Chemotherapy with
cyclophosphamide, vincristine and prednisolone (COP) in cats with
Med. 2002; 16: 179–186
[49]
Locke JE, Barber LG: Comparative aspects and clinical outcomes of
canine renal hemangiosarcoma. J Vet Intern Med. 2006; 20: 962–
967
[50]
Lott-Stolz G: Dermatofibrose und Nierenzysten beim Deutschen
Schäferhund. Kleintierprax. 1995; 30: 183–184
[51]
Madewell BR, Wilson DW, Hornof WJ et al.: Leukemoid blood
response and bone infarcts in a dog with renal tubular adenocarcinoma. J Am Vet Med Assoc. 1990; 197: 1623–1625
[52]
Marks SL, Farman CA, Peaston A: Nodular dermatofibrosis and
renal cystadenocarcinomas in a Golden Retriever. Vet Dermatol.
1993; 4: 133–137
[53]
McConnell JF, Garosi LS, Dennis R et al.: Imaging of spinal nephroblastoma in a dog. Vet Radiol Ultrasound. 2003; 44: 537–541
[77]
[54]
Militerno G, Bazzo R, Bevilacqua D et al.: Transitional cell carcinoma of the renal pelvis in two dogs. J Vet Med A Physiol Pathol
Clin Med. 2003; 50: 457–459
Vaden SL, Levine JF, Lees GE et al.: Renal biopsy: a retrospective
study of methods and complications in 283 dogs and 65 cats. J Vet
Intern Med. 2005, 19: 794–801
[78]
Valdes-Martinez A, Cianciolo R, Mai W: Association between
renal hypoechoic subcapsular thickening and lymphosarcoma in
cats. Vet Radiol Ultrasound. 2007; 48: 357–260
[79]
Vail DM, Moore AS, Ogilvie GK et al.: Feline lymphoma (145
cases): proliferation indices, cluster of differentiation, immunoreactivity, and their association with prognosis in 90 cases. J Vet Intern
Med. 1998; 12: 349–354
[80]
Walter JK, Gutberlet K, Schwegler K et al.: Vorkommen und Häufigkeit caniner Neoplasien in Sektionsgut. Kleintierprax. 1997; 42:
273–284
[55]
Mills JHL, Moore JT, Orr JP: Canine renal leiomyoma – an unusual
tumor. Can Vet J. 1977; 18: 76–78
[56]
Moe L, Lium B: Hereditary multifocal renal cystadenocarcinomas
and nodular dermatofibrosis in 51 German shepherd dogs. J Small
Anim Pract. 1997; 38: 498–505
[57]
Moe L, Lium B: Computed tomography of hereditery multifocal
renal cystadenocarcinoma in German Shepherd dogs. Vet Radiol
Ultrasound. 1997; 38: 335–343
[81]
Yamazoe K, Ohashi F, Kadosawa T et al.: Computed tomography
of renal masses in dogs and cats. J Vet Med Sci. 1994: 56, 813–816
[11]
Brearley MJ, Cooper JE: The diagnosis of bladder disease in dogs
by cystoscopy. J Small Anim Pract. 1987; 28: 75–85
[82]
Zhao D, Yamaguchi R, Tateyama S et al.: Bilateral renal lymphosarcoma in a dog. J Vet Med Sci. 1993; 55: 657–659
[12]
Brearley MJ, Cooper JE, Wedderburn N: Urinary cytology as an
adjunct to bacteriology in the laboratory investigation of canine
bladder disease. J Small Anim Pract. 1986; 27: 425–432
[13]
Brearley MJ, Thatcher C, Cooper JE: Three cases of transitional cell
carcinoma in the cat and a review of the literature. Vet Rec. 1986;
118: 91–94
[14]
Brodey RS, Riser WH: Hypertrophic pulmonary osteoarthopathy in
a dog with carcinoma of the urinary bladder. J Am Vet Med Assoc.
1973; 162: 474–478
22.2 Tumoren der Harnleiter
[1]
Berzon JL: Primary leiomyosarcoma of the ureter in a dog. J Am
Anim Vet Med Assoc. 1979; 175: 374–376
[2]
Burton CA, Day MJ, Hotston Moore A et al.: Ureteric fibro-epithelial polyps in two dogs. J Small Anim Pract. 1994; 35: 593–596
[3]
Deschamps JY, Roux FA, Fantinato M et al.: Ureteral sarcoma in a
[15]
Burnie AG, Weaver AD: Urinary bladder neoplasia in the dog: A
review of seventy cases. J Small Anim Pract. 1983; 24: 119–143
[4]
Farell M, Philbey AW, Ramsey I: Ureteral fibroepithelial polyp in a
[16]
[5]
Font A, Closa JM, Mascort J: Ureteral leiomyoma causing abnormal
micturition in a dog. J Am Anim Hosp Assoc. 1993; 29: 25–27
Chun R, Knapp DW, Widmer WR et al: Cisplatin treatment of
transitional cell carcinoma of the urinary bladder in dogs: 18 cases
(1983–1993). J Am Vet Med Assoc. 1996; 209: 1588–1591
[17]
[6]
Guilherme S, Polton G, Bray J et al.: Ureteral spindel cell sarcoma
in a dog. J Small Anim Pract. 2007; 48: 702–704
Chun R, Knapp DW, Widmer WR et al.: Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder,
J Vet Intern Med. 1997; 11: 279–283
[7]
Hanika CR, Rebar AH: Ureteral transitional cell carcinoma. Vet
Pathol. 1980; 17: 643–646
[18]
Cooper JE, Milroy JC, Turton JA et al.: Cystoscopic examination of
male and female dogs. Vet Rec. 1984; 115: 571–574
[8]
Hattel AL, Diters RW, Snavely DA: Ureteral fibropapilloma in a
dog. J Am Vet Med Assoc. 1986; 188: 873
[19]
[9]
Liska WD, Patnaik AK: Leiomyoma of the ureter of a dog. J Am
Dhawan D, Craig BA, Cheng L et al.: Effects of short term celecoxib treatment in patients with invasive transitional cell carcinoma of
the urinary bladder. Mol Cancer Ther. 2010; 9: 1371–1377
[20]
[10]
Mischke R, Buhl K, Thiele-Fischer C et al.: Ein ungewöhnlicher Fall
von maligner Histiozytose bei einem Berner Sennenhund mit Hydronephrose infolge Tumorzellinfiltration des Ureters. Prakt Tierarzt.
2002; 2: 120–127
Dhein CR, Person MW, Leathers CW et al.: Prepubic (suprapubic)
catheterization of the dog. J Am Anim Hosp Assoc. 1989; 25: 261–
264
[21]
Epstein JI, Amin MB, Reuter VR et al.: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol.
1998; 22: 1435–1448
[22]
Esplin DC: Urinary bladder fibromas in dogs: 51 cases (1981–1985).
J Am Vet Med Assoc. 1987; 190: 440–444
[23]
Abbo AH, Jones DR, Masters AR et al.: Phase I clinical trial and
pharmacokinetics of intravesical mitomycin C in dogs with localized
transitional cell carcinoma of the urinary bladder. J Vet Intern Med.
2010; 24: 1124–1130
Gerber K, Rees P: Urinary bladder botryoid rhabdomyosarcoma
with widespread metastases in an 8-month-old Labrador cross dog.
J S Afr Vet Assoc. 2009; 80: 199–203
[24]
Glickman LT, Raghavan M, Knapp DW et al.: Herbicide exposure
and the risk of transitional cell carcinoma of the urinary bladder in
Scottish Terriers. J Am Vet Med Assoc. 2004; 224:1290–1297
[2]
Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 2001; 25: 219–278
[25]
[3]
Anderson CR, McNiel EA, Gillette EL et al: Late complications of
pelvic irradiation in 16 dogs, Vet Radiol Ultrasound. 2002; 43: 187–
192
Glickman LT, Schofer FS, McKee IJ: Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household
dogs, J Toxicol Environ Health. 1989; 28: 407–414
[26]
Greene SN, Lucroy MD, Greenberg CB et al.: Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2007, 231:1056–
1060
[27]
Halliwell WH, Ackerman N: Botryoid rhabdomyosarcoma of the
urinary bladder and hypertrophic osteoarthropathy in a young dog.
J Am Vet Med Assoc. 1974; 165: 911–913
[28]
Hayes Jr HM: Canine bladder cancer: epidemiologic features. Am J
Epidemiol. 1976; 104: 673–677
[29]
Hayes Jr HM, Hoover R, Tarone RE: Bladder cancer in pet dogs: a
sentinel for environmental cancer? Am J Epidemiol. 1981; 114:
229–233
[30]
Helfand SC, Hamilton TA, Hungerford LL et al.: Comparison of
three treatments for transitional cell carcinoma of the bladder in
[31]
Heng HG, Lowry JE, Boston S et al.: Smooth muscle neoplasia of
the urinary bladder in three dogs. Vet Radiol Ultrasound. 2006; 47:
83–86
[32]
[11]
Reichle JK, Peterson RA, Mahaffey MB et al.: Ureteral fibroepithelial polyps in four dogs. Vet Radiol Ultrasound. 2003; 44: 433–437
[12]
Steffey M, Rassnick KM, Porter B et al.: Ureteral mast cell tumor
in a dog. J Am Anim Hosp Assoc. 2004; 40: 82–85
22.3 Tumoren der Harnblase
[1]
[4]
Vet Pathol. 2003; 40: 496–500
[5]
Benigni L, Lamb CR, Corzo-Menendez N et al.: Lymphoma affecting the urinary bladder in three dogs and a cat. Vet Radiol Ultrasound. 2006, 47: 592–596
[6]
Biller, DS, Kantrowitz B, Partington BP et al.: Diagnostic ultrasound of the urinary bladder. J Am Anim Hosp Assoc. 1990; 26:
397–402
[7]
Billet JP, Moore AH, Holt PE: Evaluation of a bladder tumor antigen
test for the diagnosis of lower urinary tract malignancies in dogs.
Am J Vet Res. 2002, 63: 370–373
[8]
Bloomberg SD, Brosman SA, Hausman MS et al.: The effects of
BCG on the dog bladder. Invest Urol. 1975; 12: 423–427
[9]
Boria PA, Glickman NW, Schmidt BR et al.: Carboplatin and piroxicam in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol. 2005; 3: 73–78
[10]
Borjesson DL, Christopher MM, Ling GV: Detection of canine transitional cell carcinoma using a bladder tumor antigen dipstick test.
93
94
[33]
Henry CJ, Tyler JW, McEntee MC et al.: Evaluation of a bladder
tumor antigen test as a screening test for transitional cell carcinoma
of the lower urinary tract in dogs. Am J Vet Res. 2003; 64: 1017–
1020
[54]
Macy DW, Withrow SJ, Hoopes J: Transitional cell carcinoma of
the bladder associated with cyclophosphamide administration. J
Am Anim Hosp Assoc 1983; 19: 965–969
[55]
[34]
Holt PE, Lucke VM, Brown PJ: Evaluation of a catheter biopsy technique as a diagnostic aid in lower urinary tract disease. Vet Rec.
1986; 118: 681–684
Madarame H, Ito A, Tanaka R: Urinary bladder rhabdomyosaroma
(Botryoid Rhabdomyosarcoma) in a Labrador Retriever dog. J Toxicol
Pathol. 2003; 16: 279–281
[56]
[35]
Huland E, Huland H: Local continuous high dose interleukin 2: a
new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res. 1989; 49: 5469–5474
Magunna C, Spellmeyer O, Hund M et al.: Augmentation der
Harnblase nach radikaler Resektion: erste klinische Erfahrungen mit
einem Xenoimplantat aus der Dünndarmsubmukosa des Schweins
bei Hund und Katze. Kleintierprax. 1999; 44: 805–884
[36]
Huland E, Huland H: Tumor-associated eosinophilia in interleukin2-treated patients: evidence of toxic eosinophilic degranulation on
bladder cancer cells. J Cancer Res Clin Oncol. 1992; 118:463–467
[57]
Maiolino P, DeVico G: Primary epitheliotropic T-cell lymphoma of
the urinary bladder in a dog. Vet Pathol. 2000; 37:184–186
[58]
[37]
Hume C, Seiler G, Porat-Mosenco Y et al.: Cystosonographic measurements of canine bladder tumors. Vet Comp Oncol. 2010; 8:
122–126
Marconato L, Zini E, Suslak-Brown L et al.: Toxic effext and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
J Am Vet Med Assoc. 2011; 238: 1004–1010
[38]
Kahn KN, Knapp DW, DeNicola DB et al.: Expression of cyclooxygenase-2 in transitional cell carcinoma of the bladder in dogs. Am J
Vet Res. 2000; 61: 478–481
[59]
Martinez SA, Schulman AJ: Hemangiosarcoma of the urinary bladder in a dog. J Am Vet Med Assoc. 1988; 192: 655–656
[60]
[39]
Kelly DF: Rhabdomyosarcoma of the urinary bladder in dogs. Vet
Pathol. 1973; 10: 375–384
McCarthy RJ, Lipowitz AJ, OʼBrien TD: Continent jejunal reservoir
(Kock pouch) for urinary diversion in dogs. Vet Surg. 1992; 21:
208–216
[40]
Kessler M, Kandel-Tschiederer B, Pfleghaar S et al.: Primary
malignant lymphoma of the urinary bladder in a dog: longterm
remission following treatment with radiation and chemotherapy.
Schweiz Arch Tierheilk. 2008; 150: 565–569
[61]
McCaw DL, Hogan PM, Shaw DP: Canine urinary bladder transitional cell carcinoma with skull metastasis and unusual pulmonary
metastases. Can Vet J. 1988; 29: 386–388
[62]
[41]
Knapp DW, Adams LG, DeGrand AM et al.: Sentinel lymph node
mapping of invasive urinary bladder cancer in animal models using
invisible light. Eur Urol. 2007; 52: 1700–1708
McCleary-Wheeler AL, Williams LE, Hess PR et al.: Evaluation of
an in vitro telomeric repeat amplification protocol assay to detect
telomerase activity in canine urine. Am J Vet Res. 2010; 71: 1468–
1474
[42]
Knapp DW, Chan TC, Kuczek T et al.: Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor
cells. Am J Vet Res. 1995; 56: 801–805
[63]
McLoughlin MA, Walshaw R, Thomas MW et al.: Gastric urinary
diversion in normal dog Part l: Upper urinary tract structure, function, and sepsis. Vet Surg. 1992; 21: 25–32
[43]
Knapp DW, Glickman NW, DeNicola DB et al.: Naturally-occurring
canine transitional cell carcinoma of the urinary bladder: a relevant
model of human invasive bladder cancer. Urol Oncol. 2000; 5: 47–
59
[64]
McLoughlin MA, Walshaw R, Thomas MW et al.: Gastric urinary
diversion in normal dogs Part 2: hypochloremic metabolic alkalosis.
Vet Surg. 1992; 21: 33–39
[65]
[44]
Knapp DW, Glickman NW, Widmer WR et al.: Cisplatin versus
cisplatin combined with piroxicam in a canine model of human
invasive urinary bladder cancer. Cancer Chemother Pharmacol.
2000; 46: 221–226
Meuten DJ: Tumors of the urinary bladder and urethra. In: Meuten
DJ (Hrsg.): Tumors in domestic animals. 4. Aufl. Iowa State Press,
Ames, 2002, 524–546
[66]
Mohammed SI, Craig BA, Mutsaers AJ et al.: Effects of the cyclooxygenase inhibitor piroxicam in combination with chemotherapy
on tumor response, apoptosis, and angiogenesis in a canine model
of human invasive urinary bladder cancer. Mol Cancer Ther. 2003;
2: 183–188
[67]
Moore AS, Cardona A, Shapiro W et al.: Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of
the urinary bladder or urethra: a retrospective study of 15 dogs. J
Vet Intern Med. 1990; 4: 148–152
[45]
Knapp DW, Richardson GC, Bottoms GD et al.: Phase I trial of prioxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol. 1992; 29: 214–218
[46]
Knapp DW, Richardson RC, Chan TC et al.: Piroxicam therapy in
34 dogs with transitional cell carcinoma of the urinary bladder. J Vet
Intern Med. 1994; 8: 273–278
[47]
Knottenbelt C, Mellor D, Nixon C et al.: Cohort study of COX-1
and COX-2 expression in canine rectal and bladder tumours. J Small
Anim Pract. 2006; 47: 196–200
[68]
Kuwamura M, Yoshida H, Yamate J et al.: Urinary bladder rhabdomyosarcoma (sarcoma botryoides) in a young Newfoundland dog. J
Vet Med Sci. 1998; 60: 619–621
Montgomery RD, Hankes GH: Ureterocolonic anastomosis in a
dog with transitional cell carcinoma of the bladder. J Am Vet Med
Assoc. 1987, 190: 1427–1429
[69]
Lamb CR, Trower ND, Gregory SP: Ultrasound-guided catheter
biopsy of the lower urinary tract: technique and results in 12 dogs. J
Murphy S, Gutierrez A, Lawrence J et al.: Laparoscopically implanted tissue expander radiotherapy in canine transitional cell carcinoma. Vet Radiol Ultrasound. 2008; 49: 400–405
[70]
Mutsaers AJ, Widmer WR, Knapp DW: Canine transitional cell carcinoma. J Vet Intern Med. 2003; 17: 136–144
[48]
[49]
[50]
Lee JY, Tanabe S, Shimohira H et al.: Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein
in canine transitional carcinoma. Res Vet Sci. 2007; 83: 210–216
[71]
Nickel RF, Eiermann C, Teske E et al.: Local IL-2 therapy of lower
urinary tract carcinomas in dogs. Anticancer Research. 1999, 19:
2009–2010
[51]
Leveille R, Biller DS, Kantrowitz B et al.: Sonographic investigation of transitional cell carcinoma of the urinary bladder in small
animals. Vet Radiol Ultrasound. 1992; 33: 103–107
[72]
Nickel RF: Interleukin-2 treatment of bladder and urethral carcinoma in dogs and cats. Proc. ECVS Ann Meeting Seville, 2006
[73]
[52]
Liptak JM, Dernell WS, Withrow SJ: Hemangiosarcoma of the urinary bladder in a dog. Aust Vet J. 2004; 82: 215–217
Nikula KJ, Benjamin SA, Angleton GM et al.: Transitional cell carcinoma of the urinary tract in a colony of beagle dogs. Vet Pathol.
1989; 26: 455–461
[53]
Lucroy MD, RidgwayTD, Peavy GM et al.: Preclinical evaluation of
5-aminolevulinic acid-based photodynamic therapy for canine transitional cell carcinoma. Vet Comp Oncol. 2003; 1: 76–85
[74]
Norris AM, Laing EJ, Valli VE et al.: Canine bladder and urethral
tumors: a retrospective study of 115 cases (1980–1985). J Vet
Intern Med. 1992; 6: 145–153
[75]
Nyland TG, Wallack ST, Wisner ER: Needle tract implantation following US-guided fine-needle aspiration biopsy of transitional cell
[76]
Ogilvie GK, Obradovich JE, Elmslie RE et al.: Efficacy of Mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc. 1991;
198: 1618–1621
[77]
Olausson A, Stieger SM, Loefgren S et al.: A urinary bladder fibrosarcoma in a young dog. Vet Radiol Ultrasound. 2005, 46: 135–138
[78]
Osborne CA, Low DG, Perman V et al.: Neoplasms of the canine
and feline urinary bladder. Incidence, etiologic factors, occurrence
and pathologic features. Am J Vet Res. 1968; 29: 2041–2055
[79]
Owen LN: TNM classification of tumors in domestic animals. 1.
Aufl., Geneva: World Health Organization: 1980, 34
[80]
Patnaik AK, Greene RW: Intravenous leiomyoma of the bladder in
a cat. J Am Vet Med Assoc. 1979; 175: 381–383
[81]
Patnaik AK, Schwarz PD, Greene RW: A histopathologic study of
twenty urinary bladder neoplasms in the cat. J Small Anim Pract.
1986; 27: 433–445
[82]
Patrick DJ, Fitzgerald SD, Sesterhenn IA et al.: Classification of
canine urinary bladder urothelial tumours based on the World
Health Organization/International Society of Urological Pathology
consensus classification. J Comp Pathol. 2006; 135: 190–199
[83]
Perry RE, Weller RE, Dagle GE: Transitional cell carcinoma of the
bladder with skeletal metastases in a dog. J Am Anim Hosp Assoc.
1989; 25: 547–551
[84]
Poirier VJ, Forrest LJ, Adams WM et al.: Piroxicam, mitoxantrone,
and coarse fraction radiotherapy for the treatment of transitional
cell carcinoma of the bladder in 10 dogs: a pilot study. J Am Anim
Hosp Assoc. 2004; 40:131–136
[85]
[86]
[87]
Raghavan M, Knapp DW, Bonney PL et al.: Evaluation of the
effect of dietary vegetable consumption on reducing risk of transitional cell carcinoma of the urinary bladder in Scottish terriers. J Am
Vet Med Assoc. 2005; 227: 94–100
Raghavan M, Knapp DW, Dawson MH et al.: Topical spot-on flea
and tick products and the risk of transitional cell carcinoma of the
urinary bladder in Scottish terrier dogs. J Am Vet Med Assoc. 2004;
225: 389–394
Rankin WV, Henry CJ, Turnquist SE et al.: Comparison of distributions of survivin among tissues from urinary bladders of dogs with
cystitis, transitional carcinoma, or histologically normal urinary
bladders. Am J Vet Res. 2008; 69: 1073–1078
[88]
Ridgway TD, Lucroy MD: Phototoxic effects of 635-nm light on
canine transitional cell carcinoma cells incubated with 5-aminolevulinic acid. Am J Vet Res. 2003; 64:131–136
[89]
Rocha TA, Mauldin GN, Patnaik AK et al.: Prognostic factors in
dogs with urinary bladder carcinoma. J Vet Intern Med. 2000; 14:
486–490
[90]
Saulnier-Troff FG, Busoni V, Hamaide A: A technique for resection
of invasive tumors involving the trigone area of the bladder in dogs:
preliminary results in two dogs. Vet Surg. 2008; 37: 427–437
[91]
Senior DF, Lawrence DT, Gunson C et al.: Successful treatment of
botryoid rhabdomyosarcoma in the bladder of a dog. J Am Anim
Hosp Assoc. 1993; 29: 386–390
[92]
Schmidt RE: Transitional cell carcinoma metastatic to the eye of a
dog. Vet Pathol. 1981; 18: 832–834
[93]
Schwarz PD, Egger EL, Klause SE: Modified cup-patch ileocystoplasty for urinary bladder reconstruction in a dog. J Am Vet Med
Assoc. 1991; 198: 273–277
[94]
Schwarz PD, Greene RW, Patnaik AK: Urinary bladder tumors in
the cat: a review of 27 cases. J Am Anim Hosp Assoc. 1985; 21:
237–245
[95]
Shapiro W, Kitchell BE, Fossum TW et al.: Cisplatin for treatment
Med Assoc. 1988; 193: 1530–1533
[96]
Smith JD, Vaden SL, Stone EA et al.: Management and complications following trigonal-colonic anastomosis in a dog: five-year evaluation. J Am Anim Hosp Assoc. 1996; 32: 29–35
[97]
Stamps P, Harris DL: Botryoid rhabdomyosarcoma of the urinary
bladder of a dog. J Am Vet Med Assoc. 1968; 153: 1064–1068
[98]
Stengel H, Kirchhof N, Möller-Seeling A: Botryoide Rhabdomyosarkome in der Harnblase junger Hunde. Prakt Tierarzt. 1997, 78:
186–194
[99]
Stockhaus C, Werner HG: Die Exfoliativzytologie des Harnes: Eine
hilfreiche Methode in der Diagnostik von Tumoren des Harntraktes.
[100] Stone EA, George TF, Gilson SE et al.: Partial cystectomy for urinary bladder neoplasia: surgical technique and outcome in 11 dogs.
[101] Stone EA, Withrow SJ, Page RL et al.: Ureterocolonic anastomosis
in ten dogs with transitional cell carcinoma. Vet Surg. 1988; 17:
147–153
[102] Takiguchi M, Watanabe T, Okada H et al.: Rhabdomyosarcoma
(botryoid sarcoma) of the urinary bladder in a Maltese. J Small Anim
Pract. 2002; 43: 269–271
[103] Teunissen GH, Misdorp W: Rhabdomyosarcoma of the urinary
bladder and fibromatosis of the extremities in a young dog. Zbl Vet
Med A. 1968; 15: 81–88
[104] Upton ML, Tangner CH, Payton ME: Evaluation of carbon dioxide
laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. J Am Vet Med Assoc.
2006; 228: 549–552
[105] Valli VE, Norris A, Jacobs RM et al.: Pathology of canine bladder
and urethral cancer and correlation with tumour progression and
survival. J Comp Pathol. 1995; 113: 113–130
[106] Van Noort R: Four unusual cases of malignant lymphoma in the
dog and cat. Tijdschr Diergeneesk. 1997; 122: 502–505
[107] Van Vechten M, Goldschmidt MH, Wortman JA: Embryonal rhabdomyosarcoma of the urinary bladder in dogs. Comp Contin Educ
Pract Vet. 1990; 12: 783–793
[108] Vignoli M, Rossi F, Terragni R et al.: Needle tract implantation
after fine needle aspiration biopsy (FNAB) of transitional cell carcinoma of the urinary bladder and adenocarcinoma of the lung.
[109] Walker M, Breider M: Intraoperative radiotherapy of canine bladder cancer. Vet Radiol. 1987; 28: 200–204
[110] Walker DB, Cowell RL, Clinkenbeard KD et al.: Carcinoma in the
urinary bladder of a cat: cytologic findings and a review of the literature. Vet Clin Pathol. 1993; 22: 103–108
[111] Walter JH, Gutberlet K, Schwegler K et al.: Vorkommen und Häufigkeit caniner Neoplasien in Sektionsgut. Kleintierprax. 1997; 42:
273–284
[112] Walter PA, Haynes JS, Feeney DA et al.: Radiographic appearance
of pulmonary metastases from transitional cell carcinoma. J Am
Anim Hosp Assoc. 1984, 185:411–418
[113] Weisse C, Berent A, Todd K et al.: Evaluation of palliative stenting
for management of malignant urethral obstructions in dogs. J Am
Vet Med Assoc. 2006; 229: 226–234
[114] Weller RE, Wolf AM, Oyejide A: Transitional cell carcinoma of the
bladder associated with cyclophosphamide therapy in a dog. J Am
Anim Hosp Assoc. 1979; 15: 733–736
[115] Wilson HM, Chun R, Larson VS et al.: Clinical signs, treatments,
and outcome in cats with transitional cell carcinoma of the urinary
bladder: 20 cases (1990–2004). J Am Vet Med Assoc. 2007; 231:
101–106.
[116] Wimberly HC, Lewis RM: Transitional cell carcinoma in the domestic cat. Vet Pathol. 1979; 16: 223–228
[117] Withrow SJ, Gillette EL, Hoopes PJ et al.: Intraoperative irradiation
of 16 spontaneously occurring canine neoplasms. Vet Surg. 1989;
18: 7–11
95
96
22.4 Tumoren der Harnröhre
[1]
Baines SJ, Rennie S, White RS: Prepubic urethrostomy: a longterm study in 16 cats. Vet Surg. 2001; 30: 107–113
[2]
Barrett RE, Nobel TA: Transitional cell carcinoma of the urethra in a
cat. Cornell Vet. 1976; 66: 14–26
[3]
Beck AL, Grierson JM, Ogden DM et al.: Outcome of and complications associated with tube cystostomy in dogs and cats: 76 cases
(1995–2006). J Am Vet Med Assoc. 2007; 230: 1184–1189
[4]
Brearley MJ, Cooper JE: The diagnosis of bladder disease in dogs
by cystoscopy. J Small Anim Pract. 1987; 28: 75–85
[5]
Christensen NI, Culvenor J, Langova V: Fluoroscopic stent placement for the relief of malignant urethral obstruction in a cat. Aust
Vet J. 2010; 88: 478–482
[23]
Smith JD, Stone EA, Gilson SD: Placement of a permanent cystostomy catheter to relieve urine outflow obstruction in dogs with
transitional cell carcinoma. J Am Vet Med Assoc. 1995; 206: 496–
499
[24]
Stiffler KS, McCrackin Stevenson MA et al.: Clinical use of lowprofile cystostomy tubes in four dogs and a cat. J Am Vet Med
Assoc. 2003; 223: 325–329
[25]
Struble AL, Lawson GW, Ling GV: Urethral obstruction in a dog:
an unusual presentation of T-cell lymphoma. J Am Anim Hosp
Assoc. 1997; 33: 423–426
[26]
Swalec KM, Smeak DD, Baker AL: Urethral leiomyoma in a cat. J
Am Vet Med Assoc. 1989; 195: 961–962
[27]
Takagi S, Kadosawa T, Ishiguro T et al.: Urethral transitional cell
carcinoma in a cat. J Small Anim Pract. 2005; 46: 504–506
[6]
Clark WT, Shaw SE, Pass DA: Rhabdomyosarcoma of the urethra
[28]
[7]
Davies JV, Read HM: Urethral tumours in dogs. J Small Anim Pract.
1990; 31: 131–136
Tarvin G, Patnaik A, Green R: Primary urethral tumors in dogs. J
Am Vet Med Assoc. 1978; 172: 931–933
[29]
[8]
Davies JV, Read HM: Sagittal pubic osteotomy in the investigation
and treatment of intrapelvic neoplasia in the dog. J Small Anim
Pract. 1990; 31: 123–130
Ticer JW, Spencer CP, Ackerman N: Positive contrast retrograde
urethrography: A useful procedure for evaluating urethral disorders
in the dog. Vet Radiol. 1980; 21: 2–5
[30]
Ticer JW, Spencer CP, Ackerman N: Transitional cell carcinoma oft
the urethra in four female dogs: its urethrographic appearance. Vet
Radiol. 1980; 21: 12–17
[31]
Upton ML, Tangner CH, Payton ME: Evaluation of carbon dioxide
laser ablation combined with mitoxantron and piroxicam treatment
in dogs with transitional cell carcinoma. J Am Vet Med Assoc. 2006;
228: 549–552
[9]
Davis GJ, Holt D: Two chondrosarcomas in the urethra of a German
shepherd dog. J Small Anim Pract. 2003; 44: 169–171
[10]
Dhein CR, Person MW: Prepubic catheterisation of eight dogs with
lower urinary tract disorders. J Am Anim Hosp Assoc. 2003; 223:
325–329
[11]
Holt PE, Gibbs C, Latham J: An evaluation of positive-contrastvagino-urethrography as a diagnostic aid in the bitch. J Small Anim
Pract. 1984; 25: 531–540
[32]
Weisse C, Berent A, Todd K et al.: Evaluation of palliative stenting
Vet Med Assoc. 2006; 229: 226–234
[12]
Holt PE, Lucke VM, Brown PJ: Evaluation of a catheter biopsy technique as a diagnostic aid in lower urinary tract disease. Vet Rec.
1986; 118: 681–684
[33]
White RN, Davies JV, Gregory SP: Vaginourethroplasty for treatment of urethral obstruction in the bitch. Vet Surg. 1996; 25: 503–
510
[13]
Knapp DW, Glickman NW, DeNicola DB et al.: Naturally-occurring
canine transitional cell carcinoma of the urinary bladder: a relevant
model of human invasive bladder cancer. Urol Oncol. 2000; 5: 47–
59
[34]
Wilson HM, Chun R, Larson VS et al.: Clinical signs, treatments
and outcome in cats with transitional cell carcinoma of the urinary
bladder. J Am Vet Med Assoc. 2007; 231: 101–106
[14]
Knapp DW, Glickman NW, Widmer WR et al.: Cisplatin versus
cisplatin combined with piroxicam in a canine model of human
invasive urinary bladder cancer. Cancer Chemother Pharmacol.
2000; 46: 221–226
[35]
Wilson YL, Merer DM, Moscatello AL: Comparison of three common tonsillectomy techniques: a prospective randomized, double–
blinded clinical study. Laryngoscope. 2009; 119: 162–170
[36]
Yoshioka MM, Carb A: Antepubic urethrostomy in the dog. J Am
Anim Hosp Assoc. 1982; 18: 290–294
[15]
Ko GY, Kim GC, Seo TS et al.: Covered, retrievable, expandable
urethral nitinol stent: feasibility study in dogs. Radiology. 2002;
223: 83–90
[16]
Lamb CR, Trower ND, Gregory SP: Ultrasound-guided catheter
biopsy of the lower urinary tract: technique and results in 12 dogs. J
23 Tumoren der Geschlechtsorgane
23.1 Tumoren der weiblichen Geschlechtsorgane
[17]
Liehmann LM, Doyle, Powell RM: Transpelvic urethrostomy in a
Staffordshire bull terrier: a new technique in the dog. J Small Anim
Pract. 2010; 51: 325–329
[1]
Anderson C, Pratschke K: Uterine adenocarcinoma with abdominal
metastases in an ovariohysterectomised cat. J Fel Med Surg. 2011;
13: 44–47
[18]
Liptak IM, Brutscher SP, Monnet E et al.: Transurethral resection
in the management of urethral and prostatic neoplasia in 6 dogs.
Vet Surg. 2004; 33: 505–516
[2]
Basaraba RJ, Kraft SL, Andrews GA et al.: An ovarian teratoma in
a cat. Vet Pathol. 1998; 35: 141–144
[3]
[19]
Magne ML, Hoopes PJ, Kainer RA et al.: Urinary tract carcinomas
involving the canine vagina and vestibule. J Am Anim Hosp Assoc.
1985; 21: 767–772
Bilbrey SA, Withrow SJ, Klein MK: Vulvovaginectomy and perineal
urethrostomy for neoplasms of the vulva and vagina. Vet Surg.
1989; 18: 450–453
[4]
[20]
Moroff SD, Brown BA, Matthiesen DT et al.: Infiltrative urethral
disease in female dogs: 41 cases (1980–1987). J Am Vet Med Assoc.
1991; 199: 247–251
Brodey RS, Roszel JF: Neoplasms of the canine uterus, vagina and
vulva: a clinicopathologic survey of 90 cases. J Am Vet Med Assoc.
1967; 151: 1294–1307
[5]
[21]
Newman RG, Mehler SJ, Kitchell BE et al.: Use of a balloon-expandable metallic stent to relieve malignant urethral obstruction in a
cat. J Am Vet Med Assoc. 2009; 234: 236–239
Bomhard von D: Weibliche Geschlechtsorgane. In: Nolte I, Nolte M
(Hrsg.): Praxis der Onkologie bei Hund und Katze, Epidemiologie,
Enke-Verlag. Stuttgart, 2001, 98–100
[6]
[22]
Norris AM, Laing EJ, Valli VE et al.: Canine bladder and urethral
tumors: a retrospective study of 115 cases (1980–1985). J Vet
Intern Med. 1992; 6: 145–153
Brodey RS: Canine and feline neoplasia. Adv Vet Sci Med. 1970; 14:
309–354
[7]
Buijtels JJCWM, Gier J, Kooistra HS et al.: Alterations of the pituitary-ovarian axis in dogs with functional granulosa cell tumor. Theriogenology. 2010; 73: 11–19
[8]
Cellio LM, Degner DA: Testosterone-producing thecoma in a
female cat. J Am Anim Hosp Assoc. 2000; 36: 323–325
[9]
Cooper TK, Ronnett BM, Ruben DS et al.: Uterine myxoid leiomysarcoma with widespread metastases in a cat. Vet Pathol. 2006; 43:
552–556
[10]
Cotchin A, Harvey HJ: Treatment of metastatic granulosa cell
tumor in a dog. J Am Vet Med Assoc. 1979; 174: 1304–1306
[11]
Cotchin E: Canine ovarian neoplasms. Res Vet Sci. 1961; 2: 133–
142
[12]
Cotchin E: Neoplasia in the cat. Vet Rec. 1957; 69: 425–434
[13]
de Vos JH: Uterine and cervical carcinomas in five dogs. J Vet Med A
1988; 35: 385–390
[14]
Diez-Bru N, Garcia-Real I, Martinez EM et al.: Ultrasonographic
appearance of ovarian tumors in 10 dogs. Vet Radiol Ultrasound.
1998; 39: 226–233
[15]
Dillberger J E, Altmann NH: A canine ovarian germ cell tumor with
extraembryonic differentiation. Vet Pathol. 1987; 24: 96–98
[16]
Dow C: Ovarian abnormalities in the bitch. J Comp Pathol. 1960;
70: 59–69
[17]
Eker K, Salmanoglu MR, Vural SA: Unilateral leiomyoma in the
mesosalpinx of a dog. J Am Vet Med Hosp Assoc. 2006; 42: 392–
394
[18]
Engle GC, Brodey RS: A retrospective study of 395 feline neoplasms. J Am Anim Hosp Assoc. 1969; 5: 21–25
[19]
Gelberg HB, McEntee K: Feline ovarian neoplasms. Vet Pathol.
1985; 22: 572–576
[20]
Gil da Costa RM, Santos M, Amorim I et al.: An immunohistochemical study of feline endometrial adenocarcinoma. J Comp Pathol.
2009; 140: 254–259
[21]
Greene JA, Richardson RC, Thornhill JA et al.: Ovarian papillary
cystadenocarcinoma in a bitch: case report and literature review. J
[22]
Greenlee PG, Patnaik AK: Canine ovarian tumors of germ cell origin. Vet Pathol. 1985; 22: 117–122
[23]
Günzel-Apel A-R, Buschhaus J, Urhausen C et al.: Klinische Symptomatik, diagnostische Vorgehensweise und Therapie beim so
genannten Ovarrest-Syndrom der Hündin. Tierärztl Prax. 2012; 40:
35–42
[32]
Johnston SD, Kustritz MVR, Olson PNS: Disorders of the canine
vagina, vestibule and vulva. In: Johnston SD, Kustritz MVR, Olson
PNS (Hrsg.): Canine and Feline Theriogenology. 2001; WB Saunders
Company, 2001; 225–242
[33]
Johnston SD, Kustritz MVR, Olson PNS: Disorders of the feline
vagina, vestibule and vulva. In: Johnston SD, Kustritz MVR, Olson
PNS (Hrsg.): Canine and Feline Theriogenology. 2001; WB Saunders
Company, 2001; 472–473
[34]
Kennedy PC, Cullen JM, Edwards JF et al.: Histological classification of tumors of the genital system of domestic animals. Published
by the Armed Forces Institute of Pathology, Washington, D. C.,
1998
[35]
Koch F, Kaiser E: Uteruskarzinom bei einem Hund. Tierärztl Wschr.
1970; 89: 373–377
[36]
Kydd DM, Burnie AG: Vaginal neoplasia in the bitch: A review of 40
clinical cases. J Small Anim Pract. 1986; 27: 255–263
[37]
Lium B, Moe L: Hereditary multifocal renal cystadenocarcinomas
and nodular dermatofibrosis in the German shepherd: Macroscopic
and histopathologic changes. Vet Pathol. 1985; 22: 447–455
[38]
Marino G, Quartuccio M, Cristarella S et al.: Adenoma of the uterine tube in the bitch: two case reports. Vet Res Comm. 2007; 31:
173–175
[39]
Millán Y, Gordon A, de los Monteros AE et al.: Steroid receptors
in canine and human female genital tract tumours with smooth
muscle differentiation. J Comp Pathol. 2007; 136: 197–201
[40]
Miller MA, Ramos-Vara JA, Dickerson MF et al.: Uterine neoplasia
in 13 cats. J Vet Diagn Invest. 2003; 15: 575–522
[41]
Moore AS, Kirk C, Cardona A: Intracavitary cisplatin chemotherapy
experience with 6 dogs. J Vet Int Med. 1991; 5: 227–231
[42]
Murphy ST, Kruger JM, Watson GL: Uterine adenocarcinoma in
the dog. A case report and review. J Am Anim Hosp Assoc. 1994;
30: 440–444
[43]
Nielsen SW: Classification of tumors in dogs and cats. J Am Anim
Hosp Assoc. 1983; 19: 13–52
[44]
Nielsen SW, Misdorp W, McEntee K: Tumors of the ovary. Bull
WHO 1976; 53: 203–215
[45]
Nolte I, Nolte M: Tumoren der weiblichen Geschlechtsorgane. In:
Nolte I, Nolte M (Hrsg.): Praxis der Onkologie bei Hund und Katze.
Enke-Verlag. Stuttgart, 2000, 98–100
[24]
Hayes HM, Young JL: Epidemiologic features of canine ovarian neoplasms. Gynecol Oncol. 1978; 6: 348–353
[46]
[25]
Herron MA: Tumors of the canine genital system. J Am Anim Hosp
Assoc. 1983; 19: 981–994
Norris HJ, Garner FM, Taylor HB: Pathology of feline ovarian neoplasms. J Pathol. 1969; 97: 138–143
[47]
[26]
Hill TP, Lobetti RG, Schulman ML: Vulvovaginectomy and neourethrostomy for treatment of haemangiosarcoma of the vulva and
vagina. J S Afr Vet Assoc. 2000; 71: 256–259
OʼRourke MD, Geib L: Endometrial adenocarcinoma in a cat. Cornell Vet. 1970; 60: 598–604
[48]
Olsen J, Komtebedde J, Lackner A et al.: Cytoreductive treatment
of ovarian carcinoma. J Vet Intern Med. 1994; 8: 133–135
[27]
Hori Y, Uechi M, Kanakubo K et al.: Canine ovarian serous papillary adenocarcinoma with neoplastic hypercalcemia. J Vet Med Sci.
2006; 68: 979–982
[49]
Patnaik AK, Greenlee PG: Canine ovarian neoplasms: A clinicopathologic study of 71 cases, including history of 12 granulosa cell
[28]
ovary. In: Johnston SD, Kustritz MVR, Olson PNS (Hrsg.): Canine and
Feline Theriogenology. 2001; WB Saunders Company, 2001; 193–
205
[50]
Payne-Johnson CE, Kelly DF, Davies PT: Endometrial carcinoma in
a young dog. J Comp Pathol. 1986; 96: 463–467
[51]
Pesch S, Wehrend A: Ovartumor bei einer Hündin mit Pyometra.
Tierärztl Prax. 2008; 36: 337–338, 346–350
[52]
Pires MA, Seixas F, Palmeira C et al.: Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma. Reprod Domest Anim. 2010; 45: 545–549
[53]
Salomon JF, Deneuche A, Viguier E: Vaginectomy and urethroplasty as a treatment for non-pedunculated vaginal tumours in four
bitches. J Small Anim Pract. 2004; 45: 157–161
[54]
Rollón E, Millán Y, de las Mulas JM: Effects of aglepristone, a progesterone receptor antagonist, in a dog with a vaginal fibroma. J
[55]
Sato T, Maeda H, Suzuki A et al.: Endometrial stromal sarcoma
with smooth muscle and glandular differentiation of the feline uterus. Vet Pathol. 2007; 44: 379–382
[29]
ovary. In: Johnston SD, Kustritz MVR, Olson PNS (Hrsg.): Canine and
Feline Theriogenology. 2001; WB Saunders Company, 2001; 453–
462
[30]
uterus and uterine tubes. In: Johnston SD, Kustritz MVR, Olson PNS
(Hrsg.): Canine and Feline Theriogenology. 2001; WB Saunders
Company, 2001; 206–224
[31]
uterus and uterine tubes. In: Johnston SD, Kustritz MVR, Olson PNS
(Hrsg.): Canine and Feline Theriogenology. 2001; WB Saunders
Company, 2001; 463–471
97
98
[56]
Schlafer DH, Miller RB: Neoplastic diseases of the ovary. In: Maxie
MG, Jubb KVF, Kennedy PC (Hrsg.): Pathology of domestic animals,
5. Aufl. Saunders Elsevier, New York 2007; 450–456
[11]
Ferreira AJ, Jaggy A, Varejão AP et al.: Brain and ocular metastases
from a transmissible venereal tumour in a dog. J Small Anim Pract.
2000; 41: 165–168
[57]
Schlafer DH, Miller RB: Neoplastic diseases of the tubular genitalia.
In: Maxie MG, Jubb KVF, Kennedy PC (Hrsg.): Pathology of domestic
animals, 5. Aufl. Saunders Elsevier, New York 2007; 545–549
[12]
[58]
Schmidt RE, Langham RF: A survey of feline neoplasms. J Am Vet
Med Assoc. 1967; 151: 1325–1328
Gonzalez CM, Griffey SM, Naydan DK et al.: Canine transmissible
venereal tumour: a morphological and immunohistochemical study
of 11 tumours in growth phase and during regression after chemotherapy. J Comp Pathol. 2000; 122: 241–248
[13]
[59]
Seyrek-Intras K, Wehrend A, Nak Y et al.: Unilateral hysterectomy
(cornuectomy) in the bitch and its effect on subsequent fertility.
Theriogenology 2004; 61: 1712–1717
Harmelin A, Zuckerman A, Nyska A: Correlation of Ag-NOR protein measurements with prognosis in canine transmissible venereal
tumour. J Comp Pathol. 1995; 112: 429–433
[14]
[60]
Sontas BH, Özyogurtcu H, Turna Ö et al.: Uterine Leiomyoma in a
spayed poodle bitch. A case report . Reprod Domest Anim. 2010;
45: 550–554
Hess AD, Catchatourian R, Zander AR et al.: Intralesional Bacillus
Calmette-Guérin immunotherapy of canine venereal tumors. Cancer Res. 1977; 37: 3990–3994
[15]
[61]
Stein BS: Tumors of the feline genital tract. J Am Anim Hosp Assoc.
1981; 17: 1022–1025
[62]
Thacher C, Bradley RL: Vulvar and vaginal tumors in the dog: A retrospective study. J Am Vet Med Assoc 1983; 183: 690–692
Hsiao YW, Liao KW, Hung SW et al.: Effect of tumor infiltrating
lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol. 2002;
87: 19–27
[16]
[63]
Tsioli VG, Gouletsou PG, Loukopoulos P et al.: Uterine leiomyosarcoma and pyometra in a dog. J Small Anim Pract. 2011; 52: 121–
124
Idowu AL: A retrospective evaluation of four surgical methods of
treating canine transmissible venereal tumor. J Sm Anim Pract.
1984; 25: 193–198
[17]
[64]
Wardrip SJ, Esplin DG: Uterine carcinoma with metastasis to the
myocardium. J Am Anim Hosp Assoc. 1984; 20: 261–264
Katzir N, Arman E, Cohen D et al.: Common origin of transmissible
venereal tumors (TVT) in dogs. Oncogene. 1987; 1: 445–448
[18]
Wenzlow N, Tivers MS, Selmic LE et al.: Haemangiosarcoma in
the uterine remnant of a spayed female dog. J Small Anim Pract.
2009; 50: 488–491
Laging C, Kröning T: Beobachtungen zum übertragbaren venerischen Tumor (Sticker) beim Hund. Tierarztl Prax. 1989; 17: 85–87
[19]
[66]
Wilson RB, Cave JS, Copeland JS et al.: Ovarian teratoma in two
Liao KW, Hung SW, Hsiao YW et al.: Canine transmissible venereal tumor cell depletion of B lymphocytes: molecule(s) specifically
toxic for B cells. Vet Immunol Immunopathol. 2003; 92: 149–162
[20]
[67]
Wolke RE: Vaginal leiomyoma as a cause of chronic obstipation in
Liu CC, Wang YS, Lin CY et al.: Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival
during tumoral progression and regression in an in vivo canine
model of transmissible venereal tumor. Cancer Immunol Immunother. 2008; 57: 479–491
[21]
Mozos E, Mendez A, Gomez-Villamandos JC et al.: Immunohistochemical characterization of canine transmissible venereal tumor.
Vet Pathol. 1996; 33: 257–263
[22]
Mukaratirwa S, Chitanga S, Chimatira T et al.: Combination therapy using intratumoral bacillus Calmette-Guerin (BCG) and vincristine in dogs with transmissible venereal tumours: therapeutic efficacy and histological changes. J S Afr Vet Assoc. 2009; 80: 92–96
[23]
Mukaratirwa S, Chiwome T, Chitanga S et al.: Canine transmissible venereal tumour: assessment of mast cell numbers as indicators of the growth phase. Vet Res Commun. 2006; 30: 613–621
[65]
23.2 Sticker-Sarkom, „transmissible venereal tumor“
TVT
[1]
[2]
Amber EI, Henderson RA, Adeyanju JB et al.: Single-drug chemotherapy of canine transmissible venereal tumor with cyclophosphamide, methotrexate, or vincristine. J Vet Intern Med. 1990; 4: 144–
147
Amber EI, Isitor GN, Adeyanju JB: Viral-like particles associated
with naturally occurring transmissible venereal tumor in two dogs:
preliminary report. Am J Vet Res. 1985; 46: 2613–2615
[3]
Belov K: The role of the Major Histocompatibility Complex in the
spread of contagious cancers. Mamm Genome. 2011; 22: 83–90
[24]
[4]
Bright RM, Gorman NT, Probst CW et al.: Transmissible venereal
tumor of the soft palate in a dog. J Am Vet Med Assoc. 1983;183:
893–895
Mukaratirwa S, Gruys E: Canine transmissible venereal tumour:
cytogenetic origin, immunophenotype, and immunobiology. A
review. Vet Q. 2003; 25: 101–111
[25]
[5]
Brown NO, Calvert C, MacEwen EG: Chemotherapeutic management of transmissible venereal tumors in 30 dogs. J Am Vet Med
Assoc. 1980;176: 983–986
Murchison EP: Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene. 2008; 27 (Suppl 2):19–30
[26]
Murgia C, Pritchard JK, Kim SY et al.: Clonal origin and evolution
of a transmissible cancer. Cell. 2006; 126: 477–487
[27]
Murgia C, Pritchard JK, Kim SY et al.: Clonal origin and evolution
of a transmissible cancer. Cell. 2006; 126: 445–447
[28]
Chou PC, Chuang TF, Jan TR et al.: Effects of immunotherapy of
IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
Nak D, Nak Y, Cangul IT et al.: A Clinico-pathological study on the
effect of vincristine on transmissible venereal tumour in dogs. J Vet
Med A Physiol Pathol Clin Med. 2005; 52: 366–370
[29]
Chuang TF, Lee SC, Liao KW et al.: Electroporation-mediated IL-12
gene therapy in a transplantable canine cancer model. Int J Cancer.
2009; 125: 698–707
Padovan D, Yang TJ, Fenton MA: Epidural spinal metastasis of
canine transmissible venereal sarcoma. Zbl Vet Med A. 1987; 34:
401–404
[30]
Papazoglou LG, Koutinas AF, Plevraki AG et al.: Primary intranasal
transmissible venereal tumour in the dog: a retrospective study of
six spontaneous cases. J Vet Med A Physiol Pathol Clin Med. 2001;
48: 391–400
[31]
Park MS, Kim Y, Kang MS et al.: Disseminated transmissible venereal tumor in a dog. J Vet Diagn Invest. 2006; 18: 130–133
[6]
[7]
[8]
Chandler JP, Yang TJ: Canine transmissible venereal sarcoma: distribution of T and B lymphocytes in blood, draining lymph nodes and
tumours at different stages of growth. Br J Cancer. 1981; 44: 514–
521
[9]
Cohen D: The canine transmissible venereal tumor: a unique result
of tumor progression. Adv Cancer Res. 1985; 43: 75–112
[10]
tumors. Mast cell tumor, histiocytoma, lymphosarcoma and transmissible venereal tumor. Vet Pathol. 1979; 16: 673–679
[32]
Pereira JS, Silva AB, Martins AL et al.: Immunohistochemical characterization of intraocular metastasis of a canine transmissible
venereal tumor. Vet Ophthalmol. 2000; 3: 43–47
[33]
Rebbeck CA, Thomas R, Breen M et al.: Origins and evolution of a
transmissible cancer. Evolution. 2009; 63: 2340–2349
[34]
[3]
Benazzi C, Sarli G, Brunetti B: Sertoli cell tumor in a cat. J Vet A
[4]
Bontempo RA, Zanghì A, Catone G et al.: Metastasising granulosa
cell tumour of the testis: a case report in the dog. Vet Res Commun.
2005; 29 (Suppl 2): 169–171
van Rensburg IB, Petrick SW: Extragenital malignant transmissible
venereal tumour in a bitch. J S Afr Vet Assoc. 1980; 51: 199–201
[5]
Brodey RS, Martin JE: Sertoli cell neoplasms in the dog. J Am Vet
Med Assoc. 1958; 133: 249–257
[35]
Rogers KS: Transmissible venereal tumor. Compend Contin Educ
Pract Vet. 1997; 19: 1036–1045
[6]
[36]
Rogers KS, Walker MA, Dillon HB: Transmissible venereal tumor: a
retrospective study of 20 cases. J Am Anim Hosp Assoc. 1998; 34:
463–479
Comhaire F, Matthews D, Vermuelen A: Testosterone and estradiol in dogs with testicular tumors. Acta Endocrinol. 1974; 77: 408–
416.
[7]
Cotchin E: Testicular neoplasms in dogs. J Comp Pathol. 1960; 70:
232–248
[37]
Scarpelli KC, Valladão ML, Metze K: Predictive factors for the
regression of canine transmissible venereal tumor during vincristine
therapy. Vet J. 2010; 183: 362–363
[8]
Dahlbom M, Mäkinen A, Suominen J: Testicular fine needle aspiration cytology as a diagnostic tool in dog infertility. J Small Anim
Pract. 1997; 38: 506–512
[38]
Spugnini EP, Dotsinsky I, Mudrov N et al.: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor
model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res.
2008; 27: 58
[9]
Dhaliwal RS, Kitchell BE, Knight BL et al.: Treatment of aggressive
testicular tumors in four dogs. J Am Anim Hosp Assoc. 1999; 35:
311–318
[10]
[39]
Thrall DE: Orthovoltage radiotherapy of canine transmissible venereal tumors. Vet Radiol. 1982; 23: 217–219
Dow C: Testicular tumors in the dog. J Comp Pathol. 1962; 72:
247–265
[11]
[40]
Yang TJ: Metastatic transmissible venereal sarcoma in a dog. J Am
Vet Med Assoc. 1987; 190: 555–556
Doxsee AL, Yager JA, Best SJ et al.: Extratesticular interstitial and
Sertoli cell tumors in previously neutered dogs and cats: a report of
17 cases. Can Vet J. 2006; 47: 763–766
[12]
England GC: Ultrasonographic diagnosis of non-palpable Sertoli cell
tumours in infertile dogs. J Small Anim Pract. 1999; 36: 476–480
[13]
Ferreira AJ, Peleteiro MC, Carvalho T et al.: Mixed germ cell
tumour of the spinal cord in a young dog. J Small Anim Pract. 2003;
44: 81–84
[14]
Frank LA: Comparative dermatology-canine endocrine dermatoses.
Clin Dermatol. 2006; 24: 317–325
[15]
Gembardt CH: Beitrag zur Histologie hormonell aktiver und inaktiver Hodenneoplasien des Hundes. Diss med vet. FU, Berlin. 1971
[16]
Gopinath D, Draffan D, Philbey AW et al.: Use of intralesional
oestradiol concentration to identify a functional pulmonary metastasis of canine sertoli cell tumour. J Small Anim Pract. 2009; 50:
198–200
[17]
Gouletsou PG, Galatos AD, Leontides LS et al.: Impact of fine or
large needle aspiration on the dogʼs testis: in vitro ultrasonographic,
bacteriological, gross anatomy and histological assessment. Theriogenology. 2010; 74: 1604–1614
23.3 Tumoren der männlichen
Geschlechtsorgane
[1]
Bleier T, Lewitschek HP, Reinacher M: Canine osteosarcoma of
the penile bone. J Vet Med A Physiol Pathol Clin Med. 2003; 50:
397–398
[2]
Cornegliani L, Vercelli A, Abramo F: Idiopathic mucosal penile
squamous papillomas in dogs. Vet Dermatol. 2007; 18: 439–443
[3]
Elkins AD, Pechman R, Brignac M: Urinary obstruction resulting
from a mass in the caudal os penis of a dog. J Am Anim Hosp Assoc.
1990; 26: 133–135
[4]
Galofaro V, Rapisarda G, Ferrara G et al.: Glomangioma in the prepuce of a dog. Reprod Domest Anim. 2006; 41: 568–570
[5]
Kim MS, Kim DH, Choi US: Penile extramedullary plasmacytoma in
a dog. Reprod Domest Anim. 2010; 45: 454–457
[6]
Marolf A, Specht A, Thompson M et al.: Imaging diagnosis: penile
hemangiosarcoma. Vet Radiol Ultrasound. 2006; 47: 474–475
[18]
[7]
Michels GM, Knapp DW, David M et al.: Penile prolapse and
urethral obstruction secondary to lymphosarcoma of the penis in a
dog. J Am Anim Hosp Assoc. 2001; 37: 474–477
Grieco V, Banco B, Giudice C et al.: Immunohistochemical expression of the KIT protein (CD117) in normal and neoplastic canine testes. J Comp Pathol. 2010; 142: 213–217
[19]
[8]
Mirkovic TK, Shmon CL, Allen AL: Urinary obstruction secondary
to an ossifying fibroma of the os penis in a dog. J Am Anim Hosp
Assoc. 2004; 40: 152–156
Grieco V, Riccardi E, Greppi GF et al.: Canine testicular tumours: a
study on 232 dogs. J Comp Pathol. 2008; 138: 86–89
[20]
Patnaik AK, Matthiesen DT, Zawie DA: Two cases of canine penile
neoplasm: squamous cell carcinoma and mesenchymal chondrosarcoma. J Am Anim Hosp Assoc. 1988; 24: 403–406
Grieco V, Rondena M, Romussi S et al.: Immunohistochemical
characterization of the leucocytic infiltrate associated with canine
seminomas. J Comp Pathol. 2004; 130: 278–284
[21]
Grootenhuis AJ, van Sluijs FJ, Klaij LA et al.: Inhibin, gonadotrophins and sex steroids in dogs with Sertoli cell tumours. J Endocrinol. 1990; 127: 235–242
[22]
Günzel-Apel AR, Möhrke C, Poulsen-Nautrup C: Colour-coded
and pulsed Doppler sonography of the canine testis, epididymis
and prostate gland: physiological and pathological findings. Reprod
Domestic Anim. 2001; 36: 236–240
[23]
Guimaraens Chquiloffde MA, Nascimento EF: Histopathologische
Veränderungen an Hoden und Nebenhoden bei Rüden. Kleintierprax. 1977; 22: 247–250
[24]
Hagel T, Baade S, Kirchhoff A et al.: Syndrom persistierender Müller-Gänge bei einem Yorkshire Terrier. Kleintierprax. 2010; 55: 547–
553
[25]
Hayes HM, Pendergrass TW: Canine testicular tumors. Epidemiologie features of 410 dogs. Int J Cancer. 1976; 18: 482–487
[26]
Hayes HM, Wilson GP, Pendergrass TW et al.: Canine cryptor-
[9]
[10]
Peppler C, Weissert D, Kappe E et al.: Osteosarcoma of the penile
bone (os penis) in a dog. Aust Vet J. 2009; 87: 52–55
[11]
Wakui S, Furusato M, Nomura Y et al.: Testicular epidermoid cyst
and penile squamous cell carcinoma in a dog. Vet Pathol. 1992; 29:
543–545
[12]
Web JA, Liptak JM, Hewitt SA et al.: Multilobular osteochondrosaroma of the os penis in a dog. Can Vet J. 2009; 50: 81–84
23.3.1 Tumoren der Hoden
[1]
Barrand KR, Scudamore CL: Canine hypertrophic osteoarthropathy
associated with a malignant Sertoli cell tumour. J Small Anim Pract.
2001; 42: 143–145
[2]
Bazzo R, Sarli G, Mandrioli L et al.: Sertoli cell tumour with CallExner-like bodies in a dog. J Vet Med A Physiol Pathol Clin Med.
2002; 49: 535–537
99
100
chism and subsequent testicular neoplasia: case-control study with
epidemiologic update. Teratology. 1985; 32: 51–56
[49]
Morgan RV: Blood dyscrasias associated with testicular tumors in
[27]
Hogenesch, H, Whiteley HE, Vicini DS et al.: Seminoma with
metastases in the eyes and the brain in a dog. Vet Pathol. 1987; 24:
278–280
[50]
Nieto JM, Pizarro M, Balaguer LM et al.: Canine testicular tumors
in descended and cryptorchid testes. Dtsch Tierärztl Wochenschr.
1989; 96: 186–189
[28]
Howard EB, Nielsen SW: Neoplasia in the boxer dog. Am J Vet Res.
1965; 26: 1121–1131
[51]
[29]
Inoue M, Wada N: Immunohistochemical detection of p53 and
p21 proteins in canine testicular tumours. Vet Rec. 2000; 146: 370–
372
Nødtvedt A, Gamlem H, Gunnes G et al.: Breed differences in the
proportional morbidity of testicular tumours and distribution of histopathologicyl types in a population-based canine cancer registry.
[52]
[30]
Johnston GR, Feeney DA, Johnston SD et al.: Ultrasonographic
features of testicular neoplasia in dogs: 16 cases (1980–1988). J Am
Vet Med Assoc. 2001; 198: 1779–1784
[31]
Kasbohm C: Oestrogenbedingte Knochenmarkschäden bei Hunden
mit Hodenneoplasien. Tierärztl Praxis. 1975; 3: 225–229
Ortega-Pacheco A, Rodriguez-Buenfil JC, Segura-Correa JC et al.:
Pathological conditions of the reproductive organs of male stray
dogs in the tropics: prevalence, risk factors, morphological findings
and testosterone concentrations. Reprod Domest Anim. 2006; 41:
429–437
[53]
[32]
Kawakami E, Hirano T, Hori T et al.: Testicular superoxide dismutase activity, heat shock protein 70 concentration and blood plasma
inhibin-alpha concentration of dogs with a Sertoli cell tumor in a
unilateral cryptorchid testis. J Vet Med Sci. 2007; 69: 1259–1262
Owston MA, Ramos-Vara JA: Histologic and immunohistochemical
characterization of a testicular mixed germ cell sex cord-stromal
tumor and a leydig cell tumor in a dog. Vet Pathol. 2007; 44: 936–
943
[54]
Kim JF, Yu CH, Yhee JY et al.: Canine classical seminoma: a specific
malignat type with human classifications is highly correlated with
tumor angiogenesis. BMC Cancer. 2010; 10: 243
Patnaik AK, Mostofi FK: A clinicopathologic, histologic, and immunohistochemical study of mixed germ cell-stromal tumors of the
testis of 16 dogs. Vet Pathol. 1993; 30: 287–297
[55]
Pena FJ, Anel L, Dominguez JC et al.: Laparoscopic surgery in a clinical case of seminoma in a cryptorchid dog. Vet Rec. 1998; 142:
671–672
[56]
Peters MA, de Jong FH, Teerds KJ et al.: Ageing, testicular
tumours and the pituitary-testis axis in dogs. J Endocrinol. 2000;
166: 153–161
[57]
Peters MA, de Rooij DG, Teerds KJ et al.: Spermatogenesis and
testicular tumours in ageing dogs. J Reprod Fertil. 2000; 120: 443–
452
[58]
Peters MA, Mol JA, van Wolferen ME et al.: Expression of the
insulin-like growth factor (IGF) system and steroidogenic enzymes
in canine testis tumors. Reprod Biol Endocrinol. 2003; 1: 22
[59]
Peters MA, van Sluijs FJ: Testicular tumors in dogs: a literature
review. Tijdschr Diergeneeskd. 1996; 121: 36–38
[60]
Peters MA, Teerds KJ, van der Gaag I et al.: Use of antibodies
against LH receptor, 3beta-hydroxysteroid dehydrogenase and
vimentin to characterize different types of testicular tumour in
dogs. Reproduction. 2001; 121: 287–296
[61]
Peterson MR, Frommelt RA, Dunn DG: A study of the lifetime
occurrence of neoplasia and breed differences in a cohort of German
Shepherd Dogs and Belgian Malinois military working dogs that
died in 1992. J Vet Intern Med. 2000; 14: 140–145
[62]
Post K, Kilborn SH: Canine sertoli cell tumor: A medical records
search and literary review. Can Vet J. 1987; 28: 427–431
[63]
Prange H, Katenkamp D, Baumann G et al.: Die Pathologie der
Hodentumoren des Hundes, l. Mitteilung: Epidemiologie und vergleichende epidemiologische Aspekte. Arch Exp Veterinarmed.
1986; 40: 555–565
[64]
Radi ZA, Miller DL: Immunohistochemical expression of calretinin
in canine testicular tumours and normal canine testicular tissue.
Res Vet Sci. 2005; 79:125–129
[65]
Ramos-Vara JA, Miller MA: Immunohistochemical evaluation of
GATA-4 in canine testicular tumors. Vet Pathol. 2009; 46: 893–896
[66]
Reif JS, Brodey RS: The relationship between cryptorchidism and
canine testicular neoplasia. J Am Vet Med Assoc. 1969; 155: 2005–
2010
[67]
Reif JS, Maguire TG, Kenney RM et al.: A cohort study of canine
testicular neoplasia. J Am Vet Med Assoc. 1979; 175: 719–723
[68]
Reimann-Berg N, Murua Escobar H, Nolte I et al.: Testicular
tumor in an XXY dog. Cancer Genet Cytogenet. 2008; 183: 114–
116
[69]
Reis-Filho JS, Ricardo S, Gärtner F et al.: Bilateral gonadoblastomas in a dog with mixed gonadal dysgenesis. J Comp Pathol. 2004;
130: 229–233
[33]
[34]
Kim O, Kim KS: Seminoma with hyperesterogenemia in a Yorkshire
Terrier. J Vet Med Sci. 2005; 67: 121–123
[35]
Liao AT, Chu PY, Yeh LS et al.: A 12-year retrospective study of
canine testicular tumors. J Vet Med Sci. 2009; 71: 919–923
[36]
Lipowitz AJ, Schwartz A, Wilson GP et al.: Testicular neoplasms
and concomitant clinical changes in the dog. J Am Vet Med Assoc.
1973; 163: 1364–1368
[37]
Maarschalkerweerd RJ, Endenburg N, Kirpensteijn J et al.: Influence of orchiectomy on canine behaviour. Vet Rec. 1997; 140: 617–
619
[38]
Maiolino P, Restucci B, Papparella S et al.: Correlation of nuclear
morphometric features with animal and human World Health Organization International Histological Classifications of canine spontaneous seminomas. Vet Pathol. 2004; 41: 608–611
[39]
Masserdotti C, Bonfanti U, De Lorenzi D et al.: Cytologic features
of testicular tumours in dog. J Vet Med A Physiol Pathol Clin Med.
2005; 52: 339–346
[40]
Masserdotti C, De Lorenzi D, Gasparotto L: Cytologic detection of
Call-Exner bodies in Sertoli cell tumors from 2 dogs. Vet Clin Pathol.
2008; 37: 112–114
[41]
McDonald RK, Walker M, Legendre AM et al.: Radiotherapy of
metastatic seminoma in the dog. J Vet Intern Med. 1988; 2: 103–
107
[42]
Metzger FL, Hattel AL, White DG: Hematuria, hyperestrogenemia,
and hyperprogesteronemia due to a sertoli-cell tumor in a bilateral
cryptorchid dog. Canine Pract. 1993; 18: 32–35
[43]
Meurer DG: Sonographische, zytologische und endokrinologische
Untersuchungen zu Hodentumoren und nichteoplastischen Hodenerkrankungen des Hundes. Diss med vet., Tierärztliche Hochschule
Hannover, 2000
[44]
Meurer DG, Mischke R: Klinik der Hodentumoren des Hundes.
Prakt Tierarzt. 2000; 81: 628–637
[45]
Miller MA, Hartnett SE, Ramos-Vara JA: Interstitial cell tumor and
Sertoli cell tumor in the testis of a cat. Vet Pathol. 2007; 44: 394–397
[46]
Miyoshi N, Yasuda N, Kamimura Y et al.: Teratoma in a feline
cryptorchid testis. Vet Pathol. 2001; 38: 729–730
[47]
Mischke R, Meurer D, Hoppen HO et al.: Blood plasma concentrations of oestradiol-17beta, testosterone and testosterone/oestradiol
ratio in dogs with neoplastic and degenerative testicular diseases.
Res Vet Sci. 2002; 73: 267–272
[48]
Mostachio GQ, Apparício M, Vicente WR et al.: Intraabdominal
torsion of a neoplastic testicle and prostatic cyst in a cryptorchid
dog. Schweiz Arch Tierheilkd. 2007; 149: 408–412
[70]
Restucci B, Maiolino P, Paciello O et al.: Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. J
Comp Pathol. 2003; 128: 252–259
[6]
Aumüller G, Seitz J, Lilja H et al.: Species – and organ-specificity of
secretory proteins derived from human prostate and seminal vesicles. Prostate. 1990; 17: 31–40
[71]
Restucci B, Maiolino P, Papparella S et al.: Expression of beta1
integrin in relation to histological features in normal and neoplastic
canine testicles. J Comp Pathol. 2000; 123:164–170
[7]
Bacci B, Vignoli M, Rossi F et al.: Primary prostatic leiomyosarcoma with pulmonary metastases in a dog. J Am Anim Hosp Assoc.
2010; 46: 103–106
[72]
Rosen DK, Carpenter JL: Functional ectopic interstitial cell tumor in
a castrated male cat. J Am Vet Med Assoc. 1993; 202: 1865–1866
[8]
Barsanti JA, Finco DR: Evaluation of techniques for diagnosis of
canine prostatic diseases. J Am Vet Med Assoc. 1984; 185: 198–200
[73]
Rüttinger C, Bergmann M, Fink L et al.: Expression of connexin 43
in normal canine testes and canine testicular tumors. Histochem
Cell Biol. 2008; 130: 537–548
[9]
Basinger RR, Rawlings CA, Barsanti JA et al.: Urodynamic alterations after prostatectomy in dogs without clinical prostatic disease.
Vet Surg. 1987; 16: 405–410
[74]
Sanpera N, Masot N, Janer M et al.: Oestrogen-induced bone marrow aplasia in a dog with a Sertoli cell tumour. J Small Anim Pract.
2002; 43: 365–369
[10]
Basinger RR, Rawlings CA, Barsanti JA et al: Urodynamic alterations associated with clinical prostatic disease and prostatic surgery. J Am Anim Hosp Assoc. 1989; 25: 385–392
[75]
Sapierzynski R, Malicka E, Bielecki W et al.: Tumors of the urogenital system in dogs and cats. Retrospective review of 138 cases.
Pol J Vet Sci. 2007; 10: 97–103
[11]
[76]
Sherding RG, Wilson GP: Bone marrow hypoplasia in eight dogs
with Sertoli cell tumor. J Am Vet Med Assoc. 1982; 178: 497–501
Bell FW, Klausner JS, Hayden DW et al.: Clinical and pathologic
features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970–1987). J Am Vet Med Assoc. 1991; 199:
1623–1630
[12]
[77]
Siegel ET, Forchielli E, Dorfman RI et al.: An estrogen study in the
feminized dog with testicular neopasia. J Endocrinol. 1967; 80:
272–277
Bell FW, Klausner JS, Hayden DW et al.: Evaluation of serum and
seminal plasma markers in the diagnosis of canine prostatic disorders. J Vet Intern Med. 1995; 9: 149–153
[13]
[78]
Spugnini EP, Bartolazzi A, Ruslander D: Seminoma with cutaneous
metastases in a dog. J Am Anim Hosp Assoc. 2000; 36: 253–256
Bostwick DG, Quian J, Frankel K: The incidence of high grade intraepithelial neoplasia in needle biopsies. J Urol. 1995; 154: 1791–
1794
[79]
Suess Jr R, Barr SC, Sacre BJ et al.: Bone marrow hypoplasia in a
feminized dog with an interstitial cell tumor. J Am Vet Med Assoc.
1992; 200: 1346–1348
[14]
Bradbury CA, Westropp JL, Pollard RE: Relationship between prostatomegaly, prostatic mineralization, and cytologic diagnosis. Vet
[80]
Takiguchi M, Lida T, Kudo T et al.: Malignant seminoma with systemic metastases in a dog. J Small Animal Pract. 2001; 42: 360–362
[15]
[81]
Taniyama H, Hirayama K, Nakada K et al.: Immunohistochemical
detection of inhibin-alpha, -betaB, and -betaA chains and 3betahydroxysteroid dehydrogenase in canine testicular tumors and normal testes. Vet Pathol. 2001; 38: 661–666
Bryan JN, Keeler MR, Henry CJ et al.: A population study of neutering status as a risk factor for canine prostate cancer. Prostate.
2007; 67: 1174–1181
[16]
Caney SM, Holt PE, Day MJ et al.: Prostatic carcinoma in two cats.
[17]
Chapdelaine P, Gauthier E, Ho-Kim MA et al.: Characterization
and expression of the prostatic arginine esterase gene, a canine
glandular kallikrein. DNA Cell Biol. 2009; 10: 49–59
[18]
Cooley DM, Waters DJ: Skeletal metastasis as the initial clinical
manifestation of metastatic carcinoma in 19 dogs. J Vet Intern Med.
1998; 12: 288–293
[19]
Cornell KK, Bostwick DG, Cooley DM et al.: Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate. 2000; 45: 173–183
[20]
Corazza M, Guidi G, Romagnoli S et al.: Serum total prostatic and
non-prostatic acid phosphatase in healthy dogs and in dogs with
prostatic disease. J Small Anim Pract. 1994; 35: 207–310
[21]
Cromeens DM, Johnson DE, Stephens LC et al.: Visual laser ablation of the canine prostate with a diffusing fiber and an 805-nanometer diode laser. Laser Surg Med. 1996; 19: 135–142
[22]
Della Santa D, Dandrieux J, Psalla D et al.: Primary prostatic haemangiosarcoma causing severe haematuria in a dog. J Small Anim
Pract. 2008; 49: 249–251
[23]
Algaba F, Trias I, Arce Y: Natural history of prostatic carcinoma: the
pathologist’s perspective. Rec Res Cancer Res. 2007; 175: 9–24
Dominguez PA, Dervisis NG, Cadile CD et al.: Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern
Med. 2009; 23:130–137
[24]
Anderson CR, McNiel EA, Gillette EL et al.: Late complications of
pelvic irradiation in 16 dogs. Vet Radiol Ultrasound. 2002; 43:187–
192
Durham SK, Deitze AE: Prostatic adenocarcinoma with and
without metastasis to bone in dogs. J Am Vet Med Assoc. 1986;
188: 1432–1436
[25]
Feeney DA, Johnston GR, Klausner JS et al.: Canine prostatic
disease-comparison of ultrasonographic appearance with morphologic and microbiologic findings: 30 cases (1981–1985). J Am Vet
Med Assoc. 1987; 190: 1027–1034
[26]
Freitag T, Jerram RM, Walker AM et al.: Surgical management of
common canine prostatic conditions. Compend Contin Educ Pract
Vet. 2007; 29: 656–658
[82]
Tucker AR, Smith JR: Prostatic squamous metaplasia in a cat with
interstitial cell neoplasia in a retained testis. Vet Pathol. 2008; 45:
905–909
[83]
Turk JR, Turk MA, Gallina AM: A canine testicular tumor resembling gonadoblastoma. Vet Pathol. 1981; 18: 201–207
[84]
Vegter AR, Kooistra HS, van Sluijs FJ et al.: Persistent Mullerian
duct syndrome in a Miniature Schnauzer dog with signs of feminization and a Sertoli cell tumour. Reprod Domest Anim. 2010; 45:
447–452
[85]
Wang FI, Liang SL, Chin SC: A primary retroperitoneal seminoma
invading the kidneys of a cryptorchid dog. Exp Anim. 2001; 50:
341–344
[86]
Weaver AD: Survey with follow-up of 67 dogs with testicular Sertoli
cell tumours. Vet Rec. 1983; 113: 105–107
[87]
Yu CH, Hwang DN, Yhee JY et al.: Comparative immunohistochemical characterization of canine seminomas and Sertoli cell tumors.
J Vet Sci. 2009; 10: 1–7
23.3.2 Tumoren der Prostata
[1]
[2]
[3]
Aquilina JW, McKinney L, Pacelli A et al.: High grade prostatic
intraepithelial neoplasia in military working dogs with and without
prostate cancer. Prostate. 1998; 36: 189–193
[4]
Argyle DJ: Prostate cancer in dogs and men: a unique opportunity
to study the disease. Vet J. 2009; 180: 137–138
[5]
Assin R, Balsi A, Citro G et al.: Prostate as sole unusual recurrence
site of lymphoma in a dog. In Vivo. 2008; 22: 755–757
101
102
[27]
Fujita M, Shimakura H, Hasegawa D et al.: The effect of palliative
radiation therapy on three dogs with prostatic carcinoma. J Japan
Vet Cancer Soc. 2010; 1: 20–25
[49]
McEntee M, Isaacs W, Smith C: Adenocarcinoma of the prostate:
immunohistochemical examination for secretory antigens. Prostate.
1987; 11: 163–170
[28]
Gallardo F, Mogas T, Baro T et al.: Expression of androgen, oestrogen alpha and beta, and progesterone receptors in the canine prostate: differences between normal, inflamed, hyperplastic and neoplastic glands. J Comp Pathol. 2007; 136: 1–8
[50]
Montironi R, Pomante R, Diamanti L et al.: Evaluation of intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor
(finasteride). A methodologic approach. Anal Quant Cytol Histol.
1996; 18: 461–470
[29]
Gobello C, Castex G, Corrada Y: Serum and seminal markers in the
diagnosis of disorders of the genital tract of the dog: a mini-review.
Theriogenology. 2002; 57: 1285–1291
[51]
Matsuzaki P, Cogliati B, Sanches DS et al.: Immunohistochemical
characterization of canine prostatic intraepithelial neoplasia. J Comp
Pathol. 2010; 142: 84–88
[30]
Goldsmid SE, Bellenger CR: Urinary incontinence after prostatectomy in dogs. Vet Surg. 1991; 20: 253–256
[52]
[31]
Grieco V, Riccardi E, Rondena M et al.: The distribution of oestrogen receptors in normal, hyperplastic and neoplastic canine prostate, as demonstrated immunohistochemically. J Comp Pathol.
2006; 135: 11–16
Mukaratirwa S, Chitura T: Canine subclinical prostatic disease: histological prevalence and validity of digital rectal examination as a
screening test. J S Afr Vet Assoc. 2007; 78: 66–68
[53]
Nickel RF, Teske E: Diagnosis of canine prostatic carcinoma.
Tijdschr Diergeneeskd 1992; 117: 32S
[54]
Nyland TG, Wallack ST, Wisner ER: Needle tract implantation following US-guided fine-needle aspiration biopsy of transitional cell
[32]
Hardie EM, Stone EA, Spaulding KA et al.: Subtotal canine prostatectomy with the neodymium: yttrium-aluminum-garnet laser. Vet
Surg. 1990; 19: 48–55
[33]
Hazzah TN, Brodsky EM, Post GS: Evaluation of mitoxantrone and
a COX inhibitor as a first line therapy for canine prostatic carcinoma.
Proc 28th Ann Conf Vet Cancer Soc., Seattle 2008; 19
[55]
Obradovich J, Walshaw R, Goullaud E: The influence of castration
on the development of prostatic carcinoma in the dog. 43 cases
(1978–1985). J Vet Intern Med. 1987; l: 183–187
[34]
Hubbard BS, Vulgamott JC, Liska WD: Prostatic adenocarcinoma
in a cat. J Am Vet Med Assoc. 1990; 197: 1493–1494
[56]
[35]
Kay ND, Ling GV, Nyland TG et al.: Cytological diagnosis of canine
prostatic disease using a urethral brush technique. J Am Anim Hosp
Assoc. 1989; 25: 517–526.
Pinto da Cunha N, Ghisleni G, Romussi S et al.: Prostatic sarcomatoid carcinoma in a dog: cytologic and immunohistochemical findings. Vet Clin Pathol. 2007; 36: 368–372
[57]
Powe JR, Canfield PJ, Martin PA: Evaluation of cytologic diagnosis
of canine prostatic disorders. Vet Clin Pathol. 2004; 33: 150–154
[58]
Rawlings CA, Crowell WA, Barsanti JA et al.: Intracapsular subtotal prostatectomy in normal dogs: use of an ultrasonic surgical
aspirator. Vet Surg. 1994; 23: 182–189
[36]
Krawiec DR, Heflin D: Study of prostatic disease in dogs: 177 cases
(1981–1986). J Am Vet Med Assoc. 1992; 200: 1119–1122
[37]
Lai CL, LʼEplattenier H, van den Ham R et al.: Androgen receptor
CAG repeat polymorphisms in canine prostate cancer. J Vet Intern
Med. 2008; 22: 1380–1384
[59]
Lai CL, van den Ham R, Mol J et al.: Immunostaining of the androgen receptor and sequence analysis of its DNA-binding domain in
canine prostate cancer. Vet J. 2009; 181: 256–260
Reiman-Berg N, Willenbrock S, Murua Escobar H et al.: Two new
cases of polysomy 13 in canine prostate cancer. Cytogenet Genome
Res. 2011; 132: 16–21
[60]
Lai CL, van den Ham R, van Leenders G et al.: Histopathological
and immunohistochemical characterization of canine prostate cancer. Prostate. 2008; 68: 477–488
Shor S, Helfand SC, Gorman E et al.: Diagnostic exercise: epitheloid hemangiosarcoma mimicking metastatic prostatic neoplasia in
a dog. Vet Pathol. 2009; 46: 548–552
[61]
Smith J: Canine prostatic disease: a review of anatomy, pathology,
diagnosis, and treatment. Theriogenology. 2008; 70: 375–383
[38]
[39]
[40]
Leav I, Schelling KH, Adams JY et al.: Role of canine basal cells in
postnatal prostatic development, induction of hyperplasia, and sex
hormone-stimulated growth, and the ductal origin of carcinoma.
Prostate. 2001; 48: 210–224
[62]
Sorenmo KU, Goldschmidt M, Schofer F et al.: Immunohistochemical characterization of canine prostatic carcinoma and correlation
with castration status and castration time. Vet Comp Onc. 2003; 1:
48–56
[41]
LʼEplattenier HF, Klem B, Teske E et al.: Preliminary results of intraoperative photodynamic therapy with 5-aminolevulenic acid in
dogs with prostate carcinoma. Vet J. 2008; 178: 202–207
[63]
[42]
LʼEplattenier HF, Lai CL, van den Ham R et al.: Regulation of COX2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. J Vet Intern Med. 2007; 21:
776–782
Sorenmo KU, Goldschmidt MH, Schofer FS et al.: Evaluation of
cyclooxygenase-1 and cyclooxygenase-2 expression and the effect
of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet
Comp Onc. 2004; 2: 13–23
[64]
Teske E, Naan BC, van Dijk EM et al.: Canine prostate carcinoma:
epidemiological evidence of an increased risk in castrated dogs. Mol
Cell Endocrinol. 2002; 197: 251–255
[43]
L’Eplattenier HF, van Nimwegen SA, van Sluijs FJ et al.: Partial
prostatectomy using a Nd:YAG laser for management of canine
prostatic carcinoma. Vet Surg. 2006; 35: 406–411
[65]
Teske E, Nickel RF: Zur Aussagekraft der Zytologie bei der Diagnostik des Prostatakarzinoms beim Hund. Kleintierprax. 1996; 41: 239–
247
[44]
LeRoy BE, Lech ME: Prostatic carcinoma causing urethral obstruction and obstipation in a cat. J Feline Med Surg. 2004; 6: 397–400
[66]
[45]
LeRoy BE, Northrup N: Prostate cancer in dogs: comparative and
clinical aspects. Vet J. 2009; 180: 137–138
Ticer JW, Spencer CP, Ackerman N: Positive contrast retrograde
urethrography: A useful procedure for evaluating urethral disorders
in the dog. Vet Radiol. 1980; 21: 2–5
[67]
[46]
Liptak JM, Brutscher SP, Monnet E et al.: Transurethral resection
in the management of urethral and prostatic neoplasia in 6 dogs.
Vet Surg. 2004; 33: 505–516
Turrel, JM: Intraoperative radiotherapy of carcinoma of the prostate
in ten dogs. J Am Vet Med Assoc. 1987; 190: 48–52
[68]
Tursi M, Costa T, Valenza F, Aresu L: Adenocarcinoma of the disseminated prostate in a cat. J Feline Med Surg. 2008; 10: 600–602
[47]
Lucroy MD, Bowles MH, Higbee RG et al.: Photodynamic therapy
for prostatic carcinoma in a dog. J Vet Intern Med. 2003; 17: 235–
237
[69]
Vlasin M, Rauser, Fichtel T et al.: Subtotal intracapsular prostatectomy as a useful treatment for advanced-stage prostatic malignancies. J Small Anim Pract. 2006; 47: 512–516
[48]
Mann FA, Barrett RJ, Henderson RA: Use of a retained urethral
catheter in three dogs with prostatic neoplasia. Vet Surg. 1992; 21:
342–347
[70]
Waters DJ, Bostwick DG: Prostatic intraepithelial neoplasia occurs
spontaneously in the canine prostate. J Urol. 1997; 157: 713–716
[71]
Waters DJ, Bostwick DG: The canine prostate is a spontaneous
model of intraepithelial neoplasia and prostate cancer progression.
Anticancer Res. 1997; 17: 1467–1470
[72]
Waters DJ, Patronek GJ, Bostwick DG et al.: Comparing the age at
prostate cancer diagnosis in humans and dogs. J Natl Cancer Inst.
1996; 88: 1686–1687
[73]
Weaver AD: Fifteen cases of prostatic carcinoma in the dog. Vet
Rec. 1981; 109: 71–75
[74]
Weisse C, Berent A, Todd K et al.: Evaluation of palliative stenting
Vet Med Assoc. 2006; 229: 226–234
[75]
Winter MD, Locke JE, Penninck DG: Imaging diagnosis-urinary
obstruction secondary to prostatic lymphoma in a young dog. Vet
[76]
[77]
Winkler S, Reimann-Berg N, Murua Escobar H et al.: Polysomy 13
in a canine prostate carcinoma underlining its significance in the
development of prostate cancer. Cancer Genet Cytogenet. 2006;
169: 154–158
Zambelli D, Cunot M, Raccagni R et al.: Successful surgical treatment of a prostatic biphasic tumor (sarcomatoid carcinoma) in a
cat. J Feline Med Surg. 2010; 12: 161–165
24 Kardiale und mesenteriale Tumoren
24.1 Kardiale und perikardiale Tumoren
[1]
Akkoc A, Ozyigit MO, Cangul IT: Valvular cardiac myxoma in a
dog. J Vet Med A Physiol Pathol Clin Med. 2007; 54: 356–358
[15]
Campbell MD, Gelberg HB: Endocardial ossifying myxoma of the
right atrium in a cat. Vet Pathol. 2000; 37: 460–462
[16]
Caro-Vadillo A, Pizarro-Diaz M, Martinez-Merlo E et al.: Clinical
and pathological features of a cardiac chondrosarcoma in a dog.
Vet Rec. 2004; 155: 678–680
[17]
Caruso KJ, Cowell RL, Upton ML et al.: Intrathoracic mass in a cat.
Vet Clin Pathol. 2002; 31: 193–195
[18]
Chun R, Kellihan HB, Henik RA et al.: Comparison of plasma cardiac troponin I concentrations among dogs with cardiac hemangiosarcoma, noncardiac hemangiosarcoma, other neoplasms, and pericardial effusion of nonhemangiosarcoma origin. J Am Vet Med
Assoc. 2010; 237: 806–811
[19]
Closa JM, Font A, Mascort J: Pericardial mesothelioma in a dog:
long-term survival after pericardiectomy in combination with chemotherapy. J Small Anim Pract. 1999; 40: 383–386
[20]
Crumbaker DM, Rooney MB, Case JB: Thoracoscopic subtotal pericardiectomy and right atrial mass resection in a dog. J Am Vet Med
Assoc. 2010; 237: 551–554
[21]
Di Palma S, Lombard C, Kappeler A et al.: Intracardiac ectopic thyroid adenoma in a dog. Vet Rec. 2010; 167: 709–710
[22]
Dupuy-Mateos A, Wotton PR, Blunden AS et al.: Primary cardiac
chondrosarcoma in a paced dog. Vet Rec. 2008; 163: 272–273
[23]
Ehrhart N, Ehrhart EJ, Willis J et al.: Analysis of factors affecting
survival in dogs with aortic body tumors. Vet Surg. 2002; 31: 44–48
[24]
Fews D, Scase TJ, Battersby IA: Leiomyosarcoma of the pericardium, with epicardial metastases and peripheral eosinophilia in a
dog. J Comp Pathol. 2008; 138: 224–228
[25]
Fine DM, Tobias AH, Jacob KA: Use of pericardial fluid pH to distinguish between idiopathic and neoplastic effusions. J Vet Intern
Med. 2003; 17: 525–529
[2]
Akkoc A, Ozyigit MO, Yilmaz R et al.: Cardiac metastasising rhabdomyosarcoma in a great Dane. Vet Rec. 2006; 158: 803–804
[3]
Almes KM, Heaney AM, Andrews GA.: Intracardiac ectopic thyroid
carcinosarcoma in a dog. Vet Pathol. 2008; 45: 500–504
[26]
Foale RD, White RA, Harley R et al.: Left ventricular myxosarcoma
[4]
Aresu L, Tursi M, Iussich S et al.: Use of S-100 and chromogranin
A antibodies as immunohistochemical markers on detection of
malignancy in aortic body tumors in dog. J Vet Med Sci. 2006; 68:
1229–1233
[27]
Gamlem H, Nordstoga K, Arnesen K: Canine vascular neoplasia –
a population-based clinicopathologic study of 439 tumours and
tumour-like lesions in 420 dogs. APMIS Suppl. 2008; 125: 41–54
[28]
[5]
Aupperle H, Marz I, Ellenberger C et al:. Primary and secondary
heart tumours in dogs and cats. J Comp Pathol. 2007; 136: 18–26
George C, Steinberg H: An aortic body carcinoma with multifocal
thoracic metastases in a cat. J Comp Pathol. 1989; 101: 467–469
[29]
[6]
Balli A, Lachat M, Gerber B et al.: Herztamponade durch ein Perikardmesotheliom bei einem 11-jährigen Hund: Diagnose, medikamentelle und interventionelle Behandlungen. Schweiz Arch Tierheilkd. 2003; 145: 82–87
Girard C, Helie P, Odin M: Intrapericardial neoplasia in dogs. J Vet
Diagn Invest. 1999; 11: 73–78
[30]
Gliatto JM, Crawford MA, Snider TG 3rd et al.: Multiple organ
metastasis of an aortic body tumor in a boxer. J Am Vet Med Assoc.
1987; 191: 1110–1112
[31]
Grieco V, Locatelli C, Riccardi E et al.: A case of two different
tumors in the heart of a dog. J Vet Diagn Invest. 2008; 20: 365–368
[32]
Hayes HM: An hypothesis for the aetiology of canine chemoreceptor system neoplasms, based upon an epidemiological study of 73
cases among hospital patients. J Small Anim Pract. 1975; 16: 337–
343
[7]
Baumgartner C, Glaus TM: Erworbene Herzerkrankungen beim
Hund – eine retrospektive Analyse. Schweiz Arch Tierheilkd. 2004;
146: 423–430
[8]
Ben-Amotz R, Ellison GW, Thompson MS et al.: Pericardial lipoma
in a geriatric dog with an incidentally discovered thoracic mass. J
[9]
Bracha S, Caron I, Holmberg DL et al.: Ectopic thyroid carcinoma
causing right ventricular outflow tract obstruction in a dog. J Am
Anim Hosp Assoc. 2009; 45: 138–141
[33]
Hayes HM, Sass B: Chemoreceptor neoplasia: a study of the epidemiological features of 357 canine cases. Zbl Vet Med A. 1988; 35:
401–408
[10]
Brambilla PG, Roccabianca P, Locatelli C et al.: Primary cardiac
lipoma in a dog. J Vet Intern Med. 2006; 20: 691–693
[34]
[11]
Brisson BA, Holmberg DL: Use of pericardial patch graft reconstruction of the right atrium for treatment of hemangiosarcoma in a
Hirsch VM, Jacobsen J, Mills JH: A retrospective study of canine
hemangiosarcoma and its association with acanthocytosis. Can Vet
J. 1981; 22: 152–155
[35]
Knowles S, Uhl EW, Blas-Machado U et al.: Intrapericardial ectopic thyroid carcinoma in a cat. J Vet Diagn Invest. 2010; 22: 1010–
1013
[36]
Kolm US, Kleiter M, Kosztolich A et al.: Benign intrapericardial
lipoma in a dog. J Vet Cardiol. 2002; 4: 25–29
[37]
LaRock RG, Ginn PE, Burrows CF et al.: Primary mesenchymal
chondrosarcoma in the pericardium of a dog. J Vet Diagn Invest.
1997; 9: 410–413
[12]
[13]
[14]
Brower A, Herold LV, Kirby BM: Canine cardiac mesothelioma with
granular cell morphology. Vet Pathol. 2006; 43: 384–387
Brown NO, Patnaik AK, MacEwen EG: Canine hemangiosarcoma:
retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985; 186:
56–58
Brown PJ, Rema A, Gartner F: Immunohistochemical characteristics of canine aortic and carotid body tumours. J Vet Med A Physiol
Pathol Clin Med. 2003; 50: 140–144
103
104
[38]
Linde A, Summerfield NJ, Sleeper MM et al.: Pilot study on cardiac
troponin I levels in dogs with pericardial effusion. J Vet Cardiol.
2006; 8: 19–23
[61]
Speltz MC, Manivel JC, Tobias AH et al.: Primary cardiac fibrosarcoma with pulmonary metastasis in a Labrador Retriever. Vet
Pathol. 2007; 44: 403–407
[39]
Lombard CW, Goldschmidt MH: Primary fibroma in the right
atrium of a dog. J Small Anim Pract. 1980; 21: 439–448
[62]
Tilley LP, Owens JM, Wilkins RJ: Pericardial mesothelioma with
effusion in a cat. J Am Anim Hosp Assoc. 1975; 11: 60–65
[40]
MacDonald KA, Cagney O, Magne ML: Echocardiographic and clinicopathologic characterization of pericardial effusion in dogs: 107
[63]
Venco L, Kramer L, Sola LB et al.: Primary cardiac rhabdomyosarcoma in a cat. J Am Anim Hosp Assoc. 2001; 37: 159–163
[64]
[41]
MacGregor JM, Faria ML, Moore AS et al.: Cardiac lymphoma and
pericardial effusion in dogs: 12 cases (1994–2004). J Am Vet Med
Assoc. 2005; 227: 1449–1453
Vicari ED, Brown DC, Holt DE et al.: Survival times of and prognostic indicators for dogs with heart base masses: 25 cases (1986–
1999). J Am Vet Med Assoc. 2001; 219: 485–487
[65]
[42]
Machida N, Hoshi K, Kobayashi M et al.: Cardiac myxoma of the
tricuspid valve in a dog. J Comp Pathol. 2003; 129: 320–324
Walter JH, Rudolph R: Systemic, metastatic, eu- and heterotope
tumours of the heart in necropsied dogs. Zbl Vet Med A. 1996; 43:
31–45
[43]
Machida N, Tanaka R, Takemura N et al.: Development of pericardial mesothelioma in golden retrievers with a long-term history of
idiopathic haemorrhagic pericardial effusion. J Comp Pathol. 2004;
131: 166–175
[66]
Ware WA, Hopper DL: Cardiac tumors in dogs: 1982–1995. J Vet
Intern Med. 1999; 13: 95–103
[67]
Warman SM, McGregor R, Fews D et al.: Congestive heart failure
caused by intracardiac tumours in two dogs. J Small Anim Pract.
2006; 47: 480–483
[68]
Weisse C, Soares N, Beal MW et al.: Survival times in dogs with
right atrial hemangiosarcoma treated by means of surgical resection with or without adjuvant chemotherapy: 23 cases (1986–
2000). J Am Vet Med Assoc. 2005; 226: 575–579
[69]
Williams JH: Lymphangiosarcoma of dogs: a review. J S Afr Vet
Assoc. 2005; 76: 127–131
[70]
Willis R, Williams AE, Schwarz T et al.: Aortic body chemodectoma causing pulmonary oedema in a cat. J Small Anim Pract.
2001; 42: 20–23
[71]
Wohlsein P, Cichowski S, Baumgartner W: Primary endocardial
malignant spindle-cell sarcoma in the right atrium of a dog resembling a malignant peripheral nerve sheath tumour. J Comp Pathol.
2005; 132: 340–345
[72]
Yates WD, Lester SJ, Mills JH: Chemoreceptor tumors diagnosed
at the Western College of Veterinary Medicine 1967–1979. Can Vet
J. 1980; 21: 124–129
[44]
Madarame H, Sato K, Ogihara K et al.: Primary cardiac fibrosarcoma in a dog. J Vet Med Sci. 2004; 66: 979–982
[45]
Mai W, Weisse C, Sleeper MM: Cardiac magnetic resonance imaging in normal dogs and two dogs with heart base tumor. Vet
[46]
Mansfield CS, Callanan JJ, McAllister H: Intra-atrial rhabdomyoma
causing chylopericardium and right-sided congestive heart failure in
a dog. Vet Rec. 2000; 147: 264–267
[47]
Mellanby RJ, Holloway A, Woodger N et al.: Primary chondrosarcoma in the pulmonary artery of a dog. Vet Radiol Ultrasound.
2003; 44: 315–321
[48]
Merlo M, Bo S, Ratto A: Primary right atrium haemangiosarcoma
in a cat. J Feline Med Surg. 2002; 4: 61–64
[49]
Müller P, Tschäppät R: Kardiales Hämangiosarkom bei einem
Hund. Schweiz Arch Tierheilkd. 2002; 144: 239–242
[50]
Noszczyk-Nowak A, Nowak M, Paslawska U et al.: Cases with
manifestation of chemodectoma diagnosed in dogs in Department
of Internal Diseases with Horses, Dogs and Cats Clinic, Veterinary
Medicine Faculty, University of Environmental and Life Sciences,
Wroclaw, Poland. Acta Vet Scand. 2010; 52: 35
24.2 Thymome und Tumoren des kranialen
Mediastinums
[51]
Obradovich JE, Withrow SJ, Powers BE et al.: Carotid body
tumors in the dog. Eleven cases (1978–1988). J Vet Intern Med.
1992; 6: 96–101
[1]
[52]
Ogilvie GK, Brunkow CS, Daniel GB et al.: Malignant lymphoma
with cardiac and bone involvement in a dog. J Am Vet Med Assoc.
1989; 194: 793–796
Aronsohn MG, Schunk KL, Carpenter JL et al.: Clinical and pathologig features of thymoma in 15 dogs. J Am Vet Med Assoc. 1984;
184: 1355–1362
[2]
Atwater SW, Powers BE, Park RD: Thymoma in dogs: 23 cases
(1980–1991). J Am Vet Med Assoc. 1994; 205: 1007–1013
[53]
Paltrinieri S, Riccaboni P, Rondena M et al.: Pathologic and immunohistochemical findings in a feline aortic body tumor. Vet Pathol.
2004; 41: 195–198
[3]
Coolman BR, Brewer WG, DʼAndrea GH et al.: Severe idiopathic
thymic hemorrhage in two littermate dogs. J Am Vet Med Assoc.
1994; 205: 1152–1153
[54]
Patnaik AK, Liu SK, Hurvitz AI et al.: Canine chemodectoma
(extra-adrenal paragangliomas) – a comparative study. J Small Anim
Pract. 1975; 16: 785–801
[4]
Day MJ: Review of thymic pathology in 30 cats and 36 dogs. J Small
Anim Pract. 1997; 38: 393–403
[5]
Dewey CW, Bailey CS, Shelton GD et al.: Clinical forms of acquired
myasthenia gravis in dogs: 25 cases (1988–1995). J Vet Int Med.
1997; 11: 50–57
[55]
Radi ZA, Metz A: Canine cardiac rhabdomyoma. Toxicol Pathol
2009; 37: 348–350
[56]
Sanford SE, Hoover DM, Miller RB: Primary cardiac granular cell
tumor in a dog. Vet Pathol. 1984; 21: 489–494
[6]
Dewey CW: Acquired myasthenia gravis in dogs – Part 1. Compend
Contin Educ Pract Vet. 1997; 19: 1340–1354
[57]
Sato T, Koie H, Shibuya H et al.: Extraskeletal osteosarcoma in the
pericardium of a dog. Vet Rec. 2004; 155: 780–781
[7]
Dhaliwal RS, Kitchell BE, Messick JB: Canine lymphosarcoma: clinical features. Compend Contin Educ Pract Vet. 2003; 25: 572–582
[58]
Schuller S, Van Israel N, Else RW: Third degree atrioventricular
block and accelerated idioventricular rhythm associated with a
heart base chemodectoma in a syncopal Rottweiler. J Vet Med A
[8]
Ducoté JM, Dewey CW, Coates JR: Clinical forms of acquired
myasthenia gravis in cats. Compend Contin Educ Pract Vet. 1999;
21: 440–448
[9]
[59]
Shaw SP, Rush JE: Canine pericardial effusion: pathophysiology and
cause. Compend Contin Educ Vet. 2007; 29: 400–403; quiz 404
Faissler D, Jurina K, Gaschen L et al: Peripheres Nervensystem und
Muskulatur. In: Jaggy A (Hrsg.): Atlas und Lehrbuch der Kleintierneurologie. Schlütersche Hannover 2005: 268–271
[60]
Sims CS, Tobias AH, Hayden DW et al.: Pericardial effusion due to
primary cardiac lymphosarcoma in a dog. J Vet Intern Med. 2003;
17: 923–927
[10]
Farrow CS: Veterinary diagnostic imaging. The dog and cat.
Volume I. Mosby St. Louis 2003; 388–391
[11]
Fidel JL, Pargass IS, Dark MJ et al.: Granulocytopenia associated
with thymoma in a domestic shorthaired cat. J Am Anim Hosp
Assoc. 2008; 44: 210–217
[34]
Shelton GD, Ho M, Kass PH: Risk factors for acquired myasthenia
gravis in cats: 105 cases (1986–1998). J Am Vet Med Assoc. 2000;
216: 55–57
[12]
Foley P, Shaw D, Runyon C et al.: Serum parathyroid hormonerelated protein concentration in a dog with a thymoma and persistent hypercalcemia. Can Vet J. 2000; 41: 867–870
[35]
Shelton GD, Schule A, Kass PH: Risk factors for acquired myasthenia gravis in dogs: 1154 cases (1991–1995). J Am Vet Med Assoc.
1997; 211: 1428–1431
[13]
Forster-Van Hijfte MA, Curtis CF, White RN: Resolution of exfoliative dermatitis and Malassezia pachydermatis overgrowth in a cat
after surgical thymoma resection. J Small Anim Pract. 1997; 38:
451–454
[36]
Scherrer W, Kyles A, Samii V et al.: Computed tomographic
assessment of vascular invasion and resectability of mediastinal
masses in dogs and a cat. New Zeal Vet J. 2008; 56: 330–333
[37]
[14]
Gores BR, Berg J, Carpenter JL et al.: Surgical treatment of thymoma in cats: 12 cases (1987–1992). J Am Vet Med Assoc.1994;
204: 1782–1785
Singh A, Boston SE, Poma R: Thymoma-associated exfoliative dermatitis with post-thymectomy myasthenia gravis in a cat. Can Vet J.
2010; 51: 757–760
[38]
[15]
Hunt GB, Churcher RK, Church DB et al.: Excision of a locally invasive thymoma causing cranial vena caval syndrome in a dog. J Am
Vet Med Assoc. 1997; 210: 1628–1630
Smith A: Extranodal lymphosarcoma. In August JR (Hrsg.): Consultations in feline internal medicine. 5. Auflage, St. Louis: Elsevier
Saunders 2006; 633–641
[39]
[16]
Hylands R: Veterinary diagnostic imaging. Thymoma. Can Vet J.
2006; 47: 593–596
Smith AN, Wright JC, Brawner WR et al.: Radiation therapy in the
treatment of canine and feline thymomas: a retrospective study
[17]
Kaser-Hotz B, Rohrer RR, Fidel JL et al.: Radiotherapy in three
suspect cases of feline thymoma. J Am Anim Hosp Assoc. 2001; 37
(5): 483–488
[40]
Smits B, Reid MM: Feline paraneoplastic syndrome associated with
thymoma. New Zeal Vet J. 2003; 51: 244–247
[41]
[18]
Kessler M, Kandel B: Chemotherapie des malignen Lymphoms
beim Hund: Ergebnisse und Erfahrungen mit dem „Hofheimer Protokoll“ bei 57 Patienten. Kleintierprax. 2004; 49: 341–408
Spadavecchia C, Jaggy A: Thymectomy in a cat with myasthenia
gravis: a case report focusing on perianaesthetic management.
[42]
[19]
Kirchhoff A, Walter JH: Thymome bei der Katze: Makroskopische,
histologische und immunohistochemische Befunde. Kleintierprax.
1996; 41: 177–184
Takanami I, Abiko T, Koizumi S: Therapeutic outcomes in thymectomied patients with myasthenia gravis. Ann Thorac Cardiovasc
Surg. 2009; 15: 373–377
[43]
[20]
Klebanow ER: Thymoma and acquired myasthenia gravis in the
dog: a case report and review of 13 additional cases. J Am Anim
Hosp Assoc. 1992; 28: 63–69
Teske E: Canine malignant lymphoma: a review and comparison
with human non-Hodgkinʼs lymphoma. Vet Q. 1994; 16: 209–219
[44]
Lainesse MFC, Taylor SM, Myers SL et al.: Focal myasthenia gravis
as a paraneoplastic syndrome of canine thymoma: Improvement
following thymectomy. J Am Anim Hosp Assoc. 1996; 32: 111–117
Uchida K, Awamura YA, Nakamura T et al: Thymoma and multiple
thymic cysts in a dog with acquired myasthenia gravis. J Vet Med
Sci. 2002; 64: 637–640
[45]
Van Oosterhout IC, Teske E, Vos JH et al.: Myasthenia gravis and a
thymoma in a cat. Tijdschr Diergeneeskd. 1989; 114: 499–504
[22]
Lana S, Plaza S, Hampe K et al.: Diagnosis of mediastinal masses in
dogs by flow cytometry. J Vet Int Med. 2006; 20: 1161–1165
[46]
Vilafranca M, Font A: Thymolipoma in a cat. J Feline Med Surg.
2005; 7: 125–127
[23]
Leppin R: Die Computertomographie in der Diagnostik peri- und
parakardialer Erkrankungen bei Hund und Katze. Kleintierprax.
2005; 50: 137–212
[47]
Wood SL, Rosenstein DS, Bebchuk T: Myasthenia gravis and thymoma in a dog. Vet Rec. 2001; 148: 573–574
[48]
[24]
Malik R, Gabor L, Hunt GB et al.: Benign cranial mediastinal lesions
in three cats. Austr Vet J. 1997; 75: 183–193
Yoon J, Feeney DA, Cronk DE et al.: Computed tomographic evaluation of canine and feline mediastinal masses in 14 patients. Vet
[25]
Marie JP, Lacoume YL, Laquierrière A et al.: Diaphragmatic effects
of selective resection of the upper phrenic nerve root in dogs.
Respir Physiol Neurobiol. 2006; 154: 419–430
[49]
Zitz JC, Birchard SJ, Couto GC et al.: Results of excision of thymoma in cats and dogs: 20 cases (1984–2005). J Am Vet Med
Assoc. 2008; 232: 1186–1192
[26]
Mayhew PD, Friedberg JS: Video-assisted thoracoscopic resection
of noninvasive thymomas using one-lung ventilation in two dogs.
Vet Surg. 2008; 37: 756–762
[27]
Mears EA, Jenkins CC: Canine and feline megaesophagus. Vet Clin
Small Anim. 1997; 19: 313–326
[28]
Meleo KA: The role of radiotherapy in the treatment of lymphoma
and thymoma. Vet Clin Small Anim. 1997; 27: 115–129
[1]
Andrews EJ: Pleural mesothelioma in a cat. J Comp Pathol. 1973;
83: 259–263
[29]
Patnaik AK, Lieberman PH, Erlandson RA et al.: Feline cystic thymoma: a clinicopathologic, immunohistologic, and electron microscopic study of 14 cases. J Feline Med Surg. 2003; 5: 27–35
[2]
Bacci B, Morandi F, De Meo M et al.: Ten cases of feline mesothelioma: an immunohistochemical and ultrastructural study. J Comp
Pathol. 2006; 134: 347–354
[30]
Rogers KS, Walker MA: Disorders of the mediastinum. Vet Clin
Small Anim. 1997; 19: 69–82
[3]
Betta PG: Recent advances in the biology of diffuse malignant
mesothelioma. Cancer J. 1992; 5: 249–253
[31]
Rusbridge C, White RN, Elwood CM et al.: Treatment of acquired
myasthenia gravis associated with thymoma in two dogs. J Small
Anim Pract. 1996; 36: 376–380
[4]
Breeze RG, Lauder IM: Pleural mesothelioma in a dog. Vet Rec.
1975; 96: 243–246
[5]
[32]
Scillia P, Capello M, De Troyer A: Determinants of diaphragm
motion in unilateral diaphragmatic paralysis. J Appl Physiol. 2004;
96: 96–100
Med Assoc. 2006; 229: 980–983
[6]
[33]
Scott-Moncrieff JC, Cook JR, Lantz GC: Acquired myasthenia gravis
in a cat with thymoma. J Am Vet Med Assoc. 1990; 196: 1291–
1293
Brunner P: Papillary-polypous mesothelioma of the pericardium of
a dog. Virchows Arch Abt A Path Anat. 1972; 357: 275–280
[21]
25 Tumoren der Pleura und des Peritoneums
(Mesotheliom)
105
106
[7]
Closa JM, Font A, Mascort J: Pericardial mesothelioma in a dog:
long-term survival after pericardiectomy in combination with chemotherapy. J Small Anim Pract. 1999; 40: 383–386
[8]
[31]
Corson JM: Pathology of mesothelioma. Thorac Surg Clin. 2004;
14: 447–460
Liptak JM, Brebner NS: Hemidiaphragmatic reconstruction with a
transversus abdominis muscle flap after resection of a solitary
diaphragmatic mesothelioma in a dog. J Am Vet Med Assoc. 2006;
228: 1204–1208
[32]
[9]
Craig JA, Helman RG, Walker M: Costal bone changes similar to
hypertrophic osteopathy associated with pulmonary and abdominal
mesothelioma in a dog. J Am Vet Med Assoc. 1985; 186: 1100–1101
Liu KX, Bird AE, Lenz SD et al.: Antigenexpression in normal and
neoplastic canine tissues defined by a monoclonal antibody generated against canine mesothelial cells. Vet Pathol. 1994; 31: 663–673
[33]
[10]
De Nardo P: Veterinary environmental epidemiology: the case of
respiratory pathology in the dog. Ann 1st Super Sanita. 1997; 33:
587–593
Loupal G: Beitrag zum Vorkommen von Mesotheliomen bei Hunden. Zbl Vet Med A. 1982; 29: 538–546
[34]
MacDonald KA, Cagney O, Magne ML: Echocardiographic and clinicopathologic characterization of pericardial effusion in dogs: 107
[35]
Machida N, Tanaka R, Takemura N et al.: Development of pericardial mesothelioma in Golden Retrievers with a long-term history of
idiopathic haemorrhagic pericardial effusion. J Comp Pathol. 2004;
131: 166–175
[36]
McDonald JC: Epidemiology of malignant mesothelioma – An outline. Ann Occup Hyg. 2010; 54: 851–857
[37]
McDonough SP, MacLachlan NJ, Tobias AH: Canine pericardial
mesothelioma. Vet Pathol. 1992; 29: 256–260
[38]
Mirabella F: Epidemiologic study of spontaneous mesothelioma in
dogs: its possible usefulness in reference to human pathology. Med
Lav. 1987; 78: 28–32
[39]
Misdorp W: Tumours in calves: comparative aspects. J Comp
Pathol. 2002; 127: 96–105
[40]
Moore AS, Kirk C, Cordona A: Intracavitary Cisplatin chemotherapy experience with six dogs. J Vet Int Med. 1991; 5: 227–231
[41]
Ogilvie GK, Reynolds HA, Richardson RC et al.: Phase II evaluation
Med Assoc. 1989; 195: 1580–1583
[42]
Ogilvie GK, Obradovich JE, Elmslie RE et al.: Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc. 1991;
198: 1618–1621
[43]
van Ooijen PG: Diffuse mesothelioma in the dog. Tijdschr Diergeneeskd. 1978; 20: 1116–1120
[44]
Raflo CP, Nuernberger SP: Abdominal mesothelioma in a cat. Vet
Pathol. 1978; 15: 781–783
[45]
Ramael M, Van Meerbeek J, Van Merck E: Mesothelioma: Current
insights. Cancer J. 1994; 7: 174–180
[46]
Ressel L, Poli A: Simultaneous double labelling of routinely processed paraffin tissue sections using combined immunoperoxidase,
immunofluorescence, and digital image editing. Res Vet Sci. 2010;
88: 122–126
[47]
Rice TW, Adelstien DJ, Kirby TJ et al.: Aggressive multimodality
therapy for malignant pleural mesothelioma. Ann Thorac Surg.
1994; 58: 24—29
[11]
DiPinto MN, Dunstan RW, Lee C: Cystic, peritoneal mesothelioma
[12]
Dubielzig RR: Sclerosing mesothelioma in five dogs. J Am Anim
Hosp Assoc. 1979; 15: 745–748
[13]
Dunning D, Monnet E, Orton EC et al.: Analysis of prognostic indicators for dogs with pericardial effusion: 46 cases (1985–1996). J
Am Vet Med Assoc. 1998; 212: 1276–1280
[14]
Echandi RL, Morandi F, Newman SJ et al.: Imaging diagnosis –
canine thoracic mesothelioma. Vet Radiol Ultrasound. 2007; 48:
243–245
[15]
Espino L, Vazquez S, Faílde D et al.: Localized pleural mesothelioma causing cranial vena cava syndrome in a dog. J Vet Diagn
Invest. 2010; 22: 309–312
[16]
Fine DM, Tobias AH, Jacob KA: Use of pericardial fluid pH to distinguish between idiopathic and neoplastic effusions. J Vet Intern
Med. 2003; 17: 525–529
[17]
Geib LW, de Navarez F, Clifford HE: Pleural mesothelioma in a
Dog. J Am Vet Med Assoc. 1962; 140: 1317–1319
[18]
Glickman LT, Domanski LM, Maguire TG et al.: Mesothelioma in
pet dogs associated with exposure of their owners to asbestos. Environmental Res. 1983; 32: 305–313
[19]
Harbison ML, Godleski JJ: Malignant mesothelioma in urban dogs.
Vet Pathol. 1983; 20: 531–540
[20]
Head KW, Else RW, Dubielzig R: Tumors of serosal surfaces. In:
Meuten DJ (Hrsg.): Tumors of domestic animals. 4. Aufl., Iowa State
Press, Ames 2002; S. 365–399
[21]
Hirschberger J, Pusch S: Fibronectin concentrations in pleural and
abdominal effusions in dogs and cats. J Vet Intern Med. 1996; 10:
321–325
[22]
Humphrey EW, Ewing SL, Wrigley JV et al.: The production of
malignant tumors of the lung and pleura in dogs from intratracheal
asbestos instillation and cigarette smoking. Cancer. 1981; 47:
1994–1999
[23]
Ikede BO, Zubaidy A, Gill CW: Pericardial mesothelioma with cardiac tamponade in a dog. Vet Pathol. 1980; 17: 496–500
[24]
Jaurand MC, Fleury-Feith J: Pathogenesis of malignant pleural
mesothelioma. Respirology. 2005; 10: 2–8
[48]
Rinke M, Rosenbruch M: Pleural mesothelioma in a young cat.
Dtsch Tierarztl Wochenschr. 2003; 110: 177–178
[25]
Kasbohm C, Bembardt C: Das Mesotheliom des Hundes aus zytologischer und histologischer Sicht. Tierärztl Prax. 1977; 5: 379–388
[49]
Rollins KD, Lindley C: Permetrexed: a multitargeted antifolate. Clin
Ther. 2005; 27: 1343–1382
[26]
Kerstetter KK, Krahwinkel DJ, Millis DL et al.: Pericardectomy in
740
[50]
[27]
Kim JH, Choi YK, Yoon HY et al.: Juvenile malignant mesothelioma
in a dog. J Vet Med Sci. 2002; 64: 269–271
Roggli VL, Gibbs AR, Attanoos R et al.: Pathology of asbestosis –
An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary
pathology society. Arch Pathol Lab Med. 2010; 134: 462–480
[51]
[28]
Lara A, Kosarek C, Hosoya K et al.: Palliative management of
malignant effusion with implantable vascular access ports in dogs.
In: Proc Ann Congress European Society of Veterinary Oncology
2007, Cambridge, England, 14
Rostami M, Tateyama S, Uchida K et al.: Tumors in domestic animals examined during a ten-year period (1980 to 1989) at Miyazaki
University. J Vet Med Sci. 1994; 56: 403–405
[52]
Schaer M, Meyer D: Benign peritoneal mesothelioma, hyperthyroidism, nonsuppurative hepatitis, and chronic disseminated intravascular coagulation in a cat: A case report. J Am Anim Hosp Assoc.
1988; 24: 195–202
[53]
Schoning P, Layton CE, Fortney WD et al: Sclerosing peritoneal
mesothelioma in a dog evaluated by electron microscopy and
immunoperoxidase techniques. J Vet Diagn Invest. 1992; 4: 217–
220
[29]
Leisewitz AL, Nesbit JW: Malignant mesothelioma in a seven-week
old puppy. J S Afr Vet Assoc. 1992; 63: 70–73
[30]
Lew F, Tsang P, Holland JF et al.: High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol. 1986; 6: 225–233
[54]
Seo KW, Choi US, Jung YC et al.: Palliative intravenous cisplatin
treatment for concurrent peritoneal and pleural mesothelioma in a
dog. J Vet Med Sci. 2007; 69: 201–204
[55]
Sparkes A, Murphy S, McConnell F et al.: Palliative intracavitary
carboplatin therapy in a cat with suspected pleural mesothelioma. J
Feline Med Surg. 2005; 7: 313–316
[56]
Spugnini EP, Crispi S, Scarabello A et al.: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced
mesothelioma in pets: preliminary observations. J Exp Clin Cancer
Res. 2008; 27: 6
[11]
Berg J, Weinstein MJ, Schelling SH et al.: Treatment of dogs with
osteosarcoma by administration of cisplatin after amputation or
limb-sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc.
1992; 200: 2005–2008
[12]
Berg J, Weinstein MJ, Springfield DS et al.: Results of surgery and
doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet
Med Assoc. 1995; 206: 1555–1559
[13]
Bergman PJ: Practitionerʼs guide to chemotherapy in the 90ʼs.
Hand-out 1994; Colorado State University Comparative Oncology
Unit
[14]
Biller BJ, Guth A, Burton JH et al.: Decreased ratio of CD8+ T cells
to regulatory T cells associated with decreased survival in dogs with
osteosarcoma. J Vet Intern Med. 2010; 24: 1118–1123
[57]
Stepien RL, Whitley NT, Dubielzig RR: Idiopathic or mesothelioma-related pericardial effusion: clinical findings and survival in 17
dogs studied retrospectively. J Small Anim Pract. 2000; 41: 342–
347
[15]
[58]
Taryle DA, Lakshminarayan S, Sahn SA: Pleural Mesothelioma –
An analysis of 18 cases and review of the literature. Medicine (Baltimore). 1976; 55: 153–162
Bingel SA: Hemangiosarcoma of bone in the dog. J Small Anim
Pract. 1974; 15: 303–307
[16]
Böhm P, Scherer MA: Incorporation of devitalized autografts in
dogs. Int Orthop. 1997; 21: 283–290
[59]
Tilley LP, Owens JM, Wilkins RJ et al.: Pericardial mesothelioma
with effusion in a cat. J Am Anim Hosp Assoc. 1975; 11: 60–65
[17]
[60]
Thrall DE, Goldschmidt MH: Mesothelioma in the dog: six case
reports. J Am Vet Radiol Soc. 1978; 19: 107–115
Böhm P: Die Replantation extrakorporal devitalisierter Knochenresektate als Defektrekonstruktion in der Tumororthopädie – eine
Übersicht. Z Orthop. 1998; 136: 197–204
[18]
[61]
Umphlet RC, Bertoy RW: Abdominal mesotheliom in a cat. Mod
Vet Pract. 1988; 69: 71–73
Böhm P, Fritz J, Thiede S et al.: Re-implantation of extracorporal
irradiated bone segments in musculoskeletal tumor surgery. Langenbeckʼs Arch Surg. 2003; 387: 355–365
[62]
Waite K, Gilligan D: The role of radiotherapy in the treatment of
malignant pleural mesothelioma. Clin Oncol. 2007; 19: 182–187
[19]
[63]
Weiss AT, da Costa AB, Klopfleisch R: Predominantly fibrous
malignant mesothelioma in a cat. Vet Med Int. 2010; 396794. Epub
2010 Jun 15
Boston SE, Ehrhart NP, Dernell WS et al.: Evaluation of survival
time in dogs with stage III osteosarcoma that undergo treatment:
[20]
Wolf AS, Richards WG, Tilleman TR et al.: Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg. 2010; 90:
949–956
Boston SE, Duerr F, Bacon N et al.: Intraoperative radiation for
limb sparing of the distal aspect of the radius without transcarpal
plating in five dogs. Vet Surg. 2007; 36: 314–323
[21]
Bright RM: Reconstruction of thoracic wall defects using Marlex
mesh. J Am Anim Hosp Assoc. 1981; 17: 415–420
[22]
Britt T, Clifford C, Barger A et al.: Diagnosing appendicular osteosarcoma with ultrasound-guided fine-needle aspiration: 36 cases. J
[23]
Brodey RS, Abt DA: Results of surgical treatment in 65 dogs with
osteosarcoma. J Am Vet Med Assoc. 1976; 168: 1032–1035
[64]
26 Tumoren des Skeletts
26.1 Knochentumoren des Hundes
[1]
Allen SW, Duncan JR: Malignant fibrous histiocytoma in a cat. J Am
Vet Med Assoc. 1988; 192: 90–91
[24]
Brodey RS, Riser WH: Canine osteosarcoma: A clinicopathological
study of 194 cases. Clin Orthop. 1969; 62: 54–64
[2]
Anderson MA, Dambach DM, Sorenmo K et al.: Extraskeletal
osteosarcomas in dogs: a retrospective study of 169 cases (1986–
[25]
Brodey RS, Misdorp W, Riser WH et al.: Canine skeletal chondrosarcoma: a clinicopathologic study of 35 cases. J Am Vet Med
Assoc. 1974; 165: 68–78
[3]
Ansari MM: Bone Infarcts associated with malignant sarcomas.
Comp Contin Educ Pract Vet. 1991; 13: 367–370
[26]
Brodey RS, Sauer RM, Medway W: Canine bone neoplasms. J Am
Vet Med Assoc. 1963; 143: 471–495
[4]
Ashton JA, Farese JP, Milner RJ et al.: Investigation of the effect of
pamidronate disodium on the in vitro viability of osteosarcoma cells
from dogs. Am J Vet Res. 2005; 66: 885–891
[27]
Brown NO: Canine hemangiosarcoma: Retrospective analysis 104
cases. J Am Vet Med Assoc. 1985; 186: 56–61
[28]
[5]
Bacon NJ, Ehrhart NP, Dernell WS et al.: Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic
metastases after amputation for appendicular osteosarcoma: 50
Calhoun JH, Mader JT: Antibiotic beads in the management of surgical infection. Am J Surg. 1989; 157: 443–449
[29]
Chester, DK: Multiple cartilaginous exostoses in two generations of
[30]
[6]
Bailey D, Erb H, Williams L et al.: Carboplatin and doxorubicin
combination chemotherapy for the treatment of appendicular
osteosarcoma in the dog. J Vet Int Med. 2003; 17: 199–205
Chun R, Garrett LD, Henry C et al.: Toxicity and efficacy of cisplatin
and doxorubicin combination chemotherapy for the treatment of
canine osteosarcoma. J Am Anim Hosp Assoc. 2005; 41: 382–7
[31]
[7]
Bech-Nielsen S, Haskins ME, Reif JS et al.: Frequency of osteosarcoma among first-degree relatives of St. Bernard dogs. J Natl Cancer
Inst. 1978; 60: 349–353
Cooley DM, Waters DJ: Skeletal neoplasms of small dogs: A retrospective study and literature review. J Am Anim Hosp Assoc. 1997;
33: 11–23
[32]
[8]
Belli L: Resection of pulmonary metastases in osteosarcoma: A retrospective analysis of 44 patients. Cancer. 1989; 63: 2546–2552
Coomer A, Farese J, Milner R et al.: Radiation therapy for canine
appendicular osteosarcoma. Vet Comp Oncol. 2009; 7: 15–27
[33]
[9]
Berg J: Canine osteosarcoma: Amputation and chemotherapy. Vet
Clin North Am Sm Anim Pract. 1996; 26: 111–121
Craig LE, Julian ME, Ferracone JD: The diagnosis and prognosis of
synovial tumors in dogs: 35 cases. Vet Pathol. 2002; 39: 66–73
[34]
[10]
Berg J, Gliatto JM, Wallace MK: Giant cell tumor of the accessory
carpal bone in a dog. J Am Vet Med Assoc. 1990; 197: 883–885
Crawford C, Rosenberger J: Risk for osteosarcoma in greyhounds.
Proc. VCS Symposium on canine osteosarcoma. Sedona, USA, 2006,
[35]
Crow SE: Primary hemangiosarcoma of the femur in a dog. Mod
Vet Pract. 1977; 58: 343–348
107
108
[36]
Dasgeb B, Mulligan MH, Kim CK: The current status of bone scintigraphy in malignant diseases. Semin Musculoskelet Radiol. 2007;
11: 301–311
[57]
Farese JP, Milner R, Thompson MS et al.: Stereotactic radiosurgery
for treatment of osteosarcomas involving the distal portions of the
limbs in dogs. J Am Vet Med Assoc. 2004; 125: 1567–1572
[37]
DeRegis CJ, Moore AS, Rand WM et al.: Cisplatin and doxorubicin
toxicosis in dogs with osteosarcoma. J Vet Intern Med. 2003; 17:
668–673
[58]
Farese JP, Ashton J, Milner R et al.: The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro.
In Vitro Cell Dev Biol Anim. 2004; 40: 113–117
[38]
Dernell WS, Ehrhart NP, Straw RC et al.: Tumors of the skeletal
system. In: Withrow, SJ, Vail DM (Hrsg.): Small Animal Clinical Oncology. Saunders, St Louis 2007; 540–584
[59]
[39]
Dernell WS, Schwarz PD, Withrow SJ: Mandibulectomy. In: Bojrab
MJ (Hrsg.): Current techniques in small animal surgery. Williams
and Wilkens, Baltimore 1998; 132–142
Farese JP, Kirpensteijn J, Kik M et al.: Biologic behavior and clinical
outcome of 25 dogs with canine appendicular chondrosarcoma
treated by amputation: a Veterinary Society of Surgical Oncology
retrospective study. Vet Surg. 2009; 38: 914–919
[60]
Feeney DA, Johnston GR, Grindem CB: Malignant neoplasia of
canine ribs. J Am Vet Med Assoc. 1982; 180: 927–933
[61]
Florian S, Scharvogel S, Böttcher P et al.: Das Synovialzellsarkom.
Eine Übersicht mit Fallbeispielen. Abstr. DGK-JT. 2007
[40]
Dernell WS, Straw RC, Cooper MF: Multilobular osteochondrosarcoma in 39 dogs: 1979–1993. J Am Anim Hosp Assoc. 1998; 34:
11–18
[62]
[41]
Dernell WS, Straw RC, Powers BE et al.: Correlation between survival and increasing doses of cisplatin for the treatment of appendicular osteosarcoma. Proc 13th Ann Conf Vet Cancer Soc. 1993; 92–
93
Forrest LJ, Thrall DE: Bone scintigraphy for metastasis detection in
canine osteosarcoma. Vet Rad Ultrasound. 1994; 35: 124–130
[63]
Dernell WS, VanVechten BJ, Straw RC et al.: Outcome following
treatment for vertebral tumors in 20 dogs (1986–1995). J Am
Anim Hosp Assoc. 2000; 36: 245–251
Gallegos J, Schwarz T, McAnulty JF: Massive midline occipitotemporal resection of the skull for treatment of multilobular osteochondrosarcoma in two dogs. J Am Vet Med Assoc. 2008; 233:
752–7
[64]
Dickerson ME, Page RL, LaDue TA et al.: Retrospective analysis of
axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern
Med. 2001; 15: 120–124
Gamblin RM, Straw RC, Powers BE et al.: Primary osteosarcoma
distal to the antebrachiocarpal and tarsocrural joints in nine dogs
[65]
Garma RH, Powel FR, Tompsett JW: Malignant giant cell tumor in
a dog. J Am Vet Med Assoc. 1977; 171: 546–548
[42]
[43]
[44]
Dieckmann R, Streitbürger A, Balke M et al.: Modulare endoprothetische Rekonstruktionen bei malignen Knochentumoren. OpJournal 2010; 26: 186–191
[66]
Garzotto C, Berg J: Oncology, musculoskeletal system. In: Slatter D
(Hrsg.): Textbook of Small Animal Surgery. Saunders, Philadelphia
2003; 2460–2474
[45]
DiResta GR, Aiken SW, Brown HK et al.: Influence of carboplatin
infusion on osteosarcoma blood flow. Cancer Chemother Pharmacol. 2008; 62: 545–549
[67]
Garzotto CK, Berg J, Hoffmann WE et al.: Prognostic significance
of serum alkaline phosphatase activity in canine appendicular
osteosarcoma. J Vet Int Med. 2000; 14: 587–592
[46]
Dubielzig TF, Biery DN, Brodey RS: Bone sarcomas associated with
multifocal medullary bone infarction in dogs. J Am Vet Med Assoc.
1981; 179: 64–68
[68]
Gellasch KL, Kalscheur VL, Clayton MK et al.: Fatigue microdamage in the radial predilection site for osteosarcoma in dogs. Am J
Vet Res. 2002; 63: 896–899
[47]
Egenvall A, Nodtvedt A, Von Euler H: Bone tumors in a population
of 400.000 insured Swedish dogs up to 10y of age: incidence and
survival. Can J Vet Res. 2007; 71: 292–294
[69]
[48]
Ehrhart N: Longitudinal bone transport for treatment of primary
bone tumors in dogs: technique description and outcome in 9
dogs. Vet Surg. 2005; 34: 24–34
Gibbs C, Denny HR, Lucke VM: The radiological features of nonosteogenic malignant tumours of bone in the appendicular skeleton
of the dog: a review of thirty-four cases. J Small Anim Pract. 1985;
26: 537–553
[70]
Gibson KL, Blass CE, Simpson M et al.: Malignant fibrous histiocytoma in a cat. J Am Vet Med Assoc. 1989; 194: 1443–1445
[71]
Gilson SD: Neuro-oncological surgery of the vertebral column and
spinal cord. In: Slatter DH (Hrsg.): Textbook of small animal surgery.
Saunders, Philadelphia 2003; 1277–1286
[72]
Gösling T, Brunemmer U, Länger F et al.: Primäre Knochentumoren – allgemeine Grundlagen. Op-Journal 2010; 26: 162–170
[73]
Goldschmidt MH, Thrall DE: Malignant bone tumors in the dog. In:
Newton CO, Nunamaker DM (Hrsg.): Textbook of Small Animal
Orthopedics. JB Lippincott, Philadelphia 1985; 887–902
[74]
Gorman E, Barger AM, Wypij JM et al.: Cutaneous metastasis of
primary appendicular osteosarcoma in a dog. Vet Clin Pathol. 2006;
35: 358–361
[75]
Häni H, Lang J, Heider K et al.: Osteosarcoma of the distal femur,
combined with multiple bone infarcts: the case of a 10–year-old
poodle Tierärztl Prax. 1988; 16: 303–306
[76]
Hahn KA, Richardson RC, Blevins WE et al.: Intramedullary cisplatin chemotherapy: experience in four dogs with osteosarcoma. J
[77]
Halfacree ZJ, Baines SJ, Lipscomb VJ et al.: Use of a latissimus
dorsi myocutaneous flap for one-stage reconstruction of the thoracic wall after en bloc resection of primary rib chondrosarcoma in
five dogs. Vet Surg. 2007; 36: 587–592
[78]
Hammer AS, Weeren RF, Weisbrode SE et al.: Prognostic factors
in dogs with osteosarcomas of the flat or irregular bones. J Am
Anim Hosp Assoc. 1995; 31: 321–326
[49]
Ehrhart N, Dernell WS, Hoffmannn WE et al.: Prognostic importance of alkaline phosphatase activity in serum from dogs with
appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med
Assoc. 1998; 213: 1002–1006
[50]
Enneking WF: Musculoskeletal tumor staging: 1988 update. Cancer Treat Res. 1989; 44: 39–49
[51]
Fan TM, de Lorimer LP, Carney SC et al.: Evaluation of intravenous
pamidronate administration in 33 cancer-bearing dogs with primary
or secondary bone involvement. J Vet Int Med. 2005; 19: 659–664
[52]
Fan TM, de Lorimier LP, Garrett LD, Lacoste HI: The bone biologic
effects of zoledronate in healthy dogs and dogs with malignant
osteolysis. J Vet Intern Med. 2008; 22: 380–387
[53]
Fan TM, de Lorimier LP, OʼDell-Anderson K et al.: Single-agent
pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2007; 21: 431–439
[54]
Fan TM: The Role of bisphosphonates in the management of
patients that have cancer. Vet Clin North Am Small Anim Pract.
2007; 37: 1091–1110
[55]
Fan TM: Therapeutic applications of aminobiphosphonates for treating canine osteosarcoma: present and future. Proc Vet Cancer Soc
Symposium on Canine Osteosarcoma Sedona, 2006; 53–54
[56]
Fan TM, Charney SC, de Lorimier LP et al.: Double-blind placebocontrolled trial of adjuvant pamidronate with palliative radiotherapy
and intravenous doxorubicin for canine appendicular osteosarcoma
bone pain. J Vet Intern Med. 2009; 23: 152–60
109
[79]
Hardy WD: Osteosarcoma of the canine skull. J Am Vet Radiol Soc.
1967; 8: 5–8
[102] Kotz R, Krisch K, Lack W: Hochdosierte Methotrexat-Behandlung
bei osteogenem Sarkom. Arzneim Forsch. 1980; 1953–1956
[80]
Henrichs MP, Streitbürger A, Dieckmann R et al.: Die Biopsie von
Knochentumoren. OP-Journal 2010; 26: 172–177
[81]
Hernigou PH, Thiery JP, Benoit J et al.: Methotrexate diffusion
from acrylic cement. J. Bone Joint Surg. 1989; 71: 804–811
[103] Kramer A, Walsh PJ, Seguin B: Hemipelvectomy in dogs and cats:
technique overview, variations, and description. Vet Surg. 2008; 37:
413–419
[82]
Heyman SJ, Diefenderfer DL, Goldschmidt MH et al.: Canine axial
skeletal osteosarcoma: A retrospective study of 116 cases (1986–
1989). Vet Surg. 1992; 21: 304–310
Hidaka Y, Hagio M, Uchida K et al.: Primary hemangiosarcoma of
the humerus in a Maltese dog. J Vet Med Sci. 2006; 68: 895–898
[84]
Hillers KR, Dernell WS, Lafferty MH et al.: Incidence and prognostic importance of lymph node metastases in dogs with appendicular
osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc. 2005;
226: 1364–1367
[85]
Hovy L: Experimentelle Untersuchungen zur lokalen Knochentumor-Therapie. Habilitationsschrift, Frankfurt am Main 1993
[86]
Jankowski MK, Steyn PF, Lana SE et al.: Nuclear scanning with
99mTc-HDP for the initial evaluation of osseous metastasis in
canine osteosarcoma. Vet Comp Oncol. 2003; 1: 152–158
[87]
[88]
Jeys LM, Grimer GJ, Carter SR et al.: Post operative infection and
increased survival in osteosarcoma patients: are they associated?
Ann Surg Onc. 2007; 10: 1245–1254
Jehn CT, Lewis DD, Farese JP et al.: Transverse ulnar bone transport osteogenesis: a new technique for limb salvage for the treatment of distal radial osteosarcoma in dogs. Vet Surg. 2007; 36:
324–334
[89]
Jongeward SJ: Primary bone tumors. Vet Clin North Am. 1985; 15:
609–641
[90]
Kent MS, Strom A, London CA et al.: Alternating carboplatin and
doxorubicin as adjunctive chemotherapy to amputation or limbsparing surgery in the treatment of appendicular osteosarcoma in
dogs. J Vet Int Med. 2004; 18: 540–544
[91]
Kessler M, von Bomhard D: Lokalisations- und Rasseverteilung von
Osteosarkomen bei kleinen und mittleren Hunderassen. Auswertung von 28 Fällen (unveröffentlicht), 1998
[105] Kuntz CA, Asselin TL, Dernell WS et al.: Limb salvage surgery for
osteosarcoma of the proximal humerus: outcome in 17 dogs. Vet
Surg. 1998; 27: 417–422
[106] Kuntz CA, Dernell WS, Powers BE et al.: Extraskeletal osteosarcomas in dogs: 14 cases. J Am Anim Hosp Assoc. 1998; 34: 26–30
[107] Langley-Hobbs SJ, Carmichael S, Lamb CR et al.: Polyostotic lymphoma in a young dog: a case report and literature review. J Small
Anim Pract. 1997; 38: 412–6
[108] Langova V, Straw RC, Mutsaers A et al.: Treatment of canine
osteosarcoma with surgery, carboplatin, doxorubicin and piroxicam.
Aust Vet Pract. 2004; 34: 98–102
[109] Lansdowne JL, Monnet E, Twedt DC et al.: Thoracoscopic lung
lobectomy for treatment of lung tumors in dogs. Vet Surg. 2005;
34: 530–535
[110] Lara A, Couto CG, Crawford C et al.: Clinicopathologic features of
appendicular osteosarcoma in retired racing greyhounds. Proc.
VCS Symposium on canine osteosarcoma, Sedona, USA, 2006, 17
[111] Lascelles BD, Dernell WS, Cafferty MT et al.: Improved survival
associated with postoperative wound infection in dogs treated with
limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005; 12:
1073–1083
[112] Lascelles BD, Thomson MJ, Dernell WS et al.: Combined dorsolateral and intraoral approach for the resection of tumors of the
maxilla in the dog. J Am Anim Hosp Assoc. 2003; 39: 294–305
[113] LeCouteur RA, Nimmo JS, Price SM et al.: A case of giant cell
tumor of bone (osteoclastoma) in a dog. J Am Vet Med Assoc.
1978; 14: 356–362
[114] Leibman NF, Kuntz CA, Steyn PF et al.: Accuracy of radiography,
nuclear scintigraphy, and histopathology for determining the proximal extent of distal radius osteosarcoma in dogs. Vet Surg. 2001;
30: 240–245
[92]
Kim H, Nakaichi M, Itamoto K et al.: Primary chondrosarcoma in
the skull of a dog. J Vet Sci. 2007; 8: 99–101
[93]
Kim SY, Helman LJ: Strategies to explore new approaches in the
investigation and treatment of osteosarcoma. Cancer Treat Res.
2009; 152: 517–528
[94]
Kistler KR: Canine osteosarcoma: 1462 cases reviewed to uncover
patterns of height, weight, breed, sex, age and site involvement.
Phi Zeta Awards, Univ of Pennsylvania, School of Vet Medicine,
1981
[116] Liptak JM, Dernell WS, Lascelles BD et al.: Intraoperative extracorporeal irradiation for limb sparing in 13 dogs. Vet Surg. 2004; 33:
446–456
[95]
Kirpensteijn J, Straw RC, Pardo AD et al.: Partial and total scapulectomy in the dog. J Am Anim Hosp Assoc. 1994; 30: 313–319
[96]
Kirpensteijn J, Kik M, Rutteman GR et al.: Prognostic significnace
of a new histologic grading system for canine osteosarcoma. Vet
Pathol. 2002; 39: 240–246
[117] Liptak JM, Dernell WS, Straw RC et al.: Proximal radial and distal
humeral osteosarcoma in 12 dogs. J Am Anim Hosp Assoc. 2004;
40: 461–467
[97]
[98]
[99]
Klahn S, Dervisis N, Kitchell B: A retrospective analysis of 19 cases
of periarticular histiocytic sarcoma in dogs: 2004–2008. Proc. 29th
Ann Conf Vet Cancer Soc., Austin, 2009; 29
Knecht CD, Priester WA: Musculoskeletal tumors in dogs. J Am Vet
Med Assoc. 1978; 172: 72–74
Knobloch S: Komplikationen nach Osteosynthese von Schaftfrakturen langer Röhrenknochen bei Hund und Katze. Ursachen, Therapie
und Ergebnisse in den Jahren 1980–1987. Diss med vet, München
1990
[100] Kraegel SA, Madewell BR, Simonson E et al.: Osteogenic sarcoma
and cisplatin chemotherapy in dogs: 16 cases (1986–1989). J Am
Vet Med Assoc. 1991; 199: 1057–1059
[101] Kosovsky JK, Matthiesen DT, Maretta SM et al.: Results of partial
mandibulectomy in the treatment of oral tumors in 142 dogs. Vet
Surg. 1991; 20: 397–401
[115] Liptak JM, Dernell WS, Ehrhart N et al.: Cortical allograft and
endoprosthesis for limb-sparing surgery in dogs with distal radial
osteosarcoma: a prospective clinical comparison of two different
limb-sparing techniques. Vet Surg. 2006; 35: 518–533
[118] Liptak JM, Dernell WS, Straw RC et al.: Intercalary bone grafts for
joint and limb preservation in 17 dogs with high-grade malignant
tumors of the diaphysis. Vet Surg. 2004; 33: 457–467
[119] Liptak JM, Pluhar GE, Dernell WS et al.: Limb-sparing surgery in a
dog with osteosarcoma of the proximal femur. Vet Surg. 2005; 34;
71–77
[120] Liptak JM, Kamstock DA, Dernell WS et al.: Oncologic outcome
after curative-intent treatment in 39 dogs with primary chest wall
tumors (1992–2005). Vet Surg. 2008; 37: 488–496
[121] Liptak JM, Dernell WS, Rizzo SA et al.: Reconstruction of chest
wall defects after rib tumor resection: a comparison of autogenous,
prosthetic, and composite techniques in 44 dogs. Vet Surg. 2008;
37: 479–487
[122] Liu SK, Harvey HJ: Metastatic bone neoplasms in the dog. In:
Bojrab MJ (Hrsg.): Pathophysiology in Small Animal Surgery. Lea &
Febiger, Philadelphia 1981; 712–715
[83]
[104] Kulmsee K, Hirschfeld D, Schoenrock D et al.: Synovialzellsarkom
beim Hund – Ein Fallbericht. Tierärztl Prax. 2001; 29: 88–91
110
[123] Ling GV, Morgan JP, Pool RR: Primary bone tumors in the dog: a
combined clinical, radiographic, and histologic approach to early
diagnosis. J Am Vet Med Assoc. 1974; 165: 55–67
[144] Mullins MN, Lana SE, Dernell WS et al.: Cyclooxygenase-2 expression in canine appendicular osteosarcoma. J Vet Intern Med. 2004;
1: 859–865
[124] Lord LK, Yaissle JE, Marin L et al.: Results of a web-based health
survey of retired racing Greyhounds. J Vet Intern Med. 2007; 21:
1243–1250
[145] Nagel ML, Tellhelm B: Knochentumoren des Bewegungsapparates
beim Hund. 12. Jahrestagung d. VÖK, Salzburg 1997: 109–114
[125] Loukopoulos P, Robinson WF: Clinicopathological relevance of
tumour grading in canine osteosarcoma. J Comp Pathol. 2007; 136:
65–73
[126] Lucas PW, Fan TM, Garrett LD et al.: A comparison of five different
bone resorption markers in osteosarcoma-bearing dogs, normal
dogs, and dogs with orthopaedic diseases. J Vet Int Med. 2008; 22:
1008–1013
[146] Nagel ML: Chemotherapeutische Möglichkeiten bei malignen Knochentumoren des Hundes. Gießener Kleintiertag 18. Juni 1997
[147] Norton C, Drenen CM, Emms SG: Subtotal scapulectomy as the
treatment for scapular tumour in the dog: a report of six cases.
Aust Vet J. 2006; 84: 364–366
[148] OʼBrien MG, Straw RC, Withrow SJ et al.: Resection of pulmonary
metastases in canine osteosarcoma: 36 cases (1983–1992). Vet
Surg. 1993; 22: 105–109
[127] Lurie DM, Séguin B, Schneider PD et al.: Contrast-assisted ultrasound for sentinel lymph node detection in spontaneously arising
canine head and neck tumors. Invest Radiol. 2006; 41: 415–421
[149] OʼBrien MG, Withrow SJ, Straw RC: Recent advances in the treatment of canine appendicular osteosarcoma. Comp Contin Educ
Pract Vet. 1993; 15: 613–616
[128] MacEwen EG, Kurzman ID, Rosenthal RC: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated
muramyl tripeptide. J Natl Cancer Inst. 1989; 81: 935–938
[150] Obradovich JE, Straw RC, Powers BE et al.: Canine chondrosarcoma: A clinicopathologic review of 55 cases (1983–1990). Proc
10th Ann Conf Vet Cancer Soc. 1990; 29–30
[129] MacEwen EG, Kurzman ID: Canine osteosarcoma: amputation and
chemoimmunotherapy. Vet Clin North Am Small Anim Pract. 1996;
26: 123–133
[151] Ogilvie GK, Krawiec DW, Gelberg HG: Evaluation of a short-term
saline diuresis protocol for the administration of cisplatin. Am J Vet
Res. 1988; 49: 1076–1078
[130] MacEwen EG: Adjuvant chemotherapy and immunotherapy for
canine osteosarcoma. Proc. 8th ACVIM Forum, Washington DC,
1990; 949–952
[152] Ogilvie GK, Moore AS: Managing the Veterinary Cancer Patient.
Veterinary Learning Systems Co., Inc. Trenton, New Jersey 1995
[131] MacGlennon NJ, Houlton JE, Gorman NT: Synovial sarcoma in the
dog: A review. J Small Anim Pract. 1988; 29: 139–152
[132] Marcellin-Little DJ, DeYoung DJ, Thrall DE et al.: Osteosarcoma at
the site of bone infarction associated with total hip arthroplasty in a
dog. Vet Surg. 1999; 28: 54–60
[133] Matis U, Krauser K, Schwartz-Porsche D et al.: Multiple Enchondromatosis in the dog. Vet Comp Orthop Traumatol. 1989; 4: 144–
151
Med Assoc. 1989; 195: 1580–1583
[154] Ogilvie GK, Straw RC, Jameson VJ et al.: Evaluation of single-agent
chemotherapy for treatment of clinically evident osteosarcoma
metastasis in dogs: 45 cases (1987–1991). J Am Vet Med Assoc.
1993; 202: 304–306
[155] Owen LN: Transplantation of canine osteosarcoma. Eur J Cancer.
1969; 5: 615–620
[134] Matthiesen DT, Clark GN, Orsher RJ et al.: En bloc resection of primary rib tumors in 40 dogs. Vet Surg. 1992; 21: 201–204
[156] Parchman MB, Crameri FM: Primary vertebral hemangiosarcoma
in a dog. J Am Vet Med Assoc. 1989; 194: 79–81
[135] Mauldin GN, Matus RE, Withrow SJ: Canine osteosarcoma treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Int Med. 1988; 2: 177–
180
[157] Patnaik AK: Canine extraskeletal osteosarcoma and condrosarcoma: A clinicopathologic study of 14 cases. Vet Pathol. 1990; 27:
46–50
[136] McChesney-Gillette S, Gillette EL, Powers BE et al.: Radiationinduced osteosarcoma in dogs after external beam or intraoperative
radiation therapy. Can Res. 1990; 50: 54–57
[137] Mehl ML, Séguin B, Dernell WS et al.: Survival analysis of one versus two treatment of local delivery cisplatin in a biodegradable
polymer for canine osteosarcoma. Vet Comp Oncol. 2005; 3: 81–86
[138] Mehl ML, Withrow SJ, Séguin B et al.: Spontaneous regression of
osteosarcoma in four dogs. J Am Vet Med Assoc. 2001; 219: 614–
617
[139] Mirra JM: Cysts and cyst-like lesions of bone. In: Mirra, JM, Picci P,
Gold RH (Hrsg.): Bone Tumors: Clinical, Radiographic and Pathologic Correlations. Lea & Febiger, Philadelphia 1989; 1233–1234
[140] Misdorp W, Hart AA: Some prognostic and epidemiologic factors
in canine osteosarcoma. J Natl Cancer Inst. 1979; 62: 537–545
[141] Moore AS, Dernell WS, Ogilvie GK et al.: Doxorubicin and BAY
12–9566 for the treatment of osteosarcoma in dogs: a randomized,
double-blind, placebo-controlled study. J Vet Intern Med. 2007; 21:
783–790
[142] Morello E, Buracco P, Martano M et al.: Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract. 2001; 42: 61–66
[143] Morello E, Vasconi E, Martano M et al.: Pasteurized tumoral autograft and adjuvant chemotherapy for the treatment of canine distal
radial osteosarcoma: 13 cases. Vet Surg. 2003; 32: 539–544
[158] Peter CP, Handt LK, Smith SM: Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci. 1998; 43:
1998–2002
[159] Phillips L, Hagar H, Parker R et al.: Osteosarcoma with a pathological fracture in a six-month-old dog. Vet Radiol. 1986; 27: 18–19
[160] Phillips JC, Stephenson B, Hauck M et al.: Heritability and segregation analysis of osteosarcoma in the Scottish deerhound. Genomics. 2007; 90: 354–363
[161] Phillips JC, Lembcke L, Chamberlin T: A novel locus for canine
osteosarcoma (OSA1) maps to CFA34, the canine orthologue of
human 3q26. Genomics. 2010; 96: 220–227
[162] Phillips B, Powers BE, Dernell WS et al.: Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with
amputation for appendicular osteosarcoma in dogs. J Am Anim
Hosp Assoc. 2009; 45: 33–38
[163] Pirkey-Ehrhart N, Withrow SJ, Straw RC et al.: Primary rib tumors
in 54 dogs. J Am Anim Hosp Assoc. 1995; 31: 65–69
[164] Poirer VJ, Huelsmeyer MK, Kurzman ID et al.: The bisphosphonates alendronate und zoledronate are inhibitors of canine and
human osteosarcoma cell growth in vitro. Vet Comp Onc. 2003; 1:
207–215
[165] Popovitch CA Weinstein MJ, Goldschmidt MH et al.: Chondrosarcoma: A retrospective study of 97 dogs (1987–1990). J Am Anim
Hosp Assoc. 1994; 30: 81–85
[166] Powers BE, LaRue SM, Withrow SJ et al.: Jamshidi needle biopsy
for diagnosis of bone lesions in small animals. J Am Vet Med Assoc.
1988; 193: 205–210
[167] Priester WA: The occurrence of tumors in domestic animals. NCI
Monograph No 54, November 1980
[190] Straw RC, Cook NL, LaRue SM et al.: Radiographic bone surveys. J
Am Vet Med Assoc. 1989; 195 (letters): 1489–1490
[168] Prior C, Watrous BJ, Penfold D: Radial diaphyseal osteosarcoma
with associated bone infarction in a dog. J Am Anim Hosp Assoc.
1986; 22: 43–48
[191] Straw RC, LeCouteur RA, Powers BE et al.: Multilobular osteochondrosarcoma of the canine skull: Sixteen cases. J Am Vet Med
Assoc. 1989; 195: 1764–1769
[169] Psychas V, Loukopoulos P, Polizopoulou ZS et al.: Multilobular
tumour of the caudal cranium causing severe cerebral and cerebellar compression in a dog. J Vet Sci. 2009;10: 81–83
[192] Straw RC, Powers BE, Klausner J et al.: Canine mandibular osteosarcoma: 51 cases (1980–1992). J Am Anim Hosp Assoc. 1996; 32:
257–262
[170] Puchalski SM, Kent M, Moore PF: Skeletal lesions of histiocytic sarcoma in nineteen dogs. Vet Radiol Ultrasound. 2007; 48: 539–543
[193] Straw RC, Withrow SJ, Richter SL et al.: Amputation and cisplatin
for treatment of canine osteosarcoma J Vet Int Med. 1991; 5: 205–
210
[171] Rendlund RC, Pritzker KP: Malignant fibrous histiocytoma involving the digit in a cat. Vet Pathol. 1984; 21: 442–444
[172] Rogers KS, Janovitz EB, Fooshee SK et al.: Lymphosarcoma with
disseminated skeletal involvement in a pup. J Am Vet Med Assoc.
1989; 195: 1242–1244
[173] Romanelli G, Buracco P: Implant related sarcomas (IRS) in 12 dogs
and 3 cats. Proc 25th Ann Conf Vet Cancer Soc, Huntington Beach,
2005, 69
[174] Rosen G, Suwansirikul S, Kwon C et al.: High dose methotrexate
with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer. 1974; 1151–1157
[175] Rosenberger JA, Pablo NV, Crawford PC: Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases
(1996–2005). J Am Vet Med Assoc. 2007; 231: 1076–1080
[176] Salisbury SK, Lantz GC: Long term results of partial mandibulectomy for treatment of oral tumors in 30 dogs. J Am Anim Hosp
Assoc. 1988; 24: 285–293
[177] Schnitzer T, Bone HG, Crepaldi G et al.: Therapeutic equivalence
of alendronate 70 mg once-weekly and alendronate 10 mg daily in
the treatment of osteoporosis. Alendronate Once-Weekly Study
Group. Aging (Milano). 2000; 12: 1–12
[178] Schrader SC, Burk S: Bone casts in two dogs and a review of similar
cystic lesions in the dog. J Am Vet Med Assoc. 1983; 182: 490–495
[179] Séguin B, Walsh PJ, Mason DR et al.: Use of an ipsilateral vascularized ulnar transposition autograft for limb-sparing surgery of the
distal radius in dogs: an anatomic and clinical study. Vet Surg.
2003; 32: 69–79
[180] Selvarajah GT, Kirpensteijn J, van Wolferen ME et al.: Gene
expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer. 2009; 8: 72
[194] Straw RC, Withrow SJ, Powers BE: Partial or total hemipelvectomy
in the management of sarcomas in seven dogs and two cats. Vet
Surg. 1992; 21: 183–188
[195] Straw RC, Withrow SJ: Limb-sparing surgery versus amputation
for dogs with bone tumors. Vet Clin North Am. 1996; 26: 135–143
[196] Sylvestre AM, Brash ML, Atilola MA et al.: A case series of 25
dogs with chondrosarcoma. Vet Comp Orthop Traumatol. 1992; 5:
13–17
[197] Thomas HL, Pressler BM, Robertson ID: Radiographic diagnosispolyostotic lymphoma in a 5 month old dog. Vet Radiol Ultrasound.
2001; 42: 521–523
[198] Thomas R, Wang HJ, Tsai PC et al.: Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res. 2009; 17: 365–377
[199] Thompson JP, Fugent MJ: Evaluation of survival times after limb
amputation, with or without subsequent administration of cisplatin,
for treatment of osteosarcoma in dogs: 30 cases (1979–1990). J
Am Vet Med Assoc. 1992; 200: 531–533
[200] Tilmant LL, Gorman NT, Ackerman N et al.: Chemotherapy of
synovial cell sarcoma in a dog. J Am Vet Med Assoc. 1986; 188:
530–532
[201] Tomlin JL, Sturgeon C, Pead MJ et al.: Use of the bisphosphonate
drug alendronate for palliative management of osteosarcoma in
two dogs. Vet Rec. 2000; 147: 129–132
[202] Uhl M, Theves C, Geiger J et al.: Die perkutane Knochenbiopsie:
Experimentelle Studie zum Vergleich von Knochenbiopsiesystemen.
Z Orthop Unfall. 2009; 147: 327–333
[181] Selvarajah GT, Kirpensteijn J: Prognostic and predictive biomarkers of canine osteosarcoma. Vet J. 2010; 185: 28–35
[203] Vail DM, Powers BE, Morrison WB et al.: Clinical aspects of synovial cell sarcoma (SCS) in the canine: A retrospective study of 35
cases. Proc. 10th Ann Conf Vet Cancer Soc. 1990; 31–32
[182] Shapiro W, Fossum TW, Kitchell BE: Use of cisplatin for the treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc.
1988; 4: 507–511
[204] Vail DM, Powers BE, Getzy DM et al.: Evaluation of prognosis for
dogs with synovial sarcoma: 36 cases (1986–1991). J Am Vet Med
Assoc. 1994; 205: 1300–1307
[183] Sinibaldi K, Rosen H, Liu S et al.: Tumors associated with metallic
implants in animals. Clin Orthop. 1976; 118: 257–266
[205] Von Werthern CJ, Horst C, Schwarz G: Zur Gliedmaßenamputation bei Hund und Katze: Eine Besitzerbefragung. Kleintierprax.
1999; 44, 169–176
[184] Sottnik JL, UʼRen LW et al.: Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol Immunother. 2010; 59: 367–378
[185] Spodnick GJ, Berg RJ, Rand WM et al.: Prognosis for dogs with
appendicular osteosarcoma treated with amputation alone. J Am
Vet Med Assoc. 1992; 200: 995–999
[186] Spugnini EP, Vincenzi B, Caruso G et al.: Zoledronic acid for the
treatment of appendicular osteosarcoma in a dog. J Small Anim
Pract. 2009; 50: 44–46
[187] Stevenson S, Hohn RB, Pohler OE et al.: Fracture-associated sarcoma in the dog. J Am Vet Med Assoc. 1982; 180: 1189–1194
[188] Stevenson S: Fracture-associated sarcomas. Vet Clin North Am
[189] Stockhaus C, Schoon HA, Scharvogel S et al.: Die Bedeutung der
Zytologie für den Nachweis von Knochentumoren bei Hund und
Katze. Tierärztl Prax K. 2003; 31: 117–147
[206] Wallack ST, Wisner ER, Werner JA: Accuracy of magnetic resonance imaging for estimating intramedullary osteosarcoma extent
in pre-operative planning of canine limb-salvage procedures. Vet
[207] Walter CU, Dernell WS, LaRue SM et al.: Curative-intent radiation
therapy as a treatment modality for appendicular and axial osteosarcoma: a preliminary retrospective evaluation of 14 dogs with the
disease. Vet Comp Oncol. 2005; 3: 1–7
[208] Waltman SS, Seguin B, Cooper BJ et al.: Clinical outcome of nonnasal chondrosarcoma in dogs: thirty-one cases (1986–2003). Vet
Surg. 2007; 36: 266–271
[209] Waters DJ: Bone infarction. In: Slatter D (Hrsg.): Textbook of Small
Animal Surgery: Musculoskeletal System. W.B. Saunders Co., Philadelphia 1993; 2226–2227
[210] Waters DJ: Oncology of the musculoskeletal system. In: Slatter D
(Hrsg.): Textbook of Small Animal Surgery. W.B. Saunders Co., Philadelphia 1993; 2213–2230
111
112
[211] Wesselhoeft-Ablin L, Berg J, Schelling SH: Fibrosarcoma in the
canine appendicular skeleton. J Am Anim Hosp Assoc. 1991; 27:
303–309
[14]
Kessler M, Tassani-Prell M, von Bomhard D et al.: Das Osteosarkom
der Katze: Epidemiologische, klinische und röntgenologische Aspekte
bei 78 Fällen (1990–1995). Tierärztl Prax. 1997; 25: 275–283
[212] White RAS: Mandibulectomy and maxillectomy in the dog: Long
term survival in 100 cases. J Small Anim Pract. 1991; 32: 69–74
[15]
Kramer A, Walsh PJ, Seguin B: Hemipelvectomy in dogs and cats:
technique overview, variations, and description. Vet Surg. 2008; 37:
413–419
[16]
Levitt L, Doige CE: Primary intraosseous fibrosarcoma in a cat. J
Am Vet Med Assoc. 1989; 194: 1601–1603
[17]
Liu SK, Dorfman HD, Patnaik AK: Primary and secondary bone
tumors in the cat. J Small Anim Pract. 1974; 15: 141–156
[18]
[216] Withrow SJ, Hirsch VM: Ownerʼs response to amputation of the
petʼs leg. Vet Med Small Anim Clin. 1979; 10: 332–334
Lord PF, Kapp DS, Schwartz A et al.: Osteogenic sarcoma of the
nasal cavity in a cat: post-operative control with high dose-per-fraction radiation therapy and metronidazole. Vet Radiol. 1982; 23: 23–
26
[19]
[217] Withrow SJ: Pulmonary metastasectomy for canine osteosarcoma.
Proc 8th Ann Conf Vet Cancer Soc. Estes Park, CO, 1988
Lott-Stolz G: Osteochondromatose bei der Katze. Schweiz Arch
Tierheilkd. 1988; 130: 635–638
[20]
[218] Wittig JC, Bickels J, Kellar-Graney KL et al.: Osteosarcoma of the
proximal humerus: long-term results with limb-sparing surgery. Clin
Orth Rel Res. 2002; 397: 156–176
Madewell BR, Leighton RL, Theilen GH: Amputation and Doxorubicin for treatment of canine and feline osteogenic sarcoma. Europ
J Cancer. 1978; 14: 287–293
[21]
[219] Wolfesberger B, Walter I, Hoelzl C et al.: Antineoplastic effect of
cells. Res Vet Sci. 2006; 80: 308–316
Marioni-Henry K, Van Winkle TJ, Smith SH et al.: Tumors affecting the spinal cord of cats: 85 cases (1980–2005). J Am Vet Med
Assoc. 2008; 232: 237–243
[22]
[220] Wolke RE, Nielsen SW: Site incidence of canine osteosarcoma. J
Merchav R, Dank G, Aizenberg I et al.: Chondrosarcoma of the
proximal humerus in a cat. J Small Anim Pract. 2005; 46: 454–456
[23]
Morton D: Chondrosarcoma arising in a multilobular chondroma in
a cat. J Am Vet Med Assoc. 1985; 186: 804–806
[24]
Nolan TE, Jackson DE, Novak RD: What is your diagnosis ? J Am
Vet Med Assoc. 1976; 168: 439–440
[25]
Northrup NC, Selting KA, Rassnick KM et al.: Outcomes of cats
with oral tumors treated with mandibulectomy: 42 cases. J Am
Anim Hosp Assoc. 2006; 42: 350–360
[26]
Okada M, Kitagawa M, Nagasawa A et al.: Magnetic resonance
imaging and computed tomography findings of vertebral osteosarcoma in a cat. J Vet Med Sci. 2009; 71: 513–517
[27]
Popp JA, Simpson CF: Feline malignant giant cell tumor of bone
associated with c-type virus particles. Cornell Vet. 1976; 66: 527–534
[28]
Quigley PJ, Leedale AH: Tumors involving bone in the domestic
cat: A review of 58 cases. Vet Pathol. 1983; 20: 670–686
[29]
Ranade SA, Pacchiana PD: What is your diagnosis? Osteochondromatosis. J Am Vet Med Assoc. 2011; 238: 1243–1244
[30]
Rossetti E, Bertolini G, Zotti A: Multilobular tumour of bone of the
thoracic wall in a cat. J Feline Med Surg. 2007; 9: 254–257
[31]
Szentimrey DC, Withrow SJ, Powers BE et al.: Osteomas of the
skull: A retrospective study of nine dogs and two cats (1985–1995).
Proc 15th Ann Conf Vet Cancer Soc., 1995
[32]
Thompson GK, Pool RR: Tumors of bones. In: Tumors in domestic
animals. Meuten DJ (Hrsg.): 4. Aufl. Iowa State Press, Ames, 2002;
245–317
[33]
Tischer SA: Ulnar fibrosarcoma in a cat. Mod Vet Pract. 1986; 67:
39
[34]
Turrel JM, Pool RR: Primary bone tumors in the cat. Vet Radiol.
1982; 23: 152–166
[213] Whitelock RG, Dyce J, Houlton JE et al.: A review of 30 tumors
affecting joints. Vet Comp Orthop Traumatol. 1997; 10: 146–152
[214] Withrow SJ, Doige CE: En bloc resection of a juxtacortical and
three intra-osseous osteosarcomas of the zygomatic arch in dogs. J
[215] Withrow SJ, Liptak JM, Straw RC et al.: Biodegradable cisplatin
polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg
Oncol. 2004; 11: 705–713
[221] Wootton-Gorges SL: MR imaging of primary bone tumors and
tumor-like conditions in children. Magn Reson Imaging Clin N Am.
2009; 17: 469–487
26.2 Primäre Knochentumoren der Katze
[1]
Alden CL, Helzer LL: Humeral chondrosarcoma in a cat. Mod Vet
Pract. 1981; 62: 214–216
[2]
Banks WC: Parosteal osteosarcoma in a dog and a cat. J Am Vet
Med Assoc. 1971; 158: 1412–1415
[3]
Bitetto WV, Patnaik AK, Schrader SC et al.: Osteosarcoma in cats:
[4]
Brown RJ, Trevethan WP, Henry VL: Multiple osteochondroma in a
Siamese cat. J Am Vet Med Assoc. 1972; 160: 433–435
[5]
Carpenter JL, Andrews LK, Holzworth J: Tumors and tumor-like
lesions. In: Holzworth J (Hrsg.): Diseases of the cat. Medicine and
Surgery. Saunders Co, Philadelphia 1987
[6]
Cook JL, Turk JR, Tomlinson JL et al.: Fibrosarcoma in the distal
radius and carpus of a four-year-old Persian. J Am Anim Hosp Assoc.
1998; 34: 31–33
[7]
Dimopoulou M, Kirpensteijn J, Moens H et al.: Histologic prognosticators in feline osteosarcoma: a comparison with phenotypically similar canine osteosarcoma. Vet Surg. 2008; 37: 466–471
[8]
Durham AC, Popovitch CA, Goldschmidt MH: Feline chondrosarcoma: a retrospective study of 67 cats (1987–2005). J Am Anim
Hosp Assoc. 2008; 44: 124–130
[9]
Fry PD, Jukes HF: Fracture associated sarcoma in the cat. J Small
Anim Pract. 1995; 36: 124–126
[10]
Gradner G, Weissenböck H, Kneissl S et al.: Use of latissimus
dorsi and abdominal external oblique muscle for reconstruction of a
thoracic wall defect in a cat with feline osteochondromatosis. J
27 Tumoren der Zehen
[1]
Aronson MG, Carpenter JL: Distal extremity melanocytic nevi and
malignant melanomas in dogs. J Am Anim Hosp Assoc. 1990; 26:
605–612
Jongeward SJ: Primary bone tumors. Vet Clin North Am [Small
Anim Pract]. 1985; 15: 609–641
[2]
Vet Pathol. 1979; 16: 32–40
Heldmann E, Anderson MA, Wagner-Mann C: Feline osteosarcoma: 145 cases (1990–1995). J Am Anim Hosp Assoc. 2000; 36:
518–521
[3]
Brewer WG, Mitley E, Ogilvie GK et al.: Canine digital tumors: retrospective review of 63 cases (1980–1990). Vet Cancer Soc Newslet. 1993; 17: 7
[11]
Griffith JW, Dubielzig RR, Riser WH et al.: Parosteal osteosarcoma
with pulmonary metastases in a cat. Vet Pathol. 1984; 21: 123–125
[12]
[13]
[4]
Brodzki A, Lopuszyhski W, Komsta R et al.: Die Beurteilung der
Ergebnisse in der Therapie und Analyse des Therapieverlaufs von
malignen Tumoren der Zehen beim Hund. Tierärztl Umschau. 2004;
59: 594–596, 599–600
[5]
Carpenter JL, Dayal Y, King NW et al.: Distinctive unclassified
mesenchymal tumor of the digit of dogs. Vet Pathol. 1991; 28:
296–402
[6]
Esson D, Fahrer CS, Zarfoss MK et al.: Suspected uveal metastasis
of a nail bed melanoma in a dog. Vet Ophthalmol. 2007; 10: 262–
266
[7]
Frank H, Kirchhof N, Biesenbach W et al.: Intraossäre Epidermoidzysten des Zehenendgliedes beim Hund. Berl Münch Tierärztl
Wschr. 1995; 108: 73–76
[8]
Frese K, Frank H, Eskens U: Plattenepithelkarzinome der Zehen
beim Hund. Dtsch Tierärztl Wschr. 1983; 90: 359–363
[9]
Frese K: Verlaufsuntersuchungen bei Melanomen der Haut und
Mundschleimhaut des Hundes. Vet Pathol. 1978; 15: 461–473
[10]
Frese K, Eskens U: Klassifikation und biologisches Verhalten der
Haut- und Mammatumoren von Hund und Katze. Prakt Tierarzt.
1989; 9: 69–84
[11]
Gamblin RM, Straw RC, Powers E et al.: Primary osteosarcoma
distal to the antebrachiocarpal and tarsocrural joints in nine dogs
[12]
Guerin SR, Jones BR, Alley MR et al.: Multiple digital tumours in a
Rottweiler. J Small Anim Pract. 1998; 39: 200–202
[13]
Henry CJ, Brewer WG, Whitley EM et al.: Canine digital tumors: a
veterinary cooperative oncology group retrospective study of 64
[27]
Popovich CA, Weinstein MJ, Goldschmidt MH et al.: Chondrosarcoma: a retrospective study of 97 dogs. (1987–1990). J Am Anim
Hosp Assoc. 1994; 30: 81–85
[28]
Schmidt BR, Glickman NW, DeNicola DB et al.: Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J
Am Vet Med Assoc. 2001; 218: 1783–1786
[29]
Schultheiss PC: Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. J Vet Diagn
Invest. 2006; 18: 422–425
[30]
Scott DW, Miller WH: Disorders of the claw and clawbed in dogs.
Comp Cont Educ Small Anim Pract. 1992; 14: 1448–1458
[31]
Spangler WL, Kass PH: The histologic and epidemiologic bases for
Pathol. 2006; 43: 136–149
[32]
Strande A: Plattecellekarsinom i taerne hos hund et klinisk bilde.
(Squamous cell carcinoma of the digit in the dog – clinical findings
in 34 dogs.) Norsks Veterinaertidsskrift. 1987; 99: 11–14
[33]
Wobeser BK, Kidney BA, Powers BE et al.: Diagnoses and clinical
outcomes associated with surgically amputated canine digits submitted to multiple veterinary diagnostic laboratories. Vet Pathol.
2007; 44: 355–361
28 Tumoren endokriner Organe
28.1 Tumoren der Hypophyse
[1]
Abraham LA, Helmond SE, Mitten RW et al.: Treatment of an
acromegalic cat with the dopamine agonist L-deprenyl. Aust Vet J.
2002; 80: 479–483
[14]
Hieber E: Sekundär – intraokulare (metastatische) Tumoren der
Uvea. Diss med vet, LMU München, 2004
[2]
[15]
Himsel CA, Richardson RC, Craig JA: Cisplatin chemotherapy for
Assoc. 1986; 189: 1575–1578
Abrams-Ogg ACG, Holmberg DL, Stewart WA et al.: Acromegaly
in a cat: Diagnosis by magnetic resonance imaging and treatment
by cryohypophysectomy. Can Vet J. 1993; 34: 682–685
[3]
[16]
Kessler M, von Bomhard D: Plattenepithelkarzinome bei Hunden
und Katzen – Prävalenz, Rasseprädispositionen und Primärlokalisationen. Proc. 22. Jahrestagung DVG, Bad Nauheim 1997; 398–404
Barker EN, Campbell S, Tebb AJ et al.: A comparison of the survival times of dogs treated with mitotane or trilostane for pituitarydependent hyperadrenocorticism. J Vet Intern Med. 2005; 19: 810–
815
[17]
Kessler M, Tassani-Prell M, von Bomhard D et al.: Das Osteosarkom der Katze – Epidemiologische, klinische und röntgenologische
Befunde bei 78 Tieren (1990–1995). Tierärztl Prax. 1997; 25: 275–
283
[4]
Behrend EN, Kemppainen RJ, Boozer AL et al.: Serum 17-alphahydroxyprogesterone and corticosterone concentrations in dogs
with nonadrenal neoplasia and dogs with suspected hyperadrenocorticism. J Am Vet Med Assoc. 2005; 227: 1762–1767
[18]
Kessler M, Kühnel S, Schöpper I: Plattenpithelkarzinome und
maligne Melanome im Bereich des Nagelbetts beim Hund – Klinische Befunde bei 45 Fällen. unveröffentlicht, 2012
[5]
[19]
Lettow E, Middel-Erdmann I, Keil S: Erkrankungen des Zehenendgliedes beim Hund. Kleintierprax. 1988; 33: 345–352
Benitah N, Feldman EC, Kass PH et al.: Evaluation of serum 17hydroxyprogesterone concentration after administration of ACTH in
dogs with hyperadrenocorticism. J Am Vet Med Assoc. 2005; 227:
1095–1101
[6]
[20]
Liptak JM, Dernell WS, Rizzo SA et al.: Partial foot amputation in
11 dogs. J Am Anim Hosp Assoc. 2005; 41: 47–55
Berg RI, Nelson RW, Feldman EC et al.: Serum insulin-like growth
factor-I concentration in cats with diabetes mellitus and acromegaly. J Vet Intern Med. 2007; 21: 892–898
[21]
Luna LD, Higginbotham ML, Henry CJ et al.: Feline non-ocular
melanoma: a retrospective study of 23 cases (1991–1999). J Feline
Med Surg. 2000; 2: 173–181
[7]
[22]
Madewell BR, Pool RR, Theilen GH et al.: Multiple subungual
squamous cell carcinomas in five dogs. J Am Vet Med Assoc. 1982;
180: 731–734
Bertolini G, Furlanello T, Drigo M et al.: Computed tomographic
adrenal gland quantification in canine adrenocorticotroph hormone-dependent hyperadrenocorticism. Vet Radiol Ultrasound.
2008; 49: 449–53
[8]
Bertoy EH, Feldman EC, Nelson RW et al.: Magnetic resonance
imaging of the brain in dogs with recently diagnosed but untreated
pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc.
1995; 206: 651–656
[23]
Marino DJ, Matthieson DT, Stefanacci JD et al.: Evaluation of dogs
with digit masses: 117 cases (1981–1991). J Am Vet Med Assoc.
1995; 207: 726–728
[9]
[24]
OʼBrien MG, Berg J, Engler SJ: Treatment by digital amputation of
subungual squamous cell carcinoma in dogs. 21 cases (1987–
1988). J Am Vet Med Assoc. 1992; 201: 759–761
Bilzer T: Hypophysentumoren als gemeinsame Ursache von Morbus
Cushing und Diabetes insipidus des Hundes. Tierärztl Prax. 1991;
19: 276–281
[10]
[25]
OʼRourke M: Multiple digital squamous cell carcinomas in 2 dogs.
Med Vet Pract. 1985; 66: 644–645
Blois SL, Holmberg DL: Cryohypophysectomy used in the treatment of a case of feline acromegaly. J Small Anim Pract. 2008; 49:
596–600
[26]
Paradis M, Scott DW, Breton L: Squamous cell carcinoma of the
nail bed in three related giant schnauzers. Vet Rec. 1989; 125: 322–
324
[11]
Bosje JT, Rijnberk A, Mol JA et al.: Plasma concentrations of ACTH
precursors correlate with pituitary size and restistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism.
Domest Anim Endocrinol. 2002; 22: 201–210
113
114
[12]
Boujon CE, Ritz U, Rossi GL et al.: A clinico-pathological study of
canine Cushing’s disease caused by a pituitary carcinoma. J Comp
Pathol. 1991; 105: 353–365
[13]
[14]
[15]
[16]
[17]
[31]
Braddock JA, Church DB, Robertson ID et al.: Trilostane treatment
in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J.
2003; 81: 600–607
Gould SM, Baines EA, Mannion PA et al.: Use of endogenous
ACTH concentration and adrenal ultrasonography to distinguish the
cause of canine hyperadrenocorticism. J Small Anim Pract. 2001;
42: 113–121
[32]
Brearley MJ, Polton GA, Littler RM et al.: Coarse fractionated
radiation therapy for pituitary tumours in cats: a retrospective study
of 12 cases. Vet Comp Oncol. 2006; 4: 209–217
Greco DS, Peterson ME, Davidson AP et al.: Concurrent pituitary
and adrenal tumors in dogs with hyperadrenocorticism: 17 cases
(1978–1995). J Am Vet Med Assoc. 1999; 214: 1349–1353
[33]
Gunn-More D: Feline Endocrinopathies. In: Richards JR (Hrsg.): The
Veterinary Clinics of North America. Small Animal Practice. Vol 35.
Number 1. Philadelphia: Saunders; 2005: 171–210
[34]
Hanson JM, van’t Hoofd MM, Voorhout G et al.: Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitarydependent hyperadrenocorticism. J Vet Intern Med. 2005; 19: 687–
694
[35]
Hanson JM, Teske E, Voorhout G et al.: Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitarydependent hyperadrenocorticism. J Neurosurg. 2007; 107: 830–
840
[36]
Hurty CA, Flatland B: Feline acromegaly: a review of the syndrome.
Burkhardt WA, Guscetti F, Boretti FS et al.: Adrenocorticotropic
hormone, but not trilostane, causes severe adrenal hemorrhage,
vacuolization, and apoptosis in rats. Domest Anim Endocrinol.
2011; 40: 155–64
Chapman PS, Mooney CT, Ede J et al.: Evaluation of the basal and
post-adrenocorticotrophic hormone serum concentrations of 17hydroxyprogesterone for the diagnosis of hyperadrenocorticism in
dogs. Vet Rec. 2003; 153: 771–775
Chapman PS, Kelly DF, Archer J et al.: Adrenal necrosis in a dog
receiving trilostane for the treatment of hyperadrenocorticism. J
[18]
De Fornel P, Delisle F, Devauchelle P et al.: Effects of radiotherapy
on pituitary corticotroph macrotumors in dogs: a retrospective
study of 12 cases. Can Vet J. 2007; 48: 481–486
[37]
Kaser-Hotz B, Rohrer CR, Stankeova S et al.: Radiotherapy of
pituitary tumours in five cats. J Small Anim Pract. 2002; 43: 303–
307
[19]
Den Hertog E, Braakman JC, Teske E et al.: Results of non-selective adrenocorticolysis by o,p’-DDD in 129 dogs with pituitarydependent hyperadrenocorticism. Vet Rec. 1999; 144: 12–17
[38]
[20]
Duesberg CA, Nelson RW, Feldman EC et al.: Adrenalectomy for
treatment of hyperadrenocorticism in cats: 10 cases (1988–1992). J
Am Vet Med Assoc. 1995; 207: 1066–1070
21: 1027–33
[39]
Kintzer PP, Peterson ME: Mitotane (o,p’-DDD) treatment of 200
dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern
Med. 1991; 5: 182–190
[40]
Kipperman BS, Feldman EC, Dybdal NO et al.: Pituitary tumor
size, neurologic signs, and relation to endocrine test results in dogs
with pituitary-dependent hyperadrenocorticism: 43 cases (1980–
1990). J Am Vet Med Assoc. 1992; 201: 762–767
[41]
Kooistra HS, Voorhout G, Mol JA et al.: Correlation between
impairment of glucocorticoid feedback and the size of the pituitary
gland in dogs with pituitary-dependent hyperadrenocorticism. J
Endocrinol. 1997; 152: 387–394
[42]
Lichtensteiger CA, Wortman JA, Eigenmann JE: Functional pituitary acidophil adenoma in a cat with diabetes mellitus and acromegalic features. Vet Pathol. 1986; 23: 518–521
[43]
Littler RM, Polton GA, Brearley MJ: Resolution of diabetes mellitus
but not acromegaly in a cat with a pituitary macroadenoma treated
with hypofractionated radiation. J Small Anim Pract. 2006; 47: 392–
395
[44]
Lopes MB, Scheithauer BW, Schiff D: Pituitary carcinoma. Endocrine. 2005; 28: 115–121
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
Duesberg C, Peterson ME: Adrenal disorders in cats. In: Kintzer PP
(Hrsg.): The Veterinary Clinics of North America, Small Animal Practice, Adrenal Disorders. Vol. 27. Philadelphia: Saunders; 1997: 321–
347
Feldman EC, Nelson RW, Feldman MS: Use of low- and high-dose
dexamethasone tests for distinguishing pituitary-dependent from
adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc.
1996; 209: 772–775
Feldman EC, Nelson RW: Disorders of Growth Hormone. In: Feldman EC, Nelson RW (Hrsg.): Canine and Feline Endocrinology and
Reproduction. 3. Aufl. St. Louis, Missouri: Saunders; 2004: 45–84
Feldman EC, Nelson RW: Canine hyperadrenocorticism (Cushing’s
Syndrome). In: Feldman EC, Nelson RW (Hrsg.): Canine and Feline
Endocrinology and Reproduction. 3. Aufl. St. Louis, Missouri: Saunders; 2004: 252–357
Feldman EC, Nelson RW: Hyperadrenocorticism in cats (Cushing’s
[45]
Fracassi F, Mandrioli L, Diana A et al.: Pituitary macroadenoma in
a cat with diabetes mellitus, hypercortisolism and neurological
signs. J Vet Med A Physiol Pathol Clin Med. 2007; 54: 359–363
Mayer MN, Greco DS, LaRue SM: Outcomes of pituitary tumor irradiation in cats. J Vet Intern Med. 2006; 20: 1151–1154
[46]
Galac S, Kooistra HS, Voorhout G et al.: Hyperadrenocorticism in
a dog due to ectopic secretion of adrenocorticotropic hormone.
Mayer-Stankeova S, Rohrer Bley C, Wergin M et al.: Efficacy of
radiotherapy in 13 dogs treated for pituitary tumors. Tierärztl Prax.
2004; 32: 232–237
[47]
Galac S, Kars VJ, Voorhout G et al.: ACTH-independent hyperadrenocorticism due to food-dependent hypercortisolemia in a dog: a
case report. Vet J. 2008; 177: 141–3
Meij BP, Voorhout G, Van den Ingh TS et al.: Transsphenoidal
hypophysectomy in beagle dogs: evaluation of a microsurgical technique. Vet Surg. 1997; 26: 295–309
[48]
Goossens MMC, Meyer HP, Voorhout G et al.: Urinary excretion of
glucocorticoids in the diagnosis of hyperadrenocorticism in cats.
Meij BP, Voorhout G, van den Ingh TS et al.: Results of transsphenoidal hypophysectomy in 52 dogs with pituitary-dependent hyperadrenocorticism. Vet Surg. 1998; 27: 246–261
[49]
Goossens MMC, Feldman EC, Nelson RW et al.: Cobalt 60 irradiation of pituitary gland tumors in three cats with acromegaly. J Am
Vet Med Assoc. 1998; 213: 374–376
Meij BP, Voorhout G, van den Ingh TS et al.: Transsphenoidal
hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in 7 cats. Vet Surg. 2001; 30: 72–86
[50]
Meij BP, Voorhout G, Rijnberk A: Progress in transsphenoidal
hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. Mol Cell Endocrinol. 2002; 197: 89–
96
[51]
Meij BP, van der Vlugt-Meijer RH, van den Ingh T et al.: Somatotroph and corticotroph pituitary adenoma (double adenoma) in a
cat with diabetes mellitus and hyperadrenocorticism. J Comp.
Pathol. 2004; 130: 209–215
[71]
Rees DA, Hanna FW, Davies JS et al.: Long-term follow-up results
of transsphenoidal surgery for Cushing’s disease in a single centre
using strict criteria for remission. Clin Endocrinol. 2002; 56: 541–
551
[52]
Meij BP, Auriemma E, Grinwis G et al.: Successful treatment of
acromegaly in a diabetic cat with transsphenoidal hypophysectomy.
J Feline Med Surg. 2010; 12: 406–10
[72]
[53]
Meij BP, Kooistra HS, Rijnberk A: Hypothalamus-pituitary system.
In: Rijnberk A, Kooistra HS (Hrsg.): Clinical Endocrinology of Dogs
and Cats. 2nd ed. Hannover: Schlütersche Verlagsgesellschaft;
2010: 13–54
Reusch C, Glaus T, Wess G et al.: Klinische, labordiagnostische und
spezielle endokrinologische Untersuchungen bei Hunden mit hypophysärem Cushing-Syndrom: ein Vergleich zwischen Hunden mit
Makro- und solchen mit Mikrotumoren. Kleintierprax. 2001; 46:
261–270
[73]
Reusch C, Stankeova S, Geissbühler U et al.: Zusammenhang zwischen computertomographisch ermittelter Hypophysengrösse und
dem Auftreten neurologischer Symptome bei Hunden mit CushingSyndrom. Kleintierprax. 2001; 46: 133–139
[74]
Morrison SA, Randolph J, Lothrop CD: Hypersomatotropism and
insulin-resistant diabetes mellitus in a cat. J Am Vet Med Assoc.
1989; 194: 91–94
Reusch CE: Hyperadrenocorticism. In: Ettinger SJ, Feldman EC
(Hrsg.): Textbook of Veterinary Internal Medicine. 6. Aufl. St. Louis
Missouri: Elsevier; 2005: 1592–1612
[75]
Neiger R, Ramsey I, O’Connor J et al.: Trilostane treatment of 78
dogs with pituitary-dependent hyperadrenocorticism. Vet Rec.
2002; 150: 799–804
Reusch CE, Rijnberk A: Krankheiten der endokrinen Organe. In:
Horzinek MC, Schmidt V, Lutz H (Hrsg.): Krankheiten der Katze. 4.
Aufl. Stuttgart: Enke Verlag; 2005: 555–574
[76]
Neiger R, Witt AL, Noble A et al.: Trilostane therapy for treatment
of pituitary-dependent hyperadrenocorticism in 5 cats. J Vet Intern
Med. 2004; 18: 160–164
Reusch CE, Kley S, Casella M et al.: Measurements of growth hormone and insulin-like growth factor 1 in cats with diabetes mellitus.
Vet Rec. 2006; 158: 195–200
[77]
Nelson RW, Feldman EC, Smith MC: Hyperadrenocorticism in
cats: seven cases (1978–1987). J Am Vet Med Assoc. 1988; 193:
245–250
Reusch CE, Sieber-Ruckstuhl N, Wenger M et al.: Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane. Vet Rec. 2007; 160: 219–224
[78]
Rijnberk A, Belshaw BE: An alternative protocol for the medical
management of canine pituitary-dependent hyperadrenocorticism.
Vet Rec. 1988; 122: 486–488
[79]
Ristic JM, Ramsey IK, Heath EM: The use of 17-hydroxyprogesterone in the diagnosis of canine hyperadrenocorticism. J Vet Intern
Med. 2002; 16: 433–439
[80]
Ruckstuhl NS, Nett CS, Reusch CE: Results of clinical examinations,
laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res.
2002; 63: 506–512
[81]
Sarfaty D, Carrillo JM, Peterson ME: Neurologic, endocrinologic,
and pathologic findings associated with large pituitary tumors in
dogs: eight cases (1976–1984). J Am Vet Med Assoc. 1988; 193:
854–856
[82]
Sato J, Sato R, Kinai M et al.: Pituitary chromophobe carcinoma
with a low level of serum gonadotropin and an aspermatogenesis in
a dog. J Vet Med Sci. 2001; 63: 183–185
[83]
Skelly BJ, Petrus D, Nicholls PK: Use of trilostane for the treatment
of pituitary-dependent hyperadrenocorticism in a cat. Small Anim
Pract. 2003; 44: 269–272
[84]
Schechter RD, Stabenfeldt GH, Gribble DH et al.: Treatment of
Cushing’s syndrome in the dog with adrenocorticolytic agent (o,p’DDD). J Am Vet Med Assoc. 1973; 162: 629–639
[85]
Sieber-Ruckstuhl NS, Boretti FS, Wenger M et al.: Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism
treated with trilostane. Domest Anim Endocrinol. 2006; 31: 63–75
[86]
Sieber-Ruckstuhl NS, Boretti FS, Wenger M et al.: Evaluation of
different cortisol precursors for the diagnosis of pituitary-dependent hypercortisolism in dogs. Vet Rec. 2008; 162: 673–678
[87]
Spada E, Proverbio D, Giudice C et al.: Pituitary-dependent hyperadrenocorticism and generalised toxoplasmosis in a cat with neurological signs. J Feline Med Surg. 2010; 12: 654–658
[88]
Starkey SR, Tan K, Church DB: Investigation of serum IGF-I levels
amongst diabetic and non-diabetic cats. J Feline Med Surg. 2004; 6:
149–155
[89]
Théon AP, Feldman EC: Megavoltage irradiation of pituitary macrotumors in dogs with neurologic signs. J Am Vet Med Assoc. 1998;
213: 225–231
[54]
[55]
[56]
[57]
[58]
[59]
Middleton DJ, Culvenor JA, Vasak E et al.: Growth hormone-producing pituitary adenoma, elevated serum somatomedin c concentration and diabetes mellitus in a cat. Can Vet J. 1985; 26: 169–
171
Nelson RW, Ihle SL, Feldman EC: Pituitary macroadenomas and
macrocarcinomas in dogs treated with mitotane for pituitarydependent hyperadrenocorticism: 13 cases (1981–1986). J Am Vet
Med Assoc. 1989; 194: 1612–1617
[60]
Niessen SJ, Khalid M, Petrie G et al.: Validation and application of
a radioimmunoassay for ovine growth hormone in the diagnosis of
acromegaly in cats. Vet Rec. 2007; 160: 902–907
[61]
Niessen SJ, Petrie G, Gaudiano F et al.: Feline acromegaly: an
underdiagnosed endocrinopathy? J Vet Intern Med. 2007; 21: 899–
905
[62]
Norman EJ, Mooney CT: Diagnosis and management of diabetes
mellitus in five cats with somatotrophic abnormalities. J Feline Med
Surg. 2000; 1: 183–190
[63]
Nothelfer B, Weinhold K: Formale Pathogenese, Durchschnittsalter und Rasseverteilung im Vergleich 61 Lysodren-behandelter
und 36 unbehandelter Fälle von caninem Hyperadrenokortizismus,
die in den Jahren 1975 bis 1991 am Institut für Veterinär-Pathologie
der Freien Universität Berlin seziert wurden. Berl Münch Tierärztl
Wschr. 1992; 105: 305–311
[64]
Pernicone PJ, Scheithauer BW, Sebo TJ et al.: Pituitary carcinoma:
a clinicopathologic study of 15 cases. Cancer. 1997; 79: 804–812
[65]
Peterson ME, Krieger DT, Drucker WD et al.: Immunocytochemical study of the hypophysis in 25 dogs with pituitary-dependent
hyperadrenocorticism. Acta Endocrinol. 1982; 101: 15–24
[66]
Peterson ME: Hyperadrenocorticism. In: Peterson ME (Hrsg.): The
Veterinary Clinics of North America, Small Animal Practice, Endocrinology. Vol. 14. Phildadelphia: Saunders; 1984: 731–749
[67]
Peterson ME, Taylor RS, Greco DS et al.: Acromegaly in 14 cats. J
Vet Intern Med. 1990; 4: 192–201
[68]
Peterson ME: Acromegaly in cats: are we only diagnosing the tip of
the iceberg? J Vet Intern Med. 2007; 21: 889–891
[69]
Pollard RE, Reilly CM, Uerling MR et al.: Cross-sectional imaging
characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988–2006). J Vet Intern Med.
2010; 24: 160–165
[70]
Potts GO, Creange JE, Hardomg HR et al.: Trilostane, an orally
active inhibitor of steroid biosynthesis. Steroids. 1978; 32: 257–267
115
116
[90]
Van der Vlugt-Meijer RH, Meij BP, van den Ingh T et al.: Dynamic
computed tomography of the pituitary gland in dogs with pituitarydependent hyperadrenocorticism. J Vet Intern Med. 2003; 17: 773–
780
[91]
Van Vonderen IK, Kooistra HS, Rijnberk A: Influence of veterinary
care on the urinary corticoid:creatinine ratio in dogs. J Vet Intern
Med. 1998; 12: 431–435
[92]
Watson PJ, Herrtage ME: Hyperadrenocorticism in six cats. J Small
Anim Pract. 1998; 39: 175-184
[93]
Wood FD, Pollard RE, Uerling MR et al.: Diagnostic imaging findings and endocrine test results in dogs with pituitary-dependent
hyperadrenocorticism that did or did not have neurologic abnormalities: 157 cases (1989–2005). J Am Vet Med Assoc. 2007; 231:
1081–1085
[17]
DeClue AE, Breshears LA, Pardo ID et al.: Hyperaldosteronism and
hyperprogesteronism in a cat with an adrenal cortical carcinoma. J
Vet Intern Med. 2005; 19: 355–358
[18]
DeLellis RA, Lloyd RV, Heitz PU et al. (Hrsg.): Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press;
2004. World Health Organization Classification of Tumours
[19]
Djajadiningrat-Laanen SC, Galac S, Cammelbeeck SE et al.: Urinary aldosterone to creatinine ratio in cats before and after suppression with salt or fludrocortisone acetate. J Vet Intern Med.
2008; 22: 1283–1288
[20]
Eastwood JM, Elwood CM, Hurley KJ: Trilostane treatment of a
dog with functional adrenocortical neoplasia. J Small Anim Pract.
2003; 44: 126–131
[21]
Eger C, Robinson WF, Huxtable CR: Primary aldosteronism
(Conn’s syndrome) in a cat; a case report and review of comparative
aspects. J Small Anim Pract. 1983; 24: 293–307
[22]
Emms SG, Johnston DE, Eigenmann JE et al.: Adrenalectomy in
the management of canine hyperadrenocorticism. J Am Anim Hosp
Assoc. 1987; 23: 557–564
[23]
Evans K, Hosgood G, Boon D et al.: Hemoperitoneum secondary
to traumatic rupture of an adrenal tumor in a dog. J Am Vet Med
Assoc. 1991; 198: 278–280
[24]
Feldman EC, Nelson RW, Feldman MS: Use of low and high-dose
dexamethasone tests for distinguishing pituitary-dependent from
adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc.
1996; 209: 772–775
[25]
Feldman EC, Nelson RW: Canine hyperadrenocorticism (Cushing’s
[26]
Feldman EC, Nelson RW: Hyperadrenocorticism in cats (Cushing’s
[27]
Feldman EC, Nelson RW: Pheochromocytoma and multiple endocrine neoplasia. In: Feldman EC, Nelson RW (Hrsg.): Canine and
Feline Endocrinology and Reproduction. 3. Aufl. St. Louis, Missouri:
Saunders; 2004: 440–463
[28]
Flood SM, Randolph JF, Gelzer ARM et al.: Primary hyperaldosteronism in two cats. J Am Anim Hosp Assoc. 1999; 35: 411–416
[29]
Ford SL, Feldman EC, Nelson RW: Hyperadrenocorticism caused
by bilateral adrenocortical neoplasia in dogs: four cases (1983–
1988). J Am Vet Med Assoc. 1993; 202: 789–792
[30]
Galac S, Kooistra HS, Teske E et al.: Urinary corticoid/creatinine
ratios in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical
tumour in the dog. Vet Q. 1997; 19: 17–20
[31]
Galac S, Kool MMJ, Naan EC et al.: Expression of the ACTH receptor, steroidogenic acute regulatory protein, and steroidogenic enzymes in canine cortisol-secreting adrenocortical tumors. Domest
28.2 Tumoren der Nebennieren
[1]
Anderson CR, Birchard SJ, Powers BE et al.: Surgical treatment of
adrenocortical tumors: 21 cases (1990–1996). J Am Anim Hosp
Assoc. 2001; 37: 93–97
[2]
Ash RA, Harvey AM, Tasker S: Primary hyperaldosteronism in the
cat: a series of 13 cases. J Feline Med Surg. 2005; 7: 173–182
[3]
Bailey DB, Page RL: Tumors of the endocrine system. In: Withrow
Oncology. 4 Aufl. St. Louis, Missouri: Saunders; 2007: 583–609
[4]
Barthez PY, Marks SL, Woo J et al.: Pheochromocytoma in dogs:
61 cases (1984–1995). J Vet Intern Med. 1997; 11: 272–278
[5]
Benchekroun G, de Fornel-Thibaud P, Rodríguez Piñeiro MI et
al.: Ultrasonography criteria for differentiating ACTH dependency
from ACTH independency in 47 dogs with hyperadrenocorticism
and equivocal adrenal asymmetry. J Vet Intern Med. 2010; 24:
1077–1085
[6]
Berry CR, Wright KN, Breitschwerdt EB et al.: Use of iodine metaiodobenzylguanidine scintigraphy for the diagnosis of a pheochromocytoma in a dog. Vet Radiol Ultrasound. 1993; 34: 52–55
[7]
Berry CR, DeGrado TR, Nutter F et al.: Imaging of pheochromocytoma in 2 dogs using p-[18F]fluorobenzylguanidine. Vet Radiol Ultrasound. 2002; 43: 183–186
[8]
Besso JG, Penninck, DG, Gliatto JM: Retrospective ultrasonographic evaluation of adrenal lesions in 26 dogs. Vet Radiol Ultrasound.
1997; 38. 448–455
[9]
Boag AK, Neiger R, Church DB: Trilostane treatment of bilateral
adrenal enlargement and excessive sex steroid hormone production
in a cat. J Small Anim Pract. 2004; 45: 263–266
[10]
Boord M, Griffin C: Progesterone secreting adrenal mass in a cat
with clinical signs of hyperadrenocorticism. J Am Vet Med Assoc.
1999; 214: 666–669
[11]
Bouayad H, Feeney DA, Caywood DD et al.: Pheochromocytoma
1610–1615
[12]
Breitschwerdt EB, Meuten DJ, Greenfield CL et al.: Idiopathic
hyperaldosteronism in a dog. J Am Vet Med Assoc. 1985; 187: 841–
5
[32]
Briscoe K, Barrs VR, Foster DF et al.: Hyperaldosteronism and
hyperprogesteronism in a cat. J Feline Med Surg. 2009; 11: 758–
762
Galac S, Reusch CE, Kooistra HS et al.: Adrenals. In: Rijnberk A,
Kooistra HS (Hrsg.): Clinical Endocrinology of Dogs and Cats. Hannover: Schlütersche Verlagsgesellschaft; 2010, 93–154
[33]
Brown AJ, Alwood AJ, Cole SG: Malignant pheochromocytoma
presenting as a bradyarrhythmia in a dog. J Vet Emerg Crit Care.
2007; 17: 164–169
Gilson SD, Withrow SJ, Orton EC: Surgical treatment of pheochromocytoma: technique, complications, and results in six dogs. Vet
Surg. 1994; 23: 195–200
[34]
Gilson SD, Withrow SJ, Wheeler SL et al.: Pheochromocytoma in
[13]
[14]
[15]
Chun R, Jakovljevic S, Morrison WB et al.: Apocrine gland adenocarcinoma and pheochromocytoma in a cat. J Am Anim Hosp
Assoc. 1997; 33: 33–36
[35]
Haldane S, Graves TK, Bateman S et al.: Profound hypokalemia
causing respiratory failure in a cat with hyperaldosteronism. J Vet
Emerg Crit Care. 2007; 17: 202–207
[16]
Church DB, Lamb WA, Emslie DR: Plasma cortisol concentrations
in normal dogs given hydrocortisone sodium succinate. Aust Vet J.
1999; 77: 316–317
[36]
Henry CJ, Brewer WG, Montgomery RD et al.: Clinical vignette.
Adrenal pheochromocytoma. J Vet Intern Med. 1993; 7: 199–201
[37]
Herrera MA, Mehl ML, Kass PH et al.: Predictive factors and the
effect of phenoxybenzamine on outcome in dogs undergoing adrenalectomy for pheochromocytoma. J Vet Intern Med. 2008; 22:
1333–1339
[38]
Hill KE, Scott-Moncrieff CR, Koshko MA et al.: Secretion of sex
hormones in dogs with adrenal dysfunction. J Am Vet Med Assoc.
2005; 226: 556–561
[39]
Hoerauf A, Reusch C: Darstellung der Nebennieren mittels Ultraschall: Untersuchungen bei gesunden Hunden, Hunden mit nichtendokrinen Erkrankungen sowie mit Cushing-Syndrom. Kleintierprax. 1995; 40: 351–360
[40]
Hoerauf A, Reusch C: Ultrasonographic characteristics of both
adrenal glands in 15 dogs with functional adrenocortical tumors. J
[41]
Jaffe MH, Grooters AM, Partington BP et al.: Extensive venous
thrombosis and hind-limb edema associated with adrenocortical
carcinoma in a dog. J Am Anim Hosp Assoc. 1999; 35: 306–310
[42]
Javadi S, Djajadiningrat-Laanen SC, Kooistra HS et al.: Primary
hyperaldosteronism, a mediator of progressive renal disease in cats.
[43]
[44]
444–453
Johnson KD, Henry CJ, McCaw DL et al.: Primary hyperaldosteronism in a dog with concurrent lymphoma. J Vet Med A Physiol
Pathol Clin Med. 2006; 53: 467–470
[57]
Mayo-Smith WW, Boland GW, Noto RB et al.: From the RSNA
refresher courses. State-of-the-art adrenal imaging. RG. 2001; 21:
995–1012
[58]
Millard RP, Pickens EH, Wells KL: Excessive production of sex hormones in a cat with an adrenocortical tumor. J Am Vet Med Assoc.
2009; 234: 505–508
[59]
Moore LE, Biller DS, Smith TA: Use of abdominal ultrasonography
in the diagnosis of primary hyperaldosteronism in a cat. J Am Vet
Med Assoc. 2000; 217: 213–215
[60]
Morandi F, Mays JL, Newman SJ et al.: Imaging diagnosis – bilateral adrenal adenomas and myelolipomas in a dog. Vet Radiol Ultrasound. 2007; 48: 246–249
[61]
Myers NC: Adrenal incidentalomas: diagnostic workup of the incidentally discovered adrenal mass. In: Kintzer PP (Hrsg.): The Veterinary Clinics of North America. Small Animal Practice. Adrenal Disorders. Vol. 27. Number 2. Philadelphia: Saunders; 1997: 381–400
[62]
Nelson RW: Clinical manifestations of canine pheochromocytoma.
24th Annual ACVIM. Louisville, KY; 2006: 451–452
[63]
Nemanic S, London CA, Wisner ER: Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary
20: 508–515
[64]
Norman EJ, Thompson H, Mooney CT: Dynamic adrenal function
testing in eight dogs with hyperadrenocorticism associated with
adrenocortical neoplasia. Vet Rec. 1999; 144: 551–554
[65]
Out G: Pheochromocytoma in dogs: a retrospective study of nine
cases (1981–1987). Can Vet J. 1989; 30: 526–527
[45]
Keiser M, Flückiger M, Gardelle O et al.: Mitotane-Behandlung bei
einem Hund mit einem rezidivierenden Nebennierenrindenkarzinom – ein Fallbericht. Schweiz Arch Tierheilkd. 1999; 141: 279–285
[66]
Patnaik AK, Erlandson RA, Lieberman PH et al.: Extra-adrenal
pheochromocytoma (paraganglioma) in a cat. J Am Vet Med Assoc.
1990; 197: 104–106
[46]
Kintzer PP, Peterson ME: Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms. J Am Vet Med Assoc.
1994; 205: 54–61
[67]
[47]
Kook PH, Boretti FS, Hersberger M et al.: Urinary catecholamine
and metanephrine to creatinine ratios in healthy dogs at home and
in a hospital environment and in 2 dogs with pheochromocytoma. J
Vet Intern Med. 2007; 21: 388–393
Penninck DG, Feldman EC, Nyland TG: Radiographic features of
canine hyperadrenocorticism caused by autonomously functioning
adrenocortical tumors: 23 cases (1978–1986). J Am Vet Med Assoc.
1988; 192: 1604–1608
[68]
Kook PH, Grest P, Quante S et al.: Urinary catecholamine and
metadrenaline to creatinine ratios in dogs with a phaeochromocytoma. Vet Rec. 2010; 166: 169–174
Pradelli D, Quintavalla C, Domenech O et al.: Tumour thrombus.
Direct endoluminal ‘caudal caval vein – right atrium’ extension in a
dog affected by adrenal neoplasia. Vet Res Commun. 2003; 27:
787–789
[69]
Priester WA, McKay FW: The occurrence of tumors in domestic
animals. Natl. Cancer Inst Monogr. 1980; 54: 1–210
[49]
Krontveit R, Grondalen J, Teige J: Two cases of adrenal neoplasia
in the dog. EJCAP. 2003; 13: 207–212
[70]
[50]
Kyles AE, Feldman EC, De Cock HEV et al.: Surgical management
of adrenal gland tumors with and without associated tumor
thrombi in dogs: 40 cases (1994–2001). J Am Vet Med Assoc. 2003;
223: 654–662
Quante S, Sieber-Ruckstuhl N, Wilhelm S et al.: Hyperprogesteronismus due to bilateral adrenal carcinomas in a cat with diabetes
mellitus. Schweiz Arch Tierheilkd. 2009; 151: 437–442
[71]
Labelle P, Kyles AE, Farver TB et al.: Indicators of malignancy of
canine adrenocortical tumors: histopathology and proliferation
index. Vet Pathol. 2004; 41: 490–497
Quante S, Boretti FS, Kook PH et al.: Urinary catecholamine and
metanephrine to creatinine ratios in dogs with hyperadrenocorticism or pheochromocytoma, and in healthy dogs. J Vet Intern Med.
2010; 24: 1093–1097
[72]
Lacroix A, Clavier A: The adrenal cortex: basic concepts and diagnostic procedures. In: Pinchera A (Hrsg.): Endocrinology and Metabolism. London: McGraw-Hill International (UK) Ltd.; 2001: 285–
296
Reine NJ, Hohenhaus AE, Peterson ME et al.: Deoxycorticosterone-secreting adrenocortical carcinoma in a dog. J Vet Intern Med.
1999; 13: 386–390
[73]
Reisch N, Walz MK, Erlic Z et al.: Das Phäochromozytom – noch
immer eine Herausforderung. Internist. 2009; 50: 27–35
[74]
Renschler JS, Dean GA: What is your diagnosis? Abdominal mass
aspirate in a cat with an increased Na:K ratio. Vet Clin Pathol. 2009;
38: 69–72
[75]
Reusch CE, Feldman EC: Canine hyperadrenocorticism due to adrenocortical neoplasia. J Vet Intern Med. 1991; 5: 3–10
[76]
Reusch C, Glaus T, Wess G et al.: Klinische, labordiagnostische und
spezielle endokrinologische Untersuchungen bei Hunden mit hypophysärem Cushing-Syndrom: ein Vergleich zwischen Hunden mit
Makro- und solchen mit Mikrotumoren. Kleintierpraxis. 2001; 46:
261–270
[77]
Reusch CE: Hyperadrenocorticism. In: Ettinger SJ, Feldman EC
(Hrsg.): Textbook of Veterinary Internal Medicine. 6. Aufl. St. Louis
Missouri: Elsevier; 2005: 1592–1612
[48]
[51]
[52]
[53]
Lenders JWM, Pacak K, Walther McCM et al.: Biochemical diagnosis of pheochromocytoma. Which test is best? J Am Med Assoc.
2002; 287: 1427–1434
[54]
Llabres-Diaz FJ, Dennis R: Magnetic resonance imaging of the presumed normal canine adrenal glands. Vet Radiol Ultrasound. 2003;
44: 5–19
[55]
Louvet A, Lazard P, Denis B: Phaeochromocytoma treated by en
bloc resection including the suprarenal caudal vena cava in a dog. J
[56]
MacKay AD, Holt PE, Sparkes AH: Successful surgical treatment of
a cat with primary aldosteronism. J Feline Med Surg. 1999; 1: 117–
122
117
118
[78]
Reusch CE, Schellenberg S, Wenger M: Endocrine hypertension in
small animals. Vet Clin North Am Small Anim Pract. 2010; 40: 335–
352
[98]
Van Sluijs FJ, Sjollema BE, Voorhout G et al.: Results of adrenalectomy in 36 dogs with hyperadrenocorticism caused by adreno-cortical tumour. Vet Q. 1995; 17: 113–116
[79]
Rijnberk A, Belshaw BE: An alternative protocol for the medical
management of canine pituitary-dependent hyperadrenocorticism.
Vet Rec. 1988; 122: 486–488
[99]
Van Vonderen IK, Kooistra HS, Rijnberk A: Influence of veterinary
care on the urinary corticoid:creatinine ratio in dogs. J Vet Intern
Med. 1998; 12: 431–435
[80]
Rijnberk A, Voorhout G, Kooistra HS et al.: Hyperaldosteronism in
a cat with metastasised adrenocortical tumour. Vet Q. 2001; 23:
38–43
[100] Von Dehn BJ, Nelson RW, Feldman EC et al.: Pheochromocytoma
and hyperadrenocorticism in dogs: six cases (1982–1992). J Am Vet
Med Assoc. 1995; 207: 322–324
[81]
Rijnberk A, Kooistra HS, van Vonderen IK et al.: Aldosteronoma
in a dog with polyuria as the leading symptom. Domest Anim Endocrinol. 2001; 20: 227–240
[101] Voorhout G: X-ray-computed tomography, nephrotomography,
and ultrasonography of the adrenal glands of healthy dogs. Am J
Vet Res. 1990; 51: 625–631
[82]
Rodríguez Piñeiro MI, Benchekroun G, de Fornel-Thibaud P et
al.: Accuracy of an adrenocorticotropic hormone (ACTH) immunoluminometric assay for differentiating ACTH-dependent from
ACTH-independent hyperadrenocorticism in dogs. J Vet Intern Med.
2009; 23: 850–855
[102] Voorhout G, Stolp R, Rijnberk A et al.: Assessment of survey
radiography and comparison with x-ray computed tomography for
detection of hyperfunctioning adrenocortical tumors in dogs. J Am
Vet Med Assoc. 1990; 196: 1799–1803
[83]
Rose SA, Kyles AE, Labelle P et al.: Adrenalectomy and caval
thrombectomy in a cat with primary hyperaldosteronism. J Am
Anim Hosp Assoc. 2007; 43: 209–214
[84]
Rosenstein DS: Diagnostic imaging in canine pheochromocytoma.
[85]
Rossi GP, Sechi LA, Giacchetti G et al.: Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol
Metab. 2008; 19: 88–90
[86]
Rossmeisl JH, Scott-Moncrieff JCR, Siems J et al.: Hyperadrenocorticism and hyperprogesteronemia in a cat with an adrenocortical
adenocarcinoma. J Am Anim Hosp Assoc. 2000; 36: 512–517
[87]
Santamarina G, Espino L, Vila M et al.: Aortic thromboembolism
and retroperitoneal hemorrhage associated with a pheochromocytoma in a dog. J Vet Intern Med. 2003; 17: 917–922
[88]
Scavelli TD, Peterson ME, Matthiesen DT: Results of surgical treatment for hyperadrenocorticism caused by adrenocortical neoplasia
in the dog: 25 cases (1980–1984). J Am Vet Med Assoc. 1986; 189:
1360–1364
[89]
Schirpenbach C, Reincke M: Screening for primary aldosteronism.
Best Pract Res Clin Endocrinol Metab. 2006; 20: 369–384
[90]
Schoeman JP, Stidworthy MF: Budd-Chiari-like syndrome associated with an adrenal phaeochromocytoma in a dog. J Small Anim
Pract. 2001; 42: 191–194
[91]
Schulman RL: Feline primary hyperaldosteronism. Vet Clin North
[92]
Schultz RM, Wisner ER, Johnson EG et al.: Contrast-enhanced
computed tomography as a preoperative indicator of vascular invasion from adrenal masses in dogs. Vet Radiol Ultrasound. 2009; 50:
625–629
[93]
[94]
Schwartz P, Kovak JR, Koprowski A et al.: Evaluation of prognostic
factors in the surgical treatment of adrenal gland tumors in dogs:
Scott-Moncrieff JC, Koshko MA, Brown JA et al.: Validation of a
chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol. 2003; 32: 180–
187
[103] Whittemore JC, Preston CA, Kyles AE et al.: Nontraumatic rupture
of an adrenal gland tumor causing intra-abdominal or retroperitoneal hemorrhage in four dogs. J Am Vet Med Assoc. 2001; 219:
329–333
[104] Williams JE, Hackner SG: Pheochromocytoma presenting as acute
retroperitoneal hemorrhage in a dog. J Vet Emerg Crit Care. 2001;
11: 221–227
[105] Wimpole JA, Adagra CFM, Billson MF et al.: Plasma free metanephrines in healthy cats, cats with non-adrenal disease and a cat
with suspected phaeochromocytoma. J Feline Med Surg. 2010; 12:
435–440
[106] Zeugswetter FK, Pagitz M, Hittmair K et al.: Klinische Anwendung einer chemiluminometrischen ACTH-Bestimmung beim caninen Hyperadrenokortizismus. Schweiz Arch Tierheilkd. 2011; 153:
111–116
28.3 Tumoren der Schilddrüse und Nebenschilddrüse
[1]
Atkinson M: Lymphadenomegaly associated with carbimazole. J
Small Anim Pract. 2008; 49: 426
[2]
Aupperle H, Gliesche K, Schoon H-A: Schilddrüsentumoren beim
Hund – eine regionale Besonderheit im Raum Leipzig. Dtsch Tierärztl Wschr. 2003; 110: 154–157
[3]
Barber LG: Thyroid tumors in dogs and cats. Vet Clin North Am
[4]
Berger B, Feldman EC: Primary hyperparathyreoidism in dogs: 21
[5]
Bertazzolo W, Giudice C, DellʼOrco M et al.: Paratracheal cervical
mass in a dog. Vet Clin Pathol. 2003; 32: 209–222
[6]
Birchard SJ, Roesel OF: Neoplasia of the thyroid gland in the dog. A
retrospective study of 16 cases. J Am Anim Hosp Assoc 1981; 17:
369–372
[7]
Birchard SJ: Thyroidectomy and parathyroidectomy in the dog and
cat. Probl Vet Med. 1991; 3: 277–289
[8]
Birchard SJ: Thyroidectomy in the cat. Clin Tech Small Anim Pract.
2006; 21: 29–33
[9]
Boretti FS, Sieber-Ruckstuhl NS, Gerber B et al.: Thyroid enlargement and its relationship to clinicopathological parameters and T
(4) status in suspected hyperthyroid cats. J Feline Med Surg. 2009;
11: 286–292
[95]
Syme HM, Scott-Moncrieff JC, Treadwell NG et al.: Hyperadrenocorticism associated with excessive sex hormone production by an
adrenocortical tumor in two dogs. J Am Vet Med Assoc. 2001; 219:
1725–1728
[10]
[96]
Thuroczy J, van Sluijs FJ, Kooistra HS et al.: Multiple endocrine
neoplasias in a dog: corticotrophic tumour, bilateral adrenocortical
tumours, and pheochromocytoma. Vet Quart. 1998; 20: 56–61
Bracha S, Caron I, Holmberg DL et al.: Ectopic thyroid carcinoma
causing right ventricular outflow tract obstruction in a dog. J Am
Anim Hosp Assoc. 2009; 45: 138–141
[11]
[97]
Vandenbergh AGGD, Voorhout G, van Sluijs FJ et al.: Haemorrhage from a canine adrenocortical tumour: a clinical emergency.
Vet Rec. 1992; 131: 539–540
Brearley MJ, Hayes AM, Murphy S: Hypofractionated radiation
therapy for invasive thyroid carcinoma in dogs: a retrospective analysis of survival. J Small Anim Pract. 1999; 40: 206–210
[12]
Brearley MJ: Radiation therapy for unresectable thyroid carcinomas. J Am Vet Med Assoc. 2000; 217: 466–467
[13]
Broome MR: Thyroid Scintigraphy in Hyperthyroidism. Clin Tech
[14]
Broussard JD, Peterson ME, Fox PR : Changes in clinical and laboratory findings in cats with hyperthyroidism from 1983 to 1993. J
Am Vet Med Assoc. 1995; 206: 302–305
[34]
Ferguson DC: Endocrine disruptors: should we be concerned in
veterinary medicine? In: Proc. 56th Ann Meeting Am College Vet
Path & 40th Ann Meeting Am Soc Vet Clin Path, Boston, 2005
[35]
Fineman LS, Hamilton TA, de Gortari A et al.: Cisplatin chemotherapy for treatment of thyroid carcinoma in dogs: 13 cases. J Am
Anim Hosp Assoc. 1998; 34: 109–112
[15]
Büchler F: Hyperthyreose bei der Katze. Diss med vet, München,
1999
[36]
[16]
Carver JR, Kapatkin A, Patnaik AK: A comparison of medullary thyroid carcinoma and thyroid adenocarcinoma in dogs. A retrospective study of 38 cases. Vet Surg. 1995; 24: 315–319
Flanders JA, Harvey HJ: Feline Thyroidectomy: a comparison of
postoperative hypocalcemia associated with three different surgical
techniques. Vet Surg. 1987; 16: 362–366
[37]
[17]
Cook SM, Daniel GB, Walker MA et al.: Radiographic and scintigraphic evidence of focal pulmonary neoplasia in three cats with
hyperthyroidism: diagnostic and therapeutic considerations. J Vet
Intern Med. 1993; 7: 303–308
Flanders JA, Neth S, Erb HN et al.: Functional analysis of ectopic
parathyroid activity in cats. Am J Vet Res. 1991; 52: 1336–1340
[38]
Flanders JA: Surgical options for the treatment of hyperthyroidism
in the cat. J Feline Med Surg. 1999; 1: 127–134
[39]
[18]
Daminet S: Feline Hyperthyroidism and its relation with renal function. Proc. 31st WSAVA Congress, Prag, 2006
Flanders JA: Surgical therapy of the thyroid. Vet Clin North Am Sm
Anim Pract 1994; 24: 607–621
[40]
[19]
De Wet CS, Mooney CT, Thompson PN et al.: Prevalence of and
risk factors for feline hyperthyroidism in Hong Kong. J Fel Med Surg.
1999; 11: 315–321
Gear RN, Neiger R, Skelly BJ et al.: Primary hyperparathyroidism in
29 dogs: diagnosis, treatment, outcome and associated renal failure. J Small Anim Pract. 2005; 46: 10–16
[41]
[20]
Devilee P, Van Leeuwen IS, Voesten A et al.: The canine p53 gene
is subject to somatic mutations in thyroid carcinoma. Anticancer
Res. 1994; 14: 2039–2046
Tumoren beim Hund anhand der Sektionsstatistik des Instituts für
Tierpathologie, München (1951–1969). Diss med vet, München 1990
[42]
[21]
von Dewitz M: Zum Metastasierungsmuster einiger häufig auftretender maligner Geschwülste des Hundes. Diss med vet, München
1987
Goldstein RE, Atwater DZ, Cazolli DM et al.: Inheritance, mode of
inheritance, and candidate genes for primary hyperparathyroidism
in Keeshonden. J Vet Intern Med. 2007; 21: 199–203
[43]
[22]
Drost WT, Mattoon JS, Samii VF et al.: Computed tomographic
densitometry of normal feline thyroid glands. Vet Radiol Ultrasound. 2004; 45: 112–116
Goldstein RE, Long C, Swift NC et al.: Percutaneous ethanol injection for treatment of unilateral hyperplastic thyroid nodules in cats.
J Am Vet Med Assoc. 2001; 218: 1298–1302
[44]
[23]
Drost WT, Mattoon JS, Weisbrode SE: Use of helical computed
tomography for measurement of thyroid glands in clinically normal
cats. Am J Vet Res. 2006; 67: 467–471
Graves TK, Peterson ME: Diagnostic tests for feline hyperthyroidism. Vet Clin North Am Small Anim Pract. 1994; 24: 567–576
[45]
Guptill L, Scott-Moncrieff MA, Janovitz EB et al.: Response to
high dose radioactive iodine administration in cats with thyroid carcinoma that had previously undergone surgery. J Am Vet Med
Assoc. 1995; 207: 1055–1058
[46]
Hammer KB, Holt DE, Ward CR: Altered expressions of G proteins
in thyroid gland adenomas obtained from hyperthyroid cats. Am J
Vet Res. 2000; 61: 874–879
[24]
Dye JA, Venier MC, Ward R et al.: Brominated-flame retardants
(BFRs) in cats—Possible linkage to feline hyperthyroidism? Proc 25th
Ann Forum ACVIM, Seattle 2007
[25]
Dye JA, Venier MC, Zhu L et al.: Elevated PBDE levels in pet cats:
sentinels for humans? Environ Sci Technol. 2007; 41: 6350–6356
[26]
Edinboro CH, Scott-Moncrieff JC, Glickman LT: Feline hyperthyroidism: Potential relationship with iodine supplement requirements
of commercial cat foods. J Feline Med Surg. 2010; 12: 672–679
[47]
Harari J, Patterson JS, Rosenthal RC: Clinical and pathologic features of thyroid tumors in 26 dogs. J Am Vet Med Assoc. 1968; 188:
1160–1164
[27]
Edinboro CH, Scott-Moncrieff JC, Janovitz E et al.: Epidemiologic
study of relationships between consumption of commercial canned
food and risk of hyperthyroidism in cats. J Am Vet Med Assoc. 2004;
224: 879–886
[48]
Harvey AM, Hibbert A, Barrett EL et al.: Scintigraphic findings in
120 hyperthyroid cats. J Feline Med Surg. 2009; 11: 96–106
[49]
Hayes HM, Fraumeni JF: Canine thyroid neoplasms: epidemiologic
features. J Natl Cancer Inst. 1975; 55: 931–943
Eskens U: Statistische Untersuchungen über nach Empfehlungen
der Weltgesundheitsorganisation (WHO) klassifizierte Geschwülste
des Hundes unter besonderer Berücksichtigung von Mamma- und
Hauttumoren. Diss Vet Med, Gießen 1983
[50]
Hibbert A: Feline Thyroid carcinoma. Proc. 20th Ann Congress
ECVIM-CA, Toulouse 2010, 152–154
[51]
Hibbert A, Gruffydd-Jones T, Barrett EL et al.: Feline thyroid carcinoma: diagnosis and response to high-dose radioactive iodine treatment. J Feline Med Surg. 2009; 11: 116–124
[52]
van Hoek I, Lefebvre HP, Peremans K et al.: Short- and long-term
follow-up of glomerular and tubular renal markers of kidney function in hyperthyroid cats after treatment with radioiodine. Domest
[53]
Hoffmann G, Marks SL, Taboada J et al.: Transdermal methimazole treatment in cats with hyperthyroidism. J Feline Med Surg.
2003; 5: 77–82
[54]
Hofmeister E, Kippenes H, Mealey KL et al.: Functional cystic thyroid adenoma in a cat. J Am Vet Med Assoc. 2001; 219: 190–193
[55]
Ihle SL, Nelson RW, Cook JR Jr.: Seizures as a manifestation of primary hyperparathyroidism in a dog. J Am Vet Med Assoc. 1988;
192: 71–72
[56]
Jacobs I: Die Rolle des freien Thyroxins in der Diagnostik von Schilddrüsenerkrankungen bei der Katze. Diss med vet, Hannover, 2002
[57]
Jeglum KA, Whereat A: Chemotherapy of canine thyroid carcinoma. Comp Cont Educ Small Anim Pract 1983; 96: 96–98
[28]
[29]
Feeney DA, Anderson KL: Nuclear imaging and radiation therapy in
canine and feline thyroid disease: Vet Clin North Am Small Anim
Pract. 2007; 37: 799–821
[30]
Feldman EC, Hoar B, Pollard R et al.: Pretreatment clinical and
laboratory findings in dogs with primary hyperparathyroidism: 210
[31]
Feldman EC, Nelson RW: Primary Hyperparathyroidism (PHPTH) in
dogs. In: Feldman EC, Nelson RW. (Hrsg.) Canine and feline endocrinology and reproduction. 3. Aufl. Saunders-Elsevier, St. Louis 2004;
S. 678–711
[32]
Feldman EC, Nelson RW: Primary Hyperparathyroidism in cats. In:
Feldman EC, Nelson RW. (Hrsg.): Canine and feline endocrinology
and reproduction. 3. Aufl. Saunders Elsevier, St. Louis 2004; 711–
713
[33]
Feldman EC, Wisner ER, Nelson RW et al.: Comparison of results
of hormonal analysis of samples obtained from selected venous
sites versus cervical ultrasonography for localizing parathyroid masses in dogs. J Am Vet Med Assoc. 1997; 211: 54–56
119
120
[58]
Jores K, Kessler M: Primärer Hyperparathyreoidismus beim Hund.
Diagnose, Therapie und postoperatives Management bei 19 Hunden. Tierärztl Prax. 2011; 6: 389–396
[59]
[60]
[82]
Kallet AJ, Richler KP, Feldman EC et al.: Primary hyperparathyroidism in seven cats: seven cases (1984–1989). J Am Vet Med Assoc.
1991; 197: 1767–1771
Merryman JI, Buckles EL, Bowers G et al.: Overexpression of c-ras
in hyperplasia and adenomas of the feline thyroid gland: an immunohistochemical analysis of 34 cases. Vet Pathol. 1999; 36: 117–
124
[83]
Kass PH, Peterson ME, Levy J et al.: Evaluation of environmental,
nutritional, and host factors in cats with hyperthyroidism. J Vet
Intern Med. 1999; 13: 323–329
Messinger JS, Windham WR, Ward CR: Ionized hypercalcemia in
dogs: a retrospective study of 109 cases (1998–2003). J Vet Intern
Med. 2009; 23: 514–519
[84]
Milner R.J., Channell C.D., Levy J.K. et al.: Survival times for cats
with hyperthyroidism treated with iodine 131, methimazole, or
both: 167 cases (1996–2003). J Am Vet Med Assoc 2006; 228:
559–563
[61]
Kennedy RL, Thoday KL: Autoantibodies in feline hyperthyroidism.
Res Vet Sci. 1988; 45: 300–306
[62]
Klein MK, Powers BE, Withrow SJ et al.: Treatment of thyroid carcinoma in dogs by surgical resection alone: 20 cases. (1981–1989).
J Am Vet Med Assoc. 1995; 206: 1007–1009
[85]
Mitchell M, Hurov LI, Troy GC: Canine thyroid carcinomas: clinical
occurrence, staging by means of scintiscans, and therapy of 15
cases. Vet Surg. 1979; 8: 112–118
[63]
Kraft W, Deinert M, Büchler F et al.: Symptome bei Hyperthyreose der Katze: Eine retrospektive Studie. Kleintierprax. 1999; 44:
719–732
[86]
Mooney CT: Pathogenesis of feline hyperthyroidism. J Feline Med
Surg. 2002; 4: 167–169
[87]
[64]
Kurzke E: Morphologische Grundlagen der Schilddrüsensonographie bei der Katze. Diss med vet, München, 2001
Naan EC, Kirpensteijn J, Kooistra HS et al.: Results of thyroidectomy in 101 cats with hyperthyroidism. Vet Surg. 2006; 35: 287–
293
[65]
Kusch S: Erhebungen über das Vorkommen bösartiger Blastome
beim Hund anhand der Sektionsstatistik des Institutes für Tierpathologie, München (1970—1984). Diss med vet, München 1985
[88]
Nemzek JA, Kruger JM, Walshaw R et al.: Acute onset of hypokalemia and muscular weakness in four hyperthyroid cats. J Am Vet
Med Assoc. 1994; 205: 65–67
[66]
Lagadic M, Cohn-Bendit F: Tumeurs malignes de la thyroide chez
le chien: étude retrospective de 137 cas. Prat Medic Chirurg l’Anim
Comp. 1995; 30: 85–92
[89]
Ngyen LQ, Arseven OK, Gerber H et al.: Cloning of the cat TSH
receptor and evidence against an autoimmune etiology of feline
hyperthyroidism. Endocrinology. 2002; 143: 395–402
[67]
Leav I, Schiller AL, Rijnberk A et al.: Adenomas and carcinomas of
the canine and feline thyroid. Am J Pathol. 1976; 83: 61–94
[90]
[68]
Leblanc B, Parodi AL, Lagadic M et al.: Immunocytochemistry of
canine thyroid tumors. Vet Pathol. 1991; 28: 370–380
Niessen SJ, Voyce MJ, de Villiers L et al.: Generalised lymphadenomegaly associated with methimazole treatment in a hyperthyroid
[91]
Lécuyer M, Prini S, Dunn ME et al.: Clinical efficacy and safety of
transdermal methimazole in the treatment of feline hyperthyroidism. Can Vet J. 2006; 47: 131–135
Norsworthy GD, Adams VJ, McElhaney MR et al.: Palpable thyroid
and parathyroid nodules in asymptomatic cats. J Feline Med Surg.
2002; 4: 145–151
[92]
Norsworthy GD, Adams VJ, McElhaney MR et al.: Relationship
between semi-quantitative thyroid palpation and total thyroxine
concentration in cats with and without hyperthyroidism. J Feline
Med Surg. 2002; 4: 139–143
[93]
Olczak J, Jones BR, Pfeiffer DU et al.: Multivariate analysis of risk
factors for feline hyperthyroidism in New Zealand. N Z Vet J. 2005;
53: 53–58
[94]
Pack L, Roberts RE, Dawson SD et al.: Definitive radiation therapy
for infiltrative thyroid carcinoma in dogs. Vet Radiol Ultrasound.
2001; 42: 471–474
[95]
Padgett SL, Tobias KM, Leathers CW et al.: Efficacy of parathyroid
gland autotransplantation in maintaining serum calcium concentrations after bilateral thyroparathyroidectomy in cats. J Am Anim
Hosp Assoc. 1998; 34: 219–224
[96]
Paepe D, Smets P, van Hoek I et al.: Within- and between-examiner agreement for two thyroid palpation techniques in healthy and
hyperthyroid cats. J Feline Med Surg. 2008; 10: 558–565
[97]
Patnaik AK, Liebermann PH: Canine medullary carcinoma of the
thyroid. Vet Pathol. 1978; 15; 590–599
[98]
Patnaik AK, MacEwen EG, Erlandson RA: Mediastinal parathyroid
adenocarcinoma in a dog. Vet Pathol. 1978; 15: 55–63
[99]
Peeters ME, Timmermans-Sprang EP, Mol JA: Feline thyroid adenomas are in part associated with mutations in the G (s alpha) gene
and not with polymorphisms found in the thyrotropin receptor. Thyroid. 2002; 12: 571–575
[69]
[70]
Lee JJ, Larsson C, Lui WO et al.: A dog pedigree with familial
medullary thyroid cancer. Int J Oncol. 2006; 29: 1173–1182
[71]
Liptak JM: Canine thyroid carcinoma. Clin Tech Small Anim Pract.
2007; 22: 75–81
[72]
Liptak JM, Kamstock DA, Dernell WS et al.: Cranial mediastinal
carcinomas in nine dogs. Vet Comp Oncol. 2008; 6: 19–30
[73]
Liu SK, Peterson ME, Fox PR : Hypertrophic cardiomyopathy and
hyperthyroidism in the cat. J Am Vet Med Assoc. 1984; 185: 52–57
[74]
Long CD, Goldstein RE, Hornof WJ et al.: Percutaneous ultrasound-guided chemical parathyroid ablation for treatment of primary hyperparathyroidism in dogs. J Am Vet Med Assoc. 1999; 215:
217–221
[75]
Maggio F, DeFrancesco TC, Atkins CE et al.: Ocular lesions associated with systemic hypertension in cats: 69 cases (1985–1998). J Am
Vet Med Assoc. 2000; 217: 695–702
[76]
Malik R: Dog with a functional intra-thoracic thyroid tumour. J
Small Anim Pract. 2007; 48: 474
[77]
Marks SL, Koblik PD, Hornof WJ et al.: 99mTc-pertechnetate imaging of thyroid tumors in dogs: 29 cases (1980–1992). J Am Vet
Med Assoc. 1994; 204: 756–760
[78]
Martin KM, Rossing MA, Ryland LM et al.: Evaluation of dietary
and environmental risk factors for hyperthyroidism in cats. J Am Vet
Med Assoc. 2000; 217: 853–856
[79]
Matwichuk CL, Taylor SM, Daniel GB et al.: Double-phase parathyroid scintigraphy in dogs using technetium-99M-sestamibi. Vet
[80]
Mayer MN, MacDonald VS: External beam radiation therapy for
thyroid cancer in the dog. Can Vet J. 2007; 48: 761–763
[81]
Mellanby RJ, Craig R, Evans H et al.: Plasma concentrations of
parathyroid hormone-related protein in dogs with potential disorders of calcium metabolism. Vet Rec. 2006; 159: 833–838.
[100] Peterson ME, Becker DV: Radioiodine treatment of 524 cats with
hyperthyroidism. J Am Vet Med Assoc. 1995; 207: 1422–1428
[101] Peterson ME, Graves TK, Gamble DA: Triiodothyronine (T3) suppression test: An aid in the diagnosis of mild hyperthyroidism in
cats. J Vet Intern Med. 1990; 4: 233–238
[102] Peterson ME, Kintzer PP, Cavanagh PG et al.: Feline hyperthyroidism: Pretreatment clinical and laboratory evaluation of 131 cases. J
Am Vet Med Assoc. 1983; 183: 103–110
121
[103] Peterson ME, Kintzer PP, Hurvitz AI: Methimazole treatment of
262 cats with hyperthyroidism. J Vet Intern Med. 1988; 2: 150–157
[128] Swalec KM, Birchard SJ: Recurrence of hyperthyroidism after thyroidectomy in cats. J Am Anim Hosp Assoc. 1990; 26: 433–437
[104] Peterson ME, Melián C, Nichols R: Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal
disease. J Am Vet Med Assoc. 2001; 218: 529–536
[129] Taeymans O, Dennis R, Saunders JH: Magnetic resonance imaging
of the normal canine thyroid gland. Vet Radiol Ultrasound. 2008;
49: 238–242
[106] Peterson ME, Ward CR: Etiopathologic findings of hyperthyroidism
in cats. Vet Clin North Am Small Anim Pract. 2007; 37: 633–645
[107] Phillips DE, Radlinsky MG, Fischer JR et al.: Cystic thyroid and
parathyroid lesions in cats. J Am Anim Hosp Assoc. 2003; 39: 349–
354
[108] Pollard RE, Long CD, Nelson RW et al.: Percutaneous ultrasonographically guided radiofrequency heat ablation for treatment of
primary hyperparathyroidism in dogs. J Am Vet Med Assoc. 2001;
218: 1106–1110
[109] Puille M, Auch D, Spillmann T et al.: Bestimmung von TSH und
freien Schilddrüsenhormonen in der Hyperthyreosediagnostik der
Katze. Tierärztl Prax. 2000; 28(K): 289–294
[110] Puille M, Knietsch M, Spillmann T et al.: Radioiodtherapie bei Katzen mit Hyperthyreose in Deutschland. Nuklearmedizin. 2002; 41:
245–251
[111] Puille M, Puille N: Nuklearmedizinische Diagnostik und Therapie
der felinen Hyperthyreose. Nuklearmediziner. 2010; 33: 23–31
[112] Radlinsky MG: Thyroid surgery in dogs and cats. Vet Clin North Am
[130] Taeymans O, Peremans K, Saunders JH: Thyroid imaging in the
dog: current status and future directions. J Vet Intern Med. 2007;
21: 673–684
[131] Taeymans O, Schwarz T, Duchateau L et al.: Computed tomographic features of the normal canine thyroid gland. Vet Radiol Ultrasound. 2008; 49: 13–19
[132] Théon AP, Marks SL, Feldman ES et al.: Prognostic factors and patterns of treatment failure in dogs with unresectable differentiated
thyroid carcinomas treated with megavoltage irradiation. J Am Vet
Med Assoc. 2000; 216: 1775–1779
[133] Théon AP, Van Vechten MK, Feldman E: Prospective randomized
comparison of intravenous versus subcutaneous administration of
radioiodine for treatment of hyperthyroidism in cats. Am J Vet Res.
1994; 55: 1734–1738
[134] Thompson EJ, Stirtzinger T, Lumsden JH et al.: Fine needle aspiration cytology in the diagnosis of canine thyroid carcinoma. Can Vet
J. 1980; 21: 186–188
[135] Thompson KG, Jones LP, Smylie WA et al.: Primary hyperparathyroidism in German shepherd dogs: A disorder of probable genetic
origin. Vet Pathol. 1984; 21: 370–376
[136] Trepanier LA, Hoffman SB, Kroll M et al.: Efficacy and safety of
once versus twice daily administration of methimazole in cats with
hyperthyroidism. J Am Vet Med Assoc. 2003; 222: 954–958
[113] Ramos-Vara JA, Miller MA, Johnson GC et al.: Immunohistochemical detection of thyroid transcription factor-1, thyroglobulin, and
calcitonin in canine normal, hyperplastic, and neoplastic thyroid
gland. Vet Pathol. 2002; 39: 480–487
[137] Turrel JM, Feldman EC, Nelson RW et al.: Thyroid carcinoma causing hyperthyroidism in cats: 14 cases (1981–1986). J Am Vet Med
Assoc. 1988; 193: 359–364
[114] Rasor L, Pollard R, Feldman EC: Retrospective evaluation of three
treatment methods for primary hyperparathyroidism in dogs. J Am
[138] Turrel JM, McEntee MC, Burke BP et al.: Sodium iodide I 131 treatment of dogs with nonresectable thyroid tumors: 39 cases (1990–
2003). J Am Vet Med Assoc. 2006; 229: 542–548
[115] Rebhun RB, Thamm DH: Multiple distinct malignancies in dogs: 53
cases. J Am Anim Hosp Assoc. 2010; 46: 20–30
[139] Verschueren CP: Clinico-pathological and endocrine aspects of
canine thyroid cancer. Diss med vet, Utrecht, 1992
[116] Reese S, Büchler F, Kraft W: Die sonographische Schilddrüsenuntersuchung bei der Katze. Tierärztl Prax. 2001; 29(K): 184–190
[140] Verschueren CP, Selman PJ, Mol JA et al.: Circulating thyroglobulin
measurements by homologous radioimmunassay in dogs with thyroid carcinoma. Acta Endocrinol. 1991; 125: 291–298
[117] Reese S, Müller M, Kurzke E et al.: Prävalenz morphologischer
Schilddrüsenveränderungen bei der Katze. Tierärztl Prax. 2002; 30
(K): 274–281
[118] Reimann N, Nolte I, Bonk U et al.: Trisomy 18 in a canine thyroid
adenoma. Cancer Genet Cytogenet. 1996; 90: 154–156
[119] Riensche MR, Graves TK, Schaeffer DJ: An investigation of predictors of renal insufficiency following treatment of hyperthyroidism in
cats. J Feline Med Surg. 2008; 10: 160–166
[120] Rijnberk A: Hyperthyroidism in the dog and its treatment with
radioactive iodide. Tijdschr Diergeneeskd. 1966; 91: 789–794
[121] Rozanski EA, Stobie D: Laryngeal paralysis secondary to a cystic
thyroid adenoma in a cat. Fel Pract. 1995; 23: 6–7
[122] Sartor LL, Trepanier LA, Kroll MM et al.: Efficacy and safety of
transdermal methimazole in the treatment of cats with hyperthyroidism. J Vet Intern Med. 2004; 18: 651–655
[123] Sassnau R: Epidemiologische Untersuchungen zur Prävalenz der
felinen Hyperthyreose. Diss med vet, München 2005
[124] Scarlett JM: Epidemiology of thyroid diseases of dogs and cats. Vet
[125] Scarlett JM, Moise NS, Rayl J: Feline hyperthyroidism: a descriptive
and case-control study. Prev Vet Med. 1988; 6: 295–309
[126] Schaudinn W: Die epithelialen Schilddrüsentumoren des Hundes.
Diss med vet, München 1972
[127] Sueda MT, Stefanacci JD: Ultrasound evaluation of the parathyroid
glands in two hypercalcemic cats. Vet Radiol Ultrasound. 2000; 41:
448–451
[141] van Vonderen IK, Kooistra HS, Peeters ME et al.: Parathyroid hormone immunohistochemistry in dogs with primary and secondary
hyperparathyroidism: the question of adenoma and primary hyperplasia. J Comp Pathol. 2003; 129: 61–69
[142] Wakeling J, Elliott J, Petrie A et al.: Urinary iodide concentration
in hyperthyroid cats. Am J Vet Res. 2009; 70: 741–749
[143] Wakeling J, Everard A, Brodbelt D et al.: Risk factors for feline
hyperthyroidism in the UK. J Small Anim Pract. 2009; 50: 406–414
[144] Ward CR, Achenbach SE, Peterson ME et al.: Expression of inhibitory G proteins in adenomatous thyroid glands obtained from
hyperthyroid cats. Am J Vet Res. 2005; 66: 1478–1482
[145] Watson SG, Radford AD, Kipar A et al.: Somatic mutations of the
thyroid-stimulating hormone receptor gene in feline hyperthyroidism: parallels with human hyperthyroidism. J Endocrinol. 2005;
186: 523–537
[146] Welches CD, Scavelli TD, Matthiesen DT et al.: Occurrence of
problems after three techniques of bilateral thyroidectomy in cats.
Vet Surg. 1989; 18: 392–396
[147] Wells AL, Long CD, Hornof WJ et al.: Use of percutaneous ethanol
injection for treatment of bilateral hyperplastic thyroid nodules in
[148] Williams T, Elliott J, Syme H: Association of iatrogenic hypothyroidism with azotemia and reduced survival time in cats treated for
hyperthyroidism. J Vet Intern Med. 2010; 24: 1086–1092
[105] Peterson ME: Update on recent research in feline hyperthyroidism.
Proc. 20th Ann Congress ECVIM-CA, Toulouse 2010, 155–157
122
[149] Wisner ER, Nyland TG: Ultrasonography of the thyroid and parathyroid glands. Vet Clin North Am Small Anim Pract. 1998; 28:
973–991
[16]
English RV, Breitschwerdt EB, Grindem CB et al.: Zollinger-Ellison
syndrome and myelofibrosis in a dog. J Am Vet Med Assoc. 1988;
192: 1430–4
[150] Wisner ER, Penninck D, Biller DS et al.: High-resolution parathyroid sonography. Vet Radiol Ultrasound. 1997; 38: 462–466
[17]
Feldman EC, Nelson RW: Beta-cell neoplasia: insulinoma. In: Feldman EC, Nelson RW (Hrsg.): Canine and Feline Endocrinology and
Reproduction. 3. Aufl. St. Louis, Missouri: Saunders; 2004: 616–644
[18]
Feldman EC, Nelson RW: Gastrinoma, glucagonoma, and other
APUDomas. In: Feldman EC, Nelson RW (Hrsg.): Canine and Feline
[19]
Fingeroth JM, Smeak DD, Jacobs RM: Intravenous methylene blue
infusion for intraoperative identification of parathyroid gland and
pancreatic islet-cell tumors in dogs: Part I: experimental determination of dose-related staining efficacy and toxicity. J Am Anim Hosp
Assoc. 1986; 24: 165–173
[20]
Fingeroth JM, Smeak DD: Intravenous methylene blue infusion for
intraoperative identification of pancreatic islet-cell tumors in dogs.
Part II: clinical trials and results in four dogs. J Am Anim Hosp Assoc.
1987; 24: 175–182
[21]
Fischer JR, Smith SA, Harkin KR: Glucagon constant-rate infusion:
a novel strategy for the management of hyperinsulinemic-hypoglycemic crisis in the dog. J Am Anim Hosp Assoc. 2000; 36: 27–32
[151] Wisner ER, Théon AP, Nyland TG: Ultrasonographic examination
of the thyroid gland of hyperthyroid cats: comparison to
99mTcO4–scintigraphy. Vet Radiol Ultrasound. 1994; 35: 53–58
[152] Worth AJ, Zuber RM, Hocking M: Radioiodide (131I) therapy for
the treatment of canine thyroid carcinoma. Aust Vet J. 2005; 83:
208–214
[153] Zarrin KH, Hänichen T: Comparative histopathological study of the
canine thyroid gland in London und Munich. J Small Anim Pract.
1974; 15: 329–342
[154] Zarrin KH: Naturally occurring parafollicular cell carcinoma of the
thyroid in dogs. A histological and ultrastructural study. Vet Pathol.
1977; 14: 556–566
28.4 Tumoren des endokrinen Pankreas
[1]
Allenspach K, Arnold P, Glaus T et al.: Glucagon-producing neuroendocrine tumour associated with hypoaminoacidaemia and skin
lesions. J Small Anim Pract. 2000; 41: 402–406
[22]
[2]
Altschul M, Simpson KW, Dykes NL et al.: Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a
Fukushima R, Ichikawa K, Hirabayashi M et al.: A case of canine
gastrinoma. J Vet Med Sci. 2004; 66: 993–995
[23]
Bailey DB, Page RL: Tumors of the endocrine system. In: Withrow
Oncology. 4 Aufl. St. Louis, Missouri: Saunders; 2007: 583–609
Garden OA, Reubi JC, Dykes NL et al.: Somatostatin Receptor Imaging in vivo by planar scintigraphy facilitates the diagnosis of canine
insulinomas. J Vet Intern Med. 2005; 19: 168–176
[24]
Bell R, Mooney CT, Mansfield CS et al.: Treatment of insulinoma
in a springer spaniel with streptozotocin. J Small Anim Pract. 2005;
46: 247–250
Gardner DG: Multiple endocrine neoplasia. In: Greenspan FS, Gardner DG (Hrsg.): Basic & Clinical Endocrinology. 7. Aufl. New York:
Lange Medical Books/McGraw-Hill; 2004: 829–841
[25]
Gaschen L, Kircher P, Wolfram K: Endoscopic ultrasound of the
canine abdomen. Vet Radiol Ultrasound. 2007; 48: 338–349
[26]
Green RA, Gartrell CL: Gastrinoma: a retrospective study of four
cases (1985–1995). J Am Anim Hosp Assoc. 1997; 33: 524–527
[27]
Greene SN, Bright RM: Insulinoma in a cat. J Small Anim Pract.
2008; 49: 38–40
[28]
Gross TL, O’Brien TD, Davies AP et al.: Glucagon-producing pancreatic endocrine tumors in two dogs with superficial necrolytic dermatitis. J Am Vet Med Assoc. 1990; 197: 1619–1622
[29]
Happe RP, van der Gaag I, Lamers CBHW et al.: Zollinger-Ellison
syndrome in three dogs. Vet Pathol. 1980; 17: 177–186
[30]
Hawkins KL, Summers BA, Kuhajda FP et al.: Immunocytochemistry of normal pancreatic islets and spontaneous islet cell tumors
in dogs. Vet Pathol. 1987; 24: 170–179
[31]
Hawks D, Peterson ME, Hawkins KL et al.: Insulin-secreting pancreatic (islet cell) carcinoma in a cat. J Vet Intern Med. 1992; 6: 193–
196
[32]
Hayden DW, Henson MS: Gastrin-secreting pancreatic endocrine
tumor in a dog (putative Zollinger-Ellison syndrome). J Vet Diagn
Invest. 1997; 9: 100–103
[33]
Hoenerhoff M, Kiupel M: Concurrent gastrinoma and somatostatinoma in a 10–year-old Portuguese water dog. J Comp Path. 2004;
130: 313–318
[3]
[4]
[5]
Bennett PF, Norman EJ: Mitotane (o’p’-DDD) resistance in a dog
with pituitary-dependent hyperadrenocorticism and phaeochromocytoma. Aust Vet J. 1998; 76: 101–103
[6]
Bond R, McNeil PE, Evans H et al.: Metabolic epidermal necrosis in
two dogs with different underlying diseases. Vet Rec. 1995; 136:
466–471
[7]
Braund KG, Steiss JE, Amling KA et al.: Insulinoma and subclinical
peripheral neuropathy in two dogs. J Vet Intern Med. 1987; 1: 86–
90
[8]
Brooks D, Watson GL: Omeprazole in a dog with gastrinoma. J Vet
Intern Med. 1997; 11: 379–381
[9]
Buishand FO, Kik M, Kirpensteijn J: Evaluation of clinico-pathological criteria and the Ki67 index as prognostic indicators in canine
insulinoma. Vet J. 2010; 185: 62–67
[10]
Cave TA, Evans H, Hargreaves J et al.: Metabolic epidermal necrosis in a dog associated with pancreatic adenocarcinoma, hyperglucagonaemia, hyperinsulinaemia and hypoaminoacidaemia. J Small
Anim Pract. 2007; 48: 522–526
[11]
Caywood DD, Klausner JS, O’Leary TP et al.: Pancreatic insulinsecreting neoplasms: clinical, diagnostic, and prognostic features in
73 dogs. J Am Anim Hosp Assoc. 1987; 24: 577–584
[12]
Cerundolo R, McEvoy F, McNeil PE et al.: Ultrasonographic detection of a pancreatic glucagon-secreting multihormonal islet cell
tumour in a dachshund with metabolic epidermal necrosis. Vet Rec.
1999; 145: 662–666
[34]
Hughes SM: Canine gastrinoma: a case study and literature review
of therapeutic options. N Z Vet J. 2006; 54: 242–247
[35]
Christ E, Wild D, Forrer F et al.: Glucagon-like peptide-1 receptor
imaging for localization of insulinomas. J Clin Endocrinol Metab.
2009; 94: 4398–4405
Jones BR, Nicholls MR, Badman R: Peptic ulceration in a dog associated with an islet cell carcinoma of the pancreas and an elevated
plasma gastrin level. J Small Anim Pract. 1976; 17: 593–598
[36]
King AD, Ko GTC, Yeung VTF et al.: Dual phase spiral CT in the
detection of small insulinomas of the pancreas. Br J Radiol. 1998;
71: 20–23
[37]
Kiupel M, Mueller PB, Vara JR et al.: Multiple endocrine neoplasia
in a dog. J Comp Path. 2000; 123: 210–217
[13]
[14]
Diroff JS, Sanders NA, McDonough SP et al.: Gastrin-secreting
neoplasia in a cat. J Vet Intern Med. 2006; 20: 1245–1247
[15]
Eng J, Du BH, Johnson GF et al.: Cat gastrinoma and the sequence
of cat gastrins. Regul Pept. 1992; 37: 9–13
[38]
Kraje AC: Hypoglycemia and irreversible neurologic complications
in a cat with insulinoma. J Am Vet Med Assoc. 2003; 223: 812–814
[39]
Kruth SA, Feldman EC, Kennedy PC: Insulin-secreting islet cell
tumors: Establishing a diagnosis and the clinical course for 25 dogs.
J Am Vet Med Assoc. 1982; 181: 54–58
[60]
Robben JH, Visser-Wisselaar HA, Rutteman GR et al.: In vitro and
in vivo detection of functional somatostatin receptors in canine
insulinomas. J Nucl Med. 1997; 38: 1036–1042
[61]
Robben JH, Pollak Y, Kirpensteijn J et al.: Comparison of ultrasonography, computed tomography, and single-photon emission
computed tomography for the detection and localization of canine
insulinoma. J Vet Intern Med. 2005; 19: 15–22
[62]
Robben JH, van den Brom WE, Mol JA et al.: Effect of octreotide
on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. Res
Vet Sci. 2006; 80: 25–32
[63]
Schrauwen E: Clinical peripheral polyneuropathy associated with
canine insulinoma. Vet Rec. 1991; 128: 211–212
[64]
Schrauwen E, Van Ham L, Desmidt M et al.: Peripheral polyneuropathy associated with insulinoma in the dog: clinical, pathological,
and electrodiagnostic features. Prog Vet Neurol. 1996; 7: 16–19
[65]
Seicean A, Tantau M, Badea R et al.: The applicability of radial
endoscopic ultrasonography in pancreatic diseases. J Gastrointestin
Liver Dis. 2007; 16: 77–83
[66]
Madarame H, Kayanuma H, Shida T et al.: Retrospective study of
canine insulinomas: eight cases (2005–2008). J Vet Med Sci. 2009;
71: 905–911
Shahar R, Rousseaux C, Steiss J: Peripheral polyneuropathy in a
dog with functional islet B-cell tumor and widespread metastasis. J
Am Vet Med Assoc. 1985; 187: 175–177
[67]
Mai W, Caceres AV: Dual-phase computed tomographic angiography in three dogs with pancreatic insulinoma. Vet Radiol Ultrasound. 2008; 49: 141–148
Siliart B, Stambouli F: Laboratory diagnosis of insulinoma in the
dog: a retrospective study and a new diagnostic procedure. J Small
Anim Pract. 1996; 37: 367–370
[68]
Simpson KW, Dykes NL: Diagnosis and treatment of gastrinoma.
Semin Vet Med Surg (Small Anim). 1997; 12: 274–281
[69]
Steiner JM: Unusual gastrointestinal endocrine disorders. In: Mooney CT, Peterson ME (Hrsg.): BSAVA Manual of Canine and Feline
Endocrinology. 3. Aufl. Gloucester: British Small Animal Veterinary
Association; 2004: 222–228
[70]
Straus E, Johnson GF, Yalow RS: Canine Zollinger-Ellison syndrome.
Gastroenterol. 1977; 72: 380–381
[71]
Thuroczy J, van Sluijs FJ, Kooistra HS et al.: Multiple endocrine
neoplasias in a dog: corticotrophic tumour, bilateral adrenocortical
tumours, and pheochromocytoma. Vet Quart. 1998; 20: 56–61
[72]
Tobin RL, Nelson RW, Lucroy MD et al.: Outcome of surgical versus medical treatment of dogs with beta cell neoplasia: 39 cases
(1990–1997). J Am Vet Med Assoc. 1999; 215: 226–230
[73]
Torres SM, Caywood DD, O’Brien TD et al.: Resolution of superficial necrolytic dermatitis following excision of a glucagon-secreting
pancreatic neoplasm in a dog. J Am Anim Hosp Assoc. 1997; 33:
313–319
[74]
Torres S, Johnson K, McKeever P et al.: Superficial necrolytic dermatitis and a pancreatic endocrine tumour in a dog. J Small Anim
Pract. 1997; 38: 246–250
[75]
Van der Gaag I, van den Ingh TS, Lamers CB et al.: Zollinger-Ellison syndrome in a cat. Vet Quart. 1988; 10: 151–155
[40]
Lamb CR, Simpson KW, Boswood A et al.: Ultrasonography of
pancreatic neoplasia in the dog: a retrospective review of 16 cases.
Vet Rec. 1995; 137: 65–68
[41]
Lee JJ, Larsson C, Lui WO et al.: A dog pedigree with familial
medullary thyroid cancer. Int J Oncol. 2006; 29: 1173–1182
[42]
Leifer CE, Peterson ME, Matus RE: Insulin-secreting tumor: Diagnosis and medical and surgical management in 55 dogs. J Am Vet
Med Assoc. 1986; 188: 60–64
[43]
Lothrop CD: Medical treatment of neuroendocrine tumors of the
gastroenteropancreatic system with somatostatin. In: Kirk RW
(Hrsg.): Current Veterinary Therapy X. Small animal practice. Philadelphia: Saunders; 1989: 1020–1024
[44]
Lurye JC, Behrend EN: Endocrine tumors. In: Behrend EN, Kemppainen RJ (Hrsg.): The Veterinary Clinics of North America. Small Animal Practice. Endocrinology. Vol 31. Number 5. Philadelphia: Saunders; 2001:1083–1110
[45]
[46]
[47]
McMillan FD, Barr B, Feldman EC: Functional pancreatic islet cell
tumor in a cat. J Am Anim Hosp Assoc. 1985; 21: 741–746
[48]
Middleton DJ, Watson AD: Duodenal ulceration associated with
gastrin-secreting pancreatic tumor in a cat. J Am Vet Med Assoc.
1983; 183: 461–462
[49]
Miller WH, Anderson WI, McCann JP: Necrolytic migratory erythema in a dog with a glucagon-secreting endocrine tumor. Vet
Dermatol. 1991; 2: 179–182
[50]
Minkus G, Jütting U, Aubele M et al.: Canine neuroendocrine
tumors of the pancreas: a study using image analysis technique for
the discrimination of metastatic versus nonmetastatic tumors. Vet
Pathol. 1997; 34: 138–145
[51]
Mizuno T, Hiraoka H, Yoshioka C et al.: Superficial necrolytic dermatitis associated with extrapancreatic glucagonoma in a dog. Vet
Dermatol. 2009; 20: 72–9
[52]
Moore AS, Nelson RW, Henry CJ et al.: Streptozocin for treatment
Vet Med Assoc. 2002; 221: 811–818
[53]
Oberkirchner U, Linder KE, Zadrozny L et al.: Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide. Vet
Dermatol. 2010; 21: 510–516
[76]
[54]
O’Brien TD, Hayden DW, O’Leary TP et al.: Canine pancreatic
endocrine tumors: immunohistochemical analysis of hormone content and amyloid. Vet Pathol. 1987; 24: 308–314
Van Ham L, Braund KG, Roels S et al.: Treatment of a dog with an
insulinoma-related peripheral polyneuropathy with corticosteroids.
Vet Rec. 1997; 141: 98–100
[77]
[55]
O’Brien TD, Norton F, Turner TM et al.: Pancreatic endocrine
tumor in a cat: clinical, pathological, and immunohistochemical
evaluation. J Am Anim Hosp Assoc. 1990; 26: 453–457
Vergine M, Pozzo S, Pogliani E et al.: Common bile duct obstruction due to a duodenal gastrinoma in a dog. Vet J. 2005; 170: 141–
143
[78]
[56]
Peterson ME, Randolph JF, Zaki FA et al.: Multiple endocrine neoplasia in a dog. J Am Vet Med Assoc. 1982; 180: 1476–1478
Von Dehn BJ, Nelson RW, Feldman EC et al.: Pheochromocytoma
and hyperadrenocorticism in dogs: six cases (1982–1992). J Am Vet
Med Assoc. 1995; 207: 322–324
[57]
Polton GA, White RN, Brearley MJ et al.: Improved survival in a
retrospective cohort of 28 dogs with insulinoma. J Small Anim
Pract. 2007; 48: 151–156
[79]
Walker MC, Jones BR, Guildford WG et al.: Multiple endocrine
neoplasia type 1 in a crossbred dog. J Small Anim Pract. 2000; 41:
67–70
[58]
Priester WA: Pancreatic islet cell tumors in domestic animals. Data
from 11 colleges of veterinary medicine in the United States and
Canada. J Natl Cancer Inst. 1974; 53: 227–229
[80]
Ward CR, Washabau RJ: Gastrointestinal endocrine disease. In:
Ettinger SJ, Feldman EC (Hrsg.): Textbook of Veterinary Internal
Medicine. 6. Aufl. St. Louis Missouri: Elsevier; 2005: 1622–1632
[59]
Reimer SB, Pelosi A, Frank J et al.: Multiple endocrine neoplasia
type I in a cat. J Am Vet Med Assoc. 2005; 227: 101–104
123
124
[81]
Wright KN, Breitschwerdt EB, Feldman JM et al.: Diagnostic and
therapeutic considerations in a hypercalcemic dog with multiple
endocrine neoplasia. J Am Anim Hosp Assoc. 1995; 31: 156–162
[23]
da Costa RC, Parent JM, Dobson H et al.: Ultrasound-guided fine
needle aspiration in the diagnosis of peripheral nerve sheath tumors
in 4 dogs. Can Vet J. 2008; 49: 77–81
[24]
Dahme E, Schmahl W: Nervensystem. In: Dahme E, Weiss E
(Hrsg.): Grundriß der speziellen pathologischen Anatomie der Haustiere. 5. Aufl., Ferdinand Enke Verlag, Stuttgart, 1999; 359–423
[25]
Davidson MG, Nasisse MP, Breitschwerdt EB et al.: Acute blindness associated with intracranial tumors in dogs and cats: eight
[26]
Demierre S, Bley T, Botteron C et al.: Intrakranielle Astrozytome
bei acht Katzen: Klinische und pathologische Befunde. Schweiz
Archiv Tierheilkd. 2002; 144: 66–73
[27]
Dickinson PJ, Sturges BK, Kass PH et al.: Characteristics of cisternal cerebrospinal fluid associated with intracranial meningiomas in
567
29 Tumoren des Nervensystems
[1]
Adamo PF, Cantile C, Steinberg H: Evaluation of progesterone and
estrogen receptor expression in 15 meningiomas of dogs and cats.
Am J Vet Res. 2003; 64: 1310–1318
[2]
Affolter VK, Moore PF: Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol. 2002; 39: 74–83
[3]
Aloisio F, Levine JM, Edwards JF: Immunohistochemical features of
a feline spinal cord gemistocytic astrocytoma. J Vet Diagn Invest.
2008; 20: 836–838
[4]
Baehring JM: An update on oligodendroglial neoplasms. Curr Opin
Neurol. 2005; 18: 639–644
[28]
[5]
Bagley RS: Spinal neoplasms in small animals. Vet Clin North Am
Dimski DS, Cook Jr JR: Carmustine-induced partial remission of an
astrocytoma in a dog. J Am Anim Hosp Assoc. 1990; 26: 179–182
[29]
[6]
Bailey CS, Higgins RJ: Characteristics of cisternal cerebrospinal
fluid associated with primary brain tumors in the dog: a retrospective study. J Am Vet Med Assoc. 1986; 188: 414–417
Drost WT, Love NE, Berry CR: Comparison of radiography, myelography and computed tomography for the evaluation of canine vertebral and spinal cord tumors in sixteen dogs. Vet Radiol Ultrasound. 1996; 37: 28–33
[7]
Barnhart KF, Wojcieszyn J, Storts RW: Immunohistochemical staining patterns of canine meningiomas and correlation with published immunophenotypes. Vet Pathol. 2002; 39: 311–321
[30]
Evans SM, Dayrell-Hart B, Powlis W et al.: Radiation therapy of
canine brain masses. J Vet Int Med. 1993; 7: 216–219
[31]
[8]
Benigni L, Corr SA, Lamb CR: Ultrasonographic assessment of the
canine sciatic nerve. Vet Radiol Ultrasound. 2007; 48: 428–433
Fankhauser R, Fatzer R, Luginbühl H: Reticulosis of the central
nervous system (CNS) in dogs. Adv Vet Sci Comp Med. 1972; 16:
35–71
[9]
Bley CR, Sumova A, Roos M et al.: Irradiation of brain tumors in
dogs with neurologic disease. J Vet Intern Med. 2005; 19: 849–854
[32]
Fingeroth JM, Prata RG, Patnaik AK: Spinal meningiomas in dogs:
[10]
Bradley RL, Withrow SJ, Snyder SP: Nerve sheath tumors in the
dog. J Am Anim Hosp Assoc. 1982; 18: 915–921
[33]
[11]
Braund KG: Neoplasia of the nervous system. Comp Cont Ed. 1984;
6: 717–722
Forterre F, Fritsch G, Kaiser S et al.: Surgical approach for tentorial
meningiomas in cats: a review of six cases. J Feline Med Surg. 2006;
8: 227–233
[34]
[12]
Brearley MJ, Jeffery ND, Phillips SM et al.: Hypofractionated radiation therapy of brain masses in dogs: a retrospective analysis of survival of 83 cases (1991–1996). J Vet Int Med. 1999; 13: 408–412
Forterre F, Jaggy A, Rohrbach H et al.: Modified temporal
approach for a rostro-temporal basal meningioma in a cat. J Feline
Med Surg. 2009; 11: 510–513
[35]
[13]
Brehm DM, Vite CH, Steinberg HS et al.: A retrospective evaluation of 51 cases of peripheral nerve sheath tumors in the dog. Am
Anim Hosp Assoc. 1995; 31: 349–359
Forterre F, Kaiser S, Matiasek K et al.: Rückenmarkstumoren beim
Hund: 33 Fälle (retrospektive Studie). Kleintierprax. 2002;47: 357–
364
[36]
[14]
Brellou G, Papaioannou N, Patsikas M et al.: Vertebral telangiectatic osteosarcoma in a dog. Vet Clin Pathol. 2004; 33: 159–162
Forterre F, Matiasek K, Schmahl W et al.: Periphere Nervenerkrankungen: Teil III: periphere Nerventumoren bei Hund und Katze:
retrospektive Studie über 17 Fälle. Kleintierprax. 2004; 49: 11–18
[15]
Brewer DM, Cerda-Gonzalez S, Dewey CW et al.: Spinal cord
nephroblastoma in dogs: 11 cases (1985–2007). J Am Vet Med
Assoc. 2011; 238: 618–624
[37]
Forterre F, Spreng D, Rytz U et al.: Thoracolumbar dorsolateral
laminectomy with osteotomy of the spinous process in fourteen
dogs. Vet Surg. 2007; 36: 458–463
[16]
Cantile C, Campani D, Menicagli M et al.: Pathological and immunohistochemical studies of choroid plexus carcinoma of the dog. J
Comp Pathol. 2002; 126: 183–193
[38]
Forterre F, Tomek A, Konar M et al.: Multiple meningiomas: clinical, radiological, surgical, and pathological findings with outcome in
four cats. J Fel Med Surg. 2007; 9: 36–43
[17]
Cervera V, Mai W, Vite CH et al.: Comparative magnetic resonance imaging findings between gliomas and presumed cerebrovascular accidents in dogs. Vet Radiol Ultrasound. 2011; 52: 33–40
[39]
Foster ES, Carrillo JM, Patnaik AK: Clinical signs of tumors affecting the rostral cerebrum in 43 dogs. J Vet Int Med. 1988; 2: 71–74
[40]
[18]
Chandra AM, Ginn PE: Primary malignant histiocytosis of the brain
in a dog. J Comp Pathol. 1999; 121: 77–82
Fuchs C, Meyer-Lindenberg A, Wohlsein P et al: Computertomographische Charakteristika primärer Gehirntumoren von Hund und
Katze. Berl Munch Tierarztl Wochenschr. 2003; 116: 436–442
[19]
Cherubini GB, Mantis P, Martinez TA et al.: Utility of magnetic
resonance imaging for distinguishing neoplastic from non-neoplastic brain lesions in dogs and cats. Vet Radiol Ultrasound. 2005; 46:
384–387
[41]
Fulton LM, Steinberg HS: Preliminary study of lomustine in the
treatment of intracranial masses in dogs following localization by
imaging techniques. Sem Vet Med Surg Sm Anim. 1990; 5: 241–
245
[20]
Chijiwa K, Uchida K, Tateyama S: Immunohistochemical evaluation of canine peripheral nerve sheath tumors and other soft tissue
sarcomas. Vet Pathol. 2004; 41: 307–318
[42]
Fusco JV, Hohenhaus AE, Aiken SW et al.: Autologous blood collection and transfusion in cats undergoing partial craniectomy. J
Am Vet Med Assoc. 2000; 216: 1584–1588
[21]
Chrisman CL: Electromyography in the localization of spinal cord
and nerve root neoplasia in dogs and cats. J Am Vet Med Assoc.
1975; 166: 1074–1079
[43]
Gallagher JG, Berg J, Knowles KE et al.: Prognosis after surgical
excision of cerebral meningiomas in cats: 17 cases (1986—1992). J
Am Vet Med Assoc. 1993; 203: 1437–1440
[22]
Cook JR: Chemotherapy for brain tumors. Vet Med Report. 1990; 2:
391–396
[44]
Gallagher JG, Penninck D, Boudrieau RJ et al.: Ultrasonography of
the brain and vertebral canal in dogs and cats: 15 cases (1988–
1993). J Am Vet Med Assoc. 1995; 207: 1320–1324
[45]
Gandini G, Gentilini F, Cimatti L et al.: Evaluation of the clinical
signs and computed tomographic findings in 27 dogs with intracranial space-occupying lesions (1999–2000). Vet Res Commun. 2003;
27 (Suppl 1): 399–401
[46]
Gordon LE, Thacher C, Matthiesen DT et al.: Results of craniotomy
for the treatment of cerebral meningioma in 42 cats. Vet Surg.
1994; 23: 94–100
[68]
Koestner A, Higgins RJ: Tumors of the nervous system. In: Meuten
DJ: Tumors in domestic animals. 4. Auflg. Iowa State Press, Ames,
2002; 697–738
[69]
Kostolich M, Dulisch ML: A surgical approach to the canine olfactory bulb for meningioma removal. Vet Surg. 1987; 16: 273–277
[70]
Kube SA, Bruyette DS, Hanson SM: Astrocytomas in young dogs. J
[47]
Graham JP, Newell SN, Voges AK et al.: The dural tail sign in the
diagnosis of meningiomas. Vet Radiol Ultrasound. 1998; 39: 297–
302
[71]
Lane SB, Kornegay JN, Duncan JR et al.: Feline spinal lymphosarcoma: A retrospective evaluation of 23 cats. J Vet Int Med. 1994; 8:
99–104
[48]
Greco JJ., Aiken SA, Berg JM et al.: Evaluation of intracranial
meningioma resection with a surgical aspirator in dogs: 17 cases
(1996–2004). J Am Vet Med Assoc. 2006; 229: 394–400
[72]
Lester NV, Hopkins AL, Bova FJ et al.: Radiosurgery using a stereotactic headframe system for irradiation of brain tumors in dogs. J
Am Vet Med Assoc. 2001; 219: 1562–1567, 1550
[49]
Gruber A, Kneissl S, Vidoni B et al.: Cervical spinal chordoma with
chondromatous component in a dog. Vet Pathol. 2008; 45: 650–
653
[73]
Levy MS, Mauldin G, Kapatkin AS et al.: Nonlymphoid vertebral
canal tumors in cats: 11 cases (1987–1995). J Am Vet Med Assoc.
1997; 210: 663–664
[50]
Harari J, Moore MM, Leathers CW et al.: Computed tomographicguided, free-hand needle biopsy of brain tumors in dogs. Progr Vet
Neurol. 1993; 4: 41–44
[74]
Levy MS, Kapatkin AS, Patnaik AK et al.: Spinal tumors in 37
dogs: clinical outcome and long-term survival (1987–1994). J Am
Anim Hosp Assoc. 1997; 33: 307–312
[51]
Hayes Jr HM, Priester WA, Pendergrass TW: Occurrence of nervous-tissue tumors in cattle, horses, cats and dogs. Int J Cancer.
1975; 15: 39–47
[75]
Liebel F-X, Rossmeisl JH, Lanz OI et al.: Canine spinal nephroblastoma: Long-term outcomes associated with treatment of 10 cases
(1996–2009). Vet Surg. 2011; 40: 244–252
[52]
part 2: Acquired brain disorders. Vet Clin North Am Small Anim
Pract. 2010; 40: 39–63
[76]
Linzmann H, Brunnberg L, Gruber AD et al.: A neurotropic lymphoma in the brachial plexus of a cat. J Feline Med Surg. 2009; 11:
522–524
[53]
Heidner GL, Kornegay JN, Page RL et al.: Analysis of survival in a
retrospective study of 86 dogs with brain tumors. J Vet Int Med.
1991; 5: 219–226
[77]
Lipsitz D, Higgins RJ, Kortz GD et al.: Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five
dogs. Vet Pathol. 2003; 40: 659–669
[54]
Hoffman A, Blocker T, Dubielzig R et al.: Feline periocular peripheral nerve sheath tumor: a case series. Vet Ophthalmol. 2005; 8:
153–158
[78]
Lu D, Pocknell A, Lamb CR et al.: Concurrent benign and malignant multiple meningiomas in a cat: clinical, MRI and pathological
findings. Vet Rec. 2003; 152: 780–782
[55]
Ide T, Uchida K, Kagawa Y et al.: Pathological and immunohistochemical features of subdural histiocytic sarcomas in 15 dogs. J Vet
Diagn Invest. 2011; 23: 127–132
[79]
Luttgen PJ, Braund KG, Brawner Jr. WR et al.: A retrospective
study of twenty-nine spinal tumors in the dog and cat. J Small Anim
Pract. 1980; 21: 213–226
[56]
Ide T, Uchida K, Kikuta F et al.: Immunohistochemical characterization of canine neuroepithelial tumors. Vet Pathol. 2010; 47: 741–
750
[80]
Luttgen PJ: Neoplasms of the spine. Vet Clin North Am Small Anim
Pract. 1992; 22: 973–984
[81]
[57]
Jeffery N, Brearley MJ: Brain tumors in the dog: treatment of 10
cases and review of recent literature. J Small Anim Pract. 1993; 34:
367–372
Mackenzie GB, Bellah JR, Threatte RM: What is your diagnosis?
Hemangiosarcoma of the cervical vertebrae. J Am Vet Med Assoc.
2003; 222: 1075–1076
[82]
[58]
Johnson GC: Genesis and pathology of tumors of the nervous system. Sem Vet Med Surg Sm Anim. 1990; 5: 210–222
Macri NP, Van Alstine W, Coolman RA: Canine spinal nephroblastoma. J Am Anim Hosp Assoc. 1997; 33: 302–306
[83]
[59]
Jones BR, Alley MR, Johnstone AC et al.: Nerve sheath tumours in
the dog and cat. N Z Vet J. 1995; 43: 190–196
Mamom T, Meyer-Lindenberg A, Hewicker-Trautwein M et al.:
Oligodendroglioma in the cervical spinal cord of a dog. Vet Pathol.
2004; 41: 524–526
[60]
Jung DI, Kim HJ, Park C et al.: Long-term chemotherapy with
lomustine of intracranial meningioma occurring in a miniature
schnauzer. J Vet Med Sci. 2006; 68: 383–386
[84]
Marioni-Henry K: Feline spinal cord diseases. Vet Clin North Am
Small Anim Pract. 2010; 40: 1011–1128
[85]
[61]
Kelly DF: Neuroblastoma in the dog. J Pathol. 1975; 116: 209–212
[62]
21: 1027–1033
Marioni-Henry K, Van Winkle TJ, Smith SH et al.: Tumors affecting the spinal cord of cats: 85 cases (1980–2005). J Am Vet Med
Assoc. 2008; 232: 237–243
[86]
Marioni-Henry K, Vite CH, Newton AL et al.: Prevalence of diseases of the spinal cord of cats. J Vet Intern Med. 2004; 18: 851–858
[87]
Mazur WJ, Lazar T: What is your diagnosis? Chondrosarcoma. J Am
Vet Med Assoc. 2005; 226: 1301–1302
[88]
McConnell JF, Garosi LS, Dennis R et al.: Imaging of a spinal nephroblastoma in a dog. Vet Radiol Ultrasound. 2003; 44: 537–541
[89]
McDonnell JJ, Tidwell AS, Faissler D et al.: Magnetic resonance
imaging features of cervical spinal cord meningiomas. Vet Radiol
Ultrasound. 2005; 46: 368–374
[90]
Meinecke JE, Hobbie WVJ, Hardy WD: Lymphoreticular malignancies in the cat: clinical findings. J Am Vet Med Assoc. 1979; 160:
1093–1099
[91]
Mellanby RJ, Jeffery ND, Baines EA et al.: Magnetic resonance
imaging in the diagnosis of lymphoma involving the brachial plexus
in a cat. Vet Radiol Ultrasound. 2003; 44: 522–525
[63]
Khachatryan AR, Wills TB, Potter KA: What is your diagnosis? Vertebral mass in a dog. Vet Clin Pathol. 2009; 38: 257–260
[64]
Kim HJ, Chang HS, Choi CB et al.: Infiltrative lipoma in cervical
bones in a dog. J Vet Med Sci. 2005; 67: 1043–1046
[65]
Kraft S, Ehrhart EJ, Gall D et al.: Magnetic resonance imaging characteristics of peripheral nerve sheath tumors of the canine brachial
plexus in 18 dogs. Vet Radiol Ultrasound. 2007; 48: 1–7
[66]
Kraft SL, Gavin PR, DeHaan C et al.: Retrospective review of 50
canine intracranial tumors evaluated by magnetic resonance imaging. J Vet Int Med. 1997; 11: 218–225
[67]
Koblik PD, LeCouteur RA, Higgins RJ et al.: CT-guided brain biopsy using a modified Pelorus Mark III stereotactic system: experience with 50 dogs. Vet Radiol Ultrasound. 1999; 40: 434–440
125
126
[92]
Mellor PJ, Polton GA, Brearley M et al.: Solitary plasmacytoma of
bone in two successfully treated cats. J Feline Med Surg. 2007; 9:
72–77
[93]
Michimae Y, Morita T, Sunagawa Y et al.: Anaplastic ependymoma in the cervical spinal cord of a Maltese dog. J Vet Med Sci.
2004; 66: 1155–1158
[94]
Moissonnier P, Blot S, Devauchelle P et al.: Stereotactic CT-guided brain biopsy in the dog. J Small Anim Pract. 2002; 43: 115–123
[95]
Montoliu P, Añor S, Vidal E et al.: Histological and immunohistochemical study of 30 cases of canine meningioma. J Comp Pathol.
2006; 135: 200–207
[96]
Morgan LW, Toal R, Siemering G et al.: Imaging diagnosis–infiltrative lipoma causing spinal cord compression in a dog. Vet Radiol
Ultrasound. 2007; 48: 35–37
[97]
Nakaichi M, Taura Y, Nakama S et al.: Primary brain tumors in
two dogs treated by surgical resection in combination with postoperative radiation therapy. J Vet Med Sci. 1996; 58: 773–775
[114] Sale CS, Skerritt GC, Smith KC: Spinal nephroblastoma in a crossbreed dog. J Small Anim Pract. 2004; 45: 267–271
[115] Sarfaty D, Carrillo JM, Peterson ME: Neurologic, endocrinologic,
and pathologic findings associated with large pituitary tumors in
dogs: (1976–1984). J Am Vet Med Assoc. 1988; 193: 854–856
[116] Schöniger S, Summers BA: Localized, plexiform, diffuse, and other
variants of neurofibroma in 12 dogs, 2 horses, and a chicken. Vet
Pathol. 2009; 46: 904–915
[117] Schulman FY, Johnson TO, Facemire PR et al.: Feline peripheral
nerve sheath tumors: histologic, immunohistochemical, and clinicopathologic correlation (59 tumors in 53 cats). Vet Pathol. 2009; 46:
1166–1180
[118] Schultz RM, Puchalski SM, Kent M et al.: Skeletal lesions of histiocytic sarcoma in nineteen dogs. Vet Radiol Ultrasound. 2007; 48:
539–543
[119] Sessums K, Mariani C: Intracranial meningioma in dogs and cats: a
comparative review. Compend Contin Educ Vet. 2009; 31: 330–339
[98]
Negrin A, Schatzberg S, Platt SR: The paralyzed cat. Neuroanatomic diagnosis and specific spinal cord diseases. J Feline Med Surg.
2009; 11: 361–372
[120] Shores A: Intracranial surgery. In: Slatter DD (Hrsg.): Textbook of
Small Animal Surgery. 2. Aufl., WB Saunders Co, Philadelphia 1993;
1122–1135
[99]
Niebauer GW, Habil MV, Dayrell BL et al.: Evaluation of craniotomy in dogs and cats. J Am Vet Med Assoc. 1991; 198: 89–95
[121] Siegel S, Kornegay JN, Thrall DE: Postoperative irradiation of spinal
cord tumors in 9 dogs. Vet Radiol Ultrasound. 1996; 37: 150–153
[100] Obermaier G: Beitrag zur Klassifizierung und zum „Grading“ der
Gliome des Boxerhundes nach neurohistologischen und immunhistologischen Kriterien. Diss med vet., München 1991
[122] Singh M, Foster DJ, Child G et al.: Inflammatory cerebrospinal
fluid analysis in cats: clinical diagnosis and outcome. J Feline Med
Surg. 2005; 7: 77–93
[101] OʼDriscoll JL, McDonnell JJ: What is your neurologic diagnosis?
Infiltrative lipoma of the thoracic spinal cord. J Am Vet Med Assoc.
2006; 229: 933–935
[123] Snyder JM, Shofer FS, Van Winkle TJ et al.: Canine intracranial primary neoplasia: 173 cases (1986–2003). J Vet Intern Med. 2006;
20: 669–675
[102] Palmer AC, Malinowski W, Barnett KC: Clinical signs including
papilloedema associated with brain tumors in twenty-one dogs. J
[124] Snyder JM, Lipitz L, Skorupski KA et al.: Secondary intracranial
2008; 22: 172–177
[103] Pastorello A, Constantino-Casas F, Archer J: Choroid plexus carcinoma cells in the cerebrospinal fluid of a Staffordshire Bull Terrier.
Vet Clin Pathol. 2010; 39: 505–510
[125] Spodnick GJ, Berg J, Moore FM et al.: Spinal lymphoma in cats: 21
[104] Pearson GR, Gregory SP, Charles AK: Immunohistochemical
demonstration of Wilms tumour gene product WT1 in a canine
“neuroepithelioma” providing evidence for its classification as an
extrarenal nephroblastoma. J Comp Pathol. 1997; 116: 321–327
[105] Peters M, Gaßner G, Zander S et al.: Zerebelläre Ataxie durch ein
Medulloblastom bei einem jungen Rottweiler. Tierärztl Prax. 1999;
27 (K): 172–176
[106] Petersen SA, Sturges BK, Dickinson PJ et al.: Canine intraspinal
meningiomas: imaging features, histopathologic classification, and
long-term outcome in 34 dogs. J Vet Intern Med. 2008; 22: 946–953
[107] Platt SR, Alleman AR, Lanz OL et al.: Comparison of fine-needle
aspiration and surgical-tissue biopsy in the diagnosis of canine brain
tumors.Vet Surg. 2002; 31: 65–69
[108] Polizopoulou ZS, Koutinas AF, Souftas VD et al.: Diagnostic correlation of CT-MRI and histopathology in 10 dogs with brain neoplasms. J Vet Med A Physiol Pathol Clin Med. 2004; 51: 226–231
[109] Ródenas S, Pumarola M, Añor S: Imaging diagnosis–cervical spine
chondroma in a dog. Vet Radiol Ultrasound. 2008; 49: 464–466
[110] Ródenas S, Pumarola M, Gaitero L et al.: Magnetic resonance imaging findings in 40 dogs with histologically confirmed intracranial
tumours. Vet J. 2011; 187: 85–91
[111] Rodenas S, Valin I, Devauchelle P et al.: Combined use of surgery
and radiation in the treatment of an intradural myxoid liposarcoma
[112] Rossmeisl JH Jr, Lanz OI, Waldron DR et al.: Surgical cytoreduction
for the treatment of non-lymphoid vertebral and spinal cord neoplasms in cats: retrospective evaluation of 26 cases (1990–2005).
[113] Rudich SR, Feeney DA, Anderson KL et al.: Computed tomography of masses of the brachial plexus and contributing nerve roots in
[126] Spugnini EP, Thrall DE, Price GS et al.: Primary irradiation of
canine intracranial masses. Vet Radiol Ultrasound. 2000; 41: 377–
380
[127] Stigen O, Ytrehus B, Eggertsdottir AV: Spinal cord astrocytoma in
a cat. J Small Anim Pract. 2001; 42: 306–310
[128] Stoica G, Levine J, Wolff J et al.: Canine astrocytic tumors: a comparative review. Vet Pathol. 2011; 48: 266–275
[129] Stoica G, Kim HT, Hall DG et al.: Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas. Vet Pathol. 2004;
41: 10–19
[130] Stoica G, Tasca SI, Kim HT: Point mutation of neu oncogene in animal peripheral nerve sheath tumors. Vet Pathol. 2001; 38: 679–688
[131] Strain GM: Indicators of brain mass-induced herniation. Vet J. 2006;
172: 198–199
[132] Sturges BK, Dickinson PJ, Bollen AW et al.: Magnetic resonance
imaging and histological classification of intracranial meningiomas
in 112 dogs. J Vet Intern Med. 2008; 22: 586–595
[133] Sumner JP, Simpson DJ: Surgical management of a recurrent spinal
meningioma in a cat. Aust Vet J. 2007; 85: 276–280
[134] Suzuki M, Uchida K, Morozumi M et al.: A comparative pathological study on granulomatous meningoencephalomyelitis and central
malignant histiocytosis in dogs. J Vet Med Sci. 2003; 65: 1319–
1324
[135] Tamura S, Tamura Y, Ohoka A et al.: A canine case of skull base
meningioma treated with hydroxyurea. J Vet Med Sci. 2007; 69:
1313–1315
[137] Thio T, Hilbe M, Grest P et al.: Malignant histiocytosis of the brain
in three dogs. J Comp Pathol. 2006; 134: 241–244
127
[139] Tomek A, Cizinauskas S, Doherr M et al.: Intracranial neoplasia in
61 cats: localisation, tumour types and seizure patterns. J Feline
Med Surg. 2006; 8: 243–253
30 Tumoren der Augen und Augenadnexen
[1]
Aleksanderson M, Bjerkås E, Heiene R et al.: Malignant teratoid
medulloepithelioma with brain and kidney involvement in a dog.
Vet Ophthalmol. 2004; 7: 407–411
[2]
[140] Troxel MT, Vite CH, Massicotte C et al.: Magnetic resonance imaging features of feline intracranial neoplasia: retrospective analysis
of 46 cats. J Vet Intern Med. 2004; 18: 176–189
Allgoewer I, Frieling E, Fritzsche J et al.: Das chorioidale Melanom
beim Hund. Kleintierprax. 2000; 45: 361–369
[3]
[141] Troxel MT, Vite CH, Van Winkle TJ et al.: Feline intracranial neoplasia: retrospective review of 160 cases (1985–2001). J Vet Intern
Med. 2003; 17: 850–859
Allgoewer I, Stockhaus C, Schäffer EH: Malignes Lymphom mit
okularer Manifestation bei einem Hund. Tierärztl Prax. 2003; 31:
124–125
[4]
Andrew SE: Orbital neurofibrosarcoma in a dog. Vet Ophthalmol.
1999; 2: 141–145
[142] Turrel JM, Fike JR, LeCouteur RA et al.: Radiotherapy of brain
[5]
[143] Ueno H, Morimoto M, Kobayashi Y et al.: Surgical and radiotherapy treatment of a spinal cord ependymoma in a dog. Aust Vet J.
2006; 84: 36–39
[6]
Attali-Soussay K, Jegou JP, Clerc B: Retrobulbar tumors in dogs
and cats: 25 cases. Vet Ophthalmol. 2001; 4: 19–27
[7]
Barnett KC, Crispin SM: Feline ophthalmology – An Atlas & Text.
W.B. Saunders Co., London 1998; S. 38–43, 52–54, 58–60, 67–68,
79–82, 125–126, 131, 140–142, 166–167
[144] Vandevelde M: Brain tumors in domestic animals: an overview.
Proc. Conference on Brain Tumors in Man and Animals: Research
Triangle Park, North Carolina 1984
[8]
[145] Vandevelde M, Fatzer R, Fankhauser R: Immunohistological studies on primary reticulosis of canine brain. Vet Pathol. 1981; 18,
577–588
Barsotti G, Marchetti V, Abramo F: Primary conjunctival mast cell
tumor in a Labrador Retriever. Vet Ophthalmol. 2007; 10: 60–64
[9]
[146] Vandevelde M, Richard A, Fankhauser R: Examination of cerebrospinal fluid in neurologically ill dogs and cats. Schweiz Arch Tierheilkd. 1987; 129: 443–456
Bauer GA, Spiess BM, Lutz H: Exfoliative cytology of conjunctiva
and cornea in domestic animals: a comparison of four collecting
techniques. Vet Comp Ophthalmol. 1996; 6: 181–186
[10]
Beltran WA, Colle MA, Boulouha L, et al.: A case of orbital hemangiopericytoma in a dog. Vet Ophthalmol. 2001; 4: 255–259
[147] Veraa S, Dijkman R, Meij BP et al.: Comparative imaging of spinal
extradural lymphoma in a Bordeaux dog. Can Vet J. 2010; 51: 519–
521
[11]
Bernays ME, Flemming D, Peiffer RL Jr: Primary corneal papilloma
and squamous cell carcinoma associated with pigmentary keratitis
in four dogs. J Am Vet Med Assoc. 1999; 214: 215–217
[148] Vural SA, Besalti O, Ilhan F et al.: Ventricular ependymoma in a
German Shepherd dog. Vet J. 2006; 172: 185–187
[12]
Bertoy RW, Brightman AH, Regan K: Intraocular melanoma with
multiple metastases in a cat. J Am Vet Med Assoc. 1988; 192: 87–
89
[13]
Billson FM, Mould JRB, Lee WR: Myxoid leiomyoma of the iris in a
dog. Vet Ophthalmol. 2003; 6: 173–176
[14]
Bonney CH, Koch SA, Dice PF et al.: Papillomatosis of conjunctiva
and adnexa in dogs. J Am Vet Med Assoc. 1980; 176: 48–51
[15]
Boscos CM, Ververidis HN: Ocular involvement of transmissible
venereal tumor in a dog. Vet Ophthalmol. 1998; 1: 167–170
[16]
Buchholz J, Walt H, Fidel J: Photodynamische Therapie beim felinen Plattenepithelkarzinom sowie bei verschiedenen kaninen
Tumoren. Kleintierprax. 2003; 48: 405–418
[17]
Buxbaum A, Kirtz G, Leidinger E: Multizentrisches malignes Lymphom mit konjunktivaler Manifestation bei einer Katze. Kleintierprax. 2000; 45: 699–705
[18]
Cantaloube B, Raymond-Letron I, Regnier A: Multiple eyelid apocrine hidrocystomas in two Persian cats. Vet Ophthalmol. 2004; 7:
121–125
[19]
Cassotis NJ, Dubielzig RR, Gilger BC et al.: Angioinvasive pulmonary carcinoma with posterior segment metastasis in four cats. Vet
Ophthalmol. 1999; 2: 125–131
[156] Yamauchi A, Ohta T, Okada T et al.: Secondary erythrocytosis
associated with schwannoma in a dog. J Vet Med Sci. 2004; 66:
1605–1608
[20]
Clerc B: Surgery and chemotherapy for the treatment of adenocarcinoma of the iris and ciliary body in five dogs. Vet Comp Ophthalmol. 1996; 6: 265–270
[157] Young BD, Levine JM, Porter BF et al.: Magnetic resonance imaging features of intracranial astrocytomas and oligodendrogliomas
in dogs. Vet Radiol Ultrasound. 2011; 52: 132–141
[21]
Clerc B, Krähenmann A: Augenheilkunde Hund und Katze. Paul
Parey, Berlin-Hamburg 1990
[22]
Collins BK, Collier LL, Miller MA et al.: Biologic behavior and histologic characteristics of canine conjunctival melanoma. Prog Vet
Comp Ophthalmol. 1993; 3: 135–140
[159] Zaki FA: Spontaneous central nervous system tumors in the dog.
Vet Clin North Am. 1977; 7: 153–163
[23]
Cook CS: Diode laser treatment of canine iris melanoma. Proc. 27th
Ann Meet. ACVO 1996; 27
[160] Zimmerman K, Almy F, Carter L et al.: Cerebrospinal fluid from a
10–year-old dog with a single seizure episode. Vet Clin Pathol.
2006; 35: 127–131
[24]
Cook CS, Rosenkrantz W, Peiffer RL et al.: Malignant melanoma
of the conjunctiva in a cat. J Am Vet Med Assoc. 1985; 186: 505–
506
[149] Wall M, Platt S, Selcer B et al.: Multifocal spinal papillary meningioma in a dog. Vet Radiol Ultrasound. 2005; 46: 309–312
[150] Walmsley GL, Herrtage ME, Dennis R et al.: The relationship between clinical signs and brain herniation associated with rostrotentorial mass lesions in the dog. Vet J. 2006; 172: 258–264
[151] Watrous BJ, Lipscomb TP, Heidel JR et al.: Malignant peripheral
nerve sheath tumor in a cat. Vet Radiol Ultrasound. 1999; 40: 638–
640
[152] Wessmann A, Volk HA, Chandler K et al.: Significance of surface
epithelial cells in canine cerebrospinal fluid and relationship to central nervous system disease. Vet Clin Pathol. 2010; 39: 358–364
[153] Westworth DR, Dickinson PJ, Vernau W et al.: Choroid plexus
tumors in 56 dogs (1985–2007). J Vet Intern Med. 2008; 22: 1157–
1165
[154] Wisner ER, Dickinson PJ, Higgins RJ: Magnetic resonance imaging
features of canine intracranial neoplasia. Vet Radiol Ultrasound.
2011; 52 (Suppl 1): S52–61
[155] Woo GH, Bak EJ, Lee YW et al.: Cervical chondroid chordoma in a
Shetland sheep dog. J Comp Pathol. 2008; 138: 218–223
[158] Zaki FA, Hurvitz AI: Spontaneous neoplasms of the central nervous
system of the cat. J Small Anim Pract. 1976; 17: 773–782
[138] Thomas WB, Wheeler SJ, Kramer R et al.: Magnetic resonance
imaging features of primary brain tumors in dogs. Vet Radiol Ultrasound. 1996; 37: 20–27
128
[25]
Cook CS, Wilkie DA: Treatment of presumed iris melanoma in
dogs by diode laser photocoagulation: 23 cases. Vet Ophthalmol.
1999; 2: 217–225
[48]
Hagard GM: Eyelid reconstruction using a split eyelid flap after excision of a palpebral tumor in a Persian cat. J Small Anim Pract. 2005;
8: 389–392
[26]
Corcoran KA, Peiffer RL, Koch SA: Histopathologic features of
feline ocular lymphosarcoma: 49 cases (1978–1992). Vet Comp
Ophthalmol. 1995; 5: 35–41
[49]
Hargis AM, Lee AC, Thomassen RW: Tumor and tumorlike lesions
of perilimbal conjunctiva in laboratory dogs. J Am Vet Med Assoc.
1978; 173: 1185–1190
[27]
Day MJ, Lucke VM: Melanocytic neoplasia in the cat. J Small Anim
Pract. 1995; 36: 207–213
[50]
Harris BP, Dubielzig RR: Atypical primary ocular melanoma in cats.
[28]
Donaldson D, Sansom J, Scase T et al.: Canine limbal melanoma:
30 cases (1992–2004). Part 1. Signalment, clinical and histological
features and pedigree analysis. Vet Ophthalmol. 2006; 9: 115–119
[51]
Headrick JF, Bentley E, Dubielzig RR: Canine lobular orbital adenoma: a report of 15 cases with distinctive features. Vet Ophthalmol. 2004; 7: 47–51
[29]
Donaldson D, Sansom J, Adams V: Canine limbal melanoma: 30
cases (1992–2004). Part 2. Treatment with lamellar resection and
adjunctive strontium-90β plesiotherapy – efficacy and morbidity.
[52]
Heath S, Rankin AJ, Dubielzig RR: Primary ocular osteosarcoma in
a dog. Vet Ophthalmol. 2003; 6: 85–87
[53]
Hoffman A, Blocker T, Dubielzig R et al.: Feline periocular peripheral nerve sheath tumor: a case series. Vet Ophthalmol. 2005; 8:
153–158
[54]
Hoffmann I, Köstlin R: Die sonographische Untersuchung des vorderen Augenabschnittes beim Kleintier. Teil 1: Untersuchungstechnik und echographische Normalbefunde. Tierärztl Prax. 2004; 32:
175–179
[30]
Dubielzig RR: Ocular neoplasia in small animals. Vet Clin North Am
[31]
Dubielzig RR: Ocular sarcoma following trauma in three cats. J Am
Vet Med Assoc. 1984; 184: 578–581
[32]
Dubielzig RR, Aguirre GD, Gross SL, et al.: Choroidal melanomas
in dogs. Vet Pathol. 1985; 22: 582–585
[55]
[33]
Dubielzig RR, Chappell RJ, Kalishman JB et al.: Survival in cats
with diffuse iris melanoma: a matched observational study. Proc.
28th Ann Meet ACVO 1997; 5–8
Hoffmann I, Schäffer E, Reese S et al.: Die sonographische Untersuchung des vorderen Augenabschnittes beim Kleintier. Teil 2:
Pathologische Befunde. Tierärztl Prax. 2004; 32: 238–246
[56]
[34]
Dubielzig RR, Everitt J, Shadduck JA et al.: Clinical and morphologic features of post-traumatic ocular sarcomas in cats. Vet Pathol.
1990; 27: 62–65
Hogan RN, Albert DM: Does retinoblastoma occur in animals? Prog
Vet Comp Ophthalmol. 1991; 1: 73–82
[57]
Dubielzig RR, Hawkins KL, Toy KA et al.: Morphologic features of
feline ocular sarcomas in 10 cats: Light microscopy, ultrastructure,
and immunohistochemistry. Vet Comp Ophthalmol. 1994; 4: 7–12
Holt E, Goldschmidt MH, Skorupski K: Extranodal conjunctival
Hodgkin’s-like lymphoma in a cat. Vet Ophthalmol. 2006; 9: 141–
144
[58]
Jensen OA, Kaarsholm S, Prause JU et al.: Neuroepithelial tumor
of the retina in a dog. Vet Ophthalmol. 2003; 6: 57–60
[35]
[36]
Eberle N, Simon D, Höinghaus R et al.: Konjunktivaler Mastzelltumor bei einem Golden Retriever – Ein Fallbericht. Tierärztl Prax.
2006; 34: 245–252
[59]
Kalishman JB, Chappell R, Flood LA et al.: A matched observational study of survival in cats with enucleation due to diffuse iris melanoma. Vet Ophthalmol. 1998; 1: 25–29
[37]
Featherstone HJ, Renwick P, Heinrich CL, et al.: Efficacy of lamellar resection, cryotherapy, and adjunctive grafting for the treatment
of canine limbal melanoma. Vet Ophthalmol. 2009; 12 Suppl 1: 65–
72
[60]
Kanei K, Kanemaki N, Matsuo S et al.: Excision of a feline limbal
melanoma and use of nictitans cartilage to repair the resulting corneoscleral defect. Vet Ophthalmol. 2006; 9: 255–258
[61]
[38]
Funke K: Zur vergleichenden Ophthalmopathologie des primär-intraokulären malignen Melanoms beim Haustier. Diss med vet, München-Neuherberg, 1984
Kern TJ: Orbital neoplasia in 23 dogs. J Am Vet Med Assoc. 1985;
186: 489–491
[62]
Kessler M, von Bomhard D: Intraokuläre Tumoren bei Katzen (n =
57). unveröffentlicht, 1997
[39]
Gelatt, KN (Hrsg): Veterinary Ophthalmology. 2. Aufl. Lea &
Febiger, Philadelphia-London 1991
[63]
Kirschner SE, Niyo Y, Hill BL et al.: Blindness in a dog with IgAforming myeloma. J Am Vet Med Assoc. 1988; 193: 349–350
[40]
Gelatt KN (Hrsg.): Veterinary Ophthalmology. 4. Aufl. Ames: Blackwell Publishing; 2007
[64]
[41]
Gelatt KN, Gelatt JP: Handbook of small animal surgery. Band 1.
Elsevier Science Ltd., Oxford 1994
Klosterman E, Colitz CMH, Chandler HL et al.: Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas. Vet Ophthalmol. 2006; 9: 387–394
[65]
[42]
Gelatt KN, Gelatt JP: Handbook of small animal surgery. Band 2.
Elsevier Science Ltd., Oxford 1995
Labelle P, Holmberg BJ: Ocular myxoid leiomyosarcoma in a cat.
[66]
[43]
Gelatt KN, Gelatt JP: Small Animal Ophthalmic Surgery. Oxford:
Butterworth-Heinemann; 200
Larocca RD: Eosinophilic conjunctivitis, herpes virus and mast cell
tumor of the third eyelid in a cat. Vet Ophthalmol. 2000; 3: 221–
225
[44]
Gilger BC, McLaughlin SA, Whitley RD et al.: Orbital neoplasms in
1083–1086
[67]
Lassaline ME, Gelatt KN, Brooks DE et al.: Orbitotomie for retrobulbar malignant fibrous histiocytoma in a dog. Vet Ophthalmol.
2005; 8: 1–6
[45]
Gilger BC, Whitley RD, McLaughlin SA: Modified lateral orbitotomy for removal of orbital neoplasms in two dogs. Vet Surg. 1994;
23: 53–58
[68]
Latimer KS, Kaswan RL, Sundberg JP: Corneal squamous cell carcinoma in a dog. J Am Vet Med Assoc. 1987; 190: 1430–1432
[69]
[46]
Giuliano EA, Chappell R, Fischer B et al.: A matched observational
study of canine survival with primary intraocular melanocytic neoplasia. Vet Ophthalmol. 1999; 2: 185–190
Lewin G: Eyelid reconstruction in seven dogs using a split eyelid
flap. J Small Anim Pract. 2003; 8: 346–351
[70]
Liapis IK, Genovese L: Hemangiosarcoma of the third eyelid in a
dog. Vet Ophthalmol. 2004; 7: 279–282
[71]
Liman I, Meyer-Lindenberg A, Eberle N et al.: Diagnostik und Therapieverlauf eines kaninen malignen multizentrischen Lymphoms
mit Augenbeteiligung – Ein Fallbericht. Tierärztl Prax. 2006; 34:
341–346
[47]
Grahn BH, Peiffer RL, Cullen CL et al.: Classification of feline intraocular neoplasms based on morphology, histochemical staining,
and immunhistochemical labelling. Vet Ophthalmol. 2006; 9: 395–
403
[72]
Lohmann B, Hertslet S, Hetzel U et al.: Malignes Hornhautmelanom bei einem Europäischen Kurzhaarkater. Kleintierprax. 2000;
45: 543–549
[96]
Pirie CG, Knollinger AM, Thomas CB et al.: Canine conjunctival
hemangioma and hemangiosarcoma: a retrospective evaluation of
108 cases (1989–2004). Vet Ophthalmol. 2006; 9: 215–226
[73]
Martin CL: Ophthalmic Disease in Veterinary Medicine. London:
Manson Publishing Ltd; 2005
[97]
Radi ZA, Miller DL, Nines II ME: B-cell conjunctival lymphoma in a
cat. Vet Ophthalmol. 2004; 7: 413–415
[74]
Martin CL: Augenkrankheiten bei Hund und Katze (Pferd, Wiederkäuer). Deutsche Bearbeitung: Rosenhagen CU, Schaper, AlfeldHannover 1995
[98]
Rapp E: Histopathologische Befunde zur Augenmanifestation der
Katzenleukose. Wien Tierärztl Mschr. 1991; 79: 197–201
[99]
[75]
Martin CL: Canine epibulbar melanomas and their management. J
Render JA, Ramsey DT, Ramsey CC: Contralateral uveal metastasis
of malignant anterior uveal melanoma in a dog. Vet Comp Ophthalmol. 1997; 7: 263–266
[76]
Mauldin EA, Deehr AJ, Hertzke D et al.: Canine orbital meningiomas: a review of 22 cases. Vet Ophthalmol. 2000; 3: 11–16
[100] Richter M, Stankeova S, Hauser B: Myxosarcoma in the eye and
brain in a dog. Vet Ophthalmol. 2003; 6: 183–189
[77]
McCalla TL, Moore CP: Exophthalmos in dogs and cats. Part I. anatomics and diagnostic considerations. In: The Compendium collection-ophthalmology in small animal practice. Veterinary Learning
Systems, Trenton, New Jersey 1996; 5: 122–140
[101] Roperto F, Restucci B, Crovace A: Bilateral ciliary body melanomas
in a dog. Prog Vet Comp Ophthalmol. 1993; 3: 149–151
[78]
McLaughlin SA, Ramsey DT, Lindley DM et al.: Intraocular silicone
prosthesis implantation in eyes of dogs and a cat with intraocular
neoplasia: nine cases (1983–1994). J Am Vet Med Assoc. 1995;
207: 1441–1443
[102] Rovesti GL, Guandalini A, Peiffer R: Suspected latent vertebral
metastasis of uveal melanoma in a dog: a case report. Vet Ophthalmol. 2001; 4: 75–77
[103] Rühli MB, Spiess BM: Retrobulbäre Raumforderungen bei Hund
und Katze: Symptome und Diagnostik. Tierärztl Prax. 1995; 23:
306–312
[79]
Michau TM, Proulx DR, Rushton SD et al.: Intraocular extramedullary plasmozytoma in a cat. Vet Ophthalmol. 2003; 6: 177–181
[104] Ryan AM, Diters RW: Clinical and pathologic features of canine
ocular melanomas. J Am Vet Med Assoc. 1984; 184: 60–67
[80]
Minami T, Patnaik AK: Malignant anterior uveal melanoma with
diffuse metastasis in a dog. J Am Vet Med Assoc. 1992; 201: 1894–
1896
[105] Sansom J, Barnett KC, Blunden AS et al.: Canine conjunctival papilloma: A review of five cases. J Small Anim Pract. 1996; 37: 84–86
[81]
Minamide S, Suzuki K: Corneal choristoma in a beagle dog. Aust
Vet J. 1997; 75: 93–94
[82]
Morgan RV, Ring RD, Ward DA et al.: Magnetic-resonance-imaging of ocular and orbital disease in 5 dogs and a cat. Vet Radiol Ultrasound. 1996; 37: 185–192
[106] Sato T, Yamamoto A, Shibuya H et al.: Intraocular peripheral
nerve sheath tumor in a dog. Vet Ophthalmol. 2005; 8: 283–286
[107] Schäffer EH, Funke K: Das primär-intraokuläre maligne Melanom
bei Hund und Katze. Tierärztl Prax. 1985; 13: 343–359
[108] Schäffer EH, Gordon S: Das feline okuläre Melanom. Tierärztl Prax.
1993; 21: 255–264
[83]
Multari D, Vascellari M, Mutinelli F: Hemangiosarcoma of the
third eyelid in a cat. Vet Ophthalmol. 2002; 5: 273–276
[84]
Munger RJ, Gourley IM: Cross lid flap for repair of large upper eyelid defects. J Am Vet Med Assoc. 1981; 178: 45–48
[109] Schäffer EH, Josten M: Sekundär-intraokulare (metastatische)
Tumoren der Uvea. Klinische und ophthalmopathologische Befunde
von 17 Fällen bei Hund, Katze und Kaninchen. Tierärztl Prax. 1999;
27 (K): 39–46
[85]
Naranjo C., Dubielzig RR, Friedrichs KR: Canine ocular histiocytic
sarcoma. Vet Ophthalmol. 2007; 10: 179–185
[110] Schäffer EH, Pfleghaar S, Gordon S et al.: Maligne Nickhauttumoren bei Hund und Katze. Tierärztl Prax. 1994; 22: 382–391
[86]
Nasisse MP, Davidson MG, Olivero DK et al.: Neodymium: YAG
laser treatment of primary canine intraocular tumors. Prog Vet
Comp Ophthalmol. 1994; 4: 152–157
[111] Schäffer EH, Quintanilla-Martinez L, Marquart KH: Okulare Manifestation der malignen Histiozytose beim Berner Sennenhund. Tierärztl Prax. 2003; 31: 211–217
[87]
Nell B, Suchy A: ‘D-shaped’ and ‘reverse-D-shaped’ pupil in a cat
with lymphosarcoma. Vet Ophthalmol. 1998; 1: 53–56
[112] Schäffer EH, Thyssen C: Adenom und Adenokarzinom des IrisZiliarkörperepithels beim Hund. Tierärztl Prax. 1987; 15: 73–76
[88]
Neumann W, Juchem R: Epibulbäres Melanom bei einer Katze.
Tierärztl Prax. 1988; 16: 65–68
[113] Schäffer EH, Weber K, Pfleghaar S et al.: Das feline primär-intraokuläre Sarkom. Tierärztl Prax. 1997; 25: 498–505
[89]
Norman JC, Urbanz JL, Calvarese ST: Penetrating keratoscleroplasty and bimodal grafting for treatment of limbal melanocytoma
in a dog. Vet Ophthalmol. 2008; 5: 340–345
[114] Schiller I, Spiess BM, Pospischil A: Malignes Melanom bei zwei
Katzen. Schweiz Arch Tierheilkd. 1995; 137: 50–53
[90]
OʼBrien MG, Withrow SJ, Straw RC et al.: Total and partial orbitectomy for the treatment of periorbital tumors in 24 dogs and 6 cats:
a retrospective study. Vet Surg. 1996; 25: 471–479
[91]
Peiffer RL, Terrell T: Episcleral hemangioma in a dog. J Am Vet
Med Assoc. 1978; 173: 1338–1314
[92]
Pellicane CP, Meek LA, Brooks DE et al.: Eyelid reconstruction in 5
dogs by the semicircular flap technique. Vet Comp Ophthalmol.
1994; 4: 93–103
[93]
Pereira JS, Silva ABF, Martins ALB et al.: Immunohistochemical
characterization of intraocular metastasis of a canine transmissible
venereal tumor. Vet Ophthalmol. 2000; 3: 43–47
[115] Schmidt V: Augenkrankheiten der Haustiere. 2. Aufl. Fischer, Jena
1988; 66–69
[116] Schobert CS, Labelle P, Dubielzig RR: Feline conjunctival melanoma: histopathological characteristics and clinical outcomes. Vet
Ophthalmol. 2010; 1: 43–46
[117] Spiess BM, Rühli MB, Bauer GA: Zur Therapie von retrobulbären
Neoplasien beim Kleintier. Tierärztl Prax. 1995; 23: 509–514.
[118] Spiess BM, Wilcock BP: Glioma of the optic nerve with intraocular
and intracranial involvement in a dog. J Comp Pathol. 1987; 97: 79–
83
[94]
Peterhans E, Keller M: Plastische Chirurgie der Lider beim Kleintier.
[119] Stades FC, Neumann W, Boevé MH et al. : Praktische Augenheilkunde für den Tierarzt. 3. Aufl. Hannover: Schlütersche Verlagsgesellschaft; 2006: 27–29, 50–57, 70, 99–102, 122, 155, 169, 177,
184–186, 207, 231–232
[95]
Pirie CG, Dubielzig RR: Feline conjunctival hemangioma and
hemangiosarcoma: a retrospective evaluation of eight cases (1993–
2004). Vet Ophthalmol. 2006; 9: 227–231
[120] Stades FC, Neumann W, Boeve MH et al.: Praktische Augenheilkunde für den Tierarzt. Schlütersche, 1. Aufl. Hannover 1996;
S. 47–53, 85–88, 102–103, 126, 152–153, 169, 188
129
130
[121] Sullivan TC, Nasisse MP, Davidson MG et al.: Photocoagulation of
limbal melanoma in dogs and cats: 15 cases (1989–1993). J Am Vet
Med Assoc. 1996; 208: 891–894
[13]
Faulkner JE, Budsberg SC: Results of ventral bulla osteotomy for
treatment of middle ear polyps in cats. J Am Anim Hosp Assoc.
1990; 26: 496–499
[122] Szymansky C, Boyce R, Wyman M: Transitional cell carcinoma of
the urethra metastatic to the eyes in a dog. J Am Vet Med Assoc.
1984; 185: 1003–1004
[14]
Franc M, Guaguere E, Magnol JP et al.: Tumeurs du conduit auditif
externe des carnivores. Rev Méd Vét. 1981; 132: 733–739
[15]
[123] Vascellari M, Multari D, Mutinelli F: Unicentric extranodal lymphoma of the upper eylid conjunctiva in a dog. Vet Ophthalmol.
2005; 8: 67–70
Gaag van der I: The pathology of the external ear canal in dogs and
cats. Vet Quart. 1986; 8: 307–317
[16]
[124] Virchow C: Zur Inzidenz, Differentialdiagnose und Prognose des iridoziliaren Adenoms und Adenokarzinoms bei Hund, Katze und
Kaninchen. Diss med vet, München 1996
Garosi LS, Dennis R, Penderis J et al.: Results of magnetic resonance imaging in dogs with vestibular disorders: 85 cases (1996–
1999). J Am Vet Med Assoc. 2001; 218: 385–391
[17]
[125] Walde I, Rapp E: Das Glaukom der Katze – Klinische und morphologische Aspekte (retrospektive Studie an 38 Fällen). Wien Tierärztl
Mschr. 1992; 79: 309–328
Gotthelf LN: Entzündliche Polypen. In: Gotthelf LN (Hrsg.) Ohrenerkrankungen der Kleintiere. Elsevier, Urban und Fischer, München,
2008; 342–343
[18]
Hardie EM, Linder KE, Pease AP: Aural cholesteatoma in twenty
dogs. Vet Surg. 2008; 37: 763–770
[19]
Harvey CE, Goldschmidt MH: Inflammatory polypoid growths in
the ear canal of cats. J Small Anim Pract. 1978; 19: 669–677
[20]
Kessler M, von Bomhard D: Gehörkanaltumoren bei 73 Hunden
und 124 Katzen (unveröffentlicht), 1998
[21]
Kirpensteijn J: Aural Neoplasms. Sem Vet Med Surg (Small Anim).
1993; 8: 17–23
[22]
Klose TC, MacPhail CM, Schultheiss PC et al.: Prevalence of select
infectious agents in inflammatory aural and nasopharyngeal polyps
from client-owned cats. J Feline Med Surg. 2010; 12: 769–774
[23]
Kudnig ST: Nasopharyngeal polyps in cats. Clin Tech Small Anim
Pract. 2002; 17: 174–177
[24]
Lane IF, Hall DG: Adenocarcinoma of the middle ear with osteolysis
of the tympanic bulla in a cat. J Am Vet Med Assoc. 1992; 201:
463–465
[25]
Lanz OI, Wood BC: Surgery of the ear and pinna. Vet Clin North
Am Small Anim Pract. 2004; 34: 567–599, viii
[26]
Legendre AM, Krahwinkel DJ: Feline ear tumors. J Am Anim Hosp
Assoc. 1981; 17: 1035–1037
[27]
Little CJ, Lane JG, Gibbs C et al.: Inflammatory middle ear disease
of the dog: the clinical and pathological features of cholesteatoma,
a complication of otitis media. Vet Rec. 1991; 128: 319–322
[28]
Little CJL, Pearson GR, Lane JG: Neoplasia involving the middle ear
cavity of dogs. Vet Rec. 1989; 124: 54–57
[29]
London CA, Dubielzig RR, Vail DM et al.: Evaluation of dogs and
cats with tumors of the ear canal: 145 cases (1978–1992). J Am Vet
Med Assoc. 1996; 208: 1413–1418
[30]
Lucroy MD, Vernau KM, Samii VF et al.: Middle ear tumours with
brainstem extension treated by ventral bulla osteotomy and craniectomy in two cats. Vet Comp Oncol. 2004; 2: 234–242
[31]
Marino DJ, MacDonald JM, Matthiesen DT et al.: Results of surgery and long-term follow-up in dogs with ceruminous gland adenocarcinomas. J Am Anim Hosp Assoc. 1993; 29: 560–563
[32]
Marino DJ, MacDonald JM, Matthiesen DT et al.: Results of surgery in cats with ceruminous gland adenocarcinoma. J Am Anim
Hosp Assoc. 1994; 30: 54–58
[33]
Matousek JL: Diseases of the ear pinna. Vet Clin North Am Small
Anim Pract. 2004; 34: 511–540
[34]
Matthiesen D, Scavelli T: Total ear canal ablation and lateral bulla
osteotomy in 38 dogs. J Am Anim Hosp Assoc. 1990; 26: 257–267
[35]
Miller WH, Shynley KJ: Bilateral pinnal squamous cell carcinoma in
a dog with chronic otitis externa. Vet Dermatol. 1991; 2: 37–39
[36]
Moisan PG, Watson GL: Cermunious gland tumors in dogs and
cats: a review of 124 cases. J Am Anim Hosp Assoc. 1996; 32: 448–
452
[37]
Mortellaro CM, Alfieri C, De Francesco I et al.: Perendoscopic
trans-tympanic excision (PTTE) of ear canal polyps in cats: 10 case
reports. Proc. WSAVA 2001
[38]
Muilenburg RK, Fry TR: Feline nasopharyngeal polyps. Vet Clin
[126] Ward DA, Latimer KS, Askren RM: Squamous cell carcinoma of
the corneoscleral limbus in a dog. J Am Vet Med Assoc. 1992; 200:
1503–1506
[127] Weisse I, Stötzer H: Intraokuläres Melanom bei einem jungen Beagle. Berl Münch Tierärztl Wschr. 1971; 84: 328–330
[128] Wilcock BP, Peiffer RL: Morphology and behavior of primary ocular
melanomas in 91 dogs. Vet Pathol. 1986; 23: 418–424
[129] Wilcock BP, Peiffer RL: Adenocarcinoma of the gland of the third
eyelid in seven dogs. J Am Vet Med Assoc. 1988; 193: 1549–1550
[130] Wilkie DA, Wolf ED: Treatment of epibulbar melanocytoma in a
dog, using full-thickness eyewall resection and synthetic graft. J Am
Vet Med Assoc. 1991; 198: 1019–1022
[131] Wolfer J, Grahn B: Diagnostic ophthalmology. Amelanotic melanoma in an 8-year-old cat. Can Vet J. 1995; 36: 518–519
31 Tumoren des Gehörkanals und Mittelohrs
[1]
Anders BB, Hoelzler MG, Scavelli TD et al.: Analysis of auditory
and neurologic effects associated with ventral bulla osteotomy for
removal of inflammatory polyps or nasopharyngeal masses in cats. J
Am Vet Med Assoc. 2008; 233: 580–585
[2]
Anderson DM, Robinson RK, White RA: Management of inflammatory polyps in 37 cats. Vet Rec. 2000; 147: 684–687
[3]
Bacon NJ, Gilbert RL, Bostock DE et al.: Total ear canal ablation in
the cat: indications, morbidity and long-term survival. J Small Anim
Pract. 2003; 44: 430–434
[4]
Baker G: Nasopharyngeal polyps in cats. Vet Rec. 1982; 111: 43
[5]
Bischoff MG, Kneller SK: Diagnostic imaging of the canine and
feline ear. Vet Clin North Am Small Anim Pract. 2004; 34: 437–458
[6]
Colcuc M, Degasperi B, Alton K: Ohrpolypen der Katze: zwei Fallberichte und ein pathogenetisches Modell – die chronische, sekretorische Otitis media. Wien Tierärztl Mschr. 2010; 97: 37–45
[7]
De Lorenzi D, Bonfanti U, Masserdotti C et al.: Fine-needle biopsy
of external ear canal masses in the cat: cytologic results and histologic correlations in 27 cases. Vet Clin Pathol. 2005; 34: 100–105
[8]
De Lorimier LP, Alexander SD, Fan TM: T-cell lymphoma of the
tympanic bulla in a feline leukemia virus-negative cat. Can Vet J.
2003; 44: 987–989
[9]
Devitt CM, Seim HB, Willer R et al.: Passive drainage versus primary closure after total ear canal ablation-lateral bulla osteotomy in
dogs: 59 dogs (1985–1995). Vet Surg. 1997; 26: 210–216
[10]
Diel JM: Entfernung eines Ohrpolypen bei zwei Katzen mittels PTTE
(Perendoscopic Transtympanic Excision). Prakt Tierarzt. 2008; 89:
94–98
[11]
Doust R, King A, Hammond G et al.: Assessment of middle ear
disease in the dog: a comparison of diagnostic imaging modalities. J
[12]
Fan TM, de Lorimier LP: Inflammatory polyps and aural neoplasia.
[39]
Ogawa K, Nakamura K, Hatano K et al.: Treatment and prognosis
of squamous cell carcinoma of the external auditory canal and middle ear: A multi-institutional retrospective review of 87 patients. Int
J Radiat Oncol Biol Phys. 2007; 68: 1326–1334
[40]
Pope ER: Feline inflammatory polyps. Sem Vet Med Surg (Small
Anim). 1995; 10: 87–93
[41]
[8]
Antognoni MT, Mangili V, Spaterna A et al.: Acute myeloid leukaemia in five dogs: clinical findings and cytochemical characterization. Vet Res Commun. 2003; 27 (Suppl 1): 367–371
[9]
Appelbaum FR, Deeg HJ, Storb R et al.: Cure of malignant lymphoma in dogs with peripheral blood stern cell transplantation.
Transplantation. 1986; 42: 19–22
Pratschke KM: Inflammatory polyps of the middle ear in 5 dogs.
Vet Surg. 2003; 32: 292–296
[10]
Avery A: Molecular diagnostics of hematologic malignancies. Top
[42]
Rogers KS: Tumors of the ear canal. Vet Clin North Am (Sm Anim
Pract). 1988; 18: 859–868
[11]
[43]
Roth L: Rhabdomyoma of the ear pinna in four cats. J Comp Pathol.
1990; 103: 237–240
Baker RJ, Valli VE: Dysmyelopoiesis in the cat: a haematological disorder resembling refractory anemia with excess blasts in man. Can J
Vet Res. 1986; 50: 3–6
[12]
[44]
Schmidt JF, Kaptkin A: Nasopharyngeal and ear canal polyps in the
cat. Feline Pract. 1990: 18: 16–19
[45]
Seitz SE, Losonsky JM, Marretta SM: Computed tomographic
appearance of inflammatory polyps in three cats. Vet Radiol Ultrasound. 1996; 37; 99–104
Beaver LM, Strottner G, Klein MK: Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006–2008). J Am Vet Med Assoc. 2010; 237:
1052–1055
[13]
Bell R, Cotter SM, Lillquist A et al.: Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single agent glucocorticoid treatment. Blood. 1984; 63:
380–383
[14]
Bertone ER, Snyder LA, Moore AS: Environmental tobacco smoke
and risk of malignant lymphoma in pet cats. Am J Epidemiol. 2002;
156: 268–273
[15]
Blue JT: Myelodysplasia: differentiating neoplastic from nonneoplastic syndromes of ineffective hematopoiesis in dogs. Toxicol Pathol.
2003; 31(Suppl): 44–48
[16]
Blue JT, French TW, Kranz JS: Non-lymphoid hematopoietic neoplasia in cats: a retrospective study of 60 cases. Cornell Vet. 1988;
78: 21–42
[17]
Blue JT: Myelofibrosis in cats with myelodysplastic syndrome and
acute myelogenous leukemia. Vet Pathol. 1988; 25: 154–160
[18]
Boyle TE, Holowaychuk MK, Adams AK et al.: Treatment of three
cats with hyperviscosity syndrome and congestive heart failure
using plasmapheresis. J Am Anim Hosp Assoc. 2011; 47: 50–55
[19]
Breen M, Modiano JF: Evolutionarily conserved cytogenetic changes in haematological malignancies of dogs and humans—man and
his best friend share more than companionship. Chromosome Res.
2008; 16: 145–154
[20]
Breuer W, Hermanns W, Thiele J: Myelodysplastic syndrome
(MDS), acute myeloid leukaemia (AML) and chronic myeloproliferative disorder (CMPD) in cats. J Comp Pathol. 1999; 121: 203–216
[21]
Brooks MB, Matus RE, Leifer CE et al.: Use of splenectomy in the
management of lymphoma in dogs: 16 cases (1976—1985). J Am
Vet Med Assoc. 1987; 191: 1008–1010
[22]
Abadie J, Hédan B, Cadieu E et al.: Epidemiology, pathology, and
genetics of histiocytic sarcoma in the Bernese mountain dog breed.
J Hered. 2009; 100 (Suppl 1): S19–27
Brown DE, Thrall MA, Getzy DM et al.: Cytology of canine malignant histiocytosis. Vet Clin Pathol. 1996; 23: 118–122
[23]
Adam F, Villiers E, Watson S et al.: Clinical pathological and epidemiological assessment of morphologically and immunologically
confirmed canine leukaemia. Vet Comp Oncol. 2009; 7: 181–195
Burnett RC, Vernau W, Modiano JF et al.: Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor
genes. Vet Pathol. 2003; 40: 32–41
[24]
[3]
Affolter VK, Moore PF: Feline progressive histiocytosis. Vet Pathol.
2006; 43: 646–655
Busch MD, Reilly CM, Luff JA et al.: Feline pulmonary Langerhans
cell histiocytosis with multiorgan involvement. Vet Pathol. 2008;
45: 816–824
[25]
[4]
Affolter VK, Moore PF: Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol. 2002; 39: 74–83
[5]
Ahmad S, Levy LS: The frequency of occurrence and nature of
recombinant feline leukemia viruses in the induction of multicentric
lymphoma by infection of the domestic cat with FeLV-945. Virology.
2010; 403: 103–110
Callanan JJ, Jones BA, Irvine J et al.: Histologic classification and
immunophenotype of lymphosarcomas in cats with naturally and
experimentally acquired feline immunodeficiency virus infections.
Vet Pathol. 1996; 33: 264–272
[26]
Campbell KL, Latimer KS: Polysystemic manifestations of plasma
cell myeloma in the dog: a case report and review. J Am Anim Hosp
Assoc. 1985; 21: 59–66
[6]
Alvarez FJ, Kisseberth WC, Gallant SL et al.: Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for
dogs with relapsed lymphoma. J Vet Intern Med. 2006; 20: 1178–
1183
[27]
Canfield PJ, Church DB, Russ IG: Myeloproliferative disorder involving the megakaryocytic line. J Small Anim Pract. 1993; 34: 296–
301
[28]
[7]
Ameri M, Wilkerson MJ, Stockham SL et al.: Acute megakaryoblastic leukemia in a German Shepherd dog. Vet Clin Pathol. 2010;
39: 39–45
Cangul IT, Wijnen M, Van Garderen E et al.: Clinico-pathological
aspects of canine cutaneous and mucocutaneous plasmacytomas. J
[46]
Stone EA, Goldschmidt MH, Littman MP: Squamous cell carcinoma
of the middle ear in a cat. J Small Anim Pract. 1983; 24: 647–651
[47]
ter Haar G: Inner ear dysfunction related to ear disease in dogs and
cats. Europ J Comp Anim Pract. 2006; 16: 127–135
[48]
Théon AP, Barthez PY, Madewell BR et al.: Radiation therapy of
ceruminous gland carcinomas in dogs and cats. J Am Vet Med
Assoc. 1994; 205: 566–569
[49]
Travetti O, Giudice C, Greci V et al.: Computed tomography features of middle ear cholesteatoma in dogs. Vet Radiol Ultrasound.
2010; 51: 374–379
[50]
Trevor PB, Martin RA: Tympanic bulla osteotomy for treatment of
middle-ear disease in cats: 19 cases (1984–1991). J Am Vet Med
Assoc. 1993; 202: 123–128
[51]
Veir JK, Lappin MR, Foley JE et al.: Feline inflammatory polyps: historical, clinical, and PCR findings for feline calici virus and feline herpes virus-1 in 28 cases. J Feline Med Surg. 2002; 4: 195–199
[52]
Venker-van Haagen AJ, van der Gaag I: The ear. In: Golston RT,
Hoskins JD (Hrsg.): Geriatrics and gerontology of the dog and cat.
WB Saunders Co, Philadelphia, 1995; 209–221
[53]
Yoshikawa H, Mayer MN, Linn KA et al.: A dog with squamous
cell carcinoma in the middle ear. Can Vet J. 2008; 49: 877–879
[54]
Zur G: Bilateral ear canal neoplasia in three dogs. Vet Dermatol.
2005;16: 276–280
32 Hämatopoietische Tumoren
[1]
[2]
131
132
[29]
Carter RF, Valli VEO, Lumsden JH: The cytology, histology and prevalence of cell types in canine lymphoma classified according to the
National Cancer Institute Working Formulation. Can J Vet Res. 1986;
50: 154–164
[52]
Daters AT, Mauldin GE, Mauldin GN et al.: Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma. Vet
Comp Oncol. 2010; 8: 11–22
[30]
Carter RF, Harris CK, Withrow SJ et al.: Chemotherapy of canine
lymphoma with histopathological correlation: doxorubicin alone
compared to COP as first treatment regimen. J Am Anim Hosp
Assoc. 1987; 23: 587–596
[53]
Day MJ: Immunophenotypic characterization of cutaneous lymphoid neoplasia in the dog and cat. J Comp Pathol. 1995; 112: 79–
96
[54]
[31]
Chun R: Lymphoma: which chemotherapy protocol and why? Top
[32]
Chun R, Garrett LD, Vail DM: Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2000; 14: 120–124
Deeg HJ, Apelbaum FR, Weiden L et al.: Autologous marrow
transplantation as consilidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation. Am J
Vet Res. 1985; 46: 2016–2018
[55]
Clark GN, Berg J, Engler SJ et al.: Extramedullary plasmacytomas
in dogs: results of surgical excision in 131 cases. J Am Anim Hosp
Assoc. 1992; 28: 105–111
Dobson JM, Blackwood LB, McInnes EF et al: Prognostic variables
in canine multicentric lymphosarcoma. J Small Anim Pract. 2001;
42: 377–384
[56]
Dobson J, Hoather T, McKinley TJ et al.: Mortality in a cohort of
flat-coated retrievers in the UK. Vet Comp Oncol. 2009; 7: 115–121
[33]
[34]
Cobaltzky F, Hermanns W: Acute megakaryoblastic leukemia in
one cat and two dogs. Vet Pathol. 1993; 30: 186–194
[57]
Drazner FH: Multiple myeloma in the cat. Comp Contin Educ Pract
Vet. 1982; 4: 206–214
[35]
Comazzi S, Gelain ME: Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma. Vet J.
2010; 188: 149–155
[58]
Elmslie RE, Ogilvie GK, Gilette EL et al.: Radiotherapy with and
without chemotherapy for localized lymphoma in 10 cats. Vet
Radiol. 1991; 32: 277–280
[36]
Comazzi S, Gelain ME, Bonfanti U et al.: Acute megakaryoblastic
leukemia in dogs: a report of three cases and review of the literature. J Am Anim Hosp Assoc. 2010; 46: 327–335
[59]
Engelman RW, Tyler RD, Good RA et al.: Hypercalcemia in cats
with feline-leukemia-virus-associated leukemia-lymphoma. Cancer.
1985; 56: 777–781
[37]
Comazzi S, Gelain ME, Martini V et al.: Immunophenotype predicts survival time in dogs with chronic lymphocytic leukemia. J Vet
Intern Med. 2011; 25: 100–106
[60]
Essex ME: Feline leukemia: a naturally occurring cancer of infectious origin. Epidemiol Rev. 1982; 4: 189–203
[61]
[38]
Comazzi S, Gelain ME, Spagnolo V et al.: Flow cytometric patterns
in blood from dogs with non-neoplastic and neoplastic hematologic
diseases using double labeling for CD18 and CD45. Vet Clin Pathol.
2006; 35: 47–54
Ettinger SN: Principles of treatment for feline lymphoma. Clin Tech
[62]
Evans RJ, Jones DRE, Gruffydd-Jones TJ: Essential thrombocythemia in the dog and cat: a report of four cases. J Small Anim Pract.
1982; 23: 457–467
[63]
Evans RJ, Gorman NT: Myeloproliferative disease in the dog and
cat: definition, etiology and classification. Vet Rec. 1987; 121: 437–
443
[64]
Facklam NR, Kociba GJ: Cytochemical characterization of feline leukemic cells. Vet Pathol. 1986; 23: 155–161
[65]
Favier RP, van Leeuwen M, Teske E: Essential Thombocythaemia
in two dogs. Tijdschr Diergeneeskd. 2004; 129: 360–364
[66]
Fidel J, Schiller I, Hauser B et al.: Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998–March
2005). Vet Comp Oncol. 2006; 4: 63–74
[67]
Fine DM, Tvedten HW: Chronic granulocytic leukemia in a dog. J
Am Vet Med Assoc. 1999; 214: 1809–1812
[68]
Flory AB, Rassnick KM, Al-Sarraf R et al.: Combination of CCNU
and DTIC chemotherapy for treatment of resistant lymphoma in
[69]
Friedrichs KR, Young KM: Histiocytic sarcoma of macrophage origin in a cat: case report with a literature review of feline histiocytic
malignancies and comparison with canine hemophagocytic histiocytic sarcoma. Vet Clin Pathol. 2008; 37: 121–128
[70]
Forrester SD, Fossum TW, Rogers KS: Diagnosis and treatment of
chylothorax associated with lymphoblastic lymphosarcoma in four
[71]
Forrester SD, Greco DS, Relford RL: Serum hyperviscosity syndrome associated with multiple myeloma in two cats. J Am Vet Med
Assoc. 1992; 200: 79–82
[39]
Constantino-Casas F, Mayhew D, Hoather TM et al.: The clinical
presentation and histopathologic-immunohistochemical classification of histiocytic sarcomas in the Flat Coated Retriever. Vet Pathol.
2011; 48: 764–771
[40]
Coomer AR, Liptak JM: Canine histiocytic diseases. Compend Contin Educ Vet. 2008; 30: 202–204, 208–216
[41]
Cotter SM: Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone: I. Treatment of dogs. J Am
Anim Hosp Assoc 1983; 19: 159–165
[42]
Cotter SM: Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone: II treatment of cats. J Am
Anim Hosp Assoc. 1983; 19: 166–172
[43]
Court EA, Earnest-Koons KA, Barr SC et al.: Malignant histiocytosis in a cat. J Am Vet Med Assoc. 1993; 203: 1300–1302
[44]
Court EA, Watson AD, Peaston AE: Retrospective study of 60
cases of feline lymphosarcoma. Aust Vet J. 1997; 75: 424–427
[45]
Couto CG, Ruehl W, Muir S: Plasma cell leukemia and monoclonal
(IgG) gammopathy in a dog. J Am Vet Med Assoc. 1984; 184: 90–
92
[46]
Couto CG, Cullen J, Pedroia V et al.: Central nervous system lymphosarcoma in the dog. J Am Vet Med Assoc. 1984; 184: 809–813
[47]
Couto CG: Clinicopathologic aspects of acute leukemias in the dog.
J Am Vet Med Assoc. 1985; 186: 681–685
[48]
Coyle KA, Steinberg H: Characterization of lymphocytes in canine
gastrointestinal lymphoma. Vet Pathol. 2004; 41: 141–146
[49]
Crabtree AC, Spangler E, Beard D et al.: Diagnostic accuracy of
gray-scale ultrasonography for the detection of hepatic and splenic
lymphoma in dogs. Vet Radiol Ultrasound. 2010; 51: 661–664
[72]
Fujino Y, Tezuka K, Hisasue M et al.: Clinicopathological features
and therapy of myelodysplastic syndromes in two dogs. Vet Rec.
2003; 153: 25–27
[50]
Cruz-Arámbulo R, Wrigley R, Powers B: Sonographic features of
histiocytic neoplasms in the canine abdomen. Vet Radiol Ultrasound. 2004; 45: 554–558
[73]
Fulmer AK, Mauldin GE: Canine histiocytic neoplasia: an overview.
Can Vet J. 2007; 48: 1041–1043, 1046–1050
[74]
[51]
Cruz Cardona JA, Milner R, Alleman AR et al.: BCR-ABL translocation in a dog with chronic monocytic leukemia. Vet Clin Pathol.
2011; 40: 40–47
Gabor LJ, Canfield PJ, Malik R: Immunophenotypic and histological
characterisation of 109 cases of feline lymphosarcoma. Aust Vet J.
1999; 77: 436–441
[75]
Gabor LJ, Jackson ML, Trask B et al.: Feline leukaemia virus status
of Australian cats with lymphosarcoma. Aust Vet J. 2001; 79: 476–
481
[97]
Hart S, Wurm S, Mischke R et al.: Lymphknotendiagnostik mittels
Feinnadelaspirationszytologie beim Hund. Kleintierprax. 1995; 40:
869–876
[76]
Gafner F, Bestetti GE: Feline malignant histiocytosis and the lysozyme immunoenzyme technique. Schweiz Arch Tierheilk. 1988;
130: 349–356
[98]
Harvey JW, Terrel TG, Hyde DM et al.: Well-differentiated Lymphocytic leukemia in a dog: Long-term survival without therapy.
Vet Pathol. 1981; 18: 37–47
[77]
Garrett LD, Thamm DH, Chun R et al.: Evaluation of a 6–month
chemotherapy protocol with no maintenance therapy for dogs with
lymphoma. J Vet Intern Med. 2002; 16: 704–709
[99]
Hawkins EC, Feldman BF: Immunoglobulin A myeloma in a cat
with pleural effusion and serum hyperviscosity. J Am Vet Med
Assoc. 1986; 188: 876–878
[78]
Gelain ME, Antoniazzi E, Bertazzolo W et al.: Chronic eosinophilic
leukemia in a cat: cytochemical and immunophenotypical features.
Vet Clin Pathol. 2006; 35: 454–459
[100] Hayashi A, Tanaka H, Kitamura M et al.: Acute myelomonocytic
leukemia (AML-M4) in a dog with the extradural lesion. J Vet Med
Sci. 2011; 73: 419–422
[79]
Geyer NE, Reichle JK, Valdés-Martínez A et al.: Radiographic
appearance of confirmed pulmonary lymphoma in cats and dogs.
[101] Hayes HM, Tarone RE, Cantor KP: On the association between
canine malignant lymphoma and opportunity for exposure to 2,4–
dichlorphenoxyacetic acid. Environ. Res. 1995; 70: 119–125
[80]
Giraudel JM, Pagès JP, Guelfi JF: Monoclonal gammopathies in the
dog: a retrospective study of 18 cases (1986–1999) and literature
[102] Heller DA, Clifford CA, Goldschmidt MH et al.: Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic
[81]
Gorman NT, Evans RJ: Myeloproliferative disease in the dog and
cat: Clinical presentations, diagnosis and treatment. Vet Rec. 1987;
121: 490–496
[103] Hiraoka H, Hisasue M, Nagashima N et al.: A dog with myelodysplastic syndrome: chronic myelomonocytic leukemia. J Vet Med
Sci. 2007; 69: 665–668
[82]
Greenberg CB, Boria PA, Raskin RE et al.: Effect of chemotherapy
schedule on response in Waldenströmʼs macroglobulinemia in a
dog. J Vet Intern Med. 2008; 22: 223–226
[104] Hisasue M, Nishimura T, Neo S et al.: A dog with acute myelomonocytic leukemia. J Vet Med Sci. 2008; 70: 619–621
[83]
Greenlee PG, Filippa DA, Quimby FW et al.: Lymphomas in dogs.
A morphologic, immunologic, and clinical study. Cancer. 1990; 66:
480–490
[84]
Grindem CB, Stevens JB, Perman V: Morphological classification
and clinical and pathological characteristics of spontaneous leukemia in 17 dogs. J Am Anim Hosp Assoc. 1985; 21: 219–226
[85]
Grindem CB, Stevens JB, Perman V: Cytochemical reactions in
cells from leukemic dogs. Vet Pathol. 1986; 23: 103–109
[86]
Grindem CB, Buoen LC: Cytogenetic analysis of leukemic cells in
the dog: a report of 10 cases and a review of the literature. J Comp
Pathol. 1986; 96: 623–635
[87]
[88]
Gruffydd-Jones TJ, Gaskell CJ: Clinical and radiographical features
of anterior mediastinal lymphosarcoma in the cat: A review of 30
cases. Vet Rec. 1979; 104: 304–307
Guija de Arespacochaga A, Schwendenwein I, Weissenböck H:
Retrospective study of 82 cases of canine lymphoma in Austria
based on the Working Formulation and immunophenotyping. J
Comp Pathol. 2007; 136: 186–192
[105] Hisasue M, Okayama H, Okayama T et al.: Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes. J Vet
Intern Med. 2001;15: 471–477
[106] Hodgkins EM, Zinkl JG, Madewell BR: Chronic lymphocytic leukemia in the dog. J Am Vet Med Assoc. 1980; 177: 704–707
[107] Hopper PE, Mandell CP, Turrel JM et al.: Probable essential thrombocythemia in a dog. J Vet Intern Med. 1989; 3: 79–85
[108] Hosoya K, Kisseberth WC, Lord LK et al.: Comparison of COAP
and UW-19 protocols for dogs with multicentric lymphoma. J Vet
Intern Med. 2007; 21: 1355–1363
[109] Huibregtse BA, Turner JL: Hypereosinophilic syndrome and eosinophilic leukemia: a comparison of 22 hypereosinophilic cats. J Am
Anim Hosp Assoc. 1994; 30: 591–599
[110] Hurvitz AI, MacEwen EG, Niddaugh CR et al.: Monoclonal cryoglobulinemia with macroglobulinemia in a dog. J Am Vet Med Assoc.
1977, 170: 511–513
[111] Ide K, Setoguchi-Mukai A, Nakagawa T et al.: Disseminated histiocytic sarcoma with excessive hemophagocytosis in a cat. J Vet
Med Sci. 2009; 71: 817–820
[89]
Hadden AG, Cotter SM, Rand W et al.: Efficacy and toxicosis of
VELCAP-C treatment of lymphoma in cats. J Vet Intern Med. 2008;
22: 153–157
[112] Impellizeri JA, Howell K, McKeever KP et al.: The role of rituximab
in the treatment of canine lymphoma: an ex vivo evaluation. Vet J.
2006;171: 556–558
[90]
Hafeman S, London C, Elmslie R et al.: Evaluation of liposomal
clodronate for treatment of malignant histiocytosis in dogs. Cancer
Immunol Immunother. 2010; 59: 441–552
[113] Ishizuka M, Nagai S, Sakamoto KQ et al.: Plasma pharmacokinetics and CYP3A12–dependent metabolism of c-kit inhibitor imatinib
in dogs. Xenobiotica. 2007 ; 37: 503–513
[91]
Hahn KA, Richardson AC, Teclaw RF et al.: Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma? J Vet Intern Med. 1992; 6: 3–10
[114] Jadersten M, Hellstrom-Lindberg E: New clues to the molecular
pathogenesis of myelodysplastic syndromes. Exp Cell Res. 2010;
316: 1390–1396
[92]
Hahn KA, Richardson AC, Hahn EA et al.: Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs
with lymphosarcoma. Vet Pathol. 1994; 31: 528–540
[93]
Hamilton TA, Morrison WE, DeNicola DB: Cytosine arabinoside
chemotherapy for acute megakaryocytic leukemia in a cat. J Am Vet
Med Assoc. 1991; 199: 359–361
[115] Jaffe E, Harris NL, Stein H et al.: (Hrsg.): WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. Pathology and
Genetics of Tumours of Haemopoietic and Lymphoid Tissues. IARC
Press, Lyon 2001
[94]
Hammer AS, Couto CG: Complications of multiple myeloma. J Am
[95]
Hanna FJ: Multiple myelomas in cats. Feline Med Surg. 2005; 7:
275–287
[96]
Hardy WD Jr.: Hematopoietic tumors of cats. J Am Anim Hosp
Assoc. 1981; 17: 921–940
[116] Jaillardon L, Fournel-Fleury C: Waldenströmʼs macroglobulinemia
in a dog with a bleeding diathesis. Vet Clin Pathol. 2011; 40: 351–
355
[117] Jain NC: Classification of myeloproliferative disorders using criteria
proposed by the Animal Leukaemia Study Group: a retrospective
study of 181 cases (1969–1992). Comp Haematol Int. 1993; 3:
125–134
[118] Jain NC, Blue JT, Grindem CB et al.: A report of the Animal Leukemia Study Group. Proposed criteria for classification of acute myeloid leukemia in dogs and cats. Vet Clin Pathol. 1991; 20: 63–82
133
134
[119] Jeffreys AB, Knapp DW, Carlton WW et al.: Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. J Am Anim Hosp Assoc. 2005; 41: 221–226
[142] Leifer CE, Matus RE: Chronic lymphocytic leukemia in the dog: 22
[120] Jeglum KA, Whereat A, Young KM: Chemotherapy of lymphoma
in 75 cats. J Am Vet Med Assoc. 1987; 190: 174–178
[143] Lori JC, Stein TJ, DH Thamm: Doxorubicin and cyclophosphamide
for the treatment of canine lymphoma: a randomized, placebo-controlled study. Vet Comp Oncol. 2010; 8: 188–195
[121] Jeglum KA, Young KM, Barnsley K et al.: Chemotherapy versus
chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma. Cancer. 1988; 61: 2042–2050
[144] Louwerens M, London CA, Pedersen NC et al.: Feline lymphoma
329–335
[122] Jeglum KA, Steplewski Z: Canine lymphoma: a model for clinical
trials of cytotoxic murine monoclonal antibodies. Proc. AACR. 29,
1988: 421
[145] Lurie DM, Gordon IK, Théon AP et al.: Sequential low-dose rate
half-body irradiation and chemotherapy for the treatment of canine
multicentric lymphoma. J Vet Intern Med. 2009; 23: 1064–1070
[123] Johnson RE, OʼConnor GT, Titus W et al.: Comparative clinical, histologic, and radiotherapeutic aspects of canine and human malignant lymphoma. Radiology. 1969; 93: 395–399
[146] MacEwen EG, Hurvitz AI: Diagnosis and management of monoclonal gammopathies. Vet Clin North Am Small Anim Pract. 1977; 7:
119–132
[124] Juopperi TA, Bienzle D, Bernreuter DC et al.: Prognostic markers
for myeloid neoplasms: a comparative review of the literature and
goals for future investigation. Vet Pathol. 2011; 48: 182–197
[147] MacEwen EG, Patnaik AK, Hurvitz AI et al.: Nonsecretory multiple
[125] Keller ET: Immunemediated disease as a risk factor for canine lymphoma. Cancer. 1992; 70: 2334–2337
[148] MacEwen EG, Hayes AA, Matus RE et al.: Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog.
147 cases (1978—1981). J Am Vet Med Assoc. 1987; 190: 564–568
[126] Keller RL, Avery AC, Burnett RC et al.: Detection of neoplastic lymphocytes in peripheral blood of dogs with lymphoma by polymerase
chain reaction for antigen receptor gene rearrangement. Vet Clin
Pathol. 2004; 33: 145–149
[149] MacEwen EG, Rosenthal RC, Fox LE et al.: Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase
[127] Keller ET, MacEwen EG, Rosenthal RC et al.: Evaluation of prognostic factors and sequential combination chemotherapy with
doxorubicin for canine lymphoma. J Vet Intern Med. 1993; 7: 289–
295
[150] MacDonald VS, Thamm DH, Kurzman ID et al.: Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP
protocol for dogs with lymphoma? J Vet Intern Med. 2005; 19:
732–736
[128] Kessler M, Kandel B: Chemotherapie des malignen Lymphoms
beim Hund: Ergebnisse und Erfahrungen mit dem „Hofheimer Protokoll“ bei 57 Patienten. Kleintierprax. 2004; 49: 349–358
[151] Madewell BR, Jain NC, Weller RE: Hematologic abnormalities preceding myeloid leukemia in three cats. Vet Pathol. 1979; 16: 510–
519
[129] Kessler M, von Bomhard W: Diagnostik und Therapie einer chronischen myeloischen Leukämie (CML) bei einem Dackel. Kleintierprax.
2008; 53: 73–80
[152] Madewell BR, Feldman BF: Characterization of anemias associated
419–425
[130] Kiupel M, Teske E, Bostock D: Prognostic factors for treated
canine malignant lymphoma. Vet Pathol. 1999; 36: 292–300
[153] Madewell BR: Hematological and bone marrow cytological abnormalities in 75 dogs with malignant lymphomas. J Am Anim Hosp
Assoc. 1986; 22: 235–240
[131] Kiselow MA, Rassnick KM, McDonough SP et al.: Outcome of
cats with low-grade lymphocytic lymphoma: 41 cases (1995–
2005). J Am Vet Med Assoc. 2008; 232: 405–410
[132] Kohn B, Arnold P, Kaser-Hotz B et al.: Maligne Histiozytose beim
Hund: 26 Fälle (1989–1992). Kleintierprax. 1993; 38: 409–424
[154] Madewell BR, Theilen GH: Hematopoietic neoplasms, sarcomas
and related conditions. Part IV: Canine. In: Theilen GH, Madewell BR
(Hrsg.): Veterinary Cancer Medicine, 2. Aufl. Lea & Febiger, Philadelphia 1987: 392–407
[133] Kraje AC, Patton CS, Edwards DF: Malignant histiocytosis in 3 cats.
J Vet Intern Med. 2001; 15: 252–256
[155] Mahaffey EA, Brown TP, Duncan JR et al.: Basophilic leukemia in a
dog. J Comp Pathol. 1987; 97: 393–399
[134] Krick EL, Little L, Patel R et al.: Description of clinical and pathological findings, treatment and outcome of feline large granular lymphocyte lymphoma (1996–2004). Vet Comp Oncol. 2008; 6: 102–
110
[156] Mahony OM, Moore AS, Cotter SM et al.: Alimentary lymphoma
in cats: 28 cases (1988—1993). J Am Vet Med Assoc. 1995; 207:
1593–1598
[135] Kyle KN, Wright Z: Apparent feline leukemia virus-induced chronic
lymphocytic leukemia and response to treatment. J Feline Med
Surg. 2010; 12: 341–344
[136] Laing EJ, Fitzpatrick PJ, Bennington AG et al.: Halfbody radiotherapy in the treatment of canine lymphoma. J Vet Intern Med. 1989;
3: 102–108
[137] Lana S, Plaza S, Hampe K et al.: Diagnosis of mediastinal masses in
dogs by flow cytometry. J Vet Intern Med. 2006; 20: 1161–1165
[138] Lane SB, Kornegay JN, Duncan DR et al.: Feline spinal lymphosarcoma: a retrospective evaluation of 23 cats. J Vet Intern Med. 1994;
8: 99–104
[139] LeBlanc AK, Cox SK, Kirk CA et al.: Effects of L-asparaginase on
plasma amino acid profiles and tumor burden in cats with lymphoma. J Vet Intern Med. 2007; 21: 760–763
[140] Ledieu D, Palazzi X, Marchal T et al. : Acute megakaryoblastic leukemia with erythrophagocytosis and thrombosis in a dog. Vet Clin
Pathol. 2005; 34: 52–56
[141] Leifer CE, Matus RE, Patnaik K et al.: Chronic myelogenous leukemia in the dog. J Am Vet Med Assoc. 1983; 183: 686–689
[157] Mashita T, Shimoda T, Yoshioka H et al.: A cat with acute myeloblastic leukemia without maturation (M1) treated with combination
chemotherapy. J Vet Med Sci. 2006; 68: 97–101
[158] Matus RE, Leifer CE, Gordon BR et al.: Plasmapheresis and chemotherapy of hyperviscosity syndrome associated with monoclonal
gammopathy in the dog. J Am Vet Med Assoc. 1983; 183: 215–218
[159] Matus RE, Leifer CE, MacEwen GE: Acute lymphoblastic leukemia
in the dog: a review of 30 cases. J Am Vet Med Assoc. 1983; 183:
859–862
[160] Matus RE, Leifer CE: Immunoglobulin-producing tumors. Vet Clin
North Am Sm Anim Pract. 1985; 15: 741–753
[161] Matus RE, Leifer CE, MacEwen EG et al.: Prognostic factors for
1288–1292
[162] McManus PM: Classification of myeloid neoplasms: a comparative
review. Vet Clin Pathol. 2005; 34: 189–212
[163] McManus PM, Hess RS: Myelodysplastic changes in a dog with
subsequent acute myeloid leukemia. Vet Clin Pathol. 1998; 27:
112–115
135
[164] McMillan FD: Hypercalcemia associated with lymphoid neoplasia in
two cats. Feline Pract. 1985; 15: 31–35
[185] Naranjo C, Dubielzig RR, Friedrichs KR: Canine ocular histiocytic
sarcoma. Vet Ophthalmol. 2007; 10: 179–185
[165] Mellor PJ, Haugland S, Murphy S et al.: Myeloma-related disorders
in cats commonly present as extramedullary neoplasms in contrast
to myeloma in human patients: 24 cases with clinical follow-up. J
Vet Intern Med. 2006; 20: 1376–1383
[186] Ndikuwera J, Smith DA, Obwolo MJ et al.: Chronic granulocytic
leukemia/eosinophylic leukemia in a dog? J Small Anim Pract. 1992;
33: 553–557
[167] Meyer HP, Slappendel RJ, Greydanus-van der Putten SWM: Polycythemia vera in a dog treated by repeated phlebotomies. Vet
Quart. 1993; 15: 108–111
[168] Miyamoto T, Horie T, Shimada T et al.: Longterm case study of
myelodysplastic syndrome in a dog. J Am Anim Hosp Assoc. 1999;
35: 475–481
[169] Miller C, Fish MB, Danelski TF: IgA multiple myeloma with multisystem manifestations in the dog: a case report. J Am Anim Hosp
Assoc. 1982; 18: 53–56
[170] Mischke R, Schulze U, Schuberth H-J: Multiples Myelom vom IgATyp mit biklonaler Gammopathie und Störung der primären Hämostase bei einem Deutschen Schäferhund. Prakt Tierarzt. 2000; 81:
188–195
[171] Mischke R, Freund M, Leinemann-Fink T et al.: Changes in hemostasis of dogs with acute lymphoblastic leukaemia. Berl Munch
Tierarztl Wochenschr. 1998; 111: 53–59
[172] Modiano JF, Breen M, Burnett RC et al.: Distinct B-cell and T-cell
lymphoproliferative disease prevalence among dog breeds indicates
heritable risk. Cancer Res. 2005; 65: 5654–5661
[187] Nielsen L, Andreasen SN, Andersen SD et al.: Malignant histiocytosis and other causes of death in Bernese mountain dogs in Denmark. Vet Rec. 2010; 166: 199–202
[188] Oberthaler KT, Mauldin E, McManus PM et al.: Rescue therapy
with doxorubicin-based chemotherapy for relapsing or refractory
feline lymphoma: a retrospective study of 23 cases. J Feline Med
Surg. 2009; 11: 259–265
[189] Onions DE: A prospective survey of familial canine lymphosarcoma.
J Natl Cancer Inst. 1984; 72: 909–912
[190] Owen LN, Bostock DE, Halliwell REW: Cell-mediated and humoral
immunity in dogs with spontaneous lymphosarcoma. Eur J Cancer.
1975; 11: 187–191
[191] Padgett GA, Madewell BR, Keller ET et al.: Inheritance of histiocytosis in Bernese mountain dogs. J Small Anim Pract. 1995; 36: 93–
98
[192] Park HM, Doster AR, Tashbaeva RE et al.: Clinical, histopathological and immunohistochemical findings in a case of megakaryoblastic leukemia in a dog. J Vet Diagn Invest. 2006; 18: 287–291
[193] Patel RT, Caceres A, French AF et al.: Multiple myeloma in 16 cats:
a retrospective study. Vet Clin Pathol. 2005; 34: 341–352
[194] Peterson ME, Randolph JF: Diagnosis of canine primary polycythemia and management with hydroxyurea. J Am Vet Med Assoc.
1982; 180: 415–418
[173] Mooney SC, Hayes AA: Lymphoma in the cat: an approach to diagnosis and management. Semin Vet Med Surg (Small Anim). 1986;
1: 51–57
[195] Piek CJ, Rutteman GR, Teske E: Evaluation of the results of a Lasparaginase-based continuous chemotherapy protocol versus a
short doxorubicin-based induction chemotherapy protocol in dogs
with malignant lymphoma. Vet Q. 1999; 21: 44–49
[174] Mooney SC, Patnaik AK, Hayes AA et al.: Generalized lymphadenopathy resembling lymphoma in cats: six cases (1972—1976). J Am
Vet Med Assoc. 1987; 190: 897–900
[196] Platz SJ, Breuer W, Geisel O et al.: Identification of lambda light
chain amyloid in eight canine and two feline extramedullary plasmacytomas. J Comp Pathol. 1997; 116: 45–54
[175] Mooney SC, Hayes AA, MacEwen EG et al.: Treatment and prognostic factors in lymphoma in cats: 103 cases (1977—1981). J Am
Vet Med Assoc. 1989; 194: 696–699
[197] Pohlman LM, Higginbotham ML, Welles EG et al.: Immunophenotypic and histologic classification of 50 cases of feline gastrointestinal lymphoma. Vet Pathol. 2009; 46: 259–268
[176] Moore PF, Affolter VK, Vernau W: Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet
Pathol. 2006; 43: 632–645
[198] Ponce F, Magnol JP, Ledieu D et al.: Prognostic significance of
morphological subtypes in canine malignant lymphomas during
chemotherapy. Vet J. 2004; 167: 158–166
[177] Moore AS, Cotter SM, Frimberger AE et al.: A comparison of
doxorubicin and COP for maintenance of remission in cats with lymphoma. J Vet Intern Med. 1996; 10: 372–375
[199] Postorino NC, Susaneck SJ, Withrow SJ et al.: Single agent therapy with Adriamycin for canine lymphosarcoma. J Am Anim Hosp
Assoc. 1989; 25: 221–225
[178] Moore AS, Cotter SM, Rand WM et al.: Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet
Intern Med. 2001; 15: 348–354
[200] Reagan WJ: A review of myelofibrosis in dogs. Toxic Pathol. 1993;
21: 164–169
[179] Moore AS, London CA, Wood CA et al.: Lomustine (CCNU) for the
treatment of resistant lymphoma in dogs. J Vet Intern Med. 1999;
13:395–398
[180] Moore AS, Ogilvie GK, Ruslander D et al.: Evaluation of mitoxantrone for the treatment of lymphoma in dogs. J Am Vet Med Assoc.
1994; 205: 1903–1905
[181] Moore AS, Ruslander D, Cotter SM et al.: Efficacy of, and toxicosis
associated with oral idarubicin administration in cats with neoplasia.
J Am Vet Med Assoc. 1995; 206: 1550–1554
[182] Morris JS, Dunn LK, Dobson JM: Canine lymphoid leukemia and
lymphoma with bone marrow involvement: a review of 24 cases. J
[183] Mylonakis ME, Petanides TA, Valli VE et al.: Acute myelomonocytic leukaemia with short-term spontaneous remission in a cat. Aust
Vet J. 2008; 86: 224–228
[184] Nagashima N, Kano R, Hirai A et al.: Acute monocytic leukaemia
in a cat. Vet Rec. 2005; 157: 347–349
[201] Ramaiah SK, Seguin MA, Carwile HF et al.: Biclonal gammopathy
associated with immunoglobulin A in a dog with multiple myeloma.
[202] Ramirez S, Douglass JP, Robertson ID: Ultrasonographic features
of canine abdominal malignant histiocytosis. Vet Radiol Ultrasound.
2002; 43: 167–170
[203] Rao S, Lana S, Eickhoff J et al.: Class II Major Histocompatibility
Complex expression and cell size independently predict survival in
canine B-cell lymphoma. J Vet Intern Med. 2011; 25: 1097–1105
[204] Raskin RE, Krehbiel JD: Prevalence of leukemic blood and bone
marrow in dogs with multicentric lymphoma. J Am Vet Med Assoc.
1989; 194: 1427–1429
[205] Rassnick KM, Mauldin GE, Al-Sarraf R et al.: MOPP chemotherapy
for treatment of resistant lymphoma in dogs: a retrospective study
of 117 cases (1989–2000). J Vet Intern Med. 2002; 16: 576–580
[206] Rassnick KM, Moore AS, Russell DS et al.: Phase II, open-label trial
of single-agent CCNU in dogs with previously untreated histiocytic
sarcoma. J Vet Intern Med. 2010; 24: 1528–1531
[166] Mellor PJ, Haugland S, Smith KC et al.: Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related
disorders: further evidence for primary extramedullary development in the cat. Vet Pathol. 2008; 45: 159–173
136
[207] Reed N, Begara-McGorum IM, Else RW et al.: Unusual histiocytic
disease in a Somali cat. J Feline Med Surg. 2006; 8: 129–134
[208] Richter KP: Feline gastrointestinal lymphoma. Vet Clin North Am
[209] Rissetto K, Villamil JA, Selting KA et al.: Recent trends in feline
intestinal neoplasia: an epidemiologic study of 1,129 cases in the
veterinary medical database from 1964 to 2004. J Am Anim Hosp
Assoc. 2011; 47: 28–36
[210] Roccabianca P, Vernau W, Caniatti M et al.: Feline large granular
lymphocyte (LGL) lymphoma with secondary leukemia: primary
intestinal origin with predominance of a CD3/CD8(alpha)(alpha)
phenotype. Vet Pathol. 2006; 43: 15–28
[211] Rosin A, Moore PF, Dubielzig R: Malignant histiocytosis in Bernese
mountain dogs. J Am Vet Med Assoc. 1986; 188: 1041–1045
[212] Rossi S, Gelain ME, Comazzi S: Disseminated histiocytic sarcoma
with peripheral blood involvement in a Bernese Mountain dog. Vet
Clin Pathol. 2009; 38: 126–130
[213] Ruiz de Gopegui R, Espada Y, Vilafranca M et al.: Paraproteininduced defective hemostatis in a dog with IgA (Kappa-light chain)
forming myeloma. Vet Clin Pathol. 1996; 23: 70–71
[214] Saar C: Erythro-Megakaryozythämie bei einer Katze. Berl Münch
Tierärztl Wschr. 1970; 83: 7070–7073
[215] Saba CF, Thamm DH, Vail DM: Combination chemotherapy with
L-asparaginase, lomustine, and prednisone for relapsed or refractory
[216] Safran N, Perk K, Eyal O: Isolation and preliminary characterisation
of a novel retrovirus isolated from a leukemic dog. Res Vet Scie.
1992; 52: 250–255
[217] Santoro D, Marsella R, Hernandez J: Investigation on the association between atopic dermatitis and the development of mycosis
2007; 18: 101–106
[218] Sauerbrey ML, Mullins MN, Bannink EO et al.: Lomustine and
prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004–2005). J Am Vet Med Assoc. 2007; 230:
1866–1869
[229] Simon D, Nolte I, Eberle N et al.: Treatment of dogs with lymphoma using a 12–week, maintenance-free combination chemotherapy protocol. J Vet Intern Med. 2006; 20: 948–954
[230] Simon D: Effektivität und Verträglichkeit von Chemotherapien bei
Tumorerkrankungen von Hund und Katze und Untersuchungen zu
Zytostatikarückständen in Serum und Urin des Hundes. Habilitationsschrift, TiHo Hannover, 2010
[231] Simpson JW, Else RW, Honeyman P: Successful treatment of
suspected essential thrombocythaemia in the dog. J Small Anim
Pract. 1990; 31: 345–348
[232] Skorupski KA, Clifford CA, Paoloni MC et al.: CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007; 21:
121–126
[233] Skorupski KA, Rodriguez CO, Krick EL et al.: Long-term survival in
dogs with localized histiocytic sarcoma treated with CCNU as an
adjuvant to local therapy. Vet Comp Oncol. 2009; 7: 139–144
[234] Smith M, Turrel JM: Radiophosphorus (32P) treatment of bone
marrow disorders in dogs: 11 cases (1970—1987). J Am Vet Med
Assoc. 1989; 194: 98–102
[235] Sözmen M, Tasca S, Carli E: Use of fine needle aspirates and flow
cytometry for the diagnosis, classification, and immunophenotyping of canine lymphomas. J Vet Diagn Invest. 2005; 17: 323–330
[236] Sorenmo KU, Krick E, Coughlin CM et al.: CD40–activated B cell
cancer vaccine improves second clinical remission and survival in
privately owned dogs with non-Hodgkinʼs lymphoma. PLoS One.
2011; 6(8):e24167
[237] Spodnick GJ, Berg J, Moore FM et al.: Spinal lymphoma in cats: 21
[238] Squire RA, Bush M, Melby EC et al.: Clinical and pathologic study
of canine lymphoma: clinical staging, cell classification, and therapy.
J Natl Cancer Inst. 1973; 51: 565–574
[239] Stockham SL, Keeton KS, Szladovits B: Clinical assessment of leukocytosis: distinguishing leukocytoses caused by inflammatory, glucocorticoid, physiologic, and leukemic disorders or conditions. Vet
[219] Schmidt ML, Rutteman GR, van Niel MHF et al.: Clinical and radiographic manifestations of canine malignant histiocytosis. Vet Quart.
1993; 14: 117–120
[240] Strandstrom HV, Higgins JR, Mossie K et al.: Studies with canine
sera that contain antibodies which recognize human immunodeficiency virus structural proteins. Cancer Res. 1990; 50[Suppl.]:
5628s–5630s
[220] Schneider R: Comparison of age- and sex-specific incidence rate
patterns of the leukemia complex in the cat and the dog. J Natl Cancer Inst. 1983; 70: 971–977
[241] Stützer B, Simon K, Lutz H et al.: Incidence of persistent viraemia
and latent feline leukaemia virus infection in cats with lymphoma. J
[221] Schultz RM, Puchalski SM, Kent M et al.: Skeletal lesions of histiocytic sarcoma in nineteen dogs. Vet Radiol Ultrasound. 2007; 48:
539–543
[242] Suter SE, Vernau W, Fry MM et al.: CD34+, CD41+ acute megakaryoblastic leukemia in a dog. Vet Clin Pathol. 2007; 36: 288–292
[222] Shaiken LC, Evans SM, Goldschmidt MH: Radiographic findings in
canine malignant histiocytosis. Vet Radiol. 1991; 32: 237–242
[243] Swerdlow SH, Campo E, Harris NL et al. (Hrsg.): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4. Auflage, IARC Press, Lyon, 2008
[223] Sharifi H, Nassiri SM, Esmaelli H: Eosinophilic leukaemia in a cat. J
Feline Med Surg. 2007; 9: 514–517
[244] Swinney G, Jones BR, Kissling K: A review of polycythemia vera in
the cat. Aust Vet Pract. 1992; 22: 60–66
[224] Sheafor SE, Gamblin RM, Couto CG: Hypercalcemia in two cats
with multiple myeloma. J Am Vet Med Assoc. 1996; 32: 503–508
[245] Takahashi K, Katami K, Nakamura K et al.: IgG type myeloma in a
dog. Jpn J Vet Sci. 1980; 42: 271–275
[225] Shelton GH, Grant CK, Cotter SM et al.: Feline immunodeficiency
virus (FIV) and feline leukemia virus (FeLV) infections and their relationship to lymphoid malignancies in cats: a retrospective study
(1968—1988). J Acquir Immuno Def Synd. 1990; 1623–1630
[246] Takahashi T, Otani I, Okuda M et al.: Malignant transformation of
T-cell large granular lymphocyte leukemia in a dog. J Vet Med Sci.
2007; 69: 677–681
[226] Shimoda T, Shiranaga N, Mashita T et al.: A hematological study
on thirteen cats with myelodysplastic syndrome. J Vet Med Sci.
2000: 62: 59–64
[227] Shirani D, Nassiri SM, Aldavood SJ et al.: Acute erythroid leukemia
with multilineage dysplasia in a cat. Can Vet J. 2011; 52: 389–393
[228] Simon D, Eberle N, Laacke-Singer L et al.: Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and
[247] Takeuchi Y, Iizuka H, Kanemitsu H et al.: Myeloma-related disorder with leukaemic progression in a cat. J Feline Med Surg. 2010;
12: 982–987
[248] Tarrant JM, Stokol T, Blue JT et al.: Diagnosis of chronic myelogenous leukemia in a dog using morphologic, cytochemical, and flow
cytometric techniques. Vet Clin Pathol. 2001; 30: 19–24
[249] Tasca S, Carli E, Caldin M et al.: Hematologic abnormalities and
flow cytometric immunophenotyping results in dogs with hematopoietic neoplasia: 210 cases (2002–2006). Vet Clin Pathol. 2009;
38: 2–12
137
[251] Tebb AJ, Cave T, Barron R et al.: Diagnosis and management of B
cell chronic lymphocytic leukaemia in a cat. Vet Rec. 2004; 154:
430–433
[252] Teske E, Besselink CMLT, Blankenstein MA et al.: The occurrence
of estrogen and progestin receptors and antiestrogen binding sites
(AEBS) in canine non-Hodgkinʼs lymphomas. Anticancer Res. 1987;
7: 857–860
[269] Valli VE, Jacobs RM, Norris A et al.: The histologic classification of
602 cases of feline lymphoproliferative disease using the National
Cancer Institute working formulation. J Vet Diagn Invest. 2000; 12:
295–306
[270] Valli VE, Jacobs RM, Parodi AL et al.: Histological classification of
hematopoietic tumors of domestic animals. Armed Forces Institute
of Pathology, Washington DC, 2002, 2nd Series Vol VIII
[271] Valli VE, San Myint M, Barthel A et al.: Classification of canine
malignant lymphomas according to the World Health Organization
criteria. Vet Pathol. 2011; 48: 198–211
[253] Teske E, Rutteman GR, Van Heerde P et al.: Polyethylene glycol-Lasparaginase in canine non-Hodgkinʼs lymphoma. Eur J Cancer.
1990; 26: 891–895
[272] Van Vechten M, Helfland SC, Jeglum KA: Treatment of relapsed
Med. 1990; 4: 187–191
[254] Teske E: Canine malignant lymphoma: a review and comparison
with human non-Hodgkinʼs lymphoma. Vet Quart. 1994; 16: 209–
219
[273] Vernau W, Moore PF: An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase
chain reaction. Vet Immunol Immunopathol. 1999; 69: 145–164
[255] Teske E, De Vos JP, Egberink HF et al.: Clustering in canine malignant lymphoma. Vet Quart. 1994; 16: 134–136
[274] Vezzali E, Parodi AL, Marcato PS et al.: Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma
according to the WHO. Vet Comp Oncol. 2010; 8: 38–49
[256] Teske E, van Heerde P, Rutteman GR et al.: Prognostic factors in
canine non-Hodgkinʼs lymphomas. A prospective study in 138
[257] Teske E, van Heerde P: Diagnostic value and reproducibility of
fine-needle aspiration cytology in canine malignant lymphoma. Vet
Quart. 1996; 18: 112–115
Med. 2002; 16: 179–186
[259] Teske E, Wisman P, Moore PF et al.: Histological classification and
immunophenotyping of canine non-Hodgkinʼs lymphomas. Unexpected high frequency of T-cell lymphomas with B-cell morphology.
Exp Hematol. 1994; 22: 1179–1187
[260] Terry A, Callanan JJ, Fulton R et al.: Molecular analysis of tumours
from feline immunodeficiency virus (FIV)-infected cats: An indirect
role for FIV? Intern J Cancer. 1995; 61: 227–232
[261] Thomas R, Smith KC, Ostrander EA et al.: Chromosome aberrations in canine multicentric lymphomas detected with comparative
genomic hybridisation and a panel of single locus probes. Br J Cancer. 2003; 89: 1530–1537
[262] Tomiyasu H, Fujino Y, Takahashi M et al.: Spontaneous acute
erythroblastic leukaemia (AML-M6Er) in a dog. J Small Anim Pract.
2011; 52: 445–447
[263] Tomley FM, Armstrong SJ, Mahy BWJ et al.: Reverse transcriptase
activity and particles of retroviral density in cultured canine lymphosarcoma supernatants. Br J Cancer. 1983; 47: 277–284
[264] Tsai S, Sutherland-Smith J, Burgess K et al.: Imaging characteristics of intrathoracic histiocytic sarcoma in dogs. Vet Radiol Ultrasound. 2012; 53: 21–27
[265] Tzannes S, Hammond MF, Murphy S et al.: Ownersʼ perception of
their catsʼ quality of life during COP chemotherapy for lymphoma. J
[266] Usher SG, Radford AD, Villiers EJ et al.: RAS, FLT3, and C-KIT
mutations in immunophenotyped canine leukemias. Exp Hematol.
2009; 37: 65–77
[267] Vail DM, Kisseberth WC, Obradovich JE et al.: Assessment of
potential doubling time (Tpot), argyrophilic nucleolar organizer
regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as
predictors of therapy response in canine malignant lymphoma. Exp
Hematol. 1996; 24: 807–815
[268] Valerius KD, Ogilvie GK, Mallinckrodt CH et al.: Doxorubicin
alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric
lymphoma in dogs: 121 cases (1987–1995). J Am Vet Med Assoc.
1997; 210: 512–516#+
[275] Villiers E, Baines S, Law AM et al.: Identification of acute myeloid
leukemia in dogs using flow cytometry with myeloperoxidase,
MAC387, and a canine neutrophil-specific antibody. Vet Clin Pathol.
2006; 35: 55–71
[276] Visonneau S, Cesano A, Tran T et al.: Successful treatment of
canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Clin Cancer Res. 1997; 3: 1789–1797
[277] Voegeli E, Welle M, Hauser B et al.: Das histiozytäre Sarkom beim
Berner Sennenhund in der Schweiz: Eine retrospektive Studie über
seine genetische Prädisposition. Schweiz Arch Tierheilkd. 2006;
148: 281–288
[278] von Euler H, Einarsson R, Olsson U et al.: Serum thymidine kinase
activity in dogs with malignant lymphoma: a potent marker for
prognosis and monitoring the disease. J Vet Intern Med. 2004; 18:
696–702
[279] Wagter HW, Vos AJ, van den Ingh T: [A localised histocytic sarcoma in the stomach of a dog]. Tijdschr Diergeneeskd. 2009; 134:
526–528
[280] Walton RM, Modiano JM, Thrall MA et al.: Bone marrow cytological findings in 4 dogs and a cat with hemophagocytic syndrome. J
Vet Intern Med. 1996; 10: 7–14
[281] Watson ADJ, Moore AS, Helfand SC: Primary erythrocytosis in the
cat: treatment with hydroxyurea. J Small Anim Pract. 1994; 35:
320–325
[282] Weiss AT, Klopfleisch R, Gruber AD: Prevalence of feline leukaemia provirus DNA in feline lymphomas. J Feline Med Surg. 2010; 12:
929–935
[283] Weiss DJ: A retrospective study of the incidence and the classification of bone marrow disorders in the dog at a veterinary teaching
hospital (1996–2004). J Vet Intern Med. 2006; 20: 955–961
[284] Weiss DJ: Evaluation of dysmyelopoiesis in cats: 34 cases (1996–
2005). J Am Vet Med Assoc. 2006; 228: 893–897
[285] Weiss DJ: Flow cytometric and immunophenotypic evaluation of
acute lymphocytic leukemia in dog bone marrow. J Vet Intern Med.
2001; 15: 589–594
[286] Weiss DJ: Recognition and classification of dysmyelopoiesis in the
dog: a review. J Vet Intern Med. 2005; 19: 147–154
[287] Weiss DJ, Raskin R, Zerbe C: Myelodysplastic syndrome in two
[288] Weiss DJ, Smith SA: A retrospective study of 19 cases of canine
myelofibrosis. J Vet Intern Med. 2002; 16: 174–178
[289] Weller RE, Holmberg CA, Theilen GH et al.: Canine lymphosarcoma and hypercalcemia: clinical, laboratory and pathologic evaluation of twenty-four cases. J Small Anim Pract. 1982; 23: 649–658
138
[290] Weller RE, Theilen GH, Madewell BR et al.: Chemoimmunotherapy for canine lymphosarcoma: a prospective evaluation of specific
and nonspecific immunomodulation. Am J Vet Res. 1980; 41: 516–
521
[291] Wilkerson MJ, Dolce K, Koopman T et al.: Lineage differentiation
of canine lymphoma/leukemias and aberrant expression of CD
molecules. Vet Immunol Immunopathol. 2005; 106: 179–196
[292] Willmann M, Müllauer L, Schwendenwein I et al.: Chemotherapy
in canine acute megakaryoblastic leukemia: a case report and
review of the literature. In Vivo. 2009; 23: 911–918
[293] Workman HC, Vernau W: Chronic lymphocytic leukemia in dogs
and cats: the veterinary perspective. Vet Clin North Am Small Anim
Pract. 2003; 33: 1379–1399
[294] Zavodovskaya R, Liao AT, Jones CL et al.: Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic
sarcomas of dogs. Am J Vet Res. 2006; 67: 633–641
[295] Zemann BI, Moore AS, Rand WM et al.: A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern
Med. 1998; 12: 465–470

Enke: Kleintieronkologie

Transcription

Similar documents

oj_report (openjunixx.UTB) - utb-Shop

- Hartmann

Publikationen IVPZ ab 1906_Stand_110913.xlsb

Kolonkarzinom, Rektumkarzinom, Analkarzinom